<SEC-DOCUMENT>0001213900-14-003153.txt : 20140512
<SEC-HEADER>0001213900-14-003153.hdr.sgml : 20140512
<ACCEPTANCE-DATETIME>20140512165346
ACCESSION NUMBER:		0001213900-14-003153
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20140331
FILED AS OF DATE:		20140512
DATE AS OF CHANGE:		20140512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		14834050

	BUSINESS ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0314_actinium.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<html>
<head>
    <title>f10q0314_actinium.htm</title>
    <!--Licensed to: Edgar Agents LLC-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="TEXT-INDENT: 0pt; DISPLAY: inline; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 7%; FONT-SIZE: 10pt; MARGIN-RIGHT: 7%">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 10-Q</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Mark One)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline;" face="Wingdings">x&#160;</font> QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the quarterly period ended<font style="DISPLAY: inline; FONT-WEIGHT: bold"> March 31, 2014</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline;" face="Wingdings">o&#160;</font> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the transition period from _______________________ to ___________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number: &#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">000-52446</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="49%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="49%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">88-0378336</font></div>
</td>
</tr><tr>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or Other Jurisdiction of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Incorporation or Organization)</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(I.R.S. Employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Identification No.)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="49%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">501 Fifth Avenue, 3rd Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">New York, NY</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="49%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10017</font></div>
</td>
</tr><tr>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of Principal Executive Offices)</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(646) 459-4201</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;Yes&#160; &#160;No <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;Yes&#160; &#160;No <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. &#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="20%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Large accelerated filer</font></div>
</td>
<td valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">o</font></div>
</td>
<td align="left" valign="middle" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accelerated filer</font></div>
</td>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">o</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="middle" width="20%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-accelerated filer&#160;</font></div>
</td>
<td valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font>&#160;(Do not check if a smaller reporting company)</font></div>
</td>
<td align="left" valign="middle" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Smaller reporting company&#160;&#160;&#160;</font></div>
</td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">x</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;Yes&#160;<font style="DISPLAY: inline;" face="Wingdings"> x</font>&#160; No</font></div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">PROCEEDINGS DURING THE PRECEDING FIVE YEARS:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;Yes&#160;<font style="DISPLAY: inline;" face="Wingdings">&#160;o</font>&#160; No</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">APPLICABLE ONLY TO CORPORATE ISSUERS:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">May &#173;&#173;9, 2014:&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">25,562,846</font></font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 10-Q</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For period ended March 31, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INDEX</font><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="white">
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><a href="#part1">PART I-- FINANCIAL INFORMATION</a></font></font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item1">Item 1.</a></font></div>
</td>
<td align="left" valign="bottom" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item1">Financial Statements</a></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item2">Item 2.</a></font></div>
</td>
<td align="left" valign="bottom" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item2">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item3">Item 3.</a></font></div>
</td>
<td align="left" valign="bottom" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item3">Quantitative and Qualitative Disclosures About Market Risk</a></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item4">Item 4.</a></font></div>
</td>
<td align="left" valign="bottom" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item4">Controls and Procedures</a></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" colspan="2" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#part2">PART II-- OTHER INFORMATION</a></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 1.</font></div>
</td>
<td align="left" valign="bottom" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Legal Proceedings</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item1a">Item 1A.</a></font></div>
</td>
<td align="left" valign="bottom" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item1a">Risk Factors</a></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item22">Item 2.</a></font></div>
</td>
<td align="left" valign="bottom" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item22">Unregistered Sales of Equity Securities and Use of Proceeds</a></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item33">Item 3.</a></font></div>
</td>
<td align="left" valign="bottom" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item33">Defaults Upon Senior Securities</a></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item44">Item 4.</a></font></div>
</td>
<td align="left" valign="bottom" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item44">Mine Safety Disclosures</a></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item55">Item 5.</a></font></div>
</td>
<td align="left" valign="bottom" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item55">Other Information</a></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item66">Item 6.</a></font></div>
</td>
<td align="left" valign="bottom" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#item66">Exhibits</a></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#isig">SIGNATURES</a></font></font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="part1">PART I - FINANCIAL INFORMATION</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_1"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item1">ITEM 1. &#160;FINANCIAL STATEMENTS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying condensed consolidated financial statements have been prepared by the Company and are unaudited. &#160;In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2014 and 2013 and for the periods then ended have been made. &#160;Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. &#160;It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s audited financial statements for the year ended December 31, 2013. &#160;The results of operations for the period ended March 31, 2014 are not necessarily indicative of the operating results for the full year.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Balance Sheets</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2013</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Assets</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Assets:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,877,781</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,533,366</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">667,911</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">218,389</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;Total Current Assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,545,692</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,751,755</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net of accumulated depreciation</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,214</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,920</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6,559,906</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5,765,675</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Liabilities and Stockholders' Deficit</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">615,272</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">378,955</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses - related party</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">189,537</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">81,185</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Notes payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">94,481</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">157,825</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,128,761</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,707,255</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;Total Current Liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,028,051</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,325,220</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commitments and contingencies</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stockholders' Deficit:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred stock, $0.01 par value; 50,000,000 authorized</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-0- issued and outstanding</font></font></div>
</div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock, $0.01 par value; 200,000,000 shares authorized;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,562,346 and 24,565,447 shares issued and outstanding, respectively</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,562</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,565</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid-in capital</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">69,723,045</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">64,933,145</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deficit accumulated during the development stage</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(83,216,752</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(66,517,255</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;Total Stockholders' Deficit</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,468,145</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,559,545</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Liabilities and Stockholders' Deficit</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6,559,906</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5,765,675</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statements of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Period</font></font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">from June 13,</font></font></div>
</div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Three</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Three</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2000</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Months Ended</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Months Ended</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Inception) to</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Operating Expenses:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development, net of reimbursements</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,460,968</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,085,707</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,548,346</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,676,053</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">933,135</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,100,379</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation and amortization</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,405</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,265,427</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss on disposition of equipment</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,122</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">554,308</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Operating Expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,138,426</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,022,964</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">65,468,460</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Loss From Operations</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,138,426</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,022,964</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(65,468,460</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other Income and (Expense):</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(575</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,967,215</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain on extinguishment of liability</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">260,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain (loss) on change in fair value of derivative liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,561,071</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,334,512</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,041,077</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Other Income and (Expense)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,561,071</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,333,937</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(17,748,292</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Loss &#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(16,699,497</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(689,027</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(83,216,752</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Loss Per Common Share&#160;&#160;- Basic and Diluted</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.66</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.03</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted Average Number of Common Shares Outstanding&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">- Basic and Diluted</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,228,299</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,391,665</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statements of Cash Flows</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Period</font></font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Three</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Three</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">from June 13,</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Months </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ended</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Months </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ended</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;2000 </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Inception) to</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows From Operating Activities:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,699,497</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(689,027</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(83,216,752</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" colspan="4" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments to reconcile net loss to net cash used in</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">operating activities:</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Stock-based compensation expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,926</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">94,200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,460,774</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Depreciation expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,405</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,265,427</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Loss on disposition of equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">554,308</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Amortization of debt discount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">900,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Amortization of deferred financing costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">292,692</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Gain on extinguishment of liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(260,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Loss (gain) on change in fair value of derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,561,071</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,334,512 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,041,077</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in operating assets and liabilities:</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Increase) decrease in:</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Prepaid expenses and other current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(449,522 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(50,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(370,086 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase (decrease) in:</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Accounts payable and accrued expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">236,317</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(437,121 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">957,001</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Accounts payable and accrued expenses - related party</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">108,352</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">189,537</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Used In Operating Activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,490,948 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,312,338 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(53,186,022 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows From Investing Activities:</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payment made for patent rights</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,000,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchase of property and equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,699 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,112 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(833,950 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Used In Investing Activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,699 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,112 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,833,950 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows From Financing Activities:</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Borrowings on convertible debt, net of offering costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">645,888</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sales of stock, net of offering costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,871,477</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">58,945,832</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from the exercise of options</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,220</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,273</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from the exercise of warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,709</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,491,104</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments on note payable</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(63,344 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(65,333 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(203,344 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Provided By (Used in) Financing Activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,837,062</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(65,333 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">62,897,753</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net change&#160;in cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">344,415</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,378,783 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,877,781</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash at beginning of period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,533,366</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,618,669</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash at end of period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5,877,781</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3,239,886</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5,877,781</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplemental disclosures of cash flows information:</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid for interest</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">561</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,243</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid for taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" colspan="4" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplemental disclosure of non-cash investing and financing activities:</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Beneficial conversion feature discount</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">372,850</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Insurance prepaid through premium finance</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">297,825</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value of warrants issued with debt</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">377,150</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value of warrants issued with stock</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,985,238</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value of warrants issued to the placement agent</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,170,282</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conversion of notes payable and accrued interest to stock</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">981,729</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Transfer warrant derivatives from liability to equity classification</font></font></div>
</div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">139,565</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,417,984</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 7.7pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 7.7pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 7.7pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Nature of Business &#8211;</font> Actinium Pharmaceuticals, Inc., incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;API&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase 1/2 clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &#8220;Company&#8221;, &#8220;Actinium&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that&#160;was in the market for a merger with an appropriate operating company.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&#160;&#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April&#160;11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&#8217;s common stock.&#160;&#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Basis of Presentation - Unaudited Interim Financial Information &#8211;</font> The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary&#160;for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 28, 2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Development Stage Company &#8211;</font> The Company is considered a development stage company and has had no commercial revenue to date. The Company has been focusing on the development of its clinical drug candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Principles of Consolidation &#8211;</font> The condensed consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Use of Estimates in Financial Statement Presentation &#8211;</font> The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cash and Cash Equivalents &#8211;</font> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At March 31, 2014 and December 31, 2013, all of the Company&#8217;s cash was deposited in one bank.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Property and Equipment &#8211;</font> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Impairment of Long-Lived Assets &#8211;&#160;</font>Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Derivatives &#8211;</font>&#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Fair Value of Financial Instruments &#8211;</font>&#160;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities&#160;in&#160;active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following tables set forth liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of March 31, 2014 and December 31, 2013. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 2</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 3</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;At March 31, 2014</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,128,761</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,128,761</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;At December 31, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,707,255</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,707,255</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Income Taxes &#8211;</font> The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Research and Development Costs &#8211;</font> Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Share-Based Payments &#8211;</font> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Earnings (Loss) Per Common Share &#8211;</font> The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &#160;The potentially dilutive securities (options and warrants) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the three months ended March 31, 2014, potentially issuable shares included stock options to purchase 2,265,229 shares and warrants to purchase 9,680,333 shares of the Company&#8217;s common stock. For the three months ended March 31, 2013, potentially issuable shares included stock options to purchase 2,330,134 shares and warrants to purchase 12,770,636 shares of the Company&#8217;s common stock.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Recent Accounting Pronouncements &#8211;</font> The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Subsequent Events &#8211;</font> The Company&#8217;s management reviewed all material events through the date of the condensed consolidated financial statements were issued for subsequent event disclosure consideration.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Note 2 &#8211; Related Party Transactions</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MSKCC:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2010, General Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly named General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC), a principal owner of the Company.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer Research (SKI),&#160;an entity related to MSKCC (&#8220;License Agreement&#8221;).&#160;&#160;The agreement was amended in August 2006.&#160;&#160;Pursuant to the agreement, the Company licenses certain intellectual property from SKI, including critical patents with respect to the Company&#8217;s core technology, and also supports ongoing research and clinical development of related drug candidates.&#160;&#160;</font></font><br>
</div>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is obligated to make the following milestone payments:</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Milestones</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval&#160;for each licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) upon the receipt of regulatory approval from the U.S. FDA for each&#160;licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain amounts due under the License Agreement were deferred and then forgiven under a forbearance-related arrangement.&#160;&#160;On June 19, 2011, the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement, in respect of the $50,000 annual maintenance fees and research payments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;On September 4, 2013, the Company entered into a letter agreement with SKI to set forth the amount that the Company owes SKI for the period from 2011 to 2014 under the License Agreement.&#160;&#160;The total amount that the Company owes SKI for the period from 2011 to 2014 is $815,100 plus all relevant licensed intellectual property related pass through costs to be determined.&#160;&#160;The amount owed does not include amounts the Company may owe for patent expenses under the License Agreement.&#160;&#160;As of March 31 2014, amount owed under this letter agreement for 2014 annual maintenance fee and 2014 research funding was approximately $0.2 million plus pass through costs, respectively.</font></div>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 27, 2012, the Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225.&#160;&#160;The Company will pay $31,185 for each patient that has completed the clinical trial.&#160;&#160;Upon execution of the agreement, the Company paid a start-up fee of $79,623 in 2012.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three months ended March 31, 2014 and 2013, the Company incurred $189,537 and $129,850, respectively, for maintenance fees and research conducted by MSKCC.&#160;&#160;As of March 31, 2014 and December 31, 2013, the Company has payable to MSKCC of $189,537 and $81,185, respectively, related to clinical trials.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Placement Agent:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 7, 2012, the Company entered into an engagement agreement with Healthcare Investment Banking as its placement agent for the 2012 Common Stock Offering.&#160; A director of the Company was the Head of Healthcare Investment Banking at the placement agent.&#160;&#160;&#160;Pursuant to the agreement, the placement agent was engaged as the exclusive agent for the 2012 Common Stock Offering. &#160;&#160;In consideration for its services, the placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.&#160;&#160;The placement agent or its designees have also received warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.&#160;&#160;The placement agent will also receive the same fee and expense schedule for any cash exercise of warrants within 6 months of the final closing of the 2012 Common Stock Offering and a 5% solicitation fee for any warrants exercised as a result of being called for redemption by the Company.&#160;&#160;Upon the final closing of the 2012 Common Stock Offering of the units, the placement agent has been engaged by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee of $25,000.&#160;&#160;The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company&#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.&#160;&#160;For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent.&#160;&#160;The placement agent also was engaged by the Company as placement agent for its Stock Offering and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold warrants to purchase 1,251,015 shares of the Company&#8217;s Common Stock.</font></div>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 9, 2013, the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering. The agreement entered in 2013 has similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company has uplisted its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During quarter ended March 31, 2014, the placement agent received a cash fee of approximately $0.4 million from the sale of securities and was issued warrants to purchase 68,976 shares of the Company&#8217;s Common Stock at $9 per share for a period of 5 years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 3 &#8211; Property and Equipment</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Property and equipment consisted of the following at March 31, 2014 and December 31, 2013:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="67%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Lives</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2014</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Office equipment</font></div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;3 years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,179</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,480</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="67%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: accumulated depreciation</font></div>
</td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,965</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,560</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="67%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net</font></div>
</td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,214</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,920</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Depreciation expense for the three months ended March 31, 2014 and 2013 were $1,405 and $0, respectively. The Company wrote off its remaining undepreciated property and equipment during the three months ended March 31, 2013 and recorded a loss of $4,122 on the disposition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 4 &#8211; Note Payable</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 28, 2013, the Company entered into a premium finance agreement to pay a $157,825 premium for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $15,995 in January 2014 and&#160;is required&#160;to pay $15,995 in monthly installment for nine months. For the quarter ended March 31, 2014, the Company paid $63,344 under this finance agreement. As of March 31, 2014 and December 31, 2013, the outstanding balance related to the premium finance agreement was $94,481 and $157,825, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 5 &#8211; Derivatives</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&#8217;s common stock at prices below such warrants&#8217; respective exercise prices and these provisions could result in modification of the warrants&#8217; exercise price based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined under FASB ASC Topic No. 815 &#8211; 40. The warrants granted in connection with the issuance of the Company&#8217;s Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &#8220;Lower Price&#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Activities for derivative warrant instruments during the three months ended March 31, 2014 were as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair Value</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, December 31, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,968,623</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,707,255</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Transfer from liability classification to equity classification</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(46,025</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(139,565</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,561,071</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, March 31, 2014</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,922,598</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,128,761</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the quarter ended March 31, 2014, 46,025 warrants were exercised. The fair value of these warrants totaling $139,565 were measured on the various exercise dates and reclassified to additional paid-in capital.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2014</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Market value of common stock on measurement date (1)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12.45</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.89</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjusted exercise price</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9.95</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.48</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk free interest rate (2)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.32</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.27</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant lives in years</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.5 years</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.5 years</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility (3)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">71</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">73</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected dividend yield (4)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Probability of stock offering in any period over 5 years (5)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Range of percentage of existing shares offered (6)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Offering price range (7)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The market value of common stock at the above measurement dates is based on the Company&#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for March 31, 2014.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3)&#160;&#160;</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4)&#160;&#160;</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5)&#160;&#160;</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management determines the probability of future stock offering at each evaluation date.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6)&#160;&#160;</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management estimates that the range of percentages of existing shares offered in each stock offering will be&#160;0% and 35% of the shares outstanding at March 31, 2014 and December 31, 2013, respectively.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7)&#160;&#160;</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Represents the estimated offering price range in future offerings as determined by management.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 6 &#8211; Commitments and Contingencies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">License and Research Agreements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a.</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Abbott Biotherapeutics Corp &#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Milestones</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4) Biological License Application filing with U.S. FDA</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5) First commercial sale</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6) after the first $10,000,000 in net sales</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.&#160;&#160;The milestone payment for the Phase 1 Clinical Trial was recorded as research and development expense. The Company has not initiated a Phase II Clinical Trial and no payment has been made to Abbott Biotherapeutics Corp. since the July 24, 2012 payment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Memorial Sloan Kettering Cancer Center (MSKCC) &#8211; see related party disclosure.</font></div>
</td>
</tr><tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c.&#160;&#160;</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oak Ridge National Laboratory (ORNL) &#8211; API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end.&#160;&#160;For 2013, the Company was obligated and paid approximately $0.3 million to purchase of radioactive material with ORNL.&#160;&#160;For 2014, the Company signed a contract with ORNL to purchase $0.4 million of radioactive material.</font></div>
</td>
</tr><tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d.&#160;&#160;</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company clinical trials, Phase 1 and Phase 2.&#160;&#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&#160;&#160;The down payment totaling $239,000 was paid in 2007 and 2012.&#160;&#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&#160;&#160;The total project is now estimated at approximately $2.2 million. As of March 31, 2014, approximately $1.0 million has been expensed to date. &#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></div>
</td>
</tr></table>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%" style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">e.&#160;&#160;</font></div>
</td>
<td valign="top" width="91%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On June 15, 2012, the Company entered into a license and sponsored research agreement of BC8, a novel murine monoclonal antibody, with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody).&#160;&#160;FHCRC has currently completed Phase 1 and Phase 2 of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval.&#160;&#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC.&#160;&#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA.&#160;&#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter.&#160;&#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year.&#160;&#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&#160;&#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During the quarters ended March 31, 2014 and 2013, the Company recorded fees of $37,500 and $37,500, respectively, related to this agreement.</font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">f.&#160;&#160;</font></div>
</td>
<td valign="top" width="91%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC for </font>Actimab-A<font style="DISPLAY: inline; FONT-SIZE: 10pt">.&#160;&#160;The Company will pay $31,366 for each patient that has completed the clinical trial. The Company paid a start-up fee of $19,749 in 2013.&#160;&#160;During the clinical trial additional fees apply and will be invoiced when applicable. For the three months ended March 31, 2014, the Company paid approximately $16,000 for patient enrollment.</font></font></div>
</td>
</tr><tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">g.&#160;&#160;</font></div>
</td>
<td valign="top" width="91%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center for </font>Actimab-A<font style="DISPLAY: inline; FONT-SIZE: 10pt">.&#160;&#160;The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500.&#160;&#160;The estimated cost is based on treating 24 patients through 2013.&#160;&#160;Upon execution of the agreement, the Company paid $33,946. During 2013, there was one patient treated and the Company paid $34,383 in July 2013. There have been no patients treated in 2014.</font></font></div>
</td>
</tr></table>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">h.&#160;&#160;</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. The Company paid the $22,847 start-up fee in February 2013. There were no payments made during the three months ended March 31, 2014 for this agreement.</font></div>
</td>
</tr><tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">i.&#160;&#160;</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable. The Company accrued $16,000 fee at December 31, 2013 and paid the fee in January 2014.</font></div>
</td>
</tr><tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">j.&#160;&#160;</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On January 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology Inc.&#160;&#160;(&#8220;Goodwin&#8221;). Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab&#8482;-B. Total cost of the agreement is $2,813,960. The Company paid a non-refundable payment of $562,790 upon execution of the agreement. Periodic payments will be made upon reaching certain milestones. As of March 31, 2014, the remaining cost of the agreement is $2,077,000.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&#160;New York, NY. The agreement terminated on May 31, 2013. On June 4, 2013 and amended on October&#160;4, 2013, the Company entered into a rental agreement for office space at 546 Fifth Avenue,&#160;New York, NY. This agreement terminates on July 6, 2014. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 7 &#8211; Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In January 2014, the Company completed the final tranche of a private placement of the Company&#8217;s common stock and warrants and received approximately $3.3 million total gross proceeds from accredited investors (&#8220;2014 Closing&#8221;). The Company paid its placement agent total cash fees of approximately $395,000 and paid attorney fees of $40,000 for their services. In the 2014 Closing, the Company sold 551,810 shares of common stock at $6.00 per share and granted 137,952 units of five-year warrants with an exercise price of $9.00 per share. The warrants are exercisable for a period of five years from the date of issuance. The transaction date fair value of the warrants of $0.6 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rateh1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years. As of March 31, 2014, all the warrants were outstanding.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March&#160;24, 2014, the Company filed a shelf registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) which was effective on April 17, 2014.&#160;&#160;This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the &#8220;Sales Agreement&#8221;) with MLV &amp; Co. LLC (&#8220;MLV&#8221;) dated March 24, 2014.&#160;The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock.&#160;To date 500 shares have been sold under the Sales Agreement with MLV (see Note 8 &#8211; Subsequent Event).</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Placement Agent &#8211;&#160;</font>During January 2014, in connection with 2014 Closing, the Company issued Laidlaw &amp; Co. warrants to purchase an aggregate of 68,976 shares of common stock with an exercise price of $9.00 per share. The transaction date fair value of the warrants of $0.2 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate &#8211; 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Approval of the Equity Incentive Plan</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2013, the Company granted employees, consultant and board members 312,500 shares of restricted stock. During the quarter ended March 31, 2014, the Company granted an additional 325,167 shares of restricted stock. During the three months ended March 31, 2014, 180,104 shares were issued for shares granted under the Equity Incentive Plan. Of the total shares of restricted stock, 22,500 shares vest 1 year from the grant date, 149,167 shares have a vesting period of 4 years and 150,000 shares vest at date of grant. The remaining restricted shares granted are performance based and vest over time.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All restricted stock issued and outstanding is being amortized over their respective vesting periods. The unrecognized compensation expense related to the restricted stock granted at March 31, 2014 was $1,391,318. During the three months ended March&#160;31, 2014 and 2013, the Company recorded expense of $1,410,588 and $0, respectively, related to the restricted stock granted.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock Option Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a summary of stock options:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,985,384</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.23</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.34</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,908,696</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Issued</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">291,500&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;7.86</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Exercised</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,655)</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.78</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, March 31, 2014</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,265,229</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.84</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.34</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,514,362</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the quarter ended March 31, 2014, the Company granted employees and board members 291,500 options to purchase the Company&#8217;s common stock with exercise prices ranging from $5.55 to $8.19 and a term of 10 years and vest over a 4-year period.&#160;&#160;The fair value of $1.7 million was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.88% - 2.07% (2) expected life of 6 years, (3) expected volatility of 87.76%, and (4) zero expected dividends.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During quarter ended March 31, 2014, the Company received gross proceeds of $5,220 for exercise of options for 11,655 shares of the Company&#8217;s common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at March 31, 2014 was $5,399,710. During the three months ended March&#160;31, 2014 and 2013, the Company recorded option expense of $281,404 and $94,200, respectively.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrants</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Following is a summary of warrant activities for the quarter ended March 31, 2014:</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,673,290</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.06</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.89</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 47,396,307</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Granted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">306,928</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.88</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 6.63</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Exercised</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(299,885</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.04</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, March 31, 2014</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,680,333</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.28</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.71</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">107,268,785</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the quarter ended March 31, 2014, the Company granted warrants to purchase 137,952 shares of the Company&#8217;s common stock to investors and warrants to purchase 68,976 shares of the Company&#8217;s common stock to its placement agent in connection with the 2014 Closing.</font></font></div>

<br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the three months ended March 31, 2014, the Company also granted a consultant warrants to purchase 100,000 shares of the Company&#8217;s common stock with exercise prices of $5.55 per share and a term of 10 years.&#160;&#160;These warrants vest when certain milestones are met.&#160;&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the quarter ended March 31, 2014, 299,885 warrants were exercised by the warrant holders. The Company issued 253,330 shares of common stock and received gross proceeds of $23,709.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the quarter ended March 31, 2014 and 2013, the Company recorded stock-based compensation related to the warrants of $58,934 and $0, respectively.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 8 &#8211; Subsequent Events</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In April 2014, the Company granted certain employees 50,000 shares of restricted common stock and options to purchase 600,000 shares of the Company&#8217;s common stock with exercise prices ranging from $11.76 to $11.95 and a term of 10 years. These options and restricted stock vest over a 4-year period.&#160;&#160;Effective May 12, 2014, <font style="DISPLAY: inline; FONT-SIZE: 10pt">the Company entered into a sublease agreement for office space located at 379 Thornall Street, Edison, NJ. This agreement terminates on September 30, 2016. The Company issued a security deposit of approximately $35,000 to the existing tenant.</font></font></font><br>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 28, 2014, the Company issued 500 shares of its common stock and received net proceeds of $6,000.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item2">ITEM 2. &#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORWARD-LOOKING STATEMENT NOTICE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. &#160;For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;estimate&#8221; or &#8220;continue&#8221; or comparable terminology are intended to identify forward-looking statements. &#160;These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. &#160;These factors include but are not limited to economic conditions generally and in the industries in which we may participate; competition within our chosen industry, including competition from much larger competitors; technological advances and failure to successfully develop business relationships.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description of Business</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We were incorporated under the laws of the State of Nevada on October 6, 1997. We were a shell entity that was in the market for a merger with an appropriate operating company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 28, 2012, we entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company agreed to acquire 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;Actinium&#8221;), in exchange for the issuance of common stock, par value $0.001 per share, of the Company (the &#8220;Common Stock&#8221;), which were issued to the shareholders of Actinium. As a result of the Share Exchange, the former shareholders of Actinium became the controlling shareholders of the Company. The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein Actinium is considered the acquirer for accounting and financial reporting purposes. As a result of the Share Exchange, the Company assumed the business and operations of Actinium.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 11, 2013, the change of domicile from the State of Nevada to the State of Delaware and the change of Cactus Ventures, Inc.&#8217;s name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc. became effective in accordance with Articles of Merger filed with the State of Nevada and a Certificate of Merger filed with the State of Delaware.&#160;&#160;In connection with the name change we also changed (i) the name of our subsidiary Actinium Pharmaceuticals, Inc. to Actinium Corporation, (ii) our par value to $0.001 per share, and (iii) the number of authorized shares of preferred stock to 10 million shares.&#160;Effective April 18, 2013 our new trading symbol became ATNM. On September 25, 2013, we merged with our subsidiary, Actinium Corporation, and we were the surviving entity of the merger.&#160;&#160;In January 2014 we increased our authorized shares of common stock to 200 million shares and authorized shares of preferred stock to 50 million shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into us, we merged with Actinium Corporation, and Actinium Corporation ceased to exist. As a result of the merger, Actinium Corporation stock owned by us has been cancelled and each share of Actinium Corporation not owned by us was exchanged for 0.333 shares of our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;Actinium&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at MSKCC under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. &#160;Actinium&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 26, 2014, we began trading our common stock on the NYSE MKT market under the symbol ATNM.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Plan of Operation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We develop drugs for treatment of cancer with intent to cure or significantly improve survival of the affected patients. As of now none of our drugs have been approved for sale in the United States or elsewhere. We have no commercial operations in sales or marketing of our products. All our product candidates are under development. In order to market and sell our products we must conduct clinical trials on patients and obtain regulatory approvals from appropriate regulatory agencies like the Food and Drug Administration (FDA) in the United States and similar agencies elsewhere in the world.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our products under development are monoclonal antibodies labeled with radioisotopes. We have one program with an antibody labeled with a beta emitter and several programs based on a proprietary patent protected platform technology called alpha particle immunotherapy or APIT. Our APIT technology is based on attaching actinium 225 (Ac-225) or bismuth 213 (Bi-213) alpha emitting radioisotopes to monoclonal antibodies. Alpha emitting radioisotopes are unstable chemical elements that decay by releasing alpha particles. Alpha particles can kill any cell in whose immediate proximity they are released. Monoclonal antibodies are genetically engineered proteins that target specifically certain cells, and can target cancer cells. It is crucial for the success of our drug candidates to contain monoclonal antibodies that can successfully seek cancer cells and can kill them with the attached isotope while not harming nearby normal cells. We do not have technology and operational capabilities to develop and manufacture such monoclonal antibodies and we therefore rely on collaboration with third parties to gain access to such monoclonal antibodies. We have secured rights to two monoclonal antibodies, HuM195 (Lintuzumab), in 2003 through a collaborative licensing agreement with Abbott Laboratories and BC8 in 2012 with the Fred Hutchinson Cancer Research Center. We expect to negotiate collaborative agreements with other potential partners that would provide us with access to additional monoclonal antibodies. Establishing and maintaining such collaborative agreements is a key to our success as a company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under our own sponsorship as well as activity at FHCRC, we have four product candidates in active clinical trials: Actimab&#8482;-A (HuM195-Ac-225), Iomab&#8482;-B (BC8-I-131), BC8-Y-90 and BC8-SA. At this time, the Company is actively pursuing development of Actimab&#8482;-A and Iomab&#8482;-B while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center. Actimab&#8482;-A is a combination of the monoclonal antibody we have in-licensed, Lintuzumab (HuM195), and the alpha emitting isotope actinium 225. Actimab&#8482;-A has shown promising results throughout preclinical development and an ongoing clinical trial started in 2006 in treating acute myeloid leukemia (AML) in the elderly. We have expanded the number of patients and number of clinical centers by commencing a new AML clinical trial which we have launched in 2012. This trial targets newly diagnosed AML patients over the age of 60. In order to conduct the trial we are engaged in funding, monitoring and quality assurance and control of the Lintuzumab antibody; procurement of actinium 225 isotope; funding, monitoring and quality assurance and control of the drug candidate Actimab&#8482;-A manufacturing and organizing and monitoring clinical trials. We estimate that the direct costs to completion of both parts of the ongoing Phase I/II trial will be approximately US $7 million. Iomab&#8482;-B is a combination of the in-licensed monoclonal antibody BC8 and the beta emitting radioisotope iodine 131. This construct has been extensively tested in Phase I and Phase II clinical trials in approximately 250 patients with different blood cancer indications who were in need of a hematopoietic stem cell transplantation (HSCT). Iomab&#8482;-B is used to condition the bone marrow of these patients by destroying blood cancer cells in their bone marrow and elsewhere thus allowing for a subsequent transplant containing healthy donor bone marrow stem cells. We have decided to develop this drug candidate by initially focusing on the patients over 50 with active acute myeloid leukemia in relapse and/or refractory to existing treatments. Our intention is to request the FDA to allow us to enter into a pivotal trial with Iomab&#8482;-B. We estimate the direct costs of such a trial to completion anticipated in 2015 will be approximately US $15-20 million.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have primarily management position employees and consultants who direct, organize and monitor the activities described above through contractors. Much of the<font style="FONT-STYLE: italic; DISPLAY: inline"> in vivo</font> laboratory and clinical work contracted for by the Company has been conducted at Memorial Sloan-Kettering Cancer Center in New York. We also made clinical trial arrangements with other well-known cancer centers. Our Actimab&#8482;-A drug candidate and its components are contract manufactured and maintained under our supervision by specialized contract manufacturers and suppliers in the U.S., including IsoTex Diagnostics, Oak Ridge National Laboratory, Pacific GMP, Fischer Bioservices, BioReliance and others.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are a development stage company and have never generated revenue. Currently we do not have a stable recurring source of revenues sufficient to cover our operating costs. As of March 31, 2014, we had an accumulated deficit of $83.2 million. We incurred net losses of $16.7 million and $0.7 million for the three months ended March 31, 2014 and 2013, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Opportunities, Challenges and Risks</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The market for drugs for cancer treatment is a large market in need of novel products, in which successful products can command multibillion dollars in annual sales. A number of large pharmaceutical and biotechnology company regularly acquire products in development, with preference given to products in Phase II or later clinical trials. These deals are typically structured to include an upfront payment that ranges from several million dollars to tens of million dollars or more and additional milestone payments tied to regulatory submissions and approvals and sales milestones. Our goal is to develop our product candidates through Phase II clinical trials and enter into partnership agreements with one or more large pharmaceutical and/or biotechnology companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe our future success will be heavily dependent upon our ability to successfully conduct clinical trials and preclinical development of our drug candidates. This will in turn depend on our ability to continue our collaboration with Memorial Sloan-Kettering Cancer Center and our Clinical Advisory Board members plan to continue and expand other research and clinical trial collaborations. In addition, we will have to maintain sufficient supply of actinium 225 and successfully maintain and if and when needed replenish or obtain our reserves of monoclonal antibodies. We will have to maintain and improve manufacturing procedures we have developed for production of our drug candidates from the components that include the iodine 131 and actinium 225 isotopes, monoclonal antibodies and other materials. It is possible that despite our best efforts our clinical trials results may not meet regulatory requirements for approval. If our efforts are successful, we will be able to partner our development stage products on commercially favorable terms only if they enjoy appropriate patent coverage and/or considerable know-how and other protection that ensures market exclusivity. For that reason we intend to continue our efforts to maintain existing and generate new intellectual property. Intellectual property is a key factor in the success of our business as well as market exclusivity.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To achieve the goals discussed above we intend to continue to invest in research and development at high and constantly increasing rates thus incurring further losses until one or more of our products are sufficiently developed to partner them to large pharmaceutical and biotechnology companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations &#8211; Three Months Ended March 31, 2014 Compared to the Three Months Ended March&#160;31, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth, for the periods indicated, data derived from our statements of operations:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development, net of reimbursements</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,460,968</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,085,707</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,676,053</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">933,135</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation and amortization</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,405</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,138,426</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,022,964</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other (income) expense:</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss (gain) on change in fair value of derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,561,071</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,334,512 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total other (income) expense</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,561,071</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,333,937</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,699,497</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(689,027</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenues</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recorded no commercial revenues for the three months ended March 31, 2014 and 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Expense</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expenses increased by approximately $1.4 million to approximately $2.5 million for the three months ended March 31, 2014 compared to approximately $1.1 million for the three months ended March 31, 2013. The increase is primarily attributable to the costs related to continuing the multi-center clinical trial for Actimab&#8482;-A which commenced in the third quarter of 2012 and the manufacturing of BC8, the antibody that is the key component of Iomab-B in-licensed by the Company in 2012. The increased expenses also reflect development work on significantly improving the efficacy and cost structure of the Actimab&#8482;-A manufacturing and costs related to Iomab-B&#8217;s clinical development and regulatory submissions. We expect to incur increased research and development costs in the future.</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General and Administrative Expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Overall, total general and administrative expenses increased by approximately $0.8 million to $1.7 million for the three months ended March 31, 2014 compared to approximately $0.9 million for the three months ended March 31, 2013. The increase was largely attributable to increases in professional fees, staffing,&#160;and the stock-based compensation incurred by the Company as discussed below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The increase of professional fees was mainly associated with the Company listing our common stock on the NYSE MKT. In addition to the professional fees incurred, we increased our personnel. As such, payroll-related expenses for the three months ended March 31, 2014 increased compared to the same period in 2013. We expect to incur increased general and administrative costs in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other (Income) Expense</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other expense was $12.6 million for the three months ended March 31, 2014 compared to other income of $1.3 million for the three months ended March 31, 2013. The Company recorded a loss on the change in fair value of the Company&#8217;s embedded derivative liability in the approximate amount $12.6 million during the three months ended March 31, 2014 as compared to&#160;a gain of approximately $1.3 million during the comparable three-month period ended March 31, 2013. The change is mainly attributable to the fluctuation of the Company&#8217;s stock price.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Loss</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net loss increased by approximately $16.0 million to approximately $16.7 million for the three months ended March 31, 2014 compared to approximately $0.7 million for the three months ended March 31, 2013. The increase was primarily due to an increase in the loss from change in fair value of the derivative liability, in conjunction with additional costs incurred by the Company in research and development expenses, non-cash stock-based compensation costs and professional fees as discussed above.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have financed our operations primarily through sales of the Company&#8217;s stock and the issuance of convertible promissory notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We did not have any cash or cash equivalents held in financial institutions located outside of the United States as of March 31, 2014 and December 31, 2013. We do not anticipate this practice will change in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following tables sets forth selected cash flow information for the periods indicated:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash provided by (used in) operating activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,490,948</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,312,338</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash provided by (used in) investing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,699 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,112 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash provided by (used in) financing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,837,062</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(65,333 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net&#160;change in cash</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">344,415</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,378,783</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash used in operating activities was approximately $2.5 million for the three months ended March 31, 2014 compared to approximately $2.3 million used in operations for the same period in 2013. Cash used in operations increased due to the increase in spending related to preparations and eventual launch and conduct of a multicenter clinical trial and an increase in spending related to professional fees combined with an increase in payroll-related expenses.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash provided by (used in) financing activities were approximately $2.8 million and approximately ($65,000) for the three months ended March 31, 2014 and 2013, respectively. During the three months ended March 31, 2014, the Company issued common stock and received net proceeds of approximately $2.9 million.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have experienced cumulative losses of approximately $83.2 million from inception (June 13, 2000) through March 31, 2014, and have stockholders' deficit of $13.5 million at March 31, 2014. We intend to fund our operations from a combination of equity and/or debt financing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 7.7pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Equity Offerings</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2013, we completed the sale of units pursuant the Unit Purchase Agreement, dated December 27, 2013 (the &#8220;December Purchase Agreement&#8221;), and Subscription Agreement, dated December 27, 2013 (the &#8220;December Subscription Agreement&#8221;), among the Company and certain accredited investors. The securities sold in the offering consisted of an aggregate of (i) 554,310 shares of its common stock, and (ii) warrants to purchase 138,577 shares of its Common Stock at an in exercise price of $9.00 per share, subject to adjustment (&#8220;2013 Common Stock Offering&#8221;). The warrants are exercisable for a period of five years from the date of issuance. The Company received gross proceeds of approximately $3.3 million from the sale of securities under the Purchase Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 10, 2014,&#160;we conducted the final closing (the &#8220;Final Closing&#8221;) of its private placement of securities (the &#8220;Offering&#8221;) pursuant to a Unit Purchase Agreement, dated as of January 10, 2014 (the &#8220;January Purchase Agreement&#8221;) and Subscription Agreement, dated as of January 10, 2014 (the &#8220;January Subscription Agreement&#8221;), with certain accredited investors named therein (the &#8220;Investors&#8221;)&#160;&#160;pursuant to which: the Investors at the Final Closing agreed to purchase (i) an aggregate of 551,810 shares ( the &#8220;Shares&#8221;) of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 137,952 shares of common stock at an exercise price of $9.00 per share (the &#8220;Warrants&#8221;).&#160;&#160;We received $3,310,860&#160;in gross proceeds from the sale of securities under the January Purchase Agreement at the Final Closing, bringing the total gross proceeds received by the Company in the Offering to $6,636,720. &#160;The aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March&#160;24, 2014, we filed a shelf registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) and deemed effective on April 17, 2014.&#160;&#160;This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the &#8220;Sales Agreement&#8221;) with MLV &amp; Co. LLC (&#8220;MLV&#8221;).&#160;&#160;To date 500 shares have been sold under the Sales Agreement with MLV.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sales of the our common stock through MLV, if any, will be made on the NYSE MKT LLC, on any other existing trading market for the common stock or to or through a market maker. Subject to the terms and conditions of the Sales Agreement, MLV will use commercially reasonable efforts to sell our common stock from time to time, based upon our instructions (including any price, time or size limits or other customary parameters or conditions we may impose). We will pay to MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock.&#160;&#160;We have also provided MLV with customary indemnification rights.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Off-Balance Sheet Arrangements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Seasonality</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not have a seasonal business cycle. Our revenues and operating results are generally derived evenly throughout the calendar year.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States. To prepare these consolidated&#160;financial statements, we must make estimates and assumptions that affect the reported amounts of assets and liabilities. These estimates also affect our expenses. Judgments must also be made about the disclosure of contingent liabilities. Actual results could be significantly different from these estimates. We believe that the following discussion addresses the accounting policies that are necessary to understand and evaluate our reported financial results.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Derivatives</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All derivatives are recorded at fair value and recorded on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value of Financial Instruments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160; Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160; Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160; Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Taxes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Costs</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 7.7pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Share-Based Payments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Accounting Pronouncements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There were various accounting standards and interpretations issued during 2014 and 2013, none of which are expected to have a material impact on the Company&#8217;s financial position, operations or cash flows.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<a name="item_1_3_3"><!--EFPlaceholder--></a><a name="item_1_3_11"><!--EFPlaceholder--></a><a name="ITEM7A"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item3">ITEM 3. &#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not required by smaller reporting companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_4"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item4">ITEM 4. &#160;CONTROLS AND PROCEDURES.</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Evaluation of Disclosure Controls and Procedures.</font> &#160;We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8216;&#8216;Exchange Act&#8217;&#8217;). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based upon our evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are not effective, as of March 31, 2014, in ensuring that material information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms. The ineffective was due to the material weaknesses described in Management&#8217;s Report on Internal Control over Financial Reporting as reported in our Form 10-K for the year ended December 31, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Changes in Internal Control over Financial Reporting</font>. &#160;There were no changes in our system of internal controls over financial reporting during the period covered by this report that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;<a name="part_1_2_3"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="part2">PART II &#8211; OTHER INFORMATION</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_5"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item1a">ITEM 1A. &#160;RISK FACTORS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not Applicable to a smaller reporting company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_6"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item22">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_7"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item33">ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_8"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item44">ITEM 4. MINE SAFETY DISCLOSURES</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not applicable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_9"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item55">ITEM 5. OTHER INFORMATION.</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_10"><!--EFPlaceholder--></a>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Item 1.01.&#160;&#160;Entry into a Material Definitive Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective May 12, 2014, <font style="DISPLAY: inline; FONT-SIZE: 10pt">the Company entered into a sublease agreement with Corporate Technologies, Inc. for office space located at 379 Thornall Street, Edison, NJ. The monthly rent for the first year of the lease is $8,683.33 per month and the rent thereafter is $9,334.59 per month until the end of the term.&#160;&#160;This agreement terminates on September 30, 2016. The Company issued a security deposit of approximately $35,000 to the existing tenant.</font></font><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item66">ITEM 6. EXHIBITS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit No.</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="75%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Title of Document</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Location</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%" style="TEXT-ALIGN: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.1</font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sublease Agreement, effective May 12, 2014, by and between Actinium Pharmaceuticals, In. and Corporate Technologies, Inc.</font></font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.4pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.INS</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Instance Document</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.SCH</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Schema Document</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">&#160;</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.CAL</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Calculation Linkbase Document</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.DEF</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.LAB</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Label Linkbase Document</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.PRE</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Presentation Linkbase Document</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* The Exhibit attached to this Form 10-Q shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<a name="part_1_2_4"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="isig">SIGNATURES</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>
</td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: May 12, 2014</font></font></div>
</div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;Kaushik J. Dave</font></div>
</td>
<td align="left" valign="top" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik J. Dave</font></div>
</td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and Chief Executive Officer,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and Interim Chief Financial Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Duly Authorized Officer, Principal</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Executive Officer and Principal Financial and Accounting Officer)</font></div>
</div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center">27&#160;

<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>f10q0314ex10i_actinium.htm
<DESCRIPTION>SUBLEASE AGREEMENT
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Edgar Efile Solutions Pvt Ltd.-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold">Exhibit 10.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">SUBLEASE AGREEMENT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">THIS SUBLEASE AGREEMENT (the "Sublease") is made and entered into this day of <font style="DISPLAY: inline; FONT-SIZE: 12pt">______, </font>2014 (the "Effective Date") by and between CORPORATE TECHNOLOGIES, INC., a Massachusetts corporation with a principal place of business at Three Burlington Woods, Burlington, Massachusetts 01801 ("Tenant"), and ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation with a principal place of business at 501 Fifth Avenue, New York, NY 10017 ("Subtenant").</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">WHEREAS, pursuant to a certain Lease Agreement dated June 26, 2010 attached hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font> (the "Prime Lease") by and between METRO FOUR ASSOCIATES, L.P. ("Landlord") and Tenant, Tenant has leased certain premises located at 379 Thomall Street, Edison, New Jersey (the "Building"), containing approximately 5,210 rentable square feet, all as more fully described in the Prime Lease (the "Premises"); and Subtenant desires to sublet all of the Premises from Tenant in accordance with the terms and provisions hereinafter set forth;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOW, THEREFORE, in consideration of the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">PREMISES.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Tenant for, and in consideration of the covenants hereinafter contained and made on the part of the Subtenant, does hereby sublet to Subtenant the Premises.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; For a period of two (2) weeks immediately prior to the Commencement Date, Subtenant may access the Premises on after the Effective Date, solely for purposes of installing Subtenant's furniture, fixtures and equipment; provided, that, (i) except only for the payment of Base Rent or Additional Rent specified below, Subtenant complies with all terms, conditions and provisions of this Sublease, including, without limitation, Tenant's obligations under Section 8 below, and (ii) Subtenant shall not conduct any business operations of any kind or nature in the Premises until the Commencement Date. For purposes hereof, Additional Rent shall include any amounts due from Subtenant to Tenant, other than Base Rent, under the terms of this Sublease or the Prime Lease, but expressly excluding Tenant's obligations under the Prime Lease to pay its proportionate share of Landlord's real estate taxes and operating costs which shall be the sole and exclusive responsibility of Tenant. For the avoidance of doubt, Subtenant shall not be responsible in any Operational Year (as defined in the Prime Lease) for any of Tenant's Projected Share of Increase (as defined in the Prime Lease).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Simultaneously with the execution of this Sublease, Subtenant shall purchase from Tenant, and Tenant shall sell to Subtenant, "AS IS, WHERE IS." the furniture, equipment and copiers (excluding IT and Lab equipment) belonging to Tenant and located in the Premises, all as more fully identified in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit B</font> attached hereto. Simultaneously with the execution of this Sublease, Subtenant shall deliver a payment of $5,000.00 to Tenant for such furniture, <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">equipment and copiers, and Tenant shall execute and deliver to Subtenant a Bill of Sale substantially in the form of <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit C</font> attached hereto.</font></font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-1-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subtenant shall have the right to install any signage as expressly permitted under </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the terms and conditions of the Prime Lease, subject, however, to Landlord's prior written consent and approval. Subtenant shall have access to the Premises 7 days per week, 24 hours per day, subject; however, to any limitations, restrictions or other changes set forth in the Prime Lease. All HVAC services, janitorial services and rights to parking and use of common areas shall be as specified in the Prime Lease.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">TERM OF SUBLEASE.</font> Unless sooner terminated as hereinafter provided, the</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">term of this Sublease shall commence on May 1, 2014 (the "Commencement Date") and end on September 30, 2016. Subtenant shall not have any right of first refusal on any additional space in the Building, any right to expand the size of the Premises or any right to extend the term of the Prime Lease (or this Sublease) even if Tenant has any such rights under the Prime Lease.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">INCORPORATION OF BASIC LEASE.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Sublease is expressly made subject to all of the terms, conditions, and limitations contained in the Prime Lease between Tenant and Landlord, a copy of which is attached hereto and incorporated herein as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A,</font> and any and all amendments thereto, now existing, or hereinafter entered into by Tenant and Landlord. Each of the terms, conditions, and obligations of Tenant pursuant to the Prime Lease shall be deemed a term, condition, and obligation to be performed by Subtenant hereunder with respect to the Premises as if the same were fully set forth herein and Tenant shall be entitled to enforce any and all of such terms, conditions, and obligations hereunder. Subtenant shall perform and observe the terms and conditions to be performed on the part of the Tenant with respect to the Premises and Subtenant's use and occupancy thereof, under all of the terms and provisions of the Prime Lease, except only as to the payment of Base Rent and Tenant's obligations to pay its proportionate share of real estate taxes and operating costs. Subtenant shall indemnify Tenant against any and all claims, damages, costs, expenses, or liabilities of any nature whatsoever in respect of the non-&#173;performance or non-observance of any such terms or conditions by Subtenant. This Sublease and all of the terms, provisions, and covenants herein contained, shall at all times be subject and subordinate to such Prime Lease whereby Tenant holds the Premises, and Subtenant covenants that it will not do or permit to be done on or with respect to the Premises any act or any thing whatsoever which may be in violation of any of the terms or conditions of the Prime Lease; and Subtenant further covenants and agrees that, upon termination of the Prime Lease for any reason whatsoever, other than the voluntary unilateral act of Tenant, this Sublease and all obligations hereunder not then accrued shall, at Tenant's option, cease and determine.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Tenant agrees to perform and observe the terms and conditions to be performed on the part of the Tenant under the Prime Lease with respect to the Premises occupied by Tenant.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-2-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">BASE RENT.</font> Subtenant agrees to pay to Tenant base rent ("Base Rent"), </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">payable in monthly installments according to the following schedule:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; May 1, 2014 through April 30, 2015 - $104,200.00 per annum, payable in equal </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">monthly installments of $8,683.33 each</font></div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; May 1, 2015 through September 30, 2016 - $112,015.00 per annum, payable in </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">equal monthly installments of $9,334.58 each;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each monthly installment of Base Rent shall be payable in advance on the first (1st) day of each and every month at the address of the Tenant set forth above or to such other address as Tenant may designate in writing from time to time. If any installment of Base Rent, payment of Additional Rent or any other sum due hereunder shall not be paid on or before the date the same is due, the same shall bear interest from the due date at a rate equal to the lesser of (i) the Prime Rate, as defined in the Lease, plus three percent (3%) or (ii) the maximum legally permissible rate, the payment of which shall constitute Additional Rent hereunder.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Notwithstanding the foregoing, provided that Subtenant is not default of any of its obligations under this Sublease, the first monthly installment of rent for the month of May, 2014 shall be abated, and Subtenant shall not be required to pay the same; provided; however, that if this Sublease is terminated by Tenant at any time as the result of Subtenant's default, such monthly of installment of rent shall be immediately paid by Subtenant to Tenant, in addition to, and not in lieu of, and all other damages which Tenant shall be entitled to recover as a result of Subtenant's default.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">SECURITY DEPOSIT.</font> Upon the execution of this Sublease, the Subtenant shall </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">deliver to Tenant a Letter of Credit in the amount of $34,733.32, issued by a bank, and in form and substance, all satisfactory to Tenant. During the Term hereof, and for not more than 60 days after the expiration of the Term, or for so long thereafter as Subtenant is in possession of the Premises or has unsatisfied obligations hereunder to Tenant, the Letter of Credit shall be security for the full and timely performance of Subtenant's obligations under this Sublease; which Letter of Credit may be drawn upon by Tenant and applied from time to time against outstanding obligations of Subtenant hereunder without notice or demand. Subtenant shall have no right to require Tenant to so apply the Letter of Credit, nor shall Subtenant be entitled to credit the same against rents or other sums payable hereunder. During the entire Term hereof, Subtenant shall cause said Letter of Credit to be renewed, if necessary in substantially the same form, no later than 30 days prior to the date of expiration of same. Without limiting any other remedies of Tenant, in the event that Subtenant fails to renew any Letter of Credit given hereunder at least 15 days prior to the date of expiration thereof, then Tenant shall have the right to draw down the entire amount of said Letter of Credit and hold such sums as a cash deposit. If and to the extent that Tenant makes such use of the Letter of Credit, or any part thereof, the sum so applied by Tenant (from cash or from a drawing on the Letter of Credit) shall be restored to the Letter of Credit by Subtenant upon notice from Tenant, and failure to restore same (within the grace period applicable to Base Rent hereunder) shall be a default hereunder giving rise to all of Tenant's rights and remedies applicable to a default in the payment of rent. In the event of a change of circumstance relating to the bank issuing the Letter of Credit, or Tenant otherwise reasonably believes the financial conditions of the issuing bank has been degraded, Tenant reserves the right to require Subtenant to replace the Letter of Credit from time to time with a substitute similar letter of credit issued by another bank satisfactory to Tenant.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-3-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">TENANT ELECTRIC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subtenant, throughout the Term of this Sublease, shall be responsible for and pay</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">all charges for electricity supplied by Landlord for the Premises and the Building of which they are a part in accordance with the terms and provisions of Article 15 of the Prime Lease. All payments required to be made by Tenant under Article 15 of the Prime Lease shall be paid promptly by Subtenant to Tenant, and in any event at least five (5) days before such payments are due from the Tenant to the Landlord under the Prime Lease. Upon execution of this Sublease, Subtenant shall, without cost to Tenant, take such action as shall be necessary to insure that all other utilities, such as phone, internet and the like, are billed by any providers directly to Subtenant. If the provider of any such service refuses to bill Subtenant directly for such services, then Subtenant hereby agrees to pay any such charges within twenty (20) days of its receipt of written notice from Tenant that such charges are due and payable together with copies of any bills or statements for the same, and shall provide Tenant with appropriate receipts evidencing payment, or reasonably satisfactory proof of the same, within twenty (20) after Tenant's notice. Tenant shall have no responsibility to Subtenant for the quality or availability of utilities or services to the Premises or to the Building and improvements located therein, including, but not limited to, electricity, gas, energy, telephone, garbage and trash removal and disposal, sewage or effluent removal or disposal, water, and other utilities or service. Tenant shall in no event be responsible for any interruption of utilities or equipment failure, and in the event of any such utility interruption, the Base Rent and/or Additional Rent provided for herein shall not abate or terminate in any way during the period of said interruption.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="TEXT-DECORATION: underline">USE.</font> Subtenant shall be entitled to use the Premises only for the purposes specified and permitted under the Prime Lease, and for no other purpose. Subtenant acknowledges and agrees that no trade or occupation shall be conducted in the Premises or use made thereof which would be unlawful, improper, noisy, or offensive or which will interfere with the Tenant's use and enjoyment of the Premises.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">INSURANCE.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subtenant shall, with respect to the Premises, procure and maintain throughout the term of this Sublease all insurance required to be maintained by Tenant under the Prime Lease, and all such insurance shall specifically name Landlord and its mortgagees and Tenant, and all other persons required by the Prime Lease, as additional insureds. Subtenant shall furnish to Landlord and Tenant certificates of all such insurance prior to the beginning of the term of this Sublease and each renewal policy, at least thirty (30) days prior to the expiration of the policy it renews. All insurance procured by Subtenant hereunder shall conform to all of the requirements set forth in the Prime Lease.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-4-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Tenant and Subtenant each hereby releases the other from any liability for any loss or damage to their respective portion of the Premises occupied by the said party or for injury to or death of persons occurring on or about their respective portions of the Premises or in any manner growing out of connected with their use and occupation of their respective portions of </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the Premises or the condition thereof, whether or not caused by the negligence or fault of the Tenant, the Subtenant or their respective agents, employees, licensees, invitees or assignees; provided, however, that this release (i) shall apply notwithstanding the indemnities set forth in paragraph 11 below, but only to the extent that such loss or damage or injury to or death of persons is covered (or required by this Sublease to be covered) by insurance which protects the Tenant or Subtenant or both of them as the case may be; (ii) shall not be construed to impose any other or greater liability upon either the Tenant or Subtenant than would have existed in the absence hereof; and (iii) shall be in effect only to the extent and so long as the applicable insurance policies provide that this release shall not affect the right of the insureds to recover under such policies, which clauses shall be obtained by the parties hereto whenever available. Each party shall be solely responsible for the deductibles and retentions concerning their own insurance policies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">LESSEE'S RESPONSIBILITY.</font> Except as expressly otherwise provided herein, it </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">is the intention of the parties that all Base Rent and Additional Rent payable hereunder shall be net to Tenant, such that this Sublease shall yield to Tenant at least the Base Rent and Additional Rent specified herein during the term of this Sublease. Except as expressly provided herein, Tenant shall not be obligated to pay any charge or bear any expense whatsoever against or with respect to the Premises, the rent payable hereunder shall not be subject to any reduction or offset whatsoever on account of any such charge or otherwise, and all costs, expenses and obligations of every kind and nature whatsoever, ordinary or extraordinary or foreseen or unforeseen, relating to the Premises, shall be paid by Subtenant. The obligation of Subtenant to make all payments of Base Rent and any Additional Rent, or other charges due hereunder, shall be absolute and unconditional and shall not, except as otherwise expressly provided herein, be subject to set off, deduction, recoupment or counterclaim.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">ACCEPTANCE OF PREMISES.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subtenant agrees that it is accepting the Premises "as is," and that Tenant </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">has made no representation or warranty with respect to the condition thereof.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subtenant covenants and agrees to perform in the Premises any and all </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">alterations, additions, construction, repairs, partitions and adaptations of the Premises (hereinafter collectively referred to as "Subtenant's Work") which are appropriate to put the Premises in finished condition for Subtenant's business, all in accordance with plans and specifications to be approved in writing by both Landlord and Tenant. All of Subtenant's Work shall be arranged and coordinated with Tenant, and shall be performed by Subtenant, at its sole cost and expense, in accordance with and subject to all of the terms and conditions of the Prime Lease.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; All work to be performed by Tenant as described in this Section 10 shall </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">be performed in a good and workmanlike manner and in accordance with all of the terms and conditions of the Prime Lease and shall be subject to inspection and approval by the Landlord.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-5-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; At the end of the term of this Sublease, Tenant shall be responsible for any </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">removal of improvements as exist on the Premises as of the date of the execution of this Sublease and restoration of the Premises with respect to the same, to the extent required by Article 23 of the Prime Lease; however, any and all restoration obligations with respect to any modifications, improvements or changes to the Premises on or after the date of the execution of this Sublease shall be the responsibility of Subtenant.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">INDEMNIFICATION.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subtenant agrees as follows: except as provided in paragraph 8(C) above </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">with respect to the mutual waiver of subrogation, Subtenant shall indemnify, defend and save Tenant and Landlord and their respective partners, stockholders, members, directors, managers, officers, employees, servants and agents (the "Indemnitees") harmless from and against any and all losses, claims, liability, expenses and damages arising out of or resulting from (i) any work or thing done in, on or about the Premises by or on behalf of Subtenant, its agents, servants, invitees, contractors and employees (ii) any use, occupation, condition, operation of the Premises or any part thereof or of any parking lot, street, alley, sidewalk, curb, vault, passageway or space adjacent thereto or any occurrence on any of the same on the part of Subtenant, (iii) any act or omission on the part of Subtenant or its agents, servants, invitees, contractors and employees,<font style="DISPLAY: inline; FONT-WEIGHT: bold"> (iv) </font>any accident or injury (including death) or damage to any third party or property owned by someone other than Subtenant and not under the care, custody or control of Subtenant occurring in or about the Premises or any part thereof or in or about any parking lot, street, alley, sidewalk, curb, vault, passageway or space adjacent thereto, except to the extent caused by Landlord or Tenant or their agents or employees, (v) any failure on the part of Subtenant to perform or comply with any of the covenants, agreements, terms or conditions contained in this Sublease and the Prime Lease, and (vi) any other matters for which Tenant is obligated to indemnify Landlord under the Prime Lease to the extent caused by any act or omission of Subtenant or its agents, servants, invitees, contractors and employees. In connection herewith, the Subtenant agrees to give the Tenant prompt written notice of any such violation which may be asserted by a governmental agency. Subtenant further agrees to indemnify the Indemnitees from and against all costs, expenses (including reasonable attorney's fees) and other liabilities incurred in connection with any such indemnified claim or action and/or proceeding brought thereon. If Subtenant shall breach this covenant and fail to reimburse any of the Indemnitees for such costs and expenses within fifteen (15) days after written demand, the Tenant may declare a default under this Sublease. The rights and obligations of Tenant and Subtenant under this paragraph 11 shall survive the expiration and/or earlier termination of this Sublease.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; All fixtures, equipment, and other property on or about the Premises, </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">whether the property of Subtenant or anyone claiming under Subtenant, shall be at Subtenant's sole risk and hazard, and if the whole or any part thereof shall be destroyed in any way or manner, no part of said loss or damage is to be charged to or borne by Tenant or Landlord in any case whatsoever. Subtenant agrees to exonerate and indemnify Tenant and Landlord from and against all claims, suits, obligations, liabilities and damages, including reasonable attorneys' fees, based upon or arising out of the foregoing.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-6-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">FIRE, CASUALTY AND EMINENT DOMAIN.</font> If the Premises or any part thereof shall be destroyed or damaged by fire or other casualty or be taken by eminent domain, Landlord has the option of terminating the Prime Lease or rebuilding or repairing the Premises in accordance with the terms and provisions of the Prime Lease. If the Landlord elects to rebuild or repair the Premises, Subtenant shall remain bound by this Sublease, except that during the period of repair, the Base Rent for the Premises shall be abated in the same proportion and only to the same extent that the base rent payable by Tenant pursuant to the Prime Lease shall be abated by Landlord. In the event that, as a result of any fire or any casualty or taking by eminent domain, either Landlord or Tenant shall exercise any option under the Prime Lease to terminate said Prime Lease, this Sublease shall terminate simultaneously with the Prime Lease.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">REQUIREMENT OF LESSOR'S CONSENT.</font> Wherever any consent or approval of Landlord is required under the terms and conditions of the Prime Lease for any action or conduct of Tenant (including, without limitation, any assignment of this Sublease, subletting of the Premises, or installing alterations and improvements), such consent or approval shall likewise be required to be obtained by Subtenant hereunder from both Tenant and Landlord for such action or conduct as if the requirement for such consent and/or approval were fully set forth herein. Subtenant shall reimburse Tenant promptly on demand for all reasonable legal expenses incurred by Tenant and/or Landlord in connection with all requests by Subtenant for consent or approval. Subtenant hereby acknowledges and agrees that certain requests made by Subtenant hereunder or certain events provided for in this Sublease shall be subject to and conditioned upon Tenant obtaining the prior written consent of Landlord pursuant to the Prime Lease; and Subtenant hereby covenants and agrees that Tenant shall not in any manner be held liable or responsible to Subtenant for any failure, refusal or delay by Landlord in granting such written consent in any such instance.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">SUBLESSEE'S DEFAULT.</font> If (i) the Subtenant shall default in the payment of </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">any Base Rent, Additional Rent or other sums payable by Subtenant to Tenant hereunder and such default shall continue for three (3) days after written notice from Tenant of such default without cure; or (ii) the Subtenant shall default in the performance or observance of any of the other covenants contained in this Sublease and on the Subtenant's part to be performed or observed and shall fail, within twenty (20) days after written notice from Tenant of such default to cure such default; or (iii) if the estate hereby created shall be taken on execution, or by other process of law, or if the Subtenant should be involved in financial difficulties as evidenced (a) by its commencement of a voluntary case under Title 11 of the United States Code as from time to time in effect, or by its authorizing, by appropriate proceedings of trustees or other governing body, the commencement of such voluntary case, (b) by its filing an answer or other pleading admitting or failing to deny the material allegations of a petition filed against it commencing an involuntary case under said Title 11 or seeking, consenting to or acquiescing in the relief therein provided, or by its failing to controvert timely the material allegations of any such petition, (c) by the entry of an order of relief in any involuntary case commenced under said Title 11 which is not removed by Subtenant within sixty (60) days after the date of entry, (d) by its seeking relief as a debtor under any applicable law, other than said Title 11, of any jurisdiction relating to the liquidation or reorganization of debtors or to the modification or alteration of the rights of creditors, or by its consent to or acquiescing in such relief, (e) by the entry of an order by a court of competent jurisdiction which is not removed by Subtenant within sixty (60) days after the date </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">of entry (i) finding it to be bankrupt or insolvent, (ii) ordering or approving its liquidation, reorganization or any modification or alteration of the rights of its creditors, or (iii) assuming custody of, or appointing a receiver or other custodian, of all or a substantial part of its properties; or (f) by its making an assignment for the benefit of, or entering into a composition with, its creditors, or appointing or consenting to the appointment of a receiver or other custodian for all or a substantial part of its property; then, and in any of said cases (each of which is herein sometimes called a "Terminable Default"); then Tenant may, immediately or at any time thereafter (notwithstanding any license or waiver of any former breach or waiver of the benefit thereof, or consent in any former instance) and without demand or notice or need to comply with any statute relating to summary process, in person or by agent or attorney, enter the Premises (forcibly if necessary) or any part thereof and repossess the same as of its former estate, or terminate this Sublease by written notice to Subtenant, and in either event expel Subtenant and those claiming through or under it and remove their effects without being deemed guilty of any manner of trespass and without prejudice to any remedy which otherwise might be used for arrears of rent or breach of covenants, and upon entry or notice as aforesaid, this Sublease shall terminate. Subtenant hereby waives all statutory rights (including without limitation rights of redemption) to the extent such rights may be lawfully waived, with respect to such actions by Tenant. If this Sublease is terminated as provided for herein, or otherwise for Subtenant's breach or default, Tenant shall have all rights and remedies provided to the Landlord under the Prime Lease, as if said rights and remedies were fully set forth herein, and Subtenant shall be obligated to pay and all damages, liabilities, and expenses to Tenant as provided for therein.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-7-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTICES.</font> All notices or other communications shall be given by certified, </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">registered or express mail, all such mail to be sent return receipt requested, or by facsimile, or by any reputable overnight delivery service providing proof of delivery. All notices to the parties shall be addressed to the addresses first listed above, or to such other address as they may designate in writing from time to time in the manner provided for herein and if to Tenant, a copy thereof shall be delivered to: Aaron A. Gilman, Esq., Hinckley, Allen &amp; Snyder, LLP, 28 State Street, Boston, Massachusetts 02210.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: normal">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">ENTIRE AGREEMENT AND LESSOR'S CONSENT.</font> This Sublease sets forth the entire agreement between the parties hereto, supersedes all prior dealings, and may not be modified or amended except in writing duly executed by the respective parties. This Sublease is subject to and contingent upon Tenant obtaining Landlord's consent hereto, and the parties hereto acknowledge and agree that this Sublease shall not become effective until Landlord shall have consented to this Sublease.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">PARTIAL INVALIDITY.</font> The invalidity of one or more phrases, sentences, </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">clauses or articles contained in this Sublease shall not affect the remaining portions of this Sublease or any part thereof, and in the event that <font style="FONT-STYLE: italic; DISPLAY: inline">any </font>one (1) or more of such phrases, sentences, clauses or articles should be declared invalid by the final order, decree or judgment of a Court of competent jurisdiction, this Sublease shall be construed as if such invalid phrases, sentences, clauses or articles had not been inserted in this Sublease.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">HOLDOVER.</font> If Subtenant remains on the Premises beyond the expiration of this </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sublease, such holding over shall not be deemed to create any tenancy, but Subtenant shall be a </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">tenant at sufferance only, at a daily rate equal to three (3) times the rent and other charges under this Sublease. However, all conditions of this Sublease to be performed by Subtenant shall continue in full force and effect.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-8-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">WAIVER.</font> No assent, express or implied, by Tenant to any breach of any </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">agreement or condition herein contained on the part of Subtenant to be performed or observed, and no waiver, express or implied, of any such agreement or condition shall be deemed to be a waiver of or assent to any succeeding breach of the same or any other agreement or condition, unless such waiver shall be in writing. No payment by Subtenant or acceptance by Tenant of a lesser amount than shall be from Subtenant shall be deemed to be anything but payment on account, and the acceptance by Tenant of a check for a lesser amount shall not be deemed in accord and satisfaction, and Tenant may accept said check without prejudice to recover the balance due or pursue any other remedy.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">PERSONS AND PROPERTY BOUND.</font> The word "Tenant" shall mean and bind Tenant and its successors and assigns, and the word "Subtenant" shall mean and bind Subtenant and its successors and permitted assigns, or those in any manner claiming through or under Subtenant, in each case where the context so permits. Subtenant hereby agrees for itself and each succeeding holder of its interest, or any portion thereof that Tenant and its successors in interest shall not be liable for the acts or consequences arising from and after transfer of their interest as Tenant hereunder. No individual stockholder, officer, director, or employee of Tenant shall in any manner or under any circumstances be personally liable under this Sublease.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">21.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">AUTHORITY.</font> The individuals executing this Sublease hereby represent that </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">they are empowered and duly authorized to so execute this Sublease on behalf of the parties they represent.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">22.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">RECORDING.</font> Subtenant shall not record this Sublease and any recording of this </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sublease by Subtenant shall constitute a material breach by Subtenant and shall entitle Tenant to immediately terminate this Sublease and exercise all remedies for Subtenant's default hereof.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">23.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">COUNTERPARTS AND HEADNOTES.</font> This Sublease may be executed in two (2) or more identical counterparts, each of which shall be deemed to be an original which may introduced in evidence or used for any purpose. The headnotes throughout this Sublease are for convenience of reference only, and shall in no way be deemed to limit, modify, or add to the interpretation, construction or meaning of any provision of this Sublease.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">24.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">BROKERS.</font> Tenant utilized the services of Cushman &amp; Wakefield (the "Listing </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Broker") and Subtenant utilized the services of Studley (the "Non-Listing Broker") in connection with this Sublease. Tenant and Subtenant each represents to the other that they did not involve any other brokers in procuring this Sublease. Tenant shall be solely responsible for a single commission with respect to this Sublease which shall be shared by the Non-Listing Broker and the Listing Broker per their agreement. Landlord and Tenant agree to forever indemnify, defend and hold the other harmless from and against any commissions, liabilities, losses, costs, damages or expenses (including reasonable attorneys' fees) that may be asserted against or incurred by the </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">indemnified party by any broker other than the Listing Broker and Non-Listing Broker as a result of any misrepresentation by the indemnifying party hereunder.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-9-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">25.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">GOVERNING LAW.</font> This Sublease shall be governed by, and interpreted in </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">accordance with, the laws of the State of New Jersey.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">26.&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">MISCELLANEOUS.</font> Time is of the essence of this Sublease and each of its </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">provisions. Each individual executing this Lease on behalf of each of Tenant and Subtenant represents and warrants that he or she is duly authorized to execute and deliver this Sublease and that the Tenant or Subtenant, as applicable, is a duly organized corporation, limited liability company, association or partnership under the laws of the state of its incorporation or formation, is qualified to do business in the jurisdiction in which the Building is located, is in good standing under the laws of the state of its incorporation or formation and the laws of the jurisdiction in which the Building is located, has the power and authority to enter into this Sublease, and that all corporate or partnership action requisite to authorize Tenant or Subtenant, as applicable, to enter into this Sublease has been duly taken. The submission of this Sublease to Subtenant is not an offer to sublease the Premises, or an agreement by Tenant to reserve the Premises for Subtenant. Tenant shall not be bound to Subtenant until Subtenant has duly executed and delivered an original Sublease to Tenant and Tenant has duly executed and delivered an original Sublease to Subtenant. This Sublease may be executed in any number of counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Any signature to this Sublease transmitted via facsimile (or other electronic means) shall be deemed an original signature and be binding upon the parties hereto. Subtenant represents and warrants to Tenant that neither Subtenant nor any of Subtenant's members, shareholders or other equity owners, is a person or entity with whom U.S. persons or entities are restricted from doing business under regulations of the Office of Foreign Asset Control ("OFAC") of the Department of the Treasury (including those named on OFAC's Specially Designated and Blocked Persons List) or under any statute, executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), or other governmental action.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">IN WITNESS WHEREOF, the parties hereto have caused this Sublease Agreement to be duly executed as a sealed instrument as of the day and year first above written.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="6%">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">TENANT:</font></div>

<div>CORPORATE TECHNOLOGIES, INC.</div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="6%">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SUBTENANT:</font> </font></div>

<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ACTINIUM </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PHARMACEUTICALS, INC.</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></td>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: #000000 2px solid">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></td>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: #000000 2px solid">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="justify" valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
<td align="justify" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
<td align="justify" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-10-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">IN WITNESS WHEREOF, </font>CTI has caused this Bill of Sale to be duly executed as an instrument under seal on the day and year first above set forth.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CORPORATE TECHNOLOGIES, INC.</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">&#160;</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;Harry A. Kasparian</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td align="left" nowrap valign="bottom" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">HARRY A. KASPARIAN</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
<td valign="top" width="32%">CEO and President</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="6%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Acknowledged and Accepted:</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ACTINIUM PHARMACEUTICALS, INC.</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="6%">&#160;</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></td>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">/s/ Kaushik J. Dave</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="top" width="32%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td align="left" valign="top" width="32%">Kaushik J. Dave</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="top" width="32%">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="justify" valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
<td align="justify" valign="top" width="32%">President and CEO</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="justify" valign="top" width="32%">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-11-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">EXHIBIT A TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SUBLEASE AGREEMENT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BY AND BETWEEN</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CORPORATE TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AND</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">PRIME LEASE AGREEMENT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See Attached Lease</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-12-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">EXHIBIT B TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SUBLEASE AGREEMENT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BY AND BETWEEN</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CORPORATE TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AND</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">LIST OF EQUIPMENT AND FURNISHINGS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See Attached Listing</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-13-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">EXHIBIT C TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SUBLEASE AGREEMENT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BY AND BETWEEN</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CORPORATE TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AND</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">FORM OF BILL OF SALE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See Attached Bill of Sale</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-14-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BILL OF SALE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">BILL OF SALE, </font>dated as of this&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;day of&#160;&#160;<font style="TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>, 2014, from CORPORATE </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">TECHNOLOGIES, INC., a Massachusetts corporation ("CTI") to ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation ("API").</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WITNESSETH:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.8pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In consideration of Five Thousand ($5,000.00) Dollars, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; CTI hereby grants, sells, conveys, assigns, transfers, sets over and delivers to API all of its rights, title and interest in and to the furnishings and equipment (the "Equipment") described in Schedule A attached hereto and incorporated herein, AS IS, WHERE IS, free and clear of all claims, liens, mortgages, pledges, encumbrances, charges and security interests of every kind.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; CTI covenants and agrees that it will execute, deliver and acknowledge (or cause to be executed, acknowledged and delivered) from time to time at the request of API, and without further consideration, all such instruments of conveyance, transfer, assignment and further assurance and perform or cause to be performed all such other acts as may reasonably be required in order to transfer to or further perfect in API title to the Equipment.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Any individual, partnership, corporation or other entity may rely, without further inquiry, upon the powers and rights herein granted to API and upon any notarization, certification, verification, affidavit or jurat by any notary public of any state relating to the authorization, execution and delivery of this Bill of Sale or to the authenticity of any copy, conformed or otherwise, hereof.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This instrument is executed by, and shall be binding upon, CTI and its successors and assigns, and shall inure to the benefit of API and its successors and assigns.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Bill of Sale shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Massachusetts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">[SIGNATURE PAGE TO FOLLOW]</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-15-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.2pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">IN WITNESS WHEREOF, </font>CTI has caused this Bill of Sale to be duly executed as an instrument under seal on the day and year first above set forth.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CORPORATE TECHNOLOGIES, INC.</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">&#160;</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td align="left" nowrap valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
<td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="6%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Acknowledged and Accepted:</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ACTINIUM PHARMACEUTICALS, INC.</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="6%">&#160;</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></td>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="top" width="32%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="top" width="32%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="justify" valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
<td align="justify" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="justify" valign="top" width="32%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-16-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SCHEDULE A</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION OF EQUIPMENT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-17-</font></div>

<div style="TEXT-ALIGN: center">
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>f10q0314ex31i_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
    <title>f10q0314ex31i_actinium.htm</title>
    <!--Licensed to: ef-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 31.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO SECTION 302 OF</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Kaushik J. Dave, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td valign="top" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I have reviewed this Form 10-Q of Actinium Pharmaceuticals, Inc.;</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="58%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td valign="top" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="58%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td valign="top" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="58%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td valign="top" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td valign="top" width="54%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="54%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td valign="top" width="54%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="54%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c)</font></div>
</td>
<td valign="top" width="54%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="54%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d)</font></div>
</td>
<td valign="top" width="54%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Disclosed in this report any change in the registrant&#8217;s internal control over financing reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td valign="top" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td valign="top" width="54%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="54%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td valign="top" width="54%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="bottom" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium Pharmaceutical, Inc.</font></div>
</td>
</tr><tr>
<td colspan="2" valign="middle" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></font></td>
<td align="left" valign="bottom" width="97%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="TEXT-DECORATION: underline">/s/ Kaushik J. Dave&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik J. Dave </font></font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President,&#160;Chief Executive Officer and Interim Chief Financial Officer</font></font></font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Executive Officer and Principal Financial and Accounting Officer)</font></font></font></font></div>
</div>
</div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">May 12, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
&#8232;<br>
<br>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10q0314ex32i_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
    <title>f10q0314ex32i_actinium.htm</title>
    <!--Licensed to: ef-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exhibit 32.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the Quarterly Report of Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended&#160;March 31, 2014&#160;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kaushik J. Dave, President,&#160;Chief Executive Officer&#160;and Interim Chief Financial Officer&#160;of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td valign="top" width="54%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="54%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td valign="top" width="54%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="bottom" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc.</font></div>
</td>
</tr><tr>
<td colspan="2" valign="middle" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></font></div>
</td>
<td align="left" valign="bottom" width="95%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Kaushik J. Dave </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik J. Dave </font></font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President,&#160;Chief Executive Officer and Interim Chief Financial Officer&#160;</font></font></font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Executive Officer and Principal Financial and Accounting Officer)</font></font></font></font></div>
</div>
</div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">May 12, 2014</font></div>

<div>&#160;</div>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>atnm-20140331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 7.0.3.3 [05/13/2014 01:50:29 AM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Tuesday, May 13, 2014 01:52:10 AM -->
<xbrli:xbrl xmlns:atnm="http://actiniumpharmaceuticals.com/20140331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="atnm-20140331.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_As_Of__13-Jun-2000">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2000-06-13
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2000_31-Dec-2000">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-14
</xbrli:startDate>
<xbrli:endDate>
2000-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2001">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2001-01-01
</xbrli:startDate>
<xbrli:endDate>
2001-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2006">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2006-01-01
</xbrli:startDate>
<xbrli:endDate>
2006-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2007">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-01-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Dec-2007_31-Dec-2007_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-12-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2008">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2008-01-01
</xbrli:startDate>
<xbrli:endDate>
2008-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20-May-2011_19-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-20
</xbrli:startDate>
<xbrli:endDate>
2011-06-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__27-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jun-2012_15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-06-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__19-Jul-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_07-Jul-2012_06-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-07
</xbrli:startDate>
<xbrli:endDate>
2012-08-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_08-Jul-2012_07-Aug-2012_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-08
</xbrli:startDate>
<xbrli:endDate>
2012-08-07
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-08-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Aug-2012_28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-08-01
</xbrli:startDate>
<xbrli:endDate>
2012-08-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Aug-2012_31-Aug-2012_AgreementAxis_RentalAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:RentalAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-08-01
</xbrli:startDate>
<xbrli:endDate>
2012-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-26
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Sep-2012_26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-09-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-26
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Oct-2012_22-Oct-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-10-01
</xbrli:startDate>
<xbrli:endDate>
2012-10-22
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__21-Nov-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-11-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Nov-2012_21-Nov-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-11-01
</xbrli:startDate>
<xbrli:endDate>
2012-11-21
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Dec-2012_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25-Dec-2012_28-Dec-2012_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-25
</xbrli:startDate>
<xbrli:endDate>
2012-12-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2013_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atnm:OptionsAndWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2013_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2013_StatementClassOfStockAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2013_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-May-2013_16-May-2013_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-05-01
</xbrli:startDate>
<xbrli:endDate>
2013-05-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Jul-2013_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_03-Sep-2013_04-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-03
</xbrli:startDate>
<xbrli:endDate>
2013-09-04
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__25-Sep-2013_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Sep-2013_25-Sep-2013_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-25
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Dec-2013_09-Dec-2013_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-09
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Dec-2013_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2013_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2013_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2013_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2013_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2013_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2013_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2013_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2013_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2013_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25-Jan-2014_27-Jan-2014_AgreementAxis_ManufacturingAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ManufacturingAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-25
</xbrli:startDate>
<xbrli:endDate>
2014-01-27
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Jan-2014_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Jan-2014_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Jan-2014_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:LaidlawAndCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jan-2014_31-Jan-2014_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:LaidlawAndCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jan-2014_31-Jan-2014_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20-Mar-2014_24-Mar-2014">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-03-20
</xbrli:startDate>
<xbrli:endDate>
2014-03-24
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_AgreementAxis_RentalAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:RentalAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atnm:OptionsAndWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_StatementClassOfStockAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_AgreementAxis_ManufacturingAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ManufacturingAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:PhaseSecondClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:PhaseThirdClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:BiologicalLicenseApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:FirstCommercialSaleMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:AfterFirstNetSalesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:PhaseFirstClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:NewDrugApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:ReceiptOfRegulatoryApprovalFromUSFdaMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:AfterFirstNetSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndThirteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:PeriodAxis">atnm:TwoThousandAndThirteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndFourteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:PeriodAxis">atnm:TwoThousandAndFourteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_DerivativeByNatureAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_PlanNameAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_TitleOfIndividualAxis_InvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__31-Mar-2014_TitleOfIndividualAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_StatementClassOfStockAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Mar-2014_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2000_31-Mar-2014">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-14
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_09-Feb-2014_28-Apr-2014_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-02-09
</xbrli:startDate>
<xbrli:endDate>
2014-04-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_05-Apr-2014_30-Apr-2014_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-05
</xbrli:startDate>
<xbrli:endDate>
2014-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_05-Apr-2014_30-Apr-2014_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-05
</xbrli:startDate>
<xbrli:endDate>
2014-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_05-Apr-2014_30-Apr-2014_SubsequentEventTypeAxis_SubsequentEventMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-05
</xbrli:startDate>
<xbrli:endDate>
2014-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__09-May-2014">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-05-09
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__12-May-2014_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-05-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02-May-2014_12-May-2014_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-05-02
</xbrli:startDate>
<xbrli:endDate>
2014-05-12
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw65c444c555cT{h>5;III4==1IF7=18I=E1=4FE1J456J;74=4J4 -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="pures"><xbrli:measure>atnm:pures</xbrli:measure></xbrli:unit>
<xbrli:unit id="patients"><xbrli:measure>atnm:patients</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Warrant"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>atnm:Warrant</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_3ME__31-Mar-2014">Actinium Pharmaceuticals, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_3ME__31-Mar-2014">0001388320</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_3ME__31-Mar-2014">false</dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="Context_3ME__31-Mar-2014">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="Context_3ME__31-Mar-2014">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_3ME__31-Mar-2014">2014-03-31</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="Context_3ME__31-Mar-2014">2014</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_3ME__31-Mar-2014">Q1</dei:DocumentFiscalPeriodFocus>
<dei:EntityFilerCategory contextRef="Context_3ME__31-Mar-2014">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of__09-May-2014" unitRef="shares" decimals="INF">25562846</dei:EntityCommonStockSharesOutstanding>
<us-gaap:Cash contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">5533366</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">5877781</us-gaap:Cash>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">218389</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">667911</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">5751755</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">6545692</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">13920</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">14214</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">5765675</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">6559906</us-gaap:Assets>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">81185</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">189537</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">157825</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">94481</us-gaap:NotesPayableCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">19128761</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">7325220</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">20028051</us-gaap:LiabilitiesCurrent>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">24565</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">25562</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">64933145</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">69723045</us-gaap:AdditionalPaidInCapital>
<us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">66517255</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
<us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">83216752</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">-1559545</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">-13468145</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">5765675</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">6559906</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of__31-Dec-2013" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of__31-Mar-2014" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of__31-Dec-2013" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of__31-Mar-2014" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of__31-Dec-2013" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of__31-Mar-2014" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of__31-Dec-2013" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of__31-Mar-2014" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of__28-Dec-2012_LegalEntityAxis_ActiniumMember" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of__31-Dec-2013" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of__31-Mar-2014" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of__31-Dec-2013" unitRef="shares" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of__31-Mar-2014" unitRef="shares" decimals="0">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of__31-Dec-2013" unitRef="shares" decimals="INF">24565447</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of__31-Mar-2014" unitRef="shares" decimals="INF">25562346</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of__31-Mar-2014_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">253330</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of__31-Dec-2013" unitRef="shares" decimals="INF">24565447</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of__31-Mar-2014" unitRef="shares" decimals="INF">25562346</us-gaap:CommonStockSharesOutstanding>
<us-gaap:SalesRevenueNet contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">1085707</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME__31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">37500</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">2460968</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">37500</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">31548346</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">933135</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">1676053</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">30100379</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationAndAmortization contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DepreciationAndAmortization contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">1405</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">3265427</us-gaap:DepreciationAndAmortization>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">-4122</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">-554308</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:OperatingExpenses contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">2022964</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">4138426</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">65468460</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">-2022964</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">-4138426</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">-65468460</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestExpense contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">575</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestExpense contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">1967215</us-gaap:InterestExpense>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">260000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">1334512</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">-12561071</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">-16041077</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">1333937</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">-12561071</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">-17748292</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">-689027</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">-16699497</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">-83216752</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME__31-Mar-2013" unitRef="USD_per_Share" decimals="2">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME__31-Mar-2014" unitRef="USD_per_Share" decimals="2">-0.66</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME__31-Mar-2013" unitRef="shares" decimals="INF">21391665</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME__31-Mar-2014" unitRef="shares" decimals="INF">25228299</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="shares" xsi:nil="true"/>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">94200</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">1750926</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">8460774</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">1405</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">3265427</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">900000</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">292692</us-gaap:AmortizationOfFinancingCosts>
<atnm:GainOnChangeInFairValueOfDerivatives contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">1334512</atnm:GainOnChangeInFairValueOfDerivatives>
<atnm:GainOnChangeInFairValueOfDerivatives contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">-12561071</atnm:GainOnChangeInFairValueOfDerivatives>
<atnm:GainOnChangeInFairValueOfDerivatives contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">-16041077</atnm:GainOnChangeInFairValueOfDerivatives>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">50000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">449522</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">370086</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">-437121</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">236317</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">957001</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">108352</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">189537</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">-2312338</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">-2490948</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">-53186022</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">3000000</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">1112</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">1699</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">833950</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">-1112</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">-1699</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">-3833950</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">645888</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_Custom_14-Jun-2000_31-Dec-2000" unitRef="USD" decimals="0">1750000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE__31-Dec-2001" unitRef="USD" decimals="0">2250000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE__31-Dec-2006" unitRef="USD" decimals="0">7533741</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE__31-Dec-2007" unitRef="USD" decimals="0">6600000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE__31-Dec-2008" unitRef="USD" decimals="0">6000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">2871477</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">58945832</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">5220</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">5220</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">18273</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">23709</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">3491104</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">65333</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">63344</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">203344</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">-65333</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">2837062</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">62897753</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">-2378783</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">344415</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">5877781</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__13-Jun-2000" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__31-Dec-2010" unitRef="USD" decimals="0">196135</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">5703798</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">5618669</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__31-Mar-2013" unitRef="USD" decimals="0">3239886</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">5533366</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">5877781</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:InterestPaid contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">561</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">1243</us-gaap:InterestPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">372850</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<atnm:InsurancePrepaidThroughPremiumFinance contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<atnm:InsurancePrepaidThroughPremiumFinance contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<atnm:InsurancePrepaidThroughPremiumFinance contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">297825</atnm:InsurancePrepaidThroughPremiumFinance>
<atnm:FairValueOfWarrantsIssuedWithDebt contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<atnm:FairValueOfWarrantsIssuedWithDebt contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<atnm:FairValueOfWarrantsIssuedWithDebt contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">377150</atnm:FairValueOfWarrantsIssuedWithDebt>
<atnm:FairValueOfWarrantsIssuedWithStock contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<atnm:FairValueOfWarrantsIssuedWithStock contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<atnm:FairValueOfWarrantsIssuedWithStock contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">5985238</atnm:FairValueOfWarrantsIssuedWithStock>
<atnm:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<atnm:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<atnm:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">2170282</atnm:FairValueOfWarrantsIssuedToPlacementAgent>
<atnm:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_3ME__31-Mar-2013" unitRef="USD" xsi:nil="true"/>
<atnm:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_3ME__31-Mar-2014" unitRef="USD" xsi:nil="true"/>
<atnm:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">981729</atnm:ConversionOfNotesPayableAndAccruedInterestToCommonStock>
<atnm:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">139565</atnm:FairValueOfTransferFromLiabilityClassificationToEquityClassification>
<atnm:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_Custom_14-Jun-2000_31-Mar-2014" unitRef="USD" decimals="0">5417984</atnm:FairValueOfTransferFromLiabilityClassificationToEquityClassification>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;Note 1 &amp;#8211; Description of Business and Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;div align="justify" style="text-indent: 45pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Nature of Business &amp;#8211;&lt;/font&gt;&amp;#160;Actinium Pharmaceuticals, Inc., incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;API&amp;#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase 1/2 clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &amp;#8220;Company&amp;#8221;, &amp;#8220;Actinium&amp;#8221;, &amp;#8220;Cactus&amp;#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that&amp;#160;was in the market for a merger with an appropriate operating company.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;API&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&amp;#160;&amp;#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&amp;#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&amp;#160;&amp;#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000;
 text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&amp;#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&amp;#160;&amp;#160;On April&amp;#160;11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &amp;#8220;Merger&amp;#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&amp;#8217;s common stock.&amp;#160;&amp;#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Basis of Presentation - Unaudited Interim Financial Information &amp;#8211;&lt;/font&gt;&amp;#160;The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary&amp;#160;for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&amp;#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 28, 2014.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Development Stage Company &amp;#8211;&lt;/font&gt;&amp;#160;The Company is considered a development stage company and has had no commercial revenue to date. The Company has been focusing on the development of its clinical drug candidates.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Principles of Consolidation &amp;#8211;&lt;/font&gt;&amp;#160;The condensed consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font
 style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/font&gt;&amp;#160;The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Cash and Cash Equivalents &amp;#8211;&lt;/font&gt;&amp;#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At March 31, 2014 and December 31, 2013, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Property and Equipment &amp;#8211;&lt;/font&gt;&amp;#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Impairment of Long-Lived Assets &amp;#8211;&amp;#160;&lt;/font&gt;Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Derivatives &amp;#8211;&lt;/font&gt;&amp;#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Fair Value of Financial Instruments &amp;#8211;&lt;/font&gt;&amp;#160;Fair value is defined as the
 price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities&amp;#160;in&amp;#160;active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/div&gt;
&lt;div align="right" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The following tables set forth liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of March 31, 2014 and December 31, 2013. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="40%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font
 style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Total&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="40%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="40%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="40%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;At March 31, 2014&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="7%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="7%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%"
 valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="2%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="8%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;19,128,761&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="2%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;19,128,761&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" width="40%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;At December 31, 2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="7%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="7%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="8%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;6,707,255&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;6,707,255&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Income Taxes &amp;#8211;&lt;/font&gt;&amp;#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust:
 none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Research and Development Costs &amp;#8211;&lt;/font&gt;&amp;#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Share-Based Payments &amp;#8211;&lt;/font&gt;&amp;#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&amp;#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Earnings (Loss) Per Common Share &amp;#8211;&lt;/font&gt;&amp;#160;The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&amp;#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &amp;#160;The potentially dilutive securities (options and warrants) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the three months ended March 31, 2014, potentially issuable shares included stock options to purchase 2,265,229 shares and warrants to purchase 9,680,333 shares of the Company&amp;#8217;s common stock. For the three months ended March 31, 2013, potentially issuable shares included stock options to purchase 2,330,134 shares and warrants to purchase 12,770,636 shares of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Recent Accounting Pronouncements &amp;#8211;&lt;/font&gt;&amp;#160;The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Subsequent Events &amp;#8211;&lt;/font&gt;&amp;#160;The Company&amp;#8217;s management reviewed all material events through the date of the condensed consolidated financial statements were issued for subsequent event disclosure consideration.&lt;/font&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Note 2 &amp;#8211; Related Party Transactions&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;"&gt;MSKCC:&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;In 2010, General Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly named General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC), a principal owner of the Company.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;div style="text-align: justify; text-indent: 45pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer Research (SKI),&amp;#160;an entity related to MSKCC (&amp;#8220;License Agreement&amp;#8221;).&amp;#160;&amp;#160;The agreement was amended in August 2006.&amp;#160;&amp;#160;Pursuant to the agreement, the Company licenses certain intellectual property from SKI, including critical patents with respect to the Company&amp;#8217;s core technology, and also supports ongoing research and clinical development of related drug candidates.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The Company is obligated to make the following milestone payments:&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Payments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="88%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval&amp;#160;for each licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%"
 valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" width="88%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each&amp;#160;licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Certain amounts due under the License Agreement were deferred and then forgiven under a forbearance-related arrangement.&amp;#160;&amp;#160;On June 19, 2011, the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement, in respect of the $50,000 annual maintenance fees and research payments.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;div style="text-align: justify; text-indent: 45pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;On September 4, 2013, the Company entered into a letter agreement with SKI to set forth the amount that the Company owes SKI for the period from 2011 to 2014 under the License Agreement.&amp;#160;&amp;#160;The total amount that the Company owes SKI for the period from 2011 to 2014 is $815,100 plus all relevant licensed intellectual property related pass through costs to be determined.&amp;#160;&amp;#160;The amount owed does not include amounts the Company may owe for patent expenses under the License Agreement.&amp;#160;&amp;#160;As of March 31 2014, amount owed under this letter agreement for 2014 annual maintenance fee and 2014 research funding was approximately $0.2 million plus pass through costs, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On March 27, 2012, the Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225.&amp;#160;&amp;#160;The Company will pay $31,185 for each patient that has completed the clinical trial.&amp;#160;&amp;#160;Upon execution of the agreement, the Company paid a start-up fee of $79,623 in 2012.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family:
 'times new roman'; font-size: 10pt; display: inline;"&gt;For the three months ended March 31, 2014 and 2013, the Company incurred $189,537 and $129,850, respectively, for maintenance fees and research conducted by MSKCC.&amp;#160;&amp;#160;As of March 31, 2014 and December 31, 2013, the Company has payable to MSKCC of $189,537 and $81,185, respectively, related to clinical trials.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;"&gt;Placement Agent:&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;div style="text-align: justify; text-indent: 45pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On August 7, 2012, the Company entered into an engagement agreement with Healthcare Investment Banking as its placement agent for the 2012 Common Stock Offering.&amp;#160; A director of the Company was the Head of Healthcare Investment Banking at the placement agent.&amp;#160;&amp;#160;&amp;#160;Pursuant to the agreement, the placement agent was engaged as the exclusive agent for the 2012 Common Stock Offering. &amp;#160;&amp;#160;In consideration for its services, the placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.&amp;#160;&amp;#160;The placement agent or its designees have also received warrants to purchase shares of the Company&amp;#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.&amp;#160;&amp;#160;The placement agent will also receive the same fee and expense schedule for any cash exercise of warrants within 6 months of the final closing of the 2012 Common Stock Offering and a 5% solicitation fee for any warrants exercised as a result of being called for redemption by the Company.&amp;#160;&amp;#160;Upon the final closing of the 2012 Common Stock Offering of the units, the placement agent has been engaged by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee of $25,000.&amp;#160;&amp;#160;The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company&amp;#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.&amp;#160;&amp;#160;For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent.&amp;#160;&amp;#160;The placement agent also was engaged by the Company as placement agent for its Stock Offering and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold warrants to purchase 1,251,015 shares of the Company&amp;#8217;s Common Stock.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On December 9, 2013, the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering. The agreement entered in 2013 has similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company&amp;#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company has uplisted its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;During quarter ended March 31, 2014, the placement agent received a cash fee of approximately $0.4 million from the sale of securities and was issued warrants to purchase 68,976 shares of the Company&amp;#8217;s Common Stock at $9 per share for a period of 5
 years.&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;Note 3 &amp;#8211; Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Property and equipment consisted of the following at March 31, 2014 and December 31, 2013:&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;17,179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;15,480&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(2,965&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(1,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;14,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;13,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Depreciation expense for the three months ended March 31, 2014 and 2013 were $1,405 and $0, respectively. The Company wrote off its remaining undepreciated property and equipment during the three months ended March 31, 2013 and recorded a loss of $4,122 on the disposition.&lt;/font&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Note 4 &amp;#8211; Note Payable&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;On December 28, 2013, the Company entered into a premium finance agreement to pay a $157,825 premium for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $15,995 in January 2014 and&amp;#160;is required&amp;#160;to pay $15,995 in monthly installment for nine months. For the quarter ended March 31, 2014, the Company paid $63,344 under this finance agreement. As of March 31, 2014 and December 31, 2013, the outstanding balance related to the premium finance agreement was $94,481 and $157,825, respectively.&lt;/font&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;Note 5 &amp;#8211; Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&amp;#8217;s common stock at prices below such warrants&amp;#8217; respective exercise prices and these provisions could result in modification of the warrants&amp;#8217; exercise price based on a variable that is not an input to the fair value of a &amp;#8220;fixed-for-fixed&amp;#8221; option as defined under FASB ASC Topic No. 815 &amp;#8211; 40. The warrants granted in connection with the issuance of the Company&amp;#8217;s Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &amp;#8220;Lower Price&amp;#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Activities for derivative warrant instruments during the three months ended March 31, 2014 were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,968,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman';
 font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;6,707,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Transfer from liability classification to equity classification&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(46,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(139,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td width="76%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Change in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent:
 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;12,561,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Balance, March 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,922,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;19,128,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;During the quarter ended March 31, 2014, 46,025 warrants were exercised. The fair value of these warrants totaling $139,565 were measured on the various exercise dates and reclassified to additional paid-in capital.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date.&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Market value of common stock on measurement date (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;12.45&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;5.89&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Adjusted exercise price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;9.95&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;2.48&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Risk free interest rate (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1.32&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman';
 font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1.27&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Warrant lives in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;0.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;0.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Expected volatility (3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;71&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;73&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Expected dividend yield (4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;25&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Range of percentage of existing shares offered (6)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"
 style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;35&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Offering price range (7)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;9&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;9&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td width="6%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The market value of common stock at the above measurement dates is based on the Company&amp;#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for March 31, 2014.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(3)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Because the Company does not have adequate trading
 history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(4)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(5)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Management determines the probability of future stock offering at each evaluation date.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(6)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Management estimates that the range of percentages of existing shares offered in each stock offering will be&amp;#160;0% and 35% of the shares outstanding at March 31, 2014 and December 31, 2013, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(7)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Represents the estimated offering price range in future offerings as determined by management.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;Note 6 &amp;#8211; Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;License and Research Agreements&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;
&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;a.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="91%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Abbott Biotherapeutics Corp &amp;#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Payments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="88%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right"
 width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" width="88%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="88%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" width="88%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="88%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(5) First commercial sale&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" width="88%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(6) after the first $10,000,000 in net sales&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font:
 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.&amp;#160;&amp;#160;The milestone payment for the Phase 1 Clinical Trial was recorded as research and development expense. The Company has not initiated a Phase II Clinical Trial and no payment has been made to Abbott Biotherapeutics Corp. since the July 24, 2012 payment.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;
&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;b.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="91%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Memorial Sloan Kettering Cancer Center (MSKCC) &amp;#8211; see related party disclosure.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="91%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;
&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;c.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="91%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Oak Ridge National Laboratory (ORNL) &amp;#8211; API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end.&amp;#160;&amp;#160;For 2013, the Company was obligated and paid approximately $0.3 million to purchase of radioactive material with ORNL.&amp;#160;&amp;#160;For 2014, the Company signed a contract with ORNL to purchase $0.4 million of radioactive material.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="91%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;
&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;d.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="91%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company clinical trials, Phase 1 and Phase 2.&amp;#160;&amp;#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&amp;#160;&amp;#160;The down payment totaling $239,000 was paid in 2007 and 2012.&amp;#160;&amp;#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&amp;#160;&amp;#160;The total project is now estimated at approximately $2.2 million. As of March 31, 2014, approximately $1.0 million has been expensed to date. &amp;#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top" style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top" style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;
&lt;div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;e.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="91%" valign="top" style="text-align: justify;"&gt;
&lt;div style="text-align: justify; text-indent: 0pt; display: block;"&gt;
&lt;div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On June 15, 2012, the Company entered into a license and sponsored research agreement of BC8, a novel murine monoclonal antibody, with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody).&amp;#160;&amp;#160;FHCRC has currently completed Phase 1 and Phase 2 of the clinical trial and the Company intends to start preparation for a
 pivotal trial leading to an FDA approval.&amp;#160;&amp;#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC.&amp;#160;&amp;#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA.&amp;#160;&amp;#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter.&amp;#160;&amp;#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year.&amp;#160;&amp;#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&amp;#160;&amp;#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;During the quarters ended March 31, 2014 and 2013, the Company recorded fees of $37,500 and $37,500, respectively, related to this agreement.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;
&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;f.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="91%" valign="top" style="text-align: justify;"&gt;
&lt;div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-size: 10pt; display: inline;"&gt;On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC for&amp;#160;&lt;/font&gt;Actimab-A&lt;font style="font-size: 10pt; display: inline;"&gt;.&amp;#160;&amp;#160;The Company will pay $31,366 for each patient that has completed the clinical trial. The Company paid a start-up fee of $19,749 in 2013.&amp;#160;&amp;#160;During the clinical trial additional fees apply and will be invoiced when applicable. For the three months ended March 31, 2014, the Company paid approximately $16,000 for patient enrollment.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="91%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;
&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;g.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="91%" valign="top" style="text-align: justify;"&gt;
&lt;div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-size: 10pt; display: inline;"&gt;On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center for&amp;#160;&lt;/font&gt;Actimab-A&lt;font style="font-size: 10pt; display: inline;"&gt;.&amp;#160;&amp;#160;The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500.&amp;#160;&amp;#160;The estimated cost is based on treating 24 patients through 2013.&amp;#160;&amp;#160;Upon execution of the agreement, the Company paid $33,946. During 2013, there was one patient treated and the Company paid $34,383 in July 2013. There have been no patients treated in 2014.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;
&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;h.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="91%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&amp;#160;&amp;#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&amp;#160;&amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&amp;#160;&amp;#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. The Company paid the $22,847 start-up fee in February 2013. There were no payments made during the three months ended March 31, 2014 for this agreement.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="91%"
 valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;
&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;i.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="91%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&amp;#160;&amp;#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&amp;#160;&amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&amp;#160;&amp;#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable. The Company accrued $16,000 fee at December 31, 2013 and paid the fee in January 2014.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="91%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;
&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;j.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="91%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On January 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology Inc.&amp;#160;&amp;#160;(&amp;#8220;Goodwin&amp;#8221;). Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab&amp;#8482;-B. Total cost of the agreement is $2,813,960. The Company paid a non-refundable payment of $562,790 upon execution of the agreement. Periodic payments will be made upon reaching certain milestones. As of March 31, 2014, the remaining cost of the agreement is $2,077,000.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; text-align: left; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&amp;#160;New York, NY. The agreement terminated on May 31, 2013. On June 4, 2013 and amended on October&amp;#160;4, 2013, the Company entered into a rental agreement for office space at 546 Fifth Avenue,&amp;#160;New York, NY. This agreement terminates on July 6, 2014. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination.&lt;/font&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;Note 7 &amp;#8211; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;In January 2014, the Company completed the final tranche of a private placement of the Company&amp;#8217;s common stock and warrants and received approximately $3.3 million total gross proceeds from accredited investors (&amp;#8220;2014 Closing&amp;#8221;). The Company paid its placement agent total cash fees of approximately $395,000 and paid attorney fees of $40,000 for their services. In the 2014 Closing, the Company sold 551,810 shares of common stock at $6.00 per share and granted 137,952 units of five-year warrants with an exercise price of $9.00 per share. The warrants are exercisable for a period of five years from the date of issuance. The transaction date fair value of the warrants of $0.6 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rateh1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years. As of March 31, 2014, all the warrants were outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On March&amp;#160;24, 2014, the Company filed a shelf registration statement on Form S-3 (the &amp;#8220;Registration Statement&amp;#8221;) which was effective on April 17, 2014.&amp;#160;&amp;#160;This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the &amp;#8220;Sales Agreement&amp;#8221;) with MLV &amp;amp; Co. LLC (&amp;#8220;MLV&amp;#8221;) dated March 24, 2014.&amp;#160;The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock.&amp;#160;To date 500 shares have been sold under the Sales Agreement with MLV (see Note 8 &amp;#8211; Subsequent Event).&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Placement Agent &amp;#8211;&amp;#160;&lt;/font&gt;During January 2014, in connection with 2014 Closing, the Company issued Laidlaw &amp;amp; Co. warrants to purchase an aggregate of 68,976 shares of common stock with an exercise price of $9.00 per share. The transaction date fair value of the warrants of $0.2 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate &amp;#8211; 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years.&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;Approval of the Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;During 2013, the Company granted employees, consultant and board members 312,500 shares of restricted stock. During the quarter ended March 31, 2014, the Company granted an additional 325,167 shares of restricted stock. During the three months ended March 31, 2014, 180,104 shares were issued for shares granted under the Equity Incentive Plan. Of the total shares of restricted stock, 22,500 shares vest 1 year from the grant date, 149,167 shares have a vesting period of 4 years and 150,000 shares vest at date of grant. The remaining restricted shares granted are performance based and vest over time.&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt;
 word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;All restricted stock issued and outstanding is being amortized over their respective vesting periods. The unrecognized compensation expense related to the restricted stock granted at March 31, 2014 was $1,391,318. During the three months ended March&amp;#160;31, 2014 and 2013, the Company recorded expense of $1,410,588 and $0, respectively, related to the restricted stock granted.&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;Stock Option Plan&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The following is a summary of stock options:&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font
 style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size:
 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Outstanding, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,985,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;3.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;8.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;5,908,696&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;291,500&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;7.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;10&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt;
 display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(11,655)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;0.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Outstanding, March 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;2,265,229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;3.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font&gt;8.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times
 new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;19,514,362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;During the quarter ended March 31, 2014, the Company granted employees and board members 291,500 options to purchase the Company&amp;#8217;s common stock with exercise prices ranging from $5.55 to $8.19 and a term of 10 years and vest over a 4-year period.&amp;#160;&amp;#160;The fair value of $1.7 million was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.88% - 2.07% (2) expected life of 6 years, (3) expected volatility of 87.76%, and (4) zero expected dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;During quarter ended March 31, 2014, the Company received gross proceeds of $5,220 for exercise of options for 11,655 shares of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at March 31, 2014 was $5,399,710. During the three months ended March&amp;#160;31, 2014 and 2013, the Company recorded option expense of $281,404 and $94,200, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Following is a summary of warrant activities for the quarter ended March 31, 2014:&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black;
 border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Outstanding, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;9,673,290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;4.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160; 47,396,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left"
 style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;306,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;7.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160; 6.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(299,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Outstanding, March 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new
 roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;9,680,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;4.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;107,268,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;During the quarter ended March 31, 2014, the Company granted warrants to purchase 137,952 shares of the Company&amp;#8217;s common stock to investors and warrants to purchase 68,976 shares of the Company&amp;#8217;s common stock to its placement agent in connection with the 2014 Closing. .&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;During the three months ended March 31, 2014, the Company also granted a consultant warrants to purchase 100,000 shares of the Company&amp;#8217;s common stock with exercise prices of $5.55 per share and a term of 10 years.&amp;#160;&amp;#160;These warrants vest when certain milestones are met.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;During the quarter ended March 31, 2014, 299,885 warrants were exercised by the warrant holders. The Company issued 253,330 shares of common stock and received gross proceeds of $23,709.&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;During the quarter ended March 31, 2014 and 2013, the Company recorded stock-based compensation related to the warrants of $58,934 and $0, respectively.&lt;/font&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Note 8 &amp;#8211; Subsequent Events&lt;/font&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;In April 2014, the Company granted certain employees 50,000 shares of restricted common stock and options to purchase 600,000 shares of the Company&amp;#8217;s common stock with exercise prices ranging from $11.76 to $11.95 and a term of 10 years. These options and restricted stock vest over a 4-year period.&amp;#160;&amp;#160;Effective May 12, 2014,&amp;#160;&lt;font style="display: inline; font-size: 10pt;"&gt;the Company entered into a sublease agreement for office space located at 379 Thornall Street, Edison, NJ. This agreement terminates on September 30, 2016. The Company issued a security deposit of approximately $35,000 to the existing tenant.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;On April 28, 2014, the Company issued 500 shares of its common stock and received net proceeds of $6,000.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:BusinessCombinationsPolicy contextRef="Context_3ME__31-Mar-2014">&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Nature of Business &amp;#8211;&lt;/font&gt;&amp;#160;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;API&amp;#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase 1/2 clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &amp;#8220;Company&amp;#8221;, &amp;#8220;Actinium&amp;#8221;, &amp;#8220;Cactus&amp;#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that&amp;#160;was in the market for a merger with an appropriate operating company.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;API&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&amp;#160;&amp;#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&amp;#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&amp;#160;&amp;#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&amp;#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&amp;#160;&amp;#160;On April&amp;#160;11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal;
 -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &amp;#8220;Merger&amp;#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&amp;#8217;s common stock.&amp;#160;&amp;#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&lt;/font&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;font size="2" style="font-family: times new roman,times;"&gt;&lt;font style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 60px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: inline; font-weight: bold;"&gt;Basis of Presentation - Unaudited Interim Financial Information &amp;#8211;&lt;/font&gt;&amp;#160;The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary&amp;#160;for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&amp;#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 28, 2014. &lt;/font&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<atnm:DevelopmentStageCompanyPolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;strong&gt;&lt;font size="2"&gt;Development Stage Company &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;The Company is considered a development stage company and has had no commercial revenue to date. The Company has been focusing on the development of its clinical drug candidates.&lt;/div&gt;</atnm:DevelopmentStageCompanyPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;strong&gt;&lt;font size="2"&gt;Principles of Consolidation &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;The condensed consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_3ME__31-Mar-2014">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/font&gt;&amp;#160;The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;strong&gt;&lt;font size="2"&gt;Cash and Cash Equivalents &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At March 31, 2014 and December 31, 2013, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;strong&gt;&lt;font size="2"&gt;Property and Equipment &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Impairment of Long-Lived Assets &amp;#8211;&amp;#160;&lt;/font&gt;Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.&lt;/font&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:DerivativesPolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;strong&gt;&lt;font size="2"&gt;Derivatives &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_3ME__31-Mar-2014">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Fair Value of Financial Instruments &amp;#8211;&lt;/font&gt;&amp;#160;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities&amp;#160;in&amp;#160;active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div align="right" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;div &gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The following tables set forth liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of March 31, 2014 and December 31, 2013. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" width="40%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new
 roman'; font-size: 10pt; display: inline;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="40%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="40%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="40%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;At March 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="7%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="7%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="8%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;19,128,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;19,128,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="40%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;At December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="7%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="7%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="8%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;6,707,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;6,707,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;strong&gt;&lt;font size="2"&gt;Income Taxes &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;strong&gt;&lt;font size="2"&gt;Research and Development Costs &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;strong&gt;&lt;font size="2"&gt;Share-Based Payments &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&amp;#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;strong&gt;&lt;font size="2"&gt;Earnings (Loss) Per Common Share &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&amp;#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &amp;#160;The potentially dilutive securities (options and warrants) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the three months ended March 31, 2014, potentially issuable shares included stock options to purchase 2,265,229 shares and warrants to purchase 9,680,333 shares of the Company&amp;#8217;s common stock. For the three months ended March 31, 2013, potentially issuable shares included stock options to purchase 2,330,134 shares and warrants to purchase 12,770,636 shares of the Company&amp;#8217;s common stock.&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;strong&gt;&lt;font size="2"&gt;Recent Accounting Pronouncements &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div&gt;&lt;strong&gt;&lt;font size="2"&gt;Subsequent Events &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;The Company&amp;#8217;s management reviewed all material events through the date of the condensed consolidated financial statements were issued for subsequent event disclosure consideration.&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" width="40%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="40%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="40%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="40%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt;
 margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;At March 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="7%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="7%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="8%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;19,128,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;19,128,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="40%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;At December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="7%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="7%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="8%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;6,707,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="2%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;6,707,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval&amp;#160;for each licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each&amp;#160;licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;17,179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;15,480&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(2,965&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size:
 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(1,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;14,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;13,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,968,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;6,707,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Transfer from liability classification to equity classification&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(46,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(139,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td width="76%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Change in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;12,561,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Balance, March 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,922,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;19,128,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
<atnm:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Market value of common stock on measurement date (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;12.45&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;5.89&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Adjusted exercise price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;9.95&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;2.48&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr
 bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Risk free interest rate (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1.32&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1.27&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Warrant lives in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;0.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;0.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Expected volatility (3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;71&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;73&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Expected dividend yield (4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;25&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Range of percentage of existing shares offered (6)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;35&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Offering price range (7)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;9&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;9&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td width="6%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The market value of common stock at the above measurement dates is based on the Company&amp;#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for March 31, 2014.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(3)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(4)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(5)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Management determines the probability of future stock offering at each evaluation date.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(6)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Management estimates that the range of percentages of existing shares offered in each stock offering will be&amp;#160;0% and 35% of the shares outstanding at March 31, 2014 and December 31, 2013, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(7)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="91%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt;
 margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Represents the estimated offering price range in future offerings as determined by management.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;</atnm:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock>
<atnm:MilestonePaymentsMilestoneMethodTableTextBlock contextRef="Context_3ME__31-Mar-2014">&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(5) First commercial sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(6) after the first $10,000,000 in net sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</atnm:MilestonePaymentsMilestoneMethodTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember">&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"
 colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,985,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;3.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;8.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;5,908,696&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;291,500&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;7.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;10&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(11,655)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;0.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, March 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;2,265,229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;3.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;8.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;19,514,362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_WarrantMember">&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"
 colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;9,673,290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;4.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160; 47,396,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;306,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;7.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160; 6.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&amp;#160;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(299,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, March 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;9,680,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;4.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;107,268,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">19128761</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Mar-2014_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Mar-2014_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Mar-2014_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">19128761</us-gaap:DerivativeLiabilities>
<dei:EntityIncorporationDateOfIncorporation contextRef="Context_3ME__31-Mar-2014">1997-10-06</dei:EntityIncorporationDateOfIncorporation>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of__28-Dec-2012_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of__25-Sep-2013_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="4">0.9370</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<atnm:CommonStockIssuableInConsiderationForEquityInterestAcquisition contextRef="Context_Custom_25-Dec-2012_28-Dec-2012_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="2">0.99</atnm:CommonStockIssuableInConsiderationForEquityInterestAcquisition>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_3ME__31-Mar-2014_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">Three years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<atnm:SharesExchangeRatio contextRef="Context_Custom_25-Dec-2012_28-Dec-2012_LegalEntityAxis_ActiniumMember" unitRef="pures" decimals="3">0.333</atnm:SharesExchangeRatio>
<atnm:SharesExchangeRatio contextRef="Context_Custom_01-Sep-2013_25-Sep-2013_LegalEntityAxis_ActiniumMember" unitRef="pures" decimals="3">0.333</atnm:SharesExchangeRatio>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME__31-Mar-2013_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember" unitRef="shares" decimals="INF">2330134</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME__31-Mar-2013_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="INF">12770636</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME__31-Mar-2014_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember" unitRef="shares" decimals="INF">2265229</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME__31-Mar-2014_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="INF">9680333</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<atnm:CommonStockShares contextRef="Context_As_Of__25-Sep-2013_LegalEntityAxis_ActiniumMember" unitRef="shares" decimals="INF">3970137</atnm:CommonStockShares>
<atnm:ExchangedInCommonStockShares contextRef="Context_As_Of__25-Sep-2013_LegalEntityAxis_ActiniumMember" unitRef="shares" decimals="INF">1322055</atnm:ExchangedInCommonStockShares>
<atnm:RelatedPartyMilestonesPayment contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember" unitRef="USD" decimals="0">750000</atnm:RelatedPartyMilestonesPayment>
<atnm:RelatedPartyMilestonesPayment contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember" unitRef="USD" decimals="0">1750000</atnm:RelatedPartyMilestonesPayment>
<atnm:NumberOfPatients contextRef="Context_Custom_01-Aug-2012_28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="patients" decimals="INF">24</atnm:NumberOfPatients>
<atnm:AmountPaidUnderAgreementInYearTwoThousandEleven contextRef="Context_Custom_20-May-2011_19-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">50000</atnm:AmountPaidUnderAgreementInYearTwoThousandEleven>
<atnm:AmountPaidUnderAgreementInYearTwoThousandTwelve contextRef="Context_Custom_20-May-2011_19-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">200000</atnm:AmountPaidUnderAgreementInYearTwoThousandTwelve>
<atnm:AmountPaidUnderAgreementInYearTwoThousandThirteen contextRef="Context_Custom_20-May-2011_19-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">250000</atnm:AmountPaidUnderAgreementInYearTwoThousandThirteen>
<atnm:OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen contextRef="Context_Custom_03-Sep-2013_04-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">815100</atnm:OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_Custom_20-May-2011_19-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">50000</atnm:MaintenanceFeesAndResearchPayments>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_FYE__31-Dec-2013_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="-5">200000</atnm:MaintenanceFeesAndResearchPayments>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">0</atnm:MaintenanceFeesAndResearchPayments>
<atnm:PlacementAgentServicesFees contextRef="Context_3ME__31-Mar-2014_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="-5">400000</atnm:PlacementAgentServicesFees>
<atnm:WarrantsIssuedToPurchaseCommonStock contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="shares" decimals="0">68976</atnm:WarrantsIssuedToPurchaseCommonStock>
<atnm:WarrantsIssuedToPurchaseCommonStock contextRef="Context_3ME__31-Mar-2014_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="shares" decimals="0">68976</atnm:WarrantsIssuedToPurchaseCommonStock>
<atnm:WarrantsIssuedToPurchaseCommonStock contextRef="Context_3ME__31-Mar-2014_TitleOfIndividualAxis_InvestorMember" unitRef="shares" decimals="0">137952</atnm:WarrantsIssuedToPurchaseCommonStock>
<atnm:CommonStockExercisePriceParOrStatedValuePerShare contextRef="Context_As_Of__31-Mar-2014_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="0">9</atnm:CommonStockExercisePriceParOrStatedValuePerShare>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of__27-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31185</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of__19-Jul-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31366</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">500000</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of__26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">38501</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of__21-Nov-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31771</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of__31-Jul-2013_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">34383</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" xsi:nil="true"/>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">33946</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of__26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">22847</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of__21-Nov-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">79623</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of__31-Dec-2013_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">19749</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpDueCostPaidDate contextRef="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">2013-12-31</atnm:StartUpDueCostPaidDate>
<atnm:DescriptionOfReceivablesOfPlacementAgentForServices contextRef="Context_Custom_08-Jul-2012_07-Aug-2012_SubsidiarySaleOfStockAxis_PlacementAgentMember">Placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.</atnm:DescriptionOfReceivablesOfPlacementAgentForServices>
<atnm:DescriptionOfReceivablesOfPlacementAgentForServices contextRef="Context_Custom_01-Dec-2013_09-Dec-2013_SubsidiarySaleOfStockAxis_PlacementAgentMember">Agreement entered in 2013 has similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock.</atnm:DescriptionOfReceivablesOfPlacementAgentForServices>
<atnm:DescriptionOfWarrantsReceivablesByPlacement contextRef="Context_Custom_08-Jul-2012_07-Aug-2012_SubsidiarySaleOfStockAxis_PlacementAgentMember">The placement agent or its designees have also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.</atnm:DescriptionOfWarrantsReceivablesByPlacement>
<atnm:DescriptionOfWarrantsReceivablesByPlacement contextRef="Context_Custom_01-Dec-2013_09-Dec-2013_SubsidiarySaleOfStockAxis_PlacementAgentMember">Warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable</atnm:DescriptionOfWarrantsReceivablesByPlacement>
<atnm:PeriodOfExerciseOfWarrants contextRef="Context_Custom_08-Jul-2012_07-Aug-2012_SubsidiarySaleOfStockAxis_PlacementAgentMember">Within 6 months of the final closing of the 2012 common stock Offering</atnm:PeriodOfExerciseOfWarrants>
<atnm:PeriodOfExerciseOfWarrants contextRef="Context_3ME__31-Mar-2014_SubsidiarySaleOfStockAxis_PlacementAgentMember">5 years</atnm:PeriodOfExerciseOfWarrants>
<atnm:PercentageOfSolicitationFee contextRef="Context_Custom_08-Jul-2012_07-Aug-2012_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="2">0.05</atnm:PercentageOfSolicitationFee>
<atnm:PeriodicFeeForFinancialAdvisoryServices contextRef="Context_Custom_08-Jul-2012_07-Aug-2012_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="0">25000</atnm:PeriodicFeeForFinancialAdvisoryServices>
<atnm:PeriodicFeeForFinancialAdvisoryServices contextRef="Context_Custom_01-Dec-2013_09-Dec-2013_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="0">25000</atnm:PeriodicFeeForFinancialAdvisoryServices>
<atnm:DescriptionOfAdditionalReceivableByPlacementAgent contextRef="Context_Custom_08-Jul-2012_07-Aug-2012_SubsidiarySaleOfStockAxis_PlacementAgentMember">The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.</atnm:DescriptionOfAdditionalReceivableByPlacementAgent>
<atnm:CommonStockPurchaseByHoldingOfWarrant contextRef="Context_Custom_08-Jul-2012_07-Aug-2012_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="shares" decimals="0">1251015</atnm:CommonStockPurchaseByHoldingOfWarrant>
<us-gaap:OtherResearchAndDevelopmentExpense contextRef="Context_3ME__31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">129850</us-gaap:OtherResearchAndDevelopmentExpense>
<us-gaap:OtherResearchAndDevelopmentExpense contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">189537</us-gaap:OtherResearchAndDevelopmentExpense>
<us-gaap:ArtistAdvancesAndRoyaltyGuaranteesCommitments contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">&lt;div&gt;&lt;font size="2"&gt;Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire. &lt;/font&gt;&lt;/div&gt;</us-gaap:ArtistAdvancesAndRoyaltyGuaranteesCommitments>
<us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="Context_As_Of__31-Dec-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">81185</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="Context_As_Of__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">189537</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_3ME__31-Mar-2014">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">15480</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">17179</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">1560</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">2965</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:Depreciation contextRef="Context_3ME__31-Mar-2013" unitRef="USD" decimals="0">0</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">1405</us-gaap:Depreciation>
<us-gaap:NotesPayable contextRef="Context_As_Of__28-Dec-2013_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">157825</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of__31-Dec-2013_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">157825</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of__31-Mar-2014_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">94481</us-gaap:NotesPayable>
<us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">15995</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
<us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Context_3ME__31-Mar-2014_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">63344</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
<us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent contextRef="Context_As_Of__31-Mar-2014_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">15995</us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent>
<atnm:DerivativeWarrantsUnits contextRef="Context_As_Of__31-Dec-2013" unitRef="shares" decimals="INF">1968623</atnm:DerivativeWarrantsUnits>
<atnm:DerivativeWarrantsUnits contextRef="Context_As_Of__31-Mar-2014" unitRef="shares" decimals="INF">1922598</atnm:DerivativeWarrantsUnits>
<atnm:TransferFromLiabilityClassificationToEquityClassification contextRef="Context_3ME__31-Mar-2014" unitRef="shares" decimals="INF">-46025</atnm:TransferFromLiabilityClassificationToEquityClassification>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeFairValueOfDerivativeNet>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">19128761</us-gaap:DerivativeFairValueOfDerivativeNet>
<atnm:ChangeInFairValueOfDerivativeWarrants contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">12561071</atnm:ChangeInFairValueOfDerivativeWarrants>
<atnm:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of__31-Dec-2013" unitRef="USD_per_Share" decimals="2" id="Footnote-1_1">5.89</atnm:MarketValueOfCommonStockOnMeasurementDate>
<atnm:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of__31-Mar-2014" unitRef="USD_per_Share" decimals="2" id="Footnote-1_2">12.45</atnm:MarketValueOfCommonStockOnMeasurementDate>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__31-Dec-2013" unitRef="USD_per_Share" decimals="2">2.48</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__31-Mar-2014" unitRef="USD_per_Share" decimals="2">9.95</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE__31-Dec-2013" unitRef="pure" decimals="4" id="Footnote-2_1">0.0127</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="4">0.0164</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME__31-Mar-2014" unitRef="pure" decimals="4" id="Footnote-2_2">0.0132</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE__31-Dec-2013">P6M</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_3ME__31-Mar-2014">P6M</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember">P6Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2013" unitRef="pure" decimals="2" id="Footnote-3_1">0.73</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="2">0.88</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME__31-Mar-2014" unitRef="pure" decimals="2" id="Footnote-3_2">0.71</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.8776</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE__31-Dec-2013" unitRef="pure" xsi:nil="true" id="Footnote-4_1"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_3ME__31-Mar-2014" unitRef="pure" xsi:nil="true" id="Footnote-4_2"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_FYE__31-Dec-2013" unitRef="pure" decimals="2" id="Footnote-5_1">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_3ME__31-Mar-2014" unitRef="pure" xsi:nil="true" id="Footnote-5_2"/>
<atnm:RangeOfPercentageOfExistingSharesOffered contextRef="Context_As_Of__31-Dec-2013" unitRef="pure" decimals="2" id="Footnote-6_1">0.35</atnm:RangeOfPercentageOfExistingSharesOffered>
<atnm:RangeOfPercentageOfExistingSharesOffered contextRef="Context_As_Of__31-Mar-2014" unitRef="pure" xsi:nil="true" id="Footnote-6_2"/>
<atnm:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__31-Dec-2013" unitRef="USD_per_Share" decimals="0" id="Footnote-7_1">9</atnm:FairValueAssumptionOfferingPrice>
<atnm:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__31-Mar-2014" unitRef="USD_per_Share" decimals="0" id="Footnote-7_2">9</atnm:FairValueAssumptionOfferingPrice>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME__31-Mar-2014_DerivativeByNatureAxis_WarrantMember" unitRef="USD" decimals="0">139565</us-gaap:FairValueAdjustmentOfWarrants>
<atnm:NumberOfSharesWarrantExercise contextRef="Context_3ME__31-Mar-2014_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="INF">46025</atnm:NumberOfSharesWarrantExercise>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">1500000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember" unitRef="USD" decimals="0">1750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember" unitRef="USD" decimals="0">1500000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember" unitRef="USD" decimals="0">1500000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">7750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_Custom_01-Jun-2012_15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="-6">1000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<atnm:PaymentOfLicenseFee contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">3000000</atnm:PaymentOfLicenseFee>
<atnm:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">Royalty payments of 2% of net sales will be due to FHCRC.</atnm:DescriptionOfRoyaltyPaymentToRelatedParty>
<atnm:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</atnm:DescriptionOfRoyaltyPaymentToRelatedParty>
<atnm:RoyaltyOfNetSalesPercentage contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="pure" decimals="2">0.12</atnm:RoyaltyOfNetSalesPercentage>
<atnm:FirstCommercialSalePeriod contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">P12Y6M</atnm:FirstCommercialSalePeriod>
<atnm:PurchaseOfRadioactiveMaterial contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="0">233100</atnm:PurchaseOfRadioactiveMaterial>
<atnm:PurchaseOfRadioactiveMaterial contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndThirteenMember" unitRef="USD" decimals="-5">300000</atnm:PurchaseOfRadioactiveMaterial>
<atnm:PurchaseOfRadioactiveMaterial contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndFourteenMember" unitRef="USD" decimals="-5">400000</atnm:PurchaseOfRadioactiveMaterial>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_07-Jul-2012_06-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">2200000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_01-Oct-2012_22-Oct-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">2200000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_01-May-2013_16-May-2013_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">2200000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_25-Jan-2014_27-Jan-2014_AgreementAxis_ManufacturingAgreementMember" unitRef="USD" decimals="0">2813960</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-6">1000000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_3ME__31-Mar-2014_AgreementAxis_ManufacturingAgreementMember" unitRef="USD" decimals="0">2077000</atnm:ProjectEstimatedCost>
<atnm:DownPaymentOfProjectEstimatedCostPercentage contextRef="Context_3ME__31-Mar-2014_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="pure" decimals="3">0.125</atnm:DownPaymentOfProjectEstimatedCostPercentage>
<atnm:DownPaymentForProject contextRef="Context_Custom_01-Dec-2007_31-Dec-2007_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">239000</atnm:DownPaymentForProject>
<atnm:DownPaymentForProject contextRef="Context_Custom_07-Jul-2012_06-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">1900000</atnm:DownPaymentForProject>
<atnm:DownPaymentForProject contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">239000</atnm:DownPaymentForProject>
<atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MaximumMember" unitRef="USD" decimals="-5">23500000</atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration>
<atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MinimumMember" unitRef="USD" decimals="-5">13200000</atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration>
<atnm:FundToRelatedPartyUnderAgreementForFirstTwoYear contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">150000</atnm:FundToRelatedPartyUnderAgreementForFirstTwoYear>
<atnm:FundToRelatedPartyUnderAgreementAfterYearTwo contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">250000</atnm:FundToRelatedPartyUnderAgreementAfterYearTwo>
<atnm:NonRefundableInstitutionalFee contextRef="Context_Custom_01-Aug-2012_28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">14500</atnm:NonRefundableInstitutionalFee>
<atnm:NonRefundableInstitutionalFee contextRef="Context_Custom_25-Jan-2014_27-Jan-2014_AgreementAxis_ManufacturingAgreementMember" unitRef="USD" decimals="0">562790</atnm:NonRefundableInstitutionalFee>
<atnm:PharmacyFee contextRef="Context_Custom_01-Sep-2012_26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">2025</atnm:PharmacyFee>
<atnm:AmendmentProcessingFee contextRef="Context_Custom_01-Sep-2012_26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">500</atnm:AmendmentProcessingFee>
<atnm:NoticePeriodForTerminationOfAgreement contextRef="Context_3ME__31-Mar-2014_AgreementAxis_RentalAgreementMember">This agreement terminates on July 6, 2014. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination.</atnm:NoticePeriodForTerminationOfAgreement>
<us-gaap:LeaseExpirationDate1 contextRef="Context_Custom_01-Aug-2012_31-Aug-2012_AgreementAxis_RentalAgreementMember">2014-03-31</us-gaap:LeaseExpirationDate1>
<us-gaap:LeaseExpirationDate1 contextRef="Context_Custom_02-May-2014_12-May-2014_SubsequentEventTypeAxis_SubsequentEventMember">2016-09-30</us-gaap:LeaseExpirationDate1>
<atnm:AgreementRenewalDescription contextRef="Context_3ME__31-Mar-2014_AgreementAxis_RentalAgreementMember">The agreement automatically renews on a month-to-month basis and requires a two month notice of termination.</atnm:AgreementRenewalDescription>
<us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="Context_As_Of__31-Dec-2013_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
<us-gaap:LegalFees contextRef="Context_Custom_01-Nov-2012_21-Nov-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</us-gaap:LegalFees>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">273859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">5364557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2330134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">12770636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1985384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2013_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">9673290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2265229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Mar-2014_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">9680333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE__31-Dec-2013_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="0">312500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">291500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">306928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_3ME__31-Mar-2014_PlanNameAxis_EquityIncentivePlanMember" unitRef="shares" decimals="INF">180104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_3ME__31-Mar-2014_TitleOfIndividualAxis_ConsultantMember" unitRef="shares" decimals="0">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">11655</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">299885</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2013_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">3.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Mar-2014_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">7.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">7.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_05-Apr-2014_30-Apr-2014_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD_per_Share" decimals="2">11.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_05-Apr-2014_30-Apr-2014_SubsequentEventTypeAxis_SubsequentEventMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">11.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">5.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">8.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE__31-Dec-2013_AwardTypeAxis_EmployeeStockOptionMember">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE__31-Dec-2013_AwardTypeAxis_WarrantMember">P4Y10M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_WarrantMember">P4Y8M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember">P10Y</atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
<atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_WarrantMember">P6Y7M17D</atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">3261367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">685800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">6114768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">5908696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2013_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">47396307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">19514362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Mar-2014_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">107268785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_WarrantMember" unitRef="USD" decimals="-5">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="-5">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="-5">3300000</us-gaap:ProceedsFromIssuanceOfWarrants>
<atnm:PlacementAgentCashFees contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">395000</atnm:PlacementAgentCashFees>
<atnm:PlacementAgentAttorneyFees contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">40000</atnm:PlacementAgentAttorneyFees>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">551810</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_09-Feb-2014_28-Apr-2014_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="0">500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of__31-Jan-2014_StatementClassOfStockAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:SaleOfStockPricePerShare>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of__31-Jan-2014_StatementClassOfStockAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">9.00</us-gaap:SaleOfStockPricePerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_StatementClassOfStockAxis_WarrantMember" unitRef="shares" decimals="0">137952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:DebtInstrumentTerm contextRef="Context_3ME__31-Mar-2014_StatementClassOfStockAxis_WarrantMember">P10Y</us-gaap:DebtInstrumentTerm>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="Context_As_Of__31-Jan-2014_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD_per_Warrant" decimals="2">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="Context_As_Of__31-Mar-2014" unitRef="USD_per_Warrant" decimals="2">5.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
<atnm:RegistrationStatementDescription contextRef="Context_Custom_20-Mar-2014_24-Mar-2014">&lt;div&gt;This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the &amp;#8220;Sales Agreement&amp;#8221;) with MLV &amp;amp; Co. LLC (&amp;#8220;MLV&amp;#8221;) dated March 24, 2014.&amp;#160;&lt;/div&gt;</atnm:RegistrationStatementDescription>
<atnm:MaximumOfferingPrice contextRef="Context_Custom_20-Mar-2014_24-Mar-2014" unitRef="USD" decimals="0">75000000</atnm:MaximumOfferingPrice>
<us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_Custom_20-Mar-2014_24-Mar-2014">&lt;div&gt;The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock.&amp;#160;To date 500 shares have been sold under the Sales Agreement with MLV.&lt;/div&gt;</us-gaap:SaleOfStockDescriptionOfTransaction>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms contextRef="Context_FYE__31-Dec-2013_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">Of the total shares of restricted stock, 22,500 shares vest 1 year from the grant date, 149,167 shares have a vesting period of 4 years and 150,000 shares vest at date of grant. The remaining restricted shares granted are performance based and vest over time.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
<atnm:AdditionalNumberOfRestrictedStockGranted contextRef="Context_3ME__31-Mar-2014" unitRef="shares" decimals="0">325167</atnm:AdditionalNumberOfRestrictedStockGranted>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">5399710</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="Context_As_Of__31-Mar-2014_StatementClassOfStockAxis_RestrictedStockMember" unitRef="USD" decimals="0">1391318</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME__31-Mar-2013_StatementClassOfStockAxis_RestrictedStockMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME__31-Mar-2013_StatementClassOfStockAxis_WarrantMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE__31-Dec-2013" unitRef="USD" decimals="0">94200</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME__31-Mar-2014" unitRef="USD" decimals="0">281404</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME__31-Mar-2014_StatementClassOfStockAxis_RestrictedStockMember" unitRef="USD" decimals="0">1410588</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME__31-Mar-2014_StatementClassOfStockAxis_WarrantMember" unitRef="USD" decimals="0">58934</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="-5">1700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<atnm:FairValueAssumptionsExpectedDiscountRate contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0188</atnm:FairValueAssumptionsExpectedDiscountRate>
<atnm:FairValueAssumptionsExpectedDiscountRate contextRef="Context_3ME__31-Mar-2014_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0207</atnm:FairValueAssumptionsExpectedDiscountRate>
<atnm:WarrantsExercisedByWarrantHolders contextRef="Context_3ME__31-Mar-2014_StatementClassOfStockAxis_WarrantMember" unitRef="shares" decimals="0">299885</atnm:WarrantsExercisedByWarrantHolders>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_3ME__31-Mar-2014_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">23709</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_09-Feb-2014_28-Apr-2014_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">6000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_FYE__31-Dec-2013_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="0">312500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_3ME__31-Mar-2014_PlanNameAxis_EquityIncentivePlanMember" unitRef="shares" decimals="INF">180104</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_3ME__31-Mar-2014_TitleOfIndividualAxis_ConsultantMember" unitRef="shares" decimals="0">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_05-Apr-2014_30-Apr-2014_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="0">50000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockRepurchasedDuringPeriodShares contextRef="Context_Custom_05-Apr-2014_30-Apr-2014_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="0">600000</us-gaap:StockRepurchasedDuringPeriodShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_Custom_01-Jan-2014_31-Jan-2014_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_WarrantMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_Custom_05-Apr-2014_30-Apr-2014_SubsequentEventTypeAxis_SubsequentEventMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_05-Apr-2014_30-Apr-2014_SubsequentEventTypeAxis_SubsequentEventMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of__31-Dec-2013" unitRef="USD" decimals="0">378955</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of__31-Mar-2014" unitRef="USD" decimals="0">615272</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:SecurityDeposit contextRef="Context_As_Of__12-May-2014_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">35000</us-gaap:SecurityDeposit>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-1_1" xlink:label="lab_Footnote-1_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_2" xlink:label="lab_Footnote-1_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_1" xlink:label="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_2" xlink:label="lab_Footnote-2_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_1" xlink:label="lab_Footnote-3_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_2" xlink:label="lab_Footnote-3_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-4_1" xlink:label="lab_Footnote-4_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-4" xlink:from="lab_Footnote-4_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-4_2" xlink:label="lab_Footnote-4_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-4" xlink:from="lab_Footnote-4_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-5_1" xlink:label="lab_Footnote-5_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-5" xlink:from="lab_Footnote-5_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-5_2" xlink:label="lab_Footnote-5_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-5" xlink:from="lab_Footnote-5_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-6_1" xlink:label="lab_Footnote-6_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-6" xlink:from="lab_Footnote-6_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-6_2" xlink:label="lab_Footnote-6_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-6" xlink:from="lab_Footnote-6_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-7_1" xlink:label="lab_Footnote-7_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-7" xlink:from="lab_Footnote-7_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-7_2" xlink:label="lab_Footnote-7_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-7" xlink:from="lab_Footnote-7_2"/>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-1">The market value of common stock at the above measurement dates is based on the Company's trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for March 31, 2014.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-2">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-3">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-4">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-5">Management determines the probability of future stock offering at each evaluation date.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-6">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at March 31, 2014 and December 31, 2013, respectively.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-7">Represents the estimated offering price range in future offerings as determined by management.</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>atnm-20140331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Tuesday, May 13, 2014 01:52:10 AM -->
<schema targetNamespace="http://actiniumpharmaceuticals.com/20140331" elementFormDefault="qualified" xmlns:atnm="http://actiniumpharmaceuticals.com/20140331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2013-01-31">
<annotation><appinfo>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited" id="ConsolidatedBalanceSheetsUnaudited">
<link:definition>002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" id="ConsolidatedBalanceSheetsUnauditedParenthetical">
<link:definition>003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
<link:definition>004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
<link:definition>006 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>007 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>008 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/NotePayable" id="NotePayable">
<link:definition>009 - Disclosure - Note Payable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Derivatives" id="Derivatives">
<link:definition>010 - Disclosure - Derivatives</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>011 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Equity" id="Equity">
<link:definition>012 - Disclosure - Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>013 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
<link:definition>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
<link:definition>015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
<link:definition>016 - Disclosure - Related Party Transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables" id="PropertyandEquipmentTables">
<link:definition>017 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesTables" id="DerivativesTables">
<link:definition>018 - Disclosure - Derivatives (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables" id="CommitmentsandContingenciesTables">
<link:definition>019 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" id="EquityTables">
<link:definition>020 - Disclosure - Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<link:definition>021 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<link:definition>022 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>023 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual" id="RelatedPartyTransactionsDetailsTextual">
<link:definition>024 - Disclosure - Related Party Transactions (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails" id="PropertyandEquipmentDetails">
<link:definition>025 - Disclosure - Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual" id="PropertyAndEquipmentDetailsTextual">
<link:definition>026 - Disclosure - Property and Equipment (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/NotePayableDetails" id="NotePayableDetails">
<link:definition>027 - Disclosure - Note Payable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails" id="DerivativesDetails">
<link:definition>028 - Disclosure - Derivatives (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails1" id="DerivativesDetails1">
<link:definition>029 - Disclosure - Derivatives (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual" id="DerivativesDetailsTextual">
<link:definition>030 - Disclosure - Derivatives (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails" id="CommitmentsandContingenciesDetails">
<link:definition>031 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual" id="Commitmentsandcontingenciesdetailstextual">
<link:definition>032 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" id="EquityDetails">
<link:definition>033 - Disclosure - Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" id="EquityDetailsTextual">
<link:definition>034 - Disclosure - Equity (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequenteventsDetails" id="SubsequenteventsDetails">
<link:definition>035 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd"/>
<import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="atnm_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesCTwoPreferredStockMember" id="atnm_SeriesCTwoPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesCThreePreferredStockMember" id="atnm_SeriesCThreePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesCFourPreferredStockMember" id="atnm_SeriesCFourPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GainOnChangeInFairValueOfDerivatives" id="atnm_GainOnChangeInFairValueOfDerivatives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InsurancePrepaidThroughPremiumFinance" id="atnm_InsurancePrepaidThroughPremiumFinance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfWarrantsIssuedWithDebt" id="atnm_FairValueOfWarrantsIssuedWithDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfWarrantsIssuedWithStock" id="atnm_FairValueOfWarrantsIssuedWithStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfWarrantsIssuedToPlacementAgent" id="atnm_FairValueOfWarrantsIssuedToPlacementAgent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionOfNotesPayableAndAccruedInterestToCommonStock" id="atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfTransferFromLiabilityClassificationToEquityClassification" id="atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DevelopmentStageCompanyPolicyTextBlock" id="atnm_DevelopmentStageCompanyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" id="atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePaymentsMilestoneMethodTableTextBlock" id="atnm_MilestonePaymentsMilestoneMethodTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" id="atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" id="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="ActiniumMember" id="atnm_ActiniumMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsAndWarrantsMember" id="atnm_OptionsAndWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" id="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" id="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockIssuableInConsiderationForEquityInterestAcquisition" id="atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesExchangeRatio" id="atnm_SharesExchangeRatio" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockShares" id="atnm_CommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExchangedInCommonStockShares" id="atnm_ExchangedInCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MemorialSloanKetteringCancerCenterMember" id="atnm_MemorialSloanKetteringCancerCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NewDrugApplicationMember" id="atnm_NewDrugApplicationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReceiptOfRegulatoryApprovalFromUSFdaMember" id="atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RelatedPartyMilestonesPayment" id="atnm_RelatedPartyMilestonesPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SloanKetteringInstituteOfCancerResearchMember" id="atnm_SloanKetteringInstituteOfCancerResearchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" id="atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RosemaryMazanetMember" id="atnm_RosemaryMazanetMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LaidlawAndCompanyMember" id="atnm_LaidlawAndCompanyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="JamessCapitalGroupMember" id="atnm_JamessCapitalGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GuagentiAndAssociatesMember" id="atnm_GuagentiAndAssociatesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementAxis" id="atnm_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="AgreementDomain" id="atnm_AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClinicalTrialAgreementMember" id="atnm_ClinicalTrialAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseDevelopmentAndCommercializationAgreementMember" id="atnm_LicenseDevelopmentAndCommercializationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultingServicesAgreementMember" id="atnm_ConsultingServicesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EngagementAgreementMember" id="atnm_EngagementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TransactionManagementAgreementMember" id="atnm_TransactionManagementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentMember" id="atnm_PlacementAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RelatedPartyTransactionsTextualAbstract" id="atnm_RelatedPartyTransactionsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfPatients" id="atnm_NumberOfPatients" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidUnderAgreementInYearTwoThousandEleven" id="atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidUnderAgreementInYearTwoThousandTwelve" id="atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidUnderAgreementInYearTwoThousandThirteen" id="atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" id="atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaintenanceFeesAndResearchPayments" id="atnm_MaintenanceFeesAndResearchPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentServicesFees" id="atnm_PlacementAgentServicesFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsIssuedToPurchaseCommonStock" id="atnm_WarrantsIssuedToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockExercisePriceParOrStatedValuePerShare" id="atnm_CommonStockExercisePriceParOrStatedValuePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidUnderAgreement" id="atnm_AmountPaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdditionalAmountDueUnderAgreement" id="atnm_AdditionalAmountDueUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfConditionForTerminationOfForbearancePeriod" id="atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TerminationDateOfForbearanceAgreement" id="atnm_TerminationDateOfForbearanceAgreement" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" id="atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NewEquityFinanceRaisedByCompany" id="atnm_NewEquityFinanceRaisedByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ForgivenAmountOfObligations" id="atnm_ForgivenAmountOfObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidToEachPatient" id="atnm_AmountPaidToEachPatient" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StartUpFeeForClinicalTrial" id="atnm_StartUpFeeForClinicalTrial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StartUpDueCostPaidDate" id="atnm_StartUpDueCostPaidDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfSharesTransferTerm" id="atnm_DescriptionOfSharesTransferTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionExercisePriceRange" id="atnm_OptionExercisePriceRange" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsReceivedToPurchaseCommonStock" id="atnm_OptionsReceivedToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfReceivablesOfPlacementAgentForServices" id="atnm_DescriptionOfReceivablesOfPlacementAgentForServices" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfWarrantsReceivablesByPlacement" id="atnm_DescriptionOfWarrantsReceivablesByPlacement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodOfExerciseOfWarrants" id="atnm_PeriodOfExerciseOfWarrants" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfSolicitationFee" id="atnm_PercentageOfSolicitationFee" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodicFeeForFinancialAdvisoryServices" id="atnm_PeriodicFeeForFinancialAdvisoryServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfAdditionalReceivableByPlacementAgent" id="atnm_DescriptionOfAdditionalReceivableByPlacementAgent" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockPurchaseByHoldingOfWarrant" id="atnm_CommonStockPurchaseByHoldingOfWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodicFeeReceivedByManagementFirm" id="atnm_PeriodicFeeReceivedByManagementFirm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfFullyDilutedCapitalStockEqualToCommonStock" id="atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaximumAmountOfOutOfPocketExpenses" id="atnm_MaximumAmountOfOutOfPocketExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodicAmountOfRent" id="atnm_PeriodicAmountOfRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidToPursuantLeaseAgreement" id="atnm_AmountPaidToPursuantLeaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultingFee" id="atnm_ConsultingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SettlementPaymentOfConsultingFee" id="atnm_SettlementPaymentOfConsultingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PropertyAndEquipmentTextualAbstract" id="atnm_PropertyAndEquipmentTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PremiumFinanceAgreementMember" id="atnm_PremiumFinanceAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ManagementFirmMember" id="atnm_ManagementFirmMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NotePayableAndConvertibleNotesTextualAbstract" id="atnm_NotePayableAndConvertibleNotesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockPurchaseDueToIssuanceOfWarrants" id="atnm_CommonStockPurchaseDueToIssuanceOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmortizationPeriodOfNote" id="atnm_AmortizationPeriodOfNote" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PremiumFinanceAgreementPrincipalAmount" id="atnm_PremiumFinanceAgreementPrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentUnderPremiumFinanceAgreement" id="atnm_PaymentUnderPremiumFinanceAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodicPaymentUnderPremiumFinanceAgreement" id="atnm_PeriodicPaymentUnderPremiumFinanceAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DurationOfPeriodicPaymentsForPremiumFinanceAgreement" id="atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PremiumFinanceAgreementOutstandingAmount" id="atnm_PremiumFinanceAgreementOutstandingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromConvertibleNotes" id="atnm_ProceedsFromConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" id="atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" id="atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeWarrantsIssuedWithConvertibleNotes" id="atnm_DerivativeWarrantsIssuedWithConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestmentWarrantGrantDateFairValue" id="atnm_InvestmentWarrantGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtInstrumentDiscountRelatedToBeneficialConversionFeature" id="atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtInstrumentFairValuePerShare" id="atnm_DebtInstrumentFairValuePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExtendedMaturityPeriodOfConvertibleNotes" id="atnm_ExtendedMaturityPeriodOfConvertibleNotes" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfExtendedMaturityDate" id="atnm_DescriptionOfExtendedMaturityDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" id="atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeWarrantsUnits" id="atnm_DerivativeWarrantsUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeWarrantsIssuedWithStockOffering" id="atnm_DerivativeWarrantsIssuedWithStockOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" id="atnm_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeWarrantsIssuedWithCommonStockOffering" id="atnm_DerivativeWarrantsIssuedWithCommonStockOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeWarrantsIssuedWithCommonStockOfferingOne" id="atnm_DerivativeWarrantsIssuedWithCommonStockOfferingOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativePlacementAgentWarrantsRelatedToStock" id="atnm_DerivativePlacementAgentWarrantsRelatedToStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TransferFromLiabilityClassificationToEquityClassification" id="atnm_TransferFromLiabilityClassificationToEquityClassification" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativeWarrantsIssuedWithStockOffering" id="atnm_FairValueOfDerivativeWarrantsIssuedWithStockOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" id="atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" id="atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" id="atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" id="atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ChangeInFairValueOfDerivativeWarrants" id="atnm_ChangeInFairValueOfDerivativeWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" id="atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MarketValueOfCommonStockOnMeasurementDate" id="atnm_MarketValueOfCommonStockOnMeasurementDate" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RangeOfPercentageOfExistingSharesOffered" id="atnm_RangeOfPercentageOfExistingSharesOffered" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueAssumptionOfferingPrice" id="atnm_FairValueAssumptionOfferingPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeTextualAbstract" id="atnm_DerivativeTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfRiskFreeInterestRateDetermination" id="atnm_DescriptionOfRiskFreeInterestRateDetermination" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfProbabilityOfStockOffering" id="atnm_DescriptionOfProbabilityOfStockOffering" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfSharesWarrantExercise" id="atnm_NumberOfSharesWarrantExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AbbottBiotherapeuticsCorpMember" id="atnm_AbbottBiotherapeuticsCorpMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseFirstClinicalTrialOfLicensedProductMember" id="atnm_PhaseFirstClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseSecondClinicalTrialOfLicensedProductMember" id="atnm_PhaseSecondClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseThirdClinicalTrialOfLicensedProductMember" id="atnm_PhaseThirdClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BiologicalLicenseApplicationMember" id="atnm_BiologicalLicenseApplicationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FirstCommercialSaleMember" id="atnm_FirstCommercialSaleMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AfterFirstNetSalesMember" id="atnm_AfterFirstNetSalesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePaymentAbstract" id="atnm_MilestonePaymentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LongTermPurchaseCommitmentMilestonesPayment" id="atnm_LongTermPurchaseCommitmentMilestonesPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesTable" id="atnm_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="OakRidgeNationalLaboratoryMember" id="atnm_OakRidgeNationalLaboratoryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AptivSolutionsMember" id="atnm_AptivSolutionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FredHutchinsonCancerResearchCenterMember" id="atnm_FredHutchinsonCancerResearchCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" id="atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfTexasMDAndersonCancerCenterMember" id="atnm_UniversityOfTexasMDAndersonCancerCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="JohnsHopkinsUniversityMember" id="atnm_JohnsHopkinsUniversityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LaidlawAndCoMember" id="atnm_LaidlawAndCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfPennsylvaniaMember" id="atnm_UniversityOfPennsylvaniaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FormerChiefExecutiveOfficerMember" id="atnm_FormerChiefExecutiveOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodAxis" id="atnm_PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="PeriodDomain" id="atnm_PeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandAndThirteenMember" id="atnm_TwoThousandAndThirteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandAndFourteenMember" id="atnm_TwoThousandAndFourteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProductDevelopmentAndPatentLicenseAgreementMember" id="atnm_ProductDevelopmentAndPatentLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseAgreementMember" id="atnm_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseAndSponsoredResearchAgreementMember" id="atnm_LicenseAndSponsoredResearchAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentAgreementMember" id="atnm_PlacementAgentAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeparationAndSettlementAgreementMember" id="atnm_SeparationAndSettlementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ManufacturingAgreementMember" id="atnm_ManufacturingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RentalAgreementMember" id="atnm_RentalAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesLineItems" id="atnm_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesTextualAbstract" id="atnm_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfLicenseFee" id="atnm_PaymentOfLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePaymentDate" id="atnm_MilestonePaymentDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfRoyaltyPaymentToRelatedParty" id="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RoyaltyOfNetSalesPercentage" id="atnm_RoyaltyOfNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FirstCommercialSalePeriod" id="atnm_FirstCommercialSalePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ResearchAndDevelopmentArrangement" id="atnm_ResearchAndDevelopmentArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PurchaseOfRadioactiveMaterial" id="atnm_PurchaseOfRadioactiveMaterial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProjectEstimatedCost" id="atnm_ProjectEstimatedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DownPaymentOfProjectEstimatedCostPercentage" id="atnm_DownPaymentOfProjectEstimatedCostPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DownPaymentForProject" id="atnm_DownPaymentForProject" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClinicalTrialCostForApprovalForFoodAndDrugAdministration" id="atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FundToRelatedPartyUnderAgreementForFirstTwoYear" id="atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FundToRelatedPartyUnderAgreementAfterYearTwo" id="atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementConsideration" id="atnm_AgreementConsideration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PerformanceBonusPayableUnderAgreementForService" id="atnm_PerformanceBonusPayableUnderAgreementForService" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantExercisableNoticePeriodDescription" id="atnm_WarrantExercisableNoticePeriodDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfSharesAvailabilityByExerciseOfWarrant" id="atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NonRefundableInstitutionalFee" id="atnm_NonRefundableInstitutionalFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PharmacyFee" id="atnm_PharmacyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmendmentProcessingFee" id="atnm_AmendmentProcessingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NoticePeriodForTerminationOfAgreement" id="atnm_NoticePeriodForTerminationOfAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementRenewalDescription" id="atnm_AgreementRenewalDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfAggregateAmount" id="atnm_PaymentOfAggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfFinalInstallmentForServicesByCompany" id="atnm_PaymentOfFinalInstallmentForServicesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfPerformanceBonusForServicesByCompany" id="atnm_PaymentOfPerformanceBonusForServicesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmployeesDirectorsAndConsultantsMember" id="atnm_EmployeesDirectorsAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmployeesAndBoardMembersMember" id="atnm_EmployeesAndBoardMembersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultantMember" id="atnm_ConsultantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityIncentivePlanMember" id="atnm_EquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityTextualAbstract" id="atnm_EquityTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentCashFees" id="atnm_PlacementAgentCashFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentAttorneyFees" id="atnm_PlacementAgentAttorneyFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RegistrationStatementDescription" id="atnm_RegistrationStatementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaximumOfferingPrice" id="atnm_MaximumOfferingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdditionalNumberOfRestrictedStockGranted" id="atnm_AdditionalNumberOfRestrictedStockGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueAssumptionsExpectedDiscountRate" id="atnm_FairValueAssumptionsExpectedDiscountRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsIssuedToPurchaseCommonStockOffering" id="atnm_WarrantsIssuedToPurchaseCommonStockOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromIssuanceOfStockUnderStockOfferingNet" id="atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsExercisedByWarrantHolders" id="atnm_WarrantsExercisedByWarrantHolders" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SubsequentEventsTextualAbstract" id="atnm_SubsequentEventsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>atnm-20140331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Tuesday, May 13, 2014 01:52:10 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="40" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/></calculationLink>




<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DepreciationAndAmortization" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SalesRevenueNet" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="20" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="70" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_atnm_GainOnChangeInFairValueOfDerivatives"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_atnm_GainOnChangeInFairValueOfDerivatives" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="100" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="110" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable" order="50" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#PropertyandEquipmentDetails" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="20" use="optional" weight="-1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>atnm-20140331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Tuesday, May 13, 2014 01:52:10 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#RelatedPartyTransactionsDetails" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#PropertyandEquipmentDetails" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#NotePayableDetails" roleURI="http://actiniumpharmaceuticals.com/role/NotePayableDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DerivativesDetails1" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails1"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DerivativesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#Commitmentsandcontingenciesdetailstextual" roleURI="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#EquityDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#SubsequenteventsDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequenteventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_atnm_SeriesCTwoPreferredStockMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCTwoPreferredStockMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_atnm_SeriesCThreePreferredStockMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCThreePreferredStockMember_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_atnm_SeriesCFourPreferredStockMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCFourPreferredStockMember_11" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_AssetsCurrentAbstract_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_Cash_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_AssetsCurrent_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_Assets_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_22" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20" xlink:to="loc_us-gaap_NotesPayableCurrent_23" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_24" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20" xlink:to="loc_us-gaap_LiabilitiesCurrent_25" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_Liabilities_26" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_CommitmentsAndContingencies_27" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_StockholdersEquityAbstract_28" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_PreferredStockValue_29" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_CommonStockValue_30" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_AdditionalPaidInCapital_31" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_32" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_StockholdersEquity_33" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_34" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_atnm_SeriesCTwoPreferredStockMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCTwoPreferredStockMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_atnm_SeriesCThreePreferredStockMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCThreePreferredStockMember_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_atnm_SeriesCFourPreferredStockMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCFourPreferredStockMember_11" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_16" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_17" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_18" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_19" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:label="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_7" xlink:to="loc_us-gaap_DerivativeLiabilities_8" order="0" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ActiniumMember" xlink:label="loc_atnm_ActiniumMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_atnm_ActiniumMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9" xlink:to="loc_us-gaap_ClassOfStockDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9" xlink:to="loc_us-gaap_ClassOfStockDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_us-gaap_CommonStockMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_WarrantMember_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_17" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OptionsAndWarrantsMember" xlink:label="loc_atnm_OptionsAndWarrantsMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_atnm_OptionsAndWarrantsMember_18" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_22" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_23" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_24" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SharesExchangeRatio" xlink:label="loc_atnm_SharesExchangeRatio_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_atnm_SharesExchangeRatio_25" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockShares" xlink:label="loc_atnm_CommonStockShares_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_atnm_CommonStockShares_27" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ExchangedInCommonStockShares" xlink:label="loc_atnm_ExchangedInCommonStockShares_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_atnm_ExchangedInCommonStockShares_28" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_NewDrugApplicationMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RelatedPartyMilestonesPayment" xlink:label="loc_atnm_RelatedPartyMilestonesPayment_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_9" xlink:to="loc_atnm_RelatedPartyMilestonesPayment_10" order="0" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RosemaryMazanetMember" xlink:label="loc_atnm_RosemaryMazanetMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_RosemaryMazanetMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LaidlawAndCompanyMember" xlink:label="loc_atnm_LaidlawAndCompanyMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCompanyMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_GuagentiAndAssociatesMember" xlink:label="loc_atnm_GuagentiAndAssociatesMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_GuagentiAndAssociatesMember_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_atnm_AgreementAxis_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_AgreementAxis_11" xlink:to="loc_atnm_AgreementDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_AgreementAxis_11" xlink:to="loc_atnm_AgreementDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_12" xlink:to="loc_atnm_ClinicalTrialAgreementMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_12" xlink:to="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ConsultingServicesAgreementMember" xlink:label="loc_atnm_ConsultingServicesAgreementMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_12" xlink:to="loc_atnm_ConsultingServicesAgreementMember_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EngagementAgreementMember" xlink:label="loc_atnm_EngagementAgreementMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_12" xlink:to="loc_atnm_EngagementAgreementMember_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_12" xlink:to="loc_atnm_TransactionManagementAgreementMember_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_19_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_19_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_19" xlink:to="loc_atnm_PlacementAgentMember_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_atnm_RelatedPartyTransactionsTextualAbstract_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_us-gaap_OfficersCompensation_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_NumberOfPatients_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_25" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_26" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:label="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_27" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MaintenanceFeesAndResearchPayments" xlink:label="loc_atnm_MaintenanceFeesAndResearchPayments_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_MaintenanceFeesAndResearchPayments_28" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentServicesFees" xlink:label="loc_atnm_PlacementAgentServicesFees_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_PlacementAgentServicesFees_29" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_30" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:label="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_31" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreement" xlink:label="loc_atnm_AmountPaidUnderAgreement_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_AmountPaidUnderAgreement_32" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AdditionalAmountDueUnderAgreement" xlink:label="loc_atnm_AdditionalAmountDueUnderAgreement_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_AdditionalAmountDueUnderAgreement_33" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_34" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TerminationDateOfForbearanceAgreement" xlink:label="loc_atnm_TerminationDateOfForbearanceAgreement_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_TerminationDateOfForbearanceAgreement_35" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_36" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NewEquityFinanceRaisedByCompany" xlink:label="loc_atnm_NewEquityFinanceRaisedByCompany_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_NewEquityFinanceRaisedByCompany_37" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ForgivenAmountOfObligations" xlink:label="loc_atnm_ForgivenAmountOfObligations_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_ForgivenAmountOfObligations_38" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_AmountPaidToEachPatient_39" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_40" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_StartUpDueCostPaidDate_41" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfSharesTransferTerm" xlink:label="loc_atnm_DescriptionOfSharesTransferTerm_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_DescriptionOfSharesTransferTerm_42" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OptionExercisePriceRange" xlink:label="loc_atnm_OptionExercisePriceRange_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_OptionExercisePriceRange_43" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_atnm_OptionsReceivedToPurchaseCommonStock_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_OptionsReceivedToPurchaseCommonStock_44" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_45" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_46" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodOfExerciseOfWarrants" xlink:label="loc_atnm_PeriodOfExerciseOfWarrants_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_PeriodOfExerciseOfWarrants_47" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PercentageOfSolicitationFee" xlink:label="loc_atnm_PercentageOfSolicitationFee_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_PercentageOfSolicitationFee_48" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_49" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_50" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_51" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_52" order="300" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_53" order="310" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_54" order="320" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicAmountOfRent" xlink:label="loc_atnm_PeriodicAmountOfRent_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_PeriodicAmountOfRent_55" order="330" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_atnm_AmountPaidToPursuantLeaseAgreement_56"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_AmountPaidToPursuantLeaseAgreement_56" order="340" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_57"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_57" order="350" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ConsultingFee" xlink:label="loc_atnm_ConsultingFee_58"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_ConsultingFee_58" order="360" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SettlementPaymentOfConsultingFee" xlink:label="loc_atnm_SettlementPaymentOfConsultingFee_59"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_atnm_SettlementPaymentOfConsultingFee_59" order="370" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_60"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_60" order="380" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_61"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_21" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_61" order="390" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_14" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/NotePayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_atnm_AgreementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_AgreementAxis_2" xlink:to="loc_atnm_AgreementDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_AgreementAxis_2" xlink:to="loc_atnm_AgreementDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PremiumFinanceAgreementMember" xlink:label="loc_atnm_PremiumFinanceAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_3" xlink:to="loc_atnm_PremiumFinanceAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_PlacementAgentMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ManagementFirmMember" xlink:label="loc_atnm_ManagementFirmMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_ManagementFirmMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" xlink:to="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmortizationPeriodOfNote" xlink:label="loc_atnm_AmortizationPeriodOfNote_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_atnm_AmortizationPeriodOfNote_14" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_NotesPayable_15" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_16" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_17" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_us-gaap_FairValueInputsProbabilityOfDefault_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueInputsProbabilityOfDefault_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="loc_atnm_FairValueAssumptionOfferingPrice_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_atnm_FairValueAssumptionOfferingPrice_15" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeByNatureAxis_2" xlink:to="loc_us-gaap_DerivativeNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeByNatureAxis_2" xlink:to="loc_us-gaap_DerivativeNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeTextualAbstract" xlink:label="loc_atnm_DerivativeTextualAbstract_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0" xlink:to="loc_atnm_DerivativeTextualAbstract_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfRiskFreeInterestRateDetermination" xlink:label="loc_atnm_DescriptionOfRiskFreeInterestRateDetermination_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_atnm_DescriptionOfRiskFreeInterestRateDetermination_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfProbabilityOfStockOffering" xlink:label="loc_atnm_DescriptionOfProbabilityOfStockOffering_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_atnm_DescriptionOfProbabilityOfStockOffering_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NumberOfSharesWarrantExercise" xlink:label="loc_atnm_NumberOfSharesWarrantExercise_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_atnm_NumberOfSharesWarrantExercise_18" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbottBiotherapeuticsCorpMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_BiologicalLicenseApplicationMember" xlink:label="loc_atnm_BiologicalLicenseApplicationMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_BiologicalLicenseApplicationMember_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FirstCommercialSaleMember" xlink:label="loc_atnm_FirstCommercialSaleMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_FirstCommercialSaleMember_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_AfterFirstNetSalesMember_13" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_NewDrugApplicationMember_14" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MilestonePaymentAbstract" xlink:label="loc_atnm_MilestonePaymentAbstract_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" xlink:to="loc_atnm_MilestonePaymentAbstract_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_MilestonePaymentAbstract_16" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_17" order="0" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual">
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommitmentsAndContingenciesLineItems" xlink:label="loc_atnm_CommitmentsAndContingenciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommitmentsAndContingenciesTable" xlink:label="loc_atnm_CommitmentsAndContingenciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_atnm_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_atnm_CommitmentsAndContingenciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbottBiotherapeuticsCorpMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_atnm_OakRidgeNationalLaboratoryMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_OakRidgeNationalLaboratoryMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AptivSolutionsMember" xlink:label="loc_atnm_AptivSolutionsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AptivSolutionsMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_atnm_FredHutchinsonCancerResearchCenterMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FredHutchinsonCancerResearchCenterMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_JohnsHopkinsUniversityMember" xlink:label="loc_atnm_JohnsHopkinsUniversityMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JohnsHopkinsUniversityMember_11" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCoMember_12" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_UniversityOfPennsylvaniaMember" xlink:label="loc_atnm_UniversityOfPennsylvaniaMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfPennsylvaniaMember_13" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_14" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FormerChiefExecutiveOfficerMember" xlink:label="loc_atnm_FormerChiefExecutiveOfficerMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FormerChiefExecutiveOfficerMember_15" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_AfterFirstNetSalesMember_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_20" xlink:to="loc_us-gaap_RangeMember_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_20" xlink:to="loc_us-gaap_RangeMember_21_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MaximumMember_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MinimumMember_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodAxis" xlink:label="loc_atnm_PeriodAxis_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_PeriodAxis_24" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodDomain" xlink:label="loc_atnm_PeriodDomain_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_PeriodAxis_24" xlink:to="loc_atnm_PeriodDomain_25" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodDomain" xlink:label="loc_atnm_PeriodDomain_25_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_PeriodAxis_24" xlink:to="loc_atnm_PeriodDomain_25_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TwoThousandAndThirteenMember" xlink:label="loc_atnm_TwoThousandAndThirteenMember_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndThirteenMember_26" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TwoThousandAndFourteenMember" xlink:label="loc_atnm_TwoThousandAndFourteenMember_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndFourteenMember_27" order="10" use="optional"/>








<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_AgreementAxis_31" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_AgreementAxis_31" xlink:to="loc_atnm_AgreementDomain_32" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_32_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_AgreementAxis_31" xlink:to="loc_atnm_AgreementDomain_32_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_33" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LicenseAgreementMember" xlink:label="loc_atnm_LicenseAgreementMember_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_LicenseAgreementMember_34" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_atnm_LicenseAndSponsoredResearchAgreementMember_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_LicenseAndSponsoredResearchAgreementMember_35" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_ClinicalTrialAgreementMember_36" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentAgreementMember" xlink:label="loc_atnm_PlacementAgentAgreementMember_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_PlacementAgentAgreementMember_37" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_TransactionManagementAgreementMember_38" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeparationAndSettlementAgreementMember" xlink:label="loc_atnm_SeparationAndSettlementAgreementMember_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_SeparationAndSettlementAgreementMember_39" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ManufacturingAgreementMember" xlink:label="loc_atnm_ManufacturingAgreementMember_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_ManufacturingAgreementMember_40" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RentalAgreementMember" xlink:label="loc_atnm_RentalAgreementMember_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_RentalAgreementMember_41" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_43" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_us-gaap_TechnologyServicesCosts_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_TechnologyServicesCosts_44" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_MaintenanceCosts_45" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfLicenseFee" xlink:label="loc_atnm_PaymentOfLicenseFee_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PaymentOfLicenseFee_46" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_47" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MilestonePaymentDate" xlink:label="loc_atnm_MilestonePaymentDate_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_MilestonePaymentDate_48" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_49" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RoyaltyOfNetSalesPercentage" xlink:label="loc_atnm_RoyaltyOfNetSalesPercentage_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_RoyaltyOfNetSalesPercentage_50" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_atnm_FirstCommercialSalePeriod_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_FirstCommercialSalePeriod_51" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ResearchAndDevelopmentArrangement" xlink:label="loc_atnm_ResearchAndDevelopmentArrangement_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_ResearchAndDevelopmentArrangement_52" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PurchaseOfRadioactiveMaterial" xlink:label="loc_atnm_PurchaseOfRadioactiveMaterial_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PurchaseOfRadioactiveMaterial_53" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_atnm_ProjectEstimatedCost_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_ProjectEstimatedCost_54" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_55" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DownPaymentForProject" xlink:label="loc_atnm_DownPaymentForProject_56"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_DownPaymentForProject_56" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_57"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_57" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_58"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_58" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_59"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_59" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_60"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_NumberOfPatients_60" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_61"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_AmountPaidToEachPatient_61" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_62"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_62" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_63"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_StartUpDueCostPaidDate_63" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementConsideration" xlink:label="loc_atnm_AgreementConsideration_64"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_AgreementConsideration_64" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_atnm_PerformanceBonusPayableUnderAgreementForService_65"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PerformanceBonusPayableUnderAgreementForService_65" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_66"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_66" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_67"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_67" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantExercisableNoticePeriodDescription" xlink:label="loc_atnm_WarrantExercisableNoticePeriodDescription_68"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_WarrantExercisableNoticePeriodDescription_68" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_69"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_69" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_70"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_70" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NonRefundableInstitutionalFee" xlink:label="loc_atnm_NonRefundableInstitutionalFee_71"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_NonRefundableInstitutionalFee_71" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PharmacyFee" xlink:label="loc_atnm_PharmacyFee_72"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PharmacyFee_72" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmendmentProcessingFee" xlink:label="loc_atnm_AmendmentProcessingFee_73"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_AmendmentProcessingFee_73" order="300" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NoticePeriodForTerminationOfAgreement" xlink:label="loc_atnm_NoticePeriodForTerminationOfAgreement_74"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_NoticePeriodForTerminationOfAgreement_74" order="310" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_75"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_LeaseExpirationDate1_75" order="320" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementRenewalDescription" xlink:label="loc_atnm_AgreementRenewalDescription_76"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_AgreementRenewalDescription_76" order="330" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfAggregateAmount" xlink:label="loc_atnm_PaymentOfAggregateAmount_77"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PaymentOfAggregateAmount_77" order="340" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_78"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_78" order="350" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_79"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_79" order="360" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_80"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_80" order="370" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_81"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_LegalFees_81" order="380" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_82"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_82" order="390" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_15" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_16" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_17" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_19" order="120" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_PrivatePlacementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_CommonStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9" xlink:to="loc_atnm_LaidlawAndCoMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_11" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_11" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_atnm_EmployeesDirectorsAndConsultantsMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" xlink:to="loc_atnm_EmployeesDirectorsAndConsultantsMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EmployeesAndBoardMembersMember" xlink:label="loc_atnm_EmployeesAndBoardMembersMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" xlink:to="loc_atnm_EmployeesAndBoardMembersMember_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" xlink:to="loc_us-gaap_InvestorMember_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ConsultantMember" xlink:label="loc_atnm_ConsultantMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" xlink:to="loc_atnm_ConsultantMember_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_PlanNameAxis_17" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_17" xlink:to="loc_us-gaap_PlanNameDomain_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_18_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_17" xlink:to="loc_us-gaap_PlanNameDomain_18_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EquityIncentivePlanMember" xlink:label="loc_atnm_EquityIncentivePlanMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_18" xlink:to="loc_atnm_EquityIncentivePlanMember_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_20" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21" xlink:to="loc_us-gaap_EmployeeStockOptionMember_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RangeAxis_23" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_23" xlink:to="loc_us-gaap_RangeMember_24" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_24_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_23" xlink:to="loc_us-gaap_RangeMember_24_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_24" xlink:to="loc_us-gaap_MinimumMember_25" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_24" xlink:to="loc_us-gaap_MaximumMember_26" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_27" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_27" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_27" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28" xlink:to="loc_atnm_PlacementAgentMember_29" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EquityTextualAbstract" xlink:label="loc_atnm_EquityTextualAbstract_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_atnm_EquityTextualAbstract_30" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_31" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentCashFees" xlink:label="loc_atnm_PlacementAgentCashFees_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_atnm_PlacementAgentCashFees_32" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentAttorneyFees" xlink:label="loc_atnm_PlacementAgentAttorneyFees_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_atnm_PlacementAgentAttorneyFees_33" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_34" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_35" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_36" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_37" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_DebtInstrumentTerm_38" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_39" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_40" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_41" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_42" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_43" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RegistrationStatementDescription" xlink:label="loc_atnm_RegistrationStatementDescription_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_atnm_RegistrationStatementDescription_44" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MaximumOfferingPrice" xlink:label="loc_atnm_MaximumOfferingPrice_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_atnm_MaximumOfferingPrice_45" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_46" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_47" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_48" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_49" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AdditionalNumberOfRestrictedStockGranted" xlink:label="loc_atnm_AdditionalNumberOfRestrictedStockGranted_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_atnm_AdditionalNumberOfRestrictedStockGranted_50" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_51" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_52" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_53" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_54" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_55" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_56"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_56" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="loc_atnm_FairValueAssumptionsExpectedDiscountRate_57"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_atnm_FairValueAssumptionsExpectedDiscountRate_57" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantsIssuedToPurchaseCommonStockOffering" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStockOffering_58"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStockOffering_58" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xlink:label="loc_atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet_59"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet_59" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_atnm_WarrantsExercisedByWarrantHolders_60"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_atnm_WarrantsExercisedByWarrantHolders_60" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_61"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_CommonStockSharesIssued_61" order="300" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_62"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_62" order="310" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_63"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_63" order="320" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64" order="330" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_65"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_65" order="340" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualAbstract_30" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66" order="350" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequenteventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeparationAndSettlementAgreementMember" xlink:label="loc_atnm_SeparationAndSettlementAgreementMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_atnm_SeparationAndSettlementAgreementMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8" xlink:to="loc_us-gaap_EquityComponentDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8" xlink:to="loc_us-gaap_EquityComponentDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_WarrantMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RangeAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_12" xlink:to="loc_us-gaap_RangeMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_12" xlink:to="loc_us-gaap_RangeMember_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_13" xlink:to="loc_us-gaap_MaximumMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_13" xlink:to="loc_us-gaap_MinimumMember_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_16" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_16" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FormerChiefExecutiveOfficerMember" xlink:label="loc_atnm_FormerChiefExecutiveOfficerMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17" xlink:to="loc_atnm_FormerChiefExecutiveOfficerMember_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="loc_atnm_SubsequentEventsTextualAbstract_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_atnm_SubsequentEventsTextualAbstract_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_22" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_24" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_SecurityDeposit_27" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_LeaseExpirationDate1_28" order="80" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>atnm-20140331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Tuesday, May 13, 2014 01:52:10 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DocumentAndEntityInformationAbstract" xlink:label="loc_K567K28545K5_atnm_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DocumentAndEntityInformationAbstract" xlink:to="lab_M789M40767M7_atnm_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_62JJJ544JG849J4F45GF_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_dei_EntityRegistrantName" xlink:to="lab_84LLL766LI061L6H67IH_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_K567K28545K5_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_dei_EntityCentralIndexKey" xlink:to="lab_M789M40767M7_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_62JJJ544JG849J4F45GF_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_dei_AmendmentFlag" xlink:to="lab_84LLL766LI061L6H67IH_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_K567K28545K5_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_dei_CurrentFiscalYearEndDate" xlink:to="lab_M789M40767M7_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_62JJJ544JG849J4F45GF_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_dei_DocumentType" xlink:to="lab_84LLL766LI061L6H67IH_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_K567K28545K5_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_dei_DocumentPeriodEndDate" xlink:to="lab_M789M40767M7_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_62JJJ544JG849J4F45GF_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_dei_DocumentFiscalYearFocus" xlink:to="lab_84LLL766LI061L6H67IH_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_K567K28545K5_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_dei_DocumentFiscalPeriodFocus" xlink:to="lab_M789M40767M7_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_62JJJ544JG849J4F45GF_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_dei_EntityFilerCategory" xlink:to="lab_84LLL766LI061L6H67IH_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_K567K28545K5_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_M789M40767M7_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Balance Sheets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_K567K28545K5_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StatementTable" xlink:to="lab_M789M40767M7_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StatementClassOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StatementClassOfStockAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_K567K28545K5_us-gaap_ClassOfStockDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ClassOfStockDomain" xlink:to="lab_M789M40767M7_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesAPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SeriesAPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_K567K28545K5_us-gaap_SeriesBPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_M789M40767M7_us-gaap_SeriesBPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesCPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C-1 Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SeriesCPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_K567K28545K5_us-gaap_SeriesDPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SeriesDPreferredStockMember" xlink:to="lab_M789M40767M7_us-gaap_SeriesDPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesEPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesEPreferredStockMember" xml:lang="en-US">Series E Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesEPreferredStockMember" xml:lang="en-US">Series E Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesEPreferredStockMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SeriesEPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_K567K28545K5_atnm_SeriesCTwoPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_SeriesCTwoPreferredStockMember" xml:lang="en-US">Series C Two Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_SeriesCTwoPreferredStockMember" xml:lang="en-US">Series C-2 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_SeriesCTwoPreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C two preferred stock or outstanding series C two preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_SeriesCTwoPreferredStockMember" xlink:to="lab_M789M40767M7_atnm_SeriesCTwoPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_SeriesCThreePreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SeriesCThreePreferredStockMember" xml:lang="en-US">Series C Three Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SeriesCThreePreferredStockMember" xml:lang="en-US">Series C-3 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SeriesCThreePreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C three preferred stock or outstanding series C three preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_SeriesCThreePreferredStockMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_SeriesCThreePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_K567K28545K5_atnm_SeriesCFourPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_SeriesCFourPreferredStockMember" xml:lang="en-US">Series C Four Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_SeriesCFourPreferredStockMember" xml:lang="en-US">Series C-4 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_SeriesCFourPreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C four preferred stock or outstanding series C four preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_SeriesCFourPreferredStockMember" xlink:to="lab_M789M40767M7_atnm_SeriesCFourPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StatementLineItems" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_K567K28545K5_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AssetsAbstract" xlink:to="lab_M789M40767M7_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AssetsCurrentAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_K567K28545K5_us-gaap_Cash"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_Cash" xml:lang="en-US">Cash In Bank</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_Cash" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_Cash" xlink:to="lab_M789M40767M7_us-gaap_Cash"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_K567K28545K5_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AssetsCurrent" xlink:to="lab_M789M40767M7_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net of accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_K567K28545K5_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_Assets" xlink:to="lab_M789M40767M7_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_K567K28545K5_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_M789M40767M7_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_K567K28545K5_us-gaap_AccountsPayableRelatedPartiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_M789M40767M7_us-gaap_AccountsPayableRelatedPartiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NotesPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NotesPayableCurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_K567K28545K5_us-gaap_DerivativeLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_M789M40767M7_us-gaap_DerivativeLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_LiabilitiesCurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_K567K28545K5_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_Liabilities" xlink:to="lab_M789M40767M7_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CommitmentsAndContingencies" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_K567K28545K5_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Deficit:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StockholdersEquityAbstract" xlink:to="lab_M789M40767M7_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, 100,000,000 Shares .01 Par Authorized, 0 Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, 100,000,000 shares $.01 par authorized, 0 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.01 par value; 50,000,000 authorized 0 issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PreferredStockValue" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_K567K28545K5_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, 100,000,000 shares, $.01 par authorized, 11,155,008 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.01 par value; 200,000,000 shares authorized; 25,562,346 and 24,565,447 shares issued and outstanding, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CommonStockValue" xlink:to="lab_M789M40767M7_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Paid in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AdditionalPaidInCapital" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_K567K28545K5_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Development Stage Enterprise, Deficit Accumulated During Development Stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Deficit accumulated during development stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Deficit accumulated during the development stage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="lab_M789M40767M7_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholder's Deficiency</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StockholdersEquity" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_K567K28545K5_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_M789M40767M7_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_K567K28545K5_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_M789M40767M7_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PreferredStockSharesIssued" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_K567K28545K5_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">No. of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_M789M40767M7_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_K567K28545K5_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_M789M40767M7_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock shares issued in exchange of equity securities of company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock sold, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockSharesIssued" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_K567K28545K5_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_M789M40767M7_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Statements Of Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeStatementAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_K567K28545K5_us-gaap_SalesRevenueNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SalesRevenueNet" xml:lang="en-US">Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SalesRevenueNet" xlink:to="lab_M789M40767M7_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_OperatingExpensesAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_K567K28545K5_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research recorded fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development, net of reimbursements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_M789M40767M7_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_K567K28545K5_us-gaap_DepreciationAndAmortization"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DepreciationAndAmortization" xlink:to="lab_M789M40767M7_us-gaap_DepreciationAndAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_GainLossOnDispositionOfAssets1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_GainLossOnDispositionOfAssets1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_K567K28545K5_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_OperatingExpenses" xml:lang="en-US">Total expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_OperatingExpenses" xlink:to="lab_M789M40767M7_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Net loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss From Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_OperatingIncomeLoss" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_K567K28545K5_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income and (Expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_M789M40767M7_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_InterestExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_InterestExpense" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_K567K28545K5_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gains (Losses) On Extinguishment Of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_M789M40767M7_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) On Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Loss on change in fair value of the derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Gain (loss) on change in fair value of derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Gain/loss on change in fair value of the derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_K567K28545K5_us-gaap_NonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Net Other income (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income and (Expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_M789M40767M7_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NetIncomeLoss" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_K567K28545K5_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Loss Per Common Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net Loss Per Common Share - Basic and Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_M789M40767M7_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Common Shares Outstanding - Basic and Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_K567K28545K5_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_M789M40767M7_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_K567K28545K5_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_M789M40767M7_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_K567K28545K5_us-gaap_DepreciationDepletionAndAmortization"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_M789M40767M7_us-gaap_DepreciationDepletionAndAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AmortizationOfDebtDiscountPremium"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Add: amortization of discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_K567K28545K5_us-gaap_AmortizationOfFinancingCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of deferred financing costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_M789M40767M7_us-gaap_AmortizationOfFinancingCosts"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_GainOnChangeInFairValueOfDerivatives"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain On Change In Fair Value Of Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain on change in fair value of the derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain on change in fair value of the derivatives.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Loss (gain) on change in fair value of derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_GainOnChangeInFairValueOfDerivatives" xlink:to="lab_84LLL766LI061L6H67IH_atnm_GainOnChangeInFairValueOfDerivatives"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_K567K28545K5_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">(Increase) decrease in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_M789M40767M7_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_K567K28545K5_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (decrease) in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_M789M40767M7_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_K567K28545K5_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Increase (Decrease) In Accounts Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Accounts payable and accrued expenses - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_M789M40767M7_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PaymentsToAcquireIntangibleAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payments To Acquire Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payment made for patent rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payment made for patent rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PaymentsToAcquireIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_K567K28545K5_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_M789M40767M7_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Used In Investing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US">Proceeds From Debt, Net Of Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US">Borrowings on convertible debt, net of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_K567K28545K5_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds From Issuance Of Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Sales of stock, net of offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from issuance of preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_M789M40767M7_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from the exercise of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_K567K28545K5_us-gaap_ProceedsFromWarrantExercises"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from the exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_M789M40767M7_us-gaap_ProceedsFromWarrantExercises"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RepaymentsOfNotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayments of Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payments on note payble</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payments on note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RepaymentsOfNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used in) Financing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">INCREASE IN CASH AND CASH EQUIVALENTS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net change in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_K567K28545K5_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, At Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at the beginning of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SupplementalCashFlowInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flows information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_K567K28545K5_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_InterestPaid" xlink:to="lab_M789M40767M7_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxesPaid" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_K567K28545K5_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_M789M40767M7_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Beneficial conversion feature discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_InsurancePrepaidThroughPremiumFinance" xlink:label="loc_K567K28545K5_atnm_InsurancePrepaidThroughPremiumFinance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_InsurancePrepaidThroughPremiumFinance" xml:lang="en-US">Insurance Prepaid Through Premium Finance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_InsurancePrepaidThroughPremiumFinance" xml:lang="en-US">Insurance prepaid through premium finance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_InsurancePrepaidThroughPremiumFinance" xml:lang="en-US">Insurance prepaid through premium finance.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_InsurancePrepaidThroughPremiumFinance" xlink:to="lab_M789M40767M7_atnm_InsurancePrepaidThroughPremiumFinance"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfWarrantsIssuedWithDebt" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfWarrantsIssuedWithDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfWarrantsIssuedWithDebt" xml:lang="en-US">Fair Value Of Warrants Issued With Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfWarrantsIssuedWithDebt" xml:lang="en-US">Fair value of warrants issued with debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfWarrantsIssuedWithDebt" xml:lang="en-US">Fair value of warrants issued with debt.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfWarrantsIssuedWithDebt" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FairValueOfWarrantsIssuedWithDebt"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfWarrantsIssuedWithStock" xlink:label="loc_K567K28545K5_atnm_FairValueOfWarrantsIssuedWithStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_FairValueOfWarrantsIssuedWithStock" xml:lang="en-US">Fair Value Of Warrants Issued With Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_FairValueOfWarrantsIssuedWithStock" xml:lang="en-US">Fair value of warrants issued with stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_FairValueOfWarrantsIssuedWithStock" xml:lang="en-US">Fair value of warrants issued with stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_FairValueOfWarrantsIssuedWithStock" xlink:to="lab_M789M40767M7_atnm_FairValueOfWarrantsIssuedWithStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfWarrantsIssuedToPlacementAgent" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfWarrantsIssuedToPlacementAgent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfWarrantsIssuedToPlacementAgent" xml:lang="en-US">Fair Value Of Warrants Issued To Placement Agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfWarrantsIssuedToPlacementAgent" xml:lang="en-US">Fair value of warrants issued to the placement agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfWarrantsIssuedToPlacementAgent" xml:lang="en-US">Fair value of warrants issued to the placement agent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfWarrantsIssuedToPlacementAgent" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FairValueOfWarrantsIssuedToPlacementAgent"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:label="loc_K567K28545K5_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion Of Notes Payable and Accrued Interest To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion of notes payable and accrued interest to stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion of notes payable and accrued interest to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:to="lab_M789M40767M7_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Fair Value Of Transfer From Liability Classification To Equity Classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from derivative liability classification to equity classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Fair value of Transfer from liability classification to equity classification.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer warrant derivatives from liability to equity classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_K567K28545K5_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_M789M40767M7_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_K567K28545K5_us-gaap_RelatedPartyTransactionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_M789M40767M7_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property and Equipment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_K567K28545K5_us-gaap_DebtDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Note Payable [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Amortization of debt discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DebtDisclosureAbstract" xlink:to="lab_M789M40767M7_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Note Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_K567K28545K5_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivatives [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_M789M40767M7_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_K567K28545K5_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_M789M40767M7_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_K567K28545K5_us-gaap_EquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EquityAbstract" xlink:to="lab_M789M40767M7_us-gaap_EquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_K567K28545K5_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsequentEventsAbstract" xlink:to="lab_M789M40767M7_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_K567K28545K5_us-gaap_BusinessCombinationsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Nature of Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_M789M40767M7_us-gaap_BusinessCombinationsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation - Unaudited Interim Financial Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DevelopmentStageCompanyPolicyTextBlock" xlink:label="loc_K567K28545K5_atnm_DevelopmentStageCompanyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for development Stage of the company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DevelopmentStageCompanyPolicyTextBlock" xlink:to="lab_M789M40767M7_atnm_DevelopmentStageCompanyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ConsolidationPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ConsolidationPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_K567K28545K5_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_UseOfEstimates" xml:lang="en-US">Use Of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates in Financial Statement Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_UseOfEstimates" xlink:to="lab_M789M40767M7_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_K567K28545K5_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_K567K28545K5_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment Or Disposal Of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_M789M40767M7_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_K567K28545K5_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_M789M40767M7_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_K567K28545K5_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_M789M40767M7_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Share-Based Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_K567K28545K5_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings (Loss) Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_M789M40767M7_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_K567K28545K5_us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_M789M40767M7_us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Summary of set forth liabilities measured at fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule Of Related Party Transactions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Summary of activities related to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule Of Derivative Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule of derivative warrant instruments activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Fair Value Of Derivative Warrants On Basis Of Valuation Model [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Summary of fair values of derivative warrants on basis of valuation model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Fair value of derivative warrants on basis of valuation model.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_K567K28545K5_atnm_MilestonePaymentsMilestoneMethodTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Milestone Payments Milestone Method [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Summary of milestone payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Milestone payments milestone method.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:to="lab_M789M40767M7_atnm_MilestonePaymentsMilestoneMethodTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_K567K28545K5_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AwardTypeAxis" xlink:to="lab_M789M40767M7_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_K567K28545K5_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EmployeeStockOptionMember" xlink:to="lab_M789M40767M7_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_WarrantMember" xml:lang="en-US">A Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_WarrantMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of option activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of stock option activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Summary of warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_K567K28545K5_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_M789M40767M7_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_K567K28545K5_us-gaap_FairValueInputsLevel1Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_M789M40767M7_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueInputsLevel2Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_K567K28545K5_us-gaap_FairValueInputsLevel3Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_M789M40767M7_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured On Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:label="loc_K567K28545K5_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xml:lang="en-US">Summary Of Liabilities Measured At Fair Value On Recurring Basis [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xml:lang="en-US">Summary of liabilities measured at fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:to="lab_M789M40767M7_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeLiabilities" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_K567K28545K5_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description of business and summary of significant accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_M789M40767M7_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_62JJJ544JG849J4F45GF_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_dei_LegalEntityAxis" xlink:to="lab_84LLL766LI061L6H67IH_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_K567K28545K5_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_dei_EntityDomain" xlink:to="lab_M789M40767M7_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ActiniumMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ActiniumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ActiniumMember" xml:lang="en-US">Actinium [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ActiniumMember" xml:lang="en-US">Actinium [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ActiniumMember" xml:lang="en-US">Actinium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ActiniumMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ActiniumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_K567K28545K5_us-gaap_MachineryAndEquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_M789M40767M7_us-gaap_MachineryAndEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FurnitureAndFixturesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FurnitureAndFixturesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_K567K28545K5_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CommonStockMember" xlink:to="lab_M789M40767M7_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_K567K28545K5_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_M789M40767M7_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ConvertiblePreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ConvertiblePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_K567K28545K5_us-gaap_ConvertibleNotesPayableMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_M789M40767M7_us-gaap_ConvertibleNotesPayableMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OptionsAndWarrantsMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_OptionsAndWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_OptionsAndWarrantsMember" xml:lang="en-US">Options And Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_OptionsAndWarrantsMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_OptionsAndWarrantsMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_K567K28545K5_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description of business and summary of significant accounting policies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_M789M40767M7_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_K567K28545K5_dei_EntityIncorporationDateOfIncorporation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_M789M40767M7_dei_EntityIncorporationDateOfIncorporation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of ownership interest acquired by company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_K567K28545K5_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock Issuable In Consideration For Equity Interest Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock issuable in consideration for equity interest acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock issuable in consideration for equity interest acquisition.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:to="lab_M789M40767M7_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SharesExchangeRatio" xlink:label="loc_K567K28545K5_atnm_SharesExchangeRatio"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_SharesExchangeRatio" xml:lang="en-US">Shares Exchange Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_SharesExchangeRatio" xml:lang="en-US">Shares received by each API shareholder of Actinium common stock for each API share exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_SharesExchangeRatio" xml:lang="en-US">Shares exchange ratio.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_SharesExchangeRatio" xlink:to="lab_M789M40767M7_atnm_SharesExchangeRatio"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Potentially issuable shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockShares" xlink:label="loc_K567K28545K5_atnm_CommonStockShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_CommonStockShares" xml:lang="en-US">Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_atnm_CommonStockShares" xml:lang="en-US">Common stock shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_CommonStockShares" xml:lang="en-US">Common stock shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_CommonStockShares" xlink:to="lab_M789M40767M7_atnm_CommonStockShares"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ExchangedInCommonStockShares" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ExchangedInCommonStockShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ExchangedInCommonStockShares" xml:lang="en-US">Exchanged In Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ExchangedInCommonStockShares" xml:lang="en-US">Common stock shares exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ExchangedInCommonStockShares" xml:lang="en-US">Common stock shares exchanged.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ExchangedInCommonStockShares" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ExchangedInCommonStockShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_K567K28545K5_us-gaap_RelatedPartyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RelatedPartyDomain" xlink:to="lab_M789M40767M7_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_MemorialSloanKetteringCancerCenterMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial Sloan Kettering Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">MSKCC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">MSKCC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial sloan kettering cancer center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_MemorialSloanKetteringCancerCenterMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_MemorialSloanKetteringCancerCenterMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_K567K28545K5_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category Of Item Purchased [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_M789M40767M7_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-Term Purchase Commitment, Category Of Item Purchased [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_K567K28545K5_atnm_NewDrugApplicationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_NewDrugApplicationMember" xml:lang="en-US">New Drug Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_NewDrugApplicationMember" xml:lang="en-US">New Drug Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_NewDrugApplicationMember" xml:lang="en-US">New drug application.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_NewDrugApplicationMember" xlink:to="lab_M789M40767M7_atnm_NewDrugApplicationMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt Of Regulatory Approval From U S Fda [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt of Regulatory Approval From U.S. FDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt of regulatory approval from U.S. FDA.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_K567K28545K5_us-gaap_RelatedPartyTransactionLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_M789M40767M7_us-gaap_RelatedPartyTransactionLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xml:lang="en-US">Related Party Transaction, Due From (To) Related Party, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xml:lang="en-US">Summary of milestone payments related to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RelatedPartyMilestonesPayment" xlink:label="loc_K567K28545K5_atnm_RelatedPartyMilestonesPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_RelatedPartyMilestonesPayment" xml:lang="en-US">Related Party Milestones Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_atnm_RelatedPartyMilestonesPayment" xml:lang="en-US">Milestones payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_RelatedPartyMilestonesPayment" xml:lang="en-US">Related party milestones payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_RelatedPartyMilestonesPayment" xlink:to="lab_M789M40767M7_atnm_RelatedPartyMilestonesPayment"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_SloanKetteringInstituteOfCancerResearchMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Sloan Kettering Institute Of Cancer Research [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">SKI [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Sloan kettering institute of cancer research.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_SloanKetteringInstituteOfCancerResearchMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_K567K28545K5_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Memorial Sloan Kettering Cancer Center Sloan Kettering Institute Of Cancer Research [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">MSKCC and SKI [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Memorial sloan kettering cancer center sloan kettering institute of cancer research.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:to="lab_M789M40767M7_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RosemaryMazanetMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_RosemaryMazanetMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_RosemaryMazanetMember" xml:lang="en-US">Rosemary Mazanet [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_RosemaryMazanetMember" xml:lang="en-US">Dr. Rosemary Mazanet [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_RosemaryMazanetMember" xml:lang="en-US">Rosemary mazanet.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_RosemaryMazanetMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_RosemaryMazanetMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LaidlawAndCompanyMember" xlink:label="loc_K567K28545K5_atnm_LaidlawAndCompanyMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_LaidlawAndCompanyMember" xlink:to="lab_M789M40767M7_atnm_LaidlawAndCompanyMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_JamessCapitalGroupMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_JamessCapitalGroupMember" xml:lang="en-US">Jamess Capital Group [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_JamessCapitalGroupMember" xml:lang="en-US">Jamess Capital Group LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_JamessCapitalGroupMember" xml:lang="en-US">Jamess capital group.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_JamessCapitalGroupMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_JamessCapitalGroupMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_GuagentiAndAssociatesMember" xlink:label="loc_K567K28545K5_atnm_GuagentiAndAssociatesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti and Associates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti &amp; Associates LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti and associates.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_GuagentiAndAssociatesMember" xlink:to="lab_M789M40767M7_atnm_GuagentiAndAssociatesMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementAxis" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_AgreementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AgreementAxis" xml:lang="en-US">Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_AgreementAxis" xlink:to="lab_84LLL766LI061L6H67IH_atnm_AgreementAxis"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementDomain" xlink:label="loc_K567K28545K5_atnm_AgreementDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AgreementDomain" xml:lang="en-US">Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AgreementDomain" xlink:to="lab_M789M40767M7_atnm_AgreementDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ClinicalTrialAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical Trial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical Trial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical trial agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ClinicalTrialAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ClinicalTrialAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_K567K28545K5_atnm_LicenseDevelopmentAndCommercializationAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License Development and Commercialization Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License, Development and Commercialization Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License development and commercialization agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:to="lab_M789M40767M7_atnm_LicenseDevelopmentAndCommercializationAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ConsultingServicesAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ConsultingServicesAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting Services Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting Services Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting services agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ConsultingServicesAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ConsultingServicesAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EngagementAgreementMember" xlink:label="loc_K567K28545K5_atnm_EngagementAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_EngagementAgreementMember" xml:lang="en-US">Engagement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_EngagementAgreementMember" xml:lang="en-US">Engagement agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_EngagementAgreementMember" xlink:to="lab_M789M40767M7_atnm_EngagementAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_TransactionManagementAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_TransactionManagementAgreementMember" xml:lang="en-US">Transaction Management Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_TransactionManagementAgreementMember" xml:lang="en-US">Transaction management agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_TransactionManagementAgreementMember" xml:lang="en-US">Transaction management agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_TransactionManagementAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_TransactionManagementAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_K567K28545K5_us-gaap_SubsidiarySaleOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Subsidiary, Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Subsidiary, Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_M789M40767M7_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentMember" xlink:label="loc_K567K28545K5_atnm_PlacementAgentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PlacementAgentMember" xml:lang="en-US">Placement Agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_PlacementAgentMember" xml:lang="en-US">Placement Agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_PlacementAgentMember" xml:lang="en-US">Placement agent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PlacementAgentMember" xlink:to="lab_M789M40767M7_atnm_PlacementAgentMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_RelatedPartyTransactionsTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_atnm_RelatedPartyTransactionsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_K567K28545K5_us-gaap_OfficersCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_M789M40767M7_us-gaap_OfficersCompensation" xml:lang="en-US">Base salary at annual rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_OfficersCompensation" xlink:to="lab_M789M40767M7_us-gaap_OfficersCompensation"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NumberOfPatients" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_NumberOfPatients"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NumberOfPatients" xml:lang="en-US">Number Of Patients</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NumberOfPatients" xml:lang="en-US">Number of Patients enrolled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NumberOfPatients" xml:lang="en-US">Number of Patients</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NumberOfPatients" xml:lang="en-US">Number of patients.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_NumberOfPatients" xlink:to="lab_84LLL766LI061L6H67IH_atnm_NumberOfPatients"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_K567K28545K5_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Eleven</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount paid under agreement in 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount paid under agreement in year two thousand eleven.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:to="lab_M789M40767M7_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Twelve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount paid under agreement in 2012</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount paid under agreement in year two thousand twelve.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:to="lab_84LLL766LI061L6H67IH_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_K567K28545K5_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Thirteen</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount paid under agreement in 2013</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount paid under agreement in year two thousand thirteen.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:to="lab_M789M40767M7_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xml:lang="en-US">Owed Amount Under Agreement In Year Two Thousand Eleven To Fourteen</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xml:lang="en-US">Amount owed under agreement from 2011 to 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xml:lang="en-US">Owed amount under agreement in year two thousand eleven to fourteen.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:to="lab_84LLL766LI061L6H67IH_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MaintenanceFeesAndResearchPayments" xlink:label="loc_K567K28545K5_atnm_MaintenanceFeesAndResearchPayments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance Fees and Research Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance fees and research payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance fees and research payments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_MaintenanceFeesAndResearchPayments" xlink:to="lab_M789M40767M7_atnm_MaintenanceFeesAndResearchPayments"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentServicesFees" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PlacementAgentServicesFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PlacementAgentServicesFees" xml:lang="en-US">Placement Agent Services Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PlacementAgentServicesFees" xml:lang="en-US">Placement agent services fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PlacementAgentServicesFees" xml:lang="en-US">Placement agent services fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PlacementAgentServicesFees" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PlacementAgentServicesFees"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_K567K28545K5_atnm_WarrantsIssuedToPurchaseCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants Issued To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants issued to purchase common stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants Issued To Purchase Aggregate Shares Of Common Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_WarrantsIssuedToPurchaseCommonStock" xlink:to="lab_M789M40767M7_atnm_WarrantsIssuedToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_CommonStockExercisePriceParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xml:lang="en-US">Common Stock Exercise Price Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xml:lang="en-US">Common stock exercise price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xml:lang="en-US">Common stock exercise price par or stated value per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:to="lab_84LLL766LI061L6H67IH_atnm_CommonStockExercisePriceParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreement" xlink:label="loc_K567K28545K5_atnm_AmountPaidUnderAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AmountPaidUnderAgreement" xml:lang="en-US">Amount Paid Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_AmountPaidUnderAgreement" xml:lang="en-US">Amount paid under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AmountPaidUnderAgreement" xml:lang="en-US">Amount paid under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AmountPaidUnderAgreement" xlink:to="lab_M789M40767M7_atnm_AmountPaidUnderAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AdditionalAmountDueUnderAgreement" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_AdditionalAmountDueUnderAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional Amount Due Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional amount due under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional amount due under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_AdditionalAmountDueUnderAgreement" xlink:to="lab_84LLL766LI061L6H67IH_atnm_AdditionalAmountDueUnderAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_K567K28545K5_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Description Of Condition For Termination Of Forbearance Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Condition for termination of forbearance period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Description of condition for termination of forbearance period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:to="lab_M789M40767M7_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TerminationDateOfForbearanceAgreement" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_TerminationDateOfForbearanceAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination Date Of Forbearance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination date of forbearance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination date of forbearance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_TerminationDateOfForbearanceAgreement" xlink:to="lab_84LLL766LI061L6H67IH_atnm_TerminationDateOfForbearanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_K567K28545K5_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum New Equity Financing Needed Under Condition For Termination Forbearance Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum new equity financing needed under condition for termination forbearance period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum new Equity Financing needed under condition for termination Forbearance period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:to="lab_M789M40767M7_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NewEquityFinanceRaisedByCompany" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_NewEquityFinanceRaisedByCompany"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New Equity Finance Raised By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New equity finance raised by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New equity finance raised by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_NewEquityFinanceRaisedByCompany" xlink:to="lab_84LLL766LI061L6H67IH_atnm_NewEquityFinanceRaisedByCompany"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ForgivenAmountOfObligations" xlink:label="loc_K567K28545K5_atnm_ForgivenAmountOfObligations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven Amount Of Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven amount of obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven amount of obligations.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_ForgivenAmountOfObligations" xlink:to="lab_M789M40767M7_atnm_ForgivenAmountOfObligations"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_AmountPaidToEachPatient"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AmountPaidToEachPatient" xml:lang="en-US">Amount Paid To Each Patient</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AmountPaidToEachPatient" xml:lang="en-US">Amount paid to each patient after Completing clinical trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AmountPaidToEachPatient" xml:lang="en-US">Amount to be paid for each Patient that has completed the clinical trial.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_AmountPaidToEachPatient" xlink:to="lab_84LLL766LI061L6H67IH_atnm_AmountPaidToEachPatient"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_K567K28545K5_atnm_StartUpFeeForClinicalTrial"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_StartUpFeeForClinicalTrial" xml:lang="en-US">Start Up Fee For Clinical Trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_StartUpFeeForClinicalTrial" xml:lang="en-US">Start-up fee for clinical trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_StartUpFeeForClinicalTrial" xml:lang="en-US">Start-up fee for clinical trial.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_StartUpFeeForClinicalTrial" xlink:to="lab_M789M40767M7_atnm_StartUpFeeForClinicalTrial"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_StartUpDueCostPaidDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Start Up Due Cost Paid Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Due date of start-up fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Start-up due cost paid date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Start-up due cost paid date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_StartUpDueCostPaidDate" xlink:to="lab_84LLL766LI061L6H67IH_atnm_StartUpDueCostPaidDate"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfSharesTransferTerm" xlink:label="loc_K567K28545K5_atnm_DescriptionOfSharesTransferTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description Of Shares Transfer Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description of shares transfer term transfer by AHLB on behalf of AHL</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description of shares transfer term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DescriptionOfSharesTransferTerm" xlink:to="lab_M789M40767M7_atnm_DescriptionOfSharesTransferTerm"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OptionExercisePriceRange" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_OptionExercisePriceRange"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_OptionExercisePriceRange" xml:lang="en-US">Option Exercise Price Range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_OptionExercisePriceRange" xml:lang="en-US">Option Exercise Price Range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_OptionExercisePriceRange" xml:lang="en-US">Option exercise price range.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_OptionExercisePriceRange" xlink:to="lab_84LLL766LI061L6H67IH_atnm_OptionExercisePriceRange"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_K567K28545K5_atnm_OptionsReceivedToPurchaseCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options Received To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options received to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options received to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_OptionsReceivedToPurchaseCommonStock" xlink:to="lab_M789M40767M7_atnm_OptionsReceivedToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_DescriptionOfReceivablesOfPlacementAgentForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description Of Receivables Of Placement Agent For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description of receivables of placement agent for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description of receivables of placement agent for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:to="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfReceivablesOfPlacementAgentForServices"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_K567K28545K5_atnm_DescriptionOfWarrantsReceivablesByPlacement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description Of Warrants Receivables By Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description of warrants receivables by placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description of warrants receivables by placement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:to="lab_M789M40767M7_atnm_DescriptionOfWarrantsReceivablesByPlacement"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodOfExerciseOfWarrants" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PeriodOfExerciseOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period Of Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period of exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period of exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PeriodOfExerciseOfWarrants" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PeriodOfExerciseOfWarrants"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PercentageOfSolicitationFee" xlink:label="loc_K567K28545K5_atnm_PercentageOfSolicitationFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PercentageOfSolicitationFee" xml:lang="en-US">Percentage Of Solicitation Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_PercentageOfSolicitationFee" xml:lang="en-US">Percentage of solicitation fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_PercentageOfSolicitationFee" xml:lang="en-US">Percentage of solicitation fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PercentageOfSolicitationFee" xlink:to="lab_M789M40767M7_atnm_PercentageOfSolicitationFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PeriodicFeeForFinancialAdvisoryServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Periodic Fee For Financial Advisory Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Monthly fee for financial advisory services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Periodic fee for financial advisory services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PeriodicFeeForFinancialAdvisoryServices"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_K567K28545K5_atnm_DescriptionOfAdditionalReceivableByPlacementAgent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description Of Additional Receivable By Placement Agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description of additional receivable by placement agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description of additional receivable by placement agent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:to="lab_M789M40767M7_atnm_DescriptionOfAdditionalReceivableByPlacementAgent"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_CommonStockPurchaseByHoldingOfWarrant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Common Stock Purchase By Holding Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Warrant held by placement agent to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Common stock purchase by holding of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:to="lab_84LLL766LI061L6H67IH_atnm_CommonStockPurchaseByHoldingOfWarrant"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_K567K28545K5_atnm_PeriodicFeeReceivedByManagementFirm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Periodic Fee Received By Management Firm</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Monthly fee received by management firm</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Periodic fee received by management firm.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PeriodicFeeReceivedByManagementFirm" xlink:to="lab_M789M40767M7_atnm_PeriodicFeeReceivedByManagementFirm"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage Of Fully Diluted Capital Stock Equal To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage of fully diluted capital stock equal to common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage of fully diluted capital stock equal to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_K567K28545K5_atnm_MaximumAmountOfOutOfPocketExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum Amount Of Out Of Pocket Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum amount of out of pocket expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum amount of out of pocket expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_MaximumAmountOfOutOfPocketExpenses" xlink:to="lab_M789M40767M7_atnm_MaximumAmountOfOutOfPocketExpenses"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicAmountOfRent" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PeriodicAmountOfRent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodicAmountOfRent" xml:lang="en-US">Periodic Amount Of Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodicAmountOfRent" xml:lang="en-US">Operating lease monthly amount of rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodicAmountOfRent" xml:lang="en-US">Periodic amount of rent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PeriodicAmountOfRent" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PeriodicAmountOfRent"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_K567K28545K5_atnm_AmountPaidToPursuantLeaseAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount Paid To Pursuant Lease Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount paid to pursuant lease agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount paid to pursuant lease agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AmountPaidToPursuantLeaseAgreement" xlink:to="lab_M789M40767M7_atnm_AmountPaidToPursuantLeaseAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_OtherResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OtherResearchAndDevelopmentExpense" xml:lang="en-US">Other Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OtherResearchAndDevelopmentExpense" xml:lang="en-US">Paid for research conducted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_OtherResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ConsultingFee" xlink:label="loc_K567K28545K5_atnm_ConsultingFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_ConsultingFee" xml:lang="en-US">Consulting Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_ConsultingFee" xml:lang="en-US">Consulting Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_ConsultingFee" xml:lang="en-US">Consulting expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_ConsultingFee" xlink:to="lab_M789M40767M7_atnm_ConsultingFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SettlementPaymentOfConsultingFee" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_SettlementPaymentOfConsultingFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SettlementPaymentOfConsultingFee" xml:lang="en-US">Settlement Payment Of Consulting Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SettlementPaymentOfConsultingFee" xml:lang="en-US">Settlement Payment Of Consulting Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SettlementPaymentOfConsultingFee" xml:lang="en-US">Settlement payment of consulting fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_SettlementPaymentOfConsultingFee" xlink:to="lab_84LLL766LI061L6H67IH_atnm_SettlementPaymentOfConsultingFee"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="loc_K567K28545K5_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xml:lang="en-US">Artist Advances and Royalty Guarantees, Commitments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xml:lang="en-US">Royalty description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:to="lab_M789M40767M7_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Net payable to MSKCC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule Of Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_OfficeEquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_OfficeEquipmentMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_OfficeEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_K567K28545K5_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RangeAxis" xlink:to="lab_M789M40767M7_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RangeMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_K567K28545K5_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_MaximumMember" xlink:to="lab_M789M40767M7_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_MinimumMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Property, Plant and Equipment, Net, By Type [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Office equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Equipment and parts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_K567K28545K5_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_M789M40767M7_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PropertyAndEquipmentTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PropertyAndEquipmentTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PropertyAndEquipmentTextualAbstract" xml:lang="en-US">Property and Equipment Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PropertyAndEquipmentTextualAbstract" xml:lang="en-US">Property and Equipment (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PropertyAndEquipmentTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PropertyAndEquipmentTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_K567K28545K5_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_Depreciation" xlink:to="lab_M789M40767M7_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xml:lang="en-US">Schedule Of Trading Securities and Other Trading Assets [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xml:lang="en-US">Schedule of Trading Securities and Other Trading Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PremiumFinanceAgreementMember" xlink:label="loc_K567K28545K5_atnm_PremiumFinanceAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PremiumFinanceAgreementMember" xml:lang="en-US">Premium Finance Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_PremiumFinanceAgreementMember" xml:lang="en-US">Premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PremiumFinanceAgreementMember" xlink:to="lab_M789M40767M7_atnm_PremiumFinanceAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ManagementFirmMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ManagementFirmMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ManagementFirmMember" xml:lang="en-US">Management Firm [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ManagementFirmMember" xml:lang="en-US">Management firm.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ManagementFirmMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ManagementFirmMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xml:lang="en-US">Schedule Of Trading Securities and Other Trading Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xml:lang="en-US">Schedule of Trading Securities and Other Trading Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_NotePayableAndConvertibleNotesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NotePayableAndConvertibleNotesTextualAbstract" xml:lang="en-US">Note Payable and Convertible Notes Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NotePayableAndConvertibleNotesTextualAbstract" xml:lang="en-US">Note Payable and Convertible Notes (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_atnm_NotePayableAndConvertibleNotesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_K567K28545K5_atnm_CommonStockPurchaseDueToIssuanceOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common Stock Purchase Due To Issuance Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common stock shares purchasable through warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common stock shares purchase due to issuance of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:to="lab_M789M40767M7_atnm_CommonStockPurchaseDueToIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_62JJJ544JG849J4F45GF_invest_InvestmentWarrantsExpirationDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Investment Warrants Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Warrants expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_invest_InvestmentWarrantsExpirationDate" xlink:to="lab_84LLL766LI061L6H67IH_invest_InvestmentWarrantsExpirationDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_K567K28545K5_us-gaap_DebtInstrumentFaceAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Convertible promissory note amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_M789M40767M7_us-gaap_DebtInstrumentFaceAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Amount of original issue discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Less: original issuance discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmortizationPeriodOfNote" xlink:label="loc_K567K28545K5_atnm_AmortizationPeriodOfNote"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AmortizationPeriodOfNote" xml:lang="en-US">Amortization Period Of Note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_AmortizationPeriodOfNote" xml:lang="en-US">Amortization period of note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AmortizationPeriodOfNote" xml:lang="en-US">Amortization period of note.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AmortizationPeriodOfNote" xlink:to="lab_M789M40767M7_atnm_AmortizationPeriodOfNote"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NotesPayable" xml:lang="en-US">Notes payable, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NotesPayable" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_K567K28545K5_us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US">Down payment pursuant to the agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_M789M40767M7_us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xml:lang="en-US">Due to Officers or Stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xml:lang="en-US">Amount required to pay in monthly installment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_K567K28545K5_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Promissory note interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_M789M40767M7_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PremiumFinanceAgreementPrincipalAmount" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PremiumFinanceAgreementPrincipalAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium Finance Agreement Principal Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium finance agreement principal amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium finance agreement principal amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PremiumFinanceAgreementPrincipalAmount" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PremiumFinanceAgreementPrincipalAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentUnderPremiumFinanceAgreement" xlink:label="loc_K567K28545K5_atnm_PaymentUnderPremiumFinanceAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment Under Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment under premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment under premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PaymentUnderPremiumFinanceAgreement" xlink:to="lab_M789M40767M7_atnm_PaymentUnderPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PeriodicPaymentUnderPremiumFinanceAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Periodic Payment Under Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Monthly amount payable under premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Periodic amount payable under premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PeriodicPaymentUnderPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:label="loc_K567K28545K5_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration Of Periodic Payments For Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration of periodic payments for premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration of periodic payments for premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:to="lab_M789M40767M7_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PremiumFinanceAgreementOutstandingAmount" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PremiumFinanceAgreementOutstandingAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium Finance Agreement Outstanding Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium finance agreement outstanding amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium finance agreement outstanding amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PremiumFinanceAgreementOutstandingAmount" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PremiumFinanceAgreementOutstandingAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ProceedsFromConvertibleNotes" xlink:label="loc_K567K28545K5_atnm_ProceedsFromConvertibleNotes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_ProceedsFromConvertibleNotes" xml:lang="en-US">Proceeds From Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_ProceedsFromConvertibleNotes" xml:lang="en-US">Net proceeds of promissory note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_ProceedsFromConvertibleNotes" xml:lang="en-US">Proceeds from senior subordinated unsecured convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_ProceedsFromConvertibleNotes" xlink:to="lab_M789M40767M7_atnm_ProceedsFromConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage Of Principle Amount In Which Convertible Note Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage of principle amount in which convertible note issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage of principle amount in which convertible note issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_K567K28545K5_us-gaap_DebtInstrumentMaturityDateDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Convertible note maturity term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_M789M40767M7_us-gaap_DebtInstrumentMaturityDateDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross Proceeds In Subsequent Offerings Of Common Stock Or Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross proceeds in subsequent offerings of common stock or equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross proceeds in subsequent offerings of common stock or equivalents.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:to="lab_84LLL766LI061L6H67IH_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:label="loc_K567K28545K5_atnm_DerivativeWarrantsIssuedWithConvertibleNotes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Derivative Warrants Issued With Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Common stock issued to investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Warrants issued with Convertible Notes (See Note 5), Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Derivative warrants Issued With Convertible Notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:to="lab_M789M40767M7_atnm_DerivativeWarrantsIssuedWithConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_InvestmentWarrantGrantDateFairValue" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_InvestmentWarrantGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment Warrant Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment warrant grant date fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment warrant grant date fair value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_InvestmentWarrantGrantDateFairValue" xlink:to="lab_84LLL766LI061L6H67IH_atnm_InvestmentWarrantGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:label="loc_K567K28545K5_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt Instrument Discount Related To Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Beneficial conversion feature discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt Instrument Discount Related To Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt instrument discount related to the beneficial conversion feature.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Less: discount related to the beneficial conversion feature</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:to="lab_M789M40767M7_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DebtInstrumentFairValuePerShare" xlink:label="loc_K567K28545K5_atnm_DebtInstrumentFairValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DebtInstrumentFairValuePerShare" xml:lang="en-US">Debt Instrument Fair Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DebtInstrumentFairValuePerShare" xml:lang="en-US">Convertible note fair value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DebtInstrumentFairValuePerShare" xml:lang="en-US">Debt instrument fair value per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DebtInstrumentFairValuePerShare" xlink:to="lab_M789M40767M7_atnm_DebtInstrumentFairValuePerShare"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ExtendedMaturityPeriodOfConvertibleNotes" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ExtendedMaturityPeriodOfConvertibleNotes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended Maturity Period Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended maturity Period of convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended maturity Period of convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ExtendedMaturityPeriodOfConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfExtendedMaturityDate" xlink:label="loc_K567K28545K5_atnm_DescriptionOfExtendedMaturityDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description Of Extended Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description of extended maturity date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description of extended maturity date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DescriptionOfExtendedMaturityDate" xlink:to="lab_M789M40767M7_atnm_DescriptionOfExtendedMaturityDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtConversionConvertedInstrumentAmount1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Convertible notes and the accrued interest converted into common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtConversionConvertedInstrumentAmount1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_K567K28545K5_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Common stock issued by conversion of note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_M789M40767M7_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule Of Derivative Warrant Instruments Activity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule of derivative warrant instruments activity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule of derivative warrant instruments activity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeWarrantsUnits" xlink:label="loc_K567K28545K5_atnm_DerivativeWarrantsUnits"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Derivative Warrants Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Derivative Warrants Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Total warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Beginning balance, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Balance, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Derivative warrants units.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DerivativeWarrantsUnits" xlink:to="lab_M789M40767M7_atnm_DerivativeWarrantsUnits"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeWarrantsIssuedWithStockOffering" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_DerivativeWarrantsIssuedWithStockOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Derivative Warrants Issued With Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Warrants issued with Stock Offering, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Derivative warrants issued with Stock offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_DerivativeWarrantsIssuedWithStockOffering" xlink:to="lab_84LLL766LI061L6H67IH_atnm_DerivativeWarrantsIssuedWithStockOffering"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:label="loc_K567K28545K5_atnm_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Derivative Placement Agent Warrants Related To Issuance Of Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Placement agent warrants related to issuance of Stock Offering, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Derivative Placement Agent warrants related to issuance of stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:to="lab_M789M40767M7_atnm_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeWarrantsIssuedWithCommonStockOffering" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_DerivativeWarrantsIssuedWithCommonStockOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Derivative Warrants Issued With Common Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Warrants issued with 2012 Common Stock Offering - A, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Derivative warrants issued with Common Stock Offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_DerivativeWarrantsIssuedWithCommonStockOffering" xlink:to="lab_84LLL766LI061L6H67IH_atnm_DerivativeWarrantsIssuedWithCommonStockOffering"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:label="loc_K567K28545K5_atnm_DerivativeWarrantsIssuedWithCommonStockOfferingOne"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Derivative Warrants Issued With Common Stock Offering One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Warrants issued with 2012 Common Stock Offering - B, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Derivative warrants issued with Common Stock Offering one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:to="lab_M789M40767M7_atnm_DerivativeWarrantsIssuedWithCommonStockOfferingOne"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativePlacementAgentWarrantsRelatedToStock" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_DerivativePlacementAgentWarrantsRelatedToStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Derivative Placement Agent Warrants Related To Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Placement agent warrants related to 2012 Common Stock Offering, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Derivative placement agent warrants related to stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_DerivativePlacementAgentWarrantsRelatedToStock" xlink:to="lab_84LLL766LI061L6H67IH_atnm_DerivativePlacementAgentWarrantsRelatedToStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_K567K28545K5_atnm_TransferFromLiabilityClassificationToEquityClassification"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer From Liability Classification To Equity Classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_TransferFromLiabilityClassificationToEquityClassification" xlink:to="lab_M789M40767M7_atnm_TransferFromLiabilityClassificationToEquityClassification"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeFairValueOfDerivativeNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Derivative, Fair Value, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Derivative, Fair Value, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Beginning balance, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Balance, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeFairValueOfDerivativeNet"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xlink:label="loc_K567K28545K5_atnm_FairValueOfDerivativeWarrantsIssuedWithStockOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Fair Value Of Derivative Warrants Issued With Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Warrants issued with Stock Offering, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Fair value of derivative warrants issued with stock offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xlink:to="lab_M789M40767M7_atnm_FairValueOfDerivativeWarrantsIssuedWithStockOffering"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Fair Value Of Derivative Placement Agent Warrants Related To Issuance Of Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Placement agent warrants related to issuance of Stock Offering, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Fair value of derivative placement agent warrants related to issuance of Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xlink:label="loc_K567K28545K5_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Fair Value Of Derivative Warrants Issued With Common Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Warrants issued with 2012 Common Stock Offering - A, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Fair value of derivative warrants issued with Common Stock Offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xlink:to="lab_M789M40767M7_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Fair Value Of Derivative Warrants Issued With Common Stock Offering One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Warrants issued with 2012 Common Stock Offering - B, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Fair value of derivative warrants issued with Common Stock Offering one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xlink:label="loc_K567K28545K5_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Fair Value Of Derivative Placement Agent Warrants Related To Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Placement agent warrants related to 2012 Common Stock Offering, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Fair value of derivative placement agent warrants related to stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xlink:to="lab_M789M40767M7_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ChangeInFairValueOfDerivativeWarrants" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ChangeInFairValueOfDerivativeWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change In Fair Value Of Derivative Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change in fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change in fair value of derivative warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ChangeInFairValueOfDerivativeWarrants" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ChangeInFairValueOfDerivativeWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_K567K28545K5_us-gaap_DerivativeTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DerivativeTable" xlink:to="lab_M789M40767M7_us-gaap_DerivativeTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeLineItems" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_K567K28545K5_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xml:lang="en-US">Summary Of Fair Value Of Derivative Warrants On Basis Of Valuation Model [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xml:lang="en-US">Summary of fair values of derivative warrants on basis of valuation model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="lab_M789M40767M7_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_MarketValueOfCommonStockOnMeasurementDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market Value Of Common Stock On Measurement Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market value of common stock on measurement date (1)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market value of common stock on measurement date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:to="lab_84LLL766LI061L6H67IH_atnm_MarketValueOfCommonStockOnMeasurementDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_K567K28545K5_us-gaap_FairValueAssumptionsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Adjusted exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueAssumptionsExercisePrice" xlink:to="lab_M789M40767M7_us-gaap_FairValueAssumptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate (2)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_K567K28545K5_us-gaap_FairValueAssumptionsExpectedTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Term of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Warrant lives in years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Contractual life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility (3)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_K567K28545K5_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield (4)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueInputsProbabilityOfDefault"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueInputsProbabilityOfDefault" xml:lang="en-US">Fair Value Inputs, Probability Of Default</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueInputsProbabilityOfDefault" xml:lang="en-US">Probability of stock offering in any period over 5 years (5)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueInputsProbabilityOfDefault" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueInputsProbabilityOfDefault"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_K567K28545K5_atnm_RangeOfPercentageOfExistingSharesOffered"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range Of Percentage Of Existing Shares Offered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered (6)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_RangeOfPercentageOfExistingSharesOffered" xlink:to="lab_M789M40767M7_atnm_RangeOfPercentageOfExistingSharesOffered"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FairValueAssumptionOfferingPrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueAssumptionOfferingPrice" xml:lang="en-US">Fair Value Assumption Offering Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueAssumptionOfferingPrice" xml:lang="en-US">Offering price range (7)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueAssumptionOfferingPrice" xml:lang="en-US">Fair value assumption offering price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FairValueAssumptionOfferingPrice" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FairValueAssumptionOfferingPrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_K567K28545K5_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xml:lang="en-US">Derivative Instruments, Gain (Loss) By Hedging Relationship, By Income Statement Location, By Derivative Instrument Risk [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_M789M40767M7_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeByNatureAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeByNatureAxis" xml:lang="en-US">Derivative, by Nature [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeByNatureAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeByNatureAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_K567K28545K5_us-gaap_DerivativeNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DerivativeNameDomain" xml:lang="en-US">Derivative, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DerivativeNameDomain" xlink:to="lab_M789M40767M7_us-gaap_DerivativeNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeInstrumentsGainLossLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsGainLossLineItems" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsGainLossLineItems" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsGainLossLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeTextualAbstract" xlink:label="loc_K567K28545K5_atnm_DerivativeTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DerivativeTextualAbstract" xml:lang="en-US">Derivative Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DerivativeTextualAbstract" xml:lang="en-US">Derivatives (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DerivativeTextualAbstract" xlink:to="lab_M789M40767M7_atnm_DerivativeTextualAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfRiskFreeInterestRateDetermination" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_DescriptionOfRiskFreeInterestRateDetermination"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfRiskFreeInterestRateDetermination" xml:lang="en-US">Description Of Risk Free Interest Rate Determination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfRiskFreeInterestRateDetermination" xml:lang="en-US">Description of risk free interest rate determination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfRiskFreeInterestRateDetermination" xml:lang="en-US">Description of risk free interest rate determination.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_DescriptionOfRiskFreeInterestRateDetermination" xlink:to="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfRiskFreeInterestRateDetermination"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfProbabilityOfStockOffering" xlink:label="loc_K567K28545K5_atnm_DescriptionOfProbabilityOfStockOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description Of Probability Of Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description of probability of stock offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description of probability of stock offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DescriptionOfProbabilityOfStockOffering" xlink:to="lab_M789M40767M7_atnm_DescriptionOfProbabilityOfStockOffering"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAdjustmentOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAdjustmentOfWarrants"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NumberOfSharesWarrantExercise" xlink:label="loc_K567K28545K5_atnm_NumberOfSharesWarrantExercise"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_NumberOfSharesWarrantExercise" xml:lang="en-US">Number Of Shares Warrant Exercise</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_atnm_NumberOfSharesWarrantExercise" xml:lang="en-US">Number of warrant exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_NumberOfSharesWarrantExercise" xml:lang="en-US">Number of shares warrant exercise.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_NumberOfSharesWarrantExercise" xlink:to="lab_M789M40767M7_atnm_NumberOfSharesWarrantExercise"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_LongTermPurchaseCommitmentTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentTable" xml:lang="en-US">Long-Term Purchase Commitment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentTable" xml:lang="en-US">Long-term Purchase Commitment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentTable"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_K567K28545K5_atnm_AbbottBiotherapeuticsCorpMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott biotherapeutics corp.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AbbottBiotherapeuticsCorpMember" xlink:to="lab_M789M40767M7_atnm_AbbottBiotherapeuticsCorpMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PhaseFirstClinicalTrialOfLicensedProductMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase First Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase I Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase first clinical trial of a licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PhaseFirstClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_K567K28545K5_atnm_PhaseSecondClinicalTrialOfLicensedProductMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase Second Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase II Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase second clinical trial of licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:to="lab_M789M40767M7_atnm_PhaseSecondClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PhaseThirdClinicalTrialOfLicensedProductMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase Third Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase III Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase III clinical trial of licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PhaseThirdClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_BiologicalLicenseApplicationMember" xlink:label="loc_K567K28545K5_atnm_BiologicalLicenseApplicationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological License Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological License Application filing with U.S. FDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological license application.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_BiologicalLicenseApplicationMember" xlink:to="lab_M789M40767M7_atnm_BiologicalLicenseApplicationMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FirstCommercialSaleMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FirstCommercialSaleMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FirstCommercialSaleMember" xml:lang="en-US">First Commercial Sale [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FirstCommercialSaleMember" xml:lang="en-US">First Commercial Sale [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FirstCommercialSaleMember" xml:lang="en-US">First commercial sale.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FirstCommercialSaleMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FirstCommercialSaleMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_K567K28545K5_atnm_AfterFirstNetSalesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AfterFirstNetSalesMember" xml:lang="en-US">After First Net Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_AfterFirstNetSalesMember" xml:lang="en-US">After First Net Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AfterFirstNetSalesMember" xml:lang="en-US">After first net sales.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AfterFirstNetSalesMember" xlink:to="lab_M789M40767M7_atnm_AfterFirstNetSalesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_LongTermPurchaseCommitmentLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentLineItems" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentLineItems" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MilestonePaymentAbstract" xlink:label="loc_K567K28545K5_atnm_MilestonePaymentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_MilestonePaymentAbstract" xml:lang="en-US">Milestone Payment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_MilestonePaymentAbstract" xml:lang="en-US">Summary of milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_MilestonePaymentAbstract" xlink:to="lab_M789M40767M7_atnm_MilestonePaymentAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_LongTermPurchaseCommitmentMilestonesPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Long Term Purchase Commitment Milestones Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Milestones payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Long term purchase commitment milestones payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:to="lab_84LLL766LI061L6H67IH_atnm_LongTermPurchaseCommitmentMilestonesPayment"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommitmentsAndContingenciesTable" xlink:label="loc_K567K28545K5_atnm_CommitmentsAndContingenciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_CommitmentsAndContingenciesTable" xlink:to="lab_M789M40767M7_atnm_CommitmentsAndContingenciesTable"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_OakRidgeNationalLaboratoryMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak Ridge National Laboratory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak Ridge National Laboratory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak ridge national laboratory.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_OakRidgeNationalLaboratoryMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_OakRidgeNationalLaboratoryMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AptivSolutionsMember" xlink:label="loc_K567K28545K5_atnm_AptivSolutionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AptivSolutionsMember" xml:lang="en-US">Aptiv Solutions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_AptivSolutionsMember" xml:lang="en-US">Aptiv Solutions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AptivSolutionsMember" xml:lang="en-US">Aptiv solutions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AptivSolutionsMember" xlink:to="lab_M789M40767M7_atnm_AptivSolutionsMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FredHutchinsonCancerResearchCenterMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred hutchinson cancer research center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FredHutchinsonCancerResearchCenterMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FredHutchinsonCancerResearchCenterMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_K567K28545K5_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I and Ii Clinical Trial For Actimab In Elderly Acute Myeloid Leukemia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I/II Clinical Trial For Actimab In Elderly Acute Myeloid Leukemia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I and II clinical trial for actimab in elderly acute myeloid leukemia.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:to="lab_M789M40767M7_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_UniversityOfTexasMDAndersonCancerCenterMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University Of Texas M D Anderson Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University of Texas M.D. Anderson Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University of texas M.D. anderson cancer center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_UniversityOfTexasMDAndersonCancerCenterMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_JohnsHopkinsUniversityMember" xlink:label="loc_K567K28545K5_atnm_JohnsHopkinsUniversityMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns Hopkins University [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns Hopkins University [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns hopkins university.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_JohnsHopkinsUniversityMember" xlink:to="lab_M789M40767M7_atnm_JohnsHopkinsUniversityMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_LaidlawAndCoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_LaidlawAndCoMember" xml:lang="en-US">Laidlaw and Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_LaidlawAndCoMember" xml:lang="en-US">Laidlaw &amp; Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_LaidlawAndCoMember" xml:lang="en-US">Laidlaw and company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_LaidlawAndCoMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_LaidlawAndCoMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_UniversityOfPennsylvaniaMember" xlink:label="loc_K567K28545K5_atnm_UniversityOfPennsylvaniaMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_UniversityOfPennsylvaniaMember" xml:lang="en-US">University Of Pennsylvania [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_UniversityOfPennsylvaniaMember" xml:lang="en-US">University of Pennsylvania [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_UniversityOfPennsylvaniaMember" xml:lang="en-US">University of pennsylvania.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_UniversityOfPennsylvaniaMember" xlink:to="lab_M789M40767M7_atnm_UniversityOfPennsylvaniaMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FormerChiefExecutiveOfficerMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FormerChiefExecutiveOfficerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FormerChiefExecutiveOfficerMember" xml:lang="en-US">Former Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FormerChiefExecutiveOfficerMember" xml:lang="en-US">Former Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FormerChiefExecutiveOfficerMember" xml:lang="en-US">former chief executive officer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FormerChiefExecutiveOfficerMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FormerChiefExecutiveOfficerMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodAxis" xlink:label="loc_K567K28545K5_atnm_PeriodAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PeriodAxis" xml:lang="en-US">Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PeriodAxis" xlink:to="lab_M789M40767M7_atnm_PeriodAxis"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodDomain" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PeriodDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PeriodDomain" xml:lang="en-US">Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PeriodDomain" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PeriodDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TwoThousandAndThirteenMember" xlink:label="loc_K567K28545K5_atnm_TwoThousandAndThirteenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_TwoThousandAndThirteenMember" xml:lang="en-US">Two Thousand And Thirteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_atnm_TwoThousandAndThirteenMember" xml:lang="en-US">2013 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_TwoThousandAndThirteenMember" xlink:to="lab_M789M40767M7_atnm_TwoThousandAndThirteenMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TwoThousandAndFourteenMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_TwoThousandAndFourteenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_TwoThousandAndFourteenMember" xml:lang="en-US">Two Thousand And Fourteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_TwoThousandAndFourteenMember" xml:lang="en-US">2014 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_TwoThousandAndFourteenMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_TwoThousandAndFourteenMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_K567K28545K5_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_M789M40767M7_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_K567K28545K5_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsequentEventMember" xlink:to="lab_M789M40767M7_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ProductDevelopmentAndPatentLicenseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xml:lang="en-US">Product Development and Patent License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xml:lang="en-US">Product development and patent license agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ProductDevelopmentAndPatentLicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LicenseAgreementMember" xlink:label="loc_K567K28545K5_atnm_LicenseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_LicenseAgreementMember" xml:lang="en-US">License agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_LicenseAgreementMember" xml:lang="en-US">License agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_LicenseAgreementMember" xlink:to="lab_M789M40767M7_atnm_LicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_LicenseAndSponsoredResearchAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">License and Sponsored Research Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">license and sponsored research agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">License and sponsored research agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_LicenseAndSponsoredResearchAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_LicenseAndSponsoredResearchAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentAgreementMember" xlink:label="loc_K567K28545K5_atnm_PlacementAgentAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PlacementAgentAgreementMember" xml:lang="en-US">Placement Agent Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_PlacementAgentAgreementMember" xml:lang="en-US">Placement Agent Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_PlacementAgentAgreementMember" xml:lang="en-US">Placement agent agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PlacementAgentAgreementMember" xlink:to="lab_M789M40767M7_atnm_PlacementAgentAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeparationAndSettlementAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_SeparationAndSettlementAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_SeparationAndSettlementAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_SeparationAndSettlementAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ManufacturingAgreementMember" xlink:label="loc_K567K28545K5_atnm_ManufacturingAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_ManufacturingAgreementMember" xml:lang="en-US">Manufacturing Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_ManufacturingAgreementMember" xlink:to="lab_M789M40767M7_atnm_ManufacturingAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RentalAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_RentalAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_RentalAgreementMember" xml:lang="en-US">Rental Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_RentalAgreementMember" xml:lang="en-US">Rental Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_RentalAgreementMember" xml:lang="en-US">Rental agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_RentalAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_RentalAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommitmentsAndContingenciesLineItems" xlink:label="loc_K567K28545K5_atnm_CommitmentsAndContingenciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_CommitmentsAndContingenciesLineItems" xlink:to="lab_M789M40767M7_atnm_CommitmentsAndContingenciesLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_CommitmentsAndContingenciesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_atnm_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_K567K28545K5_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Net sales in milestones payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="lab_M789M40767M7_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_TechnologyServicesCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_TechnologyServicesCosts" xml:lang="en-US">Technology Services Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_TechnologyServicesCosts" xml:lang="en-US">Technology access fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_TechnologyServicesCosts" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_TechnologyServicesCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_K567K28545K5_us-gaap_MaintenanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_MaintenanceCosts" xml:lang="en-US">Maintenance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_MaintenanceCosts" xml:lang="en-US">Annual maintenance fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_MaintenanceCosts" xlink:to="lab_M789M40767M7_us-gaap_MaintenanceCosts"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfLicenseFee" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PaymentOfLicenseFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PaymentOfLicenseFee" xml:lang="en-US">Payment Of License Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PaymentOfLicenseFee" xml:lang="en-US">License fee payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PaymentOfLicenseFee" xml:lang="en-US">License fee payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PaymentOfLicenseFee" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PaymentOfLicenseFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MilestonePaymentDate" xlink:label="loc_K567K28545K5_atnm_MilestonePaymentDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_MilestonePaymentDate" xml:lang="en-US">Milestone Payment Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_MilestonePaymentDate" xml:lang="en-US">Milestone payment date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_MilestonePaymentDate" xml:lang="en-US">Milestone payment date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_MilestonePaymentDate" xlink:to="lab_M789M40767M7_atnm_MilestonePaymentDate"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description Of Royalty Payment To Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description of royalty payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description of royalty payment to related party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RoyaltyOfNetSalesPercentage" xlink:label="loc_K567K28545K5_atnm_RoyaltyOfNetSalesPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty Of Net Sales Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty of Net Sales Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty of net sales percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_RoyaltyOfNetSalesPercentage" xlink:to="lab_M789M40767M7_atnm_RoyaltyOfNetSalesPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FirstCommercialSalePeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FirstCommercialSalePeriod" xml:lang="en-US">First Commercial Sale Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FirstCommercialSalePeriod" xml:lang="en-US">First commercial sale period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FirstCommercialSalePeriod" xml:lang="en-US">First commercial sale period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FirstCommercialSalePeriod" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FirstCommercialSalePeriod"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ResearchAndDevelopmentArrangement" xlink:label="loc_K567K28545K5_atnm_ResearchAndDevelopmentArrangement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_ResearchAndDevelopmentArrangement" xml:lang="en-US">Research and Development Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_ResearchAndDevelopmentArrangement" xml:lang="en-US">Annual research funding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_ResearchAndDevelopmentArrangement" xml:lang="en-US">Research and development arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_ResearchAndDevelopmentArrangement" xlink:to="lab_M789M40767M7_atnm_ResearchAndDevelopmentArrangement"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PurchaseOfRadioactiveMaterial" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PurchaseOfRadioactiveMaterial"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase Of Radioactive Material</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase of radioactive material used for research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase of radioactive material.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PurchaseOfRadioactiveMaterial" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PurchaseOfRadioactiveMaterial"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_K567K28545K5_atnm_ProjectEstimatedCost"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_ProjectEstimatedCost" xml:lang="en-US">Project Estimated Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_ProjectEstimatedCost" xml:lang="en-US">Project estimated cost for clinical trials of drug Ac-225-HuM195</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_ProjectEstimatedCost" xml:lang="en-US">Project estimated cost.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_ProjectEstimatedCost" xlink:to="lab_M789M40767M7_atnm_ProjectEstimatedCost"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_DownPaymentOfProjectEstimatedCostPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Down Payment Of Project Estimated Cost Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Down payment of project estimated cost percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Percentage of total estimated project cost required for down payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:to="lab_84LLL766LI061L6H67IH_atnm_DownPaymentOfProjectEstimatedCostPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DownPaymentForProject" xlink:label="loc_K567K28545K5_atnm_DownPaymentForProject"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_DownPaymentForProject" xml:lang="en-US">Down Payment For Project</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_DownPaymentForProject" xml:lang="en-US">Down payment for project</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_DownPaymentForProject" xml:lang="en-US">Down payment for project.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_DownPaymentForProject" xlink:to="lab_M789M40767M7_atnm_DownPaymentForProject"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical Trial Cost For Approval For Food and Drug Administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical trial cost for approval of food and drug administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical trial cost for approval of food and drug administration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_K567K28545K5_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund To Related Party Under Agreement For First Two Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund to related party under agreement for first two Year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:to="lab_M789M40767M7_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund To Related Party Under Agreement After Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund to related party under agreement after year two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementConsideration" xlink:label="loc_K567K28545K5_atnm_AgreementConsideration"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AgreementConsideration" xml:lang="en-US">Agreement Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_atnm_AgreementConsideration" xml:lang="en-US">Agreement consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AgreementConsideration" xml:lang="en-US">Agreement Consideration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AgreementConsideration" xlink:to="lab_M789M40767M7_atnm_AgreementConsideration"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PerformanceBonusPayableUnderAgreementForService"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance Bonus Payable Under Agreement For Service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance bonus payable under agreement for service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance Bonus Payable Under Agreement For Service.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PerformanceBonusPayableUnderAgreementForService" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PerformanceBonusPayableUnderAgreementForService"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantExercisableNoticePeriodDescription" xlink:label="loc_K567K28545K5_atnm_WarrantExercisableNoticePeriodDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant Exercisable Notice Period Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant exercisable notice period description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant exercisable notice period description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_WarrantExercisableNoticePeriodDescription" xlink:to="lab_M789M40767M7_atnm_WarrantExercisableNoticePeriodDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description Of Shares Availability By Exercise Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description of period of shares availability by exercise of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description of shares availability by exercise of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:to="lab_84LLL766LI061L6H67IH_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NonRefundableInstitutionalFee" xlink:label="loc_K567K28545K5_atnm_NonRefundableInstitutionalFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_NonRefundableInstitutionalFee" xml:lang="en-US">Non Refundable Institutional Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_NonRefundableInstitutionalFee" xml:lang="en-US">Non - refundable institutional fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_NonRefundableInstitutionalFee" xml:lang="en-US">Non refundable institutional fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_NonRefundableInstitutionalFee" xlink:to="lab_M789M40767M7_atnm_NonRefundableInstitutionalFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PharmacyFee" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PharmacyFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PharmacyFee" xml:lang="en-US">Pharmacy Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PharmacyFee" xml:lang="en-US">Annual pharmacy fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PharmacyFee" xml:lang="en-US">Pharmacy fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PharmacyFee" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PharmacyFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmendmentProcessingFee" xlink:label="loc_K567K28545K5_atnm_AmendmentProcessingFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AmendmentProcessingFee" xml:lang="en-US">Amendment Processing Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_AmendmentProcessingFee" xml:lang="en-US">Amendment processing fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AmendmentProcessingFee" xml:lang="en-US">Amendment processing fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AmendmentProcessingFee" xlink:to="lab_M789M40767M7_atnm_AmendmentProcessingFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NoticePeriodForTerminationOfAgreement" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_NoticePeriodForTerminationOfAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice Period For Termination Of Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice period for termination of agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice Period for termination of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_NoticePeriodForTerminationOfAgreement" xlink:to="lab_84LLL766LI061L6H67IH_atnm_NoticePeriodForTerminationOfAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_K567K28545K5_us-gaap_LeaseExpirationDate1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Sublease agreement termination date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Rent agreement termination date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_LeaseExpirationDate1" xlink:to="lab_M789M40767M7_us-gaap_LeaseExpirationDate1"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementRenewalDescription" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_AgreementRenewalDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AgreementRenewalDescription" xml:lang="en-US">Agreement Renewal Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AgreementRenewalDescription" xml:lang="en-US">Rental agreement renewal description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_AgreementRenewalDescription" xml:lang="en-US">Description regarding renewal of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_AgreementRenewalDescription" xlink:to="lab_84LLL766LI061L6H67IH_atnm_AgreementRenewalDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfAggregateAmount" xlink:label="loc_K567K28545K5_atnm_PaymentOfAggregateAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PaymentOfAggregateAmount" xml:lang="en-US">Payment Of Aggregate Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_PaymentOfAggregateAmount" xml:lang="en-US">Payment of aggregate amount in installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_PaymentOfAggregateAmount" xml:lang="en-US">Payment of aggregate amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PaymentOfAggregateAmount" xlink:to="lab_M789M40767M7_atnm_PaymentOfAggregateAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PaymentOfFinalInstallmentForServicesByCompany"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Payment Of Final Installment For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Outstanding payment of final installment for services by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Outstanding payment of final installment for services by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PaymentOfFinalInstallmentForServicesByCompany"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_K567K28545K5_atnm_PaymentOfPerformanceBonusForServicesByCompany"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment Of Performance Bonus For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_atnm_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment of performance bonus for services by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment of performance bonus for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:to="lab_M789M40767M7_atnm_PaymentOfPerformanceBonusForServicesByCompany"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_K567K28545K5_us-gaap_LegalFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_LegalFees" xml:lang="en-US">Accrued fees paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_LegalFees" xlink:to="lab_M789M40767M7_us-gaap_LegalFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Summary of warrants activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Summary of stock option activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Units, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Units, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of stock option granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Units, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Cancellation and Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Stock option forfeitures during period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Warrants exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of option exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Stock option cancelled during period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Warrants expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Restricted common stock and options, Exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Stock option exercise prices</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_K567K28545K5_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options outstanding and currently granted or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="lab_M789M40767M7_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Fair value of warrants determined utilizing the Black-Scholes option pricing model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfStockByClassTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfStockByClassTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_K567K28545K5_us-gaap_PrivatePlacementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PrivatePlacementMember" xlink:to="lab_M789M40767M7_us-gaap_PrivatePlacementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RestrictedStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RestrictedStockMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_K567K28545K5_us-gaap_TypeOfArrangementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_TypeOfArrangementAxis" xlink:to="lab_M789M40767M7_us-gaap_TypeOfArrangementAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_K567K28545K5_us-gaap_TitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_TitleOfIndividualAxis" xlink:to="lab_M789M40767M7_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_K567K28545K5_atnm_EmployeesDirectorsAndConsultantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees Directors And Consultants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_EmployeesDirectorsAndConsultantsMember" xlink:to="lab_M789M40767M7_atnm_EmployeesDirectorsAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EmployeesAndBoardMembersMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_EmployeesAndBoardMembersMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_EmployeesAndBoardMembersMember" xml:lang="en-US">Employees And Board Members [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_EmployeesAndBoardMembersMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_EmployeesAndBoardMembersMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_K567K28545K5_us-gaap_InvestorMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_InvestorMember" xml:lang="en-US">Investor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_InvestorMember" xlink:to="lab_M789M40767M7_us-gaap_InvestorMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ConsultantMember" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ConsultantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ConsultantMember" xml:lang="en-US">Consultant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ConsultantMember" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ConsultantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_K567K28545K5_us-gaap_PlanNameAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PlanNameAxis" xlink:to="lab_M789M40767M7_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PlanNameDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EquityIncentivePlanMember" xlink:label="loc_K567K28545K5_atnm_EquityIncentivePlanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_EquityIncentivePlanMember" xml:lang="en-US">Equity Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_EquityIncentivePlanMember" xlink:to="lab_M789M40767M7_atnm_EquityIncentivePlanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ClassOfStockLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ClassOfStockLineItems" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ClassOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EquityTextualAbstract" xlink:label="loc_K567K28545K5_atnm_EquityTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_EquityTextualAbstract" xml:lang="en-US">Equity Textual [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_EquityTextualAbstract" xlink:to="lab_M789M40767M7_atnm_EquityTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from issuance of common stock and warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentCashFees" xlink:label="loc_K567K28545K5_atnm_PlacementAgentCashFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_PlacementAgentCashFees" xml:lang="en-US">Placement Agent Cash Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_PlacementAgentCashFees" xml:lang="en-US">Placement agent cash fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_PlacementAgentCashFees" xml:lang="en-US">Placement agent cash fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_PlacementAgentCashFees" xlink:to="lab_M789M40767M7_atnm_PlacementAgentCashFees"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentAttorneyFees" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_PlacementAgentAttorneyFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PlacementAgentAttorneyFees" xml:lang="en-US">Placement Agent Attorney Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_PlacementAgentAttorneyFees" xml:lang="en-US">Placement agent attorney fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_PlacementAgentAttorneyFees" xlink:to="lab_84LLL766LI061L6H67IH_atnm_PlacementAgentAttorneyFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_K567K28545K5_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock issued, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock sold, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SaleOfStockPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SaleOfStockPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Warrants granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt instrument, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentTerm" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_K567K28545K5_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xml:lang="en-US">Exercise price of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="lab_M789M40767M7_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RegistrationStatementDescription" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_RegistrationStatementDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_RegistrationStatementDescription" xml:lang="en-US">Registration Statement Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_RegistrationStatementDescription" xml:lang="en-US">Registration statement description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_RegistrationStatementDescription" xlink:to="lab_84LLL766LI061L6H67IH_atnm_RegistrationStatementDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MaximumOfferingPrice" xlink:label="loc_K567K28545K5_atnm_MaximumOfferingPrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_MaximumOfferingPrice" xml:lang="en-US">Maximum Offering Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_MaximumOfferingPrice" xml:lang="en-US">Maximum offering price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_MaximumOfferingPrice" xlink:to="lab_M789M40767M7_atnm_MaximumOfferingPrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SaleOfStockDescriptionOfTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Common stock pursuant to sales agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SaleOfStockDescriptionOfTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_K567K28545K5_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Number of restricted stock granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xml:lang="en-US">Description restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AdditionalNumberOfRestrictedStockGranted" xlink:label="loc_K567K28545K5_atnm_AdditionalNumberOfRestrictedStockGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_AdditionalNumberOfRestrictedStockGranted" xml:lang="en-US">Additional Number Of Restricted Stock Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_AdditionalNumberOfRestrictedStockGranted" xml:lang="en-US">Additional number of restricted stock granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_AdditionalNumberOfRestrictedStockGranted" xml:lang="en-US">Number of restricted stock granted.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_AdditionalNumberOfRestrictedStockGranted" xlink:to="lab_M789M40767M7_atnm_AdditionalNumberOfRestrictedStockGranted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_K567K28545K5_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Expense related to restricted stock granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_M789M40767M7_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_62JJJ544JG849J4F45GF_invest_InvestmentWarrantsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_invest_InvestmentWarrantsExercisePrice" xml:lang="en-US">Investment Warrants, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_invest_InvestmentWarrantsExercisePrice" xml:lang="en-US">Exercise price of warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_invest_InvestmentWarrantsExercisePrice" xlink:to="lab_84LLL766LI061L6H67IH_invest_InvestmentWarrantsExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_K567K28545K5_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based compensation term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation vested period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_K567K28545K5_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Fair value of stock option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_FairValueAssumptionsExpectedDiscountRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueAssumptionsExpectedDiscountRate" xml:lang="en-US">Fair Value Assumptions Expected Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueAssumptionsExpectedDiscountRate" xml:lang="en-US">Expected discount rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_FairValueAssumptionsExpectedDiscountRate" xml:lang="en-US">Fair Value Assumptions Expected Discount Rate.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_FairValueAssumptionsExpectedDiscountRate" xlink:to="lab_84LLL766LI061L6H67IH_atnm_FairValueAssumptionsExpectedDiscountRate"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantsIssuedToPurchaseCommonStockOffering" xlink:label="loc_K567K28545K5_atnm_WarrantsIssuedToPurchaseCommonStockOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_WarrantsIssuedToPurchaseCommonStockOffering" xml:lang="en-US">Warrants Issued To Purchase Common Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_atnm_WarrantsIssuedToPurchaseCommonStockOffering" xml:lang="en-US">Warrants issued to purchase common stock offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_WarrantsIssuedToPurchaseCommonStockOffering" xml:lang="en-US">Warrants Issued To Purchase Common Stock Offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_WarrantsIssuedToPurchaseCommonStockOffering" xlink:to="lab_M789M40767M7_atnm_WarrantsIssuedToPurchaseCommonStockOffering"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xml:lang="en-US">Proceeds From Issuance Of Stock Under Stock Offering Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xml:lang="en-US">Sale of common stock, net offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xml:lang="en-US">Proceeds from issuance of stock under stock offering, net.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xlink:to="lab_84LLL766LI061L6H67IH_atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_K567K28545K5_atnm_WarrantsExercisedByWarrantHolders"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_atnm_WarrantsExercisedByWarrantHolders" xml:lang="en-US">Warrants Exercised By Warrant Holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_atnm_WarrantsExercisedByWarrantHolders" xml:lang="en-US">Warrants exercised by warrant holders.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_atnm_WarrantsExercisedByWarrantHolders" xlink:to="lab_M789M40767M7_atnm_WarrantsExercisedByWarrantHolders"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Net proceeds issuance of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_K567K28545K5_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsequentEventTable" xlink:to="lab_M789M40767M7_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_K567K28545K5_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EquityComponentDomain" xlink:to="lab_M789M40767M7_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_WarrantsNotSettleableInCashMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_WarrantsNotSettleableInCashMember" xml:lang="en-US">Warrants Not Settleable in Cash [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_WarrantsNotSettleableInCashMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_WarrantsNotSettleableInCashMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_K567K28545K5_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsequentEventLineItems" xlink:to="lab_M789M40767M7_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_atnm_SubsequentEventsTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_atnm_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent events textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_atnm_SubsequentEventsTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_atnm_SubsequentEventsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_K567K28545K5_us-gaap_StockRepurchasedDuringPeriodShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Purchase of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_M789M40767M7_us-gaap_StockRepurchasedDuringPeriodShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Term of expiration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Options and restricted stock vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SecurityDeposit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SecurityDeposit" xml:lang="en-US">Security Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SecurityDeposit" xml:lang="en-US">Security deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SecurityDeposit" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SecurityDeposit"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>atnm-20140331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Tuesday, May 13, 2014 01:52:10 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DocumentAndEntityInformation" roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#RelatedPartyTransactions" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#PropertyAndEquipment" roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#NotePayable" roleURI="http://actiniumpharmaceuticals.com/role/NotePayable"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#Derivatives" roleURI="http://actiniumpharmaceuticals.com/role/Derivatives"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#CommitmentsAndContingencies" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#Equity" roleURI="http://actiniumpharmaceuticals.com/role/Equity"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#SubsequentEvents" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#RelatedPartyTransactionsTables" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#PropertyandEquipmentTables" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DerivativesTables" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#CommitmentsandContingenciesTables" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#RelatedPartyTransactionsDetails" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#PropertyandEquipmentDetails" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#PropertyAndEquipmentDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#NotePayableDetails" roleURI="http://actiniumpharmaceuticals.com/role/NotePayableDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DerivativesDetails" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DerivativesDetails1" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails1"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#DerivativesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#Commitmentsandcontingenciesdetailstextual" roleURI="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#EquityDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140331.xsd#SubsequenteventsDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequenteventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DocumentAndEntityInformationAbstract" xlink:label="loc_atnm_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_10" order="90" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_atnm_SeriesCTwoPreferredStockMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCTwoPreferredStockMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_atnm_SeriesCThreePreferredStockMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCThreePreferredStockMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_atnm_SeriesCFourPreferredStockMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCFourPreferredStockMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_AssetsAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_AssetsCurrentAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_Cash_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_AssetsCurrent_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_Assets_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_NotesPayableCurrent_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesCurrent_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_Liabilities_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_CommitmentsAndContingencies_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_PreferredStockValue_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_CommonStockValue_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_AdditionalPaidInCapital_32" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_33" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_StockholdersEquity_34" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_atnm_SeriesCTwoPreferredStockMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCTwoPreferredStockMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_atnm_SeriesCThreePreferredStockMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCThreePreferredStockMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_atnm_SeriesCFourPreferredStockMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCFourPreferredStockMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockSharesIssued_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockSharesIssued_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_SalesRevenueNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_DepreciationAndAmortization_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_OperatingExpenses_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_InterestExpense_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_atnm_GainOnChangeInFairValueOfDerivatives_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_atnm_GainOnChangeInFairValueOfDerivatives_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_us-gaap_InterestPaid_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_us-gaap_IncomeTaxesPaid_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_InsurancePrepaidThroughPremiumFinance" xlink:label="loc_atnm_InsurancePrepaidThroughPremiumFinance_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_atnm_InsurancePrepaidThroughPremiumFinance_36" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfWarrantsIssuedWithDebt" xlink:label="loc_atnm_FairValueOfWarrantsIssuedWithDebt_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_atnm_FairValueOfWarrantsIssuedWithDebt_37" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfWarrantsIssuedWithStock" xlink:label="loc_atnm_FairValueOfWarrantsIssuedWithStock_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_atnm_FairValueOfWarrantsIssuedWithStock_38" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfWarrantsIssuedToPlacementAgent" xlink:label="loc_atnm_FairValueOfWarrantsIssuedToPlacementAgent_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_atnm_FairValueOfWarrantsIssuedToPlacementAgent_39" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:label="loc_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock_40" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification_41" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/NotePayable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Derivatives">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DevelopmentStageCompanyPolicyTextBlock" xlink:label="loc_atnm_DevelopmentStageCompanyPolicyTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_atnm_DevelopmentStageCompanyPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="loc_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_atnm_MilestonePaymentsMilestoneMethodTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_atnm_MilestonePaymentsMilestoneMethodTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:label="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" xlink:to="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_8" xlink:to="loc_us-gaap_DerivativeLiabilities_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ActiniumMember" xlink:label="loc_atnm_ActiniumMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_atnm_ActiniumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9" xlink:to="loc_us-gaap_ClassOfStockDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_us-gaap_CommonStockMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_WarrantMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OptionsAndWarrantsMember" xlink:label="loc_atnm_OptionsAndWarrantsMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_atnm_OptionsAndWarrantsMember_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_19" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SharesExchangeRatio" xlink:label="loc_atnm_SharesExchangeRatio_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_atnm_SharesExchangeRatio_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockShares" xlink:label="loc_atnm_CommonStockShares_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_atnm_CommonStockShares_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ExchangedInCommonStockShares" xlink:label="loc_atnm_ExchangedInCommonStockShares_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_atnm_ExchangedInCommonStockShares_29" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_NewDrugApplicationMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RelatedPartyMilestonesPayment" xlink:label="loc_atnm_RelatedPartyMilestonesPayment_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_10" xlink:to="loc_atnm_RelatedPartyMilestonesPayment_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RosemaryMazanetMember" xlink:label="loc_atnm_RosemaryMazanetMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_RosemaryMazanetMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LaidlawAndCompanyMember" xlink:label="loc_atnm_LaidlawAndCompanyMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCompanyMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_GuagentiAndAssociatesMember" xlink:label="loc_atnm_GuagentiAndAssociatesMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_GuagentiAndAssociatesMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_atnm_AgreementAxis_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementAxis_11" xlink:to="loc_atnm_AgreementDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_12" xlink:to="loc_atnm_ClinicalTrialAgreementMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_12" xlink:to="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ConsultingServicesAgreementMember" xlink:label="loc_atnm_ConsultingServicesAgreementMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_12" xlink:to="loc_atnm_ConsultingServicesAgreementMember_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EngagementAgreementMember" xlink:label="loc_atnm_EngagementAgreementMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_12" xlink:to="loc_atnm_EngagementAgreementMember_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_12" xlink:to="loc_atnm_TransactionManagementAgreementMember_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_19" xlink:to="loc_atnm_PlacementAgentMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_atnm_RelatedPartyTransactionsTextualAbstract_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_us-gaap_OfficersCompensation_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_NumberOfPatients_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:label="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MaintenanceFeesAndResearchPayments" xlink:label="loc_atnm_MaintenanceFeesAndResearchPayments_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_MaintenanceFeesAndResearchPayments_29" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentServicesFees" xlink:label="loc_atnm_PlacementAgentServicesFees_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_PlacementAgentServicesFees_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_31" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:label="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_32" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidUnderAgreement" xlink:label="loc_atnm_AmountPaidUnderAgreement_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_AmountPaidUnderAgreement_33" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AdditionalAmountDueUnderAgreement" xlink:label="loc_atnm_AdditionalAmountDueUnderAgreement_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_AdditionalAmountDueUnderAgreement_34" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_35" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TerminationDateOfForbearanceAgreement" xlink:label="loc_atnm_TerminationDateOfForbearanceAgreement_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_TerminationDateOfForbearanceAgreement_36" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_37" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NewEquityFinanceRaisedByCompany" xlink:label="loc_atnm_NewEquityFinanceRaisedByCompany_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_NewEquityFinanceRaisedByCompany_38" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ForgivenAmountOfObligations" xlink:label="loc_atnm_ForgivenAmountOfObligations_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_ForgivenAmountOfObligations_39" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_AmountPaidToEachPatient_40" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_41" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_StartUpDueCostPaidDate_42" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfSharesTransferTerm" xlink:label="loc_atnm_DescriptionOfSharesTransferTerm_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_DescriptionOfSharesTransferTerm_43" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OptionExercisePriceRange" xlink:label="loc_atnm_OptionExercisePriceRange_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_OptionExercisePriceRange_44" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_atnm_OptionsReceivedToPurchaseCommonStock_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_OptionsReceivedToPurchaseCommonStock_45" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_46" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_47" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodOfExerciseOfWarrants" xlink:label="loc_atnm_PeriodOfExerciseOfWarrants_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_PeriodOfExerciseOfWarrants_48" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PercentageOfSolicitationFee" xlink:label="loc_atnm_PercentageOfSolicitationFee_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_PercentageOfSolicitationFee_49" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_50" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_51" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_52" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_53" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_54" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_55" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicAmountOfRent" xlink:label="loc_atnm_PeriodicAmountOfRent_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_PeriodicAmountOfRent_56" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_atnm_AmountPaidToPursuantLeaseAgreement_57"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_AmountPaidToPursuantLeaseAgreement_57" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_58"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_58" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ConsultingFee" xlink:label="loc_atnm_ConsultingFee_59"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_ConsultingFee_59" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SettlementPaymentOfConsultingFee" xlink:label="loc_atnm_SettlementPaymentOfConsultingFee_60"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_atnm_SettlementPaymentOfConsultingFee_60" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_61"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_61" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_62"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_22" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_62" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PropertyAndEquipmentTextualAbstract" xlink:label="loc_atnm_PropertyAndEquipmentTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_atnm_PropertyAndEquipmentTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PropertyAndEquipmentTextualAbstract_1" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PropertyAndEquipmentTextualAbstract_1" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/NotePayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_atnm_AgreementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementAxis_2" xlink:to="loc_atnm_AgreementDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PremiumFinanceAgreementMember" xlink:label="loc_atnm_PremiumFinanceAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_3" xlink:to="loc_atnm_PremiumFinanceAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_PlacementAgentMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ManagementFirmMember" xlink:label="loc_atnm_ManagementFirmMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_ManagementFirmMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_9" xlink:to="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmortizationPeriodOfNote" xlink:label="loc_atnm_AmortizationPeriodOfNote_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_atnm_AmortizationPeriodOfNote_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_NotesPayable_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PremiumFinanceAgreementPrincipalAmount" xlink:label="loc_atnm_PremiumFinanceAgreementPrincipalAmount_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PremiumFinanceAgreementPrincipalAmount_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentUnderPremiumFinanceAgreement" xlink:label="loc_atnm_PaymentUnderPremiumFinanceAgreement_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PaymentUnderPremiumFinanceAgreement_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:label="loc_atnm_PeriodicPaymentUnderPremiumFinanceAgreement_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PeriodicPaymentUnderPremiumFinanceAgreement_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:label="loc_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PremiumFinanceAgreementOutstandingAmount" xlink:label="loc_atnm_PremiumFinanceAgreementOutstandingAmount_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PremiumFinanceAgreementOutstandingAmount_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ProceedsFromConvertibleNotes" xlink:label="loc_atnm_ProceedsFromConvertibleNotes_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_ProceedsFromConvertibleNotes_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:label="loc_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued_26" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:label="loc_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents_28" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:label="loc_atnm_DerivativeWarrantsIssuedWithConvertibleNotes_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DerivativeWarrantsIssuedWithConvertibleNotes_29" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_InvestmentWarrantGrantDateFairValue" xlink:label="loc_atnm_InvestmentWarrantGrantDateFairValue_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_InvestmentWarrantGrantDateFairValue_30" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:label="loc_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_31" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_32" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DebtInstrumentFairValuePerShare" xlink:label="loc_atnm_DebtInstrumentFairValuePerShare_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DebtInstrumentFairValuePerShare_33" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ExtendedMaturityPeriodOfConvertibleNotes" xlink:label="loc_atnm_ExtendedMaturityPeriodOfConvertibleNotes_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_ExtendedMaturityPeriodOfConvertibleNotes_34" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfExtendedMaturityDate" xlink:label="loc_atnm_DescriptionOfExtendedMaturityDate_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DescriptionOfExtendedMaturityDate_35" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_36" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_37" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:label="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeWarrantsUnits" xlink:label="loc_atnm_DerivativeWarrantsUnits_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_DerivativeWarrantsUnits_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeWarrantsIssuedWithStockOffering" xlink:label="loc_atnm_DerivativeWarrantsIssuedWithStockOffering_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_DerivativeWarrantsIssuedWithStockOffering_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:label="loc_atnm_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeWarrantsIssuedWithCommonStockOffering" xlink:label="loc_atnm_DerivativeWarrantsIssuedWithCommonStockOffering_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_DerivativeWarrantsIssuedWithCommonStockOffering_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:label="loc_atnm_DerivativeWarrantsIssuedWithCommonStockOfferingOne_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_DerivativeWarrantsIssuedWithCommonStockOfferingOne_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativePlacementAgentWarrantsRelatedToStock" xlink:label="loc_atnm_DerivativePlacementAgentWarrantsRelatedToStock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_DerivativePlacementAgentWarrantsRelatedToStock_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_atnm_TransferFromLiabilityClassificationToEquityClassification_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_TransferFromLiabilityClassificationToEquityClassification_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeWarrantsUnits" xlink:label="loc_atnm_DerivativeWarrantsUnits_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_DerivativeWarrantsUnits_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xlink:label="loc_atnm_FairValueOfDerivativeWarrantsIssuedWithStockOffering_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_FairValueOfDerivativeWarrantsIssuedWithStockOffering_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:label="loc_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock_12" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xlink:label="loc_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering_13" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:label="loc_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne_14" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xlink:label="loc_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock_15" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification_16" order="140" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ChangeInFairValueOfDerivativeWarrants" xlink:label="loc_atnm_ChangeInFairValueOfDerivativeWarrants_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_ChangeInFairValueOfDerivativeWarrants_17" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_18" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_DerivativeLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_6" xlink:to="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_us-gaap_FairValueInputsProbabilityOfDefault_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueInputsProbabilityOfDefault_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="loc_atnm_FairValueAssumptionOfferingPrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_atnm_FairValueAssumptionOfferingPrice_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeByNatureAxis_2" xlink:to="loc_us-gaap_DerivativeNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DerivativeTextualAbstract" xlink:label="loc_atnm_DerivativeTextualAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_12" xlink:to="loc_atnm_DerivativeTextualAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfRiskFreeInterestRateDetermination" xlink:label="loc_atnm_DescriptionOfRiskFreeInterestRateDetermination_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_atnm_DescriptionOfRiskFreeInterestRateDetermination_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfProbabilityOfStockOffering" xlink:label="loc_atnm_DescriptionOfProbabilityOfStockOffering_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_atnm_DescriptionOfProbabilityOfStockOffering_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NumberOfSharesWarrantExercise" xlink:label="loc_atnm_NumberOfSharesWarrantExercise_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_atnm_NumberOfSharesWarrantExercise_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbottBiotherapeuticsCorpMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_BiologicalLicenseApplicationMember" xlink:label="loc_atnm_BiologicalLicenseApplicationMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_BiologicalLicenseApplicationMember_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FirstCommercialSaleMember" xlink:label="loc_atnm_FirstCommercialSaleMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_FirstCommercialSaleMember_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_AfterFirstNetSalesMember_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_NewDrugApplicationMember_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MilestonePaymentAbstract" xlink:label="loc_atnm_MilestonePaymentAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" xlink:to="loc_atnm_MilestonePaymentAbstract_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_MilestonePaymentAbstract_17" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommitmentsAndContingenciesTable" xlink:label="loc_atnm_CommitmentsAndContingenciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_atnm_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbottBiotherapeuticsCorpMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_atnm_OakRidgeNationalLaboratoryMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_OakRidgeNationalLaboratoryMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AptivSolutionsMember" xlink:label="loc_atnm_AptivSolutionsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AptivSolutionsMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_atnm_FredHutchinsonCancerResearchCenterMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FredHutchinsonCancerResearchCenterMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_JohnsHopkinsUniversityMember" xlink:label="loc_atnm_JohnsHopkinsUniversityMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JohnsHopkinsUniversityMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCoMember_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_UniversityOfPennsylvaniaMember" xlink:label="loc_atnm_UniversityOfPennsylvaniaMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfPennsylvaniaMember_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FormerChiefExecutiveOfficerMember" xlink:label="loc_atnm_FormerChiefExecutiveOfficerMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FormerChiefExecutiveOfficerMember_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_AfterFirstNetSalesMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_20" xlink:to="loc_us-gaap_RangeMember_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MaximumMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MinimumMember_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodAxis" xlink:label="loc_atnm_PeriodAxis_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_PeriodAxis_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodDomain" xlink:label="loc_atnm_PeriodDomain_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PeriodAxis_24" xlink:to="loc_atnm_PeriodDomain_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TwoThousandAndThirteenMember" xlink:label="loc_atnm_TwoThousandAndThirteenMember_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndThirteenMember_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TwoThousandAndFourteenMember" xlink:label="loc_atnm_TwoThousandAndFourteenMember_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndFourteenMember_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>






<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_AgreementAxis_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementAxis_31" xlink:to="loc_atnm_AgreementDomain_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LicenseAgreementMember" xlink:label="loc_atnm_LicenseAgreementMember_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_LicenseAgreementMember_34" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_atnm_LicenseAndSponsoredResearchAgreementMember_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_LicenseAndSponsoredResearchAgreementMember_35" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_ClinicalTrialAgreementMember_36" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentAgreementMember" xlink:label="loc_atnm_PlacementAgentAgreementMember_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_PlacementAgentAgreementMember_37" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_TransactionManagementAgreementMember_38" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeparationAndSettlementAgreementMember" xlink:label="loc_atnm_SeparationAndSettlementAgreementMember_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_SeparationAndSettlementAgreementMember_39" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ManufacturingAgreementMember" xlink:label="loc_atnm_ManufacturingAgreementMember_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_ManufacturingAgreementMember_40" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RentalAgreementMember" xlink:label="loc_atnm_RentalAgreementMember_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_32" xlink:to="loc_atnm_RentalAgreementMember_41" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommitmentsAndContingenciesLineItems" xlink:label="loc_atnm_CommitmentsAndContingenciesLineItems_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_CommitmentsAndContingenciesLineItems_42" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesLineItems_42" xlink:to="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_44" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_us-gaap_TechnologyServicesCosts_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_us-gaap_TechnologyServicesCosts_45" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_us-gaap_MaintenanceCosts_46" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfLicenseFee" xlink:label="loc_atnm_PaymentOfLicenseFee_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_PaymentOfLicenseFee_47" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_48" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MilestonePaymentDate" xlink:label="loc_atnm_MilestonePaymentDate_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_MilestonePaymentDate_49" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_50" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RoyaltyOfNetSalesPercentage" xlink:label="loc_atnm_RoyaltyOfNetSalesPercentage_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_RoyaltyOfNetSalesPercentage_51" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_atnm_FirstCommercialSalePeriod_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_FirstCommercialSalePeriod_52" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ResearchAndDevelopmentArrangement" xlink:label="loc_atnm_ResearchAndDevelopmentArrangement_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_ResearchAndDevelopmentArrangement_53" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PurchaseOfRadioactiveMaterial" xlink:label="loc_atnm_PurchaseOfRadioactiveMaterial_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_PurchaseOfRadioactiveMaterial_54" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_atnm_ProjectEstimatedCost_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_ProjectEstimatedCost_55" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_56" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DownPaymentForProject" xlink:label="loc_atnm_DownPaymentForProject_57"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_DownPaymentForProject_57" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_58"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_58" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_59"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_59" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_60"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_60" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_61"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_NumberOfPatients_61" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_62"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_AmountPaidToEachPatient_62" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_63"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_63" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_64"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_StartUpDueCostPaidDate_64" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementConsideration" xlink:label="loc_atnm_AgreementConsideration_65"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_AgreementConsideration_65" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_atnm_PerformanceBonusPayableUnderAgreementForService_66"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_PerformanceBonusPayableUnderAgreementForService_66" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_67"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_67" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_68"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_68" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantExercisableNoticePeriodDescription" xlink:label="loc_atnm_WarrantExercisableNoticePeriodDescription_69"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_WarrantExercisableNoticePeriodDescription_69" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_70"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_70" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_71"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_71" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NonRefundableInstitutionalFee" xlink:label="loc_atnm_NonRefundableInstitutionalFee_72"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_NonRefundableInstitutionalFee_72" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PharmacyFee" xlink:label="loc_atnm_PharmacyFee_73"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_PharmacyFee_73" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AmendmentProcessingFee" xlink:label="loc_atnm_AmendmentProcessingFee_74"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_AmendmentProcessingFee_74" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_NoticePeriodForTerminationOfAgreement" xlink:label="loc_atnm_NoticePeriodForTerminationOfAgreement_75"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_NoticePeriodForTerminationOfAgreement_75" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_76"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_us-gaap_LeaseExpirationDate1_76" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AgreementRenewalDescription" xlink:label="loc_atnm_AgreementRenewalDescription_77"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_AgreementRenewalDescription_77" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfAggregateAmount" xlink:label="loc_atnm_PaymentOfAggregateAmount_78"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_PaymentOfAggregateAmount_78" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_79"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_79" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_80"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_80" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_81"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_81" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_82"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_us-gaap_LegalFees_82" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_83"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_43" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_83" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_20" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_22" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_23" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_PrivatePlacementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_CommonStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9" xlink:to="loc_atnm_LaidlawAndCoMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_11" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_atnm_EmployeesDirectorsAndConsultantsMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" xlink:to="loc_atnm_EmployeesDirectorsAndConsultantsMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EmployeesAndBoardMembersMember" xlink:label="loc_atnm_EmployeesAndBoardMembersMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" xlink:to="loc_atnm_EmployeesAndBoardMembersMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" xlink:to="loc_us-gaap_InvestorMember_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ConsultantMember" xlink:label="loc_atnm_ConsultantMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" xlink:to="loc_atnm_ConsultantMember_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_PlanNameAxis_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_17" xlink:to="loc_us-gaap_PlanNameDomain_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EquityIncentivePlanMember" xlink:label="loc_atnm_EquityIncentivePlanMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_18" xlink:to="loc_atnm_EquityIncentivePlanMember_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21" xlink:to="loc_us-gaap_EmployeeStockOptionMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RangeAxis_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_23" xlink:to="loc_us-gaap_RangeMember_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_24" xlink:to="loc_us-gaap_MinimumMember_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_24" xlink:to="loc_us-gaap_MaximumMember_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_27" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28" xlink:to="loc_atnm_PlacementAgentMember_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_EquityTextualAbstract" xlink:label="loc_atnm_EquityTextualAbstract_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30" xlink:to="loc_atnm_EquityTextualAbstract_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentCashFees" xlink:label="loc_atnm_PlacementAgentCashFees_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_atnm_PlacementAgentCashFees_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_PlacementAgentAttorneyFees" xlink:label="loc_atnm_PlacementAgentAttorneyFees_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_atnm_PlacementAgentAttorneyFees_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_37" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_38" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_DebtInstrumentTerm_39" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_40" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_41" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_42" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_43" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_44" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_RegistrationStatementDescription" xlink:label="loc_atnm_RegistrationStatementDescription_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_atnm_RegistrationStatementDescription_45" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_MaximumOfferingPrice" xlink:label="loc_atnm_MaximumOfferingPrice_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_atnm_MaximumOfferingPrice_46" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_47" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_48" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_49" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_50" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_AdditionalNumberOfRestrictedStockGranted" xlink:label="loc_atnm_AdditionalNumberOfRestrictedStockGranted_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_atnm_AdditionalNumberOfRestrictedStockGranted_51" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_52" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_53" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_54" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_55" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_56" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_57"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_57" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="loc_atnm_FairValueAssumptionsExpectedDiscountRate_58"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_atnm_FairValueAssumptionsExpectedDiscountRate_58" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantsIssuedToPurchaseCommonStockOffering" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStockOffering_59"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStockOffering_59" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xlink:label="loc_atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet_60"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_atnm_ProceedsFromIssuanceOfStockUnderStockOfferingNet_60" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_atnm_WarrantsExercisedByWarrantHolders_61"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_atnm_WarrantsExercisedByWarrantHolders_61" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_62"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_CommonStockSharesIssued_62" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_63"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_63" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_64"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_64" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_65"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_65" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_66"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_66" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_67"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualAbstract_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_67" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequenteventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SeparationAndSettlementAgreementMember" xlink:label="loc_atnm_SeparationAndSettlementAgreementMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_atnm_SeparationAndSettlementAgreementMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8" xlink:to="loc_us-gaap_EquityComponentDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_WarrantMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RangeAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_12" xlink:to="loc_us-gaap_RangeMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_13" xlink:to="loc_us-gaap_MaximumMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_13" xlink:to="loc_us-gaap_MinimumMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_16" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_FormerChiefExecutiveOfficerMember" xlink:label="loc_atnm_FormerChiefExecutiveOfficerMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17" xlink:to="loc_atnm_FormerChiefExecutiveOfficerMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140331.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="loc_atnm_SubsequentEventsTextualAbstract_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_19" xlink:to="loc_atnm_SubsequentEventsTextualAbstract_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_20" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_20" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_20" xlink:to="loc_us-gaap_SecurityDeposit_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_20" xlink:to="loc_us-gaap_LeaseExpirationDate1_29" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`=?[]DX`$``+H6```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F-UNVC`8AL\G[1XBGT[$
MV-FZMB+T8#^'&]+8!;CQ!XE(;,MV.[C[.8&B"E$J5*2^)T00^WL?K.B1\D[N
MUEV;/9(/C34E$_F8960JJQNS+-G?^<_1-<M"5$:KUAHJV88"NYM^_#"9;QR%
M+.TVH61UC.Z6\U#5U*F06T<FW5E8WZF8OOHE=ZI:J25Q.1Y?\<J:2":.8C^#
M32??::$>VIC]6*>?MR2>VL"R;]N%?5;)E'-M4ZF82/FCT0<IHUU"GG8.:T+=
MN/`I83!^-*&_\W+`;M_O=#2^T93-E(^_5)<P^+KE_ZQ?W5N[RD\/.4)I%XNF
M(FVKARZ=0!Z<)Z5#312[-A^N>:<:\\1](G]8'/AP$1<&Z?_?,/A,#@G"48!P
M?`;A^`+"<07"\16$XQJ$XP:$0XQ10%",*E"4*E"<*E"D*E"L*E"T*E"\*E#$
M*E#,*E',*E',*E',*E',*E',*E',*E',*E',*E',*E',6J"8M4`Q:X%BU@+%
MK`6*68OW,FM,S2#QX?/MC^DPYI5J*L1-2^'"KY/;H:\EU\J3_A-]ZE`O#O!\
M]BF.U##.O'4A=:V>SC^%IS*UWSUR:1#YV-"^3CU62^X34T][?N!!+TI]$ZQ)
M'\GF0_,\_0\``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?
M<F5L<R\N<F5L<R"B!`(HH``"````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````",DL].PS`,QN](
MO$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4
M'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBR
MBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'
MJC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB
M8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%
M#U1?````__\#`%!+`P04``8`"````"$`Z,')Y]\!``"K%0``&@`(`7AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````O)C+3L,P$$7W2/Q#Y#UU9P;*0Z1L$!);'A]@)6Y3
MT2:1;1[]>ZP*4BK!91/-)I(=U;FZ,[TGD^N;C\VZ>/,AKKJV-#29FL*W55>O
MVF5IGI_N3BY,$9-K:[?N6E^:K8_F9GY\=/W@UR[E'\5FU<<BG]+&TC0I]5?6
MQJKQ&Q<G7>_;?&?1A8U+>1F6MG?5BUMZR]/IS(:?9YCYP9G%?5V:<%^3F.)I
MV^='_W]XMUBL*G_;5:\;WZ9?GF'?N_`2&^]3/M2%I4^E&;:BW=TAF63-QOXA
M)_NA*^<"R>&9LAR>03FD+8>0'#E5EB.G2,ZYLIIS)(9860TQE*-M#D%W^$S9
M'3Y#[HAV"`H,01DU!&/C@J\?4\C,B=GVKUP^V$;F:#<R[F/M0"8<R)GGJKCB
M*2S5I;:<2R1'FU805MJ-`_N&U*V!WK`VR!F"7+0C1V#FR*CLC&F[SB_Y^QS>
MK='?2)N5$)6DK8:@'-8F-T-R\ZCD'D:G?;<,6U_3%,/Q148-O92G3K^7LEO:
MW16&"VDSDB`C29N1!!DIVB006"QM$$`.:%<*%HJTK2'H#6LSDB$C>51&#BFW
M3YMAZSOXX'PIVIDC,'-$&YH"H:D-*<RH7&/-[X\#O^W!)];Y)P```/__`P!0
M2P,$%``&``@````A`+6R`^5#`P```PL```\```!X;"]W;W)K8F]O:RYX;6R4
MEDU/XS`0AN\K[7^(<E_RU;"`:)&@72T7%FT+'",W<:F%8P?;:>F_WW%*PR0N
MT7)J)^F\'K_S>.K+J[>2>QNJ-)-B[$<GH>]1D<N"B>>Q_[#X]>/,][0AHB!<
M"CKV=U3[5Y/OWRZW4KTLI7SQ0$#HL;\VIKH(`IVO:4GTB:RH@#<KJ4IB(%3/
M@:X4)85>4VI*'L1A>!J4A`E_KW"A_D=#KE8LIU.9UR459B^B*"<&RM=K5FE_
M<KEBG#[N=^21JKHC)=3]QGV/$VUF!3.T&/LIA')+.P]475W7C,/;\R1,_&#2
M;O)>>05=D9J;!6SOH`Y^Q:,X/K6_M%8\,KK5'TDV]-Z>F"CDUOX4K-VU40(%
M;)M73ZPP:W@?AF'[[#=ESVMS>`CR`=)O'(1UFD]/--L[.))!I[*9,,SLLENQ
M=Y]):*%U_19V%OF>NF#P1=T6D2T<J]R`B9*S@H!%V37A1.0TF]M4G3U`HUJ5
M&*G$7U.!`EJ9!,DT?G]:S-Q`3;;E.I.K[$]%D<H(J8P&B^FJW!"-5,#[UIBT
MKS*E.E>LLI39]:]KS035NG%[7B.5Y!3)-&#@+?VUI(*U]T1!?Q:*"$WR!ETL
M\1-)_.Q7<J_@9-GLIM&O-:NL*S@=#FR[D;-^^ITT%);?D27'%B;G*.F\GS2E
MBFW@B&W@['\T;P0\MPM%83_I1I8E,_N6V5J!+0-#!88+Z\ITB'20G,$6S0XO
MB]F+'/CF]5+3UQH\R68;RPM.Q;Q%#G##3<;<CC!RD</<L!#4WQZ`$:8N<K#[
MG)=L0998!V,7.=P=A\9J\&XO,'J1PQ[BX$@NYBYRP!O$(<-;P2A&#HM['MSE
M4TPCC-K>9!MN"7#1MB3&/$+P)2'@HA5*.T(.J`.]G5)\H&-,+02]@H9U,+4I
M/CFQ0^TGD$`QA'%\C&(,+02]@H9U<$'PS_DQ0?9_HWA:XEF5'2D#PQH/PGHD
M&=,:.[1BTM^3LT[E&-+8@?18^H*^F9K`+:0%),'(0M#S<?C$X&H2"-I)#,&7
MA/`X2C%JB8/L^]ESW4PZ>0ZBW;S,=2+%\S1QR'1F^A$:4@PE7*[`@Z!Q&BY*
M.>$YW.#LA[T"-4X'A_OKY!\```#__P,`4$L#!!0`!@`(````(0"@O%H<YP0`
M`"(2```8````>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULE%C;;JLX%'T?:?X!
M\9Y@FUN(DAP54&>.-$<:C>;R3(F3H`*.@#;MW\\V=L!V&L+I0]O`8GFM??'&
MV7S[J$KKG39MP>JMC9?(MFB=LWU1'[?V/W\_+U:VU799O<]*5M.M_4E;^]ON
MUU\V%]:\MB=*.PL8ZG9KG[KNO':<-C_1*FN7[$QKN'-@395U\+$Y.NVYH=F^
M?Z@J'8)0X%194=N"8=W,X6"'0Y'3E.5O%:T[0=+0,NM`?WLJSNV5K<KGT%59
M\_IV7N2L.@/%2U$6W6=/:EM5OOY^K%F3O93@^P-[67[E[C_<T%=%WK"6';HE
MT#E"Z*WGR(D<8-IM]@4XX&&W&GK8VD]XG>+(=G:;/D#_%O32*O];[8E=?FN*
M_1]%32':D">>@1?&7CGT^YY?@H>=FZ>?^PS\V5A[>LC>RNXO=OF=%L=3!^GV
MP1$WMMY_IK3-(:)`LR0^9\I9"0+@MU45O#0@(ME'__=2[+O3UG:#I1\B%P/<
M>J%M]UQP2MO*W]J.5?\)$)94@H1($A?4R_ODITD\20)_KR3A7!)'N.J#E&9=
MMMLT[&)!Y8'N]ISQ.L9K(+Y&1W@9XG4O7!`G3O+$6;8VM`Q$HH4<O^]\?^.\
M0UIR"8EO(5A')%<$SP%G3<4%^#VR!L,S#A@87$!\51=?Y_8JEH.YV.LZL;B@
MKD.&97HER2W"#W5(>@L9232M4`/SM7+PUH;$C"%8Z0O'`@*U.$`\'9$\1*13
M"$T\*)DOGH.A711E?J1+BP5$%>\:_I+'D'02HNF'E>;KYV`]^`$R]`N(JM\,
M_D-$.H70Q`>Z>-ZK+NR'T]7.']*3$!B-%PM(V/<M\0(4!68.5`1&*]C^S/)7
M$2[VO97KW>G54'<QK9Z##?5C6_6]&0N(4(^#,$"^JR<I41&1ZV+7V)M2%>`B
MC)`;CH6JI8"_%2C;Y;1X#C;$&])B`9'B/60(2\1MM;S,]DA5!I<$OD?&U&C2
MHY^1SL&&=*.P8P%1M1F(1""$.0\3(W&I>MOW/1>-5:<)QU#C\X/>HPWI1EAC
MB;DJ<U<>&8M5[/@:A"!"HL"PEVH0"'RP@MX92D^WP$?9[+K!8O"I&V=@Z(LE
M1EA8>/A+#X)'8NZ8T#`/7/`9-]^%F(BP-P^#*1A+4_0N%IBI(GH,22<A>A[X
MH)OO0(Q%+0]CC4H'`J,Z,%LTP5<,?S%:^*%1CJF\+_.$HR`D>,3H!OBHFV]`
M#$;-P+BQ20.3PU,VPV-,B@5&F"`!@I\[O0"Q4BW,&V/\E=W8D<)Q`6E%8*YQ
M)'Z`46@,NT02"1!V7<_'YL:D018X0![PC*6K)X0/OOD)$6-238@I,,;J*%W`
M*>-+%RH(7+B1.PKLHY$:/&'HK4@T6M5=\`DXWX68EYJ+D5CF0F"B_J4"8AA$
MD1<9$A.L@8)5A)3A)5UHD)5+8,3[XV*Z"SX+%1<S*TM,4,V-.::QP,".W[<P
M6IK[<7*#0`9'*A%W=@K="!^-AA$/'IQ^W8!3]$V+&#,KEAC9I3XA4!/&CI#H
M&.Q&D+UQ.Y)I$6M-FA%'<G':K&ASI`DMR];*V1L_;A,(Y7!U^"K@B?!CF7$]
MQFLX',)U9[@!)_1S=J0_LN98U*U5T@-0HF4(@AIQQA<?.G;NS[@OK(.S>?_O
M";Z+H7"\1$L`'QCKKA_X`L.W.[O_`0``__\#`%!+`P04``8`"````"$`5NOF
M0Q`$```8#@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6RL5UV/FSH0
M?;]2_P/BO7PF9!,EJ1;(WENIE:JKV_:9@).@!8RPL]G]]W<&8X)-/G:EOH0P
M.7,\9V9L3Y9?7LO">"$-RVFU,EW+,0U2I33+J_W*_/G?T^<'TV`\J;*DH!59
MF6^$F5_6G_Y:GFCSS`Z$<`,8*K8R#YS7"]MFZ8&4";-H32KX94>;,N'PVNQM
M5C<DR5JGLK`]QPGL,LDK4S`LFO=PT-TN3TE,TV-)*BY(&E(D'.)GA[QFDJU,
MWT-7)LWSL?Z<TK(&BFU>Y/RM)36-,EU\W5>T2;8%Z'YU)TDJN=N7$7V9IPUE
M=,<MH+-%H&/-<WMN`]-ZF>6@`--N-&2W,A_=Q<;U3'N];!/T*R<G-OANL`,]
M_=WDV;>\(I!MJ!-68$OI,T*_9F@"9WOD_=16X$=C9&27'`O^+SW]0_+]@4.Y
MIZ`(A2VRMYBP%#(*-)8W1::4%A``?!IECJT!&4E>V^<IS_AA9?J!-9TYO@MP
M8TL8?\J1TC32(^.T_"U`;D<E2+R.!)X72&XX^ITC/#M'=V*Y$R?`Q6_X33H_
M>'YL0:!MY<)3+CBU9JXS]V<75[1%NMKLQPE/ULN&G@QH:4@(JQ/<(.X"/&7:
M1<Q](:[5`0J`)(_(LC)A+T**&33/RWH2>$O[!0J>=IAPC'%51"016%VDC:7A
M3.L_/*A.&XG!Y@)-O3"HX1\0ABPH3(842L,Y)$UG)!'2)9:&@<M$$R$AN@CH
MIZ&(RYM!%@'!*Q-::5`$7UTH%!@H]!FC(B*)Z,.7AJLN&XG0HX=0AM%C;_EP
M,-Q6@4Z`&T88:.D*!6:HPM?:(NH@\R'/5"M5W($>VHYU+'^JYF)SAT3I-XA&
M%^O.\*RZHQ?]=+U:'*'`P&=?M9'>#J+JU:H?W^?9W.%1)`>JY-MU1;"N,U#S
M'0K,4*=6^4@B^NZ4AG-J-)>-1.C=.?M(]`B^M[<$YE;T$M%'+PW7HY<(/7J<
M>P;G]NW<(UC/_4S+O<#,VJW@^O-IH#5A)`#B[FU/9VFX'KQ$Z,%#E[X_>`3K
MP6N[/108$?PD<#P]=O'[('9IN!Z[1.BQNW""O3_X%KTR/?]\@XQ-T=@4CTT;
MQ:1L1!<OP4$WR)/VH[>XN$N5LU<_,\-V+5`$9V-_&DV"T54NJ`#5]_K949HV
MBDE5A#?B'U`D+E95D78JAC#68H<IBCQWKNZ/Z(R2X<=C$X[('5??-V+D%4-7
M29H]B4A1,".E1QQG\>[IK6+4AA3#K-U.IJ-?/#F%:[_`>/[83N>:/707,%9!
M+)H]QB4NV$-O`0/,!3PL?,G^Z#I`)$;[?@F8R^MD3[XGS3ZOF%&0'0AU+)Q,
M&S'9BQ=.ZW8`W5(.$WG[]0#_P`B,?HX%X!VE7+Y@.OO_=.O_`0``__\#`%!+
M`P04``8`"````"$`57&RYF\%```1%@``&0```'AL+W=O<FMS:&5E=',O<VAE
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M[[NC*-/'`^A^95Z::>[FRXB^R+-25&);6T!GJT#'F@,[L(%IO=SDH$"FW2CY
M=F7>LT7B3$Q[O6P2]&_.S]7@LU'MQ?FW,M_\R(\<L@UUDA5X%.))0K]OI`F<
M[9'W0U.!/TMCP[?I\Z'^2YQ_Y_EN7T.Y?5`DA2TV;S&O,L@HT%B.+YDR<8``
MX+]1Y')J0$;2U^9YSC?U?F6Z4\N?35P&<..15_5#+BE-(WNN:E'\IT"LI5(D
M3DL"SPLD5QS=UA&>K2-CEN?XLWGS^BN>7NL)S\^]$E0U@N&I7^GT@L=OM%7"
MFOS':9VNEZ4X&S"I(275*94MPA9`IA.O&+I2O%<)*($DN9<L*Q.Z$9)<P?1Y
M67L^6]HO4/*LQ81C#$%$&B'K*VEC;>AIW?D<TR8:(Z<7:.J$015_@C#)(H7I
MD$)MZ$-R<$"11FB76!L&+A[V232$BH`9146XT%R7VT(70SJM3)A273%<;X9?
M&"H,%+S#D)`BC>AD:,.[+HE&4!40RN=52"=HXT&$SL0E*A2&39H9QQS+\S$@
M4@`_&+!X/BE8C%A\:QY@DN0&"9IUD-&AU.N%DF`JD90A5)A68F`%7C#\(PF)
M%%JMD$T'(7=($.V>@0/2,<4ZFF5A)M?>&W-/^E%)I"BAPOAS537+=9([4I*H
MA>"Z$;$QX7&FP\P$P8@UN<&*$C##";A>2`FFJFG'*0PDL.\XGQ0[TIBNY[3A
MBE.B,;3KY-F(KNP?*:'THV)(2X0*TY9P8LWH2MZ.X_J1>1!3$E+?Y`8)*A>\
MZ4MBI1\1RR:X_T.%&5;.)6T4M1!X#*H[Q3SQ;9[D!@^2#&O"2//MS:'QHHI)
M^<(6=%6RQF#-9-;'&J6:79[><%(2#7B/!DN6FSV9TQ^0K(X(:"MA9,4)F0)=
ME]QB<*QD+L2:24MV1Y)OT&#)\FA`)+./M#%39PJLFK18V(*"9BDF31ZU@V3W
M)*CX&D5RBP)+E>>'@=3K:RZ3Z)7IN/W9;&R*QJ9X;$J0"<<D-_]!3'(CE#/N
ML^=C=888%F-T#@F9`CGPZ%>1*5F-HA[5[1)C4X),6!%,\9^A2-+@=<3S1]-+
M@9`BAY%^B.0//5E)KZMD/#8ER(05R7V=U,@#SL_62!T/<(U(K"%3(**(K'I1
MC^IKU#EJ4X)06)'<TXFBK\PZ=33`BLBN%#(%(HI(ET<]2H<?CTT),F%%<C,G
MBF1%/ULC=2;`BDCV0Z9`6)%#]KBH1_6*.D=M2A`**Y)[-5'TE1I)&MI'9$L)
MF0(A1=YTI*A#Z?#CWE&;$F1"BN""9Z3H"S5J:*@B,I_"%H04.?1P$/4H'7X\
M-LF+J7[]4(K419.ZZ"AXN>,1/QPJ(Q//\A()EOOULC.K&RZ(2%]QT1'F+>1Z
M"B&,1GP8:7YMC4:F,#*]Z#.#D=G%D3F,-%<-([8`1H(+/G`O=^]<L(=L`;<I
MXXACN,>[9`^=!=Q;7,`[D)0+]GOF`E&S]=I=L'`A=TIW_(^TW.7'RCCP+>0:
M?AQ`FY?J2D]]J<6IN7=Z%#5<Q34?]W#URN'&9V(!>"M$K;]`2'9WF;O^'P``
M__\#`%!+`P04``8`"````"$`#,&T<#$#``#."0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6R4EEUOFS`4AN\G[3\@[@N8\!&BD*JAZC9IDZ9I']<.
MF&`5,+*=IOWW.\:$8EJA]`8">?SRGO<XG&QOGYO:>B)<4-:F-G(\VR)MS@K:
M'E/[S^^'F[5M"8G;`M>L):G]0H1]N_O\:7MF_%%4A$@+%%J1VI64W<9U15Z1
M!@N'=:2%;TK&&RSADA]=T7&"BWY14[N^YT5N@VEK:X4-OT:#E27-R3W+3PUI
MI1;AI,82_(N*=N*BUN37R#68/YZZFYPU'4@<:$WE2R]J6TV^^79L&<>'&NI^
M1@'.+]K]Q1OYAN:<"59*!^1<;?1MS8F;N*"TVQ84*E"Q6YR4J7V'-AGR;'>W
M[0/Z2\E93#Y;HF+G+YP6WVE+(&WHD^K`@;%'A7XKU"U8[+Y9_=!WX">W"E+B
M4RU_L?-70H^5A':'4)$J;%.\W!.10Z(@X_BA4LI9#0;@:#54;0U(!#_WYS,M
M9)7:J\@)8V^%`+<.1,@'JB1M*S\)R9I_&D*#E!;Q!Q$X#R(H=`(_C-<?45D-
M*G"^J,376G%U67U*]UCBW9:SLP5;#XR+#JN-C#8@_'XLD(=B[Q2<VO#3@(H%
M]/)I%P3!UGV"_/.!V6L&CB.#3")[2X31B+C@:S0'>5UO3L'*G.JA<KO7-Z9.
M_/$Q/9$M$8812&9J1&VB%6S%Y;34HM0.)DFL@M="M4?-P$X:TYKEF2T1AD=X
MT-3CLC<%0PW3YP:AF<Y>,W'?9Y1$Z\A?F42FB??=&]X`F7J[+C^U:.YQGI]F
MM,>;(/+\61&9!N#X3L"&Q<BTN!R?@N?68C.<O68N\?E^F*Q-(ELB#&_Q1[PI
M>.YM]N2]9I*^M5'LQ7XXSTT35^2F!N7D!7)=:]6BN<?$3&>OF:&U:)6$T=RC
M080!BI/UZZ_'"#`Q32XW5\&F.93,FZN9H;E^&"$OGK_F-')%@C#^C`B7W?6T
M:2\(O5EV`Z0;C!+DK^-H[F^9T?'IL:H'1D/XD62DKH65LY,:F0CVSWAW'.=W
M?C^0QR]@FG;X2'Y@?J2ML&I2PE+/B2$9KN>QOI"LZ\?1@4F8H_W'"OXW$7B5
M>P[`)6/R<J$F_OA/;/<?``#__P,`4$L#!!0`!@`(````(0"/,J:'(0,``,H)
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)R6VXZ;,!"&[ROU'9#O
MES,Y*62U"=EVI5:JJAZN'3#!6L#(=C:[;]\Q#A1(2K*](3'^_#/_C,VPO'\M
M<N.%<$%9&2+'M)%!RI@EM-R'Z.>/Q[L9,H3$98)S5I(0O1&![E<?/RR/C#^+
MC!!I@$(I0I1)62TL2\09*;`P645*F$D9+["$(=];HN($)_6B(K=<VYY8!:8E
MT@H+?HL&2U,:DXC%AX*44HMPDF,)\8N,5J)1*^);Y`K,GP_57<R*"B1V-*?R
MK19%1A$OGO8EXWB7@^]7Q\=QHUT/SN0+&G,F6"I-D+-TH.>>Y];<`J75,J'@
M0*7=X"0-T8.SV$Z1M5K6^?E%R5%T_ALB8\=/G"9?:$D@V5`F58`=8\\*?4K4
M+5ALG:U^K`OPC1L)2?$AE]_9\3.A^TQ"M0,PI'PMDK>(B!@2"C*F&RBEF.40
M`%R-@JJ=`0G!K_7OD28R"Y$W,8.I[3F`&SLBY"-5DLB(#T*RXK>&G).4%G%/
M(AY$?YH/3-\-IK/WJ/@G%7ANH^*:[BQP@LGU6"SMJTY3A"5>+3D[&K#U(')1
M8;61G04H-_G1;MJ,_2MAD"DE\J!40@1G!G(AH,@O*]^;+*T7J$Q\8M::@6O+
M>!.OSVS.&:=/1`VA2J4>O>W<L,!3:PR2WC5VN>!-_`I6\3>J:WVC&ZSO3?NA
M;,X9MT]$%PB_CVS/$=^;M4S/$6R?KB-5*@\.Q+@SM0BX3M9];][JURE<:P:J
MWU9F$.7F*A%=);9C1,\G;/3W^U2+0@37OQY\>^!3,V,^KQ+156([1O1\0B!=
MG^-U5/"@CO[@;*PU,^9/$_/ZA,Y]?S90B+KS#KR?W*"?PNT(T/,VZ7N[;:^J
M14./@R.UULRT=N`$\_D@P$UW?N)Y_F`G1WI^)$?;,:+G<?H_'M6BH<?!6W"M
MF9$8-YK0=;R0A>BJ`O1<%<?E9VB7NJ?J9E$0OB<;DN?"B-E!]4L'*M#>;5OY
M@UMWXW8"6FF%]^0KYGM:"B,G*2RUS2D\E^MFK`>2574KVC$)3;3^F\$W$X$7
MO&T"G#(FFX%J]^U7V.H/````__\#`%!+`P04``8`"````"$`=3GFP<$"``!?
M!P``&0```'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R455UOFS`4?9^T_X#\
M7@P$D@:%5$U0MTJK-$W[>':,`:L8(]MIVG^_:QQH:+HM>P%L'Q^?<^_U977S
M+!KOB2G-99NAT`^0QUHJ"]Y6&?KQ_>[J&GG:D+8@C6Q9AEZ81C?KCQ]6!ZD>
M=<V8\8"AU1FJC>E2C#6MF2#:EQUK8:642A`#0U5AW2E&BGZ3:'`4!',L"&^1
M8TC5)1RR+#EEN:1[P5KC2!1KB`']NN:='M@$O81.$/6X[ZZH%!U0['C#S4M/
MBCQ!T_NJE8KL&O#]',:$#MS]X(Q><*JDEJ7Q@0X[H>>>EWB)@6F]*C@XL&'W
M%"LS=!NF>8+P>M7'YR=G!WWR[>E:'CXI7GSA+8-@0YIL`G92/EKH?6&G8#,^
MVWW7)^"K\@I6DGUCOLG#9\:KVD"V$S!D?:7%2\XTA8`"C1_U,JAL0``\/<%M
M94!`R'/_/O#"U!F:S?UD$<Q"@'L[ILT=MY3(HWMMI/CE0*$5-9)$1Y(9J#^N
M1_]-$A])X#V0+"XEP<Y5'Z2<&+)>*7GPH/!`M^Z(+>,P!>(A.L[+&*\_A0LL
M6I);RY(AN#$0"0TI?EK'LWB%GR`O](C9G&/"*6([(&SD+&WN)N`YTB;S<0\&
M!Z,-"/"IC?>3.ZBU8*MV.&?C)D[/B<9C>B7;<T2RF$+R<\@KR40K%,'E6BTX
M0Y"9,03Q+)F>O'$8J,97S!2Q_2<B_QMBHAZD7*[>@N'"G"A;+*?2-@ZR[(LF
MC(,WWK:GR\%T:^[6WO<]T0R0RS5;\%3S_&TI.\C[![MZ<0CGZBH.H]=2<)4]
M64^2>!9<C^:<=-?0W%T53%5LRYI&>U3N;;.*(%[C[-A';R-;TV_F-V$*-POF
M\;@`_:TC%7L@JN*M]AI6`F7@+T"5<AW2#8SL^@ZQDP8Z6_]9PX^,P=T,?`"7
M4IIA8`\8?XWKWP```/__`P!02P,$%``&``@````A`(\X%3?>`@``V0<``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,C4N>&ULE%5=;YLP%'V?M/]@^;V`^0A)
M%%(UJ;I-VJ1IVL>S`P:L`D:VT[3_?M<8:*#MEKY@C(^/SSWW^K*Y?JPK],"D
MXJ)),'$\C%B3BHPW18)__;R[6F*D-&TR6HF&)?B)*7R]_?AA<Q+R7I6,:00,
MC4IPJ76[=EV5EJRFRA$M:V`E%[*F&J:R<%4K&<VZ377E^IZW<&O*&VP9UO(2
M#I'G/&6W(CW6K-&61+**:M"O2MZJ@:U.+Z&KJ;P_ME>IJ%N@./"*ZZ>.%*,Z
M77\I&B'IH8*X'TE(TX&[F[R@KWDJA1*Y=H#.M4)?QKQR5RXP;3<9APB,[4BR
M/,$W9+V/L;O==/[\YNRDSMZ1*L7ID^395]XP,!O29!)P$.+>0+]DYA-L=E_L
MONL2\%VBC.7T6.D?XO29\:+4D.T(`C)QK;.G6Z92,!1H'#\R3*FH0``\4<U-
M98`A]+$;3SS398*#A1/%7D``C@Y,Z3MN*#%*CTJ+^H\%D9[*DO@]"8P]"8F<
MT(_BY7M8@IX%QH'%=_QE1*+%_[6X-J[.IENJZ78CQ0E!Z8%RU5)3R&0-S(,_
M-IK1L;<,`Z<,R8UA23#<&?!"09(?MJ&_VK@/D)FTQ^PL!IXCADP1^P%A$@KR
M1HW@V[G&UW,W2#%@(\7DTFC;V0_GY_JS<U]!A"-DH@0<NER)`2<X/`LX")]Y
MK3B+@5(:39DA]O]"3+3!09=K,V"HY?-S`V^,V6JSF(FV8)ZR5S`CRT0=T%RN
MSH"GZD@\\V5G,:NNV$A,XEFY[2?K4;A\CFZB:_$>708\U14&LV+:64S<Z;KR
M5XMH]*-S=3]9A[O[AJ[X/;H,>*XKF)Z[LYC>K]`G,S^A"1N.?CU8^7-=ML7:
MWE$S6;`]JRJ%4G$T[9-`O./7L;/?^%US'A>@L[:T8-^H+'BC4,5RV.HY,>1*
MVMYL)UJT76<Z"`T]M7LMX1?*X#I[#H!S(?0P,<UB_"EO_P(``/__`P!02P,$
M%``&``@````A`*`T$%&<"```*3@``!D```!X;"]W;W)K<VAE971S+W-H965T
M,C0N>&ULG)O;<N(X$(;OMVK?@>)^`)MP<B79&N/SH6IK:P_7!)R$&L`4=B8S
M;[\MRQS4]NAWD@L"\N>6K+_5DAIT_\>/_:[W/3L5V_SPT#<&HWXO.ZSSS?;P
M\M#_YV_OR[S?*\K58;/:Y8?LH?\S*_I_//[^V_U[?OI6O&99V2,+A^*A_UJ6
M1VLX+-:OV7Y5#/)C=J`KS_EIORKIX^EE6!Q/V6I3W;3?#<W1:#K<K[:'OK1@
MG;K8R)^?M^O,R==O^^Q02B.G;+<JJ?W%Z_98G*WMUUW,[5>G;V_'+^M\?R03
M3]O=MOQ9&>WW]FLK?#GDI]73CI[[AW&W6I]M5Q\:YO?;]2DO\N=R0.:&LJ'-
M9UX,%T.R]'B_V=(3B&[OG;+GA_Y7PTK-:7_X>%]UT+_;[+VX>=\K7O-W_[3=
M)-M#1KU-.@D%GO+\FT##C2BBFX>-N[U*@3]/O4WVO'K;E7_E[T&V?7DM2>X)
M/9%X,&OST\F*-?4HF1F8$V%IG>^H`?3:VV^%:U"/K'X\],=4\793OM*[Z6`R
M&XT-PGM/65%Z6V&RWUN_%66^_T]"1FU*&KFKC=#_VH@Y'9CSB3&9?L`*U5<U
MA?Y_OBG3VLCL8L2@MQV?@P9%U8+%Y>:Q.;@S)[/Y1WK#(!$K,\9G.G4H!:KT
M=E;EZO'^E+_W:!"1!,5Q)8:D80G+9Z6E+A?M?R4]:2ZL?!5F'OKTI*1J0?[Z
M_7$\G]T/OY./K6O&E@R]7IFIJ3++-F:L,DZS+D,EW#,A'%,TS^,%_KF>,Q'P
M@I`71.<"3?/C-H8U/VDRK/EIDQC/YY=''))R%_E,)E_[`#VK)&BATOFI;5E`
M]5TEF2\N-55]MVQA%JS%3I-APKJ0\)K$A'F0WT3,.[6U01,9+Y@"81LS4>U$
M;<Q49>(VAO5>TF18SZ0MQ/6A%+%I>"IC52^VH!6Q98$B]F*D/M*R`^-T8-PV
MACVXUX'Q.S!!!R;LP$1M#//`N`.3=&!2/:.H3M.?HKJ(T'>_G(O/0UW<I:@O
M"^0,*V+BDA<XO,#E!1XO\'E!<"ZX"2B+JS=7`27LP$1MS#4$5G;B#DS2@4GU
MC*(%=;NBA7X$"IJTNHFN=R,VX&S)T.LE`K/N6D+"@80+"0\2/B0"2(20B"`1
M0R*!1*HC%,%IX?<!P05=+7JO8H[85&E+AAIP95@,AH0#"1<2'B1\2`20""$1
M02*6Q*):54Y&]*?V5P(MI#I"D9L6]1^06]!<;C;)V9+1R0T)!Q(N)#Q(^)`(
M(!%"(H)$+(E9)3=M^YMZ0Q.ICE#T%OF*V]V//IX+FNO-UI:V9'1Z0\*!A`L)
M#Q(^)`)(A)"((!%+HM:[;7Q#$ZF.4/2F+;BBMUA+C6ECK===W,5U9[.T+1F=
M[I!P(.%"PH.$#XD`$B$D(DE(5>?&Q.!1.X8F$DBD.D+1721//B%\=1M7GNT4
M[1K228\1!R,N1CR,^!@),!)B),)(7"/22]J&_L6&R"BQ>3]5[F8SA:J^2*AT
M#_.&S+_0%NVZ1!NQO;]=0UK5I1T-XM169`?0YJ`QV;FX'@\C/D8"C(08B3`2
M8R3!2*I%5/5%@N56_6Y!WY!Y&=4+6#K`KB&-Q$N,.#4BO6`Z7\R8L[G8AH<1
M'R,!1D*,1!B),9)@)-4BJA.(A,NM$^AG?)$);TSY+/]@UY!6?&E'@SBU%;F]
M8=E#%U?A8<3'2("1$",11F*,)!A)M8@JO,CNW`K?<?3+I)`Z^IDZMB$AC;I+
MC#@8<3'B8<3'2("1L$9DL!H;QIRMAR)L(\9(@I%4BZA.0!(I3@!&O\#9LL]@
MJP];?!U*D%9\B#C8BHL1#R,^1H(:D<K.%E.3[6U#;"/"2(R1!".I%E'%%]D?
M'@&,"=SU&3)KI(0`@V?S:DCQ`H/E@):M$.M<IPU2$UTN1CR,^!@),!)B),)(
MC)$$(ZD647U!9(8^XPLRHZ3Z`D\!B)\$\(A@L.BX;(78>L]I@[@OM%2F(AZV
MXF,DP$B(D0@C,482C*1:1/4%D37BOH"3089,-JFNT-@7Z#)2\FOUVHX:.=@2
MTVF%V#+$;8.X*\#V^-A*@)$0(Q%&8HPD&$FUB.H*(I%TZPI@?2#S3HH+F(WU
M@2XY5;M`C<RK7/=H,&+!PC&@#1<C'D9\C`08"3$2823&2(*15(LHXIN?RPU6
MM[%%HLF7!S4DEU2FR'"I`W.)`*<&E#"AVG`QXF'$QTB`D1`C$49BC"082;6(
MZ@(\02@WB7"):+9D"DVV^K-K2*/@L@WAJV^G#>*>`#..'K;B8R3`2(B1"",Q
M1A*,I%I$]83/)0O-EF0A_VF:74-:1Y!V9+R@7X<:([Z`=+`5%R,>1GR,!!@)
M,1)A),9(@I%4BZAN0'/[!Q8$IL#Y7,`F<[N&M/)+.QK$P5;<&JF=:+Z8C-GR
MU%,)<S&?L'G)Q]4$&`DQ$F$DQDB"D52+J.+SE*%^-6C*+*#X=_V^R&1;.OM,
M*8M&-7PO.S!.!\:M&8T;>1W,^!V8H`,3=F"B#DS<@4DZ,*F>45V!^E")`V)A
M,)N)0P_@-P."H)!`=5U_;%T7C2]%RS-U+7*:16Y=)+[RNO&PQJ!NF/>;MH)F
M4=@LBII%<;,H:1:E2I':E3P-!T952_;-9-MCFX[`-#(N?$Q!Q,%6W!J17](8
MK2$5UN,K1N;-S'F`&Q)B),)(C)$$(^(`TJ][7VHO#QC)`R?[[/22+;/=KNBM
M\S=Q>(@2^(_WEV)YLHE&)QUMJLX4L2L4CRSAT32>V!6*0I9P[.85BCV6\._F
M%8HXEG#SYA6*,Y;P]N85BBZ6</KF%3J/];4:Z:QECF'1V9,6GBQ];;5$$X5E
MMUZAZ<$2`:-IC28%2\2-YA6*\Y8GKPPO3:.#6L?52Y:N3B_;0]';9<^DQ6@P
MH_AQDD>]Y(<R/U;G@Y[RDHYH56]?Z4A>1C\>'PT(?L[S\OR!JAY>#OD]_@\`
M`/__`P!02P,$%``&``@````A`))H6W9R`P``,0T``!D```!X;"]W;W)K<VAE
M971S+W-H965T,S$N>&ULE%==;]HP%'V?M/\0Y;U)#*$I"*C:5=TJ;=(T[>/9
M)`ZQFL21;4K[[W?M&U("E)@^4`+'Y]YS[)Q<YK>O5>F],*FXJ!<^"2+?8W4J
M,EZO%_Z?WX]7-[ZG-*TS6HJ:+?PWIOS;Y>=/\ZV0SZI@3'O`4*N%7VC=S,)0
MI06KJ`I$PVKX)A>RHAHNY3I4C60TLXNJ,AQ%T75845[[R#"3+APBSWG*'D2Z
MJ5BMD42RDFKH7Q6\43NV*G6AJZA\WC17J:@:H%CQDNLW2^I[53I[6M="TE4)
MNE])3-,=M[TXHJ]X*H42N0Z`+L1&CS5/PVD(3,MYQD&!L=V3+%_X=V1V/XK\
M<#FW!OWE;*OVWGNJ$-NODF??><W`;=@GLP,K(9X-]"DS'\'B\&CUH]V!G]++
M6$XWI?XEMM\87Q<:MGL"BHRP6?;VP%0*C@)-,)H8IE24T`"\>A4W1P,<H:_V
M_Y9GNECXX^M@DD1C`G!OQ91^Y(;2]]*-TJ+ZAR#24B')J"6!_RT)F03Q:)+<
M.+"$V)$5^$`U7<ZEV'IP:J"F:J@Y@V0&S$;9&/S!/CJM'TD%C8;DSK`L?#CN
ML%S!_KPLX^OI/'P!3],6<X\8>.TPI$.$T$W7$K2QW])IDW>5#=A4-J:;5N[Q
M@_TRH]-EQOTR.^7GRYE%X-">B#B).G[L`#&PL9W0N$/TA,;]#LY7-N"%#Z\=
MZS@^M!@Q#I4!XFZQ`?<UCV\FG2+4C)BIW?ID$L%?!^A)ONX7=C/=+.HW$"?O
M9P<;0(R#]*3?P7G3#7C(=,0X5#9/@[U;[7QE`^YK/C8=,<F@Z=-^83?3S:)^
M`W'R?B>AZ8AQD$X@4MRU6_20[2W(I;A)'F?C">;4_BU^['P+0NN)/>\?''AR
MD&9NYMM5A^Z/NUL*W6]!+@Z82')W``/L?-00YY0C)I7<BV.&#=B/H-;^<WEC
MGM(7%#?H0]O?P[NU'4$NMA^DW?D[GF"$#=CNG'/DHJ"SZ+[R$Z<>H\[EU%^4
M=>0X[.+D\`G3@EQL/\B[`=LQQ`9L=TXZ&$,O.'`6/61["\*'Z^FPP<D5![N*
MR37[PLI2>:G8F*F4P!.B^[2;F.]&=N;MOH"!M:%K]H/*-:^55[(<ED9!`HY+
M''GQ0HO&CHTKH6%4M6\+^&G"8/B*`@#G0NC=A1FJNQ\[R_\```#__P,`4$L#
M!!0`!@`(````(0!`$8H"LA,```NL```9````>&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;)S=V7+;2).&X?.)F'M0Z/R7N(JBPO(?Q7W?]S-9IFU%2Z*#I-O=
M=S\)`B!1"0S>DON@NUU^F``!?"D(0)&?_OO/V^O5W]O]X67W_GB=O<E<7VW?
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MPJ^^;`_'QHM7\OKJ^=?AN'M;^B@;E/*+Y((B>5G[X.]S'RY2"(K(?\,BI0\7
MD74^O9V[<Y%\X>:^6"S<W9?<WT\IJ"+_#58E5[K)W1>SQ;L/;!7)F+]I9?,$
M9?Y@VV9EH_IE+ALFG[LIY(JE^X_L(^^@\.M<WM6?K$[XKG*7G9TK?'QU<N'N
MSE_J_,'JY,]EY.V%&SG_\=7)RP%SVCKYR-;!`^;6#],IF[6GX]/G3_O=[ROI
M>!*7P\\GKW]F'[R*82K]#)US^O_%5/+I53%>F<=KV>*2P(,TE[\_%TIWGV[_
MEG[P')A*W&1M40V%%WZO;,T?D'^?RQ95U7J<Y.]R=MU&W*@E-^,B?Y>WJ[1\
M$WV/JDH[%.'Z=_1`5P_T]$#?'_"[EK<-!GI@&+[DLE'4>HQ"$:['6`],PJ*7
M&K&M-@U?%#5JF\Q"$RYIK@<6\26IM5W&1?[^WM[VJP2C]_(Z7/1E?=62-J$(
MU]8$Q^UE:YO@*(V,!$=E9"0X+.]//UE.AW]P%$9&$HZYV!%ESH?=>86"@TQ6
M]'S$QU\6'&>1-0H.M/27!0??Z66W$O]S#Y"N;_6`Y)_(8=0][44]7.=*.'!9
M996_:EP42_8.KL6)*E+W1?0M%DJJ2B-N5)5F7!1*97M=6G&CJK11=%!T4?10
M].,B7U81'229HOV.AW&CWO$(Q1C%Q!<Y_\=#MI#-V&LQC5<HW*L]/$LRJEG,
MDXS:QXNX4>]X&1>Q;;N*FT)9O:MUW*@E;>)"Q\.8N%%53)##:$!R!7L+FR")
M45/0!XP)LF@C]:Y,4ASU6S<)>2R4U0]PDQ3)LMI=)B&3Q8Q>)XZE2<AE,:.W
M9%(T+UO2:IUR2FBU3N_T*2^_&J6W4.]55@O5`U4]4-,#=7_`VDDE%82&@VDF
MF'NU85L.IIUDU,_?CH/I.IB>@^G'3;ZL=O3`P0SCIG"O6NS(P8P=S"3)J+A,
M'<S,P<P=S,+!+!W,*L&4U;&Q=C`;!V.,"ZJXH""$5L3T:IL@F.DH*:RQ2DEI
M+:L??R8IKC&4D-=B1FUODQ#8.$I(;#&CCGZY:G1J9]%-$$56OY1?@O^@7WJO
MLOJE'JCJ@9H>J/L#EW/FAAYHZH&6'FB'`Y<SW<*]ZBF=!%-2IUM=!]-+,JHO
M]^,F7[[\H#K]"CUP,,/0A*?THW`@^D95X7&246]T$IJP\%0/S/3`7`\L],!2
M#ZS"@<C:ZE:_=C`;!V-,',6VN:FXH."8C<8F7BDXCJ.HH'>Q.1_;T0V@=H4Y
M'^\7%%_<.0-IZ)R+-)20E?CB$L(21PEIB2*KO<AUL#]H+]ZKK/:B!ZIZH*8'
MZOY`I+WH@:8>:.F!MA[HZ(%N.'#9\K$&U`M-F+F^'ACH@:$>&.F!L1Z8Z(&I
M'ICI@;D>6.B!I1Y8Z8&U'MCH`6-B(Y782+`_+WO+!#O4SIEJ[>:\DR.;7S<:
MTPB7%D7JQ-S$#@83.QI,['`PL>/!G`\(V=E6$.0B\1\$P7O5X[4TK_/%IV)&
MM?V*;^1-GHT2510U%'44#11-%"T4;10=%%T4/11]%`,40Q0C%&,4$Q13%#,4
M<Q0+%$L4*Q1K%!L4QC#AU!F.G>'<&0Z>X>09CI[A[!D.G^'TF=3X63U3[GY9
M/3/]&HZGY5I/I`\6,^J<J^*;M%Z)HH:BCJ*!HHFBA:*-HH.BZXORZ1)Q-N/_
M8U_#[&&1/HH!BB&*$8HQB@F**8H9BCF*!8HEBI4OK%UG[[DUUMB@,(8)Q\Y4
MN0H'SW#R#$?/</8,A\]P^@S'SP3Y2^Y85K.4V^`?:):>ULU27=BL^"9YT:=+
M&544-11U%`T4310M%&U?E$Z-+I_4YSI8HXNBAZ*/8H!BB&*$8HQB@F**8H9B
MCF*!8HEBA6*-8H/"&":<.L.Q,YP[P\$SG#S#T3.</1.$+Z75&$Z?28V?U2O+
M'^J5GK9[9?Y>GUCZ)N4-5%'44-11-%`T4;10M'WA]\I22>[[ZCN_G:C(GH"Z
M5-[%I?2B-9(6TL<2`Q1#%",48Q03%%,4,Q1S%`L42Q0K%&L4&Q3&,*DPX=09
MCIWAW!D.GN'D&8Z>";*7TFE,$+XTDIH^JU5FY=D)Z[SR]#QJ1HJG_S9^>IW=
M-8L9=?.T$J"4-:TRJ3&I,VDP:3)I,6DGD&)&78_N)"!U5;?+I,>DSV3`9,AD
MQ&3,9,)DRF3&9,YDP63)9,5DG4"*&?5`UB8!J2-&'J[UPOQXG9(W>=R6C4,H
MC4,JC4,LC4,NY:E=7F>'9)JD:.IMZ)!,DQY-N[W*#2ZKO4)7];CJJOJIS4K6
M1RE[N<JDQJ3.I,&DR:3%I!V2^],O\)F;K+I7V`E!Y/JPVK==)CTF?28#)D,F
M(R9C)A,F4R8S)G,F"R9+)BLF:R8;)M)/,6G23]DXQ%'Z*==Q"*3T4Z[C$$GC
MD$GII[PLAUQ*/TVK8_=3[['LZ/0IZ*?^4]S63:.L>C"ODO51:C]%4N,J=28-
M)DTF+2;M!%*,]U1\V]V$.JKM]ICTF0R8#)F,F(R93)A,F<R8S)DLF"R9K)BL
MF6R82$_%8TIZ*INJ@W'(I)RC\K(<4BGGJ%S'(9?24[E.Q\&D!]/NJ=[CQ-&>
MZC:GPIM]'#M758\J5P*4VEO].BFDQE7J3!I,FDQ:3-I,.DRZ3'I,^DP&3(8!
M\:\(Y_)Y>5+`OM4\LH1_?\T68TL43G?@;#'A%9DRF3&9,UDP63)9,5DSV3"1
MMHHIDK;*INI@'.(H;967Y1!(::M<QR&2TE:YCD,HY50UK8[=5KUGTO^@K?J/
MLLMBSL][%K/JE*J2]5%*SZPRJ3&I!R0(_GTV7[Y3R6_8)%,JQ>X6-7E!+29M
M)ATF728])GTF`R9#)B,F8R:3@`2[43Z()[:/IDQF3.:\+@NK2O#(F?V#8,E5
M5DS63#9,I+-BUJ2SLG$(I%P$X#IA)%.R+Q<!N(Y#*.4B`-=QB*5QR*5TUK1E
MV9U5WON?=%;O9?KBJK[1[WT63OHE]"J3&I,ZDP:3)I,6DS:3#I,NDQZ3/I,!
MDR&3$9,QDPF3*9,9DSF314@NU\C5T;T,1>3D0IU:K)BLF6R82&/%J$EC9>.0
M1VFL7,<AD=)8N8Y#)J6Q<AV'5$ICY3KIN;0;JS<Q(GK*"E=7_7D4]JFJ?LHT
MBY,MJDQJ3.I,&DR:3%I,VDPZ3+I,>DSZ3`9,ADQ&3,9,)DRF3&8!\4]XL^6$
M$]ZY17)YS]BGH0M>SA*+K+C(FLF&B?133)KT4S8.<91^RG4<`BG]E.LX1%+Z
M*==Q"*7T4ZZ3'DN[GWJS'J+]U/'*JC]9PNZKL6>K<$9%-8NDQJ3.I,&DR:3%
MI,VDPZ3+I,>DSV3`9,ADQ&3,9,)DRF3&9,YDP63)9,5DS63#1#HK!DDZ*QN'
M0$IG]>N$E]J3GJV6JZM1E,TG7="1WLIKY!!+Z:U<QR&8TENY3GHT[=[JS;70
MO;4@I\-PSNI/T;![JWHZLY+%>1Q5)C4F=28-)DTF+29M)ATF728])GTF`R9#
M)B,F8R83)E,F,R9S)@LF2R:K@`3GSPDS0-9<9,-$6BM&35HK&X<\2FOE.@Z)
ME,;*=1PR*8V5ZSBD4AHKUTG/I=U8O6D7NK'R1RQF_=D:=F-5#S%7`B1=^GQS
M2UU_JC*I,:DS:3!I,FDQ:3/I,.DRZ3'I,QDP&3(9,1DSF3"9,IDQF3-9,%DR
M604D.+U+;*PX[6G#RY'&BF6DL;)QR*,T5J[CD$AIK%S'(9/26+F.0RJEL7*=
M]%Q:C36GIUJEGZF>N+I=E5.7J"H!2FNH3&I,ZDP:3)I,6DS:3#I,NDQZ3/I,
M!DR&3$9,QDPF3*9,9DSF3!9,EDQ63-9,-DSD$\%Y%I)#'N4CP;F.0R+E`\&Y
MSB63WC>$Q#Z=W"&/\D'@O!B'1,H'@7.=]$S:S=2;,O#QL]2</],@>I9:T%/M
M*@%*;:II,Q;\KU+A*G4F#29-)BTF;28=)ETF/29])H.`^.=1^6Q6?V+#D&N,
MF(R93)A,F<R8S)DLF"R9K)BLF6R82$OU8Q1<9KB+W8*3[UC`H$E#C5;)9_-W
MZAZT?,$"5W$(HWR]0G1)B9=FPS0&!V8AKS^[7AIJM(A\U$C\D\(35C>OKE%*
M/[7*9$LE-:_)I(?1[J;>I(-H-X534W^.@M5%8]-4<SB1H<JDQJ3.I,&DR:3%
MI,VDPZ3+I,>D'Q#_2"R5[W)J<L:`:PR9C)B,F4R83)G,F,R9+)@LF:R8K)EL
MF$@7Q:1)'_5-T&G+I8*Z-"==E*LXI%%.2[E.F,>@2<JGB^N.[1!'::31]Y3+
MW1?4/7+C$$?IH]$JV82?0>EQM/NHM,2/]%&/ZU_Q51NO>-^F"$^D,JDQJ3-I
M,&DR:3%I,^DPZ3+I,>DS&3`9,ADQ&3.9,)DRF3&9,UDP63)9,5DSV3"13HI9
MDT[*INI@'!(IO927%6;R+OB6M[N\[NP.D91>RDMR"*5T4ZZ3'DN[GWIS`CYP
M7NI/(9!5.-]>*N;4!X54O*^7I7Z*I,95Z@'Q?\C)UP.7]->U-;A(DTF+29M)
MATF728])G\F`R9#)B,F8R83)E,F,R9S)@LF2R8K)FLF&B;13S)&T4S95!^,0
M2&FGO*PPD\&)<D%^R;>?"I:O3^0J#IF4DU.NXY!*^34_K8[=3N62YD?:J<?U
MZ:GZ);+B?>LYM5,D-:Y29])@TF328M)FTF'29=)CTF<R8#)D,F(R9C)A,F4R
M8S)GLF"R9+)BLF:R82+]%(,D_91-U<$X)%+Z*2_+(9/24;E.F$J_+^<R.36U
M3=HI%W$(I;33M#IV._4F"WS@[-2?6V"?G:K'GRHYG(!095)C4F?28-)DTF+2
M9M)ATF728])G,F`R9#)B,F8R83)E,F,R9[)@LF2R8K)FLF$B[12S)NV4C4,@
MY0X4UW&(I-R!XCH.H93?]\,ZWH,!\9-<ATC*[_IAC<NOVZJ=23=-,W8W]:8'
M1+NI-UFJ+`\-P+TH?U:!W575#X=*#J<>5)G4F-29-)@TF;022#&GKJ*W$Y#:
M01TF728])GTF`R9#)B,F8R83)E,F,R9S)@LF2R8K)FLF&R;25S%MTE?9.$12
M^BK7<0BE]%6NXQ!+Z:M<QR&6TENY3GHP[=[JS1"(]E;HJ?Z$`KNGJIMKE1S.
M.J@RJ3&I,VDP:08DO$Q>RJG+Y"VNT6;28=)ETF/29S)@,F0R8C)F,F$R93)C
M,F>R8+)DLF*R9K)A(OT4DR;]E(U#'*6?<AV'0$H_Y3IA).7W[?/M&G5Z(OV4
MZSC$4OHIUTD/IMU/O8D!T7[JG:O>\;FJ/Y_`[JOJP:Y*#B<=5)G4F-29-)@T
MF;022%&WWW8"4@=#ATF728])G\F`R9#)B,F8R83)E,F,R9S)@LF2R8K)FLF&
MB?163)OT5C8.D93>RG4<0BF]E>LXQ%)Z*]=QB*7T5JZ3'DRKMWI33:W>FGZN
M>N+J)E5>W;.K!"CE)TV528U)G4F#29-)BTF;28=)ETF/29_)@,F0R8C)F,F$
MR93)C,F<R8+)DLF*R9K)AHDQ#L8AC\8AD,8AD<8ADL8AD\8AE,8AE<8AEL8A
MER8,9O"@@O7<JMU/O7D"T7-5Z*?^M`+K'#6OGTG-^RBUGR*I<94ZDP:3)I,6
MDS:3#I,NDQZ3/I,!DR&3$9,QDPF3*9,9DSF3!9,EDQ63-9,-$^FG&"13<3!5
M!^.02.FGO#X.F91^RG4<4BG]E.N$N4SJE:?)FM)-TZK8_=2;+_"!?NI/+[#[
MJ7XF->^C\ND9WESA+E.^4Y<%JA;)9NZ+)?UUJS6+Y+/%PGU>3ZRH!R:E<S>8
M-)FTF+29=)ATF?28])D,F`R9C)B,F4R83)G,F,R9+)@LF:R8K`/BIR3O?66X
M_6CFAH`T4S]H*8>_-%,V81K3ZH1Q3#,.<9234UX?AT#*R2G7<8BDG)QRG?10
M^NWT]O!CNSW6GHY/GS^];???M]7MZ^OAZGGWZUTNILI7OD:&K_;;;X_7\D$S
M#_+9A]>WL;^IY!XJQ83Q:NZAFC1>RSW4DL:-+"!IO))]J"8MMY5]Z"6-#[,/
MXZ3Q:?9AGC2^SCYL3N.WERWQ^=//I^_;_M/^^\O[X>IU^TVV2N:F)(?3_N6[
M=[W9_\-Q]U.VUO75E]WQN'L[_>^/[=/7[=X#@K_M=L?P#[+A;G_O]G^=MOSG
M_Q,```#__P,`4$L#!!0`!@`(````(0#[)-DUO`8``-L?```9````>&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;)R9;6^C.!#'WY]TWP'QO@DVF(>JZ6IYV+N5
M]J33Z1Y>4T(:M"%$0+>[W_[&V"%X3`W=-VG3_)C,?V8\'M</'[[7)^M;V795
M<][99./85GDNFGUU?M[9__S]Z2ZTK:[/S_O\U)S+G?VC[.P/C[_^\O#:M%^[
M8UGV%E@X=SO[V/>7^^VV*XYEG7>;YE*>X9-#T]9Y#V_;YVUW:<M\/SQ4G[;4
M<?QMG5=G6UBX;]?8:`Z'JBC3IGBIRW,OC+3E*>_!_^Y87;JKM;I88Z[.VZ\O
ME[NBJ2]@XJDZ5?V/P:AMU<7]Y^=ST^9/)]#]G7AY<;4]O-',UU71-EUSZ#=@
M;BL<U35'VV@+EAX?]A4HX&&WVO*PLS^2^\PE]O;Q80C0OU7YVDU^M[IC\_I;
M6^V_5.<2H@UYXAEX:IJO'/V\YW^"A[?:TY^&#/S96OORD+^<^K^:U]_+ZOG8
M0[H9*.+"[O<_TK(K(*)@9D,9MU0T)W``7JVZXJ4!$<F_#S]?JWU_W-FNOV&!
MXQ+`K:>RZS]5W*1M%2]=W]3_"6A0-!JAT@C\E$:HN_$H"\+W6'&E%?AYM>*]
MWXHGK8#WT@JA&QHRPOQE15L1G2'8:=[GCP]M\VI!!8/^[I+S]4#NWXPNA)6S
M'SF\LV&%0>`Z*(EOC\QU'[;?((V%9&+!P.O($)5(=,(-0Y5)KPS/*__J;/*'
M+;@^^@^96>\_A[G_5ZNQ^,/46:HZDLP0GHJD.L)<Q&1S#!OM*(J@2M8KXC!4
M]B3:+D/QC@4#R1TS@KQ+%HETD<A,A*(/ZGB]/@[O;'@=?6>N/\9M*(U8,"9]
MBT2Z2&0F0M$'CJS7QV$U?\P-D#[!!,-Z(U'(W!#G;TI0UW4(KK]4(0(W9)'Z
M)9D`X'4,M'M;DXH^_SWZ.(SUW>R*_`E&Z*,188ZC^I8(8.H;"D"Z2&0F0I$7
MO$<>A[$\%-E8,$+>'2$^NZW[07\B`).\12(S$8H\/AZM[O<<1O(\E)Q8,#)[
MU&>4H@`D4V*V?M,I0>>J4P#3$+U5G9&JCT\-+LP>\U/#=5_C#V&=N(L*ACC#
M,G0W%.U[B?*YLXE0ETJ5S\D&1RD3GZ^1"#XH.5RG<7@*BT2[72PAJ3+8A$A%
M(H&IFW@M+B.9$5'*E?!]?U*O*[6*:0&VI+&;,0\E+!Y,P]@C,NIL`M27$@D8
MM8HO,B"9T8JJE0\)[]<J1@M5*\I)3.3\<:U>;0?!`"[O5`5FZE<"TU"\M48)
MGQ604`\>-"_2X2E<P*B7QA*:>L$\K8CU646#TAE+**J9$5%3RZ<'I'BY+1$Q
M<ZBIQ=.!A%3%6BF;II=A%TIG[&AZ3594O>#.3^CE3^$,H]TDYF=`@")Q_(B<
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M\^Z)[649R8R(*A)-2@LB9R8D%V\K5$!"Y!V-HC!$LT4B$:-*8<6`9$8KJDKH
M).O7)>4TJECML":A:\6&CHO_?Y<@9*:H4P5YHV"%-_.!4%7RH6+2?=9M*E2,
M(M->RSR\J4A(3OAP5X":<:("<&A#ZR[%`/[?6B:!-3J!^0F=_"F<5;0QQOS?
MOP!)G7!JT]:G`.!U[-FW]B'7YR*2R:^9MZ+F%,U#*W,Z,Q=IIS8JH%M.D9!$
M`O->2JWZ;(6L9$8KJM:?&HKHS%#D(2=B"8U:];XKK(P`+O!4M>!L]/K5AZ&;
M%ZI.-`OQG"X?VJ@^$S$/-=980M.4,8:*/)F%T)D^G8%N<H;D9T9$58SFHI55
M+.8:M3.AOA)3??AA#'F:S$`(29>1S(@H>OF!]/T=:G@*=RB\NTI([#M>X$:^
MZZ"8)`KC$^(%/NICJ8*XU">NCZQD$IG6TBUHJEPT*:U++UQY:@T9KZI80N*,
M2IR`^F&@C1,*-!^35&'>$"P<,@D6=ZSBVJ\NV^<R*4^GSBJ:%WY_2N`D/?YU
MO-O]2(?;V?$#N%J]Y,_E'WG[7)T[ZU0>X%'XIQE\;RLN9\6;OKEPD]93T\.E
MZO#K$2[12[C#@_9C6X>FZ:]O^/7O>"W_^#\```#__P,`4$L#!!0`!@`(````
M(0!`0F_E=00``)L0```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULG%A=
M;[,V&+V?M/^`N&_`-L80)7GU0M7ME39IFO9Q38B3H`8<`6W:?[_'-@5L$IKN
MIH3F^'!\GB^3U;>W\N2\\KHI1+5VT<)W'5[E8E=4A[7[]U]/#Y'K-&U6[;*3
MJ/C:?>>-^VWS\T^KBZB?FR/GK0,,5;-VCVU[7GI>DQ]YF34+<>85?+,7=9FU
M<%L?O.9<\VRG%I4G#_M^Z)594;F:85G?PR'V^R+GCR)_*7G5:I*:G[(6]#?'
MXMQ\L)7Y/71E5C^_G!]R49Z!8EN<BO9=D;I.F2]_'"I19]L3[/L-!5G^P:UN
M)O1ED=>B$?MV`72>%CK=<^S%'C!M5KL"=B!M=VJ^7[O?T3+%R/4V*V70/P6_
M-*//3G,4EU_J8O=;47%P&^(D([`5XEE"?^SDOV"Q-UG]I"+P1^WL^#Y[.;5_
MBLNOO#@<6P@WA1W)C2UW[X^\R<%1H%E@*IER<0(!\-<I"YD:X$CVIJZ78M<>
MURX)%Y3Y!`'<V?*F?2HDI>OD+TTKRG\U2.VH)\$="5P[$H2_3$(Z$K@.)#BB
MB(:?2_'TMI1+CUF;;5:UN#B0>B"\.6<RD=$2F*4]!$R^;@_X(M=\EXO44D`W
M$-/7#28K[Q7"D'>0Y`K$1*17$$$/\4!>KQ%L&VN<UR;!:S=PG4$;[6F5_$1#
M('P]9'BP0J1S"$,:6':_-`D&>T?/Q:$E34-BY2F-&&,1,A&I@:"$D'#@,*2!
M!6-I]T56+K(D,E-`HB%,20Q#%B-;X1B`442BN&<P!$(`Q@+GPRK!EK"HI]5A
MU9!.&`UH&&,3D8X1E%'$Z)`:AK30E':?=W*1)7'8N9:H(5HB"C"R\\[XGL38
M[S=@R&.FO'GG)-B4109:+4M#/IRC<>P/.:4+8HR@+*0AN^&<G)NC?C(O38+-
M6B56,B4:`H&[6:MS",.UV)1V7U#E(LL]*ZL2#>G<0Q0S"Y".`81%\:VL0]!X
MQ^;=IU"MLB1.NK%D7KM=XH$"8E5UVK%H1(10=".^R!H8\P%6:$N;E?-)A]%/
MCH-@TO$,`*(LPK>T?6E0(-WDQ^V8#,2Z,#I,YUN,<,1"*T-3`Q,RG^&;\96]
M^^[B0+K3&_JLLDPZC-8')TL<^72B3_-H#".8XEMM!5DCXY/83F>%G56)8ER[
MX_(E5MM.YS%&!<N#VQ<,U.T>9/:]@]@-63&:`JW\3&<AIKPK8R,`$9_X.)T;
M@=V@D<;,^SB+,85:`T0VFO#S4]]TD@16LB5H/"B@$$*[%YH`&-)#R9D2OS1(
MD!X"XUH)K"<G'4;701@S3/Q@>+@><R8FB`E!(XPI\'^-$S2=)\&D68_GQ4-$
M,()I:^TF[8CT;A["$`XS-_L.MN;*?#XJM-FS`ZLFD@[3/1V1((S&1FDS+1"E
M,1S*KA]HL#55[IM\:I6E='B`[N`=1I^H0]`P/=L8D.N'&_UZJ5^<SMF!_Y[5
MAZ)JG!/?0^GX"P:56>N72WW3BK-Z0=J*%EX*U<<C_`C`X>W)7P!X+T3[<2-?
M7_N?%3;_`0``__\#`%!+`P04``8`"````"$`+P;3;M4"``#3"```&````'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;)2676_:,!2&[R?M/UB^;SX@@8*`JDG7
MK5(G3=,^KDWB$*M)'-FFM/]^QW8*=4@9<$%BSNO7CX_M8Q8W+W6%GJF0C#=+
M''H!1K3)>,Z:S1+__G5_=8V15*3)2<4;NL2O5.*;U>=/BQT73[*D5"%P:.02
METJU<]^764EK(CW>T@8B!1<U4=`4&U^V@I+<=*HK?Q0$$[\FK,'682[.\>!%
MP3)ZQ[-M31ME302MB`)^6;)6OKG5V3EV-1%/V_8JXW4+%FM6,?5J3#&JL_G#
MIN&"K"N8]TL8D>S-VS2.[&N6"2YYH3RP\RWH\9QG_LP'I]4B9S`#G78D:+'$
MM^$\G6%_M3#Y^</H3KY[1[+DNZ^"Y8^LH9!L6":]`&O.G[3T(=<_06?_J/>]
M68`?`N6T(-M*_>2[;Y1M2@6K'<.$]+SF^>L=E1DD%&R\4:R=,EX!`'RCFNF=
M`0DA+^:Y8[DJEW@\\>)I,`Y!CM94JGNF+3'*ME+Q^J\5A9V5-1EU)O#L3,+1
MQ2;CS@2>!Y/1=1S&D_^C^'9:)DMW1)'50O`=@IT'X+(E>A^'<W#6Z1E#DH?3
M`WG1?6YU)],5U!*6]'D531;^,RQ#UDF28\G(5:0#BF@O\0%OSPAI>\]XFDV+
M80X8'=BF>UN#GUA)&!CR\,O5V(VG'\<=+!CC?"PM[F%=N\,F5C(U5'%@/ZXD
M/2EQX*)+X+2X!S=S1TZL)#9P@1M+AV,.#IR5\W.EQ2Y.W!LRL9)AG.&8@S.Y
M!$>+>SBAFX'$2KH=%7A!+YY^''>PII=@:7$/JW?$$BNQ.PJNG<$M=5KCX.DK
M\5VM.'T.M;B'USMGB95T>#&4L7&_C*2.)(HG<10=3K,#-[L$3HM[<(?:8XN$
ME9R$<R3#</9>LA6W)1OZG8@-:R2J:`'U*?"FL%F%O95L0_'65-8U5W";F-<2
M_CQ0*+N!!^*"<_76T/?>_N_(ZA\```#__P,`4$L#!!0`!@`(````(0!OFKA'
MBEX``(4V`0`4````>&PO<VAA<F5D4W1R:6YG<RYX;6SLG=MN',F9Y^\7V'=(
M"#2:`HH4CSIXNC6@*,DMMPX<D6VOL=B+9%62+*M85:Z#)/K*%_L&>[7`+"#L
MH^A1_"3[^W]?1&1D9O'0;F.TP"[@F1:K,B.^^,['J.__]?/EJ/A8S>;#R?B'
M>]N;6_>*:MR?#(;C\Q_N_7SR<N/QO6*^*,>#<C095S_<NZKF]_[UZ7_^3]_/
MYXN"=\?S'^Y=+!;3WSYX,.]?5)?E?',RK<9\<S:9798+_IR=/YA/9U4YF%]4
MU>)R]&!G:^OA@\MR.+Y7]"?+\>*'>[M[#Y_<*Y;CX5^6U:%_]'![_][3[^?#
MI]\OGCZ?])>7U7A1`$?Q8KP8+JZ*5V/?`+B_?[!X^OT#/>J/[Q9O)N/%Q9Q'
M!]6@_>V;<K99[&[WBIVM[;WVE[?L5/S7@]/Y8E;V%_^M_>9W[0\"G.^K\Z%>
M`?JWY675?NJ[@_YB.!XN+XNCBQ*$]:OE8M@O1_,>)^QOMA\/BQZ"C%DYXI%!
M];GXJ;IJ/_?=UM;6]N[CQ[L[6^VO#L#DP+#Y<E2>M[_][HR].U`>+F<SMBQ>
M#N?`5ORI*F=";O&\7'2>_6YC8WMG8W>[O7)"[<G5M/O2]M;&OUW[QE$U&TY$
M^=4[II5S\%[",_/VBM_=2//P>MAM]0+_UCE7(,G+X:B:%8<@Y'PRZ]+C^+(<
MZ8'WU70R@^+GQ>'D<EJ..T]&"D\N+R?CXG@QZ7_H%<?P1C4OWBT7)HN\WC[9
MX60\GXR&`_8?%,_*43GN5[R&P,V+]9_'Y7(PY)O[_/OX>;%VO_WZ\ZJ?A&*W
M_66D_L%\SG*_[7Q=SB],,OOZ1_67Y?!C.8);.M@_FE73<C@HJL]HB#GGD3A/
M%A>@I1\8K+0MVCN<3!9P71.,]C-',_3.#,6@107$5#S>*\;5HIB<%64?%;(<
M&7H&%>JH/RP7*W2';^4G;6\1`7@]+$^'H^%B6'61<=`WE38OIN55>3JJ#!PV
MGRVA2SQX>^$[O51L%+/*#S`M.6A[D;>3!2@-V[:_?(X$?>3`'ZMB5$/??JJ)
MY^R8[0?AW<OA0@AV(O;1MS`EE@.<M!_^[NN7KU_:'QIC7TQ&`TS/=\7SZFS8
M'RXZK`7'G%6HG@$VR`1A;6MS:YM#S@IX;%G]2[&_U4/5Z?^*<KFXF,R&?^7I
MK6(XGPOCQF$W28U)V76+8ZC2ZG,7P7J3?REV]GO[#W=Z&"_;9V>//_=[>WN/
MBO#P:B!ZT'$^K=#['ZM1AXP'`R05QH3A)2P;PW'1+Z=#!*"-PH"T)FLO9](M
MR%0QJ%A^8E(@"W[>T;E.[96$:&_ECV8,80>^TZMW5DQ'J#BL=F7F[UI%U>&(
MQ`MMF#M/=BAXUS><C-<_;7CH1:)/[LINUT(NZ4+W!ZZ\%>R5CZ^&.3SZ"P#.
MK,KQ`NWI,H]"?8>V-0UZ)_NR_?#AG9VRCOW)-G[7V/AZ;^P]S#]>=E@^`(V$
MO`@VJ*-RWE=SO)N^6[1,AI(EF57#R]/E;.ZH:'/%[ZHQ>!FYVA]<XMK)^9.H
MMY]\GEDA?_Q2GL%?5YJEUY/YO(`G!L/Y=#(W!2&KENQ<>W$7V.YQV\_9NB]G
MD\N,GNUGWIF%QAN=7+HY6P_(N]]!WJOQHD*Y+:*E:R_U.YQ^':/Z+'.Q',XO
MS!'E)-$J=?2AO;(^XOSW]6;_HL3.%"QS5@Z#%1`FL"-W-G#7'Z@-[UN<!VV]
MZG-#';ZB'#ESU60@,-+/ROFP;P1]/APM<;K:+_^Q&IY?R$T[(.Y"+Q=OEY>G
MK,,I\J4:[MY=UFUHVDQFM*X\LY>CR:<["6OV=,X:2(V"E8_7.#Z#/R_GP258
M3#!Q^`1]?&)SP(3#@D_EC)F7N)QS?O&":Q&6)J:Z;FE35QNGI=Z!">4\FI!<
MQV4-R0H^5YL(!YFP.?^<+B1=YKW=_G#P2LZ&8QQM6=S^9-YU>(U%UL]A^G\"
M[ZXC@431\^H^S.[_`H,K1#!\MQZ?NK_J,7&VT?EG8?75.,I_@\AM/+09X]7X
M(\*NX]_`&$?EE0GY93FH"F)VW)H%AKZ820HZDG6T1/=R2-%DNM*E;P/5.<DJ
MJ-HOM4_R,A'RAI,\F\QFDT\<UU0Q_(W\+H9R\@?5:1UJ3,[@CFMYXIC8B/?/
MHGF72/#7S2\1W/2K:C`OSJ2JY=U5GZM9?^AXFDSE,'91>>-+G\J9DA+=MYQ<
M=L0Q(<5U$45".[!]'`Y@HF=71)<NU_?)%$3)J!':)H*6J/6Y]$+["2-3N2A.
M2:*,Q\*IV`+L3CI:-3Y*<N/ZAXZ7T^G(##<F6M*.8EHJLF99[5^<F8X<UKFE
MCGS9/A;&BI>'P>"M!#P]M2@_=\.B:V`1*./)>,/`&28!4R!3:YL;E.4S'!`%
M4QS0.529O>*L*A<<]%H-]VH,'BQG,`U!^N)B-EF>7R"$U:724[YYQXMYV;#"
MD:EB^/5IN+@PX6CCYPZOF?O[R][#PD@VIB/2:*9SL*[C17L-["2":V@Q7&=A
ML_MA(5J/M)7A6@G,"1B;(^M%.';FA`1)35Z-UI"S1GZB/R+),81$*QV]Y]6\
M/QN:0(L3GBWGPW&%\13]CY>7E^7L2I\?#\_'M@:*-&0/)!U'I(!6A>#_G%5O
MR'Z^E:;8+O[^M_]!+/_//\%,6>"WSL(Y5MC/J<L#^M\1_V_^5^4&R&5OW7OP
M]/O^9(28PA67)*^W]<GL)<D*?^2P'`U/9T-]>E9>#D=7_O&./K!L=N4?X,9/
M9OKP@>VP>/KUB[3:]6G;'HJA/YF1ZK.$$P+X^^48!.TJZTQ2`?DHRN)T"-;Z
M%V-`/(<O/!^H_Y);D7\(SX0`1+0]Q?A_B%(IEYRL`)I+6F@T/*LX(P]@6?4L
MJDV>PKP0^YP70Z5I1M.+4ID3XFLLUO#R<CFVW%LY16\?'+TZN2_!62BK;MSF
MB;F8<A+_S8?@B-1+`IK]-PM>[0'J>268"I-X[?>)Y`X(G7P:<Y+Y\G0^'`QA
MWE[QIAI$Y'F.NUA_<_#J?J]8Y_T*LW%&#('_B&`I\0,2H.$HIDN*<@Z7_3N;
M_OUO_^M^@:L`JO%(#<]ZL#P5TI7HJLXXBR"1$@)N"QMP5Q9DV#&7)I(D1DY'
MA"&N-V83F(O_R76MIIXWO`EM0HH@F&-6V`IHJ9$HD8]=WGZP@Z@#FQ+FBYGT
ML1ZO'WC5^7H!;G!+]>CQ:%*.-WZJX`-S)0ZEFPDU4&?\9_W-\4^'A_<IF!#V
ML&QA?[/Q%:''D+^#"W1N*H;EWE:?BN>S)7X:]B]HGDUY?>3#=WHB(0A:CBG@
MD#(KR),NAAM]WRNQ<4'D23;`:&(PXKZ7?0*<XO**1!-YW5&U_("Q*&&G-Z_A
M)G9G#6>1O__M?V)E3__L=(1A@GG!^%X3;B,BT!X?<+`DE0T?DK>$<?N.B3-Y
MC^)M?\`8;DC4#FU'I``+(K()UEUI-+R<X2D5+<0!>GS@B,81+8$`<"$;((G$
MC)7+*6M/.:H[05!D$$&2PZ.JV54Q1811)PNQE\EL%,S-X@13Y+R)*6YP@OD;
MQL(@17)/R8NU+TJX]K2JQ@Y@Q)\^UTFO0;:X:KB01CD%1^0]D)D+?*:X/O\]
MJ27[TW`T\HT^<0:8QQG"\ME7IDP&0_FO=B@*-<$U,N[[)`&%V4E&BA*K40Q]
M`(25.%(H7Z&4L^I<%/[5!2^!<%G-T!P?QN@.B?LAWLYR7OP!D'!AYE%I0"-I
M@D-7FVB#GBF&H)?CW_ZR=$4/,RUED1AZ$.1'"XU*0F,D7_^VT%E_O*T^EH-2
M68=W_<5$(?K#7K']Y,DCIVW8V98MR?Y58!889>-%@*]??#];$[O]`6]7RAKY
MJF"6H"K!5LYG=3PLMJ`\U*D`OAMC87%O!,[.8ZMB(L&".\(##-!)X37R4Z)[
M\%)`H=S`]8"T8\M5O/CLWK=C9TI.:ZDR)6]]NI`LY8N6?;P7K;J]M?6;B*G5
M^>WHZ,RK_G)FR0(]?PO9UVNE+N-)?!,B`Z%,@&@O<U!9RS#V>4AYF01Z\>3)
M;0"!RRRAFO*N1:@F@,FY$-*+YPJ8=#(W<84D3Q3C@,P.&395Z#B098=-T:%Q
MN>8*3BQG<]\WE$$,2VCBTZI/H=@.C2%:S#!J$G\#,7LTHPY&&+*!)`''L[VB
M*J&?U'KV%E#U*PPCY9'-W=U=_XJ$D%X$^Y$;BO>R&N*)!MER'!H?-[=(!!MT
M@:'R&5'1`FF.62`'Y/98BBP%$%+],16@EQK;2[`B@V"P_.Q-^`W$,68OK@X;
MQ<5[TBI1\8T@>V.SZ-CE.QIE3\!3DY0N^E[Q`ZTFW4Y^;`,^P*+\4$WXYP,P
M[S6<D-Z5;X(EY)U3"I9.B70B%)5[0D9`]#I<@/=D,BU:!5&<^7Z^N]D'\!="
M1*P>85PH-(-'<L9RU72"`$@H5V`^AWTP(-QCA^4\SA5@!Y#*2S5C2![9F`,)
MDE1EKO?"BXJ5@2BN'J1K><FOQV4SC)/0$O6?K`F2HI>Q6<H9GLG/,T[N8,R\
M#73WP)2`67`A([)!(:>/&"LZ=*SH4,?=>-!<.EZ:?5+B!.^WBA:J[AVYH_@&
M#2&KBYF"A!),$0&ND=K.$IO1TX&+P7/R!#:`%(^4&&"*[JD;/](*F>N/Z[<@
MB1A]GX4<?2O$K+(.]+<@^SL$&3AWNZ9,Y0'UA_(G4%O!RL43])50%^1RVL>F
M>":W*6MW.>;%8'+)NK@"EI8*YA)"/J=.C;!)LB!1V,D\P#P0N-DB]$)J"#JN
M`NPP1%><R(03LW@`LXV^?MGVUAY.GFW>6*P)MIXZ%@\*,_49&A_'`YF<&,;$
M7Q$N._UJ+P5DW'Q,#U]K_N,<Q_!IL._[.1&1])S[2Z(!@CE+)!CL[PBU9O.+
MX90P8F8D35MGV'*W0*=+WQXU&#`Y6&=0UJ0HGKZ)49/B03(?VK.:F=DPQP/L
M5*/,[.<@K)?%D]W-1YCM5G2(DR;>2I#E+_45T9J>J#Y35,/,="VM`T%`$Y5X
MOH#E<,*6J-V<.Q3$F>-MT071IG<.F(DS"]HPA?FB:)'52S9ME-1BP^K":[E<
MH#:2A^)N!`I132\\M]M[\FBKM[V;V@KX;.4!\T7,-$7EZ*9IN[>[L]/;VM^/
MEK^&04HGW[_)E?COBZ<J:YF+?*20;8S`2)EL%*FWB'`2OW-X&5._`)_UZ.%A
M?*M4S0F\3@>.*V9INF5LAY(L&,C8M8%:DE1?NLW"B4%C5D0V)(_;IDJ>NN]M
M6S;DM;;4*"JJ1F2BYP4)2M6+<6,!48*?[-;/I#7XRU23!XQ('+%[(5?YY\WC
MS>)W!P=')G#BKGB4VBIG66P7JVM,Z&PI0/Q8YVJ1@K`I&&I"<5R[]'H^N5R'
MREF1U80CHCMY_.+08#-+#<NHX45&_J7R2^KV<TD/Z:C'8G1:)</VQ?'&?T'`
M3>-!L=&5J9XK#([,-F?MCY9$X)ECF1W6%CZ;3!9.G9GRKJ(),I_09KZ36&)$
MU)YY31CEX,FXM_3K6.5LB4=%8"B&<==&$)=9I73=?+NY93+``&E&^@1YFLC)
M\C[9L_=#5&9V-?@VDRD)!I#.JY?E&']"7H$Z%?KDC,FV??TBUBB]5I[.IL>E
M_3Q*\12B_HXLY+X;?J!+.EY2DNWX"D`8)>).RIT.QP-++9'$N&:#LR7'O\+/
M-.3B@_TZ],XO)LL1=-5)2I,;L/EGTEBFFI*+&'H?[R#:`6RX>2H?3K@37@0Q
MD?T`.J:8+S00[QJS.:/QZ*R"PP%"WAI/!RJ%]<P!*L?CI5%8WKFBR"@//]UI
M.P09>IEA3N=#TFRAZG2V5'D@9`7V5F1?3),_SQK#T"XXH?'`WU9'1RB:$4\9
M<^!6T(&'@;<?""0=)--]`?7'0OPE*M)*7PHUZ/^1PAD@T2[,<8-D[<_4(RR+
M`!U$Z*S=1RPL!R\E[@9*G^(>#*S'=GX=<H]JU<X*A\F:2$J_+7IARSO;N*A@
MA92`->=>MV%N+>BV1(2;,F-/K4[]>[$`!3#/:E>F<A(Y&ZO7::O<PI+BI!JC
MB'$%!528:;>:&LM3EA:@+U"T2AHI#9BY*0B!*_WBR#6>^S;?EEPH7UR)/&3C
M#+^,AGH<'49B^RJDO/]9+DBPJ?/,ZDC4+LEW*`0/2)9X4NM<7H8$CZ6E2\M\
M!/LC)8B>]#2#^1S>`&Y:-19/E;@/.1[)<N0X#G=++D+[BX,]%=+<)R@(Y^38
MEUT,2%BB#NJ7])>;0[DC"U?=RNTI*R/CX]GRV)<A@4CG7\&@QHS>J0!L]H\7
M>">A7_X;*XBH'H58I9O`#=)Z0:$%XSYB-(<2C_QH,D*AJ$:MBC@3<X90@3DU
MQ#MU9I65!S2#@PW%O;3""8;:NAKDD(4C;U+4)EMQZ@,+[(A?L231*X<8&572
M1HV/9\7+YZ\.^43=&A2:T`%65Z)B9MF..,YC?-.QT1A-#K)"41DT"M28"%!7
MI9MLE>A.R_&'Z^A'PPLL$28-1#[OL?YVZN(-R5[\#4R_.%[8=8B$3%Q)L@;B
M?7IMZ%&S1](`!)]CETA`4B1006V#3+,.;Z$>R;K$S-1*YA7N&ZBGY:LFLEPC
M$HM_O*!H%477=EV8RPWQD=&!)P[2]C%Z@IE6SF08%]!V0NJ4R#5V/$76\UA&
M_EE<1PUVQF?J,L1[",YVH":T\I!FLWBO^1/Q-6C2_!FE.\LFFOS3=@]S.0N2
MXB&;8<F&4)%!)J[CAU=XBT.*5B1*X;'7D_'YQFM+LQ_8,(ND.AHEY%__^X]J
M4WB38@)P\G%84>.B)'H.E8790"]YN</Z".2>Q\K3%O*@$'2^]827&<W^<`;-
M\,(H".H#\_A5JP@*ND]7V9649L@<7Y97%B<@^OCH5&:M<LB:/$\AC.CEDMXB
M=XH1^4S_4D"<4;?_"RXM,7J47@\>7E$"0CEH!,0-I!$=OD<Y.*]%)0S_+$56
ME?I"<R<G-[GW5B^0,-$H$)\FA]H08TQHGHDT#L9-1L&^,1\G'51`N)]))(FM
M17Z&!EZ&4]AB+C7G"P-L#)NNW#'U:H#.*+;.7OP4`QSV#T;*X(@UVK[JQ8M/
M*AD+O&9+=+:E&-Z\V4@>@_HZAGY.GL&'A=1K\:W2-@?H;*Q0@J2MS?+#^O&#
M%2&]Q=C;9E'WF'F(F]4C47?2B2$^0\3'Z`.KT`I3[5V]\QA%^9>E:@;Q4;(X
M"($I/Q@LO.\?&O,H4Z'`5+%Q^;&D=8:J>2\CDNN:0>0;Z5B)3EC)=]5Z]N%D
M4(TD<:ASO";8GB?CZI/3>37[Z$5Y/P:.4FEJSCTU/?SGY>#<E)09B>BD7<<#
MAKP_&&_#EB^]F]-2>MB*I=;YEKQ1DU;Z?D##H\)M#+FDP$C`OU`Q27XP@U[Z
M1)#(2Y.$"?:*FJ\ZDG%M).*QH:_$SOF,'YDGN(2G9475EI"7TZ/L1=I;<Q5U
M%F]ZR2B-%X45HBYS9?&JI9I145#,TT/2P9DV&T^9(?(3G)N]U;'DB/&.E]2L
MR6`2&3(PG0`E]T'^Q0%RML>54_D'VIGZ<8^LG@$T+M'Z=+ZVEZ=#K.:LH4'E
M"NNL[OJL3P8EE)R@7,V<0>B;Q=IEK1^OE7F@3?"5'Q#=HO2QI<,@7Y"N7W68
M9(C<YQ??Z_0X:PKZ=<Q`5I$;C\):*Q?VQ27U!2R%B8CE#+YOC94[]#LY].$@
MWB_$WDE%I$-8HM(T33R\@2AEEN%6]#?@Y#&((S/VJVA?PP`.,&[]!0S(M[*[
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MU4HP@LFICWTB^$UMV'NR8_14>KN46C<S916$%%V_R([L00P2$;+F'L"`^Y$I
M'#EV`-9$4Z:2T0S8N#=WB"2MZ)@7%`Z.#XO'JK7799=P9EG9'')Q46S]AD\<
M'B;81`/2QE>*NO@\9"*#,G;X`<[XT>F'FLTS:#);#?K3\)`4F6OK1@8/#3.?
MFPBPK-ZL%\.;Y+/8)$PI)LA!]'YK'LOW@*',\YXG#\,C-+G^6;*G-F_LD:UT
M';I`']"!()J20S?_;70T;,4PK68OEZK.O0W^\<YJ+;_;_M@&*ML?/D_N:4[J
MSLB(M86U4Q7MM3;:'ZRU/PC+=-(;S><LQ?3*AS5/-'?R#5WX$]@K9I70#L$`
MFXW+Q0.52?,X%WP@%"'*ER(PD^,'L0&:39P%]#!L@0CX&SWY?J%/O/P<'9Q\
M;4L>F@+',"@Z0T5'0:NC*%7_/8RJY;CV(+2>'&\UY;%+"OWND+;D30E^4EON
MX4OL2#U8`YA6-&-ECICUH9J:MD;=4].H(3Q49&X2F\.MU149^EKJH;(>JX;@
MZT,+_E<A2U@N,^<3TS;Y9%D1Q]-RBDIB:V!&'>!C@'N:P&'X#VJ^!-:Q1?@&
MM`[6W83(&H^;LZC^I[2-$@&J*AZLVA?G@$)HK&#REPJ18<2L5*H'Z][=`^.=
MP5L70[UL42L]>8&F,=$L(2,ARWQ=&/2^RMK3\\+9H>8]OZ%H-0#+ZU8VB&I,
M%Q(&%A?!OMA&X?S:%YMS[<:-Y\1#G%(\AG'U/")6552.8@T^U>Y*C[X[.&?\
MD:&L`]EUB#Y6`^[&,Q/-,#'Z+=%[DAT1=S(4-'3PS'1AR+Q#2'>3A$;30HUO
MYI[H84.@52#E&-;"_PR;]F'CN$_7(%K16U23XW2I4-_P;UD:V61TC[7G"$GH
MJJC`M`739,KLUNT[F4P-+)4M@@V!::I;8[)OQ1^J0;L;$`CJR:U\N>"1Y*47
M;XFRP[FBR9`2'5,4+1I4S"`6$J26_Y6ZT1\!3=*L2MCV)\RSZ>86M<O:`W&R
MV*LO,3/HC>FHG(K6C<D5909[W5-_DNR@*G`?9Q])S\BDQ"XH,RAI;W/E["`W
M3):W@$N(-^B9KF).)C2AYSI8H#=[Y4Q`@OT+8FG01-:R!JTS(CW+0*=M,'0+
M:BR*W<%;^-ZMQ:9JE1^'D^7<-&K"'YPP3?/QK@ODB*%\4YP-EF(,8-CPLE9K
M@X0L]T\CO3PHH!<BLDV33)MJ";)J#U;MU"91%VAF2XB228F*)-!:N@.+'RZ\
M,>HU;[RY3EF\B)W*ZYJPOU\<P3/PKT3$],@WU,LG\'80I<B+)K#A2@B2@4NE
M$"F;U+W6T"Q)-PP+)6`JA8L2%M,P00B".$F-HRE9,BT3+LC@N:0+I"O$O^((
MVQ,--."*!6M3%N$U>1[<FO!ZRE**%A$J*;<X=A"4_Z=X@P4#2W:#Q3C=8!'?
M<DV5W843)5@[UZZ5'VRS>'X[7NYVDMN.\/7+KSG#=+0DW2A8E66K$\J4,<&D
MZB`U]95PFHR1SFA[[281)260[Q8[B!2,;GCK?8Y"$QFM.J<S>[/X^N6$?_O,
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MOZ\.FU#1"AG1$V@9,IH$SQI+)KAT;\[OAI!BROW"7]*>9-HHD$QV3I,A`2^V
M"YHM7L^!*?*.%+.**Q"[>/I>&5:@/3(?]R3K'6MF1VYZ\K;K#7;D5A1WW\F&
MLCO)H%<V=$W&,-X4=K#@LDX*-,7O0.JT>*W>%DZ"[VXG$OX#9RG/A@<?="(?
MJJ2[NMD.9^N`B,QN*/C11Y/FQ>L%CL.ZW`NK9&G89]`%PV?'O<(7@+DO_=F<
M3>?2V1MGTW'V%-!XLMPF)%(-/W!<H&.=IWM'3U[L8?4AGJV;)UM?X^#3M-^C
M*[>^ZE!JGQU"(VB<MSLXQ_Y8UM.J_.WQ>JX_H4B$ER14'RK[,8/0(8Y=/_Z)
MZPDHD,2$.<+AW":L:!+?6O(#-$7:2NWO-LLA,2MK`.3V`HJ,,-')P?)\202G
M.Y'M82Y`2F.XDJ_T8C.B8(I?9\<I(H8C*<)2"^J:Y('4HX;BP[."5ZQ&`?RJ
MN,CP*Z_&_2)>#YS"8!)G0PEJ+[;H:]M<+1#Y8_33316>WN6:8$JI?O&!')WS
MB=96O&=Y=)&A[IW-Z`."(_K:+;7=YLW%4^$NP")G=D+%E%L-0!VXMW9#`5L7
M#[B@@IA*86\H],1"9,UF;^(C\[9JB'F']N?KV_?5<ZWS`3ULL.HZ!>.!M\\/
M;.@!?3;S80;N`O9Q96)Y[\8WASZ03P4EW6_0N:-F?8?;'91YT_$(CRNNA-'F
M*U:M.Z1LNN'E\X,4-WS]<ML^,:-Z+9^A;%!`(--4@#$[4#'&J#;`V=7&Z=5&
M^*>YM98-FER5(W@/<'=^H_\O[W8>K[W2<FVHB*31@",[K"1+JN*WA="^O67=
M]Y258QO8&0U<GO`(K=Y:V4RQ<)9RI)&W\18HKW1TS6&0FIC"'=##LPS9Y0H=
M;,)5B[+[SBGK*.:&,!:@J4`_#N\R:#&9G2(`TB`;D<WMHBT?S3`)1\_Y;3!/
M;+J/<441.3(Y=S\IUVH]DR;[QNHB`&)<K)?WBS6_\U;*@PE/7E\_Y<-P5VWX
M=`<V93:OKR\:C^^F8R)-F6YAL:@!H)@`BMN$B86\7^ZL0O%H@R3N4=HZB/[Z
MA>/6$XU[<:`Q/S)*B-!$VA"AIO7"+$L-G.LGG9ZOZ[*@5@A=9BGW')&H5@;#
MESP+/1@":.,B(4U+\=^]A(T51$^ZVR?Q?OU>8'SM\?9^CRL4J&HM02&R`)?0
MR(8WF(1BM2:/W#2E8,:1W`'S!`]G(;]3)]X2X`%DL"%_`I3(?W9#$''GJ;F(
M-Z6*>-H4B$N0N=MF:&X0#]OP`.U<5U$-NU@*'R`W".("H*%#8M')Z+&:VXS9
M[/O$<6<L)XVL]MWF?1#<ZK!#:R&W)J"I#,]=G#7O8.YP+3SKX>G.(V/8&_V0
M.H6%Y4TV+USY4YM]W4+DWD)P,`Z-[SO65TZTLNF<K<SN$O+UP'!_<GFJ"0B=
M#M;F&BA3M51MH#'1>?^*RVCH<L$&2D3/]&L%/&M&TQY@C=?PV/*OR\OR=..@
MO[.SGS@F,H*%2E(Z:[16;S_>3R8%4V"W^K`U\9=R',`SU12=J<36^6W=GV7'
MN*^0NX($<U`OF>[)=8&U8JDA&4=^`W<85:,WUAX1M>_L1NW6(=C+(.>WYADB
M)Q&JY]NF',W:]N,GO7UF;86[M>V=)[W'Z,^H&]'UFD44M]ZL#P,100KI)J/Z
M"ADQUMJSG3I%W29XPC/4L`X_I-W92&AI0/O82-4&-BH.WFLR9[=2?I1*[0>Z
M.*\3NR`6P5V]DUA4XW.FM<SK3M1V=O^1$N#B@D)J1:^+4LCVT#.:[HWM2?C@
MEM:%?U9!049=CA[8,1<?9CJVTLL[W5C$F^"8FJ+W1D&BP&F)IT&B:,[FEKZ^
M!8B%/=P"PJCX]<LM3GKK)9_%-F003SL0EH>;*XMXY\.1_?OZY16W0.31L&%%
MV`H%C[DS3@<"56#-CV1'.1%X<';?)>)%6(GB@CVVM\Q=$X[.9Y:-C#>(,AV@
MYA2<!'UY/0'<%RFQ,^.-4,DWGHTUCT:-L=[8W<1?M6]T=YH[F(B$GP<0^XRJ
M<XX:H+&THE5%):3:O84U(_9)]W-K$`/E@TI9)/E"EOZTB"C@N,Z["K'I)ILZ
M=-=V@3$M]<*_K7QA_`R>51AQV[F*//4Z:%^K'?A[(0,F95%7]OA9'?$'68#;
M"6C*2+#5.S0A8P>CJ`4G^26T>NE9RC9'+\.VM.8\@^):C)J]R1%H]%#2VRR`
MJ!MY2!<S#AA9-\Y7`M`8.0<EIKQ-UX#+A[JJS&:1W+-5CX<LM=V5%+7$]4QM
M."F+_=\(A_2V+4)Q!M$13PF$M&,$P^0\OP?JE)L--3]J=TOH-1Q>:IAF$0/W
M!78P')G-%$I_*:Q!YQFV5ZL"V1)O0`X:J;F]\:OW6Z3<0MT44PX^#N>*::.Z
MT>,9+SM&HKL-,#@)(_K1%C41#&=.$9*VT;[S6QI<C)GXH[87QA1$R;IR3ZJ3
M!=>']U52S+>53M3MJ)KM%$%(_W`;"?ZGKBWS^_*INZ@`K^HD0I-<*-D)5B),
MJ).&5%#\(S6W:)MC*Z91V]1E.5S`;1D3[2,Y4X6'6[IT3:'%:C3)K-8GJ^GA
M!92HFPDAKU')Y3F^I'(?+0,`@YN`9?!C!$P?#@U1W"?E#9!DY#"3]%E!%TQH
M$`J_;].[HYRS`P]U:0T%2!Z=<DP:1#\2=><D2&V`',''!90OR5J/(^MD@-H"
M+:T+M-@JTZA:WJX)%Y<I11^,9Y`44YP=WK2C^\7)YE6<XE5`WHBF!FPY*"CI
ME'C#`57[*91(VJ8./%E)@#4](?JYNLZ.L?-+Z8B(^<J#%B6H[%:!@'R6LT1%
MPK]E22B\R@5.LL"E9WFD#!RP/9U2ID2,);N\*DY`11K?1O4_UP69@<@!E<7I
M1&TK?!B])]J\E)<DL+3H2@-CJ[DZR6R;CB:Y=@W.:D4#,=NO2#?(6#7=.J/H
M87;=^EN[=J6F))A`?6_K.<Z+!FC8/Y%1"YONJ,FDWL%HOP,RVN#8"53[KA5\
M;LVW>SO[V[VM[?W,6F82T;'KG:@%?SHY_IX,VFW*5(/>)=&[%%5]A)HU7"/=
MXC7O7N,UV[UPB<LR)A-6=RW(B_,#4A/@UWU8,YGIO3S%_(]XEU#NG^TW2@DF
MTYQ3KO9N;J*7Y.77^&%BYN`OT2!0U[>"R>PZ(+L(H$<RJTT%XDY>0+]KI</\
MXT9Z&;*M64V^5D11(\A/6$X94%)H[Q$&/80^Y&WBQ`R=?!JBL-(OUGEKZ@O7
M*AK*X`V8H>G:^G::_3FKLUZ<^$15LG&[2T#T:HMI\KDSMD.B.UFAO9052MED
M)8^E]>I6#E,VTEJA-KF2?QX^YDZNFPKO(%%NN>LQ7):U)[(`KB<Z/M*^Y[@[
MZN$H5G'$QR]P9*8R:&VTK7[JMF+FKA4S5[][XPXJ0AH<[H88=P3U69=A.'&3
M<(;5I.OBY3F=!,/7+YJ<[A1FB._5RY>V;@/X]<NNH[#]Q6N\O=_B.3"SK"86
M^"F-OI.*:C^]OM-[\G"__6GGMQ+7M_F=M\[/:C90F2"U7XUJK[CJ]VF"A5)S
M32:5JV3`4&F*V4KH:]N]O:U]^W"ME:C:-,4>Y?G3#*LI!6/"S*`;54/)&WG4
M^$M4X&>:\UPZ1MZ\=1N`NP8+,AGN'?#&)EAD;:^WO;,C?2$AIKP?&RDZC/]6
MD!YYOJN-O/R[VYA\SY@\?Z.]6FZ!P[U)-YI@\-/X.8S,`DLEDS`M2<KM/^H]
MWMFOGPU>372M#$$0`I[.)OVP-LP?6N?]5'$FL^&WI)DB94/.=*`I+D`PKU?X
MIM3PY,F^K-CO2VZ=(FJ#;?:T.Q-_ZKI%E`E#OWX)H&<O1)6M;GM\45M22A^.
MB6U<=5O4[1J[`>G:PUU^,[$NO0"*NW+*A84RO77G<H:[:!&WE7FK81P$SU*?
M9C>NI9WT_=J3O=[>8W,B$PF;N=0.GSXGG`J#\FW&RKZZC4OWC4NS%]IKG2`N
M$8.RRG6EQWU:V,A:`&I3U7HAF#*Y#VH50,:)XE&`(9[F;ZK[9//Q='7MBUG'
M<&^".3!4,ZVX(R0&0,RY[>?))W2^1O]X\I2?`_CD06D$B<?AM_BKEZH&^*\7
MA3=DX%B<ZD4&FU^PPUNZ2ANPZ8M//YLBFRUH\O6;B]9=\IINH7M)[806`L!O
M8XVBJF>"SMB8P<AZV%F\A"C_?C;\7`TVX/L-^Q>E_=BK;U2`:]&8TI^SXN7!
M\;-"TX`GW,G7+]Y.-@M*?4;9O2U7Q!%6GPK@3<ZT*H"+*(]GS#&^(C`R+YQG
M:G\#<PECZAIP)UC].U5O+7!:1XG%UO'`&B(`L-#.BY$D.^STZ'A:Z0B1E=2Y
MM.'MGNCUC'B&:?M[$-)DT#].B7!P0=8B&%BW1$;:)#ZFIC,G76#*!M^MHY8R
M]RV<PGZ6RPK*?!TV,A:0%LO?)Y64?#TM=8KANH2)=4*5SLB-A]Y"O0YJX!QG
M],RCXT);V.4U9<X9??D(@76!1&ZS6CY_W.746E^X8;`@W%H72ZCJ/"'O9O>(
MI!LD!7RF#L"8TN[YM:-:+*-+4VYJA6LDQQ'`XY#;'XQTW===1TPY\J*3+,0-
MU&`%4UL.VO"DK3.<)*[BUQ^-HOGO#.3/<:;;4*:E`Y\T,-96G6J"\Q\L-`<+
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MU#XNEM)_61"&),:K]]`JUG<6/2.[(L>OQFQ3)=&L_47.F.WO>$F_;](96+.R
M%-C-9M*]8YCFKO8:!_$BD*9=:#_VGJL:8'V2>FJ4P3W@2@-EQ6G_:C_ZF_8'
M?_0?/:37ABA3]M?N+VL_M;49(O+V%R_BH.W'>*T$/YVUV]DV/6;C-FC4XFI8
MD41<W^L\>L3-$?%&$MD_QU>PWP+0B@QH+67ML<Y%@*Q8W^^L]=Y^&9=5R#30
MOV8WI?*7W98N-DHJ'-T!*ZT_[*P0'8=@W]`S7+:Z_JCSG#CZ\B:*!R-F58(.
M[65N:^],TG^8]:!C="VM9)YAO(0DR.>[DT-%!'":U.ZLJRI-5,/#;_]T_*)X
M\].)/9F8VD*@E2*J*T`V5O"58H/,Q)($S]KD74!UAA.FB8G?KHIG*E_P3K"T
MF=?;%H(.&/#2JA[89_7<3415W<[EI><!JEY"$+'GDX/6M)E@M[@_&RF,S];,
M[`YC_3=*M<\`(GH4G3CW64<K`ZS$0+9T6B+<"(G/0*7,_"_[YUB?P]U"G!5Y
MN=&&:@/8<UU[3G#2Q<[>2NR\J2^Y2T=%1;-R2_S0VE0SZ''P^4IS<I375&&Y
M'XJZ[K(MO`8U)DI02!_7<:;3RC`?P4KE#J5=,->%=O_.T'HV'2<M5P7!U6UI
MA*C'L[OO-(#1W?WA;;M'>H884*=R>6\H$&/CZS0(!,SGGZ/6LOK=:?7U"Z@6
M.7>IG`=AB"J(ZZVX0M#DG!,UA=/>R6V-52%NB<114JLDYWUS`CF>684NE*"4
MHJL9/SGG"5B/7UNI(^.JAO!WD(X:8W9#N1+W&0XM74_OTJJ?Y+SQX=M2!@\M
ML+QQB;;MBCW-HLC[V*5_$/,M'4?U!'Y@_:GLCW(.'*KNT0VMJD%8LX[_?-P_
MY7+"@$$]A"[A]ZBY^SMCF(9NCW](:B65@?A=BJ664U(5Q(;I>P#]9+>[4;V,
M;?X.9>A)CT]N$J'[K]A9.ZPG0TPA`0"_S%J=6^/^K.JDJ,L.V0].3R>+!7K?
MRG/EM*+/L3\'>[.ID2E'90.-M'=Z]W]G@.4("#A7I%DBDY?Y;M@PG^]YR;TY
M#A:C&U)9/O:3?E>/S1=TI;"YRJ#%Z_*446K^II-\5RZN!=6*TAD<L4XU_\5N
M\W[Y,<BJKU@#[-JO*](#HX9XHN8_+WU`PWLD[.<S[;<5)6VR[1,:2!:,I\RY
MS^67=(;:[X?K8C[OS5=5-U!3K+"VJ_X1ZR%I<WZ.?V-*<^!M>*1FDL@8G(Z$
MIV!=>]1[%%KGY6M(0>J>74998H)5'YVE>ZOJI25B,7V`HY4VZ<:(&G$PO$51
M(R5OOV6*`@F]OZ^*0\"Q.P!.;`:/PR8L6+[^NOF1VQ;^!U?>O1WD5__@TGOW
M)47\&JX=-W'_E"JD_UIR',,QWHKC+FUZXQIS8>6**9'.@P])4]BOS1HE[96U
M;6,B,9)D(8VNM-_].0V+)#T7TVVN-#%U^(&PE>3E!HGU^NG=QFFV?_T\S4Z,
M;3HG[V.]?LU(32YFW,YDWJ8/ZR0!<.U"ZY$DQ/POG&;=7>UWV-7/B1Y1)*RZ
M<0,"-Q4?)V6?JX0HO@0$OU^2Q-OQZ9.=U+'2?2U*^A$V3S]HW9(].<)U94O_
MOL;XR:=D:J)9@9,='=L$A@OYH!;RCL`(0_RD13R.7CW5-;^F!6_FJ$V&F\G8
MF\9JG#NNUK%@IX:1-HO_LH%/,W7XQ.!DA/5",UEK7#W%V]FUOW+7=^6'XOUP
M0."9V@FP3+KQ5A9Y_=W[M_RTL`9Q]:N0,M8A3\N.H"5UVJ[M[.[:H`WJTJP.
MD8RZK=,H,P\3#2S5UBRB7T=);YZ#4/PB;O6)Q$NXK"=$N'%W_*.!'><E:ZDX
MVU0&XIO:K1%MO68WQ>E/OV/*W,INZE#(SW+=$4P+"B'YSO!X+CW6X21&2Y"F
MMYKXVMJLVR.NV;!#03]RFV\.Z&K]>#S1)1DJ,7%$[]WD'_KYYSQ\3EVD4>[F
MB^7`QEET!IL//>AO,*"R\>/RS3:US'4E=&ULA?G(K"4]*HO6A$,O#M"8QG&A
MKL7?Y[HB6/!2'1^`?KNNJ-5#LKWY)%%(5,QZ'K?1K+\A+&_68'4,WZ9>.VZH
M#8QR)SIK_F+M@^R0A)4I$@,9R[A_YN,IJOS8`N_27`8_4*Q/>^D7BW?XMU6(
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MY)A&G$!\'PU(J@M613_Y8-!>\/DRWARK1&;L$XG]OV#!P/@YN<!`35=H(,%-
MS-FT30:IYCAM6Z<YE^0[5]*,8IZX55FM5SK:"'<J%Y\FGKTW%*8I9PZ`3RFG
MWF`\\G88T@$E=>@%-UO2Y1Q'1W58WT\(AWD0!+M[(SPW:R4--!IK"L=!115K
M!1\`MQ^F4`KJ0)A%`69W$%A\NATQ[KE%MM/,.>3PQ4QZ<OZ*Z/33RA0ZTA4R
M(PJYJQX?U4/DR3I0=^?P0XJN`4+'NG?+<TH#=9LRC0!=GR?YR43JQAQKNX]Z
M^]@RB6WX=S.KI[_<=P0M=LMK,D\=X,X,&TV-:M<9F5+%V=_VANH;)W<[ZB(I
M45>,4GCR#F_Z^9;M>P^>?M\G:+44P67UPSW[9/92B2GTQ`_W#LDGG,Z&>NZL
MA#GL#L8?[NWH`XT7,.-DSW$[[62F#Q_8#\0LGB9?QX_)\?2__Z@?CS$$G\#@
M4<$9TRB@U4SP[L.'YC=;`GA*XZ_R598]EQZL=;4DI*F4FP;$_>#NO"_D>[3W
M)`2,NP9+QH_-%7,'Q9@-'0V6Q6>1T9D'F9`XX@-EJ?0]&07Z.>HFMEL+_DW=
MM<I_Q[62KR8]%3%2C6<DB)0P"AP,!;,?1'"97LW%\6(83+F[=$)EI$7+.6CC
MH\G'(B+=")0/F80R[_JD^@R5WFP^QP63%L_,?K#V_\]S?=MK-X.+B2..BN/Y
M7=Y60-KR7M%XX@I\K8LA:=AP^X+R>QJ21>/)&EDA29THNH0(JTR<J?PFVZUM
M[TEI)F&L76L#B/W2;:'VL_"RXSM[D?_DO_I-$=+/ML@ORKD:EZ\123_9>\@E
MC?(D63Z&M_C/%MCB749^-Q@0,\E>SJ]AH;W>[N-=";7G)023FC=8J+Y`T+(>
MID^`'ENN7()%/=NK?M%T\?3"CM64H<53S$!]Z\A."HMRF'Z1#/U^<D$L^^-D
MRH3Z/).F1)C@E#[8::F[I(("XT@'Z2H(*7>[GBN_?J$EQU%[U:_"*WB(.@4!
M&LT"$R(<6`+^\1^2P4_,CR@R-.;:QF'>7I<H.9^ENXQ>?([SJ.NOWCYG&/SQ
MUJ/[!3?1I,&OH'S2D:,RR@S#8YAUVURVP!'B^PG4_24V`:9./B>>@$S.BALA
MB&P?[W$/`7YYN#1DRI3F9=G/ADK5V&2\J(?0P@-+W8,Z75(K7HY2)BGMV@98
M,VE<XV#A=LTW;IHL&#3=76:B%MC:.I7J/%[P0P<N2%KM5K-CYN069VAXG0B\
M)0*\/(5C=K@FZ%=:$4';M")'U7@\OQIQ>\VP3$SQ_^7`':1'CWZU'$3QOX,P
M!-=#\IYE:\H!/B4#7"1/E?N4;W0+E],].M-\V5KT9;!"Y'`ZY7@3JB02DB(I
M]6S*H..P__DZ'DUO(<NP:"M_V5+2-)XLU93B`I3"`U>IOYM,!I^`0Y78=%L=
M"L\3S>MTZ(8G[&:^(CYN:%9SE;+7XO*0<[`'R)GE.Q[9;3IJ<E_O_^[-T7VI
MX=C5C+56I]ZXG68!5Q2$^=$@63+T&:%?3%VBEI93G&6I(K07)8?=MOE@U5<3
M,IY__^__>^,9UM*2$]$9$;0U$M";:RA%DL]/'H:>\ZBBC53N<F0>1ZPNR,_8
M?\B%LD^V/(U#!]XUM_4PE%+-Z$:C\AO>5GG?XV>+L9MEG3B:D&+B^75)/QVE
M'DJZZ8!;CQ[)H^IP&"8_^,QW479D_BCT9MB3VT[?!U$"^35*Y^)[&;.7PS.9
M:YK0EQ6W0,I>_FDR^]`KWO[)0YF:`,J#Z&HFZ$R4KFQK[.'=+"PNQ5/R&M2N
M6R69)'_X'8U6*.JO7\+WS6BC)05W@WWOX6VPRUM-H4("GF`].&CN-NV%0KTH
M1`IT*&W"$S"-/M%K#FR]5+E<P+)VR21QF%5.;%$3C\7%QF*R80-&\ET%`UHK
MRZ0KL^-?CR>L86YP!(Z-.W1_85W.;0?0/[VMD>:1E9)6K_"JJ=&:%$%H0S92
M2-#\TLAND"">%V9L1(#1(/RT=*=20%@0R14#-*`A=2P[3L*/%K9"BMU&G4A<
MW+JNQ_)^4N4AG^6W(?P?]LYU*:XKN^.O<FK*CG`5,%PD!#,552&$QL1"(@+;
M2;GRH8&61(R`T-WV:-XDW_PL>K+\_FOMV]GGG&YTL3V9I,I38]/[[,O::Z_[
MY9K4'A%!$5D<FU;]Q"GA"9MN48J^1')7B&+5(+/HU/O:L2(>F3>,ICCMKL8F
MD+D)Z+[;]/36@!NQ\-$:OPJ=-GPJ=]<&^42)^`_(N-^F*F2,),N],2QTEC?[
MQ=8J2GC.MA4DHTEV'1/4SH,-HH]T0B[D%7QQQ:R+"?(FG4.8VU'(&OS%3FMF
M?_WI.[D3PC<>%\@900.CEG&I8+&T^Q'>R'.AWV+*CT\)O[Z:P.3TRFQ$)[8]
MXXFVM;9*A1LWYYI"5@2LH4W2:T?L1<O=H>U(^X,BNB4'D_^I4:AL3PCVF_75
MK?M?TD6O)TQZI=G>+G^*,94A-'J%N$R)\H@OTK"!@!>RO;QX90"**=+-KEU;
M.V*0#V%`.F"Z#).[BY3`#M&`'-LD[W\)40&5W$&]5P@S:@<*D)5=#6(45X*Z
M-0TQ0$C]"D4[7MELEK0^K^OE^'4>>AR'6CZ06P"D,GOM?,EDS+=+#")=,8/X
M$P1IR&+_3`8>LO@D2T`HD3\LJPZ)@DQG5<89F46@^"%8'LY,Q#$PQ?!&-5=2
MS1,Q.T!OR?"5!@E^48($J246&#43EU"6!P015-:9Q:@NLV+LQ17^D&Z#R?_(
M:[!7]V=;:DFE:8"N587-C".?AKF1R"+B+MCPS)#"]PF/&>%25U?I5#`G?LX6
M`S_YXJ&1JJ'#`"4H26B<4J3(&0ER';R[^8@!QW:HW<A8_>JM^N.S[YI_&KV]
M^3/$=K5Y]LSK1A\^^\Z&Z*7+14N7V!BI<A]D.`&M(FU.BC;?2.`6,5YVB4W8
M9_?'U937TE+_-:C:G>O/5:6QS=6U+T66-+Z/M0PMINWBDA)1DZ$_T.ALVBG`
MU[,5%^)UM"5)XL\1XIMMX\]%[8Q])0-^53UG,_P?)49KQ0OUX3R[_=JO9[</
M=K*DV)A2H^NJJO4,L[J`<L_(+*(C7($TZ4G)+C(#5:0SR+A1X'K3J4[10H@/
MY&\?SHQR\561NM^+&1GB_/H,R<7.ME5_]P8ZADLG/J$@BJ*(@KLB^J#J52VO
MUL;5].BC[!([7DUH6JMJ9Y=$T$^-F'KMIK=FZ9F@<FR8FRU+2`0)X-.U#H%&
MF9,E5X]P?N:=1D3J$S<B=`L]FSCC)I7;UK<>QL<.U9B[W$)[UW*S3G>6];74
M`<58>7@0DAO#N>)NLD6T%\PH7D%/,<5Y&"@8'UIP4U52`@#=\QR+C]NB1N#8
MYOV=\N">A]/H,]/FD]QWOW!31Y]VV(:M`:,QB@GD;'J7`;,J7(+3NRK%HTOB
M1+X$*)A%X.'N"1`GMXG%0#V/N,:U7<2E<EH3G0LV5PA.\FAX[4+RD&^GK1YM
MUD(QY?2W3XZ>?P+NS*[D!@[]OB!#A!I,7'V,P30MEZ],`&U<3:([8&I+?2;J
M4OUD<X?_K6^WD'H(RR@4X[:!^_9P(,";;1TC.:WC]K@555@A*OC!ML(V,(U5
M558JK_7P$2JF-7UT;'!_X44@^VB"()A%<&G*Y']3Y9!`2/9E;SG$(W9#R[\/
M/;HZ=P]64'*V_O/+6`^F_F$W<I;ZA^>QYU?]PUZ6W^N?#I#L\9]<G-4_X'SP
M@A!'DM#J7T^P,2#;AG3-3CKB=WWYU"]RCM$=<JK?_]+3;O?`4MGKS6R`;T@W
M4;;(C27>__)P=7NK'K[>.S*>][P>WMIV&^'KH8%C?!P13]RDAX.$$T;4DO2?
M9(V"(70M&"9:M/5F7#EDD8HB>C#2@]4'#TR=V%Y=W[&U1V9"$D*G9@]M$C9J
M[KN*[KIT4)!X&<JEA\W.3$/\8GWU84L+/JO3J+7U/@UX15J!=FB9U*NDYWNU
M$)*4B@C3Q5\BD5MO->]<H<!G]<C@_*[CKZ^B`3<KS<;JVL,OE:V<]>2HY6XY
MJZ"*,DD6?5HT0-I^N/IP*^C*)!0W?QO?DN@?->ZH5G=#$`.VW)W=0PK'""LR
MGK1J08LBJM&:!SJDV^;/L>V<N#1]*;:XZ<QOYR%.AS**0<79!OB2F-^ORI@&
M&,X#&`ZQ*>L8V(L'^.D,)\25EWQG@X+N]Q&$C.M0G4@M/L0@E:[*S5R^Z\#M
M>\]O[V3S/4U92C43"0H%J4U,613WXZW,0Y5.6AR5UW'&;NYL+6^N/:PIE>+B
M_@(=0,'M_M1LK6YM=O_\_I=!&KFTP0UL;W=*5A3W,6_O;8X?A:E>S2K:"^^&
MQJ)KV=2J6^N=M*.>S7L:-B>FEFQ&]GKQ/>JDIBE5RM4&4ED#MH#1$,Y&IT5E
M$;-BJ!%:9J6+.DCO*6ER8M:5.X*NEW48J1'#:%MSNQPC\@24X;09DX$MW*OK
MA++8;Y*4[+LY()J/1@$-\Y+MNB0Q7C;L*);7<L$X*E6!NFT\H";:9C*9</"6
MSBY<FD>/-S:7'Z[M=,A!<=GS3F($9HXL;()F7Y?D2G9/H+=[HT3F9J!=B\A6
M;=_IT*_.@#E^G6(LX=/D8M?W^WS8L%2--;O20;30ZFWUTXZ(8%FH"K'+&?D+
MO:9SLY'3E7+6UF=X/FW):QT!:<M$+_Z-5!KA5,]+DMK&,XI[<LRK=+*L7O;)
M9OODUAN#,@^HDE$,<I$6`53]\UN%L1;$E>AE_(A(-%873+H4$:!F0(NV6@NV
M:3F!+Z^5#0ZDILWFPQV`@T-+WH9C0M/&T^5F'SE/4?3/_T7O6MPUS15]EHI^
M+J/1:/`JB!!0!ZB3=26*.;&6&64GQE8@4Y)Q[6AS/QOXHM.E\@SD-L!C`Q5H
MFZ1>)"3V<-(*D</BA=&616L+OV%,HD+*C,7,=38>DT^A!V_!KUT29"7C7<5E
MU&,53%$)?N'5<=9ECXMVK+NY@>N1-5Q0M$7\MX[R1Y;@#%&PF+O]WNT-=P?)
M/.@#?V-\)$/@Z,!J95,?0&F-(!?HX8E`6",0\L`/$]-.6W$LLIZH&H/(QP6]
M-RV6)*1_2'LY)5;R1WCZ]>SU&^$%C:%4:$'"N.D78O>L9C5?05HAOC0<?:J;
M'EFFOI(V+\ZHE'CQ]NWL*A0T(.V2/9\0['(YFLK:9+?GQ<@C"]!]YB+A9V^N
M+(U;2?YVW.GU:W6UHY2,'"%:;[!OZ>'X?!?RH=C(90O>:98.=VG`V2PI4!1'
MNV5L)U\3CX`H2#6^-)%8"2MXX5C4G"H*/&0JRZE74OXE^1X"NJRP..&P:(7J
M%)<C&D8P=!)#<"U)"&.4AU;:0P/=03/^P?YZ-O:&C'/!)J!H!Z%-IMTTUE\S
MVJ]W(T4U7&DC/N"@C@220C+&"*?R7W4#TW9+L25K$$6&I$6+8J_UAE%';]YA
M>KG@OP^LZ5)/$"BFZYAK;QYYZ!3T&V@VER,Z0M-Y!9Y!+66J/LJ8S852;=#1
MN,A*\PPB1-01442DGKVC(.C%.47]9C]2"F($.AV2Q$M`E+(&'$7,F'!]J@11
M[D9LUA$9OID;BA;E1>R)B&%ZXPVD(Q7"`W'/9`JE-M[%ZS=NB/4`+2&<XJ_=
MO]V7#J?'0J6%'SFBNTC:#\)J6*@Z*N_)4=^(,K8#Z??$0EU>CZ"$OB4EO&*$
MQ4[G7<T;VIGQ`/1FX\-TZN^X6;>-,X)J*/S?'C>+(8&YLR/--ACAI[_K%0\`
M6UA%2Q(HRBDP0B32)L"E.#__?Y)?MKD8;:&?.0,1#(X0Y%(J=4#$A"*LKWB(
M2O=X1Q4/>P\.<X1M*/&$FH-V$]U0.(&8^U$$W"L=:8A5%9';#XQ70A<-F]JE
M+4?-'O5*O>*A<8`7/U]Q0V\N;G@HMV9TBI0$-NMHJI@*8__BG.E77IPBAZUR
M"WI.I#L>!,#*3\A+0KHUO,PLFQRLUT`S^GVUYOC6R(ZM`)53[$!:I-P"!4-W
M-E>Q`Y'VRQ1((I.+\PL,N]`Y75CO1V>BV4;VC>5#6F41YH6H0"YD24?R313=
MG\M5@\78EJS\_")35F#`WH]U*=(^O+Z3=;]A@=Y=P27"*:HI+=`AM,SQ)'L2
MW#<W"YO0GK.TCB'1U+)=WI)BFUB7@$9:W:.,%]_V[J4E6G?7QU&PL;&\UK)+
MA3U`QW(L0T>*>6QQ:NSD2/2(P$&+S5DA'GI$3V6]:RS;>'S>$G&'#`:-O>0O
M8I4VLBV13)N_OKW\D\48_O,?;C3A[4_C/SSZQ#7<WWT""A#XY7`549BE'8*3
MMD.8U[EJ4UB-&CSR%_(^<3]IXRF^Q:6TR.&Y9YYOID'L'&F!+_M>9A;A()!J
M`DY*9$,E+*02E=-EB_!/_U982URY_LO"99SX\;;(T+)X-:OS\I?=W2-[6B)!
M\2AYSQ<9V/Z`>C:EA6YI'!:/]5HM`:`'MF!W%\>$P(9V%WH)J:<%"/,6>5F$
M)+[\X_T]VYN192XT-M)^*EEI?6WE7_U-!]%J6RA-<$]8GNBA?^,I`[';<VY,
M_279#.+_=2@68D9E"W'B.^VS.*Q-_.KZ>NJWDR+%>8H);$:UA1+JTME[S\Z+
M/@U57LUN"367@(!H)G',=CQ*E8J1X<$\PCV-*W,2DAW?\DQ0*.C!9_PKCU6)
M(7%K([E<I4Y-7>TK`9U/<7=B!5,NA_HK*)<#RNG=M6D^);=`PN%(%YU*Y@I^
M$87<IS!!CK"'/:::;'S*\1,V83<15U(&)_4*K221(KC\4N)HX:>V^VJ&EFA9
MP4&C_C3P3MY<SY2)(_<B[2N!"=#\3T0RHT2&>%HUDB.!>O[3#ML&FV^D5<1M
MF[][;%')_4'_CFBL=3LVT=M*RN>7'.8SDA[2<J`3R-E2<N)[^.9.R_&0N2^+
MPTOGXZ791./36V]H$-39U::BL8^>>.Z\)?Q`5Q#NP];:`TT]'!P[7TO\%5-_
MW_]RPFW&RT%VL[>#0`:D1S'IW\X&IG.VLW"-HE1BY6_`$=*.^#.$U-@1A1D4
MP2X!503?GWQ<(''_5]=GKA)R6\*G0N(6HIM)()8CL_(LB`OGQD&BQZEM=\"=
M&ZD_G^\EK.0A]]S#G-&_\TT`_CLSS>`&-/@%`/MS<*;H[&?Z1KV:VX_01O7K
MQ4C.\`@HBNKYF,2+_&TT+-U\:_8<05RR;.3_D)_0*WE_ZSO:AT1[)T6H3)9G
MC#D;RATYK>P3;1[MJ:NLL-#^12$Y>&BEY?5<]^#8W_FRXZN(;XX;`_)OT"BA
M_)<7G(E'&,%MI`FE''4#;@;<HM!@=ZLRU9;+@)"A]K-8OGB`4'&%;EI]]@">
M5:QA,+Q0GYL583HS8G.M^8""T<7EA"]/GQSL<?.3F4B![M,4Z$YPC*Z@0\"A
MJ!RD!^EL-QZM9S9'I^>R19Q2AZ0'68QL'I6]@G35WA=JKF7M5Z69AU9,3FJW
MCC]..Q(PD3-"0Z(I9)'8+@TI.Q]!\3`)$^XHR\$*1,X"JB"]%D>EL"X]"M5D
M)V7[$M!C!7=8ZI+%-WFBWUMY@0G-(OT*89)JL:/+AQ^?N_L@+1]%:Y"IMT&5
M80&18.P``3T&H474<T%7S#O.\WK$BQ6>R6'/SH,D%FX34<?EW=6&NKA(24Z)
MRD;FYGU&H0&Y?/]GJ'[2<4%:2G;&[_TMMRG]`7+$!25&H4L@V#-J_ZRHEQ>J
MK$&CY_D_0<0/W7-^QP<OH@I?33NI<:6,,G&>V*JAO]H\36$H+ET6O4A`IG,'
MOG@I`%3]/BN4[\C77M7#]T##_YJA:E$WU(>B0/'V#;5`X]8?#3^NT+\E$THL
M'?TTNL#">8FA(N_;;[*,PS6C;YC)5]4BDL$M!$8F4QX+4AOXPA_C[->G4E7=
MMN-[0Y(8V4-RQ4.#_W-V_MJPP)Y@9"4])&3ZR"!GP5M&V)(">I!;<K319OKH
M@(U1+^5D]->Z2YQ1I/+GWQ&G2MD-<@'-EVBN=V#`RBT[<$&_H;(_KS8\:D%0
MHK@N@'-.=4[2[\R.:TG@_H6J-F&$$V5AB$_MKSG.+5.;4+FX]H1?T8('6L&*
MIC^KKF16I5U<UT9T@WDCL*S;VW?V=TL7,.)GA^I9F2^U>FJPX4*EP#"^&EDD
MLO8-?FF;#,:\)BAAEHS)I,#$LV10!=F?/BWWK=E3U!/42>(M";QML5;%R,9,
MW`<L05F=H2ZIFR^U$LY(=:@<1FMYK"S-PNI)*W**[9V"41<_$GFCO5(=EJ=G
MF[;==6XDG46ZH*@TA8#^)@USMV]=3)PHQ5&;-?LVQFU9DH&E*#L\J^<@M+4V
MJZ#M-RO&+G&"<I.)OT83/-BG!>UJ(W;LWG?Y$E78TE!T,Z5NM`??[!/DYG_P
M.S[$UL9*748LV!]("+@"QD;VL$7HA@8_Q`/U]G0&I@FJCKL6$^.3)2&C,H4R
MMPRU1:;X;0GCSLYZK^589MB5QW;;1Z&N69L^&@WL&_8[7L$)#S<*U%&(<H*8
M.93(OUN:+2(ZA,+)XLZUZ(DI#4G9#M)<%5:3R4E?6";&G(*;&7W1.S=U"[)J
M*6N")=3/@!ET7=HG233,9N#BE9Z;+*QG?\&>;JRT;:8=PB%9.-P2%$YK+[`U
M75C'#A'&6H!(&?=?`*4@W=!D(8PP3L`P`3):;`*81*LE\:5H>P__9W0[,#^V
M\@P&-J@LAL'K=XBP]CDRLW$5\ZR9&TL\7UES(LC!FI_,-[:V^2'L('TQ0N%]
M59M+@+<9\$/C491X#9DLJ;JVW@ZYL4?$S0D,<6I!(J*6.1I>C8,(FY8I>I,P
M.OSN_(>*!J%HI='H!#^N+F<K.+T("8%NU!3O%=]Q8Z?V`V-#81-PR@42L+@^
M8-NTT!I+6T2;]C6MRN!LZB)\\A3#^2L4/6,1"/Q(_DQ4W+7H"RPL9.5H7RKX
ML,*5M9M2M47V_1$FVZO76&:?H3!\I<H.>JIZ'T9$>HC+HD_^3@A-8)SVP*U'
M`:K>!06)N3,XFQ^:)YM>NSFX2K.ZH13:9,S?OO'G)]8``6;*-,V2E"V<V9W9
MW'-K:T*QSHFNE7G?$%>Q,T&P"I\GP5UW5Q*-V),S,)2?0U8'DC[:&(:_W*$O
M?N64K4SA.<<D$5;.PAT;IHP'0<R+X7*WDRPZPOM?/N4,-_2@\#M4Z$;6L;";
M`$DD9=X?N'LC=5C6S.LK7C._&#\WA5BU;Z`'%3KH*DQ=[ER@GIAF57^BU>:]
M&63=FX]WC\D-H=J;:9;*L+D8#HDS`[NMB.?E3,)<4N0C2O:O'_,7))R>Y@Y0
MR&]1+C:/0';(P2!!,97=_NG#ZAJ6IU(DF&EX1M!-)/)=M[*-C,+$]-.-Y8TM
M)03L1.^LQ,9X^-;(G>4M<OO:/N#BXCH<$^4:TJX1BV*5-TD_1VD&`G8W'W4*
MXF_Q,:>\P\%3$!'S$'?TUN:\!O#Q-4J@Z97F7B+I(]'LNAU1[Q-SVA51$71_
M%*/O(;Z+/OD[(;[GU_!GJ4;.R;D[9#@W4^G(>I>66%7JO!#LXNRN.!EF8Y(K
M+=X\<#R+09"")B,WF!Z:C5-8/I(A(3887Y91S&R<KU#R@M4NT8N>ZW%!FJ`,
M;(BZI7T+)/[[@*^]DJSH(09(R962B"5+,I0%B,G;8])BB@=,6:9Z3Q_BS^@D
MX&:XV"I0PLD9-`RCH>8ED"48"GL`.\4O-SF[O?CT@-`34:E))QRTB"F5N04^
M3KQA:11))@F0LA"V02EI:-$7+491/<'IHY>A.O&1B?\GI8]E:?%V0-R881/M
MM28_$H3`Y9E*T7[STT=0!-@2<5>B1=G`?H?%>$_YRV0(K^<O+;"#DRKHCZ@)
MB:G93AKI.RP6D_DL*,-^PG?U,L6=9(C;*^Q.*,YM;-I^SRJ6&2;KB6'XPPW7
MFL$3Y;#C5)9,`7PZ1+V"@`[\!Z<J,G@GS0^$9U+#ZS_J24R8#KJ19)24`[U[
M"PYY((.TVG)<4/";75."?W@F=\0!96<FW=GS<:+BG#"MWLGW(3]L<*N?ZW4^
M&=-I_A*Y>.G;XR?-%_.>Z6=ZG!F7TW/O(.(SZ!65=@9/[[]O+/A]<_#WSPR]
MAC+-TB@'H;C6'))K_6;2["M@H[[L];F_OC`2/%']YV8A6NBA\2Z/#=V'T'S(
M^S8T'O?D:K,1REO7F]\%AZT\[M#79"37+@`RZL<W3!EB1NLI/]?MQ%NIY]]'
M^H16'&3?B1)#GD#>13M;?ZX_/2)(`^HCA8ZAB@GU,%;S\&/:0%0*AAG(!**E
MU)QZCM8=)0%8)H"2)YLU0@R!G;9GIS9X)RIC^BC,:M(_,O8H9EQ+73(5H=[&
M_J3/45J/NG="-D+PFM:_&1DT4Y;G'W-D,PXJ"MV6=)U8D$I8`DS,K&<(FI3W
M](64+^M;WGDD1\-:0[VO$A1!U;G#D.&EYXD3F7ZV0_Z;;\:D?I@ZO^=!UWO@
M#7<1G\ERTT]P4YGG(L(_?50?HV#8'0ZIBW&199'T<AC[8!!=UVNNED1%CKDG
M4H2`2#7Y8HM>/^>I7-ZQS=_@;N\`QX64E)YT\TBID:JU'8]%KZ%U5!6>BE=1
MCZ,XZ6JSYF7>-NH?/4-CZ%-;/Y0NZ7RZ%P.R3DSR3X7'!@%V.+J%2@YLQ$CH
M&OEAI'YLUKL\_N9@<-9G&(D)*U:Q#>M:(W'*!%>]&P]""TZG9O$628=:C2T\
MUNM=S+OP(>*\ZR7.K`[NS-RI.5$/&LEA.\LL_J1S%8L_Z8`T?&*M9>J-F:5(
M6Y,5A?^_7T/B$+<@5@]S6ZJZL\%;IDISWPV]NHRP,!PN*5CX"5]@BGJ))!L$
MI9V=I&(@)=5=O@M)3-4B+*@AIW77BY9P9$$C_R'=)?2M!*D4SRR[2;MH?CT5
M86NWTQ5J`ZI(M3C#_.&5D(!&"!,R55/\YB8]=8><YHO0JQ>^E['<2#1*GB/:
MIADH<[*<>B=AL91:SAUOY`Q2);W(9JA#DG"OB#$=`NZ-EP&PK*]]J4WIPZI&
M!T%,!/CC)L`.<[428@O,K!=])BT_9I[2&XP.SFCXA48B9QP[+E#!&'-M6;DW
M2?Z$P@Z6*^;<JS'1G/\.\W&S-/KJHXXM,"=@!J;MDNN+T/6;7,)3S?V9@7.'
M=:7(+YU]!0\MW,BZ1/K.YM*XE^/7W'"XJNR6C@4%*BP,9I8,U@J'TWV5R(Q0
ME:;I8&YZ\Q]ZPP*]'%%5/<D"43.>E,0C6@1Y3E%R[6SJ!#1/6^:1B')I/(AX
M/K8VE]`_MQE>3N28"^5KTO%_Z\/PIF75B4_4:PXK"G`Q@MH[$PYG<+40.0(I
M56OWXEF!&#R.UIG"?,_%3!1@:KOH8`SZ!\X@[311:/X]0JYS%=^3Q,N$5!UV
M]3.L*\.K4AFMLG0\MI&TUEW'5]B9-A3YK?_>5HZ4UG!V,?6@'<AA/=K$.&S,
MD=QG:_#H_"=R]9$OARAV]6ZB.Y4SY9>C-UAA8;T#=!N\O*D,@-5-D4"+7514
M'KNCRO02[*,+YEIO9!N7DB9#SM28^#LBIY1,"`67XN>J&>XKQ3W(*0P\3P&V
M!2[Q!CP?M:S4N13^I"@E+7-L'DY<RJ8%X9%2&K;6-;LC"#GU/%KS:1/MQ"GU
M6752=\57?VQ^-C]4I-HDX`SPJ%RCM*V11M0L]C_QV%:K$GSQBIX5CG!E.6T8
M9<"^T,([U-Z7NRS@8^?"12@P/I_*6'Y*?$0=6F`ZMD)U`M+`=\7@";(F/1SW
M>L"?8J-]4"J\%X(AH>%OB&&A@22>B\#GPZW#'SOH:4_?JPB9!'U*`#;Z7012
M:V?E1A#*5,K95P+%L6YS#^HO9];;;`QG)FTKM$H(6@!A>:\AJ2ZS1]3MD(G`
M%U)3H!H32@I;/OGZA1P1G&"R6!)5P0@%1W6-6"]#-T._.;-95;/U9U-^&T(F
MBY?8OFTH*_X21&1=C6M?Y@.X6R?V3V_$OA;*@B9OL#=Z%-A"QH[*.9OG2K7B
M4A`D8C"<CQ+BZL2`G[>"QJ/GW#RG,F$OGJP>,^17R%:'?B/"MQ[ZKKCNCIYP
M;],/5*_U#'KU)[DY>R/<Z]&MG0WZ+5JC9*+WQ(.EL/^%VO[0]T/*XW.,1,U1
M`&I<!:OL$;'YE*D(23*\J?ARDI(\9(ZA-O1JJK-5`Z$TC';TQ<5KUM.U=B\!
M=.^:\@\DHZI<@GXD`&C>R<U\(WP"&7-1S7J5)V4#ZY(8B=@D;EA_%12]E+<J
M"L*3A$89<;<8#C+<O(5B_7$V^7."1;C[F+K\5U;\),3O<S7J`E%/>B*W'K'5
M'J81G1,P:,(#)UYK0"R&C08K:ON'@5D?CRCY?`8$>]?LV=M3915\UU?8]),W
M.#QUVN7PD#Z8-^N#'HH?UCO^JA\V.G^Z%R7)^C)^V.R,_>%^]T\/NG_:ZO[I
M8>=/)Z!F2(/H!(B:)1E9S=!7PD(,9C<>J1A.I.LJ@C2S=3BSJ>UNYP@)'4(;
M5GQQLJ=2QC\J1T@&!)Z[-VF+S8),!`B#G__[\7YS^,V)C>0K1/A8PKC#G@]3
M6G0*APP"IY8U5Z-$(TSWP=E@^GHJ'Y5T#;#?C15E3&Y0G5VX.1W3K\.VN?D@
MV2#B]YE&*'BWO6?[IG/@!54M>W$N4JPA#V/KHSBXQJ^7<K^V8:+_&@!)_?5^
M7775FYG4PZ+4-&3<M<>6\&](Z4KEEJ-:EE2UCD\#-)SG%L^4<O?T]'HZM7YI
M5I;&ZI_(9G-[LY"#'1%EATN:1D+XZ8A5:]SZ#/1&.&#-%$Q4@Q??29/5H`F3
M?*99/G&:QQ=6LTIG";9L>2(X2]`U*8&#0F":TT*?Q%.RZZ9F_`K"W#'"W"`8
M=JVDE7\C^4V#A\,)[G:]"X4@$T&"%Z#'L%QVO>O*-?5%FF]CR$'Q$H$5H-YA
MECO@8[TRLIPTAX[7X<CDY'R3'=&LGNC%Z,?FY<4Y](!J<;!XH8$7"Y/-8.CQ
M8MX8C@>0R7[PRUV4F9^:XVL%;*+\#XZC,QS>&J^BV'4XF$\IM+>M3U1XC;HU
M>=W#\L#\/)UIGXH!?#V;GF'FF<")@J_Q9?0L5$['>N'P_HW83VXX'(E3J@L2
MTXH6W@7M@9/[I[.YP]#?9^A*#B%(ZO\S]+OAZE#<`?(9LO'=^V0/+1*\%1WQ
MTDX6&7T--P]?&+C-H0[$@^>D^2N($WHAUDNUSWE4='(=G&\!W1GBL2)H$R-H
MDNH[/N%Z8Y'TRGJ!*B!IJQ[RI!U">!M,!`.C[P6I3+;4K/'/8WT@O.H;SS"*
MO5LY?;<2_C6$I1$F&!:$UZU_NB%@8S78/8-G2[+:Q]D":CC=B\:3`!D3]^H-
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MZ'->_`K8\PIPF.%,4:VDD`4Q`%)4?[%[=24G[`UF=>H&FK>A,P32U==OO![W
MW)N<@AQRP1A(VZ;L0>,)C@8TT/2S]=&05P#9D0/!:=XU_SLZN$I`[#F'["Q]
MUQ7DR7SP6_+C?N8ZSC-CJ*%<.V5^TPZU6#^MJW;TZ-:;B[^#:#*V770TNB1X
MX67Q*B8:6D\C2ZB"E;."UV_&+>3";M1+^>-:O4(1&%;F`\FU$6+;ZR_R.S7+
MUW+3L7757QST=MT9;`;166"?@E3H:<&65<\>VR*IH;,ET,6)2;]!:[W#_A;.
MT'^`A9]%SVOG\A=^^8$G3JV>9`C&4.59JR?M'DO+3=&)J`;BO>U`Z.]'']P&
M#_5=!R$[.[_CTOT0O!?[`]7;22VJ"+*%,:J_E)M.[W";<[Z-F-&YD'G?S$6^
M>[$7W':$V_I6+^#20(X<O)P;Z_TC0\^@AN9'[HQ??]@[L"(.3137A^QGV.W0
M'CP.\'X-\?V8,Q[B:CR=9T@7"DL3`0V=5\;D$<;P034CSCTA-15R1P=I#U('
M64/#D6%=V>M:(Y4,;25/,C@$.F"-N]FDI^(-CHSM.=VG,C@,X@U66M$3!]?0
MY@*<PLW,:7%Q%.ONF_-0K\4B`!'^@JVQ\Q+S83QP)@:3S1FX:Q$VN[&%]],>
MAB.-$![MK,#K6QU;^G&-+V;]8GMV_F4GM29&VO!Z=#R$UT7H^H3[#:9P?_0!
MZMNA#""Y?5#;ZWH'3\:G4XA)3&U:YK7<OJT'1?J`L*[Z"!QOR':;W2FJAC5[
MZZD7RYB;Z*.-Z(T=54'<"O1_V2.>#GV>[,_?71.1[16Z/^K[)TI.1UK]N-7[
M8(-'QU2!&F9$>?=TQ\9XEY("ZR],QAWX[`R*1P0L%_[_K;!E7R9J9V8JZS]F
M*^P:-:(A,`:4.5VI1[6(5.F8=J-4TB+J[TZPPT33D1E)Y)C^QVZ\W;'[)$KL
M$EES<MTD:TR`JY'T&G99*!=1"\S/V43H(%9_45``F7%:W]1C[[WPV#FO#Q_=
MCMW&P]BV_^^T],T=F:]B8]8.((<8ZK>+NO36-R#.0ZX'"Q2I0.U+&UK+.'Y?
MH2`Q[WJ=<K#>8LJ<5;$<R+X;3>JOHO1<_[TM-S@Z>LIL/3)QUE87SWI4>AU1
M$CAO'K^+(ECS-9&^>!+JC\IGL^QQF1/Z3?0JO<-R7CE+O4)^?.41!^_#`AU"
MYG#405VDZ>P]SUR-[ZA(11.V?:]$4%@EZA^3Y#P4+;5[@RX2VF9U=!'[,;AS
M.C_62\T)=4J$#4'NK!!L:_`6XGPYS$RN#A;N,V*$`[*>0A*3QQD0PV?.QGK$
M"Q<1;=*:'%8%O>I/`VKXW5\87D4\JX=:K&#4)30TJA'EP>J/0E^$U)^L\WNW
MJYJ>=@Q7;AOT_CB93!_]CP````#__P,`4$L#!!0`!@`(````(0`M8=U=N@L`
M`#1F```-````>&PO<W1Y;&5S+GAM;-Q=;8_BR!'^'BG_P?(F44[*#&#,`'/#
MG!9FG*RTF9QN)TJD7!09,#.^\0MGF]V9B_+?4]5^J\88VKBA-SET.V#HJJ>>
MJJZN?L'<?/?J>]IG)XK=,)CHO<NNKCG!(ERZP=-$_^NC=3'2M3BQ@Z7MA8$S
MT=^<6/_N]M>_NHF3-\_Y].PXB08B@GBB/R?)^KK3B1?/CF_'E^':">"=51CY
M=@(OHZ=.O(X<>QEC(]_K&-WN5<>WW4!/)5S["Q$AOAV];-87B]!?VXD[=STW
M>6.R=,U?7']X"L+(GGL`];5GVHM<-GM1$>^[BRB,PU5R">(ZX6KE+IPJRG%G
MW`%)MS?!QK?\)-86X29()KI17-+2=SXL)_J5KJ4FS\(E@/C=SYLP^?8WZ9]W
M?WCWKONO;[[]QP_.\I\__K[ZWH_?Z)U<#9$)/M@O\[*[5RR\G4KN9!;<WJS"
M@!AB`$W(UO5+$'X)+'P/@@',PX_=WL2_:)]M#Z[T$-XB],)(2\#+8!^[$MB^
MDWYB9GON/'+Q8RO;=[VW]+*!%UA@9)_S77`37NRD&LZK9XYH<IM&"(.SJ8]7
MJ$T^F&3CQ?TVV3_ML(G3-3BLJPU_G"YFQ7Z[I.FJQD6%PS:Z"E\1/='3?*);
M%N207K>+M%*'G4C9>-8%?6=3=C4XFV5]JV\-I5K&Q6+5;ZBP;\FD\H!"Z_WP
M[FQTRE=69UV6AL_5`[##R671A:Z[IW\/+7R<(T[./*"=QF-,*I?T6=>3E1NY
M*#RQKB(H#NIY='TGUAZ<+]H/H6\'&"QTH&8,<'4&U+O)>\]]"M+J)-ZLH0!>
M1.XZP;:%8I*UY`8'`Q,#2M?SBFJR/\!Z"Z[<WD!AFSA18,$++7O^^+:&:BN`
M&APA=M+/'?CT4V2_]0Q6<X@UB$//72**IQFK\;(Q=G9U;\WNF5Z"3!1%C5#+
MF@U/(/1^.I[)1SH;CV4+-2QX2!;Z?H`/R4(M^&\FC=.L(YFR0!;RM,3%.5GW
M<C@>CT>]J]%H-#;[/=-D),^SB':#I?/JX#1-&DU5!`-`,.Z/QE<&`.F:(Z;J
MK`CZ`&`X&(P&O;%APO\LDYT>@6Q.![IJKQ($BKQ*$"CR*IL6="1D_JRGP`J)
MXKY*$"CR*D&@R*M#R1EXJ-RK!($BKQ($BKS*%K,D]E58>53<5PD"15XE"!1Y
M55KQF67@L7*O$@2*O$H0G-NK^;1J=G]OL:6-:F4FK3[.=&$1WUP7FS7"/'4>
M1DN8(>?['KT^S!'3:[<WGK-*8$8:N4_/^#<)U_#O/$P2V%"YO5FZ]E,8V!X\
M[>0M\K][6L*6$^PN3?3DV5V\@#)N12/E)E5Q*@U%UC-Q-F$.S>[0'!A7Z81-
MDFK?6;H;OVI=H7MG7`*-R.UAPPF'0:$D"X=R5:V#7LC<)]B"N9IY6K`!Q$0>
M$H(M9-A8KC"+VDA:B-E(&@C:2%J(V@A=9U?GRIE<AAO8[=QVL&6-NMUTX4M4
MSWZ!!/B.B-D-@K2I\GFPR0Y&#[9I:BODETK?F!KX8-7Q#DL/M*C:>:#!#BL/
MM!"UD8^;W+N<\&+I`M/S#B1;?',?/PX&*$H;$CPDPV?I"?<8TET&X6Q7:^U>
MZ<1F$-!RL-IBJYDMV>@(@^W"\;Q/./S]?56,N+"(=7OSNB)'`N"<!NZ9XXD#
M?`HKQ=G3='1-7X!-=8U@Q[^FD6:OU][;P\:?.Y'%#F\P%>RJ!7K*5U-6%I2O
MV9*Z[[!E.#T5\WT4)LXB88=+V#I^'9Y^#9Y>)D@$3QO]9HU^X$F8CS;Z89EG
MIS^`%Z7Z(;B$]<N,!SQ&DP4UN(`&]3X\,A'`9#Y'`$Y0@0"/_60<0'BJ0`"3
MI!P!!&B)`.#LB8HV_:!'LAG$0*D2])]*)>28W$I.Y0FMK$N_H'^/E1:7?EO1
M3/(M!'I),[S8`Z"5RKH4JRK%$+=#3RLI@!=[*+!@U)4SY/7J<KXR0DC2!0PE
M(Y`&]C$B+RI)S@6=)8#]C$PEUB$D*#`5J88`<)1`(([H*1I_>Q2#HA&81H.B
M(9A"X,;@,_8)Z@ENA%2$`?`HZ15EG=#C1HPSTD`@J,J0)!H,52F28E"5(TM7
M&*I2)(&@*D-23ZA*D12#JAQ)7*$J11((P(B2#$D]H2I%4@RJ<F3IBKZJ%$D@
MJ,J0Q!/]$Z?(#ETV31=1R?KI%7Z7J6[I$1R43_^W??6Z.KB0VJN;-(&LO'DZ
M>TIGCN`+-I<B4VD$9^-Q9%P[U9[#R/T%)IGXA:L%7'`B';^@E[@+>N5+9*\?
MG5>8BJ:[/*^K+0/9[#);(1;'R"^SYEC/BQS]<7!I>XO;6C9+YF"M7]<.TD:4
MB[,FR$\++`@K6PJ$IUQJYX.LEHB#EM.`$5:W.UZ.!X'+4DU]+QO#*4-`4N?&
MG*.:)AC>E6.@KD(\0EU$L+<>[#!$N7!_J>T9-#!PV[E9JJK3CTM8?'Z89FME
M>6H7`I0/0T=2TM^>F_"0TE7M1H!:,20?#MOU%_#8[NQV`,_N]'8$::(H=\=U
M?WMRI]B)TN&(TE/CQ/UXOA(G@FO+VN'K2`X<I$JZ$DI/K;(!IQ]N<"`C7\H#
M)$[(D;F9,U]<6XM2%I=.E0W4/5@04*=<MN6T:!!-7^#CO&R3[@F*1T4?H/I_
MVL2)NWH3&)7/Q<A1B!!<5M4>J!..J`C:UG7[QSQ!0$<F+KX>J8YEO';ALO?K
M0D,#^H@.3H.'\Y4TNBC`5CV>#V[<<]Y77PJ[\PA\-?4=-X>IXA,I\(Y"W=+M
M/&P("%6TDBQ+P_+T^$0)%/)[A<#_";]74//)L;;(/C(9@KIREE'17:NMTE?A
M^'*GLJX-\O+Z!9^>;&QDV:P)`B[!5JP69+P-!Z"S+>TM"P(.08NYU)%QQY<$
M,EP@DX\*'O&.0/9_&N]B@-J\DW#N.0Y.EDQ;3/_DXBEJZO\K1">=F$FF;*MP
MJX05G_B$2R`I*:!:IAV)II*6#V\DUI03W"A1Q?>UEA,'8$N@5;1,P_R1;7WA
MZ3.QW"9KRP?G3;EV8>6[?5J;_9M$/MS8Y]P,X*'UC'_Q#?+=%`AZA7:^?$`N
MTWU^91=M[%`('`,A7ZKCOU)7'!K1\`YY<$??[F^U"^W]`H462\&X9CC?N![<
M"`-/@^"!G@4L+H7^-+V8'<'8)ZN8SAHXWR&RH%\UE042TCF<@8>\B"Q876PJ
M"]2GLOI@+9$%WS=L+`L"(Y.%1_!*7"9L5C?%!4TR63SW`T'NS5U^9(=52UQH
ML@@N*JOT(R9$(@M,;BJK]",XCLH"DYO**OT("(DL$Y0TE57Z$;Q`94&X-955
M^-$$QQ%9`T'NKW;ZD8]5/%DF@HO**OW(QVI?,%:IK-*/?*RBR4UQE7X$J80O
M$]YH*JOT(Y\G3,$\06TL_<AS/Q#D?CNC\A%O"$9\*J7T'3PC'&$A*L)1*J7T
M&A_E?<$H3Z64_N+CVQ2,[U1*Z2F01RPRX0UQBPH?]7EV34%VI_8RS[I\P.`X
M(P(#[OV^V'AP3_X0[^C/3D[B&@`Q",_)"TEZ=A8OV@R^"%\(XOL##J,B@NY?
MUYX=V$D8O6EX6K(0QSM]("CNCV%8<,1+,."E"*`_P>\?P$\K:,!+RA`?PUA1
M-1%3]`6>'OSJ5!,QT#I%P\<?3D.;B('6J1@^J6+])"+F0[#>%![B<RD.W2(B
M/KK!B[/D(X=GV`"0(I(>G$T2V47\\5W*$"3F`6^?4,C@4T1Z5^/\7@]9_?D`
M=TO(2<3SF*3OX-1#!/A?-@FA$5L1(3A?$!'RZ"9P3YF\$W,B$):0B!!.,!<B
MMC**H(R_V5&`O87KNELQ6F-1>1X<JO_E:WDK#<9[@K\0PFZR4<P'@*BEL[(W
M7O)8O#G1R^=_9G=K@F#*/O6]^SE,F(B)7C[_B+?!@EX,"\>0;C[&<&LE^*MM
M(G>B__M^.AS?W5O&Q:@['5V8?6=P,1Y,[RX&YFQZ=V>-NT9W]A^@#'].Y1I^
MCZ/%SY6PGU6!$^$]\SKVX$=-HLS8#/RG\MI$)R]2^.S>-P`;EM]S(SIQ\7,O
MM_\%``#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE
M;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYI
MF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&
M&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'
M8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP
M@E<15,8"'P'=B%76JM5F)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!
M)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U
M8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL
M19KU_D:MD]$L@.SC,NUNM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[
MS<$;D,4WEO#USG:WVW3P!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LM
MA6\`?*.:PA<HB(8\NC2+"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-
M`&\27)BQ0[Y<&M*\D/0%353;^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SH
MT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@A
MT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!3
M9P4.@78)Z9X*'>"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=
M+DH-<$/S*EAX.(N#<N9B5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<
MD)@HI.?XE)`2[>Y1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV
M;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<
M3RKP=$`81[TQD;)LS6T!^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\11
M4H8=T#@L8C^04PA1C/:Y*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9
MB1)?7B?<B=_!G$TP,54&2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%
M^P^6Z!T\B_<)9,7R%O6N0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/
M*&,#-6?DIC2]MX0-:-R'0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`
MWU[S-)%`IJ0#B1(NX;QHADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC
M56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;
M$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2
M(EH/&PSZ['B*U0K<6IKL&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.+"XF)XO1
M4=MK-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP
M^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+-2<K_UH#S'I1"I14H[-)L;X!P?"O20%V
M=%U+)A/BJZ*S"R/:=O8U+:5\IH@8A.,C-&(S<8#!_3I409\QE7#C82J"?H'K
M.6UM,^46YS3IBI=B!F?',4M"G)9;G:)9)ENX*4BY#.:M(![H5BJ[4>[\JIB4
MOR!5BF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\
M,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4
MD(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63Y
MWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!
M*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:
MBN#[A28&80-1?<DV'D@72#LX@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L
M+/X^I['SYLQEY^3B11H[M;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T
M#GPVF#$E33#!IRJ!H8<>F#R`Y+<<S=*MOP```/__`P!02P,$%``&``@````A
M`-9,K2R/!```21,``!D```!X;"]W;W)K<VAE971S+W-H965T,S4N>&ULE)C;
MCJLV%(;O*_4=$/>;0P+DH"1;0SAT2ZU457NWUX0X"1K`$2:3F;?O,@:"3<9F
M<@'!?/QX_5XVMC??WXM<>T,5R7"YU6W#TC54IOB8E>>M_NMG]&VI:Z1.RF.2
MXQ)M]0]$].^[WW_;W''U2BX(U1HHE&2K7^KZNC9-DEY0D1`#7U$)=TZX*I(:
M+JNS2:X52H[-0T5NSBS+,XLD*W6FL*ZF:.#3*4M1@--;@<J:B50H3VJH/[ED
M5]*I%>D4N2*I7F_7;RDNKB!QR/*L_FA$=:U(US_.):Z20PYQO]M.DG;:S<5(
MOLC2"A-\J@V0,UE%QS&OS)4)2KO-,8,(J.U:A4Y;_<5>Q_9<-W>;QJ!_,W0G
M@_\:N>![7&7'/[,2@=O03K0%#AB_4O3'D1;!P^;HZ:AI@;\K[8A.R2VO_\'W
M/U!VOM30W"Y$1`-;'S\"1%)P%&2,F4N54IQ#!>"H%1E-#7`D>6_.]^Q87[;Z
MW#/<A36W`=<.B-111B5U+;V1&A?_,<ANI9C(K!5QH/;M?==P9NYB^145>%]3
M%3AW*BMCZ;J.MUQ,KXO7JL#YH?+5@!:M")P[D:5A.Y:G-L5D!C?M%21ULMM4
M^*Y!)P`+R36A7<I>@V[74,S6OND^:SEH,BKR0E6V.O1>:!0"Z?:V\ZSYQGR#
M%$E;QF<,''MF[LUX9O^,$72",6/S*B$CAK69>X)*U#$T]V@(\:#`!&]Z@R"+
MA@8]S^#.!PI3'SI5GQ5X5N.)8R\60EWWW1,/5SS+X>,)GC$NSX2,@2!Z=T<Z
MT00F'C/.?-&_BW-F_A5G*,PYPPK`F<ZKO8@$8D'("H9!.BO!K.@9(Y@5/V$\
M[WF0,'A,;WX*;W4X#AKAH=ODF<\8&#EZ1HA@KR0")1$JB4A)Q#*"2P0(9KI'
M%(;A?!"_NQ0]8HS,(T8LFF[E6O#K6Z]Q.5`JA$HB4A*QC.`<@F%_ND,4YAWR
MK$<79%G$&'C_IUG$".:01QT2+5)*A$HB4A*QC.`L@H_/T"+Z(9K#O$,^WM*'
M1*N6?"KXC)%9I20")1$RPF8#O6T;*V',B41@(21]+'L'YQ2=)`\^V7*'*"PZ
MM!(<8HS,H3'A.H+/P9@1!K90241*(GY"V(]X.)]6O$_3,HH^)/AE"SW'9XS,
MKS'ABA^J8,R(?BF)2$G$,H)S"U+W"VG5T*)/PMS&;R&946HDZ!$ZK82QGD_>
ML+_]Z5`8J9%8BO`^T8GBH/M-2RN;32^'GSW/%F:_?@M)_6(Z$B1H55;M-'QL
MF%(B4E<DEB*\871*.3!,/E[9;`+*&R5,WOT68B'.Z?>?3XI]"TAM8B^2(*%:
M)5(CL13AG:+STNE.45KL@L(0XL,BGT(>6W_,/$>P<M\"$AL"-1*JD4B-T!T)
M6MGG=6%.L1T'MH(M4'5&>Y3G1$OQC>XFN!!F7]KO=+PT&QU">4AW0.C:0RCW
M9VO_&;^?K6&!,N:#V1K6*5!N]D*PD7%-SNBOI#IG)=%R=(*J60;=+:C85@B[
MJ/&U67\?<`U;&,W?"VQ9(5B-6@;`)XSK[H*^H-\$V_T/``#__P,`4$L#!!0`
M!@`(````(0`=%M&E&18``*2@```9````>&PO=V]R:W-H965T<R]S:&5E=#,T
M+GAM;*S=6W/:2+<&X/M=M?^#R_>?;7$PATKR5;".@$"`A*1+CT,2U\0F99PY
M_/O=C=0-O9:D5Z3V7"295P^+4R])H';[PW__>?EQ]=?N[?"\?_UX;=W<75_M
M7I_V7YY?OWV\3F+W/\/KJ\/[X^N7QQ_[U]W'ZW]WA^O_?OK?__GP]_[MS\/W
MW>[]2E1X/7R\_O[^_G-\>WMX^KY[>3S<['_N7L66K_NWE\=W\;]OWVX//]]V
MCU^.-WKY<=NYN[N_?7E\?KTN*HS?VM38?_WZ_+2S]T^_7G:O[T61M]V/QW?Q
M^`_?GW\>5+67IS;E7A[?_OSU\S]/^Y>?HL0?SS^>W_\]%KV^>GD:!]]>]V^/
M?_P0S_L?J_?XI&H?_X>5?WE^>ML?]E_?;T2YV^*!\N<\NAW=BDJ?/GQY%L]`
MONQ7;[NO'Z\_6^.\U[^^_?3A^`)MGW=_'\[^?77XOO_;>WO^,G]^W8E76[Q/
M\AWX8[__4]+@BXS$C6_9K=WC.Q"]77W9?7W\]>-]O?_;WSU_^_XNWNZ^>$;R
MB8V__&OO#D_B%15E;CK'A_&T_R$>@/CSZN59#@WQBCS^\_&Z(^[X^<O[]X_7
MW?N;_N"N:PE^]<?N\.X^RY+75T^_#N_[E[1`EGQ0NDBW+"+^+HM8=S=6[^[^
M@AJ]LH;XNZS1N?AQB$=\?#+B;_4X+B]R7Q81?Y^*#/O]WOUP(`HWO`R#\I;B
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MYFT"=9L3(8]MJH2J.J/!G`8A#19%(/[4#Z1+'_U2W>ADR".)E%"/9*6"TTVZ
M]UWS":Z543?:J.!T(W(_L1+J)DD1B#]/#Y_>SY8;4C;E@CW:K##G0XY4R940
M#^Y6#'<]YD4W&V.^^I1`#6VIY=!63W&B@M-3[-.Q\L`-&>FV$JJLHX*SL@/S
M#7(YZ?1,XBFBROHJ.)4ECR0HA'BQ]%M&Q!2*&11S*$(H%A6"//]E!3%?H0B*
M%1>]+GDKUBW,AAORPL9<],D=)9RP![/EAMQ1R@6KDG%#JN1<G#U<H\7$H<YH
M,7E8Z8IC<7.KR5L9K4:#!QK8-'!HX-+`HX%/@Z`(SCNB.[HSA]&4F_[9BW$\
M-,U:F'D+$U89<D1;5)F1^9B7%>:>/*^HRI`=ZZK*D+&RYJ9W3XZHFQ8F;F$2
M;KKWY.QCV\*D+4S&3?^>[(3R9F,TBCBI,QJEN4&D-AJ$!@\TL&G@T,"E@4<#
MGP9!$12?=>5)V)0&,Q6<#BJ]$7E+YE6&O)2A,NIXMJ#!D@81#58T6--@0X.8
M!@D-MC1(57!ZQGUZYI,IHYY-?A88PT*<B5\P+*0VA@4-'FA@T\"A@4L#CP8^
M#8(B.!L6-)C18$Z#D`8+&BQI$-%@18,U#38TB&F0T&!+@U0%IS><'24R9?0;
M?A88;[CXW'S!&R[UQVLQ>/0I6Y_N\":%$?>G#>FM!RAL)=3#=U106]2%PE-"
M%?554%LT@&(*Q0R*.10A%`LHEE!$4*R@6$.Q@2*&(H%B"T4*109%WB2,-A-?
M*UW09E*+\]:S%NK3<YA)89K:#`I;"=41C@IJ.\*%PE-"%?554%LT@&(*Q0R*
M.10A%`LHEE!$4*P*,3I^G]7MWLG_S#/J-:RQ@2*&(H%B"T4*109%WB2,-A/?
MRES09E+3-B,?@R>%:6HS*&PE5$<X*JCM"!<*3PE5U%=!;=$`BBD4,RCF4(10
M+*!80A%!L2K$H&BS49]W&2RQ@2*&(H%B"T4*109%WB2,+A,7M"[H,JEIEY$O
M$2:%:>HR*&PE5$,X*JAM"!<*3PE5U%=!;=$`BBD4,RCF4(10+*!80A%!L2I$
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MU`,FMB:J.1R=U#:'BXFGB:KKZZ2V;H#)%),9)G-,0DP6F"PQB3!98;(N27$L
MLKJ#49]<0-S@(C$F"29;3%),,DSR1F+VG[R">-Y_\OJYF"T+KI_+*87T,]Z`
MO*Z3$C7V85&G@=BZBNH71R>U_>)BXFFBZOHZJ:T;8#*M(%WRZ7=68<@EDSDF
M(28+3):81)BL,%F7I&C$>_FYD)PM;7"1&),$DRTF:4F*1RMFU+-'F^$B>2,Q
M^U!>GSWO0W#R65S.-8^#9);=1,[71<=!2&Q=1?6)HY/:/G$Q\311=7V=U-8-
M,)EB,L-DCDF(R0*3)281)BM,UIAL*DB_1_9=<04B^ZX$DRTF*289)GDC,5M0
M'(4N:4')R?<O`_)*3.2D=]2"BASG,M_0R<RV+J'ZQ-%);9^XF'B:J+J^3JH?
M2:"WU][O%),9)G-,0DP6F"PQB3!98;+&9(-)C$F"R1:35!,Y$L@'U4QOK!T&
M>2,QFTY>4#\_[K6;ORE_^H,U'YGU-2F1Z*_:B2F*#(^7A*R;;L?Y#SF-M941
M7^2>ZM`/$8Y2Y\B\A.LJHNZL<S\R_F-W[:E;--ZUKU3]70>83#&983+'),1D
M@<D2DPB3%29K3#:8Q)@DF&PQ2151@^S^>`7F>/XJ_[#8(,O4+>J'3]Y(S'Z6
M5^Y_HY^+"_[F^2SY^FHB?U0+'4Q+4CS[NYL!^6[(5C7,CB)GSHY2]2^)JXB^
M)U+#4Z#QGGREZN\IP&2JB'HPP\&@^(!5ON]DSSA3OOY>YYB$F"PP66(28;+"
M9(W)!I,8DP23+2:I(OH])2?BF0+U;V+>2,R^E7,!?J-OBRD$9M_2&356TSR#
MX\\O/%00^J6)K8S94&1H.TK5ORIN!:%WYBG3>&>^4O5W%F`R5:1\I\VSAIG:
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MCU(>93S*C<@<*^)$AHT5O!J/7`Y.O.7GN^#^D'RQ.RE1PZG2`R:V)FIWZ^BD
M=F_K8N)IHNKZ.JFM&Y2DG!$W'`W(%:\IKC'#9(Y)B,D"DV5)BN=3-=4VPD56
MF*PQV6`28Y)@LL4D+4GMVYSA&GDC,7N0SJ@`N^F*F11#,@XGG0(U]AXDMJZB
M>L3126V/N)AXFJBZODYJZP:83#&983+')"Q)V3?#.^N.'!07AI`+`]-/DDM\
M-Y%1Q*KX.+K"1=:8;#"),4DPV6*28I)ADC<2L_NJYC]8=Z)S0!M63(`8T@NI
M'3P!`A-;$]4NCDYJV\7%Q--$U?5U4ELWP&2*R0R3.28A)HL*TF>+IE8@TL\1
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MU'0@+$GQ7#I#\5M)R.F0K8NH?G%T4ML,KE%VU!,_HV?N`#Q=0U7U=5);-<!D
MBLD,DSDF(28+3):81)BL,%ECLBE)N1L<CKID),2ZAOS)$_*&)GIC[=NWQ23%
M)"M)V7T]\?F-GN3GNHKY0,V^HS,0F@]\W6*6@?$UZ(A>52Y18[_QV0KD9;9U
M%=4:CDYJ7UL7$T\35=?726W=`)-I!6$_F3BK0.1YSS$),5E@LL0DPF2%R1J3
M#28Q)@DF6TQ23#),\D9BMB"=V-'NY\NZ%1,\1O3J<HD:6[&HTT!L746UC*.3
MVI9Q,?$T475]G=36#3"95I#^B/39K`(1,L<DQ&2!R1*3"),5)FM,-IC$F"28
M;#%),<DPR1N)V8IR,L;YA61P-)2<GGW2BX+=`C7TUP,FMB:J51R=U+:*BXFG
MB:KKZZ2V;H#)M"3EZ<F@XIO\&:XRQR3$9(')$I,(DQ4F:TPVF,28))AL,4DQ
MR3#)&XG9@'(:Q04-6,RZ,$]'Z97!;H$:&Q`26U=1C>+HI+917$P\351=7R>U
M=0-,IIC,%"E^)$C\^L;AL4W5'_SG<.?F+3HW=P/VL[JA,O63U1:8+#&),%EA
MLL9D@TF,28+)%I,4DPR3O)&8#2G:YI*&E)P>$<DUA4FW0(T-"8FMJZC&<712
MVS@N)IXFJJZOD]JZ`2933&:8S#$),5E@LL0DPF2%R1J334G*;^=&HR&=>17C
M(@DF6TQ23#),\D9B]M]E4V6Z%5-E1N1;V4F)&ONOJ%.^XN)7.G:Z/7)<M749
MU2B.3FH;Q2U)6;@G?E-/KT?V#YXNHPK[YJTJ'TZ@;U5[YU-,9IC,,0DQ66"R
MQ"3"9(7)&I,-)C$F"2;;DJB1UQ6_:L3\SCS%13),\D9BMF#5?!GYW2KX<%@Q
M769$K]%W\7093&Q-5,,X.JEM!A<33Q-5U]=);=T`DRDF,TSFF(28+#!98A)A
MLL)DC<D&DQB3!)-M2<H^[`[NR-!-<8T,D[R1F&U(I\J`]N-39,1Z,^:N9-(M
M4..1$!);5U%MXNBDMDU<3#Q-5%U?)[5U`TRF)2G?VI'%9FK.<)$Y)J%Q/U;5
MG%%#5,X9Q7<3&44JYXSB(FM,-IC$F"28;#%),<DPR1N)V7R7S8_I\ODQ]W?L
MLCR>'U/6:>A/6Q/5)(Y.:IO$Q<331-7U=5);-\!D6A+Q,]['J[(W`W)V/C-!
MGZVV.3?!\(:N'1'B1['`9(E)A,D*DS4F&TQB3!),MIBDF&28Y(W$:+T>G1G3
M?-P[<O,;&'95L#0-;?50DN+W0/0['7+DM'4)U1Z.3D[M09>L<BL,N>;F::(*
M^V52/!1KV!F0BYR!OLGIGDG5J5&#/YT9+C''),1D@<D2DPB3%29K3#:8Q)@D
MF&PQ23'),,D;B=EXETV-Z?&I,?=W=&I,B1H[#T^-T554CS@ZJ6T!%Q-/$U77
MUTEMW0"3:4F*$T[+NJ<+2,]PC3DF(28+3):81)BL,%ECLL$DQB3!9(M)BDF&
M2=Y(S/:CTV+`<:^8QG+V,]F3'HL>>&3SR.&1RR./1SZ/`AY->33CT9Q'(8\6
M/%KR*.+1BD=K'FUX%/,HX=&61RF/,A[E1F0."#HY0\Z3DLMX/_TZO.]?_-WS
MMV."OICK\5D;/;I6]J1$\N?(]9H;'8O,[7@X*;7'M'GD\,CED<<CGT<!CZ8\
MFO%HSJ.01PL>+7D4\6C%HS6/-CR*>93P:,NCE$<9CW(C,H>3O.9_/M7@=X=3
M,7?@?`Y"KT].42>]`I'A1"Y\/)S4:3CI&ZK(X<KED<<CGT<!CZ8\FO%HSJ.0
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M_?`M8A6LL5SOAV\1:U^-Y;(_?,MGL>5SY1:QZMA8+G3$;R/6&AO;E5O$DF-C
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M\_ON\<ON36J!O^[W[^I_Q`"X_7O_]N?Q./CI_P0```#__P,`4$L#!!0`!@`(
M````(0"GL%+(?0,``*X+```8````>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME)9M;YLP$,??3]IW0+PO8/+41"%5H>I6:9.F/;YVP`2K@)GM-.VWWQD38IRF
MHV\2P'_?_7SGLV]]\UR5SA/A@K(Z<I$7N`ZI4Y;1>A>YOW[>7UV[CI"XSG#)
M:A*Y+T2X-YN/']8'QA]%08ATP$(M(K>0LEGYOD@+4F'AL8;4,)(S7F$)KWSG
MBX83G+63JM(/@V#N5YC6KK:PXF-LL#RG*;ECZ;XBM=1&."FQ!'Y1T$8<K57I
M&',5YH_[YBIE50,FMK2D\J4UZCI5NGK8U8SC;0GK?D93G!YMMR]GYBN:<B98
M+CTPYVO0\S4O_:4/EC;KC,(*5-@=3O+(O46K!$U<?[-N`_2;DH,PGAU1L,,G
M3K,OM"80;<B3Q-L?I"2I)!EDSG541K:,/:JI#_`I`">B%2@GXN_1S6VHO/B]
M&_/YZ/*^3=LW[F0DQ_M2?F>'SX3N"@F>9A`&%8U5]G)'1`II`%]>.%-64U:"
M"?AU*JKV$X01/VLZFLDB<B=S;[8()@CDSI8(>4^52==)]T*RZH\6H<Z4-A)V
M1N#_H,?#Y>C)DVXR_'>34>"A:3#_/X"O%]/&Z0Y+O%ES=G!@EP*N:+#:\V@%
M=E\/!D1!:6^5.'*ABF"=`C+RM`G6_A/$/.T4L5;`;Z]`0T5R5*BT`4,/`A$9
M#Z+$"D1E29'%^H/I-[3\:D784D_18G[=CP\P(`8FAMHD$]B?;\=%38K<J;'J
M26]=\VD%[),^+M.A(GE+,2`$-R;AVV1*#"LP_,Z&?F.M,,GF0T5RKCBQ#\C`
MR'@R)1Z2+89^8ZTPR4XY:Z.:G"LND,W?0Z;$0[*E1:85)AFR"B$YEUQ`6[P'
M38F':,BJKUA+!FQV*9Q++K"I^W+TX:#$%IM=!5HR8#MYUBD]EYP4@\T&Q^9X
M-B6VV.PZT)+Y\7P(K9PG>MQDOP"&X+@83]:J+32K`.-.8_I&5K$DKV@N\:D3
M>'16D3ZOS1,$6648=YH!GQV^5S27^-YU$R!]KIM\H56+<:<Q^4*K;))7-)?X
MU$EMQ&_<%0'MD+T%0ZLNXTYC<IX8='ETDD6[3</9;!Y>3T_;11>([H;T+5\1
MOB,)*4OAI&RONAL$4_NO?;O6]5']`#0^#=Z1KYCO:"V<DN0P-?`6P,9UZZ1?
M)&O:'F++)+0\[6,!?3&!.SGP0)PS)H\OZL;O.^W-/P```/__`P!02P,$%``&
M``@````A`)N3)%&M`@``4`<``!D```!X;"]W;W)K<VAE971S+W-H965T,C,N
M>&ULG%5=;YLP%'V?M/]@^;T80LB70JIF5;=*FS1-^WAVC`$K&"/;:=I_OVN<
MN$G:=6QY('P<GWO.N>:RO'Z4#7K@V@C5YCB)8HQXRU0AVBK'/[[?7<TP,I:V
M!6U4RW/\Q`V^7KU_M]PKO34UYQ8!0VMR7%O;+0@QK.:2FDAUO(4GI=*26KC4
M%3&=YK3H%\F&C.)X0B05+?8,"SV$0Y6E8/Q6L9WDK?4DFC?4@GY3B\X<V20;
M0B>IWNZZ*Z9D!Q0;T0C[U)-B)-GBOFJ5IIL&?#\F8\J.W/W%"WHIF%9&E38"
M.N*%OO0\)W,"3*ME(<"!BQUI7N;X)EFL9YBLEGT^/P7?FY-S9&JU_ZA%\5FT
M',*&-KD&;)3:.NA]X6[!8O)B]5W?@*\:%;RDN\9^4_M/7%2UA6YG8,CY6A1/
MM]PP"!1HHE'FF)AJ0``<D11N9T`@]+'_WXO"UCE.)U$VC=,$X&C#C;T3CA(C
MMC-6R5\>E!RH/,GH0`+_!Y(DB\:C;#H;P$*\HM[@+;5TM=1JCV#30$W34;<%
MDP4P.V<IY.-U!*]_L@H>'<F-8\DQ['98;J`]#ZMT-EJ2!\B4'3!KCX%CP"0!
M04!-D`0R3B6]'O*QL@.[RBYT)V7M;YR6>19R5B;]ES(.#,F<B$]G:9#O*WL,
M-#08'`?$6>7Q>>5CYF\;=8MR#,?`GLZ>^;T"CQF@`"##(W;@2^]9<.8K>\R\
M;_TTB^$7`&?6)^>%AUEWBRX%3`*_%^`Q`ZQ/_T>!6_2W\#UF@`+W43AYY=YN
MNP-?>K\,WV-\^,FKZ?O)YE]\R77%/_"F,8BIG9M:";0MW`T#]6;4S\3P``9:
M1RO^A>I*M`8UO(2E<30%Q]J/1']A5=>/E8VR,,KZTQJ^7!Q>SC@"<*F4/5ZX
MH1N^A:O?````__\#`%!+`P04``8`"````"$`]B$(Q1<#``#Y"@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R,2YX;6R4EEUOFS`4AN\G[3\@[LMG@21*4K6I
MNE7:I&G:Q[4#)E@%C&RG:?_]CC%)L9.9]J:$]O&;]YS7/?;RYJ6IG6?,.*'M
MR@V]P'5PF]."M+N5^_O7P]7,=;A`;8%JVN*5^XJY>[/^_&EYH.R)5Q@+!Q1:
MOG(K(;J%[_.\P@WB'NUP"W\I*6N0@%>V\WG',"KZ14WM1T&0^@TBK:L4%NP]
M&K0L28[O:;YO<"N4",,U$N"?5Z3C1[4F?X]<@]C3OKO*:=.!Q);41+SVHJ[3
MY(O'74L9VM90]TMXC?*C=O]R)M^0G%%.2^&!G*^,GM<\]^<^**V7!8$*9-L=
MALN5>QLN-F'D^NMEWZ`_!!_XZ+/#*WKXPDCQC;08N@TYR02VE#Y)]+&0OX+%
M_MGJASZ!'\PI<(GVM?A)#U\QV54"XDZ@(EG8HGB]QSR'CH*,%R52*:<U&("?
M3D/DUH".H)?^>2"%J%9NG'I)%L0AX,X6<_%`I*3KY'LN:/-70>$@I42B002>
M@T@8?5@D'D3@^282S9(P2:>M^*JLODOW2*#UDM&#`UL/C/,.R8T<+D!9MN?Z
MO^V!OL@UMW)1OQ1H#ID^K^,D6?K/D$,^,'?G3*03FPO$]0GQP=_))/3--!G#
M3KB<X=&D7`3%N,[(9'K2[PNY4PS4>V+>'/3$QD9H'J%Y8X]V;Q*&G33ZWCC)
M#&^*F??M#>=A-,O24$<V8R3-@BP:I:"9@RZ\WYR$37,S_9OO%&-KG(W0O('(
MV)O<@=/ARD53X2K&YM%&:!Y3W:,]7`F;_3/#5<S86VRT>&-%-'?91]Q)V'0W
M-])5S-B=^6]A(S1O\APUYLMTNG+15+J*L7FT$9K'N>[1GJZ$S?Z9Z2IF[.TL
M72NBN0MATHU;:+?7TX:_-##R':"Q03-@*Z+[NW"$3$<<JND/4^(T>N/$',\#
M9/6I="XCND_C%)GHHQK\]A$-%Q>Y&:PS6F,N#VEU>5''<H=V^#MB.])RI\8E
M-"?P,JB.J:N+>A&TZX_?+15PY>@_5G#%Q'`V!Q[`):7B^"(O1Z=+Z_H?````
M__\#`%!+`P04``8`"````"$`1T;F^:\(``#\)P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6RL6EMOXDH2?C_2_@?D]PGX`DE0R"BX[=TCG956J]ES
MG@DXP1K`"#N3F7]_JOKBKNKR!!CM/`SA<U7W5Y?NKXW]\/G[?C?Z5IW:NCDL
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M1^VV>?_GJ=[\41\JR#;4"2OPW#1?T?3W#4+@/!;>I:[`?TZC3?6R>MMU_VW>
M_U75K]L.RCV%B#"P^>:'JMHU9!2&N4FF.-*ZV0$!^'^TK[$U(".K[XLH@8GK
M3;==1.GL9GH[26,P'SU7;5?6.&0T6K^U7;/_RQC%=B@S2&H'@4\WB!_C`[_,
M^L&G\[MX\K$)1.=%K;K5X\.I>1]!LP'5]KC"UHWGLVCD$F)H]"GZ688@-3C(
M$XZRB&"50/`ME/7;8Y+,'L;?H!1K:[.4-C&WR)T%YAV'52%0A$!)@#%$U(<%
M!?H_A(6C8%B.T-(!),X@!F?A7%0(%"%0$H#%`/T1QI!"QP_WJJL$.BTB:!%2
MB5O.<6EL$OCHC3)NDO<F?1P"*0124H2%`GS"4'#97=EE.`JL/1Y<V&;6"*C\
M-+C>I`].((5`2HJPX"`0&MS']4%C'8.;>VD1^.@))\E=4(_>R+DI@10"*2G"
M*,-*OYPR&G/*%C$[)*[47"!*((5`2HHP?K?7\$-CSL\B?#^Z#U+:&_4I%4@A
MD)(BC#(>$<A&^G$7H#&G;!&_U^0"40(I!%)2A/&[OX8?&G-^%B'\!*($4@BD
MI`CC%\/61A.(2I3>H0Q?NTWHD3A[!\%@?I&EDZ`CO%7?$A(J)%0RB$>%`G5Q
M6\1&SF"'<P26#B)K34)*0H6$2@9QFJA!A*8^!MR=%9O82!?C:R!SB-,JGELK
M@&CR`_%7UHKNVTF:]!7B=%%H"-V/%UML98EFU4(TJP)2SM%;%1(J&<1IHF00
MFIC59'KS"QUMM8=&8"'>T6F?+YOZWLHUE(H%5$BH9!`/"F8,@XJG-[=(9%NO
MORX;B!+Z>*`F*9P,[7D1!PF6J(&P#?HE&D\#=<_QU`".8.4#LF-!MQ+'X,Q3
M6,=$WQ]H$B4;B\>(PA04CL;XI3G^+$;8K_H@K;S1JAF(T,]C`2D+)3[(0D(E
M<^3T4:0"^N=/CK&5-DK70-@,?6J3-#PK6D=(IZ_)@&.<!4N^<(XS?<=P.YW`
M/][`I3/1I'B0J'37!VGUD09I()R)!#GE1/+86GD!5`ZZ[>,N''3_043]=)`M
M'A%JX_41646E$1DH*)M82M:*EJUW=)4L8@N9&L6Z1J)(U(V%!,OM%T+27GQW
ML%!0I&"1Y\Z*%,E!I$@.,D6*!_O.V6@W'M)5BIY(1;=04)WPP.^L2'4<Y"M=
M..BCZC@;N81@@_F5ZDC1UP/!CLB74'C@=E:T.F8L<.P;SEG9Z@PVG+,9J,Y5
M)P.\!0YDR$$^[[F$E(0*"94,XDV$(APN]5\Z[.+=<!A"K_!D0\N"19L[1Q^H
MDE`AH9)!/"I48A+5P!&`R".>[$/F%O*<<F?E(26A0D(E@SC-`76?PCJ]\M>(
M1,J[@R`,+R6A[.7>RC6]DE`AH9)!/"34V\LS;]09"ND(+!,+^33G$E(2*B14
M,HC31.TC-/%`G$&RSC2*44Q&UT!I'T">&(3?9&3^_D$?^92U@F5/ZN,/S9PL
MJAHA>X:DT4!&TD"49(BHA"!L=CROT=DOO"/3;EPZ+41H6"3(57"L4[T?S94_
M%G&V5XEB*D710I2D,?*(HC9\]B$=0_H?ERR50F8A/VEND2!7P5E*]7XT5_YT
MPME>)5&IE"@'D;4J(26A0D(E@SC-`8G*)O=X]WHFK5*14@/!)NLVG-Q#-&7!
M*4@Y*WIOEV3^8,$9HWI<O&!3M`Y6BH$830$IZS@U3YKH0X=T0%CPOOA,OJ2.
MZ($6$2-BK`BDG!5+SM3K/$_.50J12H5P$.TZ(1I*6A42*AG$:0XH1)PE%W2=
M%(E4B(1%^&*>!K>EREI-87OP*C'U4L()XP9^>=.9[9ZJ1$H4P/QH8Q%@Z5:+
MHD9L^FQ8)O3/,1^WG?;D_6\ALOM9)$B8%TRCJM8J2)C7$\[X*JG(I%0XB#2B
MA)2$"@F5#.(TAS0%?S$ZDU6I*9F!:%8-$F352ZO-JO.C7>B%A[.]2E,RJ2D6
MHB2-D4<4M>&S#TA%<GM6?S,I%!;RD^86"7+EI=7FR@P%E,F*]6+"V>*6?O&*
MQ>-I(!,6HB2-D4<4M>&S#VA$,CW?5U(D,@/Y27.+!+GR:FESY?Q(KF8_48WL
M*M70UL&6(B0B=U9^_2H)%1(J&<23.J`:LU1O@E?>U&'NPG);"&KDFVL6B$;N
M'&E4O:/;QPMIA:^[Z!FUHXG*O+YB7M/85Z?7*J]VNW:T;M[PU12X97A\Z&'S
MWLPRNW,OSH17DMD<;QR!@KAR"U?T3RCAE32=X\EPP"<%'U#O@2L9OKJC#WCA
M:!GX0.T&?&+P@8=20U>``3Q8&;J2P15]YQK.DX`/_.0RX).`C]%<X3.%*SKU
MX16X,(A#.@>S"4$.Q@B%T4(>CG\_AV>A`USC"<2GSY:!AXJG<WR,(7W@@0%<
M&6259O,EG!.E#QS`Y_G@%7@'ZTD_>0CF7V*Q!D9:)I#"(1R;:`!_RN9/T/22
MTA*J9'ZD[&>&=Z^.J]?JWZO3:WUH1[OJ!1;`1"_LDWE[RWSI[`.9YZ:#MZ[T
MLYDMO&57P:L)$SP[OC1-Y[[`Q./^O;W'OP$``/__`P!02P,$%``&``@````A
M`%H24WNG#```P3P``!D```!X;"]W;W)K<VAE971S+W-H965T,3`N>&ULK)M;
M;^,Z#L??%]CO$.1]DMAQKFA[,/7=V`46B[.[SYG4;8-IZB+)7,ZW7](2+9%T
MDV8PY^%D^C/UET11$BW;-W_\W+\,OM>'XZYYO1T&H\EP4+]NFX?=Z]/M\#]_
M9I^6P\'QM'E]V+PTK_7M\*_Z./SC[N]_N_G1'+X>G^OZ-`"%U^/M\/ET>EN/
MQ\?M<[W?'$?-6_T*5QZ;PWYS@C\/3^/CVZ'>/+2%]B_C<#*9C_>;W>O0**P/
M']%H'A]WVSIIMM_V]>O)B!SJE\T)VG]\WKT=26V__8C<?G/X^NWMT[;9OX'$
ME]W+[O17*SH<[+?K\NFU.6R^O$"_?P;19DO:[1]*?K_;'IIC\W@:@=S8-%3W
M>35>C4'I[N9A!SU`MP\.]>/M\'.PKF:3X?CNIG70?W?UCZ/W[\'QN?F1'W8/
M_]B]UN!M&"<<@2]-\Q5-RP=$4'BL2F?M"/SK,'BH'S??7D[_;GX4]>[I^03#
M/8,>8<?6#W\E]7$+'@6943A#I6WS`@V`_P_V.PP-\,CF9_O[8_=P>KX=AI-1
M%,X6RP#L!U_JXRG;H>9PL/UV/#7[_QFKP&H9E="JP*]5F<Y'L\5D>HW(U(K`
MKQ59.8TSE4>V'/S^>N70U]8/\&M%P`^+8+*:+@"=J7UN"\*O+3C[4+F%+0>_
MUU4(,[=M*?S:@M$H7,Z"V1P'[$Q+5[8@_%*-X6@YFT7SY84^!A"6)DHP/DT`
MG.WEV$19&[3)YK2YNSDT/P:P$D`8'=\VN*X$:U2E<#7-[@+XO?B%P$65SRAS
M.P0/0&0>8=)]OPN6\YOQ=Y@H6VMSWV/#+6*RP%F!LHD$J029!+D$A02E!)4'
MQN"6SC<P>7Z';U`&?4.]NB?@G!4*1Y`%%4DD2"7(),@E*"0H):@\P!P!"\#O
M<`3*W`YA5?""9,%[?F]L0OCIC")N$G<FG7<4217)%,D5*10I%:E\PIP$_?H=
M3D(96/.YE^14LD;0EG>]U)ET7E(D5213)%>D4*14I/()\Q*LB,Q+_=LB+2MH
MW3J#.G%O"?QT/0^62Q$AG1$52Q1)%<D4R14I%"D5J7S"^@X[TA5]1VO>=TM,
MUH#K8ZQ(HDBJ2*9(KDBA2*E(Y1/64=A"64=Q4UFN,-^QV^&']Q54XDZP!*2\
M`%B)`.B,N@!0)%4D4R17I%"D5*3R"?,+YOC^9GL^^-&:]]T2+P`4211)%<D4
MR14I%"D5J7S".@H9S14=16O>44M`WPWR:B(&N3/J!EF15)%,D5R10I%2D<HG
MK.^81;'.FY1JA"G=Z7FW_7K?0*<@Y^@9_2FD3C:A0A7NE%882H9=)A%KE%@4
M0GG/=P'W7>JLR'F9ULHU*EQ!7U[D+Z6S(OF*:7&'8?[E3POIL#^;M_<<!DM*
MYS&3QL'.277>!P8QCRF46*O0^375*--:N4:%+EAJ5+&"W!>8@OF^Z`D2O\\F
M8V-]-BB`'=@;_RD?_QA<@N$%-Z;DK(20\U]*:&XR^M5\.0^%4D8VKEA.R(D7
MA%BK(A&5)5F9^N:+R2*<S7C+*[)IZ^.^P]3L"M_93,XU_#XP*%AT7HDU2C1*
M";DD/R/DM'*-"HU*0DZK(M1J\3YCHN7W&>?.%.;^A;BQ^9G?=X-$W,C<&R]C
MW+B"B48I(;9)K\1(9F0%DBY2%R*7RYT516JA44F(URC2YHJLWJN1NQ:TF&LO
MN!3-Q8)MT-0M+#&>!(&5AQ*-4HTRC7*-"HU*C2J&>)\QI9/A%,#)`C3[BKW+
M)H8N2.X#@W``W%BOQ,U?[*QHK!.+IFXVI(1@!W9:D<@.,JV5$_+7)=,N3[ZT
M5M'$+'KA;!Y,%F*EJLBH/77C+L3L[YP+/[B;V232]Z%!;'52*('+[0QUZTY*
MR/DP(^2L<HT*C4I"3JLBU+,Z88)XSA<?2X5LFNF[PB`13F+IB(/.RH630=-Y
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MJA?'ZY<#U!'+@4%P^T$]C_&0%JS\D#`D\M>,<"(6]]26`RN2R@@Y]5RI%V3$
MU>6]M[,B]8I0J\X=!EH]#KLRX<.#/>DN@YB[#'*]3JB<2;7`4>)V(W4&U)?,
MHLCWE!0N7#E\%`7"XJZU=`8D7#%A[J1+6?''MMQ0I\46,2\9*]]+AD1>SF++
M>2@CY/O%%/34"VJ#LRHUJI@6=P5FEW*"7;[?#$U2"G%([KZWB*5PX42,4VRM
M(O-TNWTFV%<PD$<)*5GA^1`\C`Q'D;S]).EIUZ:<D*NM(!V8V-VRJ&HKR<K4
M-ALM19I0D7);&?<H)HV^1R_LT";'9)XT"-/PKHGA1$RE.#16_IVG1:R@ZEM*
M5LO6DZO1*EKY_XD1RZQYY(8ZUU47).JW655=DI6I&L90Y.45JXR[5:;)%]RJ
MT^'0(!&@(HIB:\4"M"M(P9Z2EHW&T50LVAG)P%[JC:$XO\C)RH]/55DI*PO%
M;79%,N]5QAR)DYO%ISF=O7I+;77XEFH1B[]P(EH;6RL_<"V*_.@))R(X4F=%
MXY`1\H)3RQ=D=5:^=%8D7Q%JY;D7K\O#ISH/MTB$HUAG8FOEAZ,K2.U,"9EP
ME(<;&8F\%Q_MO6%.5EXPDJYS;TG(5B56BXI$WJN*._&ZQ!XB1F8E%O&("V22
M:ZU8Q!DM*.B<:!&LJ]V4#=0QE-7RET,M7UCDR9>$SLI73)X["URJYBT&Z/F%
M<(K%Q#0UB$=>()+:V!9DD=<5=$ZS"#*V<TXS5I&W-6OYPB)H%\F7A$RTA6*Q
MKD@$Y+O:PXE;9;D#,9?W-^:/':U/S2V`OT%;)*).;`&QM8(1I>XDKB"AE-#9
ML,BL%8LZTRY/OB`M%]0E(;/C3I4#C0CH?L2!F);[#KP0>2:+9XXS2$2>6$/B
MJ;%BD==34*47J2T(Q^&8(XJE-"-9/PA5305I^!Y1-95DU5M3Q6KB,8@9_!4N
M-`D_<Z%%[GXBAL//=HH[E&B4:I1IE&M4:%1J5#'$^PS;+NLSSKO5Y84+BXF%
MRZ#(G4S$<,J+5H!PR#^)12RQE]GZX-V4\G9B0GW%V*"Y:)]%$%7=<A3(!ZPQ
M/)M0PZ50JJTRC7*-"HU*C2J&N!LP`?7=@,,UOSQ<)F]EH6I0M.H6P'AJD1TN
ML60F]C(?+K=FL7;"\QS>SO.K46O.AXN0FS>Q1HE&J4:91KE&A4:E1A5#O,\R
MZVQS]PG$VX7.Z_035M=VXGB#0PB"L0O?,'"[J7F%UUKQ,7(Y/F_O=0D>G`')
M*47('R-KY5"BK5*-,HURC0J-2HTJAGB?P3._,'\@-U)]-\B?/]8*ECM_B,2-
M4F*M^!"Y[9`W%S,`?[I?B"23,/C3'),'7`C=>,0:)1JE&F4:Y1H5&I4:50SQ
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M$T5PI3T64%>@!;"*]*BMUO!*;P\/X`*\@=!S)826P9/WOBOPC2$\G^Z[`FV&
MI[A]5Z9PI;W7%&V&#Q8_]Y:`2OKK`*&^&J""7OUH_1E"HJ=)Z,4^/H/Q[>/@
MVU[7+M;P2GR//HQYWY##8\$U/OG3)>"YWAH?W>DK23B',GVUPR,O*--W)9E.
MUGA(K-7@!'B-Y[OZ"KQ>O<:7I_45>#-ZC>\]ZROP@C&4Z1LJ>%T8RO1=2<((
M^M/G?7@*#/UIKXR[2($/2-\V3_4_-X>GW>MQ\%(_PK2%SR4A:SB83U#-'R?[
M)O67Y@1?CK8O53_#I\(U?$LRP;=F'IOF1']`1\;=Q\=W_P<``/__`P!02P,$
M%``&``@````A``_Q^`2)`@``A08``!@```!X;"]W;W)K<VAE971S+W-H965T
M.2YX;6R455UOFS`4?9^T_V#YO3B0I$E12)6NZE9IE:9I'\^.N8`5C)'M-.V_
MWS5.:6BVB;Y`?#D^YY[K>YW5]9.JR2,8*W63T3B:4`*-T+ELRHS^_'%WL:3$
M.M[DO-8-9/09++U>?_RP.FBSLQ6`(\C0V(Q6SK4I8U94H+B-=`L-?BFT4=SA
MTI3,M@9XWFU2-4LFDTNFN&QH8$C-&`Y=%%+`K19[!8T+)`9J[C!_6\G6OK`I
M,89.<;/;MQ="JQ8IMK*6[KDCI42)]+YLM.';&GT_Q3,N7KB[Q1F]DL)HJPL7
M(1T+B9Y[OF)7#)G6JURB`U]V8J#(Z"9.;Q:4K5==?7Y).-B3W\16^O#9R/RK
M;`"+C<?D#V"K]<Y#[W,?PLWL;/===P#?#,FAX/O:?=>'+R#+RN%IS]&0]Y7F
MS[=@!184::)D[IF$KC$!?!(E?6=@0?A3]S[(W%4939)HELP7RQCQ9`O6W4G/
M28G86Z?5[X"*CUR!)3FRX/O(,KV,YHO)=`0)"QEU!F^YX^N5T0>"38.2MN6^
M!>,4B?_N"*UX[,:#,XI-C;E:/(7'=;Q,5NP12R>.F)N`P><KID<P%.V546V\
ML@=[95];G\I-")S*O"8RD)F^1\:#,SH[37XY[=,/R@&#Q]8;G/6(@3+2C#?H
MP=@60^E72T$Z@$9((V2\M`=WTGUQ0^14)U[^P^3E>Y0\>*@4(MW,#&JW&-+Z
M@4MF.+?_[T^_:\@?(D,G\S?'%<8^3(4"4\(GJ&M+A-[[D4ZPS_MH?]ML$M^*
M;^.S=-/=0JS_@+=`RTMXX*:4C24U%$@YB1:8D0GW2%@XW7:SN-4.Q[_[6>%U
M#]CJDPC!A=;N98'"K/\#6?\!``#__P,`4$L#!!0`!@`(````(0`?#BQE;`8`
M`.L:```8````>&PO=V]R:W-H965T<R]S:&5E=#@N>&ULK)E=;ZM&$(;O*_4_
M(.Z/,?@#&\4YBLTWK515I^TUP=A&,<8"DIS\^\[`+K`[CFM7N0GQP^SLSKNS
MR[`\?/^9'Y6WM*RRXK12]=%85=)34FRSTWZE_O7#_;90E:J.3]OX6)S2E?J1
M5NKWQU]_>7@ORI?JD*:U`AY.U4H]U/79TK0J.:1Y7(V*<WJ".[NBS.,:?I9[
MK3J7:;QM&N5'S1B/YUH>9R>U]6"5M_@H=KLL2>TB><W34]TZ*=-C7,/XJT-V
MKKBW/+G%71Z7+Z_G;TF1G\'%<W;,ZH_&J:KDB17L3T49/Q\A[I_Z-$ZX[^8'
M<9]G25E4Q:X>@3NM'2B->:DM-?#T^+#-(`*472G3W4I]TJU(-U7M\:$1Z.\L
M?:\&_RO5H7CWRFS[6W9*06V8)YR!YZ)X0=-@BP@::Z2UV\S`'Z6R37?QZ['^
MLWCWTVQ_J&&Z9Q`1!F9M/^RT2D!1<#,R9N@I*8XP`/BKY!FF!B@2_VRN[]FV
M/JS4B3&:&C-SH8.]\IQ6M9NA3U5)7JNZR/]IK73FJ_5B,"]PY5[FHYDYGC1.
MKC2<L(9P90T-8[28S:;SA0G=7VDY92WAREN:-W4);IN(X<H:SJ]V!'<;>[@R
M>WUYVQ!-UA*NK.5LI$_'<Q3V2F2P-)L.X7I?9$O6$*XW1:9#MK63CVG'YO7&
MV/0N<>"?&Z+3VKQKTMB.Z_CQH2S>%=@;H'EUCG&GT2UTRA.X%:A+Z<\R&E(9
MO3RAFY4*DD&N5K`,WQ[U^?)!>X.EDS";]04;T6+#+7"=H%M;!HX,7!EX,O!E
M$,@@E$$T`!KHU(D%Z^LKQ$(W*!8/<\U!KYXA*<,M>!-;!HX,7!EX,O!E$,@@
ME$$T`((RL(%\A3+H9J7"GM*GD3D6I5BW-@9<.J.I:++I3#JY"'$(<0GQ"/$)
M"0@)"8F&1)`-(OT*V=#-2C4$W<CR8T8PED]UZTPZW0AQ"'$)\0CQ"0D("0F)
MAD30#79P0;?+CUN^.:%U(P\/:\T(7#HM=%.7LJ@SXLUL0AQ"7$(\0GQ"`D)"
M0J(A$=2`1^,=:J"UJ`8C;7V"^^Z&$)L0AQ"7$(\0GY"`D)"0:$B$T.'9?D?H
M:"V&SL@@=$)L0AQ"7$(\0GQ"`D)"0J(A$4+'5XCAD_OZ&D!K,71&(*L&:T!^
M[G1&W1H@Q"'$)<0CQ"<D("0D)!H200THNNY0`ZU%-1@9)`(A-B$.(2XA'B$^
M(0$A(2'1D`BA8QUY1^R-N1@\1X/H*;(I<BAR*?(H\BD**`HIB@0DRH!5VW!!
MM*7L"%]DZD.6O*P+2'0PNK!0)E"RLD*VK?W@6<HS?HUE,62+;G1HP]'P8:J;
M$_$!8G.KOJ'#D#%N:F1CK$NEB]L;\/X]ZL:G*.@;8O4-GJ71A+T!]QP);D0Q
ML="[)N:/XOR9F/!^U:G9UHN"FBT2U"3(AMN2Y@Y#1J^F2Y%'&_H4!;1A2%$D
M-!3EP8IN*,^%G!K*P`K`85*U2(<29[#]2MFPT5NK"63@P&HFYQGSU2]?AS44
MW4^E"L?E5O/VC<W43>F=S>,6_<A]COK>`HZ$8.3>0F[%>IM-%U)I'W&+IC=1
M<"P%AX+_O\7-"LH^FC4JA(L;'K,#A>>BPAMF->ESSZ;(X6C2;10N1X(RIBFZ
M]YB5-(B%:.5SJ_[%,>#N^[D(.1)[E.8UXK[$L/L>1?&Q\B3BPPD3VUCY7G#'
M+HL>I6=0BW!@_43(&;+!LS6<KGX&;8H<AB90-O:^Y'QTN9799O_4D#=CC[KV
M*0JXGZN]A=R*]399&B3[A[&)$X#U+YF`6?]HXS/P']L0*Z-[\=8Z0WU.;2BR
M*7(H<BGR*/(I"B@**8H$),J#-;(LCS'#_+SW&(M5VT.%&`)G?2XMI)UT@TL7
M$[I?B#9%#D4N11Y%/D4!12%%>/;=CZL5K3W+;@\!\[3<IYOT>*R4I'C%<VI]
M`:NAP^TA.F0)G*+/<5<C=TQ^OB[?F5GPPGJA!;BZZ`D<->?TLI^%!47_!3]+
M"RKB"UP?PXB:0WO)$]1>%I97M`W43A:61_0.%!W0IMGU)6]00D";2W?@D\/3
M);[&3Q$7^E@;%ARKT;[7$PL.CBA_FEI/,*WTQGIJP8D)<*T;*WQJ.,?[]/>X
MW&>G2CFF.YCB<;-OE.W'BO9'S:JYYZ*&;PQ-87>`CTHIG`6,<1GMBJ+F/["#
M[C/5X[\```#__P,`4$L#!!0`!@`(````(0`S>.RAM`<``#0C```8````>&PO
M=V]R:W-H965T<R]S:&5E=#<N>&ULK)I?;^,V#,#?!^P[!'Z_.+;SIPF:'AI;
MV@[8@&&X;<^NXS1&DSBPW>O=MQ\I2[8H^MJDZ#U<FI\HBJ0H4;)S^_G[\3#Z
MEE=U49[67C">>*/\E)7;XO2X]O[Y*C_=>*.Z24_;]%">\K7W(Z^]SW>__G+[
M4E9/]3[/FQ%H.-5K;]\TYY7OU]D^/Z;UN#SG)VC9E=4Q;>!K]>C7YRI/MZK3
M\>"'D\G</Z;%R6LUK*I+=)2[79'E29D]'_-3TRJI\D/:@/WUOCC71MLQNT3=
M,:V>GL^?LO)X!A4/Q:%H?BBEWNB8K;X\GLHJ?3B`W]^#:9H9W>H+4W\LLJJL
MRUTS!G5^:RCW>>DO?=!T=[LMP`,,^ZC*=VOO/EC):.'Y=[<J0/\6^4MM_3VJ
M]^7+;U6Q_:,XY1!MF"><@8>R?$+1+UM$T-EGO:6:@;^JT3;?I<^'YN_RY?>\
M>-PW,-TS\`@=6VU_)'F=041!S3B<H::L/(`!\/_H6&!J0$32[^KSI=@V^[47
M3<?AS2R8S4%^])#7C2Q0IS?*GNNF//[72@5:5ZLEU%K@TVB9CV>+211<H232
M2N!3*PD6XV`Z48:\,OA4]X-/,W@_]BO]P#WE^KSK]^IX?ALY-1%)VJ1WMU7Y
M,H+LAM#4YQ372K`"768&VI&[.?G9E,!<H))[U++V8%E"L&O(HV]WP71YZW^#
MN<^TS&9`ADK$1@(G&M4F+A`ND!;PP:/.+9C+#W`+M:!;QJ"-`;V?H>.#D3!=
M$A<(%T@+$!\@E3[`!]2R]B"]^JF93:C1FU8FA(].:$I%XDZD<XP1P8BT"?$-
M[/D`WU#+V@N)<RSOM!"8\E/G.I'..48$(](FQ#E8F[9SP[N963HHK'PP8V\T
M@=78&1S,`F<^.B'3+6%$,")M0DR&P2XW&86IR9JT>S0NW9B1A!'!B+0)L6]Q
MC7TH3.W3!-RW0NHNW4ZH"RDC@A%I$V(R'E*LG?7U+$!A:K(F5D@921@1C$B;
M$/N6U#[<^:,;K+.Z5EZ\^:,B:KLF--R1D\&=4!=N1@0CTB;$G0!.'Y?'6TE3
MHPVR(LY1PI'@2!)$S<2*9:4%AGT>C1?7ASUH:Q_L?B:`&XTB"(65Y^Y6WDN9
MC@E'@B-)$/4*:YCEU>O)'K05CUBND1U\AA+3L9<2'$F"J)E8CRXW4U<O.\`:
MT<R>.9D==%)]@!D27$H21"W'8G.YY;HTV99KU(<N#AA*.!(<28*HF1`8V\SV
M.*FRN]D7V=.FA+R$O!W(CPB.C?HPB4J<M=DBG%DKL>=NW#NI/NY:%UT1"]I1
MX)T#1U2W%66$U`A&!%W41RQ2UE2X/GXMSS_S$3;7SDE=ZNPI:E$[I+(B#AA*
M-`J584I*<"1)1VH^%BS'_"GX/S`EMKFZS-GFM@B3P9J3&QK:.-!2?=XE!I&.
M4^>`(XS47%TG%K,)_*.ZI1%11E$GL>I=[Z2NE;:3+<*1+">=JTT<:*G^II`8
MI&[/>IJTU+*](`V[U(W'T@XKG^72&_.EZZ3MBETZ=7HQE`0,"8XD023RL(:(
MF;@ZPMD8$NS**Z521'<!@T!9/QES)ROB7JK;!3@2'$F"J%-.T7X]]B$OS`;U
MJR#F*.%(<"0)HF9BQ;12!&,_`V.NC;PNO%;NP&ZC-D@:>6?)QKU4'_FNHT&"
M2TF"J$M8-RV7WHB\KK*VY:SPQGC/Q=V^GXR$(\&1)(B:B:74,A,C?[-\SV$:
M+[-.\=.(GNKF[NVEES*13C@2'$F"J%<PW;97;P0?I9T%JU$?Z1CO%V[P&1)<
M2A)$S1PHR.])>UZ10XW`0&O#<2\RO50?^:ZC08)+28*H2U@UK7QZ(_)MC86)
M-*-M0HWLR#.4<"G!D22(FHG5RC(3T_Y]=\BPK7O$!8UH\-W+C.G8.YIP)#B2
M!%&OL`1:7KT1?%TP[>"S&AJ'#"4<"8XD0<1,W`\N-U-)T]5I$`VP>YGII4QR
M)1P)CB1!U/*KRFG$RZE!_:3''"4<"8XD0=3,@7(:1<$[SC(1KZ@:89"LK<6]
MT?12??!;7=#1(,&E)$'4JZLJ:L0KJD%V\'E%Y5*"(TD0-?/#*FK$*ZI!-/.=
M6V'<2YE()QP)CB1!U"L8\8HUB]+.FM7(#CY#2<20X$@21,T<J*COV]<C7E0-
M`ANMS'?OC;U4'WQ>5+F4)(AZ=551A?>>+/@:1=W2BXU4CQ*.!$?X6E6I5QU;
M,]O7I.W;N6->/>9Q?CC4HZQ\QE>@T.'NML/M^]E--(,7M"H76,L<6N9H*&M9
MF)>Z;DNX7&&]&>HS@3YJQW'[1/B*6+U/92TAM*BG%*PE@A;E.&N90HNJI&Y+
M"'W@_#U@6PA]VG,#ZP/1:4_YK`6B`Z>O(6T0'3CP#+7<0(NZX;O:`K`-'MT-
M]`G`-GA`,M0"L89;]$!+"+&&J^A0"\0:;G]#+1!KN$0-M(`[@]Z`,X.^@%F#
M5@5@%3S5'A@A`*O@R?!0"UC5/LUR(I8$LQ4^=.-]X/$6M`S-#/P6X7[00QQ^
M0-,&0S+$,?D&^/UT=0]KC)NT@3D<G$+(KB$7-I!;R@&_\QI^LW!.'_,_T^JQ
M.-6C0[Z#!3U1CT6K]E</[9=&/SI\*!OXL8)ZBKB'7Z?D\$)M@L>.75DVY@L8
MZG>_=[G['P``__\#`%!+`P04``8`"````"$`&9\W@181``"H;P``&````'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;*S=VW+;.+:`X?NIFG=P^7YLZV3'KCA3
ML7@^DS5[[VO%5F)5VY;+4CK=;S\+$D$0^-GN,+5OVND/"Y"$I44*H`X?__W'
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M]KB7="_D$:D'=O/PI[?>W<N,RC!GTX4:Z7[[)'=`_GORO%%/#9F1U1^'OS\V
M#_O'V]/9Y=GBZF(VD?"3+^O=/MBH(4]/[K_O]MOG_SL&'1Y1-\BT'43^#@SR
M3L=9VW%N.D[.IA\6D\6ENOEW>DKKX7[+W_8F%V<?%HOYY8>K]SM>MAVE`/1]
M_<F;O&Y[RM]Q-SF1K!XG6:9QY(U.]-RJ?[1]+W_ND4[T[*I_Z)N=GUU-+JYG
M?S-)$TG(\1Z;^9W]Y#1-]`RK?XR\QU?Z9N4?(^^QY/-XCW\ZL>?'4CA4EK?:
MKSY]?-O^.)'#E61I][I2![_)S42&TS5U?#IV5?9712;5I4;YK(:Y/97^4C\[
M.3+\_FDRF7P\_UVJ^;Z-N1N(L2.6.D*5KAK6<\%W(7`A="%R(78A<2%U(7,A
M=Z%PH72A<J%VH>G!N:2GRY%4P_]'CM0P*D=Z=N\TF*1-G83H"-W%<\%W(7`A
M="%R(78A<2%U(7,A=Z%PH72A<J%VH>F!E1`YQB`A<SEZ#)^(=(VH7K>G<K3I
MU8@SX7?'F*G\Z8+F3DZZD"XI$!\20$)(!(DA"22%9)`<4D!*2`6I(4U?K!S)
M/"-'ZL7"R`.;&N;V=&IGS3VRM4%R7_XR:UU(ES6(#PD@(22"Q)`$DD(R2`XI
M("6D@M20IB]6UB1!5M;>KR@5?4B.GM2[5N1/EXG)9.944!>DNWD0'Q)`0D@$
MB2$))(5DD!Q20$I(!:DA35^L7,A+FA&Y4-%V+EHYOA)7I_,EQ(/XD``20B)(
M#$D@*22#Y)`"4D(J2`UI^F)-O+P@M"9>O2:;?5!KFK%'+S62G916Y+9[!>*>
M8KJ@KD`@/B2`A)`($D,22`K)(#FD@)20"E)#FKY8>9*7NU:>WC]8J6@[%ZWT
M"@3B07Q(``DA$22&))`4DD%R2`$I(16DAC1]L29>5J4C)EY%VQ/?BM13KP@6
MSEFB"^J*`.)#`D@(B2`Q)(&DD`R20PI(":D@-:3IBY4+M>`?D8Q#N)T-3;TZ
M('DDGQ200E)$BDD)*25EI)Q4D$I21:I)C45V+M0*TEW-_]J98W)<C,H+7_WT
MO]-DE\VE4S8F2G?T2#XI((6DB!23$E)*RD@YJ2"5I(I4DQJ+[-2IM68_=>^?
M3-0.F7-0T]0OHS;*D,<HGQ200E)$BDD)*25EI)Q4D$I21:I)C45V+M2B<D0N
MVC5HOU1:LDOERBV5+LJ4"LA7.YHJU2:)`2DD1:28E)!24D;*206I)%6DFM18
M9*='K1Y'I*==;/;3TY*9TJ7:!;9GV2/YI(`4DB)23$I(*2DCY:2"5)(J4DUJ
M++)S(<_P,;E0X<[9OR6[5#ZXI=)%F5(!^6I_QTYB0`I)$2DF):24E)%R4D$J
M216I)C46V>E1:\P1I=(N2?NETE^E'C;EE^I:ASW+'LDG!:20%)%B4D)*21DI
M)Q6DDE21:E)CD9T+M8[LYT(MZZ>+,WG.CMR3G+0KTGZ:6I+!>DN::[>*NBA3
M12!?#V^.C@$I)$6DF)204E)&RDD%J215I)K46&1G3BU$^YG[F]=F[;JUGY[^
M4K:M(I"GKK_9A>63`E)(BD@Q*2&EI(R4DPI22:I(-:FQR,Z%6HCV<_'KFV.3
M=DW;SU-+<H0S932]<,NHBS)E!/+U\)?="BH@A:2(%),24DK*2#FI()6DBE23
M&HNLU$W'[10<PNW7"IK,D6E)\D@^*2"%I(@4DQ)22LI(.:D@E:2*5),:B^Q<
MN#L%[Q_2IMP-T&27BG-E;&FBNE(A^:2`%)(B4DQ*2"DI(^6D@E22*E)-:BRR
MTS-N-V#*W0!-_5+A;@"C?%)`"DD1*28EI)24D7)202I)%:DF-1;9N5#K[_X9
MYV]*I5VN]\XJZG*^.J_;I>)<^E^:*%,J74=-/J,"4DB*2#$I(:6DC)23"E))
MJD@UJ;'(3L^XW0!U)5_EHI^>;NG?/^F[%XUU1U-0'LDG!:20%)%B4D)*21DI
M)Q6DDE21:E)CD9T>M20?43WM"KZ?GI;LZG$O6:J+H\<:TZ7BD7Q20`I)$2DF
M):24E)%R4D$J216I)C46V>F161V3'A7N5$]+IBZ6ZD"GH@QY))\4D$)21(I)
M"2DE9:2<5)!*4D6J28U%=B[44GQ$J;0K]WZIM"3SWUN^N!<VIUV4*160SZB`
M%)(B4DQ*2"DI(^6D@E22*E)-:BRRTZ-6YR/2TR[F^^G!^GXY!7DDGQ200E)$
MBDD)*25EI)Q4D$I21:I)C45V+M1R>T0NVM5Y/Q?=@KU?*N[%S&D794H%Y#,J
M((6DB!23$E)*RD@YJ2"5I(I4DQJ+K/3,QJWT#^'V6463.84L21[))P6DD!21
M8E)"2DD9*2<5I))4D6I28Y&="W>E_\O;SC-N`FBR3SCN=4X3U541R2<%I)`4
MD6)20DI)&2DG%:225)%J4F.1G;EQFP`S;@)HZE<1-P$8Y9,"4DB*2#$I(:6D
MC)23"E))JD@UJ;'(SL6X38`9-P$TV:7B7N<T4:94N`G`J(`4DB)23$I(*2DC
MY:2"5)(J4DUJ+++3,VX38,9-`$W]4NGV!4PN0#X[!J20%)%B4D)*21DI)Q6D
MDE21:E)CD9V+<2O^&5?\FNQ2<2]FFBB3'FP"^(P*2"$I(L6DA)22,E).*D@E
MJ2+5I,8B.STRJR->.L]4N//:K*5^J8`\W=%$^:2`%)(B4DQ*2"DI(^6D@E22
M*E)-:BRR<Z&6W3^_C)FUJ_3>,D:3//'-BG_F7K`T4:94VK'ZZ0$%[!B2(E),
M2D@I*2/EI()4DBI236HLLM,S;L4_XXI?DYGE)<DC^:2`%)(B4DQ*2"DI(^6D
M@E22*E)-:BRR<Z&6W?U2^?5E3+N`[U=12W85N=<R9UV4J2*0SZB`%)(B4DQ*
M2"DI(^6D@E22*E)-:BRR,C<?MQEP"+=/.)IZ543R2#XI((6DB!23$E)*RD@Y
MJ2"5I(I4DQJ+[%RXFP'O7\N<<\6OR2X5]UJFB>I*A>23`E)(BD@Q*2&EI(R4
MDPI22:I(-:FQR$[/N!7_G"M^35?=FXZ6)(_DDP)22(I(,2DAI:2,E),*4DFJ
M2#6IL<C.A;OB_^43SIR;`9KL*G(O.9LH4T7M6.90Z#,J((6DB!23$E)*RD@Y
MJ2"5I(I4DQJ+[,R-VPR8<S-`D_FNC"7)(_FD@!22(E),2D@I*2/EI()4DBI2
M36HLLG,ASW"\;)LLSM1W\NP?-_>_W6UEW2*GF8$3T4R^1^;X[3+JNS6<16A+
M\B$>71M+DJ<[RDN0WO+(>>^`;Z+T6`''"DF1Z=@?WKG>&ILH/7S"L5)29CKV
MAW>N4>4F2@]?<*R25)F._>&=S?O:1.GA&VLL.]WNYH(Z:/;3_9_MZU^E6]XN
MT.6;FP[S(UGY!GEME+R92]]9GQ1PK)`4L6-,2M@Q)67LF),*=BQ)%3O6I,;J
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M8Y&=N7'[)PONGV@RA_DER2/YI(`4DB)23$I(*2DCY:2"5)(J4DUJ++)SX>Z?
MO'_B6G"31)-=*L[B;6FB3*FT8YE/WOF,"D@A*2+%I(24DC)23BI():DBU:3&
M(CL]:M?CYU]7+%2X<\)IJ5\J($]W-%$^*2"%I(@4DQ)22LI(.:D@E:2*5),:
MB^Q<J.V-?BY^_83#C9)%2W85.2][EB;*5%'749//J(`4DB)23$I(*2DCY:2"
M5)(J4DUJ++(SI[8@^IG[FX.<"G>JJ"53'\L%R"/YI(`4DB)23$I(*2DCY:2"
M5)(J4DUJ++)SX>YKJ"KZM2^_6G#/0Y/DIO>ZS=F+6YHH73,>R2<%I)`4D6)2
M0DI)&2DG%:225)%J4F.1G;IQ>QX+[GEHZI=1&V7(8Y1/"D@A*2+%I(24DC)2
M3BI():DBU:3&(CL7:O$^XI!V7.O+!P#U,_YNT9)=*LZ^\M)$Z8X>R2<%I)`4
MD6)20DI)&2DG%:225)%J4F.1E9[+<1L%AW#[C*/)U,62Y)%\4D`*21$I)B6D
ME)21<E)!*DD5J28U%MFY<#<*WC_[RT^CN&=_37:IN#OI)JHK%9)/"D@A*2+%
MI(24DC)23BI():DBU23U@S.'63TL]H[I.?Z`S/%G+I[7;]_6R_73T^[D?OM=
M_3C,U85L_W5\_.6:N\6'&W5,E/E%R[6T7`^U7%[(S]T<?K'&[7/9_1".V[*8
MRFB'JU-HF4G+;.AV%G-I.1Q?T6<A+8<Z1LNEM!RF!"U7TG+8@'1;YG*OY;TI
M`W,PEWLM[Y08:I%[+5?BAUKD7LMUX8&6A<R;[+X-M<@]D-V=@9:9/%)Y3_-0
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M/%@9*ED#\7<JO4.N"FG`/\]O/LOIA#=\IXYE`R[O+Y$'/I0,>6N(//"A%GE7
MASSPH19Y0X8\\*$6>5^#W,Y0<N5="G([0RWRG@.YG:$6>0>!W,ZAY;Q[#LOO
MI+VNOJWSU=NWS<ONY&G]54Z5%X?WZ;P=?VGM^#_[]@T<7[9[^86TPWLY'N47
M\=9R+?]"?97AU^UVK_]')O*\^XV]3_\5````__\#`%!+`P04``8`"````"$`
M,O_RT@<(``"<)```&````'AL+W=O<FMS:&5E=',O<VAE970U+GAM;)R:76_;
M.A*&[Q?8_V#XWK%(ZC.(4U0BNJ?`'N!@L>?LM6(KB5#;,B2E:?_]&6IHBS-J
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M"F'N9&0B;9L])`!_+PZU&0VH2/EC^/>]WO6OFZ6*[Z(D4`+PQ5/5]5]J$W*Y
MV+YU?7/X'T+"AL(@T@91D+U]7]X<)+1!X-]SD&1ND#6J&HJDR[Y\?&B;]P5,
M'N3=G4HSQ^(>`I^K@UHN]?JH7%`G$^2SB;)9PI*!2G30X^^/2?2P_@YMV5HD
MGR*"$L69,#TP436^`']?HD;QY3-K$'!1`?5U5?RZM^=D#6R2/5\GQQ?<Z\C+
M989,BBD1)1314V0,0G*%&9B?JX$W2VC,I03)6((AMQP1F,4+$M+4BJN$]A$D
M><AD?O(&AN7B9):,-<'D$<F&D5F).,ZR,&.5+0@3IUD@&:$)D2HIXB0:KT0$
M0)U<`6;>%>PI_HDQ'V)=8"GDB/BZ<)70/H*(B*D(?_(&9EU(Z8#DB"1#%T02
M!9ED0U:X1!:"A=$(VGT_#>,@2<8A)*DGMZ1N8)9Z1B^<(V)3#P.VZQ3XMML6
MQ<1K-X*2<10ZXT52-R<"9ZOT5]W`-/5XK`C./B)N;HPHD$!QH9#C2`\!M/MV
M%(4J&*61Q+-;$C<P33QES<X1<1/G12VN(QH1%)<%YL^EM21[`<O3K?N\)3M\
MBNE@AI-;QBMD!J,M@U(D+)YL[!258AQM]@@)]#]W_XSY^%O&+P'C^!AMXZ"$
ME8P][3!&YVB8V0ZT1U=+.A8)UX-`!G.`TU4L@H2UK"#,2B@51H+%T801<1!"
MG'&[I@TQQN>(\:]I86CJ`ZFZ#*T5@8Q;;+ZJ;1@/HKT(56"\SU$PLQWHF&X[
MG%W/*D'&CD089A'?@`I!D(@,#6Y1E%!)$*2CM5`A4`]7R)56&)JU@M4Y-Z=\
M8#QU+JXCVHM0!<8$;V\%6J?;"L4F.A>NO4H5*S'.\U#G@A"K4"5"LJ6C"9+!
M'4PP$E2'<<3;=:"/$AV3Q>%ZK0A2Y9S2K`XDW)YQ;]&"1$FS2(W5H$*,03I"
MKHP4VJDK(&7'B5RXEKN2819DX6BZ5@)EX#Y13240)E(BC0-G=5$5QBCGJT!;
MA85YN1UP5MR082ZF[LS63G$=T5Z$*)#,P?U]&&CFW&.#48%E?&-2S&"T9>P>
MI\P&]M$Q1-[DW0/-1+!!R2UC+R[@WH=Z2<$`,7$Z"J1*9=$'ARC)7/M*"W[A
MUBRY?(BX67JR=^U\)7Z1/0&4-WU8E?/7@#0T-8=LK(N=(&3<">)KP(;Q(-J+
MT#5@K-)9Q?-\6J+!NGM2-N[:5@DR;II\OREL'!^C+8,-C<,H3<>!I5(@C"OE
MRBP9FJX$YWAL)2"#EY9I(D+GP#8@A?FRC9DY5ZDM@V&B-`,-CI52#<RKKVB8
M>G3&O4VZ'@U')39PA7T?9%PVYJD`-X9(93)>A&9O'-`9IBO9HU^2(6*SGDO7
M4R6<T]AR+RS@3]\-HL),B&"\#A5@_&^^`'1+(H`[LR2.&L.-P7AI.T&4B)0:
MJSL0FL:0`0E"\V>>/',UH^\2'>-IV"X%9,Y+`3H1L]-@(5UD%?]*B$O$,LV2
M)!K%$B7FRZ_YG1AHMIBY-UL&%4`;0L%Z51!B!=.6)OP^2A,F2I,D2<>-CRJX
MR9C5]*8Z&_<Y[(%E[#YBZANS-A44B>'\QF_-M44^6#%4PDWNK*;NS(\.N67.
M6R$M'ZX'@BBILI0?%#5!_$V`H7;':-Z"4.93U*B%<_ZRW4#(K2-?VC:.!]%>
MA#:#.;5_<U53AQ;.C965,,.B;:!H^!(6OON@9T%MW\:&"AE^M)RA!FX?KB1O
M:+J<1<"VFUPAY!:7&U<Q@]%^AK:`N?/,:4+WA%I?'%8$8YUL*Q!RU4RFZ2JB
ME0^A4FZR:C6U:M=#K02$7`G3AEQGM+V8W:@3F7YT\Z"86\]LQ]2U!?]^/A]"
MT^]HIEHPD$^OMG%0B\R25(ZF0_MAK''VR4.AD;J.+0+F!;F%?/D5,QAMF7,_
M$O%1/\*;/'N@^2+GIFTAKX89C+8,:HBR-))..TDC0F;;\X9J^!07P_W;0GXQ
M>`[P,=K&L4,EDD`ZWUE3,<S`9XJ9&KG@!^\\1,B7:#&#T99!,5DJ$CD>\:F6
M_\O*X1&.B94(=@^46PC_NU?`MQ7QN$J'O:VPA*N6;<_F81%S)0P2A2+)TA%!
M)?@P"#[G<*C:EZJH]OMNL6W>S(,>$BSV\NKE(93/TCP0P%[/Q7TQ/,FQOKP!
MSX:<RI?J][)]J8_=8E\]0\C@+H&46WRZ!'_IF]/P=,53T\-3(<./K_`44`4/
M-@1W`#\W37_^!2Z\OCQ7]/@W````__\#`%!+`P04``8`"````"$`1*_1>FX%
M```J&@``&0```'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R<F5MO\C@0AN]7
MVO\0Y?[+D22`@$\EYVA76JWV<)T&`U$)04E:VG^_XS@)V-`,;"^@#(_?VO,Z
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M\MV^`;LM&!$=V'SSY9$Z@XR"C&)85"DK#]`!>)6*G$X-R$CZV;Z?\TVS7\JF
MK5B.9NJ`2Z^D;H*<2LI2]EXW9?$O@_1.BHD8G0B\=R*ZI4P,RYD^HV)V*O#>
MJQB*,;5TRWZB+Y-.!7K?#TA3II8UL:?.XR.R.Q5G4#$FBC[1GND)/&)M:N&]
M[\GD^9[,.A6=3HTN^=.'951F=SM[O+1)5XNJ/$OP2(*A]2FE#[@^I]+]O&$N
M#S/INXD$,XBJO%"9I0PCA#E2P^S_6)FVOE`_8,9F';-F#+P.C$"X/4&G)Y7U
M;F6%)GY/]$T",1"*@4@,Q"P`KT/'3-O@.Y_<8\R!42&;0TIA]G,IO?\(]IFC
M-,U</X!U'[CT1NB+>X>8#%UAB6/(]9`$$?^6L!Q>)+A%!)'PEA!%HEM$$(EO
M"=,6NI+<81QMZ"Z7?B@;3Z2?TESZQ8`K!CP6N,ZM:0OY]Q]@@GN,-8RI]3%\
M@(GN,3:O$]]CICR3C#-<CJ&X/I%C2G,Y%@.N&/!8@*TNM!+X8B`0`Z$8B,1`
MW`<N3Y9ISX0DC#-<$F`5X9)`2^<$@N//.VT%W'6Q<82BMF8,O`X%29A?+DIX
M*.&C1(`2(4I$*!&C1#)&<);`<GUCB0FKVK@EM!7L=Z[2;3I"D5HSQF9+&^R+
MA'GCLN^AH]]9YJ&$CQ(!2H0H$:%$C!+)&,$9`ONF_V$(;24:<EELV\JX9LQ(
MPEV4\%#"1XD`)4*4B%`B[HAI._^$<I%P7VK*S'2TZY_+6L!90T]^XLX/+U^T
ME6B-4)S6C!FS!B4\E/!1(D")$"4BE(@[@ED#V1<J0S*FP!D".WS.D/&B16G1
M"&'WL&8,;.OIAEQ3-&'BN,CW'OM^Q$@?)0*4"%$B0HF8$=^.-!E3X$R@9Z`G
M7&AQT8;+`\=*50>-Y-'%$0]'?!P)<"3$D>@.8CK"GCV^`PF5(AE%>%_H`>SY
M<J6S<QN_M@L;WW4'C?K#=$80#U?Q<23`D1!'(AR)!X35!M,TK]<,3=C_)`_C
MO&OTW';MVGA-T]DQCW=+J*?K#AJQPL41KT.<MC0:AFT9AO"'?!Z!_.BF,'\#
M#IG94PW2R!\H0@[1#<?1;%,H$%''C`PIQI%D%.%MH4>])VRAN%#DII?3=U?D
M&#0R!E='$0]'?!P)<"3$D0A'8AQ).H1--'/FP"RZ%$K>%7KV?,(5=E2%G`Y'
M#G,JK/!KN'*FUHVZ@B(>KN+C2(`C(8Y$.!+C"+V*IWEAKNBF86C69?/$7&%7
M[>RRM"#5CKCD<*BEK'RGU^@3*!Q#=+CB?VEO^(6XI\_ASA'N]X3XVIBO[_&N
M,8<+$>#5H0'<U)_2'?D]K7;YL98.9`M=T!1ZD5VQNW[VH2E/[97N:]G`'7W[
MZQ[^)T/@!D53`-Z69=-_H']@^"_/ZC\```#__P,`4$L#!!0`!@`(````(0!R
MZ%8"^A,``+5U```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*S=6U/<
M2);`\?>-V.]`\-Y`7:$(VQ.F=+]+,;O[3..R3310#HIN=W_[.5G*K%3F7XTI
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MSN3>_P?2/][?/6]WV\\O9Y+NO/^@_,ZK\]6Y9/KP[M.]?`.UVD^>-Y_?GWZ<
M7'?+R>GYAW?[%?2_]YOON\&_3W9?M]_CY_M/Q?W31M:VU$E5X-?M]C<5FGY2
M)(W/T3K:5Z!Y/OFT^7S[^\-+M_V>;.Z_?'V1<B_D&ZDO=OWIKV"SNY,U*FG.
MI@N5Z6[[(!]`_O_D\5YM&K)&;O_<__Q^_^GEJVI]=K58S)=7EY+FU\WN);I7
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M\$_42*51-3)K]\;`H&A>04R$:1+X$/H0^1#[D/B0^I#YD/M0^%#Z4/E0^]#X
MT/K0#<`IB.QA_HF"J#3O3V7?,Q@T,[<"-WW,5'X<@N9NR/H0<J@2)(1$D!B2
M0%)(!LDA!:2$5)`:TD!:2#<4IVBRGO^)HJDT[T^G;M7\79T.DL_RMU4[A!RJ
M!@DA$22&))`4DD%R2`$I(16DAC20%M(-Q:F:')"=JHV?TYG#D(K>%\>LU!LM
M\N-0B>G2'T&'(-,L@(20"!)#$D@*R2`YI("4D`I20QI("^F&XM1"SG".J(6*
M=FNAI3\%5\?W-22`A)`($D,22`K)(#FD@)20"E)#&D@+Z8;BK'@Y0716O#I)
MFR[.I%!'GJ:I1&Y-M$BJP?A8>$>80]!A?$!"2`2)(0DDA620'%)`2D@%J2$-
MI(5T0W'*)*>_3IE>WU>I:+<66@;C`Q)`0D@$B2$))(5DD!Q20$I(!:DA#:2%
M=$-Q5KQ<9SHK_J?'ATKDUD2+.SZ6WO@X!!W&!R2$1)`8DD!22`;)(06DA%20
M&M)`6D@W%*=,ZNK>J=/K`V0?[E;#T&"(D`)22(I(,2DAI:2,E),*4DFJ2#6I
M(;6DSB&W%NIB<WCA_X-:]->F<MIK-O&;B28Y:@T.'9?>T+!1IF%`"DD1*28E
MI)24D7)202I)%:DF-:26U#GDED==>AY1GOY*U2F/IN%0`0434$B*2#$I(:6D
MC)23"E))JD@UJ2&UI,XAMQ;JDO*(6N@KT.%0T>0>1:[\H7*(LD,%%*KI376,
MLG6-2#$I(:6DC)23"E))JD@UJ2&UI,XAMSSJVO&(\NA+S6%Y--E5NE8SPNY:
M#D@A*2+%I(24DC)23BI():DBU:2&U)(ZA]Q:R!;NU.*GS\34_1OO5,R0.XI6
M_BC2#6TQ`]O0#*R0%)%B4D)*21DI)Q6DDE21:E)#:DF=0V[EU,7G$:-(7ZL.
M1]'P\G4_?;]6]T3\400*&1618E)"2DD9*2<5I))4D6I20VI)G4-N+=05YA&U
MT!>DPUH<KE$'YV:7%_Y0.429<1&H>U%NQ4)21(I)"2DE9:2<5)!*4D6J20VI
M)74.N>51UZ%'E$=?M@[+,[R2U4,%%*C;<7XM0!&C8E)"2DD9*2<5I))4D6I2
M0VI)G4-N+=3%YA&UT->FPUH<+E>'0P5W)@]1=JB`P@DH(L6DA)22,E).*D@E
MJ2+5I(;4DCJ'G/),C[OBWX>[5_R&[&W+-2D@A:2(%),24DK*2#FI()6DBE23
M&E)+ZAQR:W'<%?^45_R&9"=DK_@OO7M?:QMU&"JDD!218E)"2DD9*2<5I))4
MD6I20VI)G4-N>=25^-OW9%-]X3[8DQFR9[YK4D`*21$I)B6DE)21<E)!*DD5
MJ28UI);4.>360EUC#VOQDT_%J-OVWD6,)IEM,*-C30I,P_U#<_L3A)`4L6%,
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MVW"8WIL\+FV425\Q5TUJ;,-A>F]6K;51)GWGY'(+KB816/`S]3CSR]?[N]]N
MMG+^*.>7(_><9O+PZ/Z`]W&JIR*&Y>[)*3<H,`WEVN-PFCI9>5=TH8TRWRC2
M-$@?DQ+;T*:?7GES*ZF-,NDSYLI)A6TX3.]]^M)&F?05<]6DQC8<IO?.X5L;
M9=)W3BZWW&I2XK5R_WO[[>_*+7N-0[WUW,:PWCT-"K*>@@)-<CIG/FQ(BM@P
M)B5LF)(R-LQ)!1N6I(H-:U+#ABVI<QJZ-5(S$\,:C0R]82WT1,:P%CVIN?_#
MJ)I>>8>U]51'V6N0P)#-%1I:[I\4GZRN%K,K;W\9F1C;+#9DDR>&W$_EY4I-
ME-K8_O@P.YMZ'SLS`;:SW)#MK#!DHTI#?>:KLYG7=64";)O:D,W<&'KU:[0F
MJE]MB]7%U7+E'9D[$[/OS]D$9L?-Q>S#W;D836IF=+`)>*<>:QMEAF-`"@W)
M<![D\KY-9*(N#T,[)B6DU)";WCOD9SIJ9O<<N6EH>RQ(I2$WO7=,KDR4S563
M&E)KR$YZ=8;VN=RZ^O,Z_47/D4?;&:=[-'DCWCLS6.NHN3UU#C0M9H>JA2;J
M8C\"?YE,E@MONXE,B$T4DQ+F3C7-5OO<%V>77ATRILE)!:G4I.Z:'392^<T>
M]S9*Q88UJ2&U;TK?.0W=ROM31OO*RR^=R<=5IUGFN/OV<RX9"?Z$A29WT*^\
M=;`V47:+#30M[)XO--3O+:?3Y6(Z];:GR&2R@R8V9),G)M.K.\S41/4[S-F9
M?Y#)3&;;66[(=E88LE&EH:O]-C>RWS<!MDUMR&9N#+E[5.\8TIJH?@.?K!:3
M^<S_[:K.!.T[=#>3\=DLNX,PV\GKYP0S3F89LD>R-2D@A:2(%),24DK*2#FI
M()6DBE23&E)+ZAQR:R0;LG-^IH;R3SWB/5.9O..VIN%N;.I?$*U-0UO,@!22
M(E),2D@I*2/EI()4DBI236I(+:ESR*V<K%6G<C\812K<*X\FN^+7,U!`"DD1
M*28EI)24D7)202I)%:DF-:26U#GDUL*?:?I!+3BA--,DZ_]PQ)^NO,OCM8VR
MI[B'AH9"1D6DF)204E)&RDD%J215I)K4D%I2YY!;'C57\_:+T%D_M2/3QF:5
MWA@:#A4=92E@5$B*2#$I(:6DC)23"E))JD@UJ2&UI,XAMQ9J'N6(6JAP;[>E
MR1TJWI7U>G:(,D4,2"$I(L6DA)22,E).*D@EJ2+5I(;4DCJ'W/(<-U\CUSXH
MCR8[+M8FRE)`"DD1*28EI)24D7)202I)%:DF-:26U#GDU&)^W,3)/MP=*H;<
MH>*=YJ]MU&&HD$)21(I)"2DE9:2<5)!*4D6J20VI)74.N>7QYS]>/^C+1(4_
M5`RYY?'F)]8VRI9'Y[(#*F141(I)"2DE9:2<5)!*4D6J20VI)74.N>7Q)RE^
M4![.0,PUV;6\)@6DD!218E)"2DD9*2<5I))4D6I20VI)G4-N+?R9@!_4@E?\
M<TUV#F--"D@A*2+%I(24DC)23BI():DBU:2&U)(ZA]Q:C%WQJYG&(W^E>\[K
M?4W#VV:DP#2T\ZTA*6+#F)2P84K*V#`G%9J\N_7>>65IH\S>N&*NFM1H&CSJ
MT9(ZIZ%;-RF1<^+\D\\8J>_GG5%K<NK61PTH,`V'==.Y+$7,%9,2YDI)&1OF
MI$*3^F$OG2^]DYS21MFZX3O63-]H<NJ&K]TY#=VZ^7,#/ULW3AK,>QH4:4T*
M-`V^0$B*V#`F)9K4MQVL:V^,I#;*K.N,N7)281L.TWLG1*6-,NDKYJI)C6TX
M3._=^VMME$G?.;G<ZOI3"S];7<XYS'MRJ@L*=)17$>^&8VBCS'>*F#XF);;A
M<)5Y@RNU429]QEPYJ;`-A^F]^VBEC3+I*^:J28UM.$SOW?EI;91)WSFYW(+[
M\Q=]P>U-C3<]8S3GM(8FI]Q]U(`"T_#U9XQLE/E&$=/'I,0V'*PP/&-DHTSZ
MC+ER4F$;#M/[SQC9*).^8JZ:U-B&P_3>)&IKHTSZSLGEEMN?#_'+_;9[6'/.
MDV@:%'=-"DQ#^Z1`2(K8,"8E;)B2,C;,204;EJ2*#6M2PX8MJ7,:.C5:'#=/
ML@]WYTDT>4\<>(>UM8TR&TY`"@WU]WY7R\O9U+]K'9D8.\,<DQ)2:JB_D2VO
M%O8.7ID)L)ES4D$J#?69YV=75ZOA_[P#2F7";3\UJ3'DG"[XCPZU)FJ?RZWL
M<5,L"TZQ:/*>(O"^S=I&V<KVN:2AH=!$];?#9Q?+U=0[4D4FQ+:*20DI-=3?
MU[^4U>\^[)&9`)LY)Q6DTI`<2^PIV\I+7YDHF[XF-:26U#GDUM.?D_'WIF\Z
M>"XX5:/)'<`K[T"_ME&FIH$FF1`W%!J27?9AA<TNO`=/(IO+1DW\)X!B&V72
M)R:][3$UI)^S.+OPSJ\RILE)!:DD5:2:U)!:0W8ZK#,T,G+]&9]]I?\_CPC)
M4UW^=:LF;W![E5K;*%.#0-/P$2%#_?YOM;RZF,V\`T#$3#$I,9ED?N2P_4SF
MWDE.:J+THZAG_JXD8^:<5)!*0_VN9"YO]'9W)94)&([U?N4.]G:-C7KE:[0F
M2F^Z%Y=3>7?YE7?%UIFH?8_N'F%\-LJ>3K_M_$HJB8U#D]U<UR;*4D`*21$I
M)B6DE)21<E)!*DD5J28UI);4.>362$UWO/V6[4+/CMA3@QM#P_.`V86W7:YM
ME!VH.I>M6,BHB!23$E)*RD@YJ2"5I(I4DQI22^H<<LOC3S"]/KF^X#R2(;N6
MUZ2`%)(B4DQ*2"DI(^6D@E22*E)-:D@MJ7/(K84_'?2#6G#69Z')'2K>->S:
M1MFA<FAH*&141(I)"2DE9:2<5)!*4D6J20VI)74.N>7Q)V]^4![.TBPT#<LS
M\7^M8VVC3"T"4DB*2#$I(:6DC)23"E))JD@UJ2&UI,XAMSS^9,L/RL-)E86F
M87EF%]YYW-I&V?(<&AH*&1618E)"2DD9*2<5I))4D6I20VI)G4-.>9;'S;/L
MP]UY%D.#`PTI((6DB!23$E)*RD@YJ2"5I(I4DQI22^H<<FMQW,R(_!4D__S8
MD#M4O"O/M8TRXR(@A:2(%),24DK*2#FI()6DBE23&E)+4G];:K]6]YMS7Y[^
M;T7U?^GF<?/\9;/>/#SL3NZVOZN_`[6:R*]M'+C_(U4WB]6U&G2R?OTERPOY
M^U7[/T&%)8>_;.4OF<^NU<W_D6R+N?2S/RGWVRP6LF3_);!D*4N6H]DN9<G^
M>@YMKF3)?G;#7S*3-O)DZ,AGFTF;?@X&;63MR"-R(VWFLG;DZ:RQ);)VY,&@
ML2536;*?2_?[F4J;_A8IEDB;_G=\_24S6=?RJQ4C_<QD7<NC^V-+9%W+@^1C
M2V1=RS/,(TLFTD:>T!A;(FWD?7YC2V1=]Y?S_J>>R+J6%YN-M9%U+>_4&EDR
ME74M;W@:62)-1EM,I(6\!7JDQ436M+R`>&R)K.G^?@@^LZQI>1/K6!M9TS+M
MQR7RQ]\^CE9:=3\2?Z/*/.:JR"/^<7[]478`[/A&/M'8![I1HVPL7FHX6D*I
MX.A@D?J-E4_N#5Z'<B>+GTANZUVGHTODCMQU.;I$;J9=JUMES";WI*2?L:++
M'2;I9VR)W"^2?L:6R-T?Z6=LB3RX(/V,K1EY#$'Z&5LB3Q!(/V-+Y.:_]#.V
M1&ZA2S]C:UKN?DL_8TODQK7T,[9$[CE+/V-+Y,$GZ6=LRY#'F*2?L27R4)+T
M,[9$GB>2?L:6R(,ZTL_8EB:/W4@_8TOD(1KI9VR)//\B_8PMD?==7*NW67`+
MD5=57*L747")O&7B6KU#@DOD!1'7ZO4/7"+O69!^QK9$>6N"]#.V1-Z!(/V,
M+9$W&D@_8TOD93S2S]@WE5?K2#]C2^2M.-+/V!)YH8WT,[9$7@LC_8QMB?)&
M%^EG;(F\C$7Z&5LB[U&1?L:6R,N\I)^Q79>\FDOZ&5LB+]J2?L:6R#NRI)^Q
M)?+R*>EG;$N45TE)/V-+Y,50TL_8$GFGD_2S7W)^.`K('\W\=OME4]X^?[E_
MVIT\;#[+R93\PK6<NS[W?W:S_X\7_<*/7[<O\M<R]^_^^"I_'G4C?_+G0OUV
M\N?M]L7\AVQHYX<_N/KA/P(```#__P,`4$L#!!0`!@`(````(0"O,-F@'1(`
M`+9S```9````>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*S=VW+;N):`X?NI
MFG=P^7[;I@Z.[4JR2Q+/9[+VS%P[CI*XVK92EM/I?OM9D`B"P,]6(I=OVND/
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M;1YD`^2_)X_WZJ4A>^3VK]W?G_>?7[Y].)U>GLW?74P]"3_YM-Z^A/=JR-.3
MNQ_;E\WC_^V#O&ZH_2"3;A#Y.S+(@8[3KN/,=/3.)E=S;WZI'OY`3VG=;;?\
M[1YR?G8UG\\NK]X=[GC9=90)H+?U-Q_RNNLI?X][2$^RNM_)LAN/?%!/[UOU
MCZ[OY>\]4T_O7?4/_;"SLW?>Q?7T%SO)DX3LM]CLW^EO[B9/[V'UCR.W^)U^
M6/G'D5LL^=QO\6\G]GP_%78SR[]]N?WX_GGS\T0.5Y*E[?=;=?#S;CP93L^I
M_<NQGV7_-,ED=JE1%FJ8#Z?27^;/5HX,?WZ<>M[[\S]E-M]U,4O&.!$K':&F
MKAK6=R%P(70A<B%V(7$A=2%S(7>A<*%TH7*A=J%QH1W`N:2GSY',AK?(D1I&
MY4COW:4&D[2)G;*5CM!=?!<"%T(7(A=B%Q(74A<R%W(7"A=*%RH7:A<:%]H!
M6`F18PP2,I.CQ_B)2,\1U>O#J1QM^CGB><X.7^YC)O*G#YHY.>E#^J1``D@(
MB2`Q)(&DD`R20PI(":D@-:2!M$.Q<B3[&3E2%PM''MC4,!].)\.LR>6"G9)E
M%R3;\H]9ZT/ZK$$"2`B)(#$D@:20#))#"D@)J2`UI(&T0[&R)@E"UJ97ZG+N
MV,2ID7:)TSM\V8F<J?LL3;VIG<I5'Z2[^9``$D(B2`Q)("DD@^20`E)"*D@-
M:2#M4*P\R4ZT\G3XR*>B[5QTLK]*5Z?Z%<2'!)`0$D%B2`))(1DDAQ20$E)!
M:D@#:8=B[7BY6#QBQZMH>\=W(HGM)X'GS9U)T`?UDP`20$)(!(DA"22%9)`<
M4D!*2`6I(0VD'8J5"[G</2(7*MK.12>#20#Q(0$DA$20&))`4D@&R2$%I(14
MD!K20-JA6#M>5J76CE>+EM>=)=1(=E(ZL2?(I3-!^J!^@D`"2`B)(#$D@:20
M#))#"D@)J2`UI(&T0['RI(H!5J(.GR9VX78V-`WF",DG!:20%)%B4D)*21DI
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M0HNJS3B78IJ&LVCJN?4P$V5F43>6R6_`J)`4D6)20DI)&2DG%:225)%J4D-J
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MI)24D7)202I)%:DF-:36(CMOJASQ!@?.25?6L,Z`$^?^DJ6..C@!NY&FYE+&
M=#.)1%3(J(@4DQ)22LI(.:D@E:2*5),:4FN1G4A5I1@F\G!Y42T$G-6>IN$\
M\R;N(L%$Z5SXI(`4DB)23$I(*2DCY:2"5)(J4DUJ2*U%=GI4>6.8GM<>']4X
M[HENXMX/(67)7UYIFAB3R+Z;IH!1(2DBQ:2$E)(R4DXJ2"6I(M6DAM1:9"=2
ME3;>(I%=B61PI:ENLE"Y'4[`Z<2]0<)$Z23YI(`4DB)23$I(*2DCY:2"5)(J
M4DUJ2*U%=MYDK[Y)WM0XS@3T+G&EV44=/-'U,2:1H$"]&M3CF=-A2(I(,2DA
MI:2,E),*4DFJ2#6I(;46V8D<*[>\8LT^8:U%D^QRL]3C&;#K>#FX0`$%9BR=
MW9`4D6)20DI)&2DG%:225)%J4D-J+;+SILH8;W'@[,HA<JX:),FY@V8YZ8LF
M)@J7,GV,3I%ONFD*2"$I(L6DA)22,E).*D@EJ2+5I(;46F0G4M4UW$2^ZBV'
M25<A&9X#^Z*)R9LW<2II*]UQ.`7[CB9SH)`=(U),2D@I*2/EI()4DBI236I(
MK456YJ9O5&W9C>.>`Z^<FO121QTZ!YH8G36?%)!"4D2*20DI)66DG%202E)%
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M8%1(BD@Q*2&EI(R4DPI22:I(-:DAM1;9Z5'UA2.FB@IWCF0=#:<*R)^"`E)(
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M&2EGQX)4LF-%JMFQ(;561SM',O6.N`94WQWCK&H[4A]2&\PJ][9?$Z5SX>NQ
M]M]:IKY:(2"%[!B18G9,2"D[9J2<'0M2R8X5J6;'AM1:'>WTJ&+`[U^BS[K:
MP>`2O2/UP:A!>MSRJ8XRBRI?DQDKT&1=J,R<^E*HHTS'2),9/M9DHA)-!X=/
M=93IF&DRP^>:K*<]<Q;QA8ZZW'T1F'?M3:[>73I!I0XR#UAI,@]8:SKX@(V.
M.O2`K0[:/:#]<G#K'B,GRN&1D\6-V9[4)SW,RV'FKMATE+GD\369M42@25;?
M@['P<N@?4<_\R'34%&LRPR>:#@Z?ZBC3,=-DMC[79*(*3=>[W%^^NW@WF3LG
MZU+'F&Z5)C-XK<E$-9H.#-[JF%TW.\VJGG'$K._*'^8%NIQU9+9R1?))`2DD
M1:28E)!24D;*206I)%6DFM206HOL7+A%DE?>CSKKJR=FLDPGSFERJ:/D$K>?
M4LX%ZLK$Z-GCDP)22(I(,2DAI:2,E),*4DFJ2#6I(;4668F<N^44E4AUY\"1
M'V';C6/7633)V;?/VA1O49JH/F^D@!22(E),2D@I*2/EI()4DBI236I(K45V
MWL9*+Z^XC7'>%UX&27+?'%OJJ$,3T,281':#FYM/`T:%I(@4DQ)22LI(.:D@
ME:2*5),:4FN1G4BW$O/*(^F<)1I-U@2<.A=R*Q-E\M:-9>Z/"Q@5DB)23$I(
M*2DCY:2"5)(J4DUJ2*U%=M[&JS;''SC[NLUP`CJ7GLMY%W5P`O8Q)I&@P(RD
MHT)21(I)"2DE9:2<5)!*4D6J20VIM<A.I"J1#"\K7WL&5.,X9\".[`GHEK#G
M?93.B$\*2"$I(L6DA)22,E).*D@EJ2+5I(;46F3GS:W1O/;`V1=OAA/0N;Q<
MSKNH@Q.PCS&)!`5F)!T5DB)23$I(*2DCY:2"5)(J4DUJ2*U%=B)5><:=@*KX
M<^PEJ!K'F8`=V1/06<^NYGV4SHA/"D@A*2+%I(24DC)23BI():DBU:2&U%ID
MYTV5,-R\O>82=%\*49^9,^N$J5/"7ZIO,%'9/3@!^QB32%!@1M)1(2DBQ:2$
ME)(R4DXJ2"6I(M6DAM1:9"?2+:R\]DC*BLN\(WL".N^?K$R4SHA/"D@A*2+%
MI(24DC)23BI():DBU:2&U%IDY^V-BC#SL2+,A7.47.JH@Q.P&\DL^'S33><V
M((6DB!23$E)*RD@YJ2"5I(I4DQI2:Y&52/G1G3<YDN[&L<^`FNP)Z!385B9*
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MWI&;`,9:9._(8H8M"T]>5?).,5OD6S*ES^BKRI-7U7@?=4@<&TN&&AU)!AI]
M;$G,:%XD+>.9E'TOWS;.9R%WH-RH6T[8(O>3W*@;2-@B=X?<J-M!V"+W>MRH
MFSO8(K\VN!A]E:L$C\0OU;08<W68&?&%3(G1!"XEYV,IESOAY(F/#24WL<D3
M'VN1^\_DB8^UR*UC\L3'6N0.+'F<L2V0^ZGD<<9:Y.XH>9RQ%KG721YGUW+>
MO^[E5Q._WWY=%[?/7^^?MB</ZR]R67*QNZ/P>?^[B_O_>>EN-?NT>9'?2]S=
M=?9-?A]S+7<=7:CO`/ZRV;SH_Y$,GO>_N/GQ_P4```#__P,`4$L#!!0`!@`(
M````(0#,+N-*.PT``,]````9````>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
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MRR^[T_&%)+X<G@[7/RO1?N^X<\*OSZ?S]LL3W?<?UF2[8^WJ#Y`_'G;GT^7T
M<!V0W+"^4+SGY7`Y)*7/G^X/=`>BV7OG_<--_]9RRO&H/_S\J6J@_Q[V/R[*
M[[W+X^F'?S[<)X?G/;4VQ4E$X,OI]$V8AO<"D?,0O+TJ`OFY=[]_V'Y_NI:G
M'\'^\/7Q2N&>TAV)&W/N_W3WEQVU*,D,[*E0VIV>Z`+HW][Q(+H&M<CVC^KG
MC\/]]?&F/YX-IO/1V"+SWI?]Y>H=A&2_M_M^N9Z._ZN-K$:J%K$;$?K)(J.!
M-1G-WJ$Q:S3H9Z-A#>;6:#F>O_TZJ%-7-T,_&XU)>QFO7/ZR<:.?C=MBL)A.
M)[.%J/L51VO<>(I?&M?I8&)/YXOW-)_%]RY^:63L?R`SYZNA7QH9RVH;X/58
M#NM^474S=WO=?OYT/OWHT=BER%]>MF(FL!R+&I8[6-TL;9?[NQY'74VHW`J9
MFS[Y4V>ZT##Y_?-X.OHT_)VZ]JZQN4,;2[=8L87HQT+6-<':!)X)?!,$)@A-
M$)D@-D%B@M0$&Q-D)LA-4)B@5,"0PM/&B,;=1\1(R(@8<>O>,9!!LXV`L`6[
MN"98F\`S@6^"P`2A"2(3Q"9(3)":8&."S`2Y"0H3E`K0`D+3P4<$1,C0A*P-
M&F-(W-4VMFHT,8+4FK11`K(&X@'Q@01`0B`1D!A(`B0%L@&2`<F!%$!*E6A!
MFW0$;?*WCU*>V(3739_^528V8Y3<U3:OQJ@U:6,$9`W$`^(#"8"$0"(@,9`$
M2`ID`R0#D@,I@)0JT6)$X?B(@25D;OHV5:-$;:P/F[O&B/I+:V2.K-:DC1J0
M-1`/B`\D`!("B8#$0!(@*9`-D`Q(#J0`4JI$BQHM:SXB:D*FBAJW]EU-++M]
M9*V`N(U7O6(5BX8U$`^\?"`!>(5`(O"*@20U$1-+VZWLN='WTM:(;W4#0AF0
MO":VO-4"2*EZ:4&B1>-'!$G(Z$&JB1HD(&[C):]\#<0#+Q](`%XAD`B\8B!)
M38P@&:,_;8W:((%0!B2OB1HD(*7JI06)%M`?$20AHP>I)FJ0@+B-EQ(D(!YX
M^4""FAB-:XR`L#7BQHU`*`:2M%[JX)KJ$WO:&K'T!H0R('GKI4K/=.FB-6+I
M4A720DF[S8\(I9#10UD3-91`W)H8(9CK-[-NC?AF/!#R@02ME]I.QM`)6R.6
MCD`H!I*T7JKT0K_JM#5BZ0T(94#RUDN57NK216O$TJ4JI$77HDQ.1W@'(J-P
M?3SLOMV=:/JG#5U'HF9,^^-FURQ4].A6PN2I//,0N0VRR;]]REA+8^^PEE9\
M0QYJ^8@"Z2CE[86QGP^E%<M'J!4C2J2C*F]<?2JM6'Z#6AFB7#JJ\L:BO9!6
M+%]J6GJXQ=8<TR0RW+^=7OXNW)0D:^-=[_!I8<IUWEDUTN(-R&VL;-DKUH@\
MU/(1!>@8(HK0,4:4H&.*:(..&:(<'0M$I>:HQTCLUM48=0P]-1;UYEZ+18TL
M==]@+XPGUXI")08M96$YB"XC&=<UHUF5#+.6B^EX8<R2'MM(-Y^1%`\8Z5=E
M:(5L)3H;)=\&MG'9$1O(RF)&LK*$D;1*&=7*B\'8J'K#!M(G8R25<T:OWD;!
M5G6S39>CQ6QI/(1+MJGJT[N`V/R_HPLTN0)YX7<BTRN"2RNT=F*U%\8*8R6M
M9!=H'1FMV8J6"(J6<3<>6\W;[N0C"A"%C'1YXR$?-59C.7/$["AK3!"EC'1Y
MXVF\82NIE2'*$16,9#JR9%1IZ7&E3J/%M<Y2R^GW;4];H6(\;6MDC'AC7;`2
MQ>0XD2MCMT'3<1NU-5N-JA'XBV7-ID:_\=A$"OF(`M0.&S1>5MJCP=R(0X0R
M,:($4=H@<:;4=E(ZVM%71AMTS!#EB(HWR9>:HQYYD7101W05>3K"HLL5RRQ^
M[KYCS244C5Y0(WW0+XTV6(DF$E.#[+%N@Z9R`EDSJF=+VYY-;=OH3QXKR4'C
M,Y+B`2M1YVLC8YO/D)"MZ@ES/#`-(E:6E<6,9&4)(VF5,EI4?:YKWF^;C:>\
M3/HPRAGI,ZKQ#"G8JN[@UG)J3<8S8\E6LE''!"'2'M!-IG*"X'[RDS5!DT^1
M\;P39W:BN\B!OD+D(EHC\A#YB`)$(:((48PH090BVB#*$.6("D2EAO2A++(>
M&",^@7W[46.=/:'G;3LLQE.C/]V)L5R'35H9-BMIPYW51;1&Y"'R$06(0D01
MHAA1@BA%M$&4(<H1%8A*#>EQ%"D/,XXBU?"3L27<?G:2(DZ@?QJVUD:&#=!:
M*K&5A\A'%"`*$46(8D0)HA31!E&&*$=4("HUI(=-Y#+,L(D9];TG_75.Y">'
M*U9CI8Y2&'^M#8?(E6Z,UH@\1#ZB`%&(*$(4(TH0I8@VB#)$.:("4:DA+9`B
MZ?,1@:QT](50@VB#Q<V_0N2RHUS%KA%YZ.@C"M`Q1!2A8XPH:9"1]33VP:FT
MXGO<H%:&*&^0FME'5&J.>MRZ<TCO'H!T`=4<J2Q2&J3%#9-([*C&K=&2R$,M
M'U&`6B&B"!UC1$F#C+@9LT4JK63<X!XSE,\;1#_8L4!4:HYZW,R\TC]\18J2
M=Q"W)I6DCC=`+CO*&U@C\AJD]`$?4=`@HZV-,1)**VZR"+5B1(ETE,LN>VYL
M@U-IQ?(;U,H0Y=)1E3<R*H6T8OE2T]*C*_(V'_!8%&]_B)6+.BIKI$1DU5@I
MR&V0$1$CC;.65GQ/'FKYB`+IJ#:9,;A":<7R$6K%B!+IJ,H;V8E46K'\!K4R
M1+ET5.6-_70AK5B^U+3T@(MD#@9<;A7?E$L2RQ\SW#528KMJK!3DLN/K)S?2
MBN_(0RT?42`=E0:#DQMIQ?(1:L6($NFHRILG-]**Y3>HE2'*I:,J;Z0!"FG%
M\J6FI8=;)"E>"_?;,@-T<`#QKI$2W%5CI2"7'>44OT;DH:./*$#'$%&$CC&B
M!!U31!MTS!#EZ%@@*C5'/49F]N;UG:2-69H&B3QBFQ3`DQMIQ1W'1;1F5&?4
MEK/YV#9S@1[;R-G>1Q0@"AG5Z4'Z<,-X>$5L()5C1`FBE%&M/!DL%DOU/^.!
MLF%S64^&*$=4,*+>+YL:SFC8JI+7@VVF@7X2[":1(Z_SSJZ1R%`H5V#<X$I:
MR6"WCHS6;%7G'<>CV=(V'EX>F\C4J(\H0!0RJA.H<XJ(GE6/V$`JQX@21"DC
M2GLH+6#(;]A*RF>(<D0%HE)#>CQ%[N6U"?9MS],F@Z.&N4;ZF%X:S_Z5W5IQ
M3-T&C65Z>\V(,@YM@XU'1H;?DUK2RC*/6GQIQ34&+"]K#!DU">W!R%AR12@3
M(TH0I8@VB#)$.:*"D3RG+1EUC%R1KX%(_S]G,7:3`5*C7B-C<!N16C6.9,4Q
M<!NDGL4PJJ?$Y6PQ&H^-K8Z'2CZB@)74YXLU,=8](5LU9_X#<RJ)4#E&E"!*
M&=53R82^G-*GD@T;R`;)$.42*1W<O(V"K9JN.YK;]*64>09>LE55HS8CT/=P
M'?WDW8<QE8R^HV*D',8@<A&M$7F(?$0!HA!1A"A&E"!*$6T098AR1`4B\65B
MM6JMVJN.4?VE8?T)V'%__KI?[9^>+KW=Z;OXBG!FT6%?B^M/'.DLQ1''`332
MH&1!)=6D9Y3<6DOGEFKO\EF2S[*K9#SB;RE!S;FMUL\&OZ./+ZNDB,EMI^RT
M'U,%735/G+*:@@R=VZES2^=9'3<Q=<IJRC0<Z+20KJC+@_9]SIIV*:A%6S8G
M["RAW9:3=I;01LD1VR!4H_T&U=-U;;1[H'JZ2F@O0/5TE=#*GNKI*J&D%-73
MU<B48J)ZNDHH.T3U=)508H?JZ2JA]`C5TQ4TRFQ0/5TEE)2@>KI**)]`]725
M4%*;ZNGJL)2BIGJZ2BCA3/5TE5"NF.KI*G%MB^KIZK244J5ZNDHH04KU=)50
M;I/JZ2JA-T0=\?XG]A!ZN=,1KVYB";V7Z8BW+K&$7JETQ`N36$)O)E(]75=`
M[QE2/5TE]-8@U=-50N\`4CU=)>["67=--,'"H5?)\;J2A4/O@2//%T[1Q=VE
M0^]#HWVP=.AE9N3)TJ$WD9'G2Z?HXN[,H>]2T#Z8.?2="?)DYM!'(LCSF5-T
M<7?NT"<5:!_,'?I$`GDR=^C[!N3YW"DJ/FRG-OJ<_&7[=9]NSU\/SY?>T_Z!
M'A3T"A)M`,_U!^GU']?F%=@OIRM]2%Z]#?M(_^.`/7V2,Q+OZSR<3E?^@RH>
MMO\K@L]_`0``__\#`%!+`P04``8`"````"$`C*]U'4H$``""#@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q.2YX;6RL5]MNXS80?2_0?Q#TOI8E^;(6;"^L
M6[M`"Q3%MGV69=H6(HF&2,?)WW=(BC0O3K(M-@])?'SF:,X,+Z/UEY>N]9[1
M0!K<;_QP,O4]U-?XT/2GC?_7M_+39]\CM.H/58M[M/%?$?&_;'_^:7W#PQ,Y
M(T0]4.C)QC]3>DF"@-1GU%5D@B^HAV^.>.@J"A^'4T`N`ZH./*AK@V@Z701=
MU?2^4$B&[]'`QV-3HQS7UP[U5(@,J*THY$_.S85(M:[^'KFN&IZNET\U[BX@
ML6_:AKYR4=_KZN3KJ<=#M6_!]TLXJVJIS3\X\EU3#YC@(YV`7"`2=3VO@E4`
M2MOUH0$'K.S>@(X;?Q<F91C[P7;-"_1W@VY$^]\C9WS[96@.OS4]@FI#GU@'
M]A@_,>K7`X,@.'"B2]Z!/P;O@([5M:5_XMNOJ#F=*;1[#HZ8L>3PFB-20T5!
M9A+-F5*-6T@`?GM=PY8&5*1ZV?@1/+@YT//&CQ>3^7(:AT#W]HC0LF&2OE=?
M"<7=/X(4CE)"9#:*P-]1!.3>CPU$'MQ67M%JNQ[PS8.U`D\BEXJMO#!9^)[T
M(YZN'+YE$)PQD1U3V?BPR"%W`EUYWL:SS^O@&2I9CYS4Y80F(Y,,5C8FF]M`
M80.E!@3@2-F"@OP`6TR%V9()I1*X^XPL#Y(A0W(;*&R@U`##0^QZB&'!/EYJ
MLA,L:./#RE"=B**EF6,J.!'\4:292<D41?EPD,)!2ATQK$`^/Z`=3`6VCFXN
MGJW,S-.1!*F\:4Y1E#D'*1RDU!'#'&Q<U]QD"3`]-_53BB$16*</^A;#5A$;
MB&EP:S*E5"`A+`[E(YPO3+.9(LFP?!2"=:*%60N@4"095NI"ACDX$]XS]PU?
MWC('!YITQT1,=P(!=S*#S$'R,>K.*1RDU*.,O)=NWA]O'A9DYBF0$'JORAG%
M]F892>*\YP?7@[!P9AUWQ4A:\/-R.9_"C]G>4LE`E0QW;)RP3NV/W;$@TYU`
M0GB,YFYN)I&-I/LIF*LPV;QB1%9O6]%C#"NK_V.%!9E6!&(URMXN(TEKE`I3
M5D9$="7D7;';H@<97D+8=O^]+SS*=#-"5F>L;9Q)EM8:"2W5QBHD))H3/EQH
MDL/#3$OLAM66VH-33-OHH;B/X8B6]4Q'R.J,-1QDDJ6U1D)WK4)"[S5'<GB8
M:85=M)H5-NM\O&O8"6RMM1&RNF-=1)EDZ=T16A`HRU-(UMB=A^M-<AYTA]VX
MFJ4/NC/>S_>*IC`K<W=\9.974>9"N0L5+L3F[KN6J+R8H\7`V:'AA#+4ML2K
M\97-R,RS0L7\GL\3N)V@.C:^2.#T=W&8]W?\@K#X*7L/>,!/HP3F+5<GC1.8
M7EQ\-TMVX,O](ITE,!$\P$-0$A&!R@G>`"[5"?U>#:>F)UZ+CN!^RD>$0;Q#
MB`]TO$WWF,+LSR_6,[SK(9B%IQ.XHH\84_D!'AVHM\?MOP```/__`P!02P,$
M%``&``@````A`-QNKO^]`@``K@<``!D```!X;"]W;W)K<VAE971S+W-H965T
M,3,N>&ULE%7;;IPP$'VOU'^P_![,92]9M&RT:90V4BM552_/7F/`"L;(]F:3
MO^\8$P3=54I>N`S'Y\R9L8?MS;.LT1/71J@FPU$08L0;IG+1E!G^]?/^ZAHC
M8VF3TUHU/,,OW.";W<</VY/2CZ;BW")@:$R&*VO;E!##*BZI"53+&_A2*"VI
MA5==$M-J3O-ND:Q)'(8K(JEHL&=(]1P.512"\3O%CI(WUI-H7E,+^9M*M.:5
M3;(Y=)+JQV-[Q91L@>(@:F%?.E*,)$L?RD9I>JC!]W.TH.R5NWLYHY>":654
M80.@(S[1<\\;LB'`M-OF`ARXLB/-BPSOH_0V"C'9;;L"_1;\9$;/R%3J]%F+
M_*MH.%0;^N0Z<%#JT4$?<A>"Q>1L]7W7@>\:Y;R@Q]K^4*<O7)25A78OP9$S
MEN8O=]PPJ"C0!/'2,3%50P)P15*XK0$5H<_=_21R6V4X7@?+=9A$`$<';NR]
M<)08L:.Q2O[QH*BG\B1Q3P+WGB19S24A/J'.WQVU=+?5ZH1@TX"D::G;@E$*
MQ)<-@1.'W3MPAF%30ZX&NO"T2\+EECQ!Y5B/N?48N`Z8:$`0$!V406V^L@,[
M95=:E\JM#XQEXLLRR7MD'#C#BU'R2;@:>+VRQT#;!H.+`3$Q"#3S#3HP[(JI
M]'H@]M(>-$,:(/.E';B3'HKK(V.=)+P><IF87+U'R8&G2C[2'9D)[7I*Z\Y;
M#$?&G9:WMZA;.)7H(YM1PY)P<]F-F]>S3X,#3Z7ZR*:;)>.]#N)C7F=G\5\K
M;M&4WT<F?8G"RTY@&DXDWZY:AYYJ]:%1:_QT]--#<EWR3[RN#6+JZ"9?#/-@
MB`Y3>1^[6OP;7Z1[/ZW)\`6F94M+_HWJ4C0&U;P`SC!8@UGMYZU_L:KMAM9!
M69B3W6,%_T4.,R$,`%PH95]?0)D,?]K=7P```/__`P!02P,$%``&``@````A
M`/J/Y\0A"P``?S,``!D```!X;"]W;W)K<VAE971S+W-H965T,3@N>&ULK)M;
M;^,Z#L??%]CO$.1]DOB2*]H>M+X;N\!B<7;W.4W=-I@D+N)T.O/ME[)$2R3=
M)#V8\W`Z_9FBI+\HBK[TYH^?^]W@1W5LMO7A=NB-)L-!==C43]O#R^WP/W^F
MWQ;#07-:'Y[6N_I0W0Y_5<WPC[N__^WFHSY^;UZKZC0`#X?F=OAZ.KVMQN-F
M\UKMU\VH?JL.<.6Y/N[7)_CU^#)NWH[5^JEMM-^-_<ED-MZOMX>A]K`Z7N.C
M?G[>;JJXWKSOJ\-).SE6N_4)QM^\;M\:]+;?7.-NOSY^?W_[MJGW;^#B<;O;
MGGZU3H>#_695O!SJX_IQ!_/^Z87K#?IN?Q'N]]O-L6[JY],(W(WU0.6<E^/E
M&#S=W3QM809*]L&Q>KX=WGNK,O2'X[N;5J#_;JN/QOGWH'FM/[+C]ND?VT,%
M:L,ZJ15XK.OORK1X4@@:CT7KM%V!?QT'3]7S^GUW^G?]D5?;E]<3+/<49J0F
MMGKZ%5?-!A0%-R-_JCQMZAT,`/X_V&]5:(`BZY^W0Q\ZWCZ=7F^'P6PTG4\"
M#\P'CU5S2K?*Y7"P>6].]?Y_VL@SKK23P#B!G\9)./(74V\Z^X*3T#B!GW]]
M)#/C!'X:)_Z79P-;HY4$?G8^O'#2SN6,"$O3#'Z:9MYDM)A.P]EB#E*>:>G!
MJK<]JG]T75ZY"&.]H&U\Q.O3^N[F6'\,8-/!DC5O:[6%O95RC)&A!]+%RF>A
M`C&BO-PK-[=#T`*BH('X_G$7A-.;\0^(R8VQ>9`V'K6(T$(%H'(;<Y!PD'*0
M<9!S4'!0.F`,LG3:0+3_#FV4&Z4-SNH!@17+9T*@!3:).4@X2#G(.,@Y*#@H
M'4"$@!W[.X10;FZ'L'.[(/$6<SKS!VWCPX_.**0F46?2J2-((D@J2"9(+D@A
M2.D2(A+,ZW>(I-Q`HG55"L(9E>#!&,%8/E6I,^E4$B01)!4D$R07I!"D=`E1
M"7)<CTHCE?M.K]O-]X<:9@0;LN=D"B"OZ&RCG+0:X=P>-/':([2UB02)32M(
M<IUHWI*EH*0S0M>I<)0)DG>M7-=L4Q>=$;HN74=$)3B8SJKT9_WVF4IPEJ),
MR@N521-7)D%BT\I*F0B2BE:9(+EH50A2NJV(`',F0$\X.!-5UG2BFG@0ALY:
M!W071<9(%SSM>=,UPR5*#)FU9YJWG"UF/G.3BD:9<)QW-LYX0A9[!>EK-I_,
M_2D[0\O.#PR0"*8J=?<</R^8LJ:":>+-NU,J$B06)#'$GFVIL,D$R04IA)_2
MM2$3A<*)3%05+`'LZ?,35JWHA#5A$<*/FLX(XR$6)#$$]K(3:FS=TJZ98S1?
MT'C,.B/L+1>DZ.V-'0]EUZR_-Z*G*OJ(H.>%;,VID@8%-F-$$L42)1*E$F42
MY1(5$I4$T3FKBL_=+;KJ_>(IY.FZ$8YJ7*\'@UA4L1HGLE;8,#8HL#LI002+
M:0,KG-"82:6O#)'-:SGZLNX+@\*)SFS^=.9-YBPCE6C4WLA1"56M>$["ZXXH
M.(KXQC3(3442Q1(EB.PD4T0VK642Y1(5B*RO$E'KBVJA:L)S6EQ5U'BFLG3#
M22,63BQM1*8A6-EPT@V#68<28Q7,S4GF^],E\Y1*3QDB-Y@ZYVY@LM`I>'^>
MOYC/F%&)WMNA4TU5!7E.TROCRQ2B5IL'I:8Z"^S21A+%$B42I1)E$N42%1*5
M!%$M5)THM<"G!=??I)L*U*V*@I!EIP?U7$CI`ZO<Y1U^+EH;&W)=,T2)M$HE
MRB3*)2HD*@FB@JFZ\G<(9BI6-WK<DE7?:7@:V1T2&Q*"))V$_H0%?V*M4+$4
MD3U*,^$]1R/JG=]M6"OT7B)JO5/!5%TI!?OJ@:BK4W(@FH+53BB"Q*[BRY7+
MM--'$0C%PBTQ3?SV(6<K>FJ0?FC:HDPXSFT[]40*'+/2O;`&5B0]&.V8BJ1J
MTG,B79F2=&E+5#+5KJN21JY*FH1N3A<H]0RRKC*#X/S"2>8&^185$I7$%Y5"
M59A<BLM5N*<+4S+UGEK5G[!UBDS#4#]0UH\&>QIZ_)8J,0TA5:@(\/P1?RJ9
MHNN@4R=#9'O+T8^;.D5O!5KIWJ:CQ9)6:R5Z;CLCBD)L4T7/E^&M.2W##5(A
M[20=MI4B8^44ZW%?0S&W!*T6K9++T3)<NO^Q%4N->6A39R:[SM&I.V;1=8%6
MNFM80U:WE*0S*BNO]"_(*DMZ7R-U.CNRLON[R%BY`6H;XK9+$)EH'`4L::?H
MQCU[_0F[O<O0RHE/]&SE+A!A9SX[Z$MT\UEG5,C^>O_+-0BD'%[P&\0"EXTV
M,E8D<+6OT(T>?\*"(S$-P0K7(45DU<JD^QRMSKHOK!6Z+Q&U[JF*JG1V\^:%
M<%3F;)=KQ,*1Y9E(%6_0D(1CUQ#'F1@KDQSYS5^*3J"A$_DB&$57.?JU\A:(
M=##.6;8H+W5%150%_!=$5.9,1(UHQ'GLUCJ"8THU)!'7-;0B&@3G;J<2O`>D
MB3\UOD@Z%.YS8P7C0O<%HK/N2^*>BJ7*<E>LZYZ7P<-5(9I&-/(\5M1&IB&)
MO*XASBHQ5JJ"/R>:;A@Z1[-TGZ,O-]I,CSK:?):L2W3R66!3`?ON)2Z7.KZ\
M=3"(11T[`B)C1:+.W'/8L$C0U]FP2(T5B3KMRW&?HR_KOD"D3]Q`"*B=@%^[
M?.XQ106$_$DB\$+.4^9LNVK$(H_ED,C75B3R>AJ*\B(Q#4T:9*DT1;=N$(J>
M<O3A*B)Z*M!*QR7KJ20]40E54>]NX@L2*G,FH4'V?B*"!R"ME46Q1(E$J429
M1+E$A40E073.?;<8RXL/^GUYBV%0Z#SPL4C=%GQC22PVETE^<&Y*R3A5*OC"
MVK3F=&T0D63(WS)%U@JS:"Q1(E$J4291+E$A44D0E8$7VNJ<F5U<KD`6W`:%
MR^X0C!#I=/2-I<S87*;+97,6'2>O8\]O)<B3?"LALOLFDBB6*)$HE2B3*)>H
MD*@DB,Y9E6AN^FA?=TP@WBY,7K5CL:H161R#()UT9[GOL3(Q#K05_-\QLC4^
M':^JC-SQ7ABF+J2@!L*=\1`8Y*Z10+&T2B1*)<HDRB4J)"H)HG-6)8L[YROW
MCZYTR-PU(DMD$%TB=J,4!]J*+I$]I.AP507@#O?"$NF"@0S3('>)!(KA#08[
MI!*)4HDRB7*)"HE*@NB<U;'OSEDMD7K&>V'NNEH@<S<%A)OB#")+Y+/;B!C>
MWB@YR!+Y]O2BPU7GNSO<"\-4YFRS&^0ND4`QO+,42R10*JTRB7*)"HE*@NB<
M_UK1$,BBP2"RB[05U!%.#O/%8:2MZ!+96I4,%UZ^?F6)6G.Z1(B<)9(HEBB1
M*)4HDRB7J)"H)(C.N:]0N+R+H*SGX6F0NT2(Z!*Q9Z"QL:)+]$F]`.\!OK1$
MLEYH/<"J.>6G1+%$B42I1)E$N42%1.I[\U;1=EQZB?3WX_K[X'UU?*FB:K=K
M!IOZ77T;#E7QW4V'\</UZ>H>/,')RZ[`>\25>D77<\5?K%3AWW,EF*Q4C=EW
MQ8<KO?T$(5QISWX^@F`&5]K7)>(*C`"R2$\_(8P`@K?O"HR@=Z;P\?Y][\C@
MH_[V$2WO'1SUV@<PJ)Z>[\/5/=S[]@T)1M3'/9"DMT7LS5?J;9KT!>_*5NIU
MF+P2>PMHTR<6O$:"-GU78M]?J0>OTAL\55VI9Z;R2CQ=P=>7DN?3%7PZ*7D\
M6\&7B9+GLQ5\:2@YO)6%>?1=@3>J,(_VRKA;*_CSA[?U2_7/]?%E>V@&N^H9
MML"D?2-ZU']`H7\YF4\Q'^L3_.%#^U7F*_RA2P6?KT]&4!P\U_4)?X%!C;L_
MG;G[/P```/__`P!02P,$%``&``@````A`(%G_.FB`P``3`L``!D```!X;"]W
M;W)K<VAE971S+W-H965T,38N>&ULK%9-CZ,X$+VOM/\!^3XAY'."0D8AP.Y(
ML])J-3M[=L`)5@-&MM/I_O=;MH'&N+MG#IU#IWEY]:A798K:?WFJ*^^1<$%9
M$Z%@-D<>:7)6T.8:H7^_9Y\^(T](W!2X8@V)T#,1Z,OA]]_V=\8?1$F(]$"A
M$1$JI6Q#WQ=Y26HL9JPE#?QR8;S&$B[YU1<M)[C0077E+^;SC5]CVB"C$/)?
MT6"7"\U)PO);31II1#BIL(3\14E;T:O5^:_(U9@_W-I/.:M;D#C3BLIG+8J\
M.@^_7AO&\;D"WT_!"N>]MKYPY&N:<R;81<Y`SC>)NIYW_LX'I<.^H.!`E=WC
MY!*A8Q!F.^0?]KH^/RBYB]'_GBC9_0].BV^T(5!L:)-JP)FQ!T7]6B@(@GTG
M.M,-^)M[!;G@6R7_8?<_";V6$KJ]!D/*5U@\)T3D4%"0F2W62BEG%20`?[V:
MJI,!!<%/$5K`C6DARP@M-[/U=KX,@.Z=B9`959+(RV]"LOH_0PHZ*2.RZD3@
MNQ,!N?=C?9.'MI5@B0][SNX>'!6XDVBQ.GA!N$%>[\?<?7#XED%PID2.2B5"
M<,8A=P%->3PL5\'>?X1*YATG=CD3QJEGJ+(IV60*I%,@&P$^.!IL04$^P)92
M4;;ZA.(>>/&YL%V>>D8?DDR!=`ID(\#RL/P0#THE0G!4AM8$Z[F==&PX"_@:
M2"N;<AHH@S$'21TD&R.6-\CG`_JC5.!9&IM;KB8=B3L2I/*FN8$RF'.0U$&R
M,6*9@R?9-3?;`BQ+FC_$#!*!@_O*S%C"LV.>**6AK?4IQ08)X+0,/H+U9M*F
M@=2')9T03+I1V-8.2P=2'Y:-A2QS,"3>,_>=M6^9@PG7NU,BMCN#@+L^@Y.#
M)%W4"R=UD&P<9>6]=?->@<E7FC#*4P79>1HD@-Z/ROG9+N>I(YD7@)YDKX5-
M)V3:D39Z@&[7<_C8PMD@`U6RW*GU8C+&?^Y.!=GN#!+`;4;N=G82IX[T,A:3
M(:QO7MHA.VTE>-7+.,CRLK.]O-\A1;8]=,CRY20Y2.(@J8/`%J&5M8[)SVP%
MYO59$WXE)U)5PLO93;WQE=<!-<M(L@[AT8*B3/%-"$?7Q6%Y.>K3/>''L-3H
M%6"*+T)X>[@Z\3*$T>OBQU5XU,O15&<5PC1S^?&N6Z;\(0"6F19?R5^87VDC
MO(I<P/I<#S=NUB%S(;LY<&82UA@]$DK86@F\UN<S>.XNC,G^`F[L#WOPX7\`
M``#__P,`4$L#!!0`!@`(````(0!B8QV/J@4``(H7```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$U+GAM;*R87W.B2!3%W[=JOP/%^PCX=Z1BIJ*(J*AHS>X^
M$T2E(F(!26:^_=P&N@-],MFXM2\!?[GW`'TN].V^^_8C/BLO89I%R66D&BU=
M5<)+D.RCRW&D_O7=_O)55;+<O^S]<W()1^K/,%._W?_YQ]UKDCYEIS#,%5*X
M9"/UE.=74].RX!3&?M9*KN&%_G-(TMC/Z6=ZU+)K&OK[(BD^:VU=[VNQ'UW4
M4L%,/Z.1'`Y1$%I)\!R'E[P42<.SG]/]9Z?HFG&U./B,7.RG3\_7+T$27TGB
M,3I'^<]"5%7BP)P?+TGJ/Y[IN7\873_@VL4/D(^C($VRY)"W2$XK;Q2?>:@-
M-5*ZO]M']`1LV)4T/(S4!\/<&;JJW=\5`_1W%+YFM7,E.R6OLS3:N]$EI-$F
MGY@#CTGRQ$+G>X8H68-LNW#`2Y5]>/"?S_DN>77"Z'C*R>X>/1%[,'/_TPJS
M@$:49%KM'E,*DC/=`/U5XHB5!HV(_Z,XOD;[_#12._U6;Z!W#`I7'L,LMR,F
MJ2K!<Y8G\3]ED%%)E2+M2H2.E4C;:!E=O7^#!EVMN!$Z5AI&:V#HP\[@\_<Q
MK#3H^)\U#/XP[(0_S:='PNCP\:03?@_ZK6-A]+D*G=Q^#P.>32>WWH-6UD=1
M;I:?^_=W:?*JT#M,%9!=??9%,$R#OAZ\T,JR$*7WN\JCDF,J#TQFI%(^%55&
MK\O+?:<SO-->J,2#*F:,,48S8L(C6#TS64L&4QG8,IC)P)'!7`8+&2QEX,I@
M)8.U##8R\&2PE<&N!C2R1WA$%?M_>,1DF$=\=,<<O)G6E@SA$3S%DL%4!K8,
M9C)P9#"7P4(&2QFX,EC)8"V#C0P\&6QEL*N!AB'T$0!#NO0]>__KS-\1EC52
MN[5WQ#"D`1^7,6TZB!>I*WDB0H0I0*9`;"`S(`Z0.9`%D"40%\@*R!K(!H@'
M9`MD5R<-CVB<P2,V@][X86,R([5==ZW3U9N6C*L@NI??NB9"A&M`ID!L(#,@
M#I`YD`60)1`7R`K(&L@&B`=D"V17)PW7R*!W7&NQ9B$_1<'3."F[EG?>M`Y-
M.^5DQ$0*S_A8CTM"4S\G$R!6E46MFC#1Z$@OWU0$<2$;A&9`')%5E^XUBV@N
M@KCT`H260%R159?N-Z57(HA+KT%H`\03677I05-Z*X*X]*XNU/"6FIX/O?V>
M7(M^Y!UOJ>'DYC*5IKDEJ9L+Q*JRW@I@"L2&K!D0![+F0!:0M03B0M8*R!JR
M-D`\R-H"V=6S&H90']DPY..!9]'-@2\):ZAK;\S79H%,1!`O$*L2*M<:K,V;
M`K$A:P;$@:PYD`5D+8&XD+4"LH:L#1`/LK9`=O6LAA=LX5[OPS_V@D4WO2B)
M01_6FA=2!SZI@LH%8]%@BS3NSE3$U(3D"<^&M)E(XT(.Q,Q%S`?2"TA;BC0N
M[8J8NI"TF%A50?UB-6(,C?;705^*60LA+KV!BWDBYH.+;3]QL9T0HHLUO*=U
M[0W>L^BF]R4QJ+;>O.]*G>6D"GIK_RV1QA]^*F+J0E*S8T/:3*1Q(0=BYB+F
M`^D%I"U%&I=V(695D6%A='^@#]H]:6Y=0](&A#V(V?Z[\*Z>U/"4-H=N,;4(
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M=T@]B=ZB/O:0)#G_P2X@=M'O?P$``/__`P!02P,$%``&``@````A`/A-(Y7R
M!```G!(``!D```!X;"]W;W)K<VAE971S+W-H965T,3<N>&ULK)AOCZHX%,;?
M;[+?@?#^RE]E).K-H*#H;K+9W-U]C5B5C%`#S#CS[>\I+4A[O+.:S)MA_''Z
ME#X]/2U,OK_G)^V-E%5&BZEN#4Q=(T5*=UEQF.K__(B^/>E:52?%+CG1@DSU
M#U+IWV>__S:YT/*E.A)2:Z!05%/]6-=GWS"J]$CRI!K0,RG@SIZ6>5+#S_)@
M5.>2)+NF47XR;-,<&7F2%3I7\,M[-.A^GZ5D0=/7G!0U%RG)*:GA^:MC=JY:
MM3R]1RY/RI?7\[>4YF>0V&:GK/YH1'4M3_WX4-`RV9Y@W.^6FZ2M=O,#R>=9
M6M**[NL!R!G\0?&8Q\;8`*799)?!")CM6DGV4_W9\C>6J1NS26/0OQFY5+W_
MM>I(+\LRV_V1%03<AGEB,["E](6%QCN&H+&!6D?-#/Q5:CNR3UY/]=_TLB+9
MX5C#=`]A1&Q@_NYC0:H4'`69@3UD2BD]P0/`7RW/6&J`(\E[<[UDN_HXU1UW
M,/1,QX)P;4NJ.LJ8I*ZEKU5-\_]XD"6DN(@M1.`J1.SQP'X:6L/1`RJ.4(&K
M4/$>?A)XYF8X<&V?Y.Y1C$1;N(JVHX?[]X0&7(6&-?`L<^QX][LY%AIP?7@,
MD&IB/EDF\;EZ?!16EQ7PSZ/C,'B&-0F[2.ID-BGI18,J`%K5.6$UQ?)9#VVJ
M\L3JDO=7N0M)RU2>F<Q4A_H%:5G!@GN;.:XS,=Y@D:0B)L`QEAPQ;R/8BF"R
M"Q6$*HA4L%3!2@6Q"M8JV/2``3YU9L%2^@JSF`PSJQUFT(*K>[;B3!O1-EFH
M(%1!I(*E"E8JB%6P5L&F!R1GH#Q\A3-,9JJ[O32R/%.V(N`Q-ERZ7'/ED'D7
MTMF%2(A(A,@2D14B,2)K1#9](MD&(_T*VYC,5+?[OCFN8DH@@N!9?NE;%]+Y
MADB(2(3($I$5(C$B:T0V?2+Y!G7[AF\#5L_K8Y:^!)1OCS<V7`>J$Z]93*1Q
MK1UMP(EE=RMS+DC?-,M3"ML"-0N%M-E40MNTE+F(NOMMUTNDL4(D[EJQ^@JJ
MRG.LN_NMZJ:O(1D(V^FG!OZ@YV9ON&$@'!Y:!YF*["`G?0<162`2"IVK[Q$B
M2]1JA4B,6JT1V?1;29;`Z4"RY/.ALVAYZ)Q8D+/=^K(\9>+G/,B!#:87-)3+
MUT(H\9,AVP?#6]JNLGM&(FC4))WE6=Y8UEUV*FU^K%!/<1?3>T"UI[7<T]!]
M4FKTIE.!GB23V1L./FX\N'"9B.P])Q9TV[-U)`]_SH.<:Y8M$`D%<;H*$`DB
M3ZLG2R]YD-+_DQRT$D'7?3\6VM>)7M_L39G'S?_T)AD.YU5L.!P^1:%LU_G]
M59,)RN9S(B>^FA'S+JC-O04B(2<.K-#K+*JY%XD@CV>Y:ZNU=8ET5XC$]_2T
MEGMRQK::Y7U=R71VX,>N#Z]IWMK^>8UI9&2O6\1?]5AMF&.TP"C$*,)HB=$*
MHQBC-4;L!;O)E.91N3W\A9F_?^2D/)`Y.9TJ+:6O[&487C]FDP[S-_7`,MM7
M=>5../1A&X5L4G@\]&$CQ#P<^;"K8!Z/?-@E,(=O!,]-J5#T`_;MX$9\8/MP
M.L8Z@>/#^0_S9]=_!HOPC<#UX>`#W.AZAF\#Y^1`_DS*0U94VHGLP2ZS2:>2
M?UW@/VJQ:V]I#5\%F@W\"%^!"*2)R9;\GM*Z_<$ZZ+XKS7X"``#__P,`4$L#
M!!0`!@`(````(0"YB`OD,@$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@
MH@0!**```0``````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````"<D4%/PR`8
MAN\F_H>&>TOIG#&D98F:G5QBXHR+-X1O*[%0`FB[?R_KNCJC)X_D?7EXOH]R
MT>LF^03G56LJ1+(<)6!$*Y795>AYO4QO4.(#-Y(WK8$*[<&C!;N\*(6EHG7P
MZ%H++BCP22093X6M4!V"I1A[48/F/HL-$\-MZS0/\>AVV'+QSG>`BSR_QAH"
MESQP?`"F=B*B$2G%A+0?KAD`4F!H0(,)'I.,X.]N`*?]GQ>&Y*RI5=C;.-.H
M>\Z6XAA.[=ZKJ=AU7=;-!HWH3_!F]?`TC)HJ<]B5`,0.^VFX#ZNXRJT">;MG
M_9MK$N_K$O_.2BD&.RH<\``RB>_1H]TI>9G=W:^7B!4YN4KS>4J*=4%H7M!Y
M\5KB4VN\SR:@'@7^33P!V.#]\\_9%P```/__`P!02P,$%``&``@````A`)>"
M,M.X`@``-`D``!``"`%D;V-0<F]P<R]A<'`N>&UL(*($`2B@``$`````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````G%913]LP$'Z?M/\0Y1U2*$P32H-&
MVXE)VZB6P!XMU[E0"]<.MA/1_?J=$UJ283QM;XY]]]UWWYU]22^?MB)J01NN
MY"P^.9[$$4BF2B[O9_%M\?GH8QP92V5)A9(PBW=@XLOL_;MTI54-VG(P$4)(
M,XLWUM8726+8!K;4'..QQ)-*Z2VU^*GO$U55G,%"L68+TB:GD\F'!)XLR!+*
MH_H`&/>(%ZW]7]!2,<?/W!6[&@EGZ:>Z%IQ1BUEFWSC3RJC*1LLG!B)-AH<I
MLLN!-9K;739)D^%GFC,J8([`646%@31YV4BO@3K15I1KDZ6MO6B!6:4CPW^A
M;*=QM*8&')U9W%+-J;1(RYGU']U:U,;J[*?2#V8#8$V:H$&_V2V'ML,U/\NF
MYYT%KL:6#J%G@@=CC@6W`LQ-M:+:>BA/SX><.Q8]XY[0OHH$>X,LI46]R!?9
M5YNK(?-##G,EC1*\I!9*<D4%E0Q(WF5*;N5_N)S\W2>W&,UUFR&J(C<U%NW`
MQ\G?)S-B-G:9TU$9#BX+,$SSVG640[YJ#)=@3"='WGBC_`#1I>X$WY%"4VDH
M<P#^",\W;-<K_-CPVN7A1?ZN+)`5W=&U\">X`,U;;/\6_+'F:KOEMM?)%10%
ML=C-^!3@!?>&7"(AN_,>Y<W:P&.#9,FR==)[K<("^DL;]CGUQGE;=5+0M=?%
MK[PSQPOC]1CH&S(+RDR\R+W.(="P*%,O:MCGS.L3$'(!_KX,N_AK_(;X&()R
MX5<_[.(/,[PR)`0^+.T_VA%_:`\B*7`.-A2'T>&!&;Y.@<OY1HQPI_EORG.K
MA9(<FP19OWH%?"J/QM,?`^DKEP_FMB[4`E_-_<0=;Z;YAFHH<1;MSU\VTFL<
MMEHXD/F&XEM6[FU>'[C_@[O^)R@[.3N>3"<X^@=[:?+<8O@:9K\!``#__P,`
M4$L!`BT`%``&``@````A`!U_OV3@`0``NA8``!,`````````````````````
M`%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,
M`@``"P`````````````````9!```7W)E;',O+G)E;'-02P$"+0`4``8`"```
M`"$`Z,')Y]\!``"K%0``&@`````````````````_!P``>&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`M;(#Y4,#```#"P``#P``
M``````````````!>"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A
M`*"\6ASG!```(A(``!@`````````````````S@T``'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+`0(M`!0`!@`(````(0!6Z^9#$`0``!@.```9````````
M`````````.L2``!X;"]W;W)K<VAE971S+W-H965T,S`N>&UL4$L!`BT`%``&
M``@````A`%5QLN9O!0``$18``!D`````````````````,A<``'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"+0`4``8`"````"$`#,&T<#$#``#."0``
M&0````````````````#8'```>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M`0(M`!0`!@`(````(0"/,J:'(0,``,H)```9`````````````````$`@``!X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!`BT`%``&``@````A`'4YYL'!
M`@``7P<``!D`````````````````F",``'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"+0`4``8`"````"$`CS@5-]X"``#9!P``&0``````````````
M``"0)@``>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+`0(M`!0`!@`(````
M(0"@-!!1G`@``"DX```9`````````````````*4I``!X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L!`BT`%``&``@````A`))H6W9R`P``,0T``!D`````
M````````````>#(``'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"+0`4
M``8`"````"$`0!&*`K(3```+K```&0`````````````````A-@``>&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+`0(M`!0`!@`(````(0#[)-DUO`8``-L?
M```9``````````````````I*``!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L!`BT`%``&``@````A`$!";^5U!```FQ```!@`````````````````_5``
M`'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+`0(M`!0`!@`(````(0`O!M-N
MU0(``-,(```8`````````````````*A5``!X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"+0`4``8`"````"$`;YJX1XI>``"%-@$`%```````````````
M``"S6```>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"+0`4``8`"````"$`+6'=
M7;H+```T9@``#0````````````````!OMP``>&PO<W1Y;&5S+GAM;%!+`0(M
M`!0`!@`(````(0#[8J5ME`8``*<;```3`````````````````%3#``!X;"]T
M:&5M92]T:&5M93$N>&UL4$L!`BT`%``&``@````A`-9,K2R/!```21,``!D`
M````````````````&<H``'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M+0`4``8`"````"$`'1;1I1D6``"DH```&0````````````````#?S@``>&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+`0(M`!0`!@`(````(0"GL%+(?0,`
M`*X+```8`````````````````"_E``!X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"+0`4``8`"````"$`FY,D4:T"``!0!P``&0````````````````#B
MZ```>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(M`!0`!@`(````(0#V
M(0C%%P,``/D*```9`````````````````,;K``!X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L!`BT`%``&``@````A`$=&YOFO"```_"<``!D`````````
M````````%.\``'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4``8`
M"````"$`6A)3>Z<,``#!/```&0````````````````#Z]P``>&PO=V]R:W-H
M965T<R]S:&5E=#$P+GAM;%!+`0(M`!0`!@`(````(0`/\?@$B0(``(4&```8
M`````````````````-@$`0!X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M+0`4``8`"````"$`'PXL96P&``#K&@``&`````````````````"7!P$`>&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!`BT`%``&``@````A`#-X[*&T!P``
M-",``!@`````````````````.0X!`'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+`0(M`!0`!@`(````(0`9GS>!%A$``*AO```8`````````````````",6
M`0!X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"+0`4``8`"````"$`,O_R
MT@<(``"<)```&`````````````````!O)P$`>&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L!`BT`%``&``@````A`$2OT7IN!0``*AH``!D`````````````
M````K"\!`'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"+0`4``8`"```
M`"$`<NA6`OH3``"U=0``&0````````````````!1-0$`>&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0"O,-F@'1(``+9S```9````
M`````````````())`0!X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!`BT`
M%``&``@````A`,PNXTH[#0``ST```!D`````````````````UEL!`'AL+W=O
M<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4``8`"````"$`C*]U'4H$``""
M#@``&0````````````````!(:0$`>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM
M;%!+`0(M`!0`!@`(````(0#<;J[_O0(``*X'```9`````````````````,EM
M`0!X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L!`BT`%``&``@````A`/J/
MY\0A"P``?S,``!D`````````````````O7`!`'AL+W=O<FMS:&5E=',O<VAE
M970Q."YX;6Q02P$"+0`4``8`"````"$`@6?\Z:(#``!,"P``&0``````````
M```````5?`$`>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+`0(M`!0`!@`(
M````(0!B8QV/J@4``(H7```9`````````````````.Y_`0!X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L!`BT`%``&``@````A`/A-(Y7R!```G!(``!D`
M````````````````SX4!`'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M+0`4``8`"````"$`N8@+Y#(!``!``@``$0````````````````#XB@$`9&]C
M4')O<',O8V]R92YX;6Q02P$"+0`4``8`"````"$`EX(RT[@"```T"0``$```
M``````````````!AC0$`9&]C4')O<',O87!P+GAM;%!+!08`````+``L`.8+
(``!/D0$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EC3BG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">1,985,384<span></span></td>
        <td class="nump">2,330,134<span></span></td>
        <td class="nump">273,859<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issued</a></td>
        <td class="nump">291,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="num">(11,655)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">2,265,229<span></span></td>
        <td class="nump">1,985,384<span></span></td>
        <td class="nump">273,859<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 3.23<span></span></td>
        <td class="nump">$ 0.96<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
        <td class="nump">$ 7.86<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercised</a></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 3.84<span></span></td>
        <td class="nump">$ 3.23<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding</a></td>
        <td class="text">8 years 4 months 2 days<span></span></td>
        <td class="text">8 years 4 months 2 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years), Issued</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">$ 5,908,696<span></span></td>
        <td class="nump">$ 685,800<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">19,514,362<span></span></td>
        <td class="nump">5,908,696<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">9,673,290<span></span></td>
        <td class="nump">12,770,636<span></span></td>
        <td class="nump">5,364,557<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issued</a></td>
        <td class="nump">306,928<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="num">(299,885)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">9,680,333<span></span></td>
        <td class="nump">9,673,290<span></span></td>
        <td class="nump">5,364,557<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 1.06<span></span></td>
        <td class="nump">$ 0.97<span></span></td>
        <td class="nump">$ 0.51<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
        <td class="nump">$ 7.88<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercised</a></td>
        <td class="nump">$ 1.04<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 1.28<span></span></td>
        <td class="nump">$ 1.06<span></span></td>
        <td class="nump">$ 0.51<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding</a></td>
        <td class="text">4 years 8 months 16 days<span></span></td>
        <td class="text">4 years 10 months 21 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years), Issued</a></td>
        <td class="text">6 years 7 months 17 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">47,396,307<span></span></td>
        <td class="nump">6,114,768<span></span></td>
        <td class="nump">3,261,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">$ 107,268,785<span></span></td>
        <td class="nump">$ 47,396,307<span></span></td>
        <td class="nump">$ 3,261,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently granted or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EEFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Office equipment</a></td>
        <td class="nump">$ 17,179<span></span></td>
        <td class="nump">$ 15,480<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
        <td class="num">(2,965)<span></span></td>
        <td class="num">(1,560)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
        <td class="nump">$ 14,214<span></span></td>
        <td class="nump">$ 13,920<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note Payable<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Note Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Note Payable</a></td>
        <td class="text"><div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Note 4 &#8211; Note Payable</font></div><div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div><div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On December 28, 2013, the Company entered into a premium finance agreement to pay a $157,825 premium for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $15,995 in January 2014 and&#160;is required&#160;to pay $15,995 in monthly installment for nine months. For the quarter ended March 31, 2014, the Company paid $63,344 under this finance agreement. As of March 31, 2014 and December 31, 2013, the outstanding balance related to the premium finance agreement was $94,481 and $157,825, respectively.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V
M-S`Q8C4S,#0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C
M,S<V-S`Q8C4S,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&5B
M-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T+U=O<FMB;V]K+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P@>&UL;G,Z=CTS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M
M8V]M.G9M;"(@>&UL;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M
M.F]F9FEC93IO9F9I8V4B('AM;&YS.G@],T0B=7)N.G-C:&5M87,M;6EC<F]S
M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S7U5N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U5N,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED
M871E9%]3=&%T96UE;G1S7V]F7T]P93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<V-R
M:7!T:6]N7V]F7T)U<VEN97-S7V%N9%]3=3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R
M='E?86YD7T5Q=6EP;65N=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DYO=&5?4&%Y86)L93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D1E<FEV871I=F5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E
M;F-I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y%
M<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M=6)S97%U96YT7T5V96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D1E<V-R:7!T:6]N7V]F7T)U<VEN97-S7V%N9%]3=3$\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$97-C<FEP=&EO
M;E]O9E]"=7-I;F5S<U]A;F1?4W4R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4F5L871E9%]087)T>5]4<F%N<V%C=&EO;G-?5&%B
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R
M='E?86YD7T5Q=6EP;65N=%]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y$97)I=F%T:79E<U]486)L97,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?
M0V]N=&EN9V5N8VEE<U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y%<75I='E?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^1&5S8W)I<'1I;VY?;V9?0G5S:6YE<W-?86YD7U-U
M,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<V-R
M:7!T:6]N7V]F7T)U<VEN97-S7V%N9%]3=30\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C(N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y296QA=&5D7U!A<G1Y7U1R86YS86-T:6]N
M<U]$970\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y2
M96QA=&5D7U!A<G1Y7U1R86YS86-T:6]N<U]$970Q/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q=6EP;65N
M=%]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4')O<&5R='E?86YD7T5Q=6EP;65N=%]$971A:6QS,3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?4&%Y86)L95]$971A
M:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1&5R
M:79A=&EV97-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D1E<FEV871I=F5S7T1E=&%I;'-?,3PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<FEV871I=F5S7T1E=&%I;'-?
M5&5X='5A;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970S,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7S$\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,S$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N
M=&EN9V5N8VEE<U\R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#,R+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^17%U:71Y7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S,N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y%<75I='E?1&5T86EL<U]497AT=6%L/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#,T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N
M='-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T
M>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@
M/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C
M=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0
M<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z
M17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*
M("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I
M=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAE8C4X.3DU7S%D9&1?
M-#$Q85\X93)A7V,S-S8W,#%B-3,P-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0O
M5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%44%!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T
M:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#`Y+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B=!8W1I;FEU;2!0:&%R;6%C975T:6-A;',L($EN8RX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<P,#`Q,S@X,S(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=F86QS93QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES
M8V%L(%EE87(@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<M+3$R+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)S$P+5$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DUA<B`S,2P-"@D)
M,C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!0
M97)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=1
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)U-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PU-C(L.#0V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X96(U.#DY-5\Q9&1D7S0Q
M,6%?.&4R85]C,S<V-S`Q8C4S,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T+U=O
M<FMS:&5E=',O4VAE970P,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P1313044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A5
M;F%U9&ET960I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@07-S971S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-2PX-S<L-S@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#4S,RPS-C8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@
M97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV-C<L.3$Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$X+#,X.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($-U
M<G)E;G0@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+#4T-2PV.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#<U,2PW-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE
M="!O9B!A8V-U;75L871E9"!D97!R96-I871I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$T+#(Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#DR,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPU-3DL.3`V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PW-C4L
M-C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-U<G)E;G0@3&EA8FEL:71I97,Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y
M86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C$U+#(W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,W."PY-34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@
M86YD(&%C8W)U960@97AP96YS97,@+2!R96QA=&5D('!A<G1Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#DL-3,W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$L,3@U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;W1E<R!P
M87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-"PT.#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-3<L.#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ.2PQ,C@L-S8Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW,#<L,C4U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M0W5R<F5N="!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C`L,#(X+#`U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<L,S(U+#(R,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD(&-O
M;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R
M<R<@1&5F:6-I=#H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL("0P+C`Q('!A<B!V86QU93L@
M-3`L,#`P+#`P,"!A=71H;W)I>F5D(#`@:7-S=65D(&%N9"!O=71S=&%N9&EN
M9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@)#`N,#$@<&%R('9A;'5E
M.R`R,#`L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE9#L@,C4L-38R+#,T-B!A
M;F0@,C0L-38U+#0T-R!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9RP@
M<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-2PU-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-"PU-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2PW,C,L,#0U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C0L.3,S+#$T
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5F:6-I="!A8V-U;75L871E9"!D=7)I;F<@=&AE(&1E=F5L;W!M96YT
M('-T86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X,RPR,38L
M-S4R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#8V+#4Q-RPR-34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@4W1O8VMH;VQD97)S)R!$969I8VET
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,RPT-C@L,30U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M-34Y+#4T-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!,:6%B:6QI=&EE<R!A;F0@4W1O8VMH;VQD97)S
M)R!$969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L
M-34Y+#DP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-2PW-C4L-C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q
M8C4S,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&5B-3@Y.35?
M,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T+U=O<FMS:&5E=',O4VAE970P
M,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14--04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A5;F%U9&ET960I("A087)E
M;G1H971I8V%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@
M=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K+"!S
M:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H
M87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U
M+#4V,BPS-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-"PU-C4L-#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL('-H87)E<R!O=71S
M=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L-38R
M+#,T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(T+#4V-2PT-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7SAE8C4X.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P
M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X96(U.#DY-5\Q9&1D
M7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0O5V]R:W-H965T<R]3:&5E=#`T+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%0C%!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS
M;VQI9&%T960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS("A5;F%U9&ET960I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ-C8@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T871E;65N=',@3V8@3W!E
M<F%T:6]N<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@17AP96YS97,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H
M(&%N9"!D979E;&]P;65N="P@;F5T(&]F(')E:6UB=7)S96UE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0V,"PY-C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X-2PW,#<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,2PU-#@L,S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-S8L,#4S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,S+#$S-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#$P
M,"PS-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0P-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(V
M-2PT,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQO<W,@;VX@9&ES<&]S:71I;VX@;V8@97%U:7!M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ,C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-30L,S`X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@3W!E<F%T:6YG($5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#$S."PT,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#`R,BPY-C0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-2PT-C@L-#8P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!&
M<F]M($]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#0L,3,X+#0R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R+#`R,BPY-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-C4L-#8X+#0V,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H
M97(@26YC;VUE(&%N9"`H17AP96YS92DZ/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-S4I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PY-C<L,C$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1V%I;B!O;B!E>'1I;F=U:7-H;65N="!O9B!L:6%B:6QI
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C8P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B`H;&]S<RD@;VX@8VAA;F=E
M(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV92!L:6%B:6QI=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L-38Q+#`W,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,S-"PU
M,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q-BPP-#$L,#<W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L($]T:&5R($EN8V]M92!A;F0@*$5X<&5N
M<V4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPU-C$L,#<Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,S,S+#DS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$W+#<T."PR.3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,38L-CDY+#0Y-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#8X.2PP,C<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X
M,RPR,38L-S4R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T($QO<W,@4&5R($-O;6UO;B!3:&%R92`M($)A<VEC
M(&%N9"!$:6QU=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#`N-C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@P+C`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@
M3G5M8F5R(&]F($-O;6UO;B!3:&%R97,@3W5T<W1A;F1I;F<@+2!"87-I8R!A
M;F0@1&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L
M,C(X+#(Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(Q+#,Y,2PV-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X96(U.#DY-5\Q9&1D7S0Q,6%?
M.&4R85]C,S<V-S`Q8C4S,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T+U=O<FMS
M:&5E=',O4VAE970P-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14150D<^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@0V%S:"!&
M;&]W<R`H56YA=61I=&5D*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,38V($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M87-H($9L;W=S($9R;VT@3W!E<F%T:6YG($%C=&EV:71I97,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$V+#8Y.2PT.3<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@V.#DL,#(W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H.#,L,C$V+#<U,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@
M=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E
M<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E
M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<U,"PY
M,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY-"PR,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX+#0V,"PW-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!E>'!E;G-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0P-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#(V-2PT,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQO<W,@;VX@9&ES<&]S:71I;VX@;V8@97%U:7!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ,C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-30L,S`X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;6]R=&EZ871I;VX@;V8@9&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5F97)R960@9FEN86YC:6YG(&-O<W1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Y,BPV.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=A:6X@;VX@97AT:6YG=6ES:&UE;G0@
M;V8@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V,"PP,#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S("AG86EN
M*2!O;B!C:&%N9V4@:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E(&QI86)I
M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPU-C$L
M,#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PS,S0L-3$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$V+#`T,2PP-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^*$EN8W)E87-E*2!D
M96-R96%S92!I;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N
M="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0T.2PU
M,C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-3`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,W,"PP.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8W)E87-E("AD96-R96%S
M92D@:6XZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S-BPS,3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,S<L,3(Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDU-RPP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS
M97,@+2!R96QA=&5D('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,#@L,S4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X.2PU,S<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@0V%S:"!5
M<V5D($EN($]P97)A=&EN9R!!8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R+#0Y,"PY-#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPS,3(L,S,X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4S+#$X-BPP,C(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-A<V@@1FQO=W,@1G)O;2!);G9E<W1I;F<@06-T:79I=&EE
M<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&%Y;65N="!M861E(&9O<B!P871E;G0@<FEG:'1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#,L,#`P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!U<F-H87-E(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-CDY*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,3$R
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#@S,RPY-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T($-A<V@@57-E9"!);B!);G9E<W1I;F<@06-T:79I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV.3DI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PQ
M,3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,RPX,S,L.34P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L;W=S($9R;VT@1FEN86YC
M:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D)O<G)O=VEN9W,@;VX@8V]N=F5R=&EB;&4@9&5B
M="P@;F5T(&]F(&]F9F5R:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8T-2PX.#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-A;&5S(&]F('-T;V-K+"!N970@;V8@;V9F97)I;F<@8V]S=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.#<Q+#0W-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU."PY-#4L.#,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('1H92!E>&5R8VES92!O9B!O
M<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#(R,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ."PR-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@=&AE(&5X97)C:7-E
M(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,RPW,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPT.3$L,3`T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT<R!O;B!N;W1E
M('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8S+#,T
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@V-2PS,S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,C`S+#,T-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@0V%S:"!0<F]V:61E9"!">2`H57-E
M9"!I;BD@1FEN86YC:6YG($%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L.#,W+#`V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#8U+#,S,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,BPX.3<L-S4S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&-H86YG92!I;B!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-#0L-#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,BPS-S@L-S@S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L.#<W+#<X,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A="!B96=I;FYI
M;F<@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#4S,RPS-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#8Q."PV-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%T(&5N9"!O
M9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L.#<W
M+#<X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,C,Y+#@X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L.#<W+#<X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@
M9&ES8VQO<W5R97,@;V8@8V%S:"!F;&]W<R!I;F9O<FUA=&EO;CH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P
M86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,C0S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R('1A>&5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N
M=&%L(&1I<V-L;W-U<F4@;V8@;F]N+6-A<V@@:6YV97-T:6YG(&%N9"!F:6YA
M;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F5N969I8VEA;"!C;VYV97)S:6]N(&9E871U
M<F4@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<R+#@U,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YS=7)A;F-E('!R
M97!A:60@=&AR;W5G:"!P<F5M:75M(&9I;F%N8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDW
M+#@R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1F%I<B!V86QU92!O9B!W87)R86YT<R!I<W-U960@=VET:"!D96)T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,W-RPQ-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@=V%R<F%N=',@
M:7-S=65D('=I=&@@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PY.#4L,C,X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER
M('9A;'5E(&]F('=A<G)A;G1S(&ES<W5E9"!T;R!T:&4@<&QA8V5M96YT(&%G
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,3<P+#(X,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!N;W1E
M<R!P87EA8FQE(&%N9"!A8V-R=65D(&EN=&5R97-T('1O('-T;V-K/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDX,2PW,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1R86YS9F5R('=A<G)A;G0@9&5R:79A=&EV97,@
M9G)O;2!L:6%B:6QI='D@=&\@97%U:71Y(&-L87-S:69I8V%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S.2PU-C4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#0Q-RPY
M.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAE
M8C4X.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C
M,S<V-S`Q8C4S,#0O5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@0G5S
M:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0
M;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D1E<V-R:7!T:6]N(&]F($)U<VEN97-S(&%N9"!3=6UM87)Y
M(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF
M:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)V9O
M;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@
M8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z
M(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[(&1I<W!L87DZ(&EN;&EN93LG/DYO=&4@,2`F(S@R,3$[($1E
M<V-R:7!T:6]N(&]F($)U<VEN97-S(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO9&EV
M/@T*/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C
M:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#0U<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM
M;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+7=E:6=H
M=#H@8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^3F%T=7)E(&]F($)U<VEN97-S
M("8C.#(Q,3L\+V9O;G0^)B,Q-C`[06-T:6YI=6T@4&AA<FUA8V5U=&EC86QS
M+"!);F,N+"!I;F-O<G!O<F%T960@;VX@2G5N92`Q,RP@,C`P,"P@:7,@82!B
M:6]T96-H;F]L;V=Y(&-O;7!A;GD@8V]M;6ET=&5D('1O(&1E=F5L;W!I;F<@
M8G)E86MT:')O=6=H('1H97)A<&EE<R!F;W(@;&EF92!T:')E871E;FEN9R!D
M:7-E87-E<R!U<VEN9R!I=',@86QP:&$@<&%R=&EC;&4@:6UM=6YO=&AE<F%P
M>2`H05!)5"D@<&QA=&9O<FT@86YD(&]T:&5R(')E;&%T960@86YD('-I;6EL
M87(@=&5C:&YO;&]G:65S+B!!4$DL('1O9V5T:&5R('=I=&@@:71S('=H;VQL
M>2!O=VYE9"!S=6)S:61I87)Y+"!-961!8W1I;FEU;2P@26YC+B`H34%)*2P@
M*&AE<F5I;F%F=&5R(')E9F5R<F5D('1O(&-O;&QE8W1I=F5L>2!A<R`F(S@R
M,C`[05!))B,X,C(Q.RD@:&%S(&EN:71I871E9"!C;VQL86)O<F%T:79E(&5F
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M<G5G($%P<&QI8V%T:6]N+B!);B`R,#$R+"!!4$D@;&%U;F-H960@82!M=6QT
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M:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R
M9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q
M-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT
M.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B
M;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US:7IE+6%D:G5S=#H@
M;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SY!8W1I;FEU;2!0:&%R;6%C975T:6-A;',L($EN8RX@9F]R;65R
M;'D@:VYO=VX@87,@0V%C='5S(%9E;G1U<F5S+"!);F,N("AT:&4@)B,X,C(P
M.T-O;7!A;GDF(S@R,C$[+"`F(S@R,C`[06-T:6YI=6TF(S@R,C$[+"`F(S@R
M,C`[0V%C='5S)B,X,C(Q.RDL('=A<R!I;F-O<G!O<F%T960@=6YD97(@=&AE
M(&QA=W,@;V8@=&AE(%-T871E(&]F($YE=F%D82!O;B!/8W1O8F5R(#8L(#$Y
M.3<N(%1H92!#;VUP86YY('=A<R!A('-H96QL(&5N=&ET>2!T:&%T)B,Q-C`[
M=V%S(&EN('1H92!M87)K970@9F]R(&$@;65R9V5R('=I=&@@86X@87!P<F]P
M<FEA=&4@;W!E<F%T:6YG(&-O;7!A;GDN/"]F;VYT/CPO9&EV/@T*/&1I=B!A
M;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#,V<'0[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E
M.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N
M=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#0U<'0[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@
M8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z
M(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
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M+"!);F,N("@F(S@R,C`[05!))B,X,C(Q.RDL(&EN(&5X8VAA;F=E(&9O<B!T
M:&4@:7-S=6%N8V4@;V8@87!P<F]X:6UA=&5L>2`Y.24@;V8@=&AE(&ES<W5E
M9"!A;F0@;W5T<W1A;F1I;F<@8V]M;6]N('-T;V-K+"!P87(@=F%L=64@)#`N
M,#$@<&5R('-H87)E+"!O9B!T:&4@0V]M<&%N>2X@5&AE(%-H87)E($5X8VAA
M;F=E(&-L;W-E9"!O;B!$96-E;6)E<B`R."P@,C`Q,BXF(S$V,#LF(S$V,#M!
M<R!A(')E<W5L="!O9B!T:&4@4VAA<F4@17AC:&%N9V4L('1H92!F;W)M97(@
M<VAA<F5H;VQD97)S(&]F($%022!B96-A;64@=&AE(&-O;G1R;VQL:6YG('-H
M87)E:&]L9&5R<R!O9B!T:&4@0V]M<&%N>2X@070@=&AE(&-L;W-I;F<L(&5A
M8V@@05!)('-H87)E:&]L9&5R(')E8V5I=F5D(#`N,S,S('-H87)E<R`H=&AE
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M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
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M)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#0U<'0[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P
M86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^07,@82!R
M97-U;'0@;V8@=&AE(%-H87)E($5X8VAA;F=E+"!T:&4@0V]M<&%N>2!I<R!N
M;W<@82!H;VQD:6YG(&-O;7!A;GD@;W!E<F%T:6YG('1H<F]U9V@@05!)+"!A
M(&-L:6YI8V%L+7-T86=E(&)I;W!H87)M86-E=71I8V%L(&-O;7!A;GD@9&5V
M96QO<&EN9R!C97)T86EN(&-A;F-E<B!T<F5A=&UE;G1S+CPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.PT*('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P
M86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T
M-7!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P
M=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L
M87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R!F;VYT+7-I>F4M861J
M=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/D]N($UA<F-H(#(P+"`R,#$S+"!I;B!A;G1I8VEP871I
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M,38P.T]N($%P<FEL)B,Q-C`[,3$L(#(P,3,L('1H92!#;VUP86YY(&-H86YG
M960@:71S(&1O;6EC:6QE(&9R;VT@=&AE(%-T871E(&]F($YE=F%D82!T;R!T
M:&4@4W1A=&4@;V8@1&5L87=A<F4@86YD(&-H86YG960@:71S(&YA;64@9G)O
M;2!#86-T=7,@5F5N='5R97,L($EN8RX@=&\@06-T:6YI=6T@4&AA<FUA8V5U
M=&EC86QS+"!);F,N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=F;VYT
M.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES
M<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA
M9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R
M9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D]N(%-E<'1E;6)E
M<B`R-2P@,C`Q,RP@:6X@86-C;W)D86YC92!W:71H(&$@0V5R=&EF:6-A=&4@
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M86YY('=A<R!E>&-H86YG960@9F]R(#`N,S,S('-H87)E<R!O9B!#;VUP86YY
M)B,X,C$W.W,@8V]M;6]N('-T;V-K+B8C,38P.R8C,38P.T$@=&]T86P@;V8@
M,RPY-S`L,3,W('-H87)E<R!O9B!!8W1I;FEU;2!#;W)P;W)A=&EO;B!C;VUM
M;VX@<W1O8VL@=V%S(&5X8VAA;F=E9"!F;W(@,2PS,C(L,#4U('-H87)E<R!O
M9B!#;VUP86YY(&-O;6UO;B!S=&]C:RXF(S$V,#L\+V9O;G0^/"]D:78^#0H\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M
M<W!A8V4Z(&YO<FUA;#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS
M1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P
M;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US:7IE+6%D
M:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
M9#L@9&ES<&QA>3H@:6YL:6YE.R<^0F%S:7,@;V8@4')E<V5N=&%T:6]N("T@
M56YA=61I=&5D($EN=&5R:6T@1FEN86YC:6%L($EN9F]R;6%T:6]N("8C.#(Q
M,3L\+V9O;G0^)B,Q-C`[5&AE(&%C8V]M<&%N>6EN9R!U;F%U9&ET960@:6YT
M97)I;2!C;VYD96YS960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE
M;G1S(&%N9"!R96QA=&5D(&YO=&5S(&AA=F4@8F5E;B!P<F5P87)E9"!I;B!A
M8V-O<F1A;F-E('=I=&@@86-C;W5N=&EN9R!P<FEN8VEP;&5S(&=E;F5R86QL
M>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E<R!O9B!!;65R:6-A("@F
M(S@R,C`[52Y3+B!'04%0)B,X,C(Q.RD@9F]R(&EN=&5R:6T@9FEN86YC:6%L
M(&EN9F]R;6%T:6]N+"!A;F0@:6X@86-C;W)D86YC92!W:71H('1H92!R=6QE
M<R!A;F0@<F5G=6QA=&EO;G,@;V8@=&AE(%5N:71E9"!3=&%T97,@4V5C=7)I
M=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;B`H=&AE("8C.#(R,#M314,F
M(S@R,C$[*2!W:71H(')E<W!E8W0@=&\@1F]R;2`Q,"U1(&%N9"!!<G1I8VQE
M(#@@;V8@4F5G=6QA=&EO;B!3+5@N($%C8V]R9&EN9VQY+"!T:&5Y(&1O(&YO
M="!I;F-L=61E(&%L;"!O9B!T:&4@:6YF;W)M871I;VX@86YD(&9O;W1N;W1E
M<R!R97%U:7)E9"!B>2!5+E,N($=!05`@9F]R(&-O;7!L971E(&9I;F%N8VEA
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M96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"!N;W1E<R!T:&5R971O
M(&-O;G1A:6YE9"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS(&%N;G5A;"!R97!O
M<G0@;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S
M,2P@,C`Q,RP@87,@9FEL960@=VET:"!T:&4@4T5#(&]N($9E8G)U87)Y(#(X
M+"`R,#$T+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P
M>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ
M(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A
M8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7=E:6=H=#H@8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^1&5V96QO<&UE
M;G0@4W1A9V4@0V]M<&%N>2`F(S@R,3$[/"]F;VYT/B8C,38P.U1H92!#;VUP
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M97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E
M=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G
M9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#,V
M<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@.7!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA
M>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU
M<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[
M(&1I<W!L87DZ(&EN;&EN93LG/E!R:6YC:7!L97,@;V8@0V]N<V]L:61A=&EO
M;B`F(S@R,3$[/"]F;VYT/B8C,38P.U1H92!C;VYD96YS960@8V]N<V]L:61A
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M=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A
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M;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ
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M;"!3=&%T96UE;G0@4')E<V5N=&%T:6]N("8C.#(Q,3L\+V9O;G0^)B,Q-C`[
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M93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I
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M<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R
M9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!D:7-P;&%Y.B!I;FQI;F4[)SY#87-H
M(&%N9"!#87-H($5Q=6EV86QE;G1S("8C.#(Q,3L\+V9O;G0^)B,Q-C`[5&AE
M($-O;7!A;GD@8V]N<VED97)S(&%L;"!H:6=H;'D@;&EQ=6ED(&%C8V]U;G1S
M('=I=&@@;W)I9VEN86P@;6%T=7)I=&EE<R!O9B!T:')E92!M;VYT:',@;W(@
M;&5S<R!T;R!B92!C87-H(&5Q=6EV86QE;G1S+B!3=6-H(&)A;&%N8V5S(&%R
M92!U<W5A;&QY(&EN(&5X8V5S<R!O9B!&1$E#(&EN<W5R960@;&EM:71S+B!!
M="!-87)C:"`S,2P@,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,L(&%L;"!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-A<V@@=V%S(&1E<&]S:71E9"!I;B!O
M;F4@8F%N:RX\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S
M='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG
M:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[
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M:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@
M=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C
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M<F]P97)T>2!A;F0@17%U:7!M96YT("8C.#(Q,3L\+V9O;G0^)B,Q-C`[36%C
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M=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#,V<'0[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@
M8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z
M(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU
M<W1I9GD@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#0U<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[
M(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL
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M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L
M;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R!F;VYT+7-I>F4M861J=7-T.B!N
M;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S
M=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN
M9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT
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M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P
M<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^#0H\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M
M<W!A8V4Z(&YO<FUA;#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N
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M/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N
M;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V
M,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)V9O;G0Z
M(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G
M:6XM;&5F=#H@-#5P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L
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M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS
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M;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`T-7!T.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[
M(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL
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M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P
M;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US:7IE+6%D
M:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N
M/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY,979E;"`S($EN<'5T
M<R`F(S@R,3$[(%5N;V)S97)V86)L92!I;G!U=',@9F]R(&1E=&5R;6EN:6YG
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M(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G
M:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO
M8VL[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO
M;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^/"]F;VYT/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I
M9GD@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#0U<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[(&9O
M;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^5&AE(&9O;&QO=VEN9R!T86)L97,@
M<V5T(&9O<G1H(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@
M;VX@82!R96-U<G)I;F<@8F%S:7,@8GD@;&5V96P@=VET:&EN('1H92!F86ER
M('9A;'5E(&AI97)A<F-H>2!A<R!O9B!-87)C:"`S,2P@,C`Q-"!A;F0@1&5C
M96UB97(@,S$L(#(P,3,N($%S(')E<75I<F5D(&)Y($%30R`X,C`L(&9I;F%N
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M;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@
M,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E
M+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/@T*
M/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-#`E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
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M97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O
M;&ED.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
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M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
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M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L
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M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
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M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
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M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
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M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
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M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
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M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
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M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R8C,38P.T%T
M($UA<F-H(#,Q+"`R,#$T/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
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M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,B4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$-R4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXM/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)0T*('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B0\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0X
M)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B0\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/C$Y+#$R."PW-C$\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T,"4@=F%L:6=N/3-$8F]T=&]M/@T*
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R8C,38P.T%T($1E8V5M8F5R(#,Q+"`R,#$S/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
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M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
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M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,B4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$-R4@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXM/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#(E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
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M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H
M=#H@-RXW<'0[(&UA<F=I;BUL969T.B`Y<'0[('=O<F0M<W!A8VEN9SH@,'!X
M.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US
M:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E
M=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^
M26YC;VUE(%1A>&5S("8C.#(Q,3L\+V9O;G0^)B,Q-C`[5&AE($-O;7!A;GD@
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M9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P
M=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y
M.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US:7IE+6%D:G5S
M=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A
M8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@9F]N="US:7IE+6%D:G5S=#H-"B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M=V5I9VAT.B!B;VQD.R!D:7-P;&%Y.B!I;FQI;F4[)SY297-E87)C
M:"!A;F0@1&5V96QO<&UE;G0@0V]S=',@)B,X,C$Q.SPO9F]N=#XF(S$V,#M2
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@87)E(&5X<&5N<V5D(&%S
M(&EN8W5R<F5D+B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0@<F5I;6)U<G-E
M;65N=',@86YD(&=R86YT<R!A<F4@<F5C;W)D960@8GD@=&AE($-O;7!A;GD@
M87,@82!R961U8W1I;VX@;V8@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O
M<W1S+CPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE
M/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`S-G!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I
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M<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R
M9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@
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M92U"87-E9"!087EM96YT<R`F(S@R,3$[/"]F;VYT/B8C,38P.U1H92!#;VUP
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M;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P
M=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y
M.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@9F]N="US:7IE+6%D:G5S
M=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A
M8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F
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M;6]N('-H87)E(&%R92!T:&4@<V%M92X@)B,Q-C`[5&AE('!O=&5N=&EA;&QY
M(&1I;'5T:79E('-E8W5R:71I97,@*&]P=&EO;G,@86YD('=A<G)A;G1S*2!W
M97)E(&5X8VQU9&5D(&9R;VT@=&AE(&1I;'5T960@;&]S<R!P97(@8V]M;6]N
M('-H87)E(&-A;&-U;&%T:6]N(&)E8V%U<V4@=&AE:7(@969F96-T('=O=6QD
M(&AA=F4@8F5E;B!A;G1I9&EL=71I=F4N($9O<B!T:&4@=&AR964@;6]N=&AS
M(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!P;W1E;G1I86QL>2!I<W-U86)L92!S
M:&%R97,@:6YC;'5D960@<W1O8VL@;W!T:6]N<R!T;R!P=7)C:&%S92`R+#(V
M-2PR,CD@<VAA<F5S(&%N9"!W87)R86YT<R!T;R!P=7)C:&%S92`Y+#8X,"PS
M,S,@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K
M+B!&;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,RP@
M<&]T96YT:6%L;'D@:7-S=6%B;&4@<VAA<F5S(&EN8VQU9&5D('-T;V-K(&]P
M=&EO;G,@=&\@<'5R8VAA<V4@,BPS,S`L,3,T('-H87)E<R!A;F0@=V%R<F%N
M=',@=&\@<'5R8VAA<V4@,3(L-S<P+#8S-B!S:&%R97,@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLN/"]F;VYT/CPO9&EV/@T*/&1I=B!A
M;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#,V<'0[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E
M.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N
M=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#0U<'0[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@
M8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z
M(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[(&1I
M<W!L87DZ(&EN;&EN93LG/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE
M;G1S("8C.#(Q,3L\+V9O;G0^)B,Q-C`[5&AE($-O;7!A;GD@9&]E<R!N;W0@
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M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#,V<'0[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H
M:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y
M;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#0U<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ
M92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z
M(&)O;&0[(&1I<W!L87DZ(&EN;&EN93LG/E-U8G-E<75E;G0@179E;G1S("8C
M.#(Q,3L\+V9O;G0^)B,Q-C`[5&AE($-O;7!A;GDF(S@R,3<[<R!M86YA9V5M
M96YT(')E=FEE=V5D(&%L;"!M871E<FEA;"!E=F5N=',@=&AR;W5G:"!T:&4@
M9&%T92!O9B!T:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@
M<W1A=&5M96YT<R!W97)E(&ES<W5E9"!F;W(@<W5B<V5Q=65N="!E=F5N="!D
M:7-C;&]S=7)E(&-O;G-I9&5R871I;VXN/"]F;VYT/CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&5B-3@Y.35?,61D
M9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+SAE8C4X.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P
M-"]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;&%T960@
M4&%R='D@5')A;G-A8W1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N=#H@,3-P
M>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@
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M(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P
M;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N
M/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US
M<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="US='EL93H@:71A;&EC.R!F;VYT+7=E:6=H=#H@
M8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^35-+0T,Z/"]F;VYT/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P
M.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N=#H@
M,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#0U<'0[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G
M:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO
M8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SY);B`R,#$P+"!'96YE<F%L($%T;&%N=&EC($=R;W5P($QI;6ET960@
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M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T
M-7!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P
M=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L
M87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS
M1&IU<W1I9GD@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY/;B!&
M96)R=6%R>2`Q,2P@,C`P,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@
M3&EC96YS92P@1&5V96QO<&UE;G0@86YD($-O;6UE<F-I86QI>F%T:6]N($%G
M<F5E;65N="!W:71H(%-L;V%N+4ME='1E<FEN9R!);G-T:71U=&4@;V8@0V%N
M8V5R(%)E<V5A<F-H("A32TDI+"8C,38P.V%N(&5N=&ET>2!R96QA=&5D('1O
M($U32T-#("@F(S@R,C`[3&EC96YS92!!9W)E96UE;G0F(S@R,C$[*2XF(S$V
M,#LF(S$V,#M4:&4@86=R965M96YT('=A<R!A;65N9&5D(&EN($%U9W5S="`R
M,#`V+B8C,38P.R8C,38P.U!U<G-U86YT('1O('1H92!A9W)E96UE;G0L('1H
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M("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P
M=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G
M9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#0U
M<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA
M>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SY4:&4@0V]M<&%N>2!I<R!O8FQI9V%T960@=&\@;6%K92!T
M:&4@9F]L;&]W:6YG(&UI;&5S=&]N92!P87EM96YT<SH\+V9O;G0^/"]D:78^
M#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI
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M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SX-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/DUI;&5S=&]N97,\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA
M8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#)P>#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/E!A>6UE;G1S/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/B@Q*2!F:6QI;F<@;V8@86X@3F5W($1R=6<@07!P
M;&EC871I;VX@*"8C.#(R,#M.1$$F(S@R,C$[*2!O<B!R96=U;&%T;W)Y(&%P
M<')O=F%L)B,Q-C`[9F]R(&5A8V@@;&EC96YS960@<')O9'5C=#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
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M>3H@:6YL:6YE.R<^-S4P+#`P,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
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M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M,2PW-3`L,#`P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L
M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O
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M;&%T97(@;V8Z("@Q*2`Q,"!Y96%R<R!F<F]M('1H92!F:7)S="!C;VUM97)C
M:6%L('-A;&4L(&]R("@R*2!W:&5N('1H92!P871E;G1S(&5X<&ER92X\+V9O
M;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT
M.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B
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M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG
M.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^0V5R=&%I;B!A;6]U;G1S(&1U92!U
M;F1E<B!T:&4@3&EC96YS92!!9W)E96UE;G0@=V5R92!D969E<G)E9"!A;F0@
M=&AE;B!F;W)G:79E;B!U;F1E<B!A(&9O<F)E87)A;F-E+7)E;&%T960@87)R
M86YG96UE;G0N)B,Q-C`[)B,Q-C`[3VX@2G5N92`Q.2P@,C`Q,2P@=&AE($-O
M;7!A;GD@;F]N971H96QE<W,@86=R965D('1O('!A>2!32TD@*&$I("0U,"PP
M,#`@:6X@,C`Q,2P@*&(I("0R,#`L,#`P(&EN(#(P,3(@86YD("AC*2`D,C4P
M+#`P,"!I;B`R,#$S('5N9&5R('1H:7,@86=R965M96YT+"!I;B!R97-P96-T
M(&]F('1H92`D-3`L,#`P(&%N;G5A;"!M86EN=&5N86YC92!F965S(&%N9"!R
M97-E87)C:"!P87EM96YT<RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^#0H\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`T-7!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[3VX@4V5P=&5M8F5R(#0L(#(P,3,L('1H92!#
M;VUP86YY(&5N=&5R960@:6YT;R!A(&QE='1E<B!A9W)E96UE;G0@=VET:"!3
M2TD@=&\@<V5T(&9O<G1H('1H92!A;6]U;G0@=&AA="!T:&4@0V]M<&%N>2!O
M=V5S(%-+22!F;W(@=&AE('!E<FEO9"!F<F]M(#(P,3$@=&\@,C`Q-"!U;F1E
M<B!T:&4@3&EC96YS92!!9W)E96UE;G0N)B,Q-C`[)B,Q-C`[5&AE('1O=&%L
M(&%M;W5N="!T:&%T('1H92!#;VUP86YY(&]W97,@4TM)(&9O<B!T:&4@<&5R
M:6]D(&9R;VT@,C`Q,2!T;R`R,#$T(&ES("0X,34L,3`P('!L=7,@86QL(')E
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M:"`S,2`R,#$T+"!A;6]U;G0@;W=E9"!U;F1E<B!T:&ES(&QE='1E<B!A9W)E
M96UE;G0@9F]R(#(P,30@86YN=6%L(&UA:6YT96YA;F-E(&9E92!A;F0@,C`Q
M-"!R97-E87)C:"!F=6YD:6YG('=A<R!A<'!R;WAI;6%T96QY("0P+C(@;6EL
M;&EO;B!P;'5S('!A<W,@=&AR;W5G:"!C;W-T<RP@<F5S<&5C=&EV96QY+CPO
M9F]N=#X\+V1I=CX-"CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y
M;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#0U<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L
M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O
M<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D]N($UA<F-H(#(W
M+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86X@861D:71I;VYA
M;"!C;&EN:6-A;"!T<FEA;"!A9W)E96UE;G0@=VET:"!-4TM#0R!#86YC97(@
M0V5N=&5R('=I=&@@<F5S<&5C="!T;R!C;VYD=6-T:6YG(&$@4&AA<V4@,2\R
M('1R:6%L(&]F(&-O;6)I;F%T:6]N('1H97)A<'D@;V8@;&]W(&1O<V4@8WET
M87)A8FEN92!A;F0@9G)A8W1I;VYA=&5D(&1O<V4@;V8@3&EN='5Z=6UA8BU!
M8S(R-2XF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!W:6QL('!A>2`D,S$L,3@U
M(&9O<B!E86-H('!A=&EE;G0@=&AA="!H87,@8V]M<&QE=&5D('1H92!C;&EN
M:6-A;"!T<FEA;"XF(S$V,#LF(S$V,#M5<&]N(&5X96-U=&EO;B!O9B!T:&4@
M86=R965M96YT+"!T:&4@0V]M<&%N>2!P86ED(&$@<W1A<G0M=7`@9F5E(&]F
M("0W.2PV,C,@:6X@,C`Q,BX\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A
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M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE
M9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H-"B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SY&;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-"!A
M;F0@,C`Q,RP@=&AE($-O;7!A;GD@:6YC=7)R960@)#$X.2PU,S<@86YD("0Q
M,CDL.#4P+"!R97-P96-T:79E;'DL(&9O<B!M86EN=&5N86YC92!F965S(&%N
M9"!R97-E87)C:"!C;VYD=6-T960@8GD@35-+0T,N)B,Q-C`[)B,Q-C`[07,@
M;V8@36%R8V@@,S$L(#(P,30@86YD($1E8V5M8F5R(#,Q+"`R,#$S+"!T:&4@
M0V]M<&%N>2!H87,@<&%Y86)L92!T;R!-4TM#0R!O9B`D,3@Y+#4S-R!A;F0@
M)#@Q+#$X-2P@<F5S<&5C=&EV96QY+"!R96QA=&5D('1O(&-L:6YI8V%L('1R
M:6%L<RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)V9O;G0Z(#$S<'@O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B
M;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S
M=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG
M.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="US='EL93H@:71A;&EC.R!F;VYT+7=E:6=H=#H@8F]L9#L@
M9&ES<&QA>3H@:6YL:6YE.R<^4&QA8V5M96YT($%G96YT.CPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF
M(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)V9O
M;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ
M(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX-"CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#0U<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY/;B!!=6=U<W0@-RP@,C`Q
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M0V]M;6]N(%-T;V-K($]F9F5R:6YG+B`F(S$V,#LF(S$V,#M);B!C;VYS:61E
M<F%T:6]N(&9O<B!I=',@<V5R=FEC97,L('1H92!P;&%C96UE;G0@86=E;G0@
M=VEL;"!R96-E:79E("AA*2!A(&-A<V@@9F5E(&5Q=6%L('1O(#$P)2!O9B!T
M:&4@9W)O<W,@<')O8V5E9',@<F%I<V5D(&EN('1H92`R,#$R($-O;6UO;B!3
M=&]C:R!/9F9E<FEN9RP@*&(I(&$@;F]N+6%C8V]U;G1A8FQE(&5X<&5N<V4@
M<F5I;6)U<G-E;65N="!E<75A;"!T;R`R)2!O9B!T:&4@9W)O<W,@<')O8V5E
M9',@<F%I<V5D(&EN('1H92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9RP@
M86YD("AC*2!R96EM8G5R<V5M96YT(&]F("0Q,#`L,#`P(&9O<B!L96=A;"!E
M>'!E;G-E<R!I;F-U<G)E9"!B>2!T:&4@<&QA8V5M96YT(&%G96YT+B8C,38P
M.R8C,38P.U1H92!P;&%C96UE;G0@86=E;G0@;W(@:71S(&1E<VEG;F5E<R!H
M879E(&%L<V\@<F5C96EV960@=V%R<F%N=',@=&\@<'5R8VAA<V4@<VAA<F5S
M(&]F('1H92!#;VUP86YY)B,X,C$W.W,@0V]M;6]N(%-T;V-K(&EN(&%N(&%M
M;W5N="!E<75A;"!T;R`Q,"4@;V8@=&AE('-H87)E<R!O9B!C;VUM;VX@<W1O
M8VL@:7-S=65D(&%S('!A<G0@;V8@=&AE('5N:71S('-O;&0@:6X@=&AE(#(P
M,3(@0V]M;6]N(%-T;V-K($]F9F5R:6YG(&%N9"!T:&4@<VAA<F5S(&]F($-O
M;6UO;B!3=&]C:R!I<W-U86)L92!U<&]N(&5X97)C:7-E(&]F('1H92!"('=A
M<G)A;G1S(&EN8VQU9&5D(&EN('-U8V@@=6YI=',N)B,Q-C`[)B,Q-C`[5&AE
M('!L86-E;65N="!A9V5N="!W:6QL(&%L<V\@<F5C96EV92!T:&4@<V%M92!F
M964@86YD(&5X<&5N<V4@<V-H961U;&4@9F]R(&%N>2!C87-H(&5X97)C:7-E
M(&]F('=A<G)A;G1S('=I=&AI;B`V(&UO;G1H<R!O9B!T:&4@9FEN86P@8VQO
M<VEN9R!O9B!T:&4@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<@86YD(&$@
M-24@<V]L:6-I=&%T:6]N(&9E92!F;W(@86YY('=A<G)A;G1S(&5X97)C:7-E
M9"!A<R!A(')E<W5L="!O9B!B96EN9R!C86QL960@9F]R(')E9&5M<'1I;VX@
M8GD@=&AE($-O;7!A;GDN)B,Q-C`[)B,Q-C`[57!O;B!T:&4@9FEN86P@8VQO
M<VEN9R!O9B!T:&4@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<@;V8@=&AE
M('5N:71S+"!T:&4@<&QA8V5M96YT(&%G96YT(&AA<R!B965N(&5N9V%G960@
M8GD@=&AE($-O;7!A;GD@=&\@<')O=FED92!C97)T86EN(&9I;F%N8VEA;"!A
M9'9I<V]R>2!S97)V:6-E<R!T;R!T:&4@0V]M<&%N>2!F;W(@82!P97)I;V0@
M;V8@870@;&5A<W0@-B!M;VYT:',@9F]R(&$@;6]N=&AL>2!F964@;V8@)#(U
M+#`P,"XF(S$V,#LF(S$V,#M4:&4@86=R965M96YT(&%L<V\@<')O=FED97,@
M=&AA="`H:2D@:68@=&AE($-O;7!A;GD@8V]N<W5M;6%T97,@86YY(&UE<F=E
M<BP@86-Q=6ES:71I;VXL(&)U<VEN97-S(&-O;6)I;F%T:6]N(&]R(&]T:&5R
M('1R86YS86-T:6]N("AO=&AE<B!T:&%N('1H92!3:&%R92!%>&-H86YG92D@
M=VET:"!A;GD@<&%R='D@:6YT<F]D=6-E9"!T;R!I="!B>2!T:&4@<&QA8V5M
M96YT(&%G96YT+"!T:&4@<&QA8V5M96YT(&%G96YT('=O=6QD(')E8V5I=F4@
M82!F964@97%U86P@=&\@,3`E(&]F('1H92!A9V=R96=A=&4@8V]N<VED97)A
M=&EO;B!I;B!S=6-H('1R86YS86-T:6]N<RP@86YD("AI:2D@:68L('=I=&AI
M;B!A('!E<FEO9"!O9B`Q,B!M;VYT:',@869T97(@=&5R;6EN871I;VX@;V8@
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M8VAE9'5L92!S970@9F]R=&@@:6X@=&AE($%U9W5S="`W+"`R,#$R(&5N9V%G
M96UE;G0@86=R965M96YT+B8C,38P.R8C,38P.T9O<B!A('!E<FEO9"!E;F1I
M;F<@;VYE('EE87(@869T97(@=&AE(&5X<&ER871I;VX@;V8@86QL(&QO8VLM
M=7`@86=R965M96YT<R!E;G1E<F5D(&EN=&\@:6X@8V]N;F5C=&EO;B!W:71H
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M;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z
M(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE
M/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`T-7!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I
M<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^3VX@1&5C96UB97(@.2P@,C`Q,RP@=&AE($-O;7!A
M;GD@96YT97)E9"!I;G1O(&%N;W1H97(@96YG86=E;65N="!A9W)E96UE;G0@
M=VET:"!I=',@<&QA8V5M96YT(&%G96YT(&9O<B!T:&4@,C`Q,R!#;VUM;VX@
M4W1O8VL@3V9F97)I;F<N(%1H92!A9W)E96UE;G0@96YT97)E9"!I;B`R,#$S
M(&AA<R!S:6UI;&%R('1E<FUS(&%S('1H92`R,#$R(&%G<F5E;65N="P@:6YC
M;'5D:6YG(&$@8V%S:"!F964@97%U86P@=&\@,3`E(&]F('1H92!G<F]S<R!P
M<F]C965D<R!R86ES960L(&$@;F]N+6%C8V]U;G1A8FQE(&5X<&5N<V4@<F5I
M;6)U<G-E;65N="!E<75A;"!T;R`R)2!O9B!T:&4@9W)O<W,@<')O8V5E9',@
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M=&AL>2!F964@;V8@)#(U+#`P,"X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^#0H\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M
M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D1U<FEN
M9R!Q=6%R=&5R(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!T:&4@<&QA8V5M96YT
M(&%G96YT(')E8V5I=F5D(&$@8V%S:"!F964@;V8@87!P<F]X:6UA=&5L>2`D
M,"XT(&UI;&QI;VX@9G)O;2!T:&4@<V%L92!O9B!S96-U<FET:65S(&%N9"!W
M87,@:7-S=65D('=A<G)A;G1S('1O('!U<F-H87-E(#8X+#DW-B!S:&%R97,@
M;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!#;VUM;VX@4W1O8VL@870@)#D@<&5R
M('-H87)E(&9O<B!A('!E<FEO9"!O9B`U#0H@>65A<G,N/"]F;VYT/CPO9&EV
M/@T*/&1I=CXF(S$V,#L\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7SAE8C4X.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W
M,#%B-3,P-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X96(U.#DY
M-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0O5V]R:W-H965T<R]3:&5E
M=#`X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4')O<&5R='D@86YD($5Q=6EP;65N=#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE
M;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O<&5R='D@86YD($5Q=6EP;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@86QI9VX],T1J=7-T:69Y('-T
M>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^3F]T92`S("8C
M.#(Q,3L@4')O<&5R='D@86YD($5Q=6EP;65N=#PO9F]N=#X\+V1I=CX\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@
M=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L87DZ
M(&EN;&EN93LG/CPO9F]N=#XF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S
M=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG
M.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+V1I=CX\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
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M870@36%R8V@@,S$L(#(P,30@86YD($1E8V5M8F5R(#,Q+"`R,#$S.CPO9F]N
M=#X\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q
M,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C
M:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/CPO9F]N=#XF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S
M='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I
M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X
M.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQT86)L92!S='EL93TS
M1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
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M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXR,#$T/"]F;VYT/CPO9&EV/CPO
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED
M=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^/&1I=B!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^,C`Q
M,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$-C<E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
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M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
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M/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#LS
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M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B0\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS
M1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/C$W+#$W.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0-"B!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H
M="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
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M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
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M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
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M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#)P>#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SX\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B@Q+#4V
M,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXI/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C
M8V5E9F8^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#8W)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY0<F]P97)T
M>2!A;F0@97%U:7!M96YT+"!N970\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
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M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
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M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
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M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!X.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SX\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`T<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L
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M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@
M=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^/"]F;VYT/B8C
M,38P.SPO9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)V9O;G0Z
M(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R
M9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L
M;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^1&5P<F5C:6%T:6]N(&5X<&5N<V4@9F]R('1H92!T:')E92!M;VYT
M:',@96YD960@36%R8V@@,S$L(#(P,30@86YD(#(P,3,@=V5R92`D,2PT,#4@
M86YD("0P+"!R97-P96-T:79E;'DN(%1H92!#;VUP86YY('=R;W1E(&]F9B!I
M=',@<F5M86EN:6YG('5N9&5P<F5C:6%T960@<')O<&5R='D@86YD(&5Q=6EP
M;65N="!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@
M,C`Q,R!A;F0@<F5C;W)D960@82!L;W-S(&]F("0T+#$R,B!O;B!T:&4@9&ES
M<&]S:71I;VXN/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W
M-C<P,6(U,S`T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAE8C4X
M.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-"]7;W)K<VAE971S+U-H
M965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY.;W1E(%!A>6%B;&4\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY.;W1E(%!A>6%B;&4@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T92!0
M87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A
M;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,W!X.R!F
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/DYO
M=&4@-"`F(S@R,3$[($YO=&4@4&%Y86)L93PO9F]N=#X\+V1I=CX\9&EV(&%L
M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$S<'@[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P
M<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L
M.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^/&1I
M=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,W!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B!A=71O
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R!T97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/D]N($1E8V5M8F5R(#(X+"`R
M,#$S+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!P<F5M:75M(&9I;F%N
M8V4@86=R965M96YT('1O('!A>2!A("0Q-3<L.#(U('!R96UI=6T@9F]R(&ET
M<R!D:7)E8W1O<B!A;F0@;V9F:6-E<B!L:6%B:6QI='D@:6YS=7)A;F-E('!O
M;&EC>2X@4'5R<W5A;G0@=&\@=&AE(&%G<F5E;65N="P@=&AE($-O;7!A;GD@
M<&%I9"!A(&1O=VX@<&%Y;65N="!O9B`D,34L.3DU(&EN($IA;G5A<GD@,C`Q
M-"!A;F0F(S$V,#MI<R!R97%U:7)E9"8C,38P.W1O('!A>2`D,34L.3DU(&EN
M(&UO;G1H;'D@:6YS=&%L;&UE;G0@9F]R(&YI;F4@;6]N=&AS+B!&;W(@=&AE
M('%U87)T97(@96YD960@36%R8V@@,S$L(#(P,30L('1H92!#;VUP86YY('!A
M:60@)#8S+#,T-"!U;F1E<B!T:&ES(&9I;F%N8V4@86=R965M96YT+B!!<R!O
M9B!-87)C:"`S,2P@,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,L('1H92!O
M=71S=&%N9&EN9R!B86QA;F-E(')E;&%T960@=&\@=&AE('!R96UI=6T@9FEN
M86YC92!A9W)E96UE;G0@=V%S("0Y-"PT.#$@86YD("0Q-3<L.#(U+"!R97-P
M96-T:79E;'DN/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W
M-C<P,6(U,S`T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAE8C4X
M.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-"]7;W)K<VAE971S+U-H
M965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY$97)I=F%T:79E<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D1E<FEV871I=F5S(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I
M=F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG
M;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M
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M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P
M=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)V9O
M;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ
M(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
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M;W0@86X@:6YP=70@=&\@=&AE(&9A:7(@=F%L=64@;V8@82`F(S@R,C`[9FEX
M960M9F]R+69I>&5D)B,X,C(Q.R!O<'1I;VX@87,@9&5F:6YE9"!U;F1E<B!&
M05-"($%30R!4;W!I8R!.;RX@.#$U("8C.#(Q,3L@-#`N(%1H92!W87)R86YT
M<R!G<F%N=&5D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S=6%N8V4@;V8@
M=&AE($-O;7!A;GDF(S@R,3<[<R!3=&]C:R!/9F9E<FEN9R!A;F0@,C`Q,B!#
M;VUM;VX@4W1O8VL@3V9F97)I;F<L('1H92!#;VYV97)T:6)L92!.;W1E<R`H
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M<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`S-G!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M
M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C
M:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P
M=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^06-T:79I
M=&EE<R!F;W(@9&5R:79A=&EV92!W87)R86YT(&EN<W1R=6UE;G1S(&1U<FEN
M9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T('=E<F4@
M87,@9F]L;&]W<SH\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD
M:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/E5N:71S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY&86ER(%9A;'5E/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R
M/CQT<CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#<V)2!V86QI9VX],T1B;W1T;VT^/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D)A
M;&%N8V4L($1E8V5M8F5R(#,Q+"`R,#$S/"]F;VYT/CPO9&EV/CPO=&0^/'1D
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M#0H@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
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M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C
M;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0W-B4@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
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M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY4<F%N<V9E<B!F
M<F]M(&QI86)I;&ET>2!C;&%S<VEF:6-A=&EO;B!T;R!E<75I='D@8VQA<W-I
M9FEC871I;VX\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B@T-BPP,C4\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXI/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
M)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM
M;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXH,3,Y+#4V-3PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
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M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
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M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
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M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
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M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL
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M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C
M:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
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M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
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M:6YL:6YE.R<^,3(L-38Q+#`W,3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$-S8E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
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M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT
M<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M-S8E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M-'!X.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/D)A;&%N8V4L($UA<F-H(#,Q+"`R,#$T/"]F;VYT/CPO9&EV/CPO
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M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'@[(&)O<F1E<BUB;W1T;VTM<W1Y
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M)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
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M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'@[(&)O<F1E<BUB;W1T;VTM<W1Y
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CPO
M=&%B;&4^/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N=#H@
M,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C
M:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S
M='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I
M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X
M.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/D1U<FEN9R!T:&4@<75A<G1E<B!E;F1E9"!-
M87)C:"`S,2P@,C`Q-"P@-#8L,#(U('=A<G)A;G1S('=E<F4@97AE<F-I<V5D
M+B!4:&4@9F%I<B!V86QU92!O9B!T:&5S92!W87)R86YT<R!T;W1A;&EN9R`D
M,3,Y+#4V-2!W97)E(&UE87-U<F5D(&]N('1H92!V87)I;W5S(&5X97)C:7-E
M(&1A=&5S(&%N9"!R96-L87-S:69I960@=&\@861D:71I;VYA;"!P86ED+6EN
M(&-A<&ET86PN/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T
M>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`T-7!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG
M:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[
M(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^/"]F;VYT/B8C,38P.SPO9&EV/CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R
M9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V
M,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT.B`Q,W!X
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@
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M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/'1A8FQE('-T>6QE/3-$
M)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/DUA<F-H(#,Q+#PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H-"B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/D1E8V5M8F5R(#,Q+#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
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M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O
M;&ED.R<@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN
M+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
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M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
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M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY-87)K
M970@=F%L=64@;V8@8V]M;6]N('-T;V-K(&]N(&UE87-U<F5M96YT(&1A=&4@
M*#$I/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXU+C@Y/"]F;VYT/CPO
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M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
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M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
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M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXE
M/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL-
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M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ+C(W
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M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/E=A<G)A;G0@;&EV97,@:6X@>65A<G,\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C`N-2!Y96%R<SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
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M96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SY%>'!E8W1E9"!V;VQA=&EL:71Y("@S*3PO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXW,SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXE/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H
M:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0W-B4@=F%L:6=N/3-$8F]T
M=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SY%>'!E8W1E9"!D:79I9&5N9"!Y:65L9"`H-"D\+V9O;G0^/"]D:78^
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXM/"]F;VYT/CPO=&0^
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M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[(&1I<W!L87DZ(&EN;&EN93LG/BT\+V9O;G0^/"]T9#X\=&0@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO
M<CTS1"-C8V5E9F8^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#<V)2!V86QI
M9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/E!R;V)A8FEL:71Y(&]F('-T;V-K(&]F9F5R:6YG(&EN
M(&%N>2!P97)I;V0@;W9E<B`U('EE87)S("@U*3PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/BT\+V9O;G0^/"]T9#X\=&0@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^,C4\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
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M97)E9"`H-BD\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI
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M(&EN;&EN93LG/BT\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M,S4\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
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M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY/9F9E<FEN9R!P<FEC
M92!R86YG92`H-RD\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Q)2!V
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M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4]
M,T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R
M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P
M;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/'1A8FQE('-T>6QE/3-$)W=I9'1H
M.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M/'1R/CQT9"!W:61T:#TS1#8E('9A;&EG;CTS1'1O<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@]
M,T0S)2!V86QI9VX],T1T;W`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXH,2D\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED
M=&@],T0Y,24@=F%L:6=N/3-$=&]P/CQD:78@86QI9VX],T1J=7-T:69Y('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY4:&4@;6%R:V5T('9A;'5E(&]F
M(&-O;6UO;B!S=&]C:R!A="!T:&4@86)O=F4@;65A<W5R96UE;G0@9&%T97,@
M:7,@8F%S960@;VX@=&AE($-O;7!A;GDF(S@R,3<[<R!T<F%D:6YG('!R:6-E
M('%U;W1E9"!O;B!T:&4@3U1#($UA<FME=',@9F]R($1E8V5M8F5R(#,Q+"`R
M,#$S(&%N9"!O;B!T:&4@3EE312!-2U0@9F]R($UA<F-H(#,Q+"`R,#$T+CPO
M9F]N=#X\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV(&%L:6=N
M/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US
M<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0Z(#$S
M<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0V)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
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M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/B@R*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!W:61T
M:#TS1#DQ)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4]
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M;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@
M,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E
M+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/'1A8FQE
M('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^/'1R/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M-B4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0S)2!V86QI
M9VX],T1T;W`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXH,RDF(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M=VED=&@],T0Y,24@=F%L:6=N/3-$=&]P/CQD:78@86QI9VX],T1J=7-T:69Y
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY"96-A=7-E('1H92!#;VUP
M86YY(&1O97,@;F]T(&AA=F4@861E<75A=&4@=')A9&EN9PT*(&AI<W1O<GD@
M=&\@9&5T97)M:6YE(&ET<R!H:7-T;W)I8V%L('1R861I;F<@=F]L871I;&ET
M>2P@=&AE('9O;&%T:6QI='D@9F%C=&]R('=A<R!E<W1I;6%T960@8GD@;6%N
M86=E;65N="!U<VEN9R!T:&4@:&ES=&]R:6-A;"!V;VQA=&EL:71I97,@;V8@
M8V]M<&%R86)L92!C;VUP86YI97,@:6X@=&AE('-A;64@:6YD=7-T<GD@86YD
M(')E9VEO;BX\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^
M/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\+V9O;G0^)B,Q-C`[
M/"]D:78^/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/'1A8FQE('-T>6QE/3-$
M)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^/'1R/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$-B4@=F%L:6=N
M/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0S)2!V86QI9VX],T1T;W`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXH
M-"DF(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Y
M,24@=F%L:6=N/3-$=&]P/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM
M;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SY-86YA9V5M96YT(&1E=&5R;6EN960@=&AE
M(&1I=FED96YD('EI96QD('1O(&)E(#`E(&)A<V5D('5P;VX@:71S(&5X<&5C
M=&%T:6]N('1H870@:70@=VEL;"!N;W0@<&%Y(&1I=FED96YD<R!F;W(@=&AE
M(&9O<F5S965A8FQE(&9U='5R92X\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CPO
M=&%B;&4^/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N
M=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B
M;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0Z
M(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0V)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N
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M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B@U*28C,38P.R8C,38P.SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!W:61T:#TS1#DQ)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG
M;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
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M=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG
M.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQT86)L92!S='EL93TS1"=W:61T:#H@
M,3`P)3L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT
M<CX\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#8E('9A;&EG;CTS1'1O<#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^*#8I)B,Q-C`[
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$.3$E('9A;&EG
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M:6X@96%C:"!S=&]C:R!O9F9E<FEN9R!W:6QL(&)E)B,Q-C`[,"4@86YD(#,U
M)2!O9B!T:&4@<VAA<F5S(&]U='-T86YD:6YG(&%T($UA<F-H(#,Q+"`R,#$T
M(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RP@<F5S<&5C=&EV96QY+CPO9F]N=#X\
M+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV(&%L:6=N/3-$:G5S
M=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG
M.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQT86)L92!S='EL93TS1"=W:61T:#H@
M,3`P)3L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT
M<CX\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#8E('9A;&EG;CTS1'1O<#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^*#<I)B,Q-C`[
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$.3$E('9A;&EG
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M93X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT.B`Q,W!X
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#<N-W!T.R!M87)G:6XM
M;&5F=#H@.7!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[
M('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SX\+V9O;G0^)B,Q-C`[/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V
M-S`Q8C4S,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&5B-3@Y
M.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T+U=O<FMS:&5E=',O4VAE
M970Q,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@
M86YD($-O;G1I;F=E;F-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD($-O
M;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P
M=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L
M87DZ(&EN;&EN93LG/DYO=&4@-B`F(S@R,3$[($-O;6UI=&UE;G1S(&%N9"!#
M;VYT:6YG96YC:65S/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=F;VYT
M.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES
M<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A
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M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M
M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!D:7-P
M;&%Y.B!I;FQI;F4[)SX\+V9O;G0^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M
M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C
M:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+V1I
M=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)V9O;G0Z(#$S<'@O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE
M9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
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M;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SXF(S$V,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/@T*
M/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@=VED=&@],T0V)2!V
M86QI9VX],T1T;W`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0S)2!V86QI9VX],T1T;W`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[)SX-"CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/F$N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!W:61T:#TS1#DQ)2!V86QI
M9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT
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M;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P+B`H9F]R;65R;'D@1F%C970@0FEO
M=&5C:"!F;W)M97)L>2!K;F]W;B!A<R!0<F]T96EN($1E<VEG;B!,86)S*2!I
M;B`R,#`S('1O('-E8W5R92!E>&-L=7-I=F4@<FEG:'1S('1O(&$@<W!E8VEF
M:6,@86YT:6)O9'D@=VAE;B!C;VYJ=6=A=&5D('=I=&@@86QP:&$@96UI='1I
M;F<@<F%D:6]I<V]T;W!E<RX@57!O;B!E>&5C=71I;VX@;V8@=&AE(&%G<F5E
M;65N="P@=&AE($-O;7!A;GD@;6%D92!A(&QI8V5N<V4@9F5E('!A>6UE;G0@
M;V8@)#,L,#`P+#`P,"X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y
M('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM
M<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P
M<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^5&AE($-O;7!A;GD@86=R965D('1O(&UA
M:V4@;6EL97-T;VYE('!A>6UE;G1S('1O=&%L:6YG("0W+#<U,"PP,#`@9F]R
M('1H92!A8VAI979E;65N="!O9B!T:&4@9F]L;&]W:6YG(&%G<F5E9"!T;R!A
M;F0@8V]N=')A8W1E9"!M:6QE<W1O;F5S.CPO9F]N=#X\+V1I=CX-"CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX-"CQT86)L92!S='EL
M93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/DUI;&5S
M=&]N97,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#)P>#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$
M,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/E!A>6UE;G1S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N
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M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
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M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
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M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C<U,"PP
M,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M(&)G8V]L;W(],T1W:&ET93X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X
M."4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
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M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/C<U,"PP,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
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M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
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M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C$L-3`P+#`P,#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
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M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ+#<U,"PP,#`\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C
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M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ+#4P
M,"PP,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0X."4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B@V*2!A9G1E<B!T:&4@9FER<W0@
M)#$P+#`P,"PP,#`@:6X@;F5T('-A;&5S/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
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M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C$L-3`P+#`P,#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\
M9&EV('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[
M/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q
M,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN
M+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
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M.B`H,2D@,3(N-2!Y96%R<R!A9G1E<B!T:&4@9FER<W0@8V]M;65R8VEA;"!S
M86QE+"!O<B`H,BD@=VAE;B!T:&4@<&%T96YT<R!E>'!I<F4N/"]F;VYT/CPO
M9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N=#H@,3-P
M>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`W+C=P=#L@;6%R9VEN
M+6QE9G0Z(#EP=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y
M('-T>6QE/3-$)V9O;G0Z#0H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@
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M8W,@0V]R<"X@82!M:6QE<W1O;F4@<&%Y;65N="!O9B`D-S4P+#`P,"!O;B!*
M=6QY(#(T+"`R,#$R+B8C,38P.R8C,38P.U1H92!M:6QE<W1O;F4@<&%Y;65N
M="!F;W(@=&AE(%!H87-E(#$@0VQI;FEC86P@5')I86P@=V%S(')E8V]R9&5D
M(&%S(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E+B!4:&4@0V]M
M<&%N>2!H87,@;F]T(&EN:71I871E9"!A(%!H87-E($E)($-L:6YI8V%L(%1R
M:6%L(&%N9"!N;R!P87EM96YT(&AA<R!B965N(&UA9&4@=&\@06)B;W1T($)I
M;W1H97)A<&5U=&EC<R!#;W)P+B!S:6YC92!T:&4@2G5L>2`R-"P@,C`Q,B!P
M87EM96YT+CPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T
M>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P
M)3L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M/@T*/'1D('=I9'1H/3-$-B4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SY-96UO<FEA;"!3;&]A;B!+971T97)I;F<@0V%N8V5R($-E;G1E
M<B`H35-+0T,I("8C.#(Q,3L@<V5E(')E;&%T960@<&%R='D@9&ES8VQO<W5R
M92X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!W:61T
M:#TS1#8E('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0S
M)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$.3$E('9A
M;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('=I9'1H
M/3-$-B4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#,E
M('9A;&EG;CTS1'1O<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z
M(#!P=#LG/@T*/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^8RXF(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('=I9'1H/3-$.3$E('9A;&EG;CTS1'1O<#X-"CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY/86L@
M4FED9V4@3F%T:6]N86P@3&%B;W)A=&]R>2`H3U).3"D@)B,X,C$Q.R!!4$D@
M:7,@8V]N=')A8W1E9"!T;R!P=7)C:&%S92`D,C,S+#$P,"!O9B!R861I;V%C
M=&EV92!M871E<FEA;"!T;R!B92!U<V5D(&9O<B!R97-E87)C:"!A;F0@9&5V
M96QO<&UE;G0L('=I=&@@82!R96YE=V%L(&]P=&EO;B!A="!T:&4@8V]N=')A
M8W0@96YD+B8C,38P.R8C,38P.T9O<B`R,#$S+"!T:&4@0V]M<&%N>2!W87,@
M;V)L:6=A=&5D(&%N9"!P86ED(&%P<')O>&EM871E;'D@)#`N,R!M:6QL:6]N
M('1O('!U<F-H87-E(&]F(')A9&EO86-T:79E(&UA=&5R:6%L('=I=&@@3U).
M3"XF(S$V,#LF(S$V,#M&;W(@,C`Q-"P@=&AE($-O;7!A;GD@<VEG;F5D(&$@
M8V]N=')A8W0@=VET:"!/4DY,('1O('!U<F-H87-E("0P+C0@;6EL;&EO;B!O
M9B!R861I;V%C=&EV92!M871E<FEA;"X\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!W:61T:#TS1#8E('9A;&EG;CTS1'1O<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@=VED=&@],T0S)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('=I9'1H/3-$.3$E('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D('=I9'1H/3-$-B4@=F%L:6=N/3-$=&]P/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
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M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SY!<'1I=E-O;'5T:6]N<R!P<F]V:61E<R!P<F]J
M96-T(&UA;F%G96UE;G0@<V5R=FEC97,@9F]R('1H92!S='5D>2!O9B!T:&4@
M9')U9R!!8RTR,C4M2'5-,3DU("A!8W1I;6%B+4$I('5S960@:6X@=&AE($-O
M;7!A;GD@8VQI;FEC86P@=')I86QS+"!0:&%S92`Q(&%N9"!0:&%S92`R+B8C
M,38P.R8C,38P.U1H92!T;W1A;"!P<F]J96-T(&ES(&5S=&EM871E9"!T;R!C
M;W-T(&%P<')O>&EM871E;'D@)#$N.2!M:6QL:6]N(&%N9"!R97%U:7)E<R!A
M(#$R+C4E(&1O=VX@<&%Y;65N="!O9B!T:&4@=&]T86P@97-T:6UA=&5D('!R
M;VIE8W0@8V]S="XF(S$V,#LF(S$V,#M4:&4@9&]W;B!P87EM96YT('1O=&%L
M:6YG("0R,SDL,#`P('=A<R!P86ED(&EN(#(P,#<@86YD(#(P,3(N)B,Q-C`[
M)B,Q-C`[3VX@075G=7-T(#8L(#(P,3(L($]C=&]B97(@,C(L(#(P,3(@86YD
M($UA>2`Q-BP@,C`Q,RP@=&AE(&%G<F5E;65N="!W87,@86UE;F1E9"!T;R!P
M<F]V:61E(&9O<B!A9&1I=&EO;F%L('-E<G9I8V5S+B8C,38P.R8C,38P.U1H
M92!T;W1A;"!P<F]J96-T(&ES(&YO=R!E<W1I;6%T960@870@87!P<F]X:6UA
M=&5L>2`D,BXR(&UI;&QI;VXN($%S(&]F($UA<F-H(#,Q+"`R,#$T+"!A<'!R
M;WAI;6%T96QY("0Q+C`@;6EL;&EO;B!H87,@8F5E;B!E>'!E;G-E9"!T;R!D
M871E+B`F(S$V,#M!<'1I=E-O;'5T:6]N<R!B:6QL<R!T:&4@0V]M<&%N>2!W
M:&5N('-E<G9I8V5S(&%R92!R96YD97)E9"!A;F0@=&AE($-O;7!A;GD@<F5C
M;W)D<R!T:&4@<F5L871E9"!E>'!E;G-E('1O(')E<V5A<F-H(&%N9"!D979E
M;&]P;65N="!C;W-T<RX\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\9&EV/B8C,38P.SPO9&EV/@T*/'1A8FQE('-T>6QE/3-$)W=I
M9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^#0H\='(^#0H\=&0@=VED=&@],T0V)2!V86QI9VX],T1T;W`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
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M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY/;B!*=6YE(#$U+"`R,#$R+"!T
M:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!L:6-E;G-E(&%N9"!S<&]N<V]R
M960@<F5S96%R8V@@86=R965M96YT(&]F($)#."P@82!N;W9E;"!M=7)I;F4@
M;6]N;V-L;VYA;"!A;G1I8F]D>2P@=VET:"!&<F5D($AU=&-H:6YS;VX@0V%N
M8V5R(%)E<V5A<F-H($-E;G1E<B`H1DA#4D,I+B!4:&4@0V]M<&%N>2!W:6QL
M(&)U:6QD('5P;VX@<')E=FEO=7,@86YD(&]N9V]I;F<@8VQI;FEC86P@=')I
M86QS+"!W:71H($)#."`H;&EC96YS960@86YT:6)O9'DI+B8C,38P.R8C,38P
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M;&EO;B!T;R`D,C,N-2!M:6QL:6]N+"!D97!E;F1I;F<@;VX@=&AE('1R:6%L
M(&1E<VEG;B!A<R!R97%U:7)E9"!B>2!T:&4@1D1!+B8C,38P.R8C,38P.U5N
M9&5R('1H92!T97)M<R!O9B!T:&4@<W!O;G-O<F5D(')E<V5A<F-H(&%G<F5E
M;65N="P@=&AE($-O;7!A;GD@=VEL;"!F=6YD('1H92!&2$-20R!L86(@=VET
M:"`D,34P+#`P,"!P97(@>65A<B!F;W(@=&AE(&9I<G-T('1W;R!Y96%R<R!A
M;F0@)#(U,"PP,#`@=&AE<F5A9G1E<BXF(S$V,#LF(S$V,#M087EM96YT<R!M
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M<F-I86P@<V%L92!O9B!T:&4@9')U9RP@<F]Y86QT>2!P87EM96YT<R!O9B`R
M)2!O9B!N970@<V%L97,@=VEL;"!B92!D=64@=&\@1DA#4D,N/"]F;VYT/CPO
M9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY$=7)I
M;F<@=&AE('%U87)T97)S(&5N9&5D($UA<F-H(#,Q+"`R,#$T(&%N9"`R,#$S
M+"!T:&4@0V]M<&%N>2!R96-O<F1E9"!F965S(&]F("0S-RPU,#`@86YD("0S
M-RPU,#`L(')E<W!E8W1I=F5L>2P@<F5L871E9"!T;R!T:&ES(&%G<F5E;65N
M="X\+V9O;G0^/"]D:78^#0H\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H
M:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)V9O;G0Z(#$S<'@O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX-
M"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D('=I9'1H/3-$-B4@
M=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
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M<W1I9GD[('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D]N($IU;'D@,3DL(#(P
M,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&-L:6YI8V%L('1R:6%L
M(&%G<F5E;65N="!W:71H($9(0U)#(&9O<B8C,38P.SPO9F]N=#Y!8W1I;6%B
M+4$\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/BXF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!W:6QL('!A>2`D,S$L
M,S8V(&9O<B!E86-H('!A=&EE;G0@=&AA="!H87,@8V]M<&QE=&5D('1H92!C
M;&EN:6-A;"!T<FEA;"X@5&AE($-O;7!A;GD@<&%I9"!A('-T87)T+75P(&9E
M92!O9B`D,3DL-S0Y(&EN(#(P,3,N)B,Q-C`[)B,Q-C`[1'5R:6YG('1H92!C
M;&EN:6-A;"!T<FEA;"!A9&1I=&EO;F%L(&9E97,@87!P;'D@86YD('=I;&P@
M8F4@:6YV;VEC960@=VAE;B!A<'!L:6-A8FQE+B!&;W(@=&AE('1H<F5E(&UO
M;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-"P@=&AE($-O;7!A;GD@<&%I9"!A
M<'!R;WAI;6%T96QY("0Q-BPP,#`@9F]R('!A=&EE;G0@96YR;VQL;65N="X\
M+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=VED=&@],T0V)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('=I9'1H
M/3-$,R4@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('=I9'1H/3-$
M-B4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
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M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D]N($%U9W5S="`R
M."P@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@8VQI;FEC86P@
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M<F]X:6UA=&5L>2`D-3`P+#`P,"P@=VAI8V@@:6YC;'5D97,@82!N;VXM(')E
M9G5N9&%B;&4@:6YS=&ET=71I;VYA;"!F964@;V8@)#$T+#4P,"XF(S$V,#LF
M(S$V,#M4:&4@97-T:6UA=&5D(&-O<W0@:7,@8F%S960@;VX@=')E871I;F<@
M,C0@<&%T:65N=',@=&AR;W5G:"`R,#$S+B8C,38P.R8C,38P.U5P;VX@97AE
M8W5T:6]N(&]F('1H92!A9W)E96UE;G0L('1H92!#;VUP86YY('!A:60@)#,S
M+#DT-BX@1'5R:6YG(#(P,3,L('1H97)E('=A<R!O;F4@<&%T:65N="!T<F5A
M=&5D(&%N9"!T:&4@0V]M<&%N>2!P86ED("0S-"PS.#,@:6X@2G5L>2`R,#$S
M+B!4:&5R92!H879E(&)E96X@;F\@<&%T:65N=',@=')E871E9"!I;B`R,#$T
M+CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\9&EV/B8C,38P.SPO9&EV/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q
M,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\
M='(^#0H\=&0@=VED=&@],T0V)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R<^#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SYH+B8C,38P.R8C,38P.SPO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=VED=&@],T0Y,24@=F%L:6=N/3-$
M=&]P/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/D]N(%-E<'1E;6)E<B`R-BP@,C`Q,BP@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&$@8VQI;FEC86P@=')I86P@86=R965M96YT('=I=&@@
M2F]H;G,@2&]P:VEN<R!5;FEV97)S:71Y+B8C,38P.R8C,38P.U1H92!0:&%S
M92`Q+S(@8VQI;FEC86P@=')I86P@=VEL;"!B92!C;VYD=6-T960@=VET:"!!
M8W1I;FEU;2`R,C4N)B,Q-C`[)B,Q-C`[5&AE(&-L:6YI8V%L('1R:6%L('=I
M;&P@8F4@8V]N9'5C=&5D('5N9&5R('1H92!P<F]T;V-O;',@97-T86)L:7-H
M960@8GD@=&AE($-O;7!A;GD@86YD('!U<G-U86YT('1O(&%N($EN=F5S=&EG
M871I;VYA;"!.97<@1')U9R!%>&5M<'1I;VX@*$E.1"`Q,#@P-RD@:&5L9"!B
M>2!T:&4@0V]M<&%N>2XF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!W:6QL('!A
M>2`D,S@L-3`Q('!E<B!P871I96YT+"!W:&\@:&%S(&-O;7!L971E9"!T:&4@
M8VQI;FEC86P@=')I86PN(%1H92!#;VUP86YY(&ES(')E<75I<F5D('1O('!A
M>2!A('-T87)T+75P(&9E92!O9B`D,C(L.#0W+"!A;B!A;FYU86P@<&AA<FUA
M8WD@9F5E(&]F("0R+#`R-2!A;F0@86X@86UE;F1M96YT('!R;V-E<W-I;F<@
M9F5E(&]F("0U,#`L('=H96X@87!P;&EC86)L92X@5&AE($-O;7!A;GD@<&%I
M9"!T:&4@)#(R+#@T-R!S=&%R="UU<"!F964@:6X@1F5B<G5A<GD@,C`Q,RX@
M5&AE<F4@=V5R92!N;R!P87EM96YT<R!M861E(&1U<FEN9R!T:&4@=&AR964@
M;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T(&9O<B!T:&ES(&%G<F5E;65N
M="X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!W:61T
M:#TS1#8E('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0S
M)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$.3$E#0H@
M=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=VED
M=&@],T0V)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$
M,R4@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R<^#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SYI+B8C,38P.R8C,38P.SPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@=VED=&@],T0Y,24@=F%L:6=N/3-$=&]P/@T*/&1I=B!A
M;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D]N
M($YO=F5M8F5R(#(Q+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M82!C;&EN:6-A;"!T<FEA;"!A9W)E96UE;G0@=VET:"!T:&4@56YI=F5R<VET
M>2!O9B!096YN<WEL=F%N:6$N)B,Q-C`[)B,Q-C`[5&AE(%!H87-E(#$O,B!C
M;&EN:6-A;"!T<FEA;"!W:6QL(&)E(&-O;F1U8W1E9"!W:71H($%C=&EN:75M
M(#(R-2XF(S$V,#LF(S$V,#M4:&4@8VQI;FEC86P@=')I86P@=VEL;"!B92!C
M;VYD=6-T960@=6YD97(@=&AE('!R;W1O8V]L<R!E<W1A8FQI<VAE9"!B>2!T
M:&4@0V]M<&%N>2!A;F0@<'5R<W5A;G0@=&\@86X@26YV97-T:6=A=&EO;F%L
M($YE=R!$<G5G($5X96UP=&EO;B`H24Y$(#$P.#`W*2!H96QD(&)Y('1H92!#
M;VUP86YY+B8C,38P.R8C,38P.U1H92!#;VUP86YY('=I;&P@<&%Y("0S,2PW
M-S$@<&5R('!A=&EE;G0L('=H;R!H87,@8V]M<&QE=&5D('1H92!C;&EN:6-A
M;"!T<FEA;"X@5&AE($-O;7!A;GD@=VEL;"!B92!R97%U:7)E9"!T;R!P87D@
M82!S=&%R="UU<"!F964@;V8@)#$V+#`P,"!A;F0@861D:71I;VYA;"!A9&UI
M;FES=')A=&EV92!F965S+"!W:&5N(&%P<&QI8V%B;&4N(%1H92!#;VUP86YY
M(&%C8W)U960@)#$V+#`P,"!F964@870@1&5C96UB97(@,S$L(#(P,3,@86YD
M('!A:60@=&AE(&9E92!I;B!*86YU87)Y(#(P,30N/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=VED=&@],T0V)2!V86QI9VX],T1T
M;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!W:61T:#TS1#DQ)2!V86QI9VX],T1T;W`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!W:61T:#TS1#8E('9A;&EG;CTS1'1O
M<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0S)2!V86QI9VX],T1T;W`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[)SX-"CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/FHN
M)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!W:61T:#TS
M1#DQ)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R
M9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^3VX@2F%N=6%R>2`R-RP@,C`Q-"P@
M=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@;6%N=69A8W1U<FEN9R!A9W)E
M96UE;G0@=VET:"!';V]D=VEN($)I;W1E8VAN;VQO9WD@26YC+B8C,38P.R8C
M,38P.R@F(S@R,C`[1V]O9'=I;B8C.#(R,3LI+B!';V]D=VEN('=I;&P@;W9E
M<G-E92!T:&4@8W5R<F5N="!';V]D($UA;G5F86-T=7)I;F<@4')A8W1I8V5S
M("AC1TU0*2!P<F]D=6-T:6]N(&]F(&$@;6]N;V-L;VYA;"!A;G1I8F]D>2!A
M;G1I8VEP871E9"!T;R!B92!U<V5D(&EN(&%N('5P8V]M:6YG('!H87-E(#,@
M8VQI;FEC86P@=')I86P@;V8@26]M86(F(S@T.#([+4(N(%1O=&%L(&-O<W0@
M;V8@=&AE(&%G<F5E;65N="!I<R`D,BPX,3,L.38P+B!4:&4@0V]M<&%N>2!P
M86ED(&$@;F]N+7)E9G5N9&%B;&4@<&%Y;65N="!O9B`D-38R+#<Y,"!U<&]N
M(&5X96-U=&EO;B!O9B!T:&4@86=R965M96YT+B!097)I;V1I8R!P87EM96YT
M<R!W:6QL(&)E(&UA9&4@=7!O;B!R96%C:&EN9R!C97)T86EN(&UI;&5S=&]N
M97,N($%S(&]F($UA<F-H(#,Q+"`R,#$T+"!T:&4@<F5M86EN:6YG(&-O<W0@
M;V8@=&AE(&%G<F5E;65N="!I<R`D,BPP-S<L,#`P+CPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@=&5X="UA
M;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M
M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[
M/"]D:78^#0H\9&EV('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ
M(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^3VX@075G=7-T(#$L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R
M960@:6YT;R!A(')E;G1A;"!A9W)E96UE;G0@9F]R(&]F9FEC92!S<&%C92!A
M="`U,#$@1FEF=&@@079E;G5E+"8C,38P.TYE=R!9;W)K+"!.62X@5&AE(&%G
M<F5E;65N="!T97)M:6YA=&5D(&]N($UA>2`S,2P@,C`Q,RX@3VX@2G5N92`T
M+"`R,#$S(&%N9"!A;65N9&5D(&]N($]C=&]B97(F(S$V,#LT+"`R,#$S+"!T
M:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!R96YT86P@86=R965M96YT(&9O
M<B!O9F9I8V4@<W!A8V4@870@-30V($9I9G1H($%V96YU92PF(S$V,#M.97<@
M66]R:RP@3EDN(%1H:7,@86=R965M96YT('1E<FUI;F%T97,@;VX@2G5L>2`V
M+"`R,#$T+B!5<&]N('1H92!E>'!I<F%T:6]N(&]F('1H92!T97)M+"!T:&4@
M86=R965M96YT(&%U=&]M871I8V%L;'D@<F5N97=S(&]N(&$@;6]N=&@M=&\M
M;6]N=&@@8F%S:7,@86YD(')E<75I<F5S(&$@='=O(&UO;G1H(&YO=&EC92!O
M9B!T97)M:6YA=&EO;BX\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R
M85]C,S<V-S`Q8C4S,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T+U=O<FMS:&5E
M=',O4VAE970Q,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D5Q=6ET>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D5Q=6ET>2!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM
M<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P
M<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L87DZ(&EN;&EN93LG/DYO=&4@
M-R`F(S@R,3$[($5Q=6ET>3PO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)V9O
M;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!D
M:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL
M93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M26X@2F%N=6%R>2`R,#$T+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@=&AE(&9I
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M("0S.34L,#`P(&%N9"!P86ED(&%T=&]R;F5Y(&9E97,@;V8@)#0P+#`P,"!F
M;W(@=&AE:7(@<V5R=FEC97,N($EN('1H92`R,#$T($-L;W-I;F<L('1H92!#
M;VUP86YY('-O;&0@-34Q+#@Q,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%T
M("0V+C`P('!E<B!S:&%R92!A;F0@9W)A;G1E9"`Q,S<L.34R('5N:71S(&]F
M(&9I=F4M>65A<B!W87)R86YT<R!W:71H(&%N(&5X97)C:7-E('!R:6-E(&]F
M("0Y+C`P('!E<B!S:&%R92X@5&AE('=A<G)A;G1S(&%R92!E>&5R8VES86)L
M92!F;W(@82!P97)I;V0@;V8@9FEV92!Y96%R<R!F<F]M('1H92!D871E(&]F
M(&ES<W5A;F-E+B!4:&4@=')A;G-A8W1I;VX@9&%T92!F86ER('9A;'5E(&]F
M('1H92!W87)R86YT<R!O9B`D,"XV(&UI;&QI;VX@=V%S(&1E=&5R;6EN960@
M=71I;&EZ:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO
M9&5L('5T:6QI>FEN9R!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I;VYS.B!R:7-K
M(&9R964@:6YT97)E<W0@<F%T96@Q+C8T)2P@97AP96-T960@=F]L871I;&ET
M>2`M(#@X)2P@97AP96-T960@9&EV:61E;F0@>6EE;&0@+2`P)2P@86YD(&$@
M8V]N=')A8W1U86P@;&EF92!O9B`U('EE87)S+B!!<R!O9B!-87)C:"`S,2P@
M,C`Q-"P@86QL('1H92!W87)R86YT<R!W97)E(&]U='-T86YD:6YG+CPO9F]N
M=#X\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!D
M:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL
M93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D]N($UA<F-H
M)B,Q-C`[,C0L(#(P,30L('1H92!#;VUP86YY(&9I;&5D(&$@<VAE;&8@<F5G
M:7-T<F%T:6]N('-T871E;65N="!O;B!&;W)M(%,M,R`H=&AE("8C.#(R,#M2
M96=I<W1R871I;VX@4W1A=&5M96YT)B,X,C(Q.RD@=VAI8V@@=V%S(&5F9F5C
M=&EV92!O;B!!<')I;"`Q-RP@,C`Q-"XF(S$V,#LF(S$V,#M4:&ES(%)E9VES
M=')A=&EO;B!3=&%T96UE;G0@8V]N=&%I;F5D('1W;R!P<F]S<&5C='5S97,Z
M("AI*2!A(&)A<V4@<')O<W!E8W1U<R!W:&EC:"!C;W9E<G,@=&AE(&]F9F5R
M:6YG+"!I<W-U86YC92!A;F0@<V%L92!B>2!T:&4@0V]M<&%N>2!O9B!U<"!T
M;R`D,C`P+#`P,"PP,#`@;V8@:71S(&-O;6UO;B!S=&]C:RP@<')E9F5R<F5D
M('-T;V-K+"!W87)R86YT<R!A;F0O;W(@=6YI=',[(&%N9"`H:6DI(&$@<V%L
M97,@86=R965M96YT('!R;W-P96-T=7,@8V]V97)I;F<@=&AE(&]F9F5R:6YG
M+"!I<W-U86YC92!A;F0@<V%L92!B>2!U<R!O9B!U<"!T;R!A(&UA>&EM=6T@
M86=G<F5G871E(&]F9F5R:6YG('!R:6-E(&]F("0W-2PP,#`L,#`P(&]F(&ET
M<R!C;VUM;VX@<W1O8VL@=&AA="!M87D@8F4@:7-S=65D(&%N9"!S;VQD('5N
M9&5R(&$@<V%L97,@86=R965M96YT("AT:&4@)B,X,C(P.U-A;&5S($%G<F5E
M;65N="8C.#(R,3LI('=I=&@@34Q6("9A;7`[($-O+B!,3$,@*"8C.#(R,#M-
M3%8F(S@R,C$[*2!D871E9"!-87)C:"`R-"P@,C`Q-"XF(S$V,#M4:&4@0V]M
M<&%N>2!W:6QL('!A>2!-3%8@:6X@8V%S:"P@=7!O;B!T:&4@<V%L92!O9B!C
M;VUM;VX@<W1O8VL@<'5R<W5A;G0@=&\@=&AE(%-A;&5S($%G<F5E;65N="P@
M86X@86UO=6YT(&5Q=6%L('1O(#,N,"4@;V8@=&AE(&=R;W-S('!R;V-E961S
M(&9R;VT@=&AE('-A;&4@;V8@8V]M;6]N('-T;V-K+B8C,38P.U1O(&1A=&4@
M-3`P('-H87)E<R!H879E(&)E96X@<V]L9"!U;F1E<B!T:&4@4V%L97,@06=R
M965M96YT('=I=&@@34Q6("AS964@3F]T92`X("8C.#(Q,3L@4W5B<V5Q=65N
M="!%=F5N="DN/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P
M>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\
M+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R
M9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L
M;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L
M87DZ(&EN;&EN93LG/E!L86-E;65N="!!9V5N="`F(S@R,3$[)B,Q-C`[/"]F
M;VYT/D1U<FEN9R!*86YU87)Y(#(P,30L(&EN(&-O;FYE8W1I;VX@=VET:"`R
M,#$T($-L;W-I;F<L('1H92!#;VUP86YY(&ES<W5E9"!,86ED;&%W("9A;7`[
M($-O+B!W87)R86YT<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@-C@L
M.3<V('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=VET:"!A;B!E>&5R8VES92!P
M<FEC92!O9B`D.2XP,"!P97(@<VAA<F4N(%1H92!T<F%N<V%C=&EO;B!D871E
M(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S(&]F("0P+C(@;6EL;&EO;B!W
M87,@9&5T97)M:6YE9"!U=&EL:7II;F<@=&AE($)L86-K+5-C:&]L97,@;W!T
M:6]N('!R:6-I;F<@;6]D96P@=71I;&EZ:6YG('1H92!F;VQL;W=I;F<@87-S
M=6UP=&EO;G,Z(')I<VL@9G)E92!I;G1E<F5S="!R871E("8C.#(Q,3L@,2XV
M-"4L(&5X<&5C=&5D('9O;&%T:6QI='D@+2`X."4L(&5X<&5C=&5D(&1I=FED
M96YD('EI96QD("T@,"4L(&%N9"!A(&-O;G1R86-T=6%L(&QI9F4@;V8@-2!Y
M96%R<RX\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO9&EV
M/CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@
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M<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN
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M86XG.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE
M9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M1'5R:6YG(#(P,3,L('1H92!#;VUP86YY(&=R86YT960@96UP;&]Y965S+"!C
M;VYS=6QT86YT(&%N9"!B;V%R9"!M96UB97)S(#,Q,BPU,#`@<VAA<F5S(&]F
M(')E<W1R:6-T960@<W1O8VLN($1U<FEN9R!T:&4@<75A<G1E<B!E;F1E9"!-
M87)C:"`S,2P@,C`Q-"P@=&AE($-O;7!A;GD@9W)A;G1E9"!A;B!A9&1I=&EO
M;F%L(#,R-2PQ-C<@<VAA<F5S(&]F(')E<W1R:6-T960@<W1O8VLN($1U<FEN
M9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"`Q.#`L
M,3`T('-H87)E<R!W97)E(&ES<W5E9"!F;W(@<VAA<F5S(&=R86YT960@=6YD
M97(@=&AE($5Q=6ET>2!);F-E;G1I=F4@4&QA;BX@3V8@=&AE('1O=&%L('-H
M87)E<R!O9B!R97-T<FEC=&5D('-T;V-K+"`R,BPU,#`@<VAA<F5S('9E<W0@
M,2!Y96%R(&9R;VT@=&AE(&=R86YT(&1A=&4L(#$T.2PQ-C<@<VAA<F5S(&AA
M=F4@82!V97-T:6YG('!E<FEO9"!O9B`T('EE87)S(&%N9"`Q-3`L,#`P('-H
M87)E<R!V97-T(&%T(&1A=&4@;V8@9W)A;G0N(%1H92!R96UA:6YI;F<@<F5S
M=')I8W1E9"!S:&%R97,@9W)A;G1E9"!A<F4@<&5R9F]R;6%N8V4@8F%S960@
M86YD('9E<W0@;W9E<B!T:6UE+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$
M)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L-"B!W
M;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C
M,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#0U
M<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA
M>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SY!;&P@<F5S=')I8W1E9"!S=&]C:R!I<W-U960@86YD(&]U
M='-T86YD:6YG(&ES(&)E:6YG(&%M;W)T:7IE9"!O=F5R('1H96ER(')E<W!E
M8W1I=F4@=F5S=&EN9R!P97)I;V1S+B!4:&4@=6YR96-O9VYI>F5D(&-O;7!E
M;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@=&AE(')E<W1R:6-T960@<W1O
M8VL@9W)A;G1E9"!A="!-87)C:"`S,2P@,C`Q-"!W87,@)#$L,SDQ+#,Q."X@
M1'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F(S$V,#LS,2P@
M,C`Q-"!A;F0@,C`Q,RP@=&AE($-O;7!A;GD@<F5C;W)D960@97AP96YS92!O
M9B`D,2PT,3`L-3@X(&%N9"`D,"P@<F5S<&5C=&EV96QY+"!R96QA=&5D('1O
M('1H92!R97-T<FEC=&5D('-T;V-K(&=R86YT960N/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L
M;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0Z
M(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^
M4W1O8VL@3W!T:6]N(%!L86X\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@
M,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O
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M;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`S-G!T.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z
M(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
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M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G
M:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N
M=#X\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(^/&9O;G0-"B!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[(&1I<W!L87DZ(&EN;&EN93LG/E)E;6%I;FEN9SPO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY!9V=R96=A=&4\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/DYU;6)E<B!O9CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G
M:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
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M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/DEN=')I;G-I8SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
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M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/E5N
M:71S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY%>&5R8VES92!0<FEC93PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED
M.R<@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE
M9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^5&5R;2`H:6X@>65A<G,I/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
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M96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SY686QU93PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H-"B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#4R)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D]U='-T86YD:6YG
M+"!$96-E;6)E<B`S,2P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/C$L.3@U+#,X-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#LD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXS+C(S
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#LD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXU+#DP."PV.38\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$=VAI=&4^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#4R)2!V86QI9VX],T1B;W1T;VT^/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.TES<W5E9#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^,CDQ+#4P,"8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE
M9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[-RXX-CPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
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M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
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M8F]T=&]M.B`R<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[17AE<F-I<V5D/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z('-O;&ED.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXH,3$L-C4U*3PO9F]N
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M.B!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
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M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
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M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
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M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/D]U='-T86YD:6YG+"!-87)C:"`S,2P@,C`Q
M-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!X.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!D;W5B;&4[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P>#L@
M8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXR+#(V-2PR,CD\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`T<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O
M=6)L93LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#LD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#1P>#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXS+C@T/"]F
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M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG
M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[)SX\9F]N=#XX+C,T/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S#0H@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#LD/"]F;VYT
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M;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I
M=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z
M(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#0U<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SY$=7)I;F<@=&AE('%U87)T97(@96YD960@36%R
M8V@@,S$L(#(P,30L('1H92!#;VUP86YY(&=R86YT960@96UP;&]Y965S(&%N
M9"!B;V%R9"!M96UB97)S(#(Y,2PU,#`@;W!T:6]N<R!T;R!P=7)C:&%S92!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!W:71H(&5X97)C:7-E
M('!R:6-E<R!R86YG:6YG(&9R;VT@)#4N-34@=&\@)#@N,3D@86YD(&$@=&5R
M;2!O9B`Q,"!Y96%R<R!A;F0@=F5S="!O=F5R(&$@-"UY96%R('!E<FEO9"XF
M(S$V,#LF(S$V,#M4:&4@9F%I<B!V86QU92!O9B`D,2XW(&UI;&QI;VX@=V%S
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M86XG.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B
M;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=F;VYT
M.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A
M8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D1U<FEN9R!Q=6%R=&5R(&5N
M9&5D($UA<F-H(#,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!R96-E:79E9"!G<F]S
M<R!P<F]C965D<R!O9B`D-2PR,C`@9F]R(&5X97)C:7-E(&]F(&]P=&EO;G,@
M9F]R(#$Q+#8U-2!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM
M;VX@<W1O8VLN/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P
M>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ
M(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)V9O
M;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US
M<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^06QL(&]P=&EO;G,@:7-S
M=65D(&%N9"!O=71S=&%N9&EN9R!A<F4@8F5I;F<@86UO<G1I>F5D(&]V97(@
M=&AE:7(@<F5S<&5C=&EV92!V97-T:6YG('!E<FEO9',N(%1H92!U;G)E8V]G
M;FEZ960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@870@36%R8V@@,S$L(#(P,30@
M=V%S("0U+#,Y.2PW,3`N($1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H)B,Q-C`[,S$L(#(P,30@86YD(#(P,3,L('1H92!#;VUP86YY(')E
M8V]R9&5D(&]P=&EO;B!E>'!E;G-E(&]F("0R.#$L-#`T(&%N9"`D.30L,C`P
M+"!R97-P96-T:79E;'DN/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N
M=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A
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M<F]M86XG.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM
M;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[
M('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#L@9&ES<&QA>3H@:6YL:6YE.R<^5V%R<F%N=',\+V9O;G0^/"]D:78^/&1I
M=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D9O
M;&QO=VEN9R!I<R!A('-U;6UA<GD@;V8@=V%R<F%N="!A8W1I=FET:65S(&9O
M<B!T:&4@<75A<G1E<B!E;F1E9"!-87)C:"`S,2P@,C`Q-#H\+V9O;G0^/"]D
M:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N=#H@,3-P>"]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#0U<'0[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H
M:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P
M>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/B8C,38P.SQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
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M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
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M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D%G
M9W)E9V%T93PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
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M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D%V97)A9V4\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
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M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^26YT<FEN<VEC/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.PT*(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#)P>#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N
M/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SY5;FET<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C
M:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/E1E<FT@*&EN('EE87)S*3PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O
M;&ED.R<@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN
M+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^5F%L=64\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
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M<W1A;F1I;F<L($1E8V5M8F5R(#,Q+"`R,#$S/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
M)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM
M;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXY+#8W,RPR.3`\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H
M="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C$N,#8\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C0N.#D\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@-#<L
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M;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F=`T*('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#LF(S$V,#M'<F%N=&5D/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXS,#8L.3(X/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXW+C@X/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
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M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[)B,Q-C`[17AE<F-I<V5D/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N
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M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#)P>#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SX\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
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M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/BD\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI
M9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW
M:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^,2XP
M-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#DE
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M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0U,B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`T<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^3W5T<W1A;F1I;F<L($UA<F-H(#,Q+"`R,#$T/"]F
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M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P>#L@8F]R
M9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXY+#8X,"PS,S,\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L
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M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C$N,C@\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C0N-S$\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L
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M96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXQ,#<L,C8X+#<X-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CPO=&%B
M;&4^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
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M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#0U<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SY$=7)I;F<@=&AE('%U87)T97(@96YD960@36%R
M8V@@,S$L(#(P,30L('1H92!#;VUP86YY(&=R86YT960@=V%R<F%N=',@=&\@
M<'5R8VAA<V4@,3,W+#DU,B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[
M<R!C;VUM;VX@<W1O8VL@=&\@:6YV97-T;W)S(&%N9"!W87)R86YT<R!T;R!P
M=7)C:&%S92`V."PY-S8@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@
M8V]M;6]N('-T;V-K('1O(&ET<R!P;&%C96UE;G0@86=E;G0@:6X@8V]N;F5C
M=&EO;B!W:71H('1H92`R,#$T($-L;W-I;F<N("X\+V9O;G0^)B,Q-C`[/"]D
M:78^/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C
M:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=F;VYT.B`Q
M,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN
M9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D1U<FEN9R!T:&4@=&AR964@;6]N
M=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!A;'-O(&=R
M86YT960@82!C;VYS=6QT86YT('=A<G)A;G1S('1O('!U<F-H87-E(#$P,"PP
M,#`@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K
M('=I=&@@97AE<F-I<V4@<')I8V5S(&]F("0U+C4U('!E<B!S:&%R92!A;F0@
M82!T97)M(&]F(#$P('EE87)S+B8C,38P.R8C,38P.U1H97-E('=A<G)A;G1S
M('9E<W0@=VAE;B!C97)T86EN(&UI;&5S=&]N97,@87)E(&UE="XF(S$V,#LF
M(S$V,#L\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I
M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X
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M86XG.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE
M9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M1'5R:6YG('1H92!Q=6%R=&5R(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"`R.3DL
M.#@U('=A<G)A;G1S('=E<F4@97AE<F-I<V5D(&)Y('1H92!W87)R86YT(&AO
M;&1E<G,N(%1H92!#;VUP86YY(&ES<W5E9"`R-3,L,S,P('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@86YD(')E8V5I=F5D(&=R;W-S('!R;V-E961S(&]F("0R
M,RPW,#DN/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
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M('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#0U<'0[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@
M,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E
M+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY$=7)I
M;F<@=&AE('%U87)T97(@96YD960@36%R8V@@,S$L(#(P,30@86YD(#(P,3,L
M('1H92!#;VUP86YY(')E8V]R9&5D('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;B!R96QA=&5D('1O('1H92!W87)R86YT<R!O9B`D-3@L.3,T(&%N9"`D,"P@
M<F5S<&5C=&EV96QY+CPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7SAE8C4X.3DU7S%D9&1?-#$Q85\X93)A
M7V,S-S8W,#%B-3,P-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X
M96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0O5V]R:W-H965T
M<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4W5B<V5Q=65N="!%=F5N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=6)S97%U96YT(&5V96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,W!X
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/DYO=&4@."`F(S@R,3$[(%-U8G-E<75E
M;G0@179E;G1S/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=C;VQO<CH@
M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[
M('1E>'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET
M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@
M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
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M9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^#0H\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^26X@07!R:6P@
M,C`Q-"P@=&AE($-O;7!A;GD@9W)A;G1E9"!C97)T86EN(&5M<&QO>65E<R`U
M,"PP,#`@<VAA<F5S(&]F(')E<W1R:6-T960@8V]M;6]N('-T;V-K(&%N9"!O
M<'1I;VYS('1O('!U<F-H87-E(#8P,"PP,#`@<VAA<F5S(&]F('1H92!#;VUP
M86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K('=I=&@@97AE<F-I<V4@<')I8V5S
M(')A;F=I;F<@9G)O;2`D,3$N-S8@=&\@)#$Q+CDU(&%N9"!A('1E<FT@;V8@
M,3`@>65A<G,N(%1H97-E(&]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@
M=F5S="!O=F5R(&$@-"UY96%R('!E<FEO9"XF(S$V,#LF(S$V,#M%9F9E8W1I
M=F4@36%Y(#$R+"`R,#$T+"8C,38P.SQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="US:7IE.B`Q,'!T.R<^=&AE($-O;7!A;GD@96YT97)E
M9"!I;G1O(&$@<W5B;&5A<V4@86=R965M96YT(&9O<B!O9F9I8V4@<W!A8V4@
M;&]C871E9"!A="`S-SD@5&AO<FYA;&P@4W1R965T+"!%9&ES;VXL($Y*+B!4
M:&ES(&%G<F5E;65N="!T97)M:6YA=&5S(&]N(%-E<'1E;6)E<B`S,"P@,C`Q
M-BX@5&AE($-O;7!A;GD@:7-S=65D(&$@<V5C=7)I='D@9&5P;W-I="!O9B!A
M<'!R;WAI;6%T96QY("0S-2PP,#`@=&\@=&AE(&5X:7-T:6YG('1E;F%N="X\
M+V9O;G0^/"]F;VYT/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]D:78^
M#0H\9&EV('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3-P>#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z
M(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UI;F1E;G0Z(#!P=#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W
M<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/D]N($%P<FEL
M(#(X+"`R,#$T+"!T:&4@0V]M<&%N>2!I<W-U960@-3`P('-H87)E<R!O9B!I
M=',@8V]M;6]N('-T;V-K(&%N9"!R96-E:79E9"!N970@<')O8V5E9',@;V8@
M)#8L,#`P+CPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T
M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
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M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R
M85]C,S<V-S`Q8C4S,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T+U=O<FMS:&5E
M=',O4VAE970Q-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15!#044^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@
M;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H4&]L:6-I97,I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG
M;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.871U<F4@
M;V8@0G5S:6YE<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE
M9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L87DZ(&EN
M;&EN93LG/DYA='5R92!O9B!"=7-I;F5S<R`F(S@R,3$[/"]F;VYT/B8C,38P
M.SQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY!4$DL(&EN
M8V]R<&]R871E9"!O;B!*=6YE(#$S+"`R,#`P+"!I<R!A(&)I;W1E8VAN;VQO
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M8G-I9&EA<GDL($UE9$%C=&EN:75M+"!);F,N("A-04DI+"`H:&5R96EN869T
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M;BU+971T97)I;F<@0V%N8V5R($-E;G1E<B`H35-+0T,I('5N9&5R(&%N($U3
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M+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@
M,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^#0H\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
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M86-T=7,@5F5N='5R97,L($EN8RX@*'1H92`F(S@R,C`[0V]M<&%N>28C.#(R
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M>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@
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M("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`T-7!T.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P
M=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^3VX@1&5C
M96UB97(@,C@L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A('1R
M86YS86-T:6]N("AT:&4@)B,X,C(P.U-H87)E($5X8VAA;F=E)B,X,C(Q.RDL
M('!U<G-U86YT('1O('=H:6-H('1H92!#;VUP86YY(&%C<75I<F5D(#$P,"4@
M;V8@=&AE(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@97%U:71Y('-E8W5R:71I
M97,@;V8@06-T:6YI=6T@4&AA<FUA8V5U=&EC86QS+"!);F,N("@F(S@R,C`[
M05!))B,X,C(Q.RDL(&EN(&5X8VAA;F=E(&9O<B!T:&4@:7-S=6%N8V4@;V8@
M87!P<F]X:6UA=&5L>2`Y.24@;V8@=&AE(&ES<W5E9"!A;F0@;W5T<W1A;F1I
M;F<@8V]M;6]N('-T;V-K+"!P87(@=F%L=64@)#`N,#$@<&5R('-H87)E+"!O
M9B!T:&4@0V]M<&%N>2X@5&AE(%-H87)E($5X8VAA;F=E(&-L;W-E9"!O;B!$
M96-E;6)E<B`R."P@,C`Q,BXF(S$V,#LF(S$V,#M!<R!A(')E<W5L="!O9B!T
M:&4@4VAA<F4@17AC:&%N9V4L('1H92!F;W)M97(@<VAA<F5H;VQD97)S(&]F
M($%022!B96-A;64@=&AE(&-O;G1R;VQL:6YG('-H87)E:&]L9&5R<R!O9B!T
M:&4@0V]M<&%N>2X@070@=&AE(&-L;W-I;F<L(&5A8V@@05!)('-H87)E:&]L
M9&5R(')E8V5I=F5D(#`N,S,S('-H87)E<R`H=&AE("8C.#(R,#M%>&-H86YG
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M;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C
M:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@
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M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]D:78^#0H\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D]N($UA<F-H
M(#(P+"`R,#$S+"!I;B!A;G1I8VEP871I;VX@;V8@=&AE($-O;7!A;GD@8VAA
M;F=I;F<@:71S(&YA;64@=&\@06-T:6YI=6T@4&AA<FUA8V5U=&EC86QS+"!)
M;F,N(&%N9"!I=',@9&]M:6-I;&4@9G)O;2!.979A9&$@=&\@1&5L87=A<F4L
M('1H92!#;VUP86YY)B,X,C$W.W,@<W5B<VED:6%R>2P@06-T:6YI=6T@4&AA
M<FUA8V5U=&EC86QS+"!);F,N+"!C:&%N9V5D(&ET<R!N86UE('1O($%C=&EN
M:75M($-O<G!O<F%T:6]N+B8C,38P.R8C,38P.T]N($%P<FEL)B,Q-C`[,3$L
M(#(P,3,L('1H92!#;VUP86YY(&-H86YG960@:71S(&1O;6EC:6QE(&9R;VT@
M=&AE(%-T871E(&]F($YE=F%D82!T;R!T:&4@4W1A=&4@;V8@1&5L87=A<F4@
M86YD(&-H86YG960@:71S(&YA;64@9G)O;2!#86-T=7,@5F5N='5R97,L($EN
M8RX@=&\@06-T:6YI=6T@4&AA<FUA8V5U=&EC86QS+"!);F,N/"]F;VYT/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P
M86-E.B!N;W)M86P[#0H@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS
M1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P
M;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/D]N(%-E<'1E;6)E<B`R-2P@,C`Q,RP@:6X@86-C;W)D
M86YC92!W:71H(&$@0V5R=&EF:6-A=&4@;V8@3W=N97)S:&EP($UE<F=I;F<@
M06-T:6YI=6T@0V]R<&]R871I;VX@:6YT;R!T:&4@06-T:6YI=6T@4&AA<FUA
M8V5U=&EC86QS+"!);F,N("AF:6QE9"!I;B!$96QA=V%R92P@=&AE($-O;7!A
M;GD@;65R9V5D("AT:&4@)B,X,C(P.TUE<F=E<B8C.#(R,3LI(&EN=&\@:71S
M96QF($%C=&EN:75M($-O<G!O<F%T:6]N("AA(#DS+C<E(&]W;F5D('-U8G-I
M9&EA<GDI+"!A;F0@06-T:6YI=6T@0V]R<&]R871I;VX@8V5A<V5D('1O(&5X
M:7-T+B!!<R!A(')E<W5L="!O9B!T:&4@365R9V5R+"!!8W1I;FEU;2!#;W)P
M;W)A=&EO;B!S=&]C:R!O=VYE9"!B>2!T:&4@0V]M<&%N>2!H87,@8F5E;B!C
M86YC96QL960@86YD(&5A8V@@<VAA<F4@;V8@06-T:6YI=6T@0V]R<&]R871I
M;VX@;F]T(&]W;F5D(&)Y('1H92!#;VUP86YY('=A<R!E>&-H86YG960@9F]R
M(#`N,S,S('-H87)E<R!O9B!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K
M+B8C,38P.R8C,38P.T$@=&]T86P@;V8@,RPY-S`L,3,W('-H87)E<R!O9B!!
M8W1I;FEU;2!#;W)P;W)A=&EO;B!C;VUM;VX@<W1O8VL@=V%S(&5X8VAA;F=E
M9"!F;W(@,2PS,C(L,#4U('-H87)E<R!O9B!#;VUP86YY(&-O;6UO;B!S=&]C
M:RX\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT871I;VX@+2!5;F%U
M9&ET960@26YT97)I;2!&:6YA;F-I86P@26YF;W)M871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)SX\
M9F]N="!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`V,'!X.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S
M.B!A=71O.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^0F%S:7,@;V8@4')E
M<V5N=&%T:6]N("T@56YA=61I=&5D($EN=&5R:6T@1FEN86YC:6%L($EN9F]R
M;6%T:6]N("8C.#(Q,3L\+V9O;G0^)B,Q-C`[5&AE(&%C8V]M<&%N>6EN9R!U
M;F%U9&ET960@:6YT97)I;2!C;VYD96YS960@8V]N<V]L:61A=&5D(&9I;F%N
M8VEA;"!S=&%T96UE;G1S(&%N9"!R96QA=&5D(&YO=&5S(&AA=F4@8F5E;B!P
M<F5P87)E9"!I;B!A8V-O<F1A;F-E('=I=&@@86-C;W5N=&EN9R!P<FEN8VEP
M;&5S(&=E;F5R86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E<R!O
M9B!!;65R:6-A("@F(S@R,C`[52Y3+B!'04%0)B,X,C(Q.RD@9F]R(&EN=&5R
M:6T@9FEN86YC:6%L(&EN9F]R;6%T:6]N+"!A;F0@:6X@86-C;W)D86YC92!W
M:71H('1H92!R=6QE<R!A;F0@<F5G=6QA=&EO;G,@;V8@=&AE(%5N:71E9"!3
M=&%T97,@4V5C=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;B`H=&AE
M("8C.#(R,#M314,F(S@R,C$[*2!W:71H(')E<W!E8W0@=&\@1F]R;2`Q,"U1
M(&%N9"!!<G1I8VQE(#@@;V8@4F5G=6QA=&EO;B!3+5@N($%C8V]R9&EN9VQY
M+"!T:&5Y(&1O(&YO="!I;F-L=61E(&%L;"!O9B!T:&4@:6YF;W)M871I;VX@
M86YD(&9O;W1N;W1E<R!R97%U:7)E9"!B>2!5+E,N($=!05`@9F]R(&-O;7!L
M971E(&9I;F%N8VEA;"!S=&%T96UE;G1S+B!4:&4@=6YA=61I=&5D(&EN=&5R
M:6T@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT
M<R!F=7)N:7-H960@<F5F;&5C="!A;&P@861J=7-T;65N=',@*&-O;G-I<W1I
M;F<@;V8@;F]R;6%L(')E8W5R<FEN9R!A9&IU<W1M96YT<RD@=VAI8V@@87)E
M+"!I;B!T:&4@;W!I;FEO;B!O9B!M86YA9V5M96YT+"!N96-E<W-A<GDF(S$V
M,#MF;W(@82!F86ER('-T871E;65N="!O9B!T:&4@<F5S=6QT<R!F;W(@=&AE
M(&EN=&5R:6T@<&5R:6]D<R!P<F5S96YT960N($EN=&5R:6T@<F5S=6QT<R!A
M<F4@;F]T(&YE8V5S<V%R:6QY(&EN9&EC871I=F4@;V8@=&AE(')E<W5L=',@
M9F]R('1H92!F=6QL('EE87(N(%1H97-E('5N875D:71E9"!I;G1E<FEM(&-O
M;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@<VAO
M=6QD(&)E(')E860@:6X@8V]N:G5N8W1I;VX@=VET:"!T:&4@875D:71E9"!C
M;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@;V8@=&AE($-O;7!A
M;GD@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"!N
M;W1E<R!T:&5R971O(&-O;G1A:6YE9"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&%N;G5A;"!R97!O<G0@;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q,RP@87,@9FEL960@=VET:"!T:&4@4T5#(&]N
M($9E8G)U87)Y(#(X+"`R,#$T+B`\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$979E;&]P;65N
M="!3=&%G92!#;VUP86YY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
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M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<FEN8VEP;&5S(&]F($-O;G-O;&ED871I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV/CQS=')O;F<^/&9O;G0@<VEZ93TS1#(^
M4')I;F-I<&QE<R!O9B!#;VYS;VQI9&%T:6]N("8C.#(Q,3L\+V9O;G0^/"]S
M=')O;F<^)B,Q-C`[5&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC
M:6%L('-T871E;65N=',@:6YC;'5D92!T:&4@0V]M<&%N>28C.#(Q-SMS(&%C
M8V]U;G1S(&%N9"!T:&]S92!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS('=H;VQL
M>2!O=VYE9"!S=6)S:61I87)I97,N($%L;"!S:6=N:69I8V%N="!I;G1E<F-O
M;7!A;GD@86-C;W5N=',@86YD('1R86YS86-T:6]N<R!H879E(&)E96X@96QI
M;6EN871E9"X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5S92!O9B!%<W1I;6%T97,@:6X@1FEN86YC:6%L
M(%-T871E;65N="!0<F5S96YT871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT
M.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#5P=#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B
M;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/CQF;VYT('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!D:7-P
M;&%Y.B!I;FQI;F4[)SY5<V4@;V8@17-T:6UA=&5S(&EN($9I;F%N8VEA;"!3
M=&%T96UE;G0@4')E<V5N=&%T:6]N("8C.#(Q,3L\+V9O;G0^)B,Q-C`[5&AE
M('!R97!A<F%T:6]N(&]F('1H97-E(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@
M9FEN86YC:6%L('-T871E;65N=',@:6X@8V]N9F]R;6ET>2!W:71H(&%C8V]U
M;G1I;F<@<')I;F-I<&QE<R!G96YE<F%L;'D@86-C97!T960@:6X@=&AE(%5N
M:71E9"!3=&%T97,@;V8@06UE<FEC82!R97%U:7)E<R!M86YA9V5M96YT('1O
M(&UA:V4@97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<R!T:&%T(&%F9F5C="!T
M:&4@<F5P;W)T960@86UO=6YT<R!O9B!A<W-E=',@86YD(&QI86)I;&ET:65S
M(&%T('1H92!D871E(&]F('1H92!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T
M871E;65N=',@86YD('1H92!R97!O<G1E9"!A;6]U;G1S(&]F(')E=F5N=65S
M(&%N9"!E>'!E;G-E<R!D=7)I;F<@=&AE(')E<&]R=&EN9R!P97)I;V0N($%C
M='5A;"!R97-U;'1S(&-O=6QD(&1I9F9E<B!F<F]M('1H;W-E(&5S=&EM871E
M<RX\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX\<W1R;VYG/CQF
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M(&]F($9$24,@:6YS=7)E9"!L:6UI=',N($%T($UA<F-H(#,Q+"`R,#$T(&%N
M9"!$96-E;6)E<B`S,2P@,C`Q,RP@86QL(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@8V%S:"!W87,@9&5P;W-I=&5D(&EN(&]N92!B86YK+CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M<&5R='D@86YD($5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^/'-T<F]N9SX\9F]N="!S:7IE/3-$,CY0<F]P97)T>2!A
M;F0@17%U:7!M96YT("8C.#(Q,3L\+V9O;G0^/"]S=')O;F<^)B,Q-C`[36%C
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M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS1&IU<W1I9GD@
M<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#0U<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+7=E:6=H
M=#H@8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^26UP86ER;65N="!O9B!,;VYG
M+4QI=F5D($%S<V5T<R`F(S@R,3$[)B,Q-C`[/"]F;VYT/DUA;F%G96UE;G0@
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M;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5R:79A=&EV97,\+W1D/@T*("`@("`@("`\=&0@8VQA
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M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I
M<B!686QU92!O9B!&:6YA;F-I86P@26YS=')U;65N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL
M93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@-#5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT
M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D
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M;"!);G-T<G5M96YT<R`F(S@R,3$[/"]F;VYT/B8C,38P.T9A:7(@=F%L=64@
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M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S
M='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG
M:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#0U<'0[('=O<F0M<W!A8VEN9SH@,'!X
M.R!D:7-P;&%Y.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/DQE=F5L(#$@26YP=71S("8C.#(Q,3L@56YA
M9&IU<W1E9"!Q=6]T960@<')I8V5S(&EN(&%C=&EV92!M87)K971S(&9O<B!I
M9&5N=&EC86P@87-S971S(&]R(&QI86)I;&ET:65S('1H870@=&AE(')E<&]R
M=&EN9R!E;G1I='D@:&%S('1H92!A8FEL:71Y('1O(&%C8V5S<R!A="!T:&4@
M;65A<W5R96UE;G0@9&%T92X\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=F
M;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO9&EV/CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@-#5P=#L@=V]R
M9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N
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M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^/&1I=B!A;&EG
M;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`T-7!T.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY,979E;"`S($EN<'5T
M<R`F(S@R,3$[(%5N;V)S97)V86)L92!I;G!U=',@9F]R(&1E=&5R;6EN:6YG
M('1H92!F86ER('9A;'5E<R!O9B!A<W-E=',@;W(@;&EA8FEL:71I97,@=&AA
M="!R969L96-T(&%N(&5N=&ET>2=S(&]W;B!A<W-U;7!T:6]N<R!A8F]U="!T
M:&4@87-S=6UP=&EO;G,@=&AA="!M87)K970@<&%R=&EC:7!A;G1S('=O=6QD
M('5S92!I;B!P<FEC:6YG('1H92!A<W-E=',@;W(@;&EA8FEL:71I97,N/"]F
M;VYT/CPO9&EV/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=F;VYT.B`Q
M,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN
M+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N=#H@,3-P
M>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9&EV(#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^5&AE(&9O;&QO
M=VEN9R!T86)L97,@<V5T(&9O<G1H(&QI86)I;&ET:65S(&UE87-U<F5D(&%T
M(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,@8GD@;&5V96P@=VET
M:&EN('1H92!F86ER('9A;'5E(&AI97)A<F-H>2!A<R!O9B!-87)C:"`S,2P@
M,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,N($%S(')E<75I<F5D(&)Y($%3
M0R`X,C`L(&9I;F%N8VEA;"!A<W-E=',@86YD(&QI86)I;&ET:65S(&%R92!C
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M1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P
M=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L
M87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T0G
M9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P
M>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$-#`E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L
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M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
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M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SY,979E;"`S/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R
M+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI
M9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/E1O=&%L/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#0P)2!V86QI
M9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
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M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#DE
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
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M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!B9V-O
M;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$-#`E('9A
M;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[070@36%R8V@@,S$L(#(P,30\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#(E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0W)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXM/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
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M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
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M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B0\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#@E('9A;&EG
M;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/C$Y+#$R."PW-C$\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#(E('9A
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M,T1W:&ET93X\=&0@86QI9VX],T1L969T('=I9'1H/3-$-#`E('9A;&EG;CTS
M1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[070@1&5C96UB97(@,S$L(#(P,3,\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#(E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0W)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXM/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,B4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#@E('9A;&EG;CTS1&)O='1O;3X\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C8L
M-S`W+#(U-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,B4@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS
M1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/C8L-S`W+#(U-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/CPO9F]N=#X\+W1D/CPO='(^
M/"]T86)L93X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#<N-W!T.R!M
M87)G:6XM;&5F=#H@.7!T.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@
M8FQO8VL[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SX\+V9O;G0^)B,Q-C`[/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/CQS=')O;F<^/&9O
M;G0@<VEZ93TS1#(^26YC;VUE(%1A>&5S("8C.#(Q,3L\+V9O;G0^/"]S=')O
M;F<^)B,Q-C`[5&AE($-O;7!A;GD@=7-E<R!T:&4@87-S970@86YD(&QI86)I
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M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@1&5V
M96QO<&UE;G0@0V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV/CQS=')O;F<^/&9O;G0@<VEZ93TS1#(^4F5S96%R8V@@86YD($1E
M=F5L;W!M96YT($-O<W1S("8C.#(Q,3L\+V9O;G0^/"]S=')O;F<^)B,Q-C`[
M4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S(&%R92!E>'!E;G-E9"!A
M<R!I;F-U<G)E9"X@4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(')E:6UB=7)S
M96UE;G1S(&%N9"!G<F%N=',@87)E(')E8V]R9&5D(&)Y('1H92!#;VUP86YY
M(&%S(&$@<F5D=6-T:6]N(&]F(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!C
M;W-T<RX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E+4)A<V5D(%!A>6UE;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX\<W1R;VYG/CQF;VYT('-I>F4]
M,T0R/E-H87)E+4)A<V5D(%!A>6UE;G1S("8C.#(Q,3L\+V9O;G0^/"]S=')O
M;F<^)B,Q-C`[5&AE($-O;7!A;GD@97-T:6UA=&5S('1H92!F86ER('9A;'5E
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M<&%I9"UI;B!C87!I=&%L+CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16%R;FEN9W,@*$QO<W,I(%!E<B!#
M;VUM;VX@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
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M;6]N('-H87)E(&%R92!T:&4@<V%M92X@)B,Q-C`[5&AE('!O=&5N=&EA;&QY
M(&1I;'5T:79E('-E8W5R:71I97,@*&]P=&EO;G,@86YD('=A<G)A;G1S*2!W
M97)E(&5X8VQU9&5D(&9R;VT@=&AE(&1I;'5T960@;&]S<R!P97(@8V]M;6]N
M('-H87)E(&-A;&-U;&%T:6]N(&)E8V%U<V4@=&AE:7(@969F96-T('=O=6QD
M(&AA=F4@8F5E;B!A;G1I9&EL=71I=F4N($9O<B!T:&4@=&AR964@;6]N=&AS
M(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!P;W1E;G1I86QL>2!I<W-U86)L92!S
M:&%R97,@:6YC;'5D960@<W1O8VL@;W!T:6]N<R!T;R!P=7)C:&%S92`R+#(V
M-2PR,CD@<VAA<F5S(&%N9"!W87)R86YT<R!T;R!P=7)C:&%S92`Y+#8X,"PS
M,S,@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K
M+B!&;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,RP@
M<&]T96YT:6%L;'D@:7-S=6%B;&4@<VAA<F5S(&EN8VQU9&5D('-T;V-K(&]P
M=&EO;G,@=&\@<'5R8VAA<V4@,BPS,S`L,3,T('-H87)E<R!A;F0@=V%R<F%N
M=',@=&\@<'5R8VAA<V4@,3(L-S<P+#8S-B!S:&%R97,@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLN/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E;G0@06-C;W5N
M=&EN9R!0<F]N;W5N8V5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^/'-T<F]N9SX\9F]N="!S:7IE/3-$,CY296-E;G0@06-C
M;W5N=&EN9R!0<F]N;W5N8V5M96YT<R`F(S@R,3$[/"]F;VYT/CPO<W1R;VYG
M/B8C,38P.U1H92!#;VUP86YY(&1O97,@;F]T(&5X<&5C="!T:&%T(&%N>2!R
M96-E;G1L>2!I<W-U960@86-C;W5N=&EN9R!P<F]N;W5N8V5M96YT<R!W:6QL
M(&AA=F4@82!S:6=N:69I8V%N="!I;7!A8W0@;VX@=&AE(')E<W5L=',@;V8@
M;W!E<F%T:6]N<RP@9FEN86YC:6%L('!O<VET:6]N+"!O<B!C87-H(&9L;W=S
M(&]F('1H92!#;VUP86YY+CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/CQS=')O;F<^/&9O
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M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7SAE8C4X.3DU7S%D9&1?-#$Q85\X93)A
M7V,S-S8W,#%B-3,P-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X
M96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0O5V]R:W-H965T
M<R]3:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@
M4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H5&%B;&5S*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E
M<V-R:7!T:6]N(&]F($)U<VEN97-S(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!S
M970@9F]R=&@@;&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V86QU92!O
M;B!A(')E8W5R<FEN9R!B87-I<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQT86)L92!S='EL93TS
M1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/CQT<CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$-#`E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T
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M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/DQE=F5L(#(\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q
M,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB
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M/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY4;W1A;#PO
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N
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M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY$97)I=F%T:79E(&QI
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M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
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M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q
M-C`[070@36%R8V@@,S$L(#(P,30\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#(E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0W)2!V86QI
M9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXM/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,B4@=F%L:6=N
M/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0X)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ.2PQ,C@L-S8Q/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
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M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B0\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS
M1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/C$Y+#$R."PW-C$\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/CQT<B!B9V-O;&]R/3-$=VAI=&4^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#0P)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R8C,38P.T%T($1E
M8V5M8F5R(#,Q+"`R,#$S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0R)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$-R4@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^+3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,B4@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#<E('9A;&EG
M;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/BT\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#(E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0X)2!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXV+#<P-RPR-34\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#(E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXV+#<P-RPR-34\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SX\+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R
M9VEN+7)I9VAT.B`W+C=P=#L@;6%R9VEN+6QE9G0Z(#EP=#L@=V]R9"US<&%C
M:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^/"]F;VYT/B8C,38P.SPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&5B
M-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+SAE8C4X.3DU7S%D9&1?-#$Q85\X93)A7V,S
M-S8W,#%B-3,P-"]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS
M86-T:6]N<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-U;6UA<GD@;V8@86-T:79I=&EE<R!R96QA=&5D('1O(')E
M;&%T960@<&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$S<'@[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT
M.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\=&%B;&4@<W1Y;&4],T0G=VED
M=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
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M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM
M<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^4&%Y;65N=',\+V9O;G0^
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M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^*#$I(&9I;&EN
M9R!O9B!A;B!.97<@1')U9R!!<'!L:6-A=&EO;B`H)B,X,C(P.TY$028C.#(R
M,3LI(&]R(')E9W5L871O<GD@87!P<F]V86PF(S$V,#MF;W(@96%C:"!L:6-E
M;G-E9"!P<F]D=6-T/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#LG/C<U,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^,2PW-3`L,#`P/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@86QI9VX],T1J
M=7-T:69Y('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@
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M<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#LG/CPO9F]N=#XF(S$V,#L\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAE8C4X.3DU7S%D9&1?
M-#$Q85\X93)A7V,S-S8W,#%B-3,P-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0O
M5V]R:W-H965T<R]3:&5E=#$W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="`H5&%B;&5S
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O
M9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,W!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
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M('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V
M-R4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED
M.R<^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[3&EV97,\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,3`E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/C(P,30\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
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M,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
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M,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
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M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.S,@>65A<G,\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R
M:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^,3<L,3<Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
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M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^*#(L.38U/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,G!X.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H-"B`Q,'!T.R<^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^*#$L-38P/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,G!X.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG
M/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@-'!X.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SX\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'@[(&)O<F1E<BUB;W1T;VTM
M<W1Y;&4Z(&1O=6)L93LG/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^,30L,C$T/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T
M<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXQ,RPY,C`\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE
M/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3-P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X
M="UI;F1E;G0Z(#!P=#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P
M86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/CPO9F]N=#XF(S$V
M,#L\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7SAE8C4X.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X96(U.#DY-5\Q9&1D7S0Q,6%?
M.&4R85]C,S<V-S`Q8C4S,#0O5V]R:W-H965T<R]3:&5E=#$X+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5R:79A=&EV97,@
M*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY$97)I=F%T:79E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!D
M97)I=F%T:79E('=A<G)A;G0@:6YS=')U;65N=',@86-T:79I='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R<^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
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M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
M)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM
M;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ+#DV."PV,C,\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
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M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C
M;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0W-B4@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
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M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY4<F%N<V9E<B!F
M<F]M(&QI86)I;&ET>2!C;&%S<VEF:6-A=&EO;B!T;R!E<75I='D@8VQA<W-I
M9FEC871I;VX\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B@T-BPP,C4\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXI/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H-"B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
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M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
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M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
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M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#<V)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY#:&%N9V4@:6X@9F%I<B!V86QU
M93PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM
M<W1Y;&4Z('-O;&ED.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXM/"]F;VYT/CPO9&EV/CPO
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW
M:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
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M:6YL:6YE.R<^,3(L-38Q+#`W,3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$-S8E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
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M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT
M<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M-S8E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M-'!X.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/D)A;&%N8V4L($UA<F-H(#,Q+"`R,#$T/"]F;VYT/CPO9&EV/CPO
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M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'@[(&)O<F1E<BUB;W1T;VTM<W1Y
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M)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
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M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
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M93X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT.B`Q,W!X
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE
M9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M/"]F;VYT/B8C,38P.SPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!F86ER('9A;'5E<R!O
M9B!D97)I=F%T:79E('=A<G)A;G1S(&]N(&)A<VES(&]F('9A;'5A=&EO;B!M
M;V1E;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\=&%B;&4@<W1Y;&4],T0G
M=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/D1E8V5M8F5R(#,Q+#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C
M:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
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M9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED
M.R<@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE
M9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
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M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY-87)K970@
M=F%L=64@;V8@8V]M;6]N('-T;V-K(&]N(&UE87-U<F5M96YT(&1A=&4@*#$I
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
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M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
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M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXU+C@Y/"]F;VYT/CPO=&0^
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT
M<@T*(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0W-B4@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G
M:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY2:7-K(&9R964@:6YT97)E<W0@<F%T
M92`H,BD\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX]
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M:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
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M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ+C(W/"]F
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M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/E=A<G)A;G0@;&EV97,@:6X@>65A<G,\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C`N-2!Y96%R<SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SY%>'!E8W1E9"!V;VQA=&EL:71Y("@S*3PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXW,SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXE/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0W-B4@=F%L:6=N/3-$8F]T=&]M
M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SY%>'!E8W1E9"!D:79I9&5N9"!Y:65L9"`H-"D\+V9O;G0^/"]D:78^/"]T
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M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXM/"]F;VYT/CPO=&0^/'1D
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M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/BT\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS
M1"-C8V5E9F8^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#<V)2!V86QI9VX]
M,T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/E!R;V)A8FEL:71Y(&]F('-T;V-K(&]F9F5R:6YG(&EN(&%N
M>2!P97)I;V0@;W9E<B`U('EE87)S("@U*3PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/BT\+V9O;G0^/"]T9#X\=&0@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.@T*(&EN;&EN93LG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXR-3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXE/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0W-B4@=F%L:6=N/3-$8F]T=&]M
M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SY286YG92!O9B!P97)C96YT86=E(&]F(&5X:7-T:6YG('-H87)E<R!O9F9E
M<F5D("@V*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/BT\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^,S4\
M+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY/9F9E<FEN9R!P<FEC92!R
M86YG92`H-RD\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI
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M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
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M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R
M/CPO=&%B;&4^/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G
M9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P
M=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y
M.B!B;&]C:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q
M,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R
M/CQT9"!W:61T:#TS1#8E('9A;&EG;CTS1'1O<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#L@;6%R9VEN+6QE9G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0S
M)2!V86QI9VX],T1T;W`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXH,2D\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@]
M,T0Y,24@=F%L:6=N/3-$=&]P/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G
M:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY4:&4@;6%R:V5T('9A;'5E(&]F(&-O
M;6UO;B!S=&]C:R!A="!T:&4@86)O=F4@;65A<W5R96UE;G0@9&%T97,@:7,@
M8F%S960@;VX@=&AE($-O;7!A;GDF(S@R,3<[<R!T<F%D:6YG('!R:6-E('%U
M;W1E9"!O;B!T:&4@3U1#($UA<FME=',@9F]R($1E8V5M8F5R(#,Q+"`R,#$S
M(&%N9"!O;B!T:&4@3EE312!-2U0@9F]R($UA<F-H(#,Q+"`R,#$T+CPO9F]N
M=#X\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M
M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C
M:6YG.B`P<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0Z(#$S<'@O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0V)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
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M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B@R*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!W:61T:#TS
M1#DQ)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G
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M("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[#0H@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\=&%B;&4@
M<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X\='(^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0V
M)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#,E('9A;&EG
M;CTS1'1O<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/B@S*28C,38P.R8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!W
M:61T:#TS1#DQ)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG;CTS1&IU<W1I9GD@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
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M=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P86-E.B!N;W)M
M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D
M:78^/&1I=B!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/'1A8FQE('-T>6QE/3-$)W=I
M9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^/'1R/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$-B4@=F%L:6=N/3-$
M=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0S)2!V86QI9VX],T1T;W`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXH-"DF
M(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Y,24@
M=F%L:6=N/3-$=&]P/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SY-86YA9V5M96YT(&1E=&5R;6EN960@=&AE(&1I
M=FED96YD('EI96QD('1O(&)E(#`E(&)A<V5D('5P;VX@:71S(&5X<&5C=&%T
M:6]N('1H870@:70@=VEL;"!N;W0@<&%Y(&1I=FED96YD<R!F;W(@=&AE(&9O
M<F5S965A8FQE(&9U='5R92X\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CPO=&%B
M;&4^/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N=#H@
M,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C
M:SL@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0Z(#$S
M<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0V)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
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M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/B@U*28C,38P.R8C,38P.SPO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!W:61T:#TS1#DQ)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG;CTS
M1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/DUA;F%G96UE
M;G0@9&5T97)M:6YE<R!T:&4@<')O8F%B:6QI='D@;V8@9G5T=7)E('-T;V-K
M(&]F9F5R:6YG(&%T(&5A8V@@979A;'5A=&EO;B!D871E+CPO9F]N=#X\+V1I
M=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM
M<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P
M<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@
M<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P
M)3L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#8E('9A;&EG;CTS1'1O<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^*#8I)B,Q-C`[)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$.3$E('9A;&EG;CTS
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M96%C:"!S=&]C:R!O9F9E<FEN9R!W:6QL(&)E)B,Q-C`[,"4@86YD(#,U)2!O
M9B!T:&4@<VAA<F5S(&]U='-T86YD:6YG(&%T($UA<F-H(#,Q+"`R,#$T(&%N
M9"!$96-E;6)E<B`S,2P@,C`Q,RP@<F5S<&5C=&EV96QY+CPO9F]N=#X\+V1I
M=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)SL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM
M<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P
M<'@[(&1I<W!L87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@
M<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P
M)3L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#8E('9A;&EG;CTS1'1O<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^*#<I)B,Q-C`[)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$.3$E('9A;&EG;CTS
M1'1O<#X\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.PT*(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SY297!R97-E;G1S('1H92!E<W1I;6%T960@;V9F97)I;F<@
M<')I8V4@<F%N9V4@:6X@9G5T=7)E(&]F9F5R:6YG<R!A<R!D971E<FUI;F5D
M(&)Y(&UA;F%G96UE;G0N/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\+W1A8FQE
M/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0Z(#$S<'@O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@-RXW<'0[(&UA<F=I;BUL
M969T.B`Y<'0[('=O<F0M<W!A8VEN9SH@,'!X.R!D:7-P;&%Y.B!B;&]C:SL@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/CPO9F]N=#XF(S$V,#L\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7SAE8C4X.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W
M,#%B-3,P-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X96(U.#DY
M-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0O5V]R:W-H965T<R]3:&5E
M=#$Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*%1A8FQE<RD\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F
M(&UI;&5S=&]N92!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G8V]L;W(Z(",P,#`P
M,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,W!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
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M/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^36EL97-T;VYE<SPO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#@X)2!V86QI9VX],T1B;W1T;VT^/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^-S4P+#`P,#PO9F]N=#X\
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M*#(I('=H96X@0V]M<&%N>2!I;FET:6%T97,@82!0:&%S92!)22!#;&EN:6-A
M;"!4<FEA;"!O9B!A(&QI8V5N<V5D('!R;V1U8W0\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXW-3`L,#`P/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#@X)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#LG/C$L-3`P+#`P,#PO9F]N=#X\+V1I=CX\+W1D
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^*#0I($)I;VQO
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/C$L-S4P
M+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^,2PU,#`L,#`P/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.@T*
M(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$
M=VAI=&4^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@X)2!V86QI9VX],T1B
M;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#LG/B@V*2!A9G1E<B!T:&4@9FER<W0@)#$P+#`P,"PP,#`@:6X@;F5T
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M,2PU,#`L,#`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CPO
M9&EV/CQD:78^)B,Q-C`[/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V
M-S`Q8C4S,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&5B-3@Y
M.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T+U=O<FMS:&5E=',O4VAE
M970R,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14=&04,^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^17%U:71Y("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@
M0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE
M;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(&]P=&EO;B!A8W1I=FET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,W!X.R!F;VYT+7-T
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M<F]K92UW:61T:#H@,'!X.R<^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
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M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L
M:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
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M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
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M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
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M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^079E<F%G93PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
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M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^5V5I9VAT960\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^4F5M86EN:6YG/"]F;VYT
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^3G5M8F5R(&]F/"]F;VYT/CPO9&EV/CPO=&0^
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^079E<F%G93PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[)SY);G1R:6YS:6,\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\
M='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#)P>#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N
M/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY5;FET<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^17AE<F-I<V4@
M4')I8V4\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C
M:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/E1E<FT@*&EN('EE87)S*3PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O
M;&ED.R<@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^5F%L=64\+V9O;G0^/"]D:78^/"]T9#X\
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M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
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M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
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M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^3W5T
M<W1A;F1I;F<L($1E8V5M8F5R(#,Q+"`R,#$S/"]F;VYT/CPO9&EV/CPO=&0^
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^,2PY.#4L,S@T/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9`T*(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^,RXR,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX]
M,T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^-2PY,#@L-CDV
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS
M1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0U,B4@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
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M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#LG/C(Y,2PU,#`F(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^,3`F(S$V,#L\+V9O;G0^/"]D
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M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#4R)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
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M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#)P>#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SX\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B@Q,2PV
M-34I/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z('-O;&ED.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXP+C<X/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
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M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M8F]T=&]M.B`R<'@[)SX\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
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M9'1H.B`T<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^,BPR
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M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!X.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!D;W5B;&4[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`T<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG
M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
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M=&]M.B`T<'@[)SX\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#LG/C@N,S0\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
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M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^,3DL-3$T
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M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O
M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+V9O;G0^)B,Q-C`[/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-U;6UA<GD@;V8@;W!T:6]N(&%C=&EV:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA
M;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M
M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
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M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
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M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
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M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
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M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
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M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\
M9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[)SY296UA:6YI;F<\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^06=G<F5G871E/"]F;VYT/CPO
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M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\
M9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY.=6UB97(@;V8\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT-
M"B!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[)SY%>&5R8VES92!0<FEC93PO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L
M<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^5&5R;2`H:6X@>65A<G,I/"]F;VYT/CPO9&EV/CPO=&0^
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M,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY686QU93PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
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M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
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M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
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M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
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M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M+W1D/CQT9`T*(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXQ+C`V/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+C@Y/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[1W)A;G1E9#PO9F]N=#X\+V1I=CX\+W1D
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^,S`V+#DR.#PO9F]N=#X\+V1I=CX\+W1D
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^-RXX.#PO9F]N=#X\+V1I
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#8N
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M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R8C,38P
M.T5X97)C:7-E9#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E
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M.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
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M>#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
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M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#)P
M>#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SX\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/C$N,#0\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D#0H@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
M<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0U,B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`T<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^3W5T<W1A;F1I;F<L($UA<F-H(#,Q+"`R,#$T/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E
M<BUB;W1T;VTM=VED=&@Z(#1P>#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U
M8FQE.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'@[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z(&1O=6)L93LG/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^.2PV.#`L,S,S/"]F;VYT/CPO9&EV/CPO
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M9'1H.B`T<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
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M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^,3`W+#(V."PW.#4\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV
M/CQD:78^)B,Q-C`[/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q
M8C4S,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&5B-3@Y.35?
M,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T+U=O<FMS:&5E=',O4VAE970R
M,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P141+044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF
M:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T86EL<RD@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!L:6%B:6QI=&EE<R!M96%S=7)E9"!A
M="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L
M:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DL
M,3(X+#<V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-BPW,#<L,C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,979E;"`Q(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F
M(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U
M<G)I;F<@8F%S:7,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQE=F5L(#(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@;&EA8FEL:71I97,@;65A<W5R
M960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<SPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I
M=F4@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5V96P@,R!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M
M;6%R>2!O9B!L:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N
M(&$@<F5C=7)R:6YG(&)A<VES/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DL,3(X+#<V,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BPW,#<L
M,C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X
M96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?
M8S,W-C<P,6(U,S`T+U=O<FMS:&5E=',O4VAE970R,BYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M13-404<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@
M0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<R`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#4^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/D]P=&EO;G,@06YD(%=A
M<G)A;G1S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3,\8G(^3W!T:6]N<R!!;F0@5V%R<F%N=',@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-#QB<CY#;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CY#;VUM;VX@
M4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-#QB<CY-86-H:6YE<GD@86YD(&5Q=6EP;65N="!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#(X+"`R,#$R/&)R/D%C=&EN:75M(%M-96UB97)=/&)R/G!U<F5S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,C4L(#(P,3,\8G(^
M06-T:6YI=6T@6TUE;6)E<ET\8G(^<'5R97,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@0G5S
M:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0
M;VQI8VEE<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($EN8V]R<&]R871I;VXL
M($1A=&4@;V8@26YC;W)P;W)A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^3V-T(#8L#0H)"3$Y.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O
M9B!O=VYE<G-H:7`@:6YT97)E<W0@86-Q=6ER960@8GD@8V]M<&%N>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,RXW
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!3=&]C:R!I<W-U86)L92!I;B!C;VYS:61E<F%T:6]N(&9O
M<B!E<75I='D@:6YT97)E<W0@86-Q=6ES:71I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.2XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('!A<B!V86QU92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D('5S
M969U;"!L:79E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)U1H<F5E('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!R96-E:79E9"!B>2!E86-H($%0
M22!S:&%R96AO;&1E<B!O9B!!8W1I;FEU;2!C;VUM;VX@<W1O8VL@9F]R(&5A
M8V@@05!)('-H87)E(&5X8VAA;F=E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`N,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,"XS,S,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!O=&5N=&EA;&QY(&ES<W5A
M8FQE('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#(V-2PR,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#,S,"PQ,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+#8X,"PS,S,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPW-S`L-C,V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VL@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L.3<P+#$S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K('-H87)E<R!E>&-H
M86YG960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PS,C(L,#4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&5B-3@Y.35?,61D9%\T,3%A
M7SAE,F%?8S,W-C<P,6(U,S`T+U=O<FMS:&5E=',O4VAE970R,RYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14I*04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4F5L871E9"!0
M87)T>2!4<F%N<V%C=&EO;G,@*$1E=&%I;',I("A-96UO<FEA;"!3;&]A;B!+
M971T97)I;F<@0V%N8V5R($-E;G1E<B!;365M8F5R72P@55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE=R!$<G5G($%P
M<&QI8V%T:6]N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@;6EL97-T;VYE('!A>6UE;G1S
M(')E;&%T960@=&\@<F5L871E9"!P87)T>3PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE<R!P87EM96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E
M:7!T(&]F(%)E9W5L871O<GD@07!P<F]V86P@1G)O;2!5+E,N($9$02!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT<R!R96QA=&5D('1O(')E
M;&%T960@<&%R='D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DUI;&5S=&]N97,@<&%Y;65N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PW-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R
M85]C,S<V-S`Q8C4S,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T+U=O<FMS:&5E
M=',O4VAE970R-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P130T0DD^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@*$1E=&%I;',@
M5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#,^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`P.2P@,C`Q,SQB<CY0;&%C96UE;G0@
M06=E;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^075G+B`P-RP@,C`Q,CQB<CY0;&%C96UE;G0@06=E;G0@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-#QB<CY0;&%C96UE;G0@06=E;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY-4TM#0R!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$S/&)R/DU32T-#(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^35-+0T,@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CY-4TM#0R!;365M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE
M;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`R-RP@,C`Q,CQB<CY-4TM#0R!;365M8F5R73QB<CY#;&EN:6-A;"!4
M<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`P-"P@,C`Q,SQB<CY32TD@6TUE;6)E<ET\8G(^
M3&EC96YS92P@1&5V96QO<&UE;G0@86YD($-O;6UE<F-I86QI>F%T:6]N($%G
M<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#$Y+"`R,#$Q/&)R/E-+22!;365M8F5R73QB<CY,:6-E;G-E
M+"!$979E;&]P;65N="!A;F0@0V]M;65R8VEA;&EZ871I;VX@06=R965M96YT
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,30\8G(^4TM)(%M-96UB97)=/&)R/DQI8V5N<V4L($1E=F5L
M;W!M96YT(&%N9"!#;VUM97)C:6%L:7IA=&EO;B!!9W)E96UE;G0@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CY32TD@6TUE;6)E<ET\8G(^3&EC96YS92P@1&5V96QO<&UE;G0@
M86YD($-O;6UE<F-I86QI>F%T:6]N($%G<F5E;65N="!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA
M=&5D(%!A<G1Y(%1R86YS86-T:6]N<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO
M=6YT('!A:60@=6YD97(@86=R965M96YT(&EN(#(P,3$\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N
M="!P86ED('5N9&5R(&%G<F5E;65N="!I;B`R,#$R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!P
M86ED('5N9&5R(&%G<F5E;65N="!I;B`R,#$S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!O=V5D
M('5N9&5R(&%G<F5E;65N="!F<F]M(#(P,3$@=&\@,C`Q-#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,34L,3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-86EN
M=&5N86YC92!F965S(&%N9"!R97-E87)C:"!P87EM96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!L86-E;65N="!A9V5N="!S97)V:6-E<R!F965S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S
M(&ES<W5E9"!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VLL('-H87)E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV."PY-S8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:R!E>&5R8VES92!P<FEC92!P97(@<VAA<F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U
M;G0@<&%I9"!T;R!E86-H('!A=&EE;G0@869T97(@0V]M<&QE=&EN9R!C;&EN
M:6-A;"!T<FEA;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,Q+#$X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T87)T+75P(&9E92!F;W(@8VQI;FEC86P@=')I
M86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Y+#8R
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$97-C<FEP=&EO;B!O9B!R96-E:79A8FQE<R!O9B!P;&%C96UE
M;G0@86=E;G0@9F]R('-E<G9I8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG06=R965M96YT(&5N=&5R960@:6X@,C`Q,R!H87,@<VEM:6QA
M<B!T97)M<R!A<R!T:&4@,C`Q,B!A9W)E96UE;G0L(&EN8VQU9&EN9R!A(&-A
M<V@@9F5E(&5Q=6%L('1O(#$P)2!O9B!T:&4@9W)O<W,@<')O8V5E9',@<F%I
M<V5D+"!A(&YO;BUA8V-O=6YT86)L92!E>'!E;G-E(')E:6UB=7)S96UE;G0@
M97%U86P@=&\@,B4@;V8@=&AE(&=R;W-S('!R;V-E961S(')A:7-E9"!A;F0@
M=V%R<F%N=',@=&\@<'5R8VAA<V4@<VAA<F5S(&]F('1H92!#;VUP86YY)W,@
M0V]M;6]N(%-T;V-K+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=0;&%C96UE;G0@86=E;G0@=VEL;"!R96-E:79E("AA
M*2!A(&-A<V@@9F5E(&5Q=6%L('1O(#$P)2!O9B!T:&4@9W)O<W,@<')O8V5E
M9',@<F%I<V5D(&EN('1H92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9RP@
M*&(I(&$@;F]N+6%C8V]U;G1A8FQE(&5X<&5N<V4@<F5I;6)U<G-E;65N="!E
M<75A;"!T;R`R)2!O9B!T:&4@9W)O<W,@<')O8V5E9',@<F%I<V5D(&EN('1H
M92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9RP@86YD("AC*2!R96EM8G5R
M<V5M96YT(&]F("0Q,#`L,#`P(&9O<B!L96=A;"!E>'!E;G-E<R!I;F-U<G)E
M9"!B>2!T:&4@<&QA8V5M96YT(&%G96YT+CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<V-R:7!T
M:6]N(&]F('=A<G)A;G1S(')E8V5I=F%B;&5S(&)Y('!L86-E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U=A<G)A;G1S('1O('!U<F-H
M87-E('-H87)E<R!O9B!T:&4@0V]M<&%N>2=S($-O;6UO;B!3=&]C:R!I;B!A
M;B!A;6]U;G0@97%U86P@=&\@,3`E(&]F('1H92!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K(&ES<W5E9"!O<B!I<W-U86)L93QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=4:&4@<&QA8V5M96YT(&%G96YT
M(&]R(&ET<R!D97-I9VYE97,@:&%V92!A;'-O(')E8V5I=F5D('=A<G)A;G1S
M('1O('!U<F-H87-E('-H87)E<R!O9B!T:&4@0V]M<&%N>2=S($-O;6UO;B!3
M=&]C:R!I;B!A;B!A;6]U;G0@97%U86P@=&\@,3`E(&]F('1H92!S:&%R97,@
M;V8@8V]M;6]N('-T;V-K(&ES<W5E9"!A<R!P87)T(&]F('1H92!U;FET<R!S
M;VQD(&EN('1H92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9R!A;F0@=&AE
M('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@:7-S=6%B;&4@=7!O;B!E>&5R8VES
M92!O9B!T:&4@0B!W87)R86YT<R!I;F-L=61E9"!I;B!S=6-H('5N:71S+CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!E<FEO9"!O9B!E>&5R8VES92!O9B!W87)R86YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=7:71H:6X@-B!M;VYT:',@
M;V8@=&AE(&9I;F%L(&-L;W-I;F<@;V8@=&AE(#(P,3(@8V]M;6]N('-T;V-K
M($]F9F5R:6YG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@<V]L
M:6-I=&%T:6]N(&9E93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^36]N=&AL>2!F964@9F]R(&9I;F%N8VEA;"!A
M9'9I<V]R>2!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@861D
M:71I;VYA;"!R96-E:79A8FQE(&)Y('!L86-E;65N="!A9V5N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=4:&4@86=R965M96YT(&%L<V\@
M<')O=FED97,@=&AA="`H:2D@:68@=&AE($-O;7!A;GD@8V]N<W5M;6%T97,@
M86YY(&UE<F=E<BP@86-Q=6ES:71I;VXL(&)U<VEN97-S(&-O;6)I;F%T:6]N
M(&]R(&]T:&5R('1R86YS86-T:6]N("AO=&AE<B!T:&%N('1H92!3:&%R92!%
M>&-H86YG92D@=VET:"!A;GD@<&%R='D@:6YT<F]D=6-E9"!T;R!I="!B>2!T
M:&4@<&QA8V5M96YT(&%G96YT+"!T:&4@<&QA8V5M96YT(&%G96YT('=O=6QD
M(')E8V5I=F4@82!F964@97%U86P@=&\@,3`E(&]F('1H92!A9V=R96=A=&4@
M8V]N<VED97)A=&EO;B!I;B!S=6-H('1R86YS86-T:6]N<RP@86YD("AI:2D@
M:68L('=I=&AI;B!A('!E<FEO9"!O9B`Q,B!M;VYT:',@869T97(@=&5R;6EN
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M92!S8VAE9'5L92!S970@9F]R=&@@:6X@=&AE($%U9W5S="`W+"`R,#$R(&5N
M9V%G96UE;G0@86=R965M96YT+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@:&5L9"!B
M>2!P;&%C96UE;G0@86=E;G0@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-3$L,#$U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4&%I9"!F;W(@<F5S96%R8V@@8V]N9'5C=&5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#DL-3,W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Y+#@U,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)O>6%L='D@9&5S8W)I<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV/CQF;VYT('-I>F4],T0R/E5N9&5R('1H92!A9W)E
M96UE;G0L('1H92!#;VUP86YY('-H86QL('!A>2!T;R!-4TM#0R!O;B!A(&-O
M=6YT<GDM8GDM8V]U;G1R>2!B87-I<R!A(')O>6%L='D@;V8@,B4@;V8@;F5T
M('-A;&5S(&]F(&%L;"!L:6-E;G-E9"!P<F]D=6-T<R!U;G1I;"!T:&4@;&%T
M97(@;V8Z("@Q*2`Q,"!Y96%R<R!F<F]M('1H92!F:7)S="!C;VUM97)C:6%L
M('-A;&4L(&]R("@R*2!W:&5N('1H92!P871E;G1S(&5X<&ER92X@/"]F;VYT
M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@<&%Y86)L92!T;R!-4TM#0SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.#DL-3,W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#$L,3@U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&5B-3@Y.35?,61D9%\T,3%A7SAE
M,F%?8S,W-C<P,6(U,S`T+U=O<FMS:&5E=',O4VAE970R-2YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P145&04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4')O<&5R='D@86YD
M($5Q=6EP;65N="`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!P<F]P
M97)T>2!A;F0@97%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^57-E9G5L($QI=F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]F9FEC92!E<75I<&UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3<L,3<Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-2PT
M.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQE<W,Z($%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,BPY-C4I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU-C`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@
M86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q-"PR,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$S+#DR,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U
M,S`T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAE8C4X.3DU7S%D
M9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-"]7;W)K<VAE971S+U-H965T,C8N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5*14%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R
M;W!E<G1Y(&%N9"!%<75I<&UE;G0@*$1E=&%I;',@5&5X='5A;"D@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$V-B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="`H
M5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5P<F5C:6%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PT,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N(&1I<W!O<VET
M:6]N(&]F(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H-"PQ,C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@U-30L,S`X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W
M-C<P,6(U,S`T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAE8C4X
M.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-"]7;W)K<VAE971S+U-H
M965T,C<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5:0T%%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DYO=&4@4&%Y86)L92`H1&5T86EL<RD@*%!R96UI=6T@1FEN86YC92!!
M9W)E96UE;G0@6TUE;6)E<ETL(%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,C@L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R96UI=6T@1FEN86YC
M92!!9W)E96UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T92!087EA8FQE(&%N9"!#;VYV97)T
M:6)L92!.;W1E<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO=&5S('!A>6%B;&4L(&]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y-"PT.#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$U-RPX,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$U-RPX,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O=VX@<&%Y;65N="!P=7)S=6%N="!T;R!T
M:&4@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-2PY.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,RPS-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06UO=6YT(')E<75I<F5D('1O('!A>2!I;B!M;VYT
M:&QY(&EN<W1A;&QM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q-2PY.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U,S`T
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAE8C4X.3DU7S%D9&1?
M-#$Q85\X93)A7V,S-S8W,#%B-3,P-"]7;W)K<VAE971S+U-H965T,C@N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4S3$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E<FEV
M871I=F5S("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,38V($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H
M961U;&4@;V8@9&5R:79A=&EV92!W87)R86YT(&EN<W1R=6UE;G1S(&%C=&EV
M:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F5G:6YN:6YG(&)A;&%N8V4L(%5N:71S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#DV."PV,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%N<V9E<B!F<F]M(&QI86)I
M;&ET>2!C;&%S<VEF:6-A=&EO;B!T;R!E<75I='D@8VQA<W-I9FEC871I;VXL
M(%5N:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-BPP,C4I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%L86YC92P@56YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L.3(R+#4Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L.3(R+#4Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG(&)A;&%N8V4L($9A
M:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BPW
M,#<L,C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5')A;G-F97(@9G)O;2!L:6%B:6QI='D@8VQA<W-I9FEC871I
M;VX@=&\@97%U:71Y(&-L87-S:69I8V%T:6]N+"!&86ER(%9A;'5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,SDL-38U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L-#$W+#DX-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-H86YG92!I;B!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,BPU-C$L,#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92P@1F%I<B!686QU93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.2PQ,C@L-S8Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.2PQ
M,C@L-S8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\X96(U.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&5B-3@Y.35?,61D9%\T,3%A7SAE
M,F%?8S,W-C<P,6(U,S`T+U=O<FMS:&5E=',O4VAE970R.2YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P135!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5R:79A=&EV97,@
M*$1E=&%I;',@,2D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY-87(N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!F86ER('9A;'5E<R!O9B!D97)I
M=F%T:79E('=A<G)A;G1S(&]N(&)A<VES(&]F('9A;'5A=&EO;B!M;V1E;#PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUA<FME="!V86QU92!O9B!C;VUM;VX@<W1O8VL@;VX@
M;65A<W5R96UE;G0@9&%T92`H,2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3(N-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-2XX.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!9&IU<W1E9"!E>&5R8VES92!P<FEC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y+CDU/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C0X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2:7-K(&9R964@:6YT97)E<W0@<F%T92`H,BD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,S(E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C(W)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELR73PO
M<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M(&QI=F5S(&EN('EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG-B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-B!M
M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D
M('9O;&%T:6QI='D@*#,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW,2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/'-U<#Y;,UT\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<S+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\<W5P/ELS73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N9"!Y:65L9"`H-"D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;
M-%T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/'-U<#Y;-%T\+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8F%B:6QI='D@;V8@<W1O8VL@;V9F97)I;F<@:6X@86YY
M('!E<FEO9"!O=F5R(#4@>65A<G,@*#4I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S5=/"]S=7`^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;-5T\+W-U<#X\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@<&5R8V5N
M=&%G92!O9B!E>&ES=&EN9R!S:&%R97,@;V9F97)E9"`H-BD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;-ET\+W-U
M<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELV
M73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9E
M<FEN9R!P<FEC92!R86YG92`H-RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\<W5P/ELW73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CQS=7`^6S==/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-3X\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@
M("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S%=/"]T9#X-"B`@("`@("`@/'1D
M(&-O;'-P86X],T0T('9A;&EG;CTS1'1O<#Y4:&4@;6%R:V5T('9A;'5E(&]F
M(&-O;6UO;B!S=&]C:R!A="!T:&4@86)O=F4@;65A<W5R96UE;G0@9&%T97,@
M:7,@8F%S960@;VX@=&AE($-O;7!A;GDG<R!T<F%D:6YG('!R:6-E('%U;W1E
M9"!O;B!T:&4@3U1#($UA<FME=',@9F]R($1E8V5M8F5R(#,Q+"`R,#$S(&%N
M9"!O;B!T:&4@3EE312!-2U0@9F]R($UA<F-H(#,Q+"`R,#$T+CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-
M"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,ET\+W1D/@T*("`@("`@("`\
M=&0@8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P/E1H92!R:7-K+69R964@:6YT
M97)E<W0@<F%T92!W87,@9&5T97)M:6YE9"!B>2!M86YA9V5M96YT('5S:6YG
M('1H92!4<F5A<W5R>2!":6QL(&%S(&]F('1H92!R97-P96-T:79E(&UE87-U
M<F5M96YT(&1A=&4N/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P
M/ELS73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-"!V86QI9VX],T1T
M;W`^0F5C875S92!T:&4@0V]M<&%N>2!D;V5S(&YO="!H879E(&%D97%U871E
M('1R861I;F<@:&ES=&]R>2!T;R!D971E<FUI;F4@:71S(&AI<W1O<FEC86P@
M=')A9&EN9R!V;VQA=&EL:71Y+"!T:&4@=F]L871I;&ET>2!F86-T;W(@=V%S
M(&5S=&EM871E9"!B>2!M86YA9V5M96YT('5S:6YG('1H92!H:7-T;W)I8V%L
M('9O;&%T:6QI=&EE<R!O9B!C;VUP87)A8FQE(&-O;7!A;FEE<R!I;B!T:&4@
M<V%M92!I;F1U<W1R>2!A;F0@<F5G:6]N+CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D
M('9A;&EG;CTS1'1O<#Y;-%T\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS
M1#0@=F%L:6=N/3-$=&]P/DUA;F%G96UE;G0@9&5T97)M:6YE9"!T:&4@9&EV
M:61E;F0@>6EE;&0@=&\@8F4@,"4@8F%S960@=7!O;B!I=',@97AP96-T871I
M;VX@=&AA="!I="!W:6QL(&YO="!P87D@9&EV:61E;F1S(&9O<B!T:&4@9F]R
M97-E96%B;&4@9G5T=7)E+CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS
M1'1O<#Y;-5T\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L:6=N
M/3-$=&]P/DUA;F%G96UE;G0@9&5T97)M:6YE<R!T:&4@<')O8F%B:6QI='D@
M;V8@9G5T=7)E('-T;V-K(&]F9F5R:6YG(&%T(&5A8V@@979A;'5A=&EO;B!D
M871E+CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN
M97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;-ET\+W1D
M/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P/DUA;F%G
M96UE;G0@97-T:6UA=&5S('1H870@=&AE(')A;F=E(&]F('!E<F-E;G1A9V5S
M(&]F(&5X:7-T:6YG('-H87)E<R!O9F9E<F5D(&EN(&5A8V@@<W1O8VL@;V9F
M97)I;F<@=VEL;"!B92`P)2!A;F0@,S4E(&]F('1H92!S:&%R97,@;W5T<W1A
M;F1I;F<@870@36%R8V@@,S$L(#(P,30@86YD($1E8V5M8F5R(#,Q+"`R,#$S
M+"!R97-P96-T:79E;'DN/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$
M=&]P/ELW73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-"!V86QI9VX]
M,T1T;W`^4F5P<F5S96YT<R!T:&4@97-T:6UA=&5D(&]F9F5R:6YG('!R:6-E
M(')A;F=E(&EN(&9U='5R92!O9F9E<FEN9W,@87,@9&5T97)M:6YE9"!B>2!M
M86YA9V5M96YT+CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X96(U.#DY
M-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P
M,6(U,S`T+U=O<FMS:&5E=',O4VAE970S,"YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P151/04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5R:79A=&EV97,@*$1E=&%I;',@
M5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY-87(N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1&5R:79A=&EV97,@*%1E>'1U86PI/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F%N9V4@;V8@<&5R8V5N=&%G92!O9B!E>&ES=&EN9R!S:&%R97,@;V9F
M97)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X<&5C=&5D(&1I=FED96YD('EI96QD/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS
M=7`^6S)=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<FEV871I=F5S("A4
M97AT=6%L*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@=V%R<F%N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`Q,SDL-38U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F('=A<G)A;G0@97AE<F-I<V5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPP,C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#4^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\
M=&0@=F%L:6=N/3-$=&]P/ELQ73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N
M/3-$-"!V86QI9VX],T1T;W`^36%N86=E;65N="!E<W1I;6%T97,@=&AA="!T
M:&4@<F%N9V4@;V8@<&5R8V5N=&%G97,@;V8@97AI<W1I;F<@<VAA<F5S(&]F
M9F5R960@:6X@96%C:"!S=&]C:R!O9F9E<FEN9R!W:6QL(&)E(#`E(&%N9"`S
M-24@;V8@=&AE('-H87)E<R!O=71S=&%N9&EN9R!A="!-87)C:"`S,2P@,C`Q
M-"!A;F0@1&5C96UB97(@,S$L(#(P,3,L(')E<W!E8W1I=F5L>2X\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^
M#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S)=/"]T9#X-"B`@("`@("`@
M/'1D(&-O;'-P86X],T0T('9A;&EG;CTS1'1O<#Y-86YA9V5M96YT(&1E=&5R
M;6EN960@=&AE(&1I=FED96YD('EI96QD('1O(&)E(#`E(&)A<V5D('5P;VX@
M:71S(&5X<&5C=&%T:6]N('1H870@:70@=VEL;"!N;W0@<&%Y(&1I=FED96YD
M<R!F;W(@=&AE(&9O<F5S965A8FQE(&9U='5R92X\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W-C<P,6(U
M,S`T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAE8C4X.3DU7S%D
M9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-"]7;W)K<VAE971S+U-H965T,S$N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$535T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O
M;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A$971A:6QS*2`H06)B;W1T
M($)I;W1H97)A<&5U=&EC<R!#;W)P(%M-96UB97)=+"!54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&AA<V4@22!#;&EN
M:6-A;"!4<FEA;"!O9B!A(&QI8V5N<V5D('!R;V1U8W0@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R
M>2!O9B!M:6QE<W1O;F4@<&%Y;65N=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE<R!P87EM96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-3`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0:&%S92!)
M22!#;&EN:6-A;"!4<FEA;"!O9B!A(&QI8V5N<V5D('!R;V1U8W0@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W5M;6%R>2!O9B!M:6QE<W1O;F4@<&%Y;65N=#PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE<R!P87EM96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&AA
M<V4@24E)($-L:6YI8V%L(%1R:6%L(&]F(&$@;&EC96YS960@<')O9'5C="!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F5S('!A
M>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)I;VQO9VEC86P@3&EC96YS92!!<'!L:6-A=&EO;B!F:6QI;F<@=VET
M:"!5+E,N($9$02!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-
M:6QE<W1O;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9I<G-T($-O;6UE<F-I86P@4V%L92!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F5S('!A>6UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%F
M=&5R($9I<G-T($YE="!386QE<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N
M92!P87EM96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y-:6QE<W1O;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?
M8S,W-C<P,6(U,S`T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAE
M8C4X.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-"]7;W)K<VAE971S
M+U-H965T,S(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4V6$1-/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A$971A:6QS
M(%1E>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ-C8@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#4^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXS
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#,^,2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2F%N+B`R-RP@,C`Q-#QB<CY-86YU9F%C='5R
M:6YG($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/DUA;G5F86-T=7)I;F<@06=R
M965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D%U9RX@,S$L(#(P,3(\8G(^4F5N=&%L($%G<F5E;65N="!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$T/&)R/E)E;G1A;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY!8F)O='0@
M0FEO=&AE<F%P975T:6-S($-O<G`@6TUE;6)E<ET\8G(^4')O9'5C="!$979E
M;&]P;65N="!A;F0@4&%T96YT($QI8V5N<V4@06=R965M96YT(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,30\8G(^06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P(%M-96UB97)=/&)R
M/D%F=&5R($9I<G-T($YE="!386QE<R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/D%B8F]T="!"
M:6]T:&5R87!E=71I8W,@0V]R<"!;365M8F5R73QB<CY!9G1E<B!&:7)S="!.
M970@4V%L97,@6TUE;6)E<ET\8G(^4')O9'5C="!$979E;&]P;65N="!A;F0@
M4&%T96YT($QI8V5N<V4@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^06)B;W1T
M($)I;W1H97)A<&5U=&EC<R!#;W)P(%M-96UB97)=/&)R/E!H87-E($D@0VQI
M;FEC86P@5')I86P@;V8@82!L:6-E;G-E9"!P<F]D=6-T(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^35-+0T,@6TUE;6)E<ET\8G(^0VQI;FEC86P@5')I86P@06=R965M96YT
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,C<L(#(P,3(\8G(^35-+0T,@6TUE;6)E<ET\8G(^0VQI;FEC86P@5')I
M86P@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^3V%K(%)I9&=E($YA=&EO;F%L
M($QA8F]R871O<GD@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CY/86L@4FED9V4@3F%T:6]N86P@
M3&%B;W)A=&]R>2!;365M8F5R73QB<CXR,#$S(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^3V%K
M(%)I9&=E($YA=&EO;F%L($QA8F]R871O<GD@6TUE;6)E<ET\8G(^,C`Q-"!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87D@
M,38L(#(P,3,\8G(^07!T:78@4V]L=71I;VYS(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,C(L(#(P,3(\8G(^07!T
M:78@4V]L=71I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D%U9RX@,#8L(#(P,3(\8G(^07!T:78@4V]L=71I;VYS(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,#<\8G(^07!T:78@4V]L=71I;VYS(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^07!T
M:78@4V]L=71I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^07!T:78@4V]L=71I;VYS(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,34L(#(P,3(\8G(^1G)E9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C:"!#
M96YT97(@6TUE;6)E<ET\8G(^;&EC96YS92!A;F0@<W!O;G-O<F5D(')E<V5A
M<F-H(&%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/D9R960@2'5T8VAI;G-O;B!#
M86YC97(@4F5S96%R8V@@0V5N=&5R(%M-96UB97)=/&)R/FQI8V5N<V4@86YD
M('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CY&
M<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H($-E;G1E<B!;365M8F5R
M73QB<CYL:6-E;G-E(&%N9"!S<&]N<V]R960@<F5S96%R8V@@86=R965M96YT
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,30\8G(^1G)E9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C
M:"!#96YT97(@6TUE;6)E<ET\8G(^0VQI;FEC86P@5')I86P@06=R965M96YT
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^1G)E9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C
M:"!#96YT97(@6TUE;6)E<ET\8G(^0VQI;FEC86P@5')I86P@06=R965M96YT
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;"X@,3DL(#(P,3(\8G(^1G)E9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C
M:"!#96YT97(@6TUE;6)E<ET\8G(^0VQI;FEC86P@5')I86P@06=R965M96YT
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,34L(#(P,3(\8G(^1G)E9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C
M:"!#96YT97(@6TUE;6)E<ET\8G(^36%X:6UU;2!;365M8F5R73QB<CYL:6-E
M;G-E(&%N9"!S<&]N<V]R960@<F5S96%R8V@@86=R965M96YT(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,34L(#(P
M,3(\8G(^1G)E9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C:"!#96YT97(@
M6TUE;6)E<ET\8G(^36EN:6UU;2!;365M8F5R73QB<CYL:6-E;G-E(&%N9"!S
M<&]N<V]R960@<F5S96%R8V@@86=R965M96YT(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%U9RX@,C@L(#(P,3(\8G(^56YI
M=F5R<VET>2!O9B!497AA<R!-+D0N($%N9&5R<V]N($-A;F-E<B!#96YT97(@
M6TUE;6)E<ET\8G(^0VQI;FEC86P@5')I86P@06=R965M96YT(%M-96UB97)=
M/&)R/G!A=&EE;G1S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;"X@,S$L(#(P,3,\8G(^56YI=F5R<VET>2!O9B!497AA<R!-+D0N($%N
M9&5R<V]N($-A;F-E<B!#96YT97(@6TUE;6)E<ET\8G(^0VQI;FEC86P@5')I
M86P@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,C8L(#(P,3(\8G(^2F]H;G,@2&]P:VEN<R!5;FEV
M97)S:71Y(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G<F5E;65N="!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$T/&)R/DIO:&YS($AO<&MI;G,@56YI=F5R<VET>2!;365M8F5R
M73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`R,2P@,C`Q,CQB<CY5
M;FEV97)S:71Y(&]F(%!E;FYS>6QV86YI82!;365M8F5R73QB<CY#;&EN:6-A
M;"!4<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY5;FEV97)S:71Y(&]F
M(%!E;FYS>6QV86YI82!;365M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E
M96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@
M*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!S86QE<R!I;B!M:6QE<W1O;F5S('!A>6UE;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!F964@<&%Y
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N
M97,@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW+#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E<V-R:7!T:6]N(&]F(')O>6%L='D@<&%Y;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=#;VUP86YY
M('-H86QL('!A>2!T;R!!8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`@;VX@
M82!C;W5N=')Y+6)Y+6-O=6YT<GD@8F%S:7,@82!R;WEA;'1Y(&]F(#$R)2!O
M9B!N970@<V%L97,@;V8@86QL(&QI8V5N<V5D('!R;V1U8W1S('5N=&EL('1H
M92!L871E<B!O9CH@*#$I(#$R+C4@>65A<G,@869T97(@=&AE(&9I<G-T(&-O
M;6UE<F-I86P@<V%L92P@;W(@*#(I('=H96X@=&AE('!A=&5N=',@97AP:7)E
M+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B=2;WEA;'1Y('!A>6UE;G1S(&]F(#(E(&]F(&YE
M="!S86QE<R!W:6QL(&)E(&1U92!T;R!&2$-20RX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O
M>6%L='D@;V8@3F5T(%-A;&5S(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BXP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&:7)S="!C;VUM97)C:6%L('-A;&4@<&5R:6]D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$R('EE87)S
M(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA
M<V4@;V8@<F%D:6]A8W1I=F4@;6%T97)I86P@=7-E9"!F;W(@<F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C,S+#$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;VIE8W0@97-T:6UA=&5D(&-O<W0@9F]R(&-L:6YI
M8V%L('1R:6%L<R!O9B!D<G5G($%C+3(R-2U(=4TQ.34\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.#$S+#DV,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#<W+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&]W;B!P87EM96YT(&]F('!R;VIE8W0@97-T:6UA
M=&5D(&-O<W0@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BXU,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O=VX@<&%Y;65N="!F;W(@<')O:F5C=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,Y
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,SDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-L:6YI8V%L('1R:6%L(&-O
M<W0@9F]R(&%P<')O=F%L(&]F(&9O;V0@86YD(&1R=6<@861M:6YI<W1R871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,RPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L,C`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1G5N9"!F;W(@1G)E9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C:"!#96YT
M97(@;&%B("@@4&5R('EE87(@9F]R('1H92!F:7)S="!T=V\@>65A<G,@*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=6YD(&9O<B!&<F5D($AU
M=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H($-E;G1E<B!L86(@*"!T:&5R96%F
M=&5R("D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M(%!A=&EE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@<&%I
M9"!T;R!E86-H('!A=&EE;G0@869T97(@0V]M<&QE=&EN9R!C;&EN:6-A;"!T
M<FEA;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S$L,3@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,38L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#,V-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T
M+#,X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,X+#4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PW-S$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&%R="UU<"!F964@
M9F]R(&-L:6YI8V%L('1R:6%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<Y+#8R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-S0Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S,L.30V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(R+#@T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&%R="UU<"!D=64@8V]S="!P86ED
M(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/D1E8R`S,2P-"@D),C`Q,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M;VX@+2!R969U;F1A8FQE(&EN<W1I='5T:6]N86P@9F5E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-C(L-SDP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-"PU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YN=6%L('!H87)M86-Y(&9E93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#`R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT('!R;V-E<W-I
M;F<@9F5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T:6-E('!E<FEO
M9"!F;W(@=&5R;6EN871I;VX@;V8@86=R965M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG5&AI<R!A9W)E96UE;G0@=&5R;6EN
M871E<R!O;B!*=6QY(#8L(#(P,30N(%5P;VX@=&AE(&5X<&ER871I;VX@;V8@
M=&AE('1E<FTL('1H92!A9W)E96UE;G0@875T;VUA=&EC86QL>2!R96YE=W,@
M;VX@82!M;VYT:"UT;RUM;VYT:"!B87-I<R!A;F0@<F5Q=6ER97,@82!T=V\@
M;6]N=&@@;F]T:6-E(&]F('1E<FUI;F%T:6]N+CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y296YT(&%G<F5E;65N="!T97)M:6YA=&EO;B!D871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DUA<B`S,2P-
M"@D),C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5N=&%L
M(&%G<F5E;65N="!R96YE=V%L(&1E<V-R:7!T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG5&AE(&%G<F5E;65N="!A=71O;6%T
M:6-A;&QY(')E;F5W<R!O;B!A(&UO;G1H+71O+6UO;G1H(&)A<VES(&%N9"!R
M97%U:7)E<R!A('1W;R!M;VYT:"!N;W1I8V4@;V8@=&5R;6EN871I;VXN/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@97AP96YS97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,38L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&9E97,@<&%I
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(')E8V]R
M9&5D(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPT
M-C`L.38X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+#`X-2PW,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#,Q+#4T."PS-#8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,S<L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S-RPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&5B-3@Y.35?,61D9%\T,3%A
M7SAE,F%?8S,W-C<P,6(U,S`T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+SAE8C4X.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-"]7;W)K
M<VAE971S+U-H965T,S,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5#,T)'/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D5Q=6ET>2`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&]C:R!/<'1I;VYS(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@<W1O8VL@;W!T:6]N
M(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!5;FET<RP@0F5G:6YN:6YG(&)A;&%N
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3@U+#,X-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M,S,P+#$S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(W,RPX-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y,2PU,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$L-C4U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M
M8F5R(&]F(%5N:71S+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPR-C4L,C(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY.#4L,S@T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<S+#@U.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L($)E
M9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,N,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$N,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!
M=F5R86=E($5X97)C:7-E(%!R:6-E+"!)<W-U960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-RXX-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%
M>&5R8VES92!0<FEC92P@97AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I
M<V4@4')I8V4L($5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#,N.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#,N,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,CD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M96EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!497)M("AI
M;B!Y96%R<RDL($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG."!Y96%R<R`T(&UO;G1H<R`R(&1A>7,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG."!Y96%R<R`T(&UO
M;G1H<R`R(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N
M=')A8W1U86P@5&5R;2`H:6X@>65A<G,I+"!)<W-U960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN
M=')I;G-I8R!686QU92P@0F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-2PY,#@L-CDV/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V.#4L.#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L
M=64L($5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!686QU92P@
M16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Y+#4Q-"PS-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#DP."PV.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V%R<F%N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F('-T;V-K(&]P=&EO;B!A
M8W1I=FET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.=6UB97(@;V8@56YI=',L($)E9VEN;FEN9R!B86QA;F-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#8W,RPR.3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPW
M-S`L-C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PS-C0L-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^27-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,#8L.3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(Y.2PX.#4I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@56YI
M=',L($5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY+#8X,"PS,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY+#8W,RPR.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,V-"PU-3<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!
M=F5R86=E($5X97)C:7-E(%!R:6-E+"!"96=I;FYI;F<@8F%L86YC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C`V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+CDW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C4Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@27-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<N.#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H
M=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L(&5X97)C:7-E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C`T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!
M=F5R86=E($5X97)C:7-E(%!R:6-E+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C(X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C`V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C4Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;2`H
M:6X@>65A<G,I+"!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S0@>65A<G,@."!M;VYT:',@,38@9&%Y<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<T('EE87)S(#$P
M(&UO;G1H<R`R,2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG
M($-O;G1R86-T=6%L(%1E<FT@*&EN('EE87)S*2P@27-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-B!Y96%R<R`W(&UO;G1H<R`Q-R!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!"96=I;FYI;F<@
M8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<L,SDV
M+#,P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L,3$T+#<V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L,C8Q+#,V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@
M5F%L=64L($5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$P-RPR-C@L-S@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-RPS.38L,S`W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#(V,2PS-C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X96(U
M.#DY-5\Q9&1D7S0Q,6%?.&4R85]C,S<V-S`Q8C4S,#0-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO.&5B-3@Y.35?,61D9%\T,3%A7SAE,F%?8S,W
M-C<P,6(U,S`T+U=O<FMS:&5E=',O4VAE970S-"YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-)
M2$L^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^17%U:71Y("A$971A:6QS(%1E
M>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$V-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,C0L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$T/&)R/E!L86-E;65N="!!9V5N="!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/D5M<&QO
M>65E(%-T;V-K($]P=&EO;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/D5M<&QO>65E(%-T;V-K
M($]P=&EO;B!;365M8F5R73QB<CY-:6YI;75M(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^16UP
M;&]Y964@4W1O8VL@3W!T:6]N(%M-96UB97)=/&)R/DUA>&EM=6T@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-#QB<CY%<75I='D@26YC96YT:79E(%!L86X@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY%
M;7!L;WEE97,@1&ER96-T;W)S($%N9"!#;VYS=6QT86YT<R!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T
M/&)R/DEN=F5S=&]R(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^0V]N<W5L=&%N="!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R
M,#$T/&)R/E!R:79A=&4@4&QA8V5M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P,30\8G(^5V%R<F%N
M="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$T/&)R/E=A<G)A;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CY787)R86YT
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA
M;BX@,S$L(#(P,30\8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^0V]M
M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIA;BX@,S$L(#(P,30\8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=
M/&)R/DQA:61L87<@86YD($-O(%M-96UB97)=/&)R/E!L86-E;65N="!!9V5N
M="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$T/&)R/E)E<W1R:6-T960@4W1O8VL@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB
M<CY297-T<FEC=&5D(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5Q=6ET>2!497AT=6%L(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V-E961S(&9R;VT@27-S=6%N8V4@;V8@5V%R<F%N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,L,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;&%C96UE;G0@86=E;G0@8V%S:"!F
M965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,SDU+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;&%C96UE;G0@
M06=E;G0@071T;W)N97D@1F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VL@<V]L9"P@4VAA<F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4U,2PX,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F(%-T;V-K+"!0<FEC92!097(@4VAA
M<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!G<F%N
M=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$S-RPY-3(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E
M(&]F('=A<G)A;G1S(&1E=&5R;6EN960@=71I;&EZ:6YG('1H92!";&%C:RU3
M8VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO9&5L/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T($EN<W1R=6UE
M;G0L(%1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE
M<F-I<V4@<')I8V4@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C4U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@5F%L=64@07-S=6UP=&EO;G,L(%)I<VL@1G)E92!)
M;G1E<F5S="!2871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2XS,B4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+C(W)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XV-"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!!
M<W-U;7!T:6]N<RP@17AP96-T960@5F]L871I;&ET>2!2871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S
M=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@W+C<V)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C@X+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($%S<W5M<'1I;VYS+"!%
M>'!E8W1E9"!$:79I9&5N9"!2871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELS73PO<W5P/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,UT\+W-U
M<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($%S<W5M<'1I;VYS+"!%>'!E
M8W1E9"!497)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@
M;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V(&UO;G1H
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y296=I<W1R871I;VX@4W1A=&5M96YT($1E
M<V-R:7!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=CY4:&ES(%)E9VES=')A=&EO;B!3=&%T96UE;G0@8V]N=&%I;F5D('1W;R!P
M<F]S<&5C='5S97,Z("AI*2!A(&)A<V4@<')O<W!E8W1U<R!W:&EC:"!C;W9E
M<G,@=&AE(&]F9F5R:6YG+"!I<W-U86YC92!A;F0@<V%L92!B>2!T:&4@0V]M
M<&%N>2!O9B!U<"!T;R`D,C`P+#`P,"PP,#`@;V8@:71S(&-O;6UO;B!S=&]C
M:RP@<')E9F5R<F5D('-T;V-K+"!W87)R86YT<R!A;F0O;W(@=6YI=',[(&%N
M9"`H:6DI(&$@<V%L97,@86=R965M96YT('!R;W-P96-T=7,@8V]V97)I;F<@
M=&AE(&]F9F5R:6YG+"!I<W-U86YC92!A;F0@<V%L92!B>2!U<R!O9B!U<"!T
M;R!A(&UA>&EM=6T@86=G<F5G871E(&]F9F5R:6YG('!R:6-E(&]F("0W-2PP
M,#`L,#`P(&]F(&ET<R!C;VUM;VX@<W1O8VL@=&AA="!M87D@8F4@:7-S=65D
M(&%N9"!S;VQD('5N9&5R(&$@<V%L97,@86=R965M96YT("AT:&4@)B,X,C(P
M.U-A;&5S($%G<F5E;65N="8C.#(R,3LI('=I=&@@34Q6("9A;7`[($-O+B!,
M3$,@*"8C.#(R,#M-3%8F(S@R,C$[*2!D871E9"!-87)C:"`R-"P@,C`Q-"XF
M(S$V,#L\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DUA>&EM=6T@3V9F97)I;F<@4')I8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!P=7)S=6%N="!T;R!S86QE
M<R!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV/E1H92!#;VUP86YY('=I;&P@<&%Y($U,5B!I;B!C87-H+"!U<&]N('1H
M92!S86QE(&]F(&-O;6UO;B!S=&]C:R!P=7)S=6%N="!T;R!T:&4@4V%L97,@
M06=R965M96YT+"!A;B!A;6]U;G0@97%U86P@=&\@,RXP)2!O9B!T:&4@9W)O
M<W,@<')O8V5E9',@9G)O;2!T:&4@<V%L92!O9B!C;VUM;VX@<W1O8VLN)B,Q
M-C`[5&\@9&%T92`U,#`@<VAA<F5S(&AA=F4@8F5E;B!S;VQD('5N9&5R('1H
M92!386QE<R!!9W)E96UE;G0@=VET:"!-3%8N/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!)<W-U960@5&\@
M4'5R8VAA<V4@0V]M;6]N(%-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X+#DW-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,W+#DU
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV."PY-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(')E<W1R:6-T960@<W1O8VL@
M9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3@P+#$P-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q,BPU,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5S8W)I<'1I;VX@<F5S=')I8W1E9"!S=&]C:SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B=/9B!T:&4@=&]T86P@<VAA<F5S(&]F(')E<W1R:6-T960@<W1O8VLL(#(R
M+#4P,"!S:&%R97,@=F5S="`Q('EE87(@9G)O;2!T:&4@9W)A;G0@9&%T92P@
M,30Y+#$V-R!S:&%R97,@:&%V92!A('9E<W1I;F<@<&5R:6]D(&]F(#0@>65A
M<G,@86YD(#$U,"PP,#`@<VAA<F5S('9E<W0@870@9&%T92!O9B!G<F%N="X@
M5&AE(')E;6%I;FEN9R!R97-T<FEC=&5D('-H87)E<R!G<F%N=&5D(&%R92!P
M97)F;W)M86YC92!B87-E9"!A;F0@=F5S="!O=F5R('1I;64N/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%D9&ET:6]N86P@;G5M8F5R(&]F(')E<W1R:6-T960@<W1O8VL@9W)A
M;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R-2PQ-C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96-O9VYI
M>F5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PS.3DL-S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,Y.2PW
M,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#,Y,2PS,3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E;G-E(')E;&%T960@
M=&\@<F5S=')I8W1E9"!S=&]C:R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C@Q+#0P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY-"PR,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4X+#DS-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0Q,"PU.#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C
M;VUP96YS871I;VX@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P('EE87)S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@=F5S=&5D('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S0@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@
M<W1O8VL@;W!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X<&5C=&5D(&1I<V-O=6YT(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C@X)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N,#<E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V%R<F%N=',@17AE<F-I<V5D($)Y(%=A<G)A;G0@2&]L
M9&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,CDY+#@X-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T
M;V-K+"!3:&%R97,L($ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(U+#4V,BPS-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C0L-38U+#0T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U
M+#4V,BPS-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C4S+#,S,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O
M;2!)<W-U86YC92!O9B!#;VUM;VX@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(S+#<P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F('-T;V-K(&]P=&EO;B!G<F%N=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR.3$L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.#`L,3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S$R+#4P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:R!O<'1I;VX@97AE<F-I<V4@<')I8V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#4N-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#@N,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('1H92!E
M>&5R8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`U+#(R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M."PR-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`U+#(R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&]P=&EO
M;B!E>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Q+#8U-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1D(&-O;'-P86X],T0R-3X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI
M9VX],T1T;W`^6S%=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0R-"!V
M86QI9VX],T1T;W`^5&AE(')I<VLM9G)E92!I;G1E<F5S="!R871E('=A<R!D
M971E<FUI;F5D(&)Y(&UA;F%G96UE;G0@=7-I;F<@=&AE(%1R96%S=7)Y($)I
M;&P@87,@;V8@=&AE(')E<W!E8W1I=F4@;65A<W5R96UE;G0@9&%T92X\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO
M=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S)=/"]T9#X-"B`@("`@
M("`@/'1D(&-O;'-P86X],T0R-"!V86QI9VX],T1T;W`^0F5C875S92!T:&4@
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M;F0@<F5G:6]N+CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;
M,UT\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#(T('9A;&EG;CTS1'1O
M<#Y-86YA9V5M96YT(&1E=&5R;6EN960@=&AE(&1I=FED96YD('EI96QD('1O
M(&)E(#`E(&)A<V5D('5P;VX@:71S(&5X<&5C=&%T:6]N('1H870@:70@=VEL
M;"!N;W0@<&%Y(&1I=FED96YD<R!F;W(@=&AE(&9O<F5S965A8FQE(&9U='5R
M92X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&5B-3@Y.35?,61D9%\T
M,3%A7SAE,F%?8S,W-C<P,6(U,S`T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+SAE8C4X.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-"]7
M;W)K<VAE971S+U-H965T,S4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$57-4%%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S("A$971A:6QS*2`H
M4W5B<V5Q=65N="!%=F5N="!;365M8F5R72P@55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA>2`Q,BP@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D%P<BX@,C@L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q-#QB<CY-87AI;75M(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L
M(#(P,30\8G(^36EN:6UU;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$T/&)R/E=A<G)A;G0@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W5B<V5Q=65N="!%=F5N=',@*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!R
M97-T<FEC=&5D('-T;V-K(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!C;VUM;VX@<W1O
M8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S=')I8W1E9"!C;VUM;VX@<W1O8VL@86YD(&]P=&EO;G,L($5X97)C
M:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$Q+CDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,2XW-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1E<FT@;V8@97AP:7)A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M<'1I;VYS(&%N9"!R97-T<FEC=&5D('-T;V-K('9E<W1I;F<@<&5R:6]D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S0@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VL@:7-S=65D+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<')O8V5E9',@:7-S=6%N8V4@
M;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-E8W5R:71Y(&1E<&]S:70\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U8FQE87-E(&%G
M<F5E;65N="!T97)M:6YA=&EO;B!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#Y397`@,S`L#0H)"3(P,38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&5B-3@Y.35?,61D9%\T,3%A
M7SAE,F%?8S,W-C<P,6(U,S`T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+SAE8C4X.3DU7S%D9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-"]7;W)K
M<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C
M:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN
M1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q.2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C,N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(T+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(W+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R."YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,CDN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#,P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S(N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#,S+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970S-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S4N
M:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7SAE8C4X.3DU7S%D
=9&1?-#$Q85\X93)A7V,S-S8W,#%B-3,P-"TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract', window );"><strong>Summary of fair values of derivative warrants on basis of valuation model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MarketValueOfCommonStockOnMeasurementDate', window );">Market value of common stock on measurement date (1)</a></td>
        <td class="nump">$ 12.45<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">$ 5.89<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Adjusted exercise price</a></td>
        <td class="nump">$ 9.95<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 2.48<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (2)</a></td>
        <td class="nump">1.32%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="nump">1.27%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Warrant lives in years</a></td>
        <td class="text">6 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">6 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="nump">71.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="nump">73.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (4)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Probability of stock offering in any period over 5 years (5)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
        <td class="nump">25.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RangeOfPercentageOfExistingSharesOffered', window );">Range of percentage of existing shares offered (6)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
        <td class="nump">35.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueAssumptionOfferingPrice', window );">Offering price range (7)</a></td>
        <td class="nump">$ 9<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
        <td class="nump">$ 9<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">The market value of common stock at the above measurement dates is based on the Company's trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for March 31, 2014.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[4]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[5]</td>
              <td style="vertical-align: top;" valign="top">Management determines the probability of future stock offering at each evaluation date.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[6]</td>
              <td style="vertical-align: top;" valign="top">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at March 31, 2014 and December 31, 2013, respectively.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[7]</td>
              <td style="vertical-align: top;" valign="top">Represents the estimated offering price range in future offerings as determined by management.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueAssumptionOfferingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value assumption offering price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueAssumptionOfferingPrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MarketValueOfCommonStockOnMeasurementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Market value of common stock on measurement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MarketValueOfCommonStockOnMeasurementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RangeOfPercentageOfExistingSharesOffered">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of percentage of existing shares offered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RangeOfPercentageOfExistingSharesOffered</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed upon price for the exchange of the underlying asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsProbabilityOfDefault">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of likelihood a loan will not be repaid and instead default, used as an input to measure fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bbb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueInputsProbabilityOfDefault</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3LAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">166 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract', window );"><strong>Schedule of derivative warrant instruments activity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeWarrantsUnits', window );">Beginning balance, Units</a></td>
        <td class="nump">1,968,623<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_TransferFromLiabilityClassificationToEquityClassification', window );">Transfer from liability classification to equity classification, Units</a></td>
        <td class="num">(46,025)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeWarrantsUnits', window );">Balance, Units</a></td>
        <td class="nump">1,922,598<span></span></td>
        <td class="nump">1,922,598<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Beginning balance, Fair Value</a></td>
        <td class="nump">$ 6,707,255<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification', window );">Transfer from liability classification to equity classification, Fair Value</a></td>
        <td class="num">(139,565)<span></span></td>
        <td class="num">(5,417,984)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ChangeInFairValueOfDerivativeWarrants', window );">Change in fair value</a></td>
        <td class="nump">12,561,071<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Balance, Fair Value</a></td>
        <td class="nump">$ 19,128,761<span></span></td>
        <td class="nump">$ 19,128,761<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ChangeInFairValueOfDerivativeWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of derivative warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ChangeInFairValueOfDerivativeWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DerivativeWarrantsUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative warrants units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DerivativeWarrantsUnits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_TransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_TransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeFairValueOfDerivativeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeTextualAbstract', window );"><strong>Derivatives (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RangeOfPercentageOfExistingSharesOffered', window );">Range of percentage of existing shares offered</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">35.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeTextualAbstract', window );"><strong>Derivatives (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
        <td class="nump">$ 139,565<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfSharesWarrantExercise', window );">Number of warrant exercised</a></td>
        <td class="nump">46,025<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at March 31, 2014 and December 31, 2013, respectively.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DerivativeTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DerivativeTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfSharesWarrantExercise">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares warrant exercise.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NumberOfSharesWarrantExercise</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RangeOfPercentageOfExistingSharesOffered">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of percentage of existing shares offered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RangeOfPercentageOfExistingSharesOffered</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details) (Abbott Biotherapeutics Corp [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Phase I Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Phase II Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Phase III Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Biological License Application filing with U.S. FDA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">First Commercial Sale [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">After First Net Sales [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 1,500,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongTermPurchaseCommitmentMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Long term purchase commitment milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_LongTermPurchaseCommitmentMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePaymentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MilestonePaymentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">Note 3 &#8211; Property and Equipment</font></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"></font>&#160;</div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Property and equipment consisted of the following at March 31, 2014 and December 31, 2013:</font></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font>&#160;</div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;Lives</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2014</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2013</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="67%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Office equipment</font></div></td><td width="9%" valign="bottom"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;3 years</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">17,179</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td
 align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">15,480</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Less: accumulated depreciation</font></div></td><td width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(2,965</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">)</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(1,560</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">)</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Property and equipment, net</font></div></td><td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">14,214</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">13,920</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font>&#160;</div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Depreciation expense for the three months ended March 31, 2014 and 2013 were $1,405 and $0, respectively. The Company wrote off its remaining undepreciated property and equipment during the three months ended March 31, 2013 and recorded a loss of $4,122 on the disposition.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6XDM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">166 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="5">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3">3 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jan. 27, 2014

</div>
          <div>Manufacturing Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Manufacturing Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2012

</div>
          <div>Rental Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Rental Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Phase I Clinical Trial of a licensed product [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 27, 2012

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Oak Ridge National Laboratory [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Oak Ridge National Laboratory [Member]

</div>
          <div>2013 [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Oak Ridge National Laboratory [Member]

</div>
          <div>2014 [Member]</div>
        </th>
        <th class="th">
          <div>May 16, 2013

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 22, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 06, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 19, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Maximum [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Minimum [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 28, 2012

</div>
          <div>University of Texas M.D. Anderson Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]

</div>
          <div>patients</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013

</div>
          <div>University of Texas M.D. Anderson Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 26, 2012

</div>
          <div>Johns Hopkins University [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Johns Hopkins University [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 21, 2012

</div>
          <div>University of Pennsylvania [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>University of Pennsylvania [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Net sales in milestones payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PaymentOfLicenseFee', window );">License fee payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,750,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty', window );">Description of royalty payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Royalty payments of 2% of net sales will be due to FHCRC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RoyaltyOfNetSalesPercentage', window );">Royalty of Net Sales Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FirstCommercialSalePeriod', window );">First commercial sale period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">12 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PurchaseOfRadioactiveMaterial', window );">Purchase of radioactive material used for research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">233,100<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProjectEstimatedCost', window );">Project estimated cost for clinical trials of drug Ac-225-HuM195</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,813,960<span></span></td>
        <td class="nump">2,077,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DownPaymentOfProjectEstimatedCostPercentage', window );">Down payment of project estimated cost percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DownPaymentForProject', window );">Down payment for project</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,900,000<span></span></td>
        <td class="nump">239,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">239,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration', window );">Clinical trial cost for approval of food and drug administration</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,500,000<span></span></td>
        <td class="nump">13,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear', window );">Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo', window );">Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfPatients', window );">Number of Patients</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidToEachPatient', window );">Amount paid to each patient after Completing clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,185<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,366<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="nump">34,383<span></span></td>
        <td class="nump">38,501<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">31,771<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StartUpFeeForClinicalTrial', window );">Start-up fee for clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">79,623<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,749<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,946<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,847<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StartUpDueCostPaidDate', window );">Start-up due cost paid date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NonRefundableInstitutionalFee', window );">Non - refundable institutional fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">562,790<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PharmacyFee', window );">Annual pharmacy fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,025<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmendmentProcessingFee', window );">Amendment processing fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NoticePeriodForTerminationOfAgreement', window );">Notice period for termination of agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">This agreement terminates on July 6, 2014. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Rent agreement termination date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Mar. 31,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AgreementRenewalDescription', window );">Rental agreement renewal description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The agreement automatically renews on a month-to-month basis and requires a two month notice of termination.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Accrued fees paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research recorded fees</a></td>
        <td class="nump">$ 2,460,968<span></span></td>
        <td class="nump">$ 1,085,707<span></span></td>
        <td class="nump">$ 31,548,346<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 37,500<span></span></td>
        <td class="nump">$ 37,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementRenewalDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description regarding renewal of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AgreementRenewalDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmendmentProcessingFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amendment processing fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmendmentProcessingFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidToEachPatient">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount to be paid for each Patient that has completed the clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidToEachPatient</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Clinical trial cost for approval of food and drug administration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommitmentsAndContingenciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommitmentsAndContingenciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of royalty payment to related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfRoyaltyPaymentToRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DownPaymentForProject">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Down payment for project.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DownPaymentForProject</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DownPaymentOfProjectEstimatedCostPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of total estimated project cost required for down payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DownPaymentOfProjectEstimatedCostPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FirstCommercialSalePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>First commercial sale period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FirstCommercialSalePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fund to related party under agreement after year two.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FundToRelatedPartyUnderAgreementAfterYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fund to related party under agreement for first two Year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongTermPurchaseCommitmentMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Long term purchase commitment milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_LongTermPurchaseCommitmentMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NonRefundableInstitutionalFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non refundable institutional fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NonRefundableInstitutionalFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NoticePeriodForTerminationOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notice Period for termination of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NoticePeriodForTerminationOfAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfPatients">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of patients.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NumberOfPatients</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PaymentOfLicenseFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License fee payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PaymentOfLicenseFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PharmacyFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Pharmacy fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PharmacyFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ProjectEstimatedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Project estimated cost.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ProjectEstimatedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PurchaseOfRadioactiveMaterial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase of radioactive material.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PurchaseOfRadioactiveMaterial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RoyaltyOfNetSalesPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty of net sales percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RoyaltyOfNetSalesPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StartUpDueCostPaidDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up due cost paid date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_StartUpDueCostPaidDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StartUpFeeForClinicalTrial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up fee for clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_StartUpFeeForClinicalTrial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseExpirationDate1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LegalFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4SAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 5,877,781<span></span></td>
        <td class="nump">$ 5,533,366<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">667,911<span></span></td>
        <td class="nump">218,389<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">6,545,692<span></span></td>
        <td class="nump">5,751,755<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
        <td class="nump">14,214<span></span></td>
        <td class="nump">13,920<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">6,559,906<span></span></td>
        <td class="nump">5,765,675<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">615,272<span></span></td>
        <td class="nump">378,955<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable and accrued expenses - related party</a></td>
        <td class="nump">189,537<span></span></td>
        <td class="nump">81,185<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
        <td class="nump">94,481<span></span></td>
        <td class="nump">157,825<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">19,128,761<span></span></td>
        <td class="nump">6,707,255<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">20,028,051<span></span></td>
        <td class="nump">7,325,220<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 50,000,000 authorized 0 issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 200,000,000 shares authorized; 25,562,346 and 24,565,447 shares issued and outstanding, respectively</a></td>
        <td class="nump">25,562<span></span></td>
        <td class="nump">24,565<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">69,723,045<span></span></td>
        <td class="nump">64,933,145<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(83,216,752)<span></span></td>
        <td class="num">(66,517,255)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Deficit</a></td>
        <td class="num">(13,468,145)<span></span></td>
        <td class="num">(1,559,545)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Deficit</a></td>
        <td class="nump">$ 6,559,906<span></span></td>
        <td class="nump">$ 5,765,675<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 12<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 18<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 210<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.32)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 25<br><br> -Article 7<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 32<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 21<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>24
<FILENAME>0001213900-14-003153-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-14-003153-xbrl.zip
M4$L#!!0````(`+R&K$2^8E-]5K0``&O?"0`1`!P`871N;2TR,#$T,#,S,2YX
M;6Q55`D``^0T<5/D-'%3=7@+``$$)0X```0Y`0``[#UK<ZLXEM^G:OZ#)Y_;
M"4\#F<Z=RK.O;R=Q)LGMZ:[=+1<!V59=#&X>2=Q;M;]])1X&;,!@A(UM=75U
M.PCIO(^.CH[$S__ZG!J==V`[T#(O3MA3YJ0#3,W2H3F^./G^>M>53_[UY>]_
M^_D?W6[G%V`"6W6!WO$<U-ZY_:O[^]7S?=2](YTRI_PIW_DO1CQC^3..884.
MPYZ+S#FG="X?_J?3[49#7:D.&@;U\0?@3MFXS7]R8VG>%)ANYP&A,H+HW0_H
M3C#$6QVZEMWY+82),#[MG<IXJ%</.+HZ_ZGSH,X[+/]39X$`=\XR"($0QN>;
M;<!S_-\.(MYTSE77G%Z<3%QW=GYVIFHN-*$WG4U4>ZIJP'.AIAK.J69-?8H8
MGF=/PHX&-'\L.GY\?)SB04\M>XS>9/@SW/R&"(U>QZTZ7'1(OMP["QH7KZX,
M_<'[[[**HISYK8M7'9CU(AJ4/?O]X?Y%FX"IVH6FXZJFEL(%%N"^_#YT+(%C
MI:(>P1M1!\WR3->>IZEU@'8ZMM[/PD;,4+[+L-V8I9IGVT@!\_J%K;@CE^ZH
M`YC=!S5DP-'!S`8:5N9<DI0SU=9LRP!G(Z047?`Y,U131<HWOT-_1P.!3VV2
M#1BW9$"&YCMPW.PN05M&)U.%FI/=QV_"7=BE+L`M(,VG"[VR>-LR36^:W4%W
M[3-W/D/O6V87O05LJ"WZK>^4[F"#42Y:O3/4&KWH0"V;8-200:[CSNR<]U%+
M1@?/Z8Y5=;;H,U*=-Q^1L"%#"F%+5W7=_&ZHT89OG@N<1#?,"2>SC]^2!<NU
M"\2'6E->Q<WT*F+@5=S8JQ38[^_WV*E@!XF]R[GC^XUG,.KXWN8\M(5BGW0V
MLZT9L%V(2$IX/W\`3.C%B0.G,V/Q;.)K`_:_W<BWGGXZ^LE9-$]<6Z8+/MW.
M"T!N&?GXE`O7PD:(;#A\<7CI#`>CX1!Q\YMGHD$9YB3N@"84Z,[COZ&.GZ#I
MQ>[XY*:IB_3GNO_KR1<T$,O+,L\Q/Y\M=\8#GF5#0,R`EIZ`Z+M5%SW`J'69
M7I?EX]YQ:_0D[G^6HKF8"=>>XUK3(2LLF##DV>X-T-K'$$2P[=X@/YQDB1#W
M3[8OD-:3'=!$P+-)@%%K/1[>_7$[3'"-;3/7?,_&L.6YQFZ):[TV<ZU7E6N]
M+7%-:C/7I*I<DYKB6NCEF)AO21X.GX&!P[LGA-W\U59-1_6G$.=JGFRY_(3.
M\'+FPO<7R_#\%Q[`]`W8VY%!R$(PQHN=Z(&.0*)@$VK0#7#IZ!"U!TNT,,PX
M+T_>R1<\P9YG$?GS62:\A"02J&VJ+WZDW@)]6;(RN<U6)E>U,KDIKH4!U8)O
M;+OBAV1`Q:X$`Z0"JE4F#"\_5%M_13&M[T%N451KS0%X<2WMQV"&36P_W$B*
MC),OT>-<>IKP&-N183A=<$SW09UC&;)#5@D#9/2[PG3Q8EBJ^2MP782'.>XC
M_*"+UGN#T37.F-C/P`%HM30).#.\'-L`8([X?>^AAD0`;L`[,*R9_]C4KZTI
M6B-K4#7@7RJ&NNBS'TI4>2ZJQ,$"E5N+83#S)2408K"1')J?+G&20D0*6=KQ
MXPXH+E6VX/C;M01*.8V5]4QCCI^ECK\AQ[\[&?Y'M9'3VA-?FR.W%`U[+RM.
M0I.TC67%59F8$9F6C;QW>GH)YI1K1""P,^?D:P.:>)/G%?<]]*FW+(\:F76+
M.-VXTJ)E*-_EI,:4EA6C:+*2TM[90/_JN=H$H6.9Z0"H0&G#``9%+2\S-+"%
M1HEZ+3%V^*R:X\#3/:B?<.I-#U2URW*RR8"RA#SJ@%_P)A)I/`.D9+L-8T)A
MIWC4QH1\&36F`S6FI&RI,35D3-1H6F<T+5?H>,]GH=!4N:ER;SE)YZMWA=V9
M57L@G*3S$]G&MFS@J-;+.]7Z7:^7I51FF;03EV*E1>9QZ8TK*S#=N&_4R4GH
MWTI.3D9^CKR3B_1%3NB+%.O+B_?F0!VJ]OQ%-<!@Y*>N??5X,E0M,*GQWCBH
M7&I";<BB:6O:(%?5!HF\-D0I8GDCC_'=A/YQ!7<^&+V"3]5YN$$Q!7H2^78Z
M[P5Z5HE1!SGYR5TNH>_D5S`+]:6J3%6Y:><M5UVOI+6??,WF0N/YQ.^TDCZC
M'WNCG;FRSZ2BM4)OL(20ZW5?P*RRF_MF34SGJS7[@3QP;,G4JQ7QY2"<V/)\
MK'2YQ.*"_'R\4$ZJJ%11ZSE>I:KC3>LV^=EVH+FA;G/Q;YIH:4FBA64JZ@OJ
MP''-3=1L]]%ZK[4>>0*FZ<R-=]6$*O6`Q9PY"!^X-%FS;)=KKH:?22@H55:J
MK/4=<*7#5JOZ33ZW&98J<\-[,%:-6Y^@8"8.[R=IM_;I`)XO81Y-LBG\M^&*
MN";S>)P8BXJ*C:Q1(L&)E8R2:R1GE3XW2N/F]L3-U<[(!AJRE3.R7'N/2JTP
MH;%C-AP]*M7DI+83&=*C4FV6%3TJ18]*M5MI^8<@E@I/]_&MFB>7X@N^:GS!
MXP-F3<07RURC=<Y-FCVM<SXL"RCKQ@].D0G,7T>@29>($AWBQ>L[>`&:9T-\
M?>7MIV9X.M#O;&MZ;4UGGNM?"#(8W:JVB;CH/`'[9:+:X&J>/8"O>L&JP$'6
M'`:=>Y(":)`GH6[F<>:X=?$%<=1W\=>&ZCC)4F9\-8UE^G_OAPKEDA(OQ%9H
MHL+/%CZ*`%P;:LC%'Y8"9-)%E2!;"?8J]5)"^(VG85HK]#AST\IE<"H3L,($
M\EOYX75\_)#MQ;_I'DLK]EAX?!U=1:,1NVP#M6RQT82'P"KI"#TK0<]*E'1W
M4J/NCH]*B_DA(\2_Z>VC6]1Q>OMH@;M7T(1?R=VC#D)C[IX38QNA)35U79N2
M*JAI[`0%3\5&WBBKQ6!I23?UQ04\B2GQ;WH0?RO:4.U["F&'YBZ(CJL>^:5H
MX\D&4V0H=]#$\^J>1!6Y<W8A-5OPW@W5L2Y5-[8K%5$_A;.5;XE@S:>E;NW)
MVVU+Z'351E=M[5BUM=5":/7H`0OW%;HX,.Z;.GR'NJ<:J;G/N8$VT%S+=GPK
M,1W/</>G`B*3MM`/E*/PJ'1CI1BY77'D:BB]E8IL&A8VNAS:B0SI'-9F6='+
M;P^G%'K'&X&M5%IZ;<$17UNP#PI*B^UW4&R_N]"(YOL/0(IW*K1_4PT/7,T7
M/[\BAN)9?GZ/LUU!P!2U]<V9YSI^`]MNX4;67([".$`N()5*/F`'=SR2YZCD
MD^S@CT?R_+Y+/KZEZ)OJ?R-)P-]67?Q.S]\/JNF-4)SCX<AEWZ?O(F*VD)H5
M<&JVRO5%08?FOI>`"Z<CL=-C9LV:LR_+9AUY"5GN5::R#0>&6BC#%=T=XFSN
M8'2)63%.E`BH4#?4#W\?*GSQP*KQR-IY:;B9[([J`5:83@)B6^H.MV,-B0\Z
M1M9`9ZIMGH45JNXAKZ@"^>KB3%6@N2:J!#3:H2I`@R4:++4N6-I;8T+\`W]Z
MB+S;=_2?197+TO/(2B*]NOW30^S`=P!9)OK3V4,/G$UX;""9'""BLD5,I/Z_
MAO]_LN$[:EO8_)YHXGIGG4W8,2H%QT1WI@A#3EC\;E6QZ2H/>81D)1ZB#@V<
MJ5ZZ;*CM7*NL>5NYHDF@5].TXVJ:%FL(K?H^0J'3PX!;]#GT,.`>6@@]2''`
MPJ57TC?H[NB5]'M@`0>60SZ<S.JVIK>4MWI&/_;FU$VN[6=2<=QBIH=AVGT8
M9G\TB7YYXLB^/-%B7:2%5E3X],L3QZP$M+[N*,5.*^J.4.CTW-<1"OW)MM!(
M[OS)4/W-"EQ_Y&]<7,T72?D'%><8@3U/MK=;$^(BF;7DQ;Z@@,[C5I(JQ0UO
M;Y;K7D'+G0!;G0&TY-*<:\N>A=G[>\L<OP)[^N39VD1U``ZZH1M(Y!H--;;L
M^6#41VX[>D,/0@_\$RW=+%-/W;`R&(69:!V)6O>T/='+ZO44Q7RMD^./<-I0
M-%$T54U`U*#:8%"O$VA3>VJO/966#S6G'9L3&M&PQEA,T<[H#`M"W9_"KL,S
MH?4RH6:S8[.Y@[;CQ@52>%>96LMNK"57%-1(=FPDER,7V+YX'H&+Y;(GVW:'
M9R-YDJ`FTH;53.#!Z&JFA89333[4G`C7$FUL5X_@X\;VQH>_F"%0G+0E4\H3
M"36:MAC-,]``G+F#T3,8>P@X>@U)R[;>50/7*GU_N=-5:D8[-J/R0J*&12BX
M6RXF\6?\]%FI)S2BZ4;IFOW8=6YCU%90]%*1ZU3[6[KZI^:T;XN@#;('U-#;
M9^@#]<<SU,?@T0^^5>->?;-L/X`X4,-:1S#5'$*:,WSR4?+???VP7B>6YZBF
MC@P7;P2[`!SJZKN&AI7SD#%C0XA%[*7ZW+@^WUD>U>?F]#G-WN/6YQO@7Y0&
MW\'5',G#L_?PIHEL&F@5>U9!LZ&:C^HTO&7)OTVQ;VJ8OG=\5]Z>>)PD%=$'
MIO-H.6YYE[Q6:_B,KY\-\K_0A%-ONA^*0/"ZK?+37<2J1&E\DF=4X2HJG/I)
M%:ZJPB5Y=MP*]PI=?-=*W]3A.]0]-?@(6]]\!PZ**/=#JS)IB*6=)H:*>U7<
MZ'7',]R]B5AS!!Y\(GF)EJ.2=_REIU;>N+O\@9\T$\A_[HI>CTI>]ULBP[U:
M8>_J+L>=R:KYJQE3E7Z'OOFXT\L8BSA]4$I+;U,\*'%6\$'?K(GI?+5F/Q`Z
MWTWX#FP'T43]3A%?J*_9DG*6K7H\..TC4.ZY?XI!;\4[!EG22^[V5:;TSKI#
MD.*="NW?5,,#5_/%SZ^(H7A!-;_'58W!VC1JZYLSSW7\!K;=PHTLL1R%L>46
MD$HE'["#.Q[)<U3R27;PQR-Y?M\E'WZV$0'XYN'O=S),:[=#TMM(#--E>ETV
M\17&G6TC1=]#5;IWX"W\]*7<O9PE$F6E/^';=J,A_EE>@KN*7)=1*JF#T.7D
MYM1!C%6`9Z@Z;%T=T+]B177@F:VK0TYITF&I28VB(JJ*[?1,^UK$N;OORK>C
ME+,EJABN.%#,]*#.VQ=K+@??8BJT(+SL8KD%$P[+[;?'):_*D^4:6TPQ"7E2
MV>Y@ND76FI!N"1^75H=J/NX?W6[GNPG=S@OP=^@ZG6XW>O[WO_7_C_WON]^>
MOH)/<"/V)/F/9_`G_-*?_`#OMS^@_?G1$S5!$#11%+77_YU\$?_9[_>%BPNV
M?R==L'+_XI:]$.YNV6^"V/OV3TFX$+X)(8``$P^#QDKHX,]K(?Z'SZ=`=3P;
M?`EYX#=&V$=MT=]XC(P1O[_<K`P''4O@6.D<M54?;3C#@2U&93&N7Y(*OB1>
M?O2FP#^?MR'HE?[XX0TPK2DTLX8MRZ#4$&=I[(LIGWD)@M-@<5-%/N(NJV+V
M=R3\IJK#J2Y$%I8W8MBZH:S#DKT62=NG*D2+D+2QH=\:_MY/R@?\K`-X?NL[
MKV<PAHZ+8>*#9)W0>SR#47[M^<F72S24";UIYPGIYE35_$LT5,/YJ=,WM=.?
MS_*&QSC%;7CKWU:-OJF#SU_!O"3LY+R1.U8$Z!*1KF/R[PQU7!+`"!$"@K%3
MW:,QKSW;QH^@@TC^`ZCV;>"42P[?10Z]R[,!@+RQ(E@WEN9-PSFLY/@LT_UW
M,'BR\_*`P<G@:IC'B<KT^*FQE@'%I-VA)TX%4&D@2^-D@PDPJ0+HWVP6F,0X
M:96]@P:PHRM<2H)XF:H&ZM5Y!C/+1G8S[N#/4*KF/*F_J8&7S"0NK?`G*&?@
MN3@HU/%062AD+&`ZV"/X+X5S<4<'&D2(.1<G_<<[Q'!1['&RT$O95`%@C.*B
M]D-U)D6((&[<``TCPB<0P5-X`@OFY(LH\CS?0R@D!ZX(:,'V0D"R)$DRFP_H
MR08S%>JWG[/PZ^4#?%G0I>,`UPE-E@3!'"OSLA*C40(L62Q+<:O7DQ26W1A+
MXEP3)9&51#%&B`CH<JP04:RK<"5`YWY1ZA$080++*W@"+`..$%JE&,2BP$BH
MCE;`1C+*T4-KF17EJ`RLI#J(BL+T"H%IFN6A*/5)G:MO!D@42$)`TBADEI63
M5)<`2QC-<OHA*R(O;8[GH^6"Z&6"W&-%2>82[,L`4P^+4LQ1!"$Y*:U!(K[L
MXQZJ;]"`A#6J)S$2EW2S10`)(59.AQ26DZ4>6QVS9A@E\9S()9TQ821*,85C
M&$YF1+8L%O&5A/AKYA@H"NJ`J:&W-^3)IP//36A<G+BV!T[.R`#+H[T`&`I/
M1@#1&Q2N^E4QY"FJ#F0#2A+Q=QTRTGJ"`IB$32^#J`&^G)KB948Y\)>Z#H-K
ML9Y0M-DWK]49=%6#B&L3%)YGA>1\F0VL/C[EX@A%XGBF(CZ)*SM?7'4,;O$Y
MBID-'7`#1CA_C>96;^KY$^J-_T7;Y1Y$6-E#P?C2-%$7KZU264I`,L^Q**KD
MFJ+2MX")9>C`=H(+G$C(ILNB^%1,JM4JG%I8E.)=E^6%GLR61R,Q<:'9HAG6
MK"P3U@$EB.!F2XLJ"*9G)Q1-#VS_R(?N.]DG8/OIG(WXF-@G22#,GWQA3ADF
MG20H@0)QI+-YNRVD@RS9I>=.+!O^!?3J',[)SHE,\$\>JLN`B:&8P<\MH=AW
M'(\@!]?@%4`C@E-YEA'!J60RF"2S<M+`];`CQK:\)'4<:F[B6S@YXA\WO`=C
MU0A2Y,'5^^%N6%@=4<+U<+[K83,#X3)NIR8Q%;W[[K&MXM8)8MN8/^>8%6]9
M`)8,=J4,C"&*&V$?[J]=!4$J0&S59VZ&5'EOY*]H>:&W1:0J'2U?)VV\YU8D
MZA+(-S$%E9#U>D??W!Q40NHYZ/D?]'A&:T'3`WF;+DM[R%424QL,7R4E56;X
M->>VR@.++D9"ZYW$XCG<=]R(<>D\,B.+$I/0L$)X9!';PKU:T>=;T&)QA@:V
MT"@+O)>.MQ=QB9?$Y%2P/1ZM220*/4;IR3M!C`JOKM&GD61%04[YTM)X_@),
M8*L&>N]2GZ(8'%>:X6T@8CX"YXGY1)IH#4#"N*W9!^M)/4;DMX9<'1$S+,/P
MDK(1KC=@9J/!_&]DX/>GN(KJ+_]/TK-G35#K:B.85)H\%U0=C.H(B4,1%R=5
M1O$7%9KW%HI#S1OHS"S'W[@8C():"+:^#78%EDMDWHO!U42L!ONZHBCPC+P)
MHH,9+A1&@6*H_:6*%]?L\S$<I_02I3@K,&HC4,P.@>5E@>L11:"&=)!J]V04
M,U3%IV]JUA1@,1)0Y'RAQ&`(8+%&3_,E4P^+.K93()YLI/HX=`(.N=6`F-P-
M6AJ])N`J:YXRP]=@-*OT)(XM1RGV7P[F.UK+FK>?6!8>="8X%!N,;L`;\;4K
M$8!5F+T9P!KLYWKIQ-I:!++KJA(SR^+9IKF$I:I27A#9U#;W&IC$$5RWF<R)
M/9:1,HN_&D.QCF=C>XR`$)8V1/C1,JVT)R27_^!Y7DD68^;"(H909>$V@%(M
M84J2('/)`O!R"`*7:!S1DQ4F&:BGQJ\%>*TR]Q1%4,B`KB.(U8*<7$1N5=M$
MPG&BO9XKU8$:SBQ`PW-S<N[%XLC==^HRITQB/;X&,F$DRVZ.(2239VP:1K**
MD),H%\S:_P%P/$'P+M^1W8W!HX?38(.1WS&1=*\IY[S$/\LKR`H2$=1FZ&R'
MH%([&1R'7)K24H)*ZT]$7H'B1%]7N0(F&$&_%CG28Z#C,WG(;V^>5EHJY>>2
M<5YIR(VANV99((F,DEP2[@#A&M,!7CFBF;DF^LET%_IM@"TG'.O`W#3SF`>3
M"(Y-Y2++()U\'BRE;J#CGS4*[T8F+4DB`*LL7C<#6$,FRE)5R%H$\K$-+J;&
MWP"PG)RC>,1$41W6YE(H`:M.]@"YZ-3ATP+8&$?_0@F\QAR8UQ-\PU??7%P4
MBP46+3D)+$D6B8/2,(DC6'IMN444R20.*B$<)_8T&ZCX.$+P_[X9GMN^"4LF
M,\]O$\BCIIW$9FALAY`U&QB"(B;WG5I%29VI56(8N=<L74O'>O$\K6G(=^J)
M4PPD-@9YB>78(E+*(+(=4M:X=K['LU)+*:D3,XA2ZH3%%NA*GR$G'5LT`'Y-
M[,[(O%CHA@H1((U[G;VGI;/_-2AY!"Z^LN7)MO"U5_K5_#M:U_7-Q9XAKLA_
M)^5E.)[E>%Y.I1I+0F\.YS7!`R<HC"+L&N=:U10\*_<8CJM+`M(E_^#YJW6I
M_>E!&ZF9BV(HB'W-YB%/T=%P$@`K'7C?"&"M:J[EDU[K,"A$-_>2&`++$C:Y
MF5D><G/XKBOI2R9B=X)OG30<SRMBD5J4PC_'S/LF6N`0]^UI!2D/NCF$UZX*
MDQJR$X3K>'5^64<VHP"]K@&@.W>V-<6))S3*8(1/JN#ZZD9R2F0@5KO'9".(
M=6KD!%&6$S'#>@SR\(U>&HS2)S21S0</`&KTGU2@(3@\Q#!K=S*63B%O@E9#
MA-W]<9LX!\6PQ6M";H](Z15?D23RO"2P^T&*M.;"DY5C[NTE12XF9?7$?HM(
M(>2LR6*Q)HLC2ZR0+/5J%4-KS`RBK*"Y@>>:HLQO',S\0U2WG\#6H+-194YI
MK=@8X!H^<5R..64")(_=\/)#M?7%YQNB??#$@"5.C6V=BEI))4[B"2`;WKL>
MO==H_+@)K'7I8XE1LKFP#*P64G62!H+"LHQ0'<EG,`O7D8-1\DK,^JN_'C[[
MGCQUF`V(%#)K@F^>%X0&D:FS[\Q4QRUG7;?8I":ZBE\29'G8S6&\+E!`!MM;
MGWEH%N4Z2T5.5B3I_]M[U^:V<60!]'NJ\A]P<S)[["I9T<-Z)3M3Y3C);G;R
M\(V=V;N?IB`2DKBA2`T?=G1^_>UN@"^)>DLV*6%K9T:62*#1Z#<:W:V=D8ZO
M8$E0^`\&@^ZYC60ER^_/G@_L)93?Z7:Z*:@WF?^0<*^2G9>7Z4L[3P;U3B9D
M3LW]_2WB"JC/\Z9`:"MKE=:;,?0;*/"=ITW*GZR(8/3:F2OG:TU\($B7!RA:
M';S3W2T&J(WEH+;KW7:[]\2@KB6DFHUFK]MM%P.K6S3L>"JL[D7\+`$UNBF)
M!7GWD";5SF1%)$/O,N4V%TT7CKV+4]:X;*ZS.KRN<\=_H@&Y)4Z79VIL.OQF
M^%L]_-XJ(6'T_:/CPP]4]<MU[H47X/&J3'`W+&[++[$1X@?!@W!!2;V=4M4/
M`\.3X&&G_+E&-WV"M0U,<68IO!AZ&#M3.7=W(\\-AR.50"V-Y[WMY'YG7&??
M=IQQIUQIV=%C?0AB>%.YM2HNH8K@_=L*1ON\][Z_V=;>B^UFVXE;.G7DEO5F
M7P_.O9X9['&Z_>S"80+XO6ZK@3EL:\Z_&M0[]\;FAJQ8-MPV66=C!&TSZ^[;
MLM:LNPBK>J?6Z#96[<XL&#'@B7[)!N229-K(!KMS4W4J][IE!X1A[0W<)PR[
M)#UWZYU&3^WFEC#E$265&AP(#R/F47;TE$K`6F!GT#6@.U=V`\A^NX?$M&:/
M^L;L#:3#KV\7:7E9[_2ZEWM>;F0P?O6&W%'7MJZQN*-MF5&--3!)?.#L[)4N
M;L<%?WV\8F>[V!,8[[1:0X>F<`*5.@V.ZXV+W<N%?P=(>&NOS6*__<T.WIC6
M/>,VC/KKB_\"^JS!]`7S@ZDM?GTQ@!=?LWIS\O.5XWJ`*O:_@346/G/$`P-T
M<.=_W\!,MNN]9O\C$PO>,)SJ(B"DP3NOF>,Z0GUK.=CM_36K38(WS!8!\,"%
M/^$8*L;G<(8W;,R]H>5<>'B=7#VJOK+%(/KFP?7,Y-7:Y.<;9EK^Q.;3UZR/
M"(!'1E8@Z!F1#(XKNO"M_Q,7W,351N#)[P-/!,8H>?KB0?1_6+`:!!Y^=7^(
MBP?+#$9RRA=_&P9O$(7X=AIG%P,^MFP`)0==,02`6%H*??$@Y'+[KFVFEF(Y
MM@7@T40H2%B=_8V/)V_^I]NHU]^P=\(W/(M..YD[8&]#'Y[V?<8=D]V&8T#;
M%+]/D0Q+:(9%1(,K>(501,MY!22!GY\_B^CC*>FA0%M-J*^W:WO`$LU#;/>:
M*;;;"G67K2/BI025"P12SM+76N+,>O;#N+E<FCOJ.MPMXQ9I+DYQ>I9%8S)<
MWI*]`A,8KC=Q/;Q1PT!&@%($$=*L,-2,\#-("M:W0*X8(P=(;XA=C*A+-?YW
M;`7X6N""GJ1ZO"@S^I[@/P+I2C.\&<@G>-((Y,EL:R#@*W@@$%@R!M>)YS@^
MPP4-F17`=/9DQ-D$+_<8MF#6>!PZKAQFRLZN;C[>G3/`38#D3E*,?F2>O!1$
MW_@6[!#W6`PTS%]E\&H%0!T*>OX!7!J:[V'DVC;(P`<'WO;#OF^9%@C%"OLL
MS`AY$EGL[//5Q_,*.X/W!:C@04#SRLPF1`+PIBWP/%/`@#S9G09LP\W'^*_Z
MFW,V@I]AZ,#BLL*);?.^*TO=,C&`M2%D""*L8PA8<(#(@Y!R5G`F,`O!6+1\
M0C";>"X0!?P?-+HA)@%^7(I&1!)"X(<3V'JY\P(IQ(>]?]5@!A`=4@D+/+`R
M));C!S[._1P`KL8N?;ZU7>Y<_$ZRAEJ:4V5K)DM:`P)O?[^^/@<;RX2_N,/H
M;QAWZF-`S&$JOWO(99,[]@68ZYT7#MG59&(KFZD*3S$\V:G@E@*"0L<8X<ZS
M<6@'UH4AYXK)FOE1J6P%K^4P;H3PPW@*-&N9(!K#'V)L<2"OSY^`NF`:M*F(
M9&(.Z[SQF=O_K]S?"HL(W%,UJ0E)9E*5FE@'=@KVQ@P-@?1IR20,B9$!LCMB
M2#Y`A&C!,+#'-@@0!@:_"Q:=0^@/K+YK(A,!XG_`.H@R9G98$#-Z`*2G6()/
M8.R)AR0&CTUA9\P()#R+9^!_3-D$6!M$48!D1KP<,6R5W8V$HE%[9LM]I+!9
MY*!<`+L!YAAQH.*^$(X$-,(G?H\K7H!\1*`5(-KZ@"O`)`(#M#4[#XJ`1`(\
M6+8M)P1-(1>-A")-<!(ZIC6@7$-8Y'0B"'2U!P_(R,`$5D`[DX]R>!8`@I%@
M:=45=I#6]X]N4#VR6W)<N#V(>;/<XD"6'`L/%.0/!W0NJLEK;@2AS_X`!(-]
M$SUWAIHMI4&OI=F1TJ*5C()5LR[Z74Z2UL$5]D!*.&7_2+V$$]O\@20%?B8O
M&__X(NZYR=%*^FH$;A\>;5=8O=?K2%FI(*1A.?-'`B23H'9@),@22I;STMA`
M'C]$0'(*])<`(:Q,$Y`Z:?D=%Y.,S*]5HN@)>*/9UKRQRO3/2K-";9\6;2NW
M[ZO#W@F#,N59HUM15FB0XGVR/4&26`X86IP%21>8.8$F&]R]_VE0[9ZL9)J$
M'MZ="-!<DW9A>A(NK\V:`&KMETA*6;)5&-GJJ<Y60K:>]841>C+E$TVWY2+Z
M;+'C@@XC$PIF$EO1W'1:BXX'2JV?UABD%@CY7F\5@`8%MV&?@#PJ:,ZR>TKN
M>8G=^AB(/48E'"O1,`H)4N1F<<@P!"K=V+EMJJ98+W&.45"#R@&_(1;VF1'E
MYDJ5)>%0S765`0R6H<''@I["<*H'CAPN:O;1#.!7@7P>@(5G*TQPV%\<+/46
M0&4("VW@6K79;,J?_#D:BE?^#5VCC(>9WN8TCFG3LE/&&VK.`\=!B:D%S(#H
MIZQRT$_2-\7=?5"G4^1KA.`;H=>(+V?`0"48SXL^)$Z170^!BEP:C0Y_1H-7
MT'*(C'T;-RH]6=["<RD@AXA(?<L0*`!&FEF2"9[7P%;S'\*%CZ]@AV3W]:C6
M(?CMX!W"._TIZ?\T9BO2V0#F0418E'CMH\,B7:Z(I3TY7Q*`17P.HG`_P(#N
M.GF-(1@M?N2E*4`J:E*P&0R8$=\5JC9OPDB,CW%P98#(A%YUUB#2<_GQV4+,
MYA-*PL7A\0N7OHO0$MDNZ%'AJ157@2%/##`FHIZ=P1AYXF!_F20\R.[!YV+Y
MXA$5Q,$.DJO2;)*SP8,4[D"G]<$"*!SP9E=Z:3I:K9VKLEH@:VJLR%(`00->
M%KR"(COE/:3\B2B01>%1'@=Z8%D<.+!ON9.,C1"/D(KX&L(+.'"F"JL$&-\E
MR7%@3GS^3/.BYL6G]`8^4^BW42,;LTG&,88.#6O"HQ/7-#L2BT8''0X9CNXJ
M8UR&17UFNF,8UP9K%*",0A'P^CMA\P<RD%,S90*FZ4.-5<=!D3V6"^"UBI1@
M$#[/F`*$7(%Q8"??U.L19N;0(/*6E1=N489&_'6T8,+,'+PT3'Y$:26NM=V@
M9=73X_90LNH63&7E$[?2\FK&`.?L&A/5*4.)^.WK@P,6_LB:L,_"(^F5)Q!D
MQ(/<Q!7!A0%P.QGRN9)+FO;FG*?[F2S^C(=+,P+C"WN0#](99[UFM?/+W.'N
MN72.<E\R\$":7!?QT_(#\(CG32X)3"5_`.G>RBG[T\S:\,R5SL7(4K)M%0XA
M;UPZ9^Z"I8!CDS]DUHU&3RT3,(#Q\E3"2K_X"A``CAJ^WZST.K5*O=E)C9F/
MN<7N/<)5KS0;C4JMU9J';2$\A0N2ZABWCG$?^?9MF9V$77N(I].YJNR"?7=X
M:%H8#:*$9FO,XO15^`9W2CZY.I7ICN)DRO]$/13&0UMJ:,/%C5;U9%9$M5#R
M1EE#&#=*YRU,\$*0C.//*\@D.@?&+@P[L>'=H6Q<C8D_!@:EDEC5=X=`)/M5
M"D]0<:`1,V'V[]7;*OO'U=5-1L.AV(R6EJS!2K`F]=B",)H7(F!RF</0YBJ&
M.LB!ZC8Y'L#GXU@H9IY;OI][?/'^.@,K30M;/Z%HG\L^8'9&O7;Q_TI5J[)4
MNCC_MQ@<=GOQ_U4IX=3#\(0])5M@"EX!:3S`KAV:(AV$3BU>!D==-Y"[YPEU
M*@(:,D8GH1!)!GA>Y-*!C*#N1DJ#T'-D?#(*=R+$DL_E$V<4[Z72E;@2)=0\
M1#OE2:6>/5<G/F09*1K".(OR)X&7^5#(%"-'&,+WP:!)F$2>)`^XY24`1KB3
M1DP2SXV6*N.Z/E(]<BX>`T2\&KV"M@GN2#0CR!AXW:24K'NQ:()!"&B8"NX1
MDOU=T>R/W-`V,1O'$YS('M[Y;^C(\[68[J,I5@\XXYY'8"/$3`!<9G*.U%2>
M+!&=)#B,.@M*^W,P_)5P?)[%Q1TGC"/X>$(5\<?O:TU+QQW2<H[7"1Q(`XF^
M%V(:MSKJNM1^K/9C"X#;0EDG[Y+,3-1YPX3IU[,[4@'UU,D=3V=\,ADQC^+C
M48[MB*.\(`\'JYB1#+@73DBA-91-V>2AV$4<N(9,BG:E4$G/!'(+`UYQ4J:)
M*;(&'JCC@(<.NVL!4$SOLJ<%P&(!<).8ZA1W2-VO6U,$;&*I1(;K0FM`=30A
M*1&,7%_,V"*9I_.O*,A+#6!@^:F[6V16Q2(H,TN2BI3V=(1MC6$%:QZ;ZTN`
M.[/#\V<'"[?HP,LI2K;O4GB\AXT<DS,/7D@28HFO"&?C,NN)/!D&21]E^IO*
M07P(J0*3$/<;/E'^OI_RB-&D&O,?`E.&%#)0]''?#\<JA8RNE'#*U%(NJ[H!
M)=.B:`8NV^/@JW:J!YK*43/5N8C*^5LCRK1H'F4(RH>$;*?G,S/T9%Z&2.=[
MD8N.H9)`NI'2T3;((98W7*(35%0F\?JU4"^C)-""O-3;MZ4@QYJ#)`KH0ZKZ
MX(8^:N2@^A2%',&\(%9M"\8S$Y.09+$+&V7A?;<Q7BV.T\/QABY=APM&E'-K
MXU5C$*U]S#0%T$0"6I7=AL:(];F-L6<9)PS]D"2YS!3'=V',#^\^7N,UUA#]
M9K0YZ7YEH#)H5)CKDI:?%_Q*`L"YQYD(%9XXFB`P?15?I"NK?>[\T#*PC$RD
M96"IMV]K-UVV@I/'4'%'NM4"\#,W1C"*)]\4\9N<\M'Q?$G>,C!</U!WM<&Z
M-:RH[@$'2#V.\%T@-"`XZ#CS'K/,E3%E@F03@]`&\76?%I08MP=A]N^1<&+3
MD68-Z#@*!"C8B&9%&8QJ^KA>@6&$XU!^CD&BPRT:8NSB'9`X-RX2W_+<#X5]
M-,X0$W!15KL@;RT_.HA2DE!F^X)>J#*LTF]YTN8<<XP7R$*+9'^:%B7,T>3&
MB%,F#@C^U/O%XT:=DJ&%Z9%OWY;"].,863TZ,?CD.L.+3W2G3/5_34O5?`KY
MG+C6X*Q:XL$'`0/#V#2,$G:4I9!,]0!R4)#<O)>'K)[*TI7A`,L#@8>W_PSZ
MPI1YAN26DX!4=;:C:TIC/J6#9WGHBS>'L%0#'G('>&/:<JQQ.%:GJV!SIISG
M@1MZ8./^%7(/ZX$H\U&>1G\<X`5K@3<-5?9BDC\@!74B]`<AE=T)`50_NA5&
M!N?`=@$?@`17J9'D!!H1(X4H6JNJ/$S\RXSMJA8LKSU2+1V`=XQ*R"(PK<PV
M^FAORPGP=D>4`2!/D>05-(IAX&%5:E.BDW/*:Z1(@PQFJ.(8!H:#@P>,"!/N
M,']``I2=,LI&ST*M#YQ*>N"DA>\!3YP]<)(#,A77*-,%#JZ9>F/6;$TSI&11
MY7)CG0D15-F'^`$ID%,7OH$$S"2>"K:<$Y6=D'9P=M8^5U>H_PKQ,F7T*-TI
ME5:N)[)?QLE!F)6#B4'\GENVO)4[2(&%C\6RS50EO]1(<E8<C[YT36&G:W/@
ME]'H;M\7WKVLV"-?-GG`E5&-(AP?_F]H#J7]C][`)M%0+:>TG#HE.46"XX](
MU:=S<Z/>!>O(KT3\H%5BB@&Q.*<DN>?/I*"01MY#DL.G*AR`2>)CK1RNW.<*
MFG=8CY^,)E5:%XR]Z"QFJN[9,92.6$DH764CLF(B"47ET:P)E_7<TG)T9(%3
MZQFC5,Y-^J8Y"M&4?>A,PD"='@U)5J(LQ=@JO"-OQ%.='S<2FTHT4FHNI4A*
M@)2UC%1-F3O*A*;:B*F3)G5H!`;F[/"ADY)_$BII^N6N#,LWXI0VFJJOM?0K
MI_3;*5HL16>!<'L0Z?<)L^-8':06\6FZ`O)W1X(.3+D/WHP]U>1P5A7Y&DEQ
MQZ+B@U@!R*#S#_7&6'`\_R"[A#+_-$-JAGQZW!Z0(1MY#*F^DD5*@9V<.;ZD
MY#GR6"*^EFD;>$$RT7Y1WKR,3*38%`P$8='HI@561H!.@T>Q)OE7=!MAC%L4
MY^IE@2`?2M41SA4$"4E:3O(Y*U`J.8,F\F75#+C^2#+%ZT<_BZL:M-8*1&Z&
M-':FXCPRB1`-#ZR*"(NX=_&VC@2J(I."IC+C>8*=FBO,\(1IP>.6_P/^`A*L
MGDN,)T:3=/X\,OA4W@\%[.AH@^[H>)[;5W48^].,:]>?TL]"W1F*"]R"/"WD
MB80^W2WS@806[FL*]V:^M37GG\@JS"KP$T?G4X&A).4NS]:*K]0YRM#Z7Y_)
MRK%)5A_ONV$0R;5LKE^.(ZA\T-!'"..@4RP59\'80,(0712;0D]#ON1'*0HA
M7W0L:^7V43R#@A;$F"A+?.;+.LG8$R$E(I1/E1,DYZGKM3*;`^P(FR07'M19
M<R==2=B$DTQ:)S6-RH.D;QY?W5ZS+A:$2K*!%Z43X_&@Z@85A^<MCX0<[,0T
MB<2G0D$2?KS_A:)52CA86?H*B#II3"TLY7=F+IMEKZ0`E+Z?OBZ<#*HJNRHA
M&J+%JN9?-E>2H1U%XRLJZV2:SL!.@FPP1VJD16B3L3%X;!)UO5NYGX2U3>0X
M\IH6XT\N!S8R$P^^6S\WBI0\:C\DV<!"84`]@L6AU<@;;,0+AH6)U%*PZQW]
M/>&FJ?Y.3>JE/IM9UB$8?GUQ6?OE!7(C_=)W@\`=/Q&Y!.9*8.L%A56!UYL'
M+P*I3R<A%_+;"T7<?1"/(`"RORG::""%9G^AH5XSNLZ"5.`B$<!4C?RV6[++
M3G[7K;2T*DK3+15(6B%'RDPF98+U1$EZWW<_59!5$W4A8(W`R]%Y1TW5!XDM
M:9HN!*R:IO<2S\!:FL=*T:\R?H#V"9X,UCQK:H:3"@EWF7!<)E@U/6A8,[#F
M*7%-$"<,JR:(`MI!RP\C"F_K)O=>TL<VJW*/2[OK6O=J6#4]:%BUZM6P:H(H
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M@S^IVC86P<@U93'+N+,B%9J3$P8X895]AQW&RF^6K]ZH8)5>X5%O`OYS69&2
M5,WNN"1)TC?`CTON)A5/DM*8U"\@!F2VN\/2;HO8X,8328$762^<>C,XG#K;
MX(A>W.71Y@^JY-.#9=M881@;D,DZ(]B38J;?@5P;]D*08[G4CM'S9_IQ1VTO
M\I"%6.:I^B4<*]90M12)IW`"7\+45*S.HD(M8]?#O-@?`LL68\4^K.<7EQ2=
MGR1>RR#$:GFR!8;`1I!Y\U:P8T3<$J*"$TX\]]ZB(O+8(<@/\A922<.;=-.,
MB72F/`SW5=T7RXMZ<B`8NA!?&:695D9K;=_S9T7=P"W5T3?A"TKZDF6M[H7M
MRH9IUZZ_5L7WS`!F:@"#!HB$*S4*IIJB6(L+)=?"%SUAC?LA2."D<^[0HWI]
MF6X8_6FZ#R2.C96^S-"(:DAY2R$KH)C2'<RTG#KR[=M22MV.@/4OWI)U<B.+
M#F]J/">MP.<;6PD.4L(/`+_,G4A3ZH%[9E2OG:2/[/?=GZ;LS[=8W.#BUABY
M6)=0O9GI74.B)YX&S-\Q/.'C8OR9LG[<#^+?"9#$K#.I@2U*.PM@PMI[T]2O
M*%R]8&E7W/2P:KYT\W*"1RYRKH5$RN;WL"NE3YB/.UC&5:0ENM#(]TE"#QTT
M3V7?3"KNA^B/^Y='[=F`EDD\,S&>V.Y4B'3_-30NE=7*L)(L=@Z1K82IBUQV
M;JJ_2`NYD'C%AFN@=!(<8:>S+'#Q!M`(/@MM22%@7Z?=`02]DE$UI&44(45#
M(S2I7G&N-Q"JAV8\#?A<@>M1R>_D=^FX5-D-.AANZ)-Q'X.86854J%@U$?R`
MN)<!.2RR,J[L#$J-X6<FB)$EBTIFR5O`MBE2R&Y3E;V7?9O11>@+1PPL=!*H
M&QUX%9$V5K"B`@9<FJ9%T.+N<<N\P%Y_?&(%W-8:MY0B6VO<4F_?EAKW/?>P
M1K?/SCZYOG_.;D"07TM%0LIX0^VK!#E)0\N0%KEEARC`1#03")V,B@1X<.>E
M\"/YBFI::1"EB]"1>$M#QL.<V03P_&BD"2>A:BP`Y&J9D29W1!"%I]3K<>\Z
M%&1I#0K*WA2>'[D?$I4H_D#5<5!+3DA)1G/JW@T#['9*4Z:ZDR8ALDCFOEN-
ME_56LFH)R4[MLI:)'?IR+_&J=])NL,IN+<<0&<6)G7%<!U1<Y`52FVHA`T\S
M9($+H2;6<\O'?\ANX6-195EZF[@!JCC9`W8>*';F1I7B82I0@N17GL/*R4U5
M_4;B-ML1+/EP@"+'&LBJW9C!0]E+%4LWJV@CE9<?`39E6S&8RXJ`JK(/2B7+
MYN$P;##R41?#?-EK6)7,JBS?#V655[D7<9>4M/U*D;E)"*.`\<$:E4:[56DT
M>M$[Z<5GGNQ5VMU:I=ELQCN]GEFY_FJ:>UA-LUFKU)N7*U=3;U0ZG5JEW6QO
MNISBJ3IMJ6A+Y<BW;^L()I8!9%?)J=>-YSKPV1#;Q`E,%Z%W`^4#JJY%Y/7A
M/$IFH9),)IQD)Z2S&A+[/%.1'_MP8U=N1VE^'SQ.DDDNZ!;2(WZZ7\#$]<F5
MHCZ8J4[C62&F954IB5W+JE)OW[9QS+#OB[]"E%?O[S<73AF#)3F@58?3*)-`
M\&`$RD/Y(>Y5L,YSP^%H+NQGN+C?,E;F4,55&;J*Y0^8^$$DT02Y'23WJ"->
ML@Z:!5=K@)6,\28<#5P];\5A\-]?A?[%D//)ZZ_>D#OJ\/@Z!@7^N'+,&^GF
MT9]?!W%7XML8M'?QQ/#T;2)L$W5P`^,98/O?`96\1=K[[?FSOT=S?\-F<L*\
MP:#J7=(^.#5L_!HN#"GMFQC\^N):?OZS^?G]GW\VZQ=@XUZ@K?[BMY,[XBX?
M%WX!!X0U,NW*%!TP(@26IH1Y`EXNK)]RGP^ZA<7JGG7D]*X4'E7#QMBY9:CO
MUB#OS[>_7U\?:Y/O$I+J$]I33R>;/SH8[:E5V#^$`[:`S:X"&^-?!OL'F",3
M]LD:6RAP3=<AP8N6BS),\/P/A'`2LK'0`AFY&"]R'_`H$LT/R[0HM^T*Q+1C
MA6/V3^`(BI=^"LPJ.\/M$!Z\XO`QO#('QD<'#[ND>:.`.<?HT6<Q=LE\NK5=
M[K#?:=O0R;O&S#J/75/->79&7'9>P6YH41M;@LXKOG]VD@2I/:ZM-V1.8]##
MA*/73.$H=T4%NQ%RF%&_.NR#Z'LA2"-6IR!WK9'-%R")0:T=0;YPD#8&^EV5
M3+H=!K'Q?$UXZ-\H;XA=#3V1M#:4(NDB$4D?'<!]$$J?3LFG.*WN[/;WC^>5
MA.SCOKG,4\8N2CN48NPL,H4;M3<*NF3J^+?ZF_-JWMUZ=%!Y`BCF`8QEY-^"
M%81#(!!$2COWY9O0\\-4N\IXH"P*;0F5SV")`8=QL3>YC5D/F.TP\3""%J@N
MXK#NBCI(0"09>/2#21<3'JCP'*`25(L,[[E+3@3PH$D8(P<X>CB532NY[;N@
M?R9X:H>'64,7Y\BD&AI`&S1A.N>0\A$EVDTO!*CP^,RDW(\\M&SB=6CQI?6)
MWI!,$-\"UNP#SB,Q-^8_Y)EQTDT89@/[#U/K)BJA<!V726]D,3GKD6XU[J'U
M:XF;N2YH_*7&43V\9%^O8Z@C]#F2$#DQP/5O$&^*M">_(Z[;NVV+Y"@S_73(
M9>U>)X6[/%]V`(M=$[YPV-R]$'QWW7HRY5)R9_5S-K!LM(CQ#K;#OL`0[]!#
MO9I,P.N6<8AT@.#+NZMT2`"34SPQQ$1(UYLR/L%47VXG&Q-G[BH?'G-W7;RF
MMYV8+&]1F(55ETM.0KH(Z6+<=%JU"K@7NU@$1:;T72N0'JM0;9S+(@HRS\\0
MUD1%`.?D9))L_KUZ6V4?WEW%5QV23="2L]"PGH0DJU=.29:M74Y+Y[L4*Q"H
M([,'W)"H>-3"8SI_A'D<$SY-SA;Q?C6C7$QO>M&?7JB/=..+2G:X4VX'4U2/
MC5_PWWCQR^>V3/W`X6:UG\\PL=-6]^8#RKAXS="1J=?85'#/3Y3JP/+4Q7IY
ML$HC4T(]ZNBX'%1T-"A^3BQ/Z)2-8I";YO^";<BU.GR/JK:9H0!>C&3"7.:`
M3!N/"XWAV7B`'`=('5KW\$&^R_&+/O`M)C!<1*?D=*%/YK?GGI!_==B_0D>P
M>H_N%=:S@@AW#/ZVL7H!R2I93@($T^WO']D9/V<OI36#.0KR];,^?-FHI;]M
M$,QG!OZ0>;P9+]ORT[(0?HT2"U066#0-=QS,5!AS3%QPJ#C<0*C+BW'V0'02
MN8X`TLF;FL^/*#4KS=>W8A+(5AV7T9WA)>E4<F_2&4B4*@5L#C]CZ438VT!>
M?Y%R*ZFS&(WH/@#0^$94)D45&2`S`J4##H77.Y9)NX6Y48$;`#GN/C>(FI?=
M>JM2!W%"M^[1.`)Q*>XQ?RJVDO(SHR*Q.N%^<B5(5I2!\?OI2C^+D[SD$MP'
MRMM5UR35C>U8)Z37AK5JX&E:FC2QHGHY_L:8O")[,+I+KB[&IR%*2>0YDD``
M"(?Y8IBD,/T>B^)!*,L;4#H;QFI^1K6!7M:J#<P>L:G:$^[#/$XKD1H`-6>O
M3`'60DY;EWI#4/)+]FYT2.POS:)-*DT!TN.,RX`R]V=4@?1#L^G[LSF@>!D2
M*T=B26)V(ZM'O&JH\63]D[[ER,,P+./+)^2QVNX#2$)XV)@&8+_"(U*6##QY
M>TSF>^(#\/`G@#S\OW#,^Q=71J/16BAGHQ73/7*T65\VZY5ZMY4J@@.0B$B;
M8%45K`<#Y"),>;4S@X_<>;Y/J"Z:,,*H7.82MQX+>>%==EAC<!%.2&3"&R\[
MO4J[T8R,9>TV%X./M&`[R(8\?[;]EJQ=ZR>R1&9,WKA>TLMZMU=I-3OTW,MZ
MHU?I@H.9L38J)":6.YI*W,GZ420?U["Y4A#.]=++@HL2">165'M*!0(',]!W
M2:C-`I^ZG)`58]HK+HY7?.2G$?*+[6[?WMA<UH$!?P9QI8FV*$1;<-US+*&<
MK_&EK[7,>.$,HS(F,W;[/P6W@Y&!I?:2R[KL+7=^D)GNT[W@2<QN?!AY^C@=
M16^C@I542^XK=OR`-U.:CEW!$CS0/>[LK5WR^_%O`(*JXZX`1L9T9H#)O]FU
M[M6WV94A1!)95&M7%A\V[-#'$H=K+Y[E0?+1R59MD7UC`+NJ[K*_`"*+`E"&
M0`@PILY5F2I!E[A1<;M`*;]$N!UZ5$?1<PTA3)]YW)+QJA4PR]`\1Y:^4$6W
MR+*(2B]G^@4D$S=VGS>*_F=G($-&G1,@HFPQQ&H[46`KMM545<UUB.(N![MJ
M"TR!)<30@I,5Q?#^H<+Y@K*'JVL=9I:+YSG1D4[NMB7C92J)1V70?"I)'CT<
M.D0WH!]7(S@Z$4K-D(4L*@X9*F?5,RP_KE_T-EE]7#42IO1#,%8)BK4Q372<
M1FQ<7C0.#D:TYALC88:V#&FBG"""3X,6`X4R#.!I1^:^`AOK*V'$PO55SNT:
M..*L]0O=FC"L0#&H2$"(9XS`,*-F&%A@#J?H"[H(RVU;U6\"\A1C6:\^VT9C
M<:Q@&]C3-)$O0M!3H-JHD62;Z>J1J@$?W?Q-"E1Q\][R,9DN$E,SMWE58R85
M4,=L@@"8%2OMQYLBGZ`_[&D<UVBTD+G7N.Q,1!/7-J9HS)EUCA72TV"@;`W'
M8]6A"EMU>4/A@7@Q_@JMJ,9?'_L*X'%E.M2$>HFZ1@5)12)VIK["ME$XC:S'
M_%[5Q3^7RE.&;3#R#XJ6\B:D3V4%"^32`A%/)6PCMN`+13L?`D[PNN6,(HD8
M,@6_K^2J18BJ1'R2WB<@*+4_?(#1.GDRP3.1JKF]AQTP/*N/U-]W[\5LR7YJ
M*H!LH>@'R=-CO@76#O>2X=*(7JCS2!)3;B?:7(@*K.O(_84"=XYF54.TV)#H
M@R&!S<$4NC(PID&:I&P&+D^W1$HJ)<==2OAF+;%<8RN7S#^D.4?(HQ"\*XOI
M-=&FR.X'EA?O"R7K@`#`$&$\O)^U^"PR-1PAET.D.D_#%2E:99\'M1*T.V>-
MM+Z+;0S@R\B*\]D8EXO]$2B_=G<M3!R>-KWFVP[EF:"H!',$^;4+6^X%%BHU
MK$+FIW9:)2+@<Q4IP--Z-1+X)&.2;:RD[`/U9.X*L.3W@B+)E4:K7JG56QO:
M#?I02SO')0KI+')5XTAF;W6J@2,5[V*/=85#VESDDV6-BF12^1+:2)&>0DWH
M1YI&9BBELX^BFB?;.&*5_;M8"RNS/ZZ+@O)8N1)5EBK!JJS%>7NV"9\C'S!/
MI&(E4,L)LSV*MK!/HSS6U*%`HEO3P?1P8EO4[4<ZY7$[@X$T#Y1ZA@VD2R1?
MN#H7?9_NE;38S-412BV$GTX(OY/-4("KO8"D:UX'C#PNC*,@*6F'5NALMLYE
MG*T3IX5C%C@^FV(E*:O\2&;DBJUVM]+KK--,(B.]P&![V:/V(;)OR*Q7VGK^
M3*:MK\&)BXDVJ:>\04WC="GD&Y4J=H,%$J\<\SUX3%2[2M="+A87K7L2166.
MFYDRQ]$>$[7'&[R0[/3^/>7^9;<EE^GU!JVMU+5*?SR5GA$S(A(S,C1(9FP4
MU(BKL8&.7"?-9/%INM[>QZV[7TS!5/3M6`=7QU7*CFZ!/VXA.UF+(OZ4?P6]
MW9F_@U[88EMJ'8L+#!RN2%L.@9:M+%N"WT_@+BZNSC:/\#5K%Y2$;NJUQR2<
MO`)E)28BM$E.CW*.9!F:`?;"`,T38X!7*2MB&WOBJ>%?`.J"`D4%A+1@=8*6
M09HG6@I2HO,X$%P>2#4I'$+^YI=LW5(BE[:RX-?!P#)$$E/;0".OEOXEMDX2
M@FK*L[3-395"ET?<CG%+2^:+2\JNN7WK47G92C!V*O5.;_]&>'$(NP0\^/R9
MYL+3YL)6Y;*[N`IJ:;EP@;655'(^1#2]M+SQ2?C^:\8-(QR'JJV;F'C"L"CW
M;B]F6:%C(ZFHVC%"?KB#E*(IV:<^32J9]#]K5'KMUA,%0DLK+<\/X(X57<AL
MN/%:XFB)LZ!#3Z75/H"]J27.@8*,BQ![>12(S<_MJV#9]AUI=`,3^+*<,OY(
MEK&QE+Y<**5--^S;X@C8XA"QDL?%=\G48OVRTGC,E)R2\NJ1+$.+'"URGASA
M]6:EUWA$2[P0O)JRCY.F6+/+?OST]4*G^1]FNS*;I&]=//6UY52X/ZZ3,-BX
MSJ_LD?.R7KFLM619W)EROK(Z1%R6T,-+G>Y@0)4`/(%E?O'^%#8_4/#(1EEY
M]Z],>=-Z'0";JEZP@1(=;UC;6-\!BP9<5NJ-!E/5D1`SKJQ@M?CR<G(S>9,K
MQNFKR>]$_W"WD&<)?A/R:"*ARB^DLHOHDKZ[YY[%D4$RWT8W/Z,O%_$-DMK%
M:.9AUYN,@!5?,QX&;IY0S&?77-X!/G$?XJ%R.'`%<\UQZ#Q;S_-^+D?.,MC&
M]X)R[M321'0%^C)S!9J^NI'%J9>J<DTR1TTR*TV@$R&%1]KX'(.A8+20+@;5
MZ*[1>`KT[=@*QZK@3[J"DVHUQT&OMSJ5;J.5/!M5=8W*#J.:=2FITX,]XWW+
MMJAF(R@Z&G2"53_!"%A1+'BF4P=LEA-UDY/U:EN57J^%A93^Q9V0>]/8"DE8
MP/*C,HFI+]524@-$580`QH#;=MQ?R<'F)]*BJ+*HX<'JJBX9R%^VFY7FY66Z
ME],<=JMLT[8$;A@`J+*(89_;-%RJS0#5EEFXEU@3YF7OLG+9K:NF"W)+UVWQ
ME%@_"ZR8K*'C6?<<A_P(V/5"*J`(AM(_A0F,,+S"V:A<C:[)4BP78=[^6%*3
MI94Q2)(]7YZTK#>M*-USM)O]>-MQ-U,)+VE3*$NA1E7WDGI=,R^H>EXH'/$Y
MJM;G8SDL^?X$'6HCH`*I(NH</0@#D*RR:*!C+"_UE2DX2`-2I;^^P-Y@5,PW
M`BWU6DIW),7#U9NJ*#I]$<-JJ#K,5-&;E+!I@=&0*8F<-T]V<&RZC=57L%(@
MF9?4H`?18,EFCAPK-D_"V,H8<,O#:&4H*ZO%<JM1>S.P?@KS`HCU@C[%OX!$
M<V5E<=JM`6V5U.<?KF[?LJO;:W;G3BP#/+$JZ]:SPO"R)N,=\78.\3^R&&9>
MW>!HBY;M4$X=WF5%_^4PLW5ZS\!"N+?<T$?+1U6^=XBL\$%AGL?%[.?[-JBE
M1"0(?U@7IF7+SFLY!$GE)&65.+#%0B.JI"TK+F<V%&O8I6DL?NQ>1.WA%#%G
MZ/0,2U\GM>^,U'+)N,4^<W(B(A&$)?W^.=*+P@(.U1?PJQPGP,YW(=B%T[CF
MYCFR!5<`)V7PSC+D],E]@%]N\)D4*9W'U$F=G..2Y\NQ$+7C0)FCBJNJ/J$#
M*BQ-SW(3Y3;MDY41*[A#!L:]B*YB2DOM4Y;?TN7@'4H#!F/7EST+\#$G)),4
M85Q:I101:>)`IOKF/%I'"C<QE8$@5IX&"&QC-/?<&BC+K"&%L:+IO6;[!/7>
MYF;(HQR\G*0-DKA=)`G-V&"/V<=*O+5-HNR7,OK/?54)S5^[OIDN$G70(E%E
M3C4N&>RZ'LMV"/Z.376VS44H&8V4&79-WUNVS$77\P]T/4^!R-<J-52P"Z/E
M!J_()5G*A<F"@Z<W>CLIM/%=F$[["&L@O)7GA97YL\5=LV\+6`*@/,4*3JOB
M1*77[E;:C0/47]P"Z.?/3K?XBR[]<M*,V*YT:IU*HW6`^_]/3=N[5']9IOC+
MPZL:T@,HW:<'M3Q(U9!J0BTP4K5S.)^<1,=GX!-2UE"2OFO8W/>3_)S`I4LX
M<S\<GQ511DA/P&X]NVQ7:HT#6JVEY>`M"E.5A[++`^DI\&"]V:NT#E$Z[G28
M<%TGM=A^::$9L@S`%=.,+P/F-'":YLKJ+1YWO<+K$7>&F'V?NG.Q?U.AT#DP
MNF:JKIFZ)V1?G"SKZ++)6@0\M@AX_JR00J#>`'^[7JEUZAM(@Y(RCCZ^U9#J
M4S$-Z9%!J@FUA`[Y<=2YCQ-_LS<V'\^Q*$3UUT)5:GYZ).CZR3OF,3?`)N]U
M3Y:)MO;."[:.`@B#TBH67;;]L<5.KU)O="N=]B9Q@&.0.[IT>T$*B"S;+EU3
M[O%+MR<56I;7)Y5I<TEQ+:K6$A52,F5IJ6R)-%FX+2E&YP:PH3#72Y7](X<8
M"XZE.\VHC#K68G-#/ZG19/)`58+S1)0S*HN5HIS!W%&@`*R8>H%UT?C$@FD*
M5[?I)&DKNPFZ2\/ZV[$.KG2-JT/1;5:4Q37NYFM=*2EH<-M0C:]#G\HJJIJ4
M\$7?<MRQ!?N!8\D4>/A-V$DQ/5GNBE[S_7!,]2)]+$(G.`C@J$:S/Q(B(%FX
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MO.E5>UJO%1DX3<.K8U'5RYSTZ:.C8>W/S2'NF^7_8`-L*&91'W(_8!ZY;0WM
MMA4"[**(B'JUV2BUB/CE,;7;_LO9:RK>#Q4W.L=+Q5OY;<>FT?ZMNF?:UKV@
MSL53P;U->MH53X,==VI.K=K:>(\*R)G'?8BHZ:L<]*5=G#G$O?\Y$08&[^Y=
MFP>REOI94[LWA0"[*(9A7CFG8S$+-06?!`7G9),="P7K`ZE%.@U68`&8)IM:
MPC;9V:76:X4`NRA2(:=F:8F$@CZ:>GJP-25K[^T)-=V-Y_:C#ECN($HT'`P$
M55NP',:=*9O`7Z[)W'OA,>7LL[.65H6%`%L+D((02Z&!*P-.BT+)>4W72D3*
MVM7;*$.#6GB`Z@,EAZ%W+O\2/RT_0!7HC[A'I35`)8)#>-;6:J\08.<(B^?/
MM.+3BJ^$."V*XFN>GN([9=_O:^3F4;8]\T@3GG6T@CL(V"7+63Z%BSB:@#4!
MEYJ`-RT6_%AE*VE=)U:,<=F.Z;J'F^)XN[J'BJ?3QEK@3I94;]G.1GMROD^6
MVGRLI2+=[GGL1S1UMRJ3T*O/('<-B5IX3&#-V/&R*A,\H&JOO._>B[EZ$SZS
M?-;G?E(&^]H=3[@SE73;;=0[;WP&$LE,_(J_0C=(GO]Z=\UDE0L?(/98NG(@
M5O!N4@5M]?"7_]R^9Y]_OZ,GLX6^EU>7U3JRZ#I2:\LGUY8*L=E&);.Z4ZNZ
MLJFZ;:Z6'JVJ\RS_QT7.!=P'[C-3P#=C>-QD_2E`ZO"AU'2R.#HJH#N/%."4
MO;5LF_&XQ#H,A!F"5HZ*U(JIW(IIE3K2&DAK(*V!EFJ@YOG&AM[I:*6WPN"A
M+]+.$S-=',H-V(B#1N&F^"M$):7\J.?/V,@"YPS44.`F6HM9X$+)'RP#Y$_D
M=27WL"JR45%R+VO`#7B:E!]H0FM,K4`6Z;[4T/$0ENPR8B#<'@D/^NA8\BXP
MON;S,2I;$_8%`);MD(:6Z^Q?+SZE'BRABLN@?VGC'JWBM(K3*FZIBKO4*FXQ
M=CXGZB3E8U%KJNQ]*E!G?<%JOZB08CAQ'=)J@NY?R2Y4P8@'\"4@##PPU)$3
M/HW'D3%$V9T*?#(AB-L'80`>F7;$RJBEM".FM9364GO24BVMI3;34C[IDDGV
M4I14)[-WHZ+&AR)IF*C#?UKK:*VCM<Z):YVVUCIK:9TH!.=+'X?.E>9O(_G+
MKB-9CE1",[J)?*6^2)`/+A9&XIJM7Z(3K&B@,/`#^$EIM&R.!;TSEZ!129U^
MV5.M[[2^T_I.Z[L3UG<=K>\68^>;F&!@#GO0H]I)CIW<O-M'H,^4MQ7][+,E
MF1H'4SZ/E&RVMN;I5#MS&]DKJ>Y9?0[U]U>A?S'D?/+Z'=#`/4=+XZ,#4(:X
MZ?Z58_Y3F("(X14:(70J^<[R#=O%1)P[6-%;7/EOSY_]/1KGVAV/K2!Z^QIF
MA[>%8^2_"9OI(&*^B<&O+Z[EYS^;G]__^6>S?@$FT@4:1R]^TP;+(8B&OG@0
M<@%]US87T-$7-Q"LS>+$X_H;EMIE,ETS^[Q05#Q_=O0'RKE<EJR[H$+OF*GW
M$^@\QQ=$IM]`/Y+?=37T!.FU=8A5;]JC;]H:JDOOS];BY['TYV6KV-@ZB-5U
ME\HV&V'Z%V5#8P`I<)F=$D9>)(SP#U/<"]N=4+2*Q\()_)5@!-:\Y9ELPCU*
M"@L!N1XNVAAE,MLLG[E]V%\R^6&J,?\A\`1?#J12QG"K,"X53@8>KCS^'0!]
M$#+Q&M8/O@/LIH32G7([F,9/5AF8`^3=6XYAA[[E.FIT`,"`R8>8/<<]\5J;
M`0OY\%A"/7)%CQSL49-ZJ<^G<1]U=K&/$C6:(]H2QHWXXNB%7-X"!.>&B59J
MT\*CXZJ/Y1;86\L%E>#QB0@#R_!!D7B3C).7UF09+<;9C>>:H1&P=VFU!=KB
M!A0`?(QL[MC,EHILR<15=H;B3'CVE'T`.22?$J#CXJ]_..Z#@PH*)@\$J)QW
MPH<-8)]XWS]'%=2HU9JH^7QA8%Q+_"3]="]D!0R?$>1XGF(-+`/`#:R^:TY!
M^@D'XQ#_#:7N)%"Y/1EQ)L#)I<,@3/AV+=\%(A"@`K]C^ISX"?-0-H(ZZ(GU
M=B6CF,?<A-]BU3\0L5K&%U\V*R#6\9^-B/156OXE@3;UMU:TVN!]$H.76"`Q
M/Q-3,C8T`[`>;62IEYU*IT6$'V>6<F-D@4")6$,:K+;M/M"9:3PT"AJ,&WJ<
M.@?$D_CKF)Q'><>Y.'98!KT+JONH<2[DUZ]9([N,TE9Y^QP3XH;FQDY(>W)K
M=`'`?:!OH'OY[87BGK[-48)E?U.DBBN:^86&>LU\U[;,-W/MW.;(I6P-W6Z4
M4#P=<LF8+1N(CJ>'O.P`YO5"+"RP3P_@#*'FES'-7XMR'KO=_$J')5=R9_5S
MZ3'%<4?'"BS*K0.W<,3!P_G(KN%YNLYZYUGP;[#E8O_'Q)QO]!VW$WHRH^?Y
MLX*6DUQ*$0M@+3E!Y!2K7'\CEY2RS$6->JLLN%$.SB[ZO<ATOE!()DT.3E)$
M-E:+R,/+R$)33IFH7,NLDY!9)V_8-=>06EILE8;03TQLU2NMVFD*KA,WMB[/
M\:C0=H<DE>*3Q\D$I)*\+#RP;'E5*QBQ[]7;*OOP[DJ+J$+!>B(B2MM6)RJD
M6N?L@^7Y`14`%YZ!II//;:'%4*%@/1$QI"VEDQ1"[7/&!X%05;Q('+VLUZ+T
M(\R@<D1`8FG+$TDME[1<.D6YM+XTTIEZ!<G4*_@]GH/0Z7>Z.;(D4]4?<=NF
MJH^!NRQ9%YO&<,!ZZ`3>]*(_O5`?L;BDA>'"Z-*(.V#U!A5"B34+10QAEMF8
M(5YL"2R;X+$Y:BEW\)KA:7.]46VQJ>">/Z>^9JSI"G,]%I^^4'TQRD>F,I?6
MLCJ59:##I[F9O@/;/G^F&7<OC)O.L!V+@`JW2@9($FPI_[W>H.18JN[J8;FB
MJ,)X\ER:WR?<,I<GY?/Y%%Y*6H\R=V&>?X7VE#4NJ6)1HYI7G^-NE),)'"?]
MRJ.%^NS!`E9.]X2!Z8`FH\\+;LMA!5L0)%4V>_$.*]A&9QCFDI-7'-!Q8[CP
MU;X`^4%Y^\L%897YEF-(I&;P$(U6;HES-`RT1JT8?3GOT2_G%<+#TG?I-D-M
M/U?$;^BR'??]NL]B[))FN;5=[K#?B==1$U]S4!8>NZ8T=7;V^?;WZ^OSS)4[
M7V#'*YLT%E[XQOKK4=&<[>^'E9\=BP3;PN)AA8EXEGVWM?!=@%I#"]]5*/K*
M?[!OECD4[`N=_F-.`.^['J>N3F=?OWWYE!6Y5S<?L79&ZD(AV/R3$%P-=!=>
M-IK-2AT]G8&\!,Q5+T(,4:",EXTU0HQDH$>SR$VIJ&O%\`"L"1.G)I2;H*K1
M1K,SX9BY>_P!QI8E8=,.'#I)2=$/G))<.CZ9>.Y/JOX'/LG+6K6)_I=-/3Y2
M:UNT)((4$;4,DLN9T!%0"WE9\4KB4;+XK%4O8V`6`*`573%@TXI.*[HGDN+Y
M0E`KNG05#U`@][>N324H?`RC8Z,F^O!?`?(WU6G0%]Z]98BDA9,?A.8TNF)O
M>N&071D7C4;KXI_AYWJOQ<ZPW.>8]R^NSJ5JLS(MZ)D11=`"E-=^)0[B40T0
M^KPX%$@5`&(PK72#1-`4ANL'LPJL7NW%.D-6SOHKM#Q*3,;#@5^8B95!4O')
M()XF&3N:$"=8"%MFH*140:/9HW`GZEO2L++:2(>@61CW_.JPJW`(=,7:,BI8
M85^-P,4*[XU&)0G7?N935F]74OJ=)W538$8.GTQEE\A=IHW$P(NR<*(-7A_G
MCON0P@V?0WFCVHA07F57=&J3K5A?F=^D6KQ)<0Q5!6<)=NK9PA*X9@BX#^_Z
M6>L&3W%BVN4>NL9XA*5,G?2C,E+LJX[1TG]6<^/4"X/'2`S^_@JO1"6.EQR:
M%#@>EZ<OE%A\JN#L]FHT`OQ@FG3'"1Y14XA#*M.51+,M$O/P<R0;\A5/S1S0
MEZU(+Z1EV4RIK73)2'\"DM+%'Q.)%JL*$-%OK[L@ET&X@X1CX]##WL5CUW$-
MF]1$5/)*.:,?<*!_A@$>$_H@M55X,BZ2&\4I/_SS^MOU>?:`3?8]"2U;G39.
M/'%ON:&L!NTZ0Q?UYIR90-,"D.PL/OZ/8#K/=S9Q:E(G1NB!]`]`TV`?9%N@
MA,^Q.B+MGYUZ3E\`;JFG)58+"[@7(/S89UG>%T#E^OP9FUCWI#;E$+:039^I
M`!%>(9`*\![]U05:-WT:2>IPZ,%R237-ER9#\!`U<5TR:>E(73;F/FX%"GC6
MY\Z/2(G),OV$I850D$5%[:SI%6D<*4<?AI/M``9`P:##FXG:QU?`\*FVHB\J
M,`)H5$*"ZZ2&,64=-CJD)<.,@,+?`4NY8"69*-AMP(\[Y2PA[YG`!T(^"-6N
M2BJQ>5\2V,NZ.IV>P"28.)*T+J5#\^#!C?))8("7#?4TGNX*RC#)A3DJUA*=
M"S]PSR00HC-V.3^U`V(&+,*2%BT]-UM%E;D/TBB2H"OS>@@4X1!HN1!<+3B,
MK\=;%DUOAB(9G/@S3:]Q;2W"!IK_^9N$[\UDV*1]ADK.J@9L-MTG#Z0=3L7W
M*=O7*]):3A7S+O0BNOPK!`$G/*Q$C%Y$3N.I^<!BG'DQ$#)EZV6S@^F9DF/D
MYVQWJDHLJTB681I8Q+HK[6M=YE!G1>BL"!VO+&^\<E!*%ZM@2,P==3UG"MR"
M>F\-9VK6+<C6)Y;V$LBH!5L81T6W@W2EGT"V$J9?OP3UW&RWR6ZEKI,3\$PH
M)(GM*\D=BIV@>6\GZZG)$T'IYER$$ZH_3%9CK]*Y[*F\T68N;"DC8A9Q2>R1
M+`0P+6WIL43VGN7<N^#CF3**Q^5U;!"Z5?9!&>/!")"/[FDPRK=-LCN9=[)9
M;\?U8R,,"<=S;7N!V7&:9XH'D=I%6:P^I"PE^1R#TL]WF[72?QREKX[6&MV=
MU3YJR^\.>+&>;\E+2W?B)^C8S]5W57:%H:I4=%0%11_?2)@]SZ2P'L!JN`[>
MGUJ@J"U_5F>J2Y85U4*(NOB8=)8*;MD%>/$8TU(-?F"R($STO+0;+M'Y7PCF
M#(`P?Y]CG!<CAI[@!&?C,E+7>&+GN>%PM-@(V:C7`AD)+YO-2N^R767*?HG#
M&YZ0&5,4/U,&%<*4<Z"H!KJL-+M-M)'D[0Z$$<D%!AKQ>R&#NG1W)%J-&DY:
M59=[,D&.ZYA1Z[H2ZKJ13LA90R?=BDD@QI3@T=Y9+?W+'3D^^Z<[^0&".*6@
M%HI>=1SVJC$[<'PJ(55%U.,&-95CA6/6:+06GQZM&BJ,SW)`S00NEAE')0#R
MQ_)'R5%0W"$$DU1#SP\Y9=C@6=I'YQZUQC#*U_T"J'^'24GO?XJQ3),]^_CE
M'>"^6^N<LY&P9T?=Q+/N@OJJT]&0DMJH"=T-G6HK==85T-W!/!>[T:AT+SL5
M7"-WG!`S<$;<&W-CFCQ2J35:A!1\"!-]B```E8;P?=1>T9,MJ;-GG.DY3Q\A
M5Q-G`0*5]$'TO9![647V@/]*[C^J\RTS<?U7^NGJ>&VCD/\1^TM%@@U%[?-G
M!0/OR/9;VPP+4&MIFV$-F^&+>Z],AOK.)D,PY\G>",?QI_8]=RRN#8>=#(=Z
MI=/9V7"(T+"&]:""VV0;).%V;HYA=#_`7*5[ZB;HKS`+N&%X(<P41\MA?(ZM
M&PU)=TJ--Y/[0Y0<(DV&?W$GLACRO%FMU'7(^PAW6ZOT!:C]KU;IZYQ'1T*S
MDW>0.:/18>QPP(U`.EPS"OT?KFL^@!A6S7`=K',]!;V7?Q'X[&_J7FNC]D:]
M&7]3?W->C8<C+>2BF2!D\1J574L/@'>7AN@&;W/2#8PSXQ^?;\ZC@ETJ&,OS
M$HSI@V%-HGRPZ(:LA8XP"R>@+W'H"=D=S5E3`4;]""CO*]@ONXTW%V]!IU$`
M/`I[9Z_)@.\)KG2WWJSTVK7<\V\,;J=BV^G\R5:[4>GT:C)1<G&DN0K&E&>Y
MIF4DOG*DSLEGSI9=,H07<%APTIYTT44:>6EE#`_3>TL66.MTBM0I>%Z`'6'/
MW/6R1#?&5WQ"=X0H.Y1<54=^Z_A)*,TR_A'&J-S!``09HR6A"8R!P`_6`#V:
M>^&$HI)L-KH2_W&]'Q7VY3]2GB1#8<ZZY9!L`X;'VWN1"5UET=6.RY1-'=W?
M@X?5_;]DGLOTM;^=UG+97G<MZ4!=LA@_+N8F0]>7JLTY`D;E$WE:*N)KLW<5
M>1C`C@8HR>VI+'3@RU*1%#R\"-P+^A"5B<S>Y,2L?/FSXZ*^H9D4<'@+<:',
M^_NKT+\8<CYY#?@;6P%)YBO'O(9G@;J%8UC"?Q>7T;D#RGV+%/[;\V=_C]Z\
M!?_SQ\BU\:SW/8`43+^`PLUYB>H;P!_?Q.#7%]?R\Y_-S^___+-9OP#!?H&8
M>_';"B/F21*4RR\7Z(L'(1?0A]U:("IP[U@G4^5#;NI"&MI&FI<J@3Q7BQ57
MAQ6:#'-I[F,V5I(5Z-GXT,!RR-;ECC$2TH:>>-8]R&`&XQKQ;;[4"#$I=]Y0
MM`D$)8"/\HAR+KF'%\LBD6H(ZU[,Y4HV,U5@4*$,/=?WY5&3,'UY!0R#1>KJ
MDD71-=<#PS_E5]"!SS5(1=B9K',Q9W1CF=)D07P8WZEG!O='\=6263A[K3CN
M)6WW`(!PQ#2YBW)9B],^`4>6E]Q_!]>(T):&<J90#8@-UFK5P5FH8<%C3XZ9
MQ6G`7K:KZ@(9/4/01+?WZLU.I==JL-"QY)VG`>#[@BZ:Q3LAJ_V0.^$9EH\Q
M3J737O8R(TN\)3OHB>@=\E/H+B(^#8Y'-)6ZO$;[19>QD'+@-\O'X*BAAB3V
MX])/HR<&'#`%_G88W^**9T6P:M5V<H^,^\P44OMBI#:P;.O_HO/`M]C#_>+6
M`'6)N)-Q5EP>/C!V36'/O#!P;=M](.\6()2!6?\U\RS_!RR"XHQH[X!E!S:&
M&-6K[<M?*G1]G^+$]Z[-<;Q@RBY8MYO^"827!>+$9%,+8[L7K/9+19I<<1TB
M/'6UK0&M69617EC0P+:S:*&C43<,_(#3-;_%-LA32E*M5$[>,2)*3K9#52&>
M44(#RZ8*7?Y(V`-0$T-UBD!B#QA/JAT'\_/'[/:BR<[P[93H_Y9^Y39Z):T$
M5$XAB@\Q&,BK@3CD%8@'F]55.&S!H0NX!/DS$"]SDD3H)("VH&N'H2]`BIQ9
MY[`FS#%,_:#@,"C$14@`=XEJ<%9B*2DOU..=UIF#)I`,X43>?JXEW5%0O@99
MW5O!6^,P++IJZHNT)GX%HIM4Q!N:ZLPB2.6MV,1I2@%-X$9"<P7`H9_`B3%$
MT)\A:.\AC#N4ZD"^GM([G=:RQ<BK)6-P9O'R!DRIDB))7\JCNGG@9RGDEGZ_
MBG[/D@9JQ,^?_I#/XS^`\2K[].DZ8U_`$YG73/*SI:B.Z+J:)IN<LSJ<Q7+(
MRJC(J!S=+E?WES.K3I\HXD,S*Y"Y.V-L;\#`597U_IK5VB^1"LVSH19-E@9;
MEL-A>*56&2%)0FD*Y3D@)8@\P^@M^3K=C*]S&_9]`!:??7\/_S[7>DOKK>+I
MK=Q1U_#N;V*7XHI<BA3I+SB24GG@6?\,!83K.$):R,14B[T&)1`_@3]B\X<9
M$18+_72A2Y0;*6G,VMU*K]->Y'%LZ"YL;MLW"F';9\34X>U\+?:*+?9TN%)5
M<LS699&Q2CSE!2RA!0T2SRD?+9=_`[>MFJ%-B4?>D]F+7K'>C@MNC2>V.Z5<
M.5`8?F@':/.C!NF[6)]I3*EP/FO6&Y6438X%JD%W@?X+(A\OOE66*JVSQNWU
M"!`T"Y)DOF:C5:FW.^M.M\:-^7JW5JG7+J,1*8*EC!<,):JO(V@2)R-7YE39
MUW0MU<505K"@:0IO&#AF=55[*W*):%(R5P#,RUYZX>3[<'J-?-8XW'F9*M05
M5?5*S\&#./I)PTOS*$FF2`.:73H&6F$>Y"-RKN4M19R'!D97G"$Y%M.(V)W+
MGS\[,6/C)`7C%1;XFV'6='0G%=RFJ[J"+/FQZP4PLJFX@(Y8DEI?,VSJ2YX+
M':P9-G3H/3SO$N"AD/L0U>'-U`<3\V#%G!G,WB]"E^5EO=+LP3_U[EHB,:&_
M=2N=16!2ZG7ELEZKM+I=6>]L>:FSQ4LIINS0#LBIV*_K.B"4_<*^2F]_+6<C
MKP&Z3FIY$B?C,;?B)'7H72;,1?V-_7`\QD@BZ`HI\%T5^%IWMQXK(:S9/L$-
M*RCS/%J)2[IF\;CU/Y)K/^J.1P:QT24/[*/KCI_TYD_YP4/2@]V`+QI%!U6#
MIS=:@T?@K;&W*7UDT`V`\MQY^S?Y&,)<JF]+M5\E!D_+C;7!>Y6R6;3UHHFS
M3)@L.'AZHX\(O..V7J[NA<>'0ALO!0!/BPUMO!06O$7$^?Q9`8$M."X+`-YQ
M:S7MDVMRVB,:OD4Y59J>-#WMP^B.+D<<"3UI:TSSP*9H^!)2`4YW<"0\4'SP
MCIN>="!#4]/^T(#5K=3-.DU1FJ+V4B,I\"S'MXPCH:=M;+X(3I5`=2&_?LT:
M3Y<3MW[\J^"P+P"WCPG^GH+V0F7N]?&F\QN6_4TERN%Z9GZAH5YC:0;+?'-L
M?/D=JY3LB2>+3B-EAEW3]W8(?A]55;C!J@J:T`L/NR;T+:\J"&_,SBQ'WIH]
MUY1>>-@UI6^'X#^PULTIT+>.*Q?EE']S4)\_.W5<%AP\G6UT(N#IC3X1\/1&
M;V=9L/Z0K,Q?7_R/80@Q&+Q8M`K5O:O5^&7ABA;=K"V\5?DU*8=2F6^0N+FY
M2>N*459?C+&BD&@9(,TBM;<6&:IWRD*']4JOVZHTNY?;>CCEV\="@[HN4DLK
M^!*$O-Q5RATE0S:KC2W$O^9%K:B.FR^ZU:;64<4`5>NH$^?%5J57ZU;:O?;Q
M,>0"5Y4J))VDHYJ@[2,5\SR^+2\CI"<@9!J].A9Z7H8937D:TI/FD00EG6IW
M$VU<AOTK#Z65!](3X(FZ5AE[@_3YL_+`^L@,\O2@%AVI^S_U6RM]Z@@\K2B+
M>!-G:S$=%#KI;"W(]Y^C6(!EKRMP#H^$\NKZLWJ]TFZU-DD_/F8^*2_DFL,U
MA^<BNU;M=#5WEQ3R`@"W*0^N:UJ6C(TN-`^5%/("`*=YZ%1X:-^GGXL6>WD4
M#GLFAS?;2'#SP./*_(^U</GT4F)55&IK8_=RH;%KNF'?%D5"PN%,_O6Q4%Y!
MVZ@TVJU*H]';?_B^)$RDA<$AV*!<VN6P26A:`"W-P3[$?8B2\.RIR)[B0+JU
M8[7(C#XXN^'GPR1DEX2X'H5)GC\K$)MH/5H.UMQS,DVOTJI?5IKMQHFQ>BH2
M\HHZW.8M6S>3+V2KY:?8DI/L5_XN]+!1>3`2[*^0>[!T)@`?YDPPK$)/7+OC
M"7>F;`AX#.`9,9[8[E3`Q-PQP:/@GLG&=`W>9RKW.VIVS@*734(8DOLB/9:D
MB6ZCWGGCPZ:-QZ[#9)?T!RL8,1$5XYM@,3Z?P<1#A'<`JV0O6]56"P=^V:W6
M>P0#ARWUQMAJO5Z3=<WHZWOA!\R]A\5Q=GF!W[.)\"S7K*9H,OY$/=RYY:&T
M"P4.]K)>[3#`M`U+80\<(.6V$=H<D1#Z$0+?HL]U<6N,7!M`E0N_0,#Q@;%K
M"KO*_N">A;+(A_?@9<M9\TUXTK!#$S;SK'Z.6VFX(=""!R#0:JO=[B_L@C6J
MM<XO[*QQ#IB;"`/ALZT!/=*6^*BPLV;JUWL75F'95D#]Z;N=:J?]2X5P=G9Y
MSOY/>&[R+#"F!:QB^M5"\N]2D7I0SLS*M0*@XI1%V?IBS!.&L.[AH:'G^CZ(
M&-<0PO2)X3%X68.)O40$P=>1,,/O9=X2\T?<$_3..E)MOYRCF40SR:9='VP[
MIF*+;@.2L'>3<S`&],SZ@CZ-72^`$4VI.X'`02D"M:,^`,8AM8K/25WJ5QEJ
MSM`!OG*'#KT'M#\1CL]Q0E(D#C`2#V;8DE0JL%RSUZMTZK4J2UDEP<@3`G2@
M$XS\-$\G]!2/@@O!TCMS7(ZA3E,M.X8"N;S1K5<N:_+-E[W+2J-6JZ06:$]+
MJ.F.E'`+[CP<^9;0%P]"+J#OVN:"7?HW]]`W6%X?7@O\1^2;#ZYMNP\H32WP
MA9@?CF%59.P_R+UB'&6=%5A"VC6K7,'7*_=6Q8C45KTXM$ESDMNZ@3C,"_D>
MSKS\N9%YN2=SDL)[T=K4H_5:[1>%S0VP_8(9PK85D+^^J,F_57P3_TZ2JQ:%
M2PM[2%5&\'2)SA,!3V_T$8%W=)W)GC_+FKFZ779QP-.28YLC46V_:.(L%28+
M#I[>Z","[^CLE^P9@.[\7!CPM-C0QDMAP=/$>43@';=.TQZY)J<]HN&;&'/+
ML9RAIB=-3_LPN8=#3PQY<"Q&M[;%-`]LBH8O(35(<P='P@/%!^^XZ4F',30U
M[0\-U_"4QXT@Y+:F*$U1>T##1R`HR_$MXTCH:1N;K]"ELDH.^^;E0)X_V[((
MZ9%QYG?'6I&B?#Q44F;8'ZW([I'1=U1\GMW@K5E-Z(6'71/Z=@B^P\O>9Y8C
MKS9O4D.^S-129M@UI6^'X#^P%,$IT+>.+.M3_K)BLN#@Z8T^$?#T1I\(>'JC
MM[,K]M+*+L>J+%=9Q4SQ^W?"H,I=T3WOYK;&9AG*M98'TA/H]MJKM#O-2J-7
MTQ2G(=6\D2W>6JUMTA.\=%NH(=5LL05*+JO=`W06*<X6K@5I=LP3I80$"^RR
M4VGVVI5FK7-\I+'OKEZ+?)?GSTJX\\FG?\C"Q,>W_V6$]`2D3[/6KO0:FW2W
M+=TN:D@U9VR!DDZUJ]E"0ZK98J&YVJZV=8Q50[H]I$L8I&"0%A"G^S\.6BNK
MIK1G17G>5I1F>@!_J]`I2H_0''5E>EMQ<'"X/J5K(Z&\]L!9H]>K=+NM)^*@
MTHJCK5-]M<C1(N>T14Z]6GO$IJ\EY9Z2+Z.@D&[0?+5D"-?+*-(RB@/IULV'
M2X;Q0B]CWX>GBQ:[J&%TN4SK3%9HMO7/XYD-A6@@_0A&]^5">]-TP[XM-D+"
M\V=%D68'Q$-Y#>]>I=VM59K-`T3]CXR-CF09C\,%Y=(N+S<G?BUU=G/W#Y&?
M<F2<6O)E%`?2K?V=1;9SR;CMLMJI:VX[[F5H'7QZ?%VO=2J-=K?2><RCND+P
M12IX\HK:K.8M>]..SOMNL'W0_KU9-.D^UD_3\/A=Z&$3ZU7=J2OTQ+4[GG!G
MRH;R/D#4ZMIG@<LF(3S/?0&[U:GT6@WFC[@'(+F#]*MRU[N->N>-#WLT'KL.
MK`<0@T-8SKV`/SR?<6?!X"`K>IWV-F/#0+!Z0XQAKQD?XK\M!QYS'&$$%CSZ
M8`4C&@[7RZYMUP?$5%DUR\6::C6;EYO-@Y$G!`/F"$;^&KS.;=^-&9XCP_BA
M'6"#^WSNK]4JL!.;<B@QGXCJ*TZPOB*]_+)5;;78!*02#4B"@<-^>F/\M5Z3
M%>JJ>6ET=R,!0\5`HFB!71'`\\(+./`^H!3%C0,SX=!C$>2.L]0PT43\B$2\
M2!)K$5.$W5G;DE"Y>0EK/@A@OXCY3=:?TB#J9S9R;5,`C[.[E%2R?#^$1QNM
M9J793$N;C%1!:>$)0UCW\.S0<WVP`3S7$,*4PJ71K'1JO:KF<*W7CYOIB!.P
M^E!6MP-O8)3>E.QRT>?(?L!!$^'XG(QB3]@<%3^H^!1/*M4,MGA3#OVR5H%'
M_0F:TO?"GBYFJ;^_"OV+(>>3U[<XIV+N]W^%5C#]X@;BG>4;8'J'GK@#9+Y%
MI/_V_-G?XY?"OB_^"F'#W]_#O_SX(31,$/W?Q.#7%]?R\Y_-S^___+-9OP!D
M7"`:7OPV0Z"S9+;)IC21/.07\G`CH@;Z[IY[%D>RS'S[("3]15\NHE;<X(O1
MS,.N-QD!`[QF/`S</#<^GTER*1:HTWV(A\JA^Q4DG<^UL\PRSV'S;)C+'+.T
MOM'&T$09=/>!RN1$2&*LRV)#M/Z&)23%)$TMI-WGSS3YG`;YK`SD:8HH-D7,
M;4SN\/,K+AH)'F34CPZ[`A?;7A+9BWQD,9[8[E3`J*U9OQ[^$X"?'DB3(6MT
MNQ.T'F9"=WN,#`"40[1[!K!.]K)>KW;:.!=^ZK46!0F8C`A$L$GG(%Z#G(VB
M!.X]F%&<75[@>QA\L%PS-S3P?C"0%@^86U-6;R@/)RLX5N_?[/ZD-X3JJ0-X
ME@/KX\S'_`G$)A]Z0L8R@35AF0/`"R.>9$"Y9+/Q@#4[/5BUZSG<MMEM`*\$
M%?8>H'"="OOR+T2)Y:?&0IQ9#KP-^^.P6S$)5/'*&BVMG>N$`53"`#LTF#)3
M3%S?"A#M?`*NUD]K#(/94_:RV:+-5W:D^&D!"Z+A*AP@N!QS<>$??8^]*H#,
MUQJ@X!K@,/3Q-1:=W;Q@J>*(5D;,X='#XK"$(X)L4**-C++8@4H(3IUV*E2]
MT`2X*P%N3VNYP9"4J[O(:TV[MF]#'S#D^T!+?93!J*1N7-LRIMOYMCKX\ACQ
MZ+E1,SYG_GM?>!!Z`ID]VO.T0[KDO''_2[BZ^5B!+PS@0]<CJP&DU+]"!X]Q
M4<"!S<;00F!]"SQG8^0`:0RG%"-">8=BS0I4@,@4]\)V)ZC6^Y[@/X*1YX9#
M.E/U^,0"^-!4L:V!/(."V;`3/,*%%HW/$!=#DI;<!JG`)MP++,,6S!J/0\>5
MPTS9&<!\=XZ'N0&2H[0W\<<X6(7?^!9@!JRW&&B8O\IHN8$[%/0\F98XW\/(
MM<%(<1\<-`2!62W3XMZTPCX+\PH,/,<*QQ7VT3&J[.SSU<?S"CN#]P5PZ2"@
M>0?"\R02@'?L*`K&>+*QC1KB.OZK_N:<@54,J+<"BTL;VK9Y'S<![4DQ@+4A
M9`@BK&,(6'"`/8,P-JS!4N5]V_+EH36H$*`G"H`[!MAM9((M0R,B"2'PPPEL
MO=QYP6[D(=ZK!C.`2"P#I`88R/!OPG+\P,>YGP/`U=BES[>VRYV+WTD6X(Y>
M<X#(8]=DR@(";W^_OCYG(4@.L+(=1G_#N%/?,D"]`)K1"+>&)`%AN"]`U.^\
M<`B*=P+2D+ZNPE.H?L'B!JP"@D+'&)$I.@[MP+J0;8A83-9@&0/67-HC@A%<
M&VZ$\,-X"C1KF2"ZPA]B;'$@K\^?@+I@&I341#(9Y\3M_U?N+VI^2>"@YP6%
M6Q%)B@O0G";601?(<\T0#'.@3PM3?9@A,3)`28$8D@\0(5HP#.RQ#8R+9[2N
M81,20.U:?==$)@+$_\#<"Z2,F1T6Q(P>`.DIEB`K'`P6Q,&$3V%GS`BD>\L4
MX.]X4S8!UD;C'\F,>#EB6&GN2QJU9[:<C)59Y*!<<&%G?2`MH.*^$"JO(L(G
M?H\K7H!\1""X#X"V/N!*W!,P0%NS\Z`(2"3`@P7>#4T(<E\N&@FE#U@$GP2%
MCFF!I^;1(J<3=5`D]^`!&1F8P*(DK`4HAV<!(!@)EK;*5UGD%VAUO.KP:*5E
M>Z@<N*)CZS":7^DUE.@`BR%`Z@!S^TK/(;*$!SKLAP-J$379-7;Q]MD?@#*P
M7J+GSE#YI)3<3#P'%%TEHP/5K(M^EY.DU62%/9">3)DH4G7@Q#9_B"-)MP$*
M.?CCB[CG)D=#YJL1N!B^:%=8O=?K9*,7."P'-TV`\(`UH:A`69/0IIR7QH8-
M_R%DJ`54C``YJ:P'$`QI$>M.!"IP$'#*0MK!CSL4M3?;)TCM&\7RM?@Y_(9\
M=9+6."J6TLC&4F8BGX1#+E,U9X7.+>6&O?]IC+@S%%GI,0D]/\0\$AA%FE>9
M[#;CK]#"6>JUVB^1)(GBFFCR)K>VF:!#ZBC8:4DS8H48/5ML_Z/?Q82"F41+
M-#=:)O,AU%YO%8#I(%,%K4+,B`\%>UFKUNI)$EUE)O8NQ6(6APP/X:4W.+=-
MN:'P*Q2FH!;`_(X%<F9$N;E2K4@XU-F_LB/!P#+X6-!3&._PP!_"1<T^F@'\
M*I#/RV3="A,<]A<'2[V5A-IJU6:S&07F9FDH7ODW]#`RCEIZFS.!/-RT[)3Q
MAIKSP&$,7BU@!D0_9=QFSB=R4RSQY>P1"2BJ>%YTQ7"*['H(5.32:'3X,QJ\
M@MH]LIEMW*CT9'D+7Y1O.4M$I&(-`\QF5-ND/269@-L!8P?\A\"SEE>P0^!O
M!"!W_T^FG0@Z6)&Y8'P&LQ5ILP/S("(LGU)2T>Z7GDO$TIZ<3\Y.+@?@<P`N
MNV.@,^,)]'K)^0K!L/`C9T<!4E&3TGE3A=X%%P_C%7XZ&W6,@RLCP2>ZI7I6
M9*4D<_EHF8S)_8G87!XJX?#XA3P4B=`2V1?HF.`!592`XXD!AA;4LS,8(X<6
MLWE(>,2Y[+%\\8@*XI@!R55IVLC9X$&*&J#O]X`G;0XXA7G.SD[^3?DOJ&@K
MX5&=E/6T2G+\`C`_P"LH5E-6>,HNCV(V%`GD<4P#EL6!2_J6.\GH\7B$5'`S
M.AM7$80`0YG$W9I;-+<\L4TMTSX;\KB^228FQK$,:R+51-:`8L1$4=3=(?/+
M7672RAB=STQW#./:0B9A**<;7G\GP"LG,W-1?D<ZPKY\L@J+K)I<`*]53``C
MPGDF271:FWQ3KT>8F4.#R%M67F!!J>OXZVC!A)DY>&F8_-C)2EP?ISQY_DQ+
ME/)(E"0)J-%*2Y498Y.S:U"+U@`/:(@KOCXX8,V.K`G[+#R2,7EL*[U[<HE6
M.-(#X$DR6G/EBS1CS3FO[C-9MQEOCF8$]A3V(!^D,\YZS6KGE[GSP'/I".2^
M9`A*GL=S.<QM`N]OWG21P%3R!Y"NG)Q2W8")UH;'='240A:';2O7GSQ/Z8BX
M"Y8"1GS^D%F7$;V2C',,XZU*S,N/`@`"P"G!]YN57J=6J3<[J3'S,;?8E46X
MZI5FHU&IM5KSL,W`L_K*P>(4BTPB!O<M_^O@*G8=Y2/RWUM>.,BR*+`=MA;/
MY=495JW0W_D\_HB9/CLG]2Q-O6TG^5^/E.K3Y\:/H8?G>5%!J_\9T/_F!>&B
MJP1$)DB--WC^ZP22FB_8=X>'IH4^^T>,8%IC]B&.!'QT<&GRR=4I'W<4S5`>
M"$K0,![:4D,#$0(*Y;6=5;$'F78F4R30NT\?TDX\,>$RVCHOVI,8"AA3,.S$
MAG>'`N0[Q[0)^!UU1!Q1^.X0B&0?2;8'X0RR/!,,_5Z]K;)_7%W=9&0S,GRT
MM&0-5H(U*8$7!#N\$`&3RQR&-E>1KD$.5+=)$!>?CR-6UYC0XONY0>;WUQE8
M:5IUZ0GE_@<\BJ[7+OY?J234D7P7Y_\6@\-N+_X_T`T$/"#4GI(6`_?2)5D-
MV+5#4Z1#A:G%RQ"6ZP9R]SRA8M<@VV-T$@J19(!C12X=R#C7;J0T"#U'1I&B
MH!1"S$UD;_G$&47E9)(OK$298AZBG9)"4L^>J[@\Z71%0^AI*W\%9!>XYC*?
MPA$&B&]0Q0F3R#.Y`;>\!,`(=U+])E&W:*DR^H:708ES,5@;\6KT"FI5W)%H
M1I"I\+I)^2?W8M$$@Q#0@%GC4;+Y;FCV1VYHFYAZX`ENJGH5_PV=F8(5T12K
M!YQQ_R*P*<]=WAN,H_WJZF"3B$X2',8&!>4X.1@`23@^SU;@CA/&<58\1XCX
MX_>UIJ6@M+3YXG4"!])`HN^%0`-Q#FZ5K:/[U]+J:`?PP!F_?I>D\=QB:$@M
M<2]&`.HC9YAK$M"=SF1J1G/'^[509>`?J5$S&B05'$M%RGDZ48G)Z%<4ZXI2
MPT8<=YZL++Q^0;MY+YR0G'"DLNR!>FRF#EQ#YO*YDCS2,T7YT%$ND8F9708>
M8.&`*H06;]X&6Y&VX*YC1@`^>8PMNTGT(IFGJ>FWV[1-I$2D-!9RHB1YJ>F"
MD>N+&3F0>3H_%U)F3X)P\\&,(R^/SCU`I,5$DYDE.:Q-6QG"MN3U$K.:SZ3+
M-BZ]P=]]\77P'K3+F+3Y9OG1.G!0W-3H[Y(XDZT%#9.8S[>Q@L_8W.M9TM+$
M38=!_4WY#!_"?<8T@/V:QLJ6\U/6#@K9,?\A\-!.(8,NMOE^.(ZNUV%N)*>S
M4F6.J%1>>3!),\#S0G$E9I]B3B19O?(-4T5KU*G[&A[$HGF4:I`/B9]80@#^
M,)/Z!*D35WFC#L,!TD201I1!QHY,U8RBKRBLXO6OX^)G)4-&*7!_=.68^!\L
M-W#/;5S38V@'G)+00A]2D^^FT"-M[I/Q/0+>`HJS+1C>3*0QD:D+XL7"G-8Q
MWCR(<U<RE:`P-1]O(@#5]?$8'"`5":15=AN"B=[G-KI<TCP._9"(7*:QX+LP
MYH=W'Z\Q53U$(P/%/>50!WGU*/)LOL3OR8T_(508(E+W#"5C85IZGSL_%NF4
M=?8]32@W'AX7!M,;6&L`;^);9'T\CB4A)Y=N:33SYH3RF1LCD*J>'$C$`W%*
M*E!E/T`(&*X?J+QU$)"&%=T!X<#W'D=Y?8'2&1!,T0Z\&1OQHPD4(,#C@6V^
M3Q.4NFW[;ZRU%4D?FC4@;Q4(#<2,65$R1TT?W]TPC'`<RL\Q2.3[TA!C%Q-Y
MXJ.9B,QE6$"6-)'O#O&$%FD:B_Y8?N2G*HJ1Q\'`/U7PS2?@.TJQ->9HTC@4
M52`1!GX5GM?0Y,:(4X@9&"3U?C[-K4M":;+[.$9`\*&OWCO0C:[/[:^#3["S
MGS![Z8HPN1,):LNGP)9/LOW(2;CM%[3O3&Y\1@+D)[-^3DP'4,:6>/"!^F$8
MFX91G$@1MF0J+(@GB*GO98#`4R>8TMRQ/.!&S"\TZ`M3GNZ0V4'<RSV/`I,J
M$6K,IQ0TD0$+S$W".Q48H`DP;QI<OG$X5I$!4!PIXV#@AAXHJJB&D=(!,I+R
M<8!IU@)S&=6941+[DE(DD4B#D*[6A0"J'^6=D=88V"[@`Y#@*AF71$\0,9+#
M4>5X2;4C^F5&`:D%R\1*NO0F[\P+9A&85F8;?52:<@+,38FB5])OEDEN9*.A
M>Y[:E"CJ0Z=)9$E)8TW=8C'0G0H>T*,BW&'L2P*4G3(ZJ<]"O8X5M8TL2LNR
M=V#AW5.D[%$,K-1TFVM*]&K-U`"S&C*-7HEP907AW0$15-F'^`')7JD$89"/
M9F+]@TYPHJL$4N5F9Y7UMV"2OT),OHL>E34O2*%Z(OME'*;$^""&*/D]MVR9
MQ3E(@86/Q91JJIN6:B0Y*XY'7[JFL-/W+?#+:'2W[POO7EZ4DB^#L\"5_D:&
MQ(?_&YI#:6J@X9&UW><(;3&AI,D),?P'KN3K('8&/SJPF>$XL>6T+CP:74@<
M]4<DT=+'9_&>K^'T)WR)PM<4`Z)][JO[LE@PA3390Q)D5XGB('=]O!;$E0%;
M01T&$E%J!MIGJA`3.=13E6C%J.<-,$KZLD(DJB/&I<N:UH3+VZ5I\3*RP*P$
M-RD52DTG[*)L22E!9Q(&*@0P)!&"RT(O$$O84&(Q76ER(VFB)`:=G=$9A@1(
MF01(I120578"W=1.A0N4YP]:=';XT$F)!0F5U&^Y*\/+Y#BEC?KX]5XK;Q8D
MO6D/Y3,?638MQ<(JT20%6_EDTR<\56!UD"G$1^F*@-\=>3H)3+,/WHG-Y20"
MINX;CI0PBJXJXT4G@R(IZHVQX!A)(75*!RZ:833#/"G#-/(81GTE2PX`N3MS
M?$,G5&0(1WPG8]>8NY9HC^A@6+HO*38"!2LL&MT$K\\(T!;UR"&5?T7'[6-$
M>GP@E@6"3'-5%22741,2LYSD<Y;A*SF#)OR_:@9<?R0YXO6C^<Y510EK!2(W
M0QH[4\Z@/*E#Q8T7J&$1]RZFHTB@*O)D9"H/@B=8AZK"#'"#+7C<\G_`7R(P
MJN<2XXG1(7T*CPPF=?A!7CT%YR@)Q?/<OKJRW9]F/(;^E'X6*BDF+E<!\LY9
M$N8O([N7U71?O_]!F7:CW,*WF6^MS-G?LN:)\O?C$%LJ'I"<"^;9*G%.EZ,,
ME?_UF2P"D1P]\KX;!I'<R1Y(YC@ZRL<*?80PCC7$4FL6C+4E0+;=62$I[OCY
MOXS8WPG;N.C#89Y<9_*/B4>0K7WFR^HC6`PLQ:W*/<@)4_)4JJ4\N@.5:Y,0
MP<"W-1<Y3CQT3N)AG?-:NN20SD*]NKUF7;Q\EF0/+$H_P'"[#3]:`RL.D%H>
MR1M/@.D2QT)340<)/V:0H923P@96EDY)4I'[U,)2+E0F72V;(@50^GXZ=309
M5-5B4/(L1.-.S;]LKB2C(XJ'5M01XS2=L9'$<V".U$B+T";#,/!8TLMLU7X2
MUE:(U`7B-=-_LU3\K:7KVMC_N9%#OQ,B98TUM2+U`!9>V:(8+\.+4`JT7U_4
MY-^JTR?^'4\9M]E<T#CTLE;DQL\E:%%]@`;RC84-Y"E!#7??Q<UWH@/`&;DE
MRS^6IPVNBHDL%]$E)8_R0*H)>1[7SY]M%R74I%P$4J[GZ+;3I>7M0BZ:DC4E
MEYR2[_!._O'1\:N4;:^M_">`-,]2RN&<@D%='OR6!U)-"1K2)8I:D\))0JI)
MH6"6SJ+0?N$MV"1-/'T<LCQ]M)0[K?6KAE13@H94JU<-J2:%)[:T6'](T<1?
M7_R/80@Q&+Q8L:"CM+URZWS.%G38W!)3J7O%)84%>]PH,J19I';6HL9L#F7A
MR?'BF(U^S12:*8Z1*9X_TVQQ).;`RUU5??<8&;#>J]0;W4JG?=1)7)H/BT-Q
M._-A3B1)\V&1B7N!;TH9V=HS33S3N7LJVCDM!*3:#B^CU-%,H9E",X5FBJ=#
MZE$ZC.U*I]:I-%HMS1R%`+6LS'&47EPYF6,]U^T578+-6T^!+UYWJITYFNA-
MRGGU.K--N57%DO*D:Q4>S13Q=@QW+.[XS\<H>RLG8S#;-G5OTZT$0E_5CTP*
M!R=5I,8B&+EQTS75[D)V:J/Y`YR_RKX#66$E*LM7;U2PYJ;PJ*`R_[FL$D2J
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MO*J`2M('Z]KUM^G_D1DOW5?+H/$B@J..-E3W#8O`X&XN?-$3UK@?`E4F+5Z&
M'M5LRA3"GND?RV5W6S,THN(EWE+(%FS=&MN2[>LUQE^(&+[)1@^$Q\<0MK?8
M??;B+9'QC:R6MZ/03?KZS%=QE[U]94O@B63!!^Z945U0VB'9O*<_3<FMMWCK
M\>+6&+G4BDR^F2GM3=L33Q,UT)6==;,U=[@?9'OS)N+`I)8K2!$6P(2%<::I
M7Y$`O6!I'Y?TL%&3N%0G(MG4F!8Y5THXI2L\H1HX^DDOD;@:HD07*@>?J'CH
MH%B3'4RH\H[P4\V(HEX$JA,E+&(\L=VI$.EF`RB4E+1C6'$-*TC+YC>R>6AF
M;BJ.1`NYD'@U4L0;E_7/`A=O`(W@L]"6%`)R.:U&$/1L]VOB1$5(T=`(3:HQ
M@NL-A.IF$D\#NCIP/2I=F?PN%5X56VS=6V[HDU*(0<RL0@H=+&D$^B.NF4N*
M3E:0DSU:J,O3S`0QLF3%IRQY"]@V10K9;:IBIU;J4@2JI2\<,;!0N5#K!=!&
MD<12L**0`ER:ID70XNYQR[S`QA9\8@7<7MB%;BTQDY9,[[F'A?;\&^&1H'@,
MB13-R<X^N;Y_SF!NZE^+76:)@7:23HK0B5HL0TIURPYQ@T4T,6Q*1H2P=+-:
MHC\48XK#4LU6W]*0\3!G-L$_/QI)BDFH"H@"9BPSDG2.""*S3[T>MSY@@9N1
M,"`,J4N64F&R_CR2!X@";'OIA'1:-"<.W3#`UB<TY=(^9N]6XV6]E:Q:0K)3
MNZQE8H>^W$N\3Y-TJZBR6\LQ,GTDJ4*UZU"3+VE)4$,E(0VZ&;+`A5"[I;GE
MXS\DU_D8C-\LO4W<`$6`;`@S#Q0[<Z.*DS`5"`FR3<YAY63JJ+K"<4.H")9\
M.$#0&5$CYKXP>"@;JV#=.67%4YG*I&$ES&5%0%6Q@RU-DNF;)OO79K-A*YE5
M6;X?RL)7<B_B:LAI_4X6[R2$44`XLT:ET6Y5&HU>]$YZ\9DG>Y5VMU9I-IOQ
M3J^G=M=?37,/JVDV:Y5Z\W+E:NJ-2J=3J[2;[4V7DR_)5XCEM`3_(AY2O8%!
M-L)'66'/S^T4?"!W`6M+L`00EH5D-Y%NNA@Q`7=0&A.JC#.9#SBMVEQA9MM:
M9N8G9Y'X@V=;P<(,1A#9<E%'1]B\I%5:NBHD=>^C=NY8*#KISY3=[06;NNE.
MI7?Y-NS[8,VADW'_N%N;S,SDU#OM9881QK.-OW`+;>KV"!H*T*V:>P&GN^%P
ME-?X<^TFJ"1W%9E01?5D630+!MT,D+ZA)^(&E<N<][4V)+<7T*<DE/-917"^
M@KFFJIY2N^]M^^3IFHNZYF*A#ZUTJ;J=<:UK+A8!4DW(>R)D77&Q$(2LZ]3I
MBHLEAU13LJZXN#J-1=OXNOK+\>&W/)!J2M"0ZN(O&E)-"H6V=$I[MU)77-2<
MI"'5E*`AU>I50ZI)X9@K+CY_5C3K:T%E"UUSL8"0ZAO\910[FBDT4VBF."6F
M*&TH1E=</+5*;YH/BTAQNN+BJ?&AKKBXGE^J*RX6$U)MA9=1ZFBFT$RAF4(S
MQ=,A]2@=QG(6E=/,\?20GH`75T[F6,]UTQ47RUAQ<9/KW9D;_L9(F*$MO@Y4
MZ9X;+$]UA_O"J5B9?X?DL.W5\#QRF:6$3=#6Q`V47\@+,=%^T7?WW+,X4D[F
M6UGU)?ER$47A%ER,9AYVO<D(</&:\3!P\RZFY]-Q+DT!_;@/\5`YE%G*2^H+
M+CVI,=3])7FG:8N(SBRSSDO]>=60RYRSO+8YJG#4SY8M_`"VV-]6\F^#KOVO
M8VV=7IHK;04CE*CFX2F0R5K9WVN8.8],VB4&;U7N7(%`?6KP=DN8ZZ[GVY=+
MB9W5S]D`C$5G2.6>'?8%WGCGA4-V-9G8EB$KOIW]315-:M3>?'EW%?]5?W..
M9:@\,<3:<*XW97R"U0^YG6Q(7,P01I.EDN`)K'[[2"<=3TG_JR$M+>$4Y$BW
M8%CIM&H5<&0>)Q10`-&YUGGN<0K.QKFLR2ZK]AG"F@2RF/><+$QJ;'ZOWE;9
MAW=7<877!/E:.A82TA.06?5*&:76'@.86'S;&DR/,2@5/&I0JFB4O5'X=-/H
M9SIR>N-AL=9@>F/#[EXYYON_0HOZ,>A8J8Z5+I>:[9PTBD)'>)ZH].`1Q`$3
M_'ZR[K>/&B]6MR6AFW+51RL8$6UW?;'LE',DR]`,L!<&.$"=RT)3SB8E=?+L
MB:>&?_WR(`6%M-`ABIVK*Q0![/(@N#R0:E(HQ+GA,HE<VO#WU\$`>_B)*-"Q
M@4;>*)9:-NLD(:@FFPKN;>'E'6$<O[1DKD\Y<T\,.I5ZIU>JXX+'N`R@>5#S
MX./Q8*MRV2W7D=W!$PVVCJ67EC<^"1\/1@PC'(=T:,5,[.QL6)2WM1>CK-"1
MD51,[1@A/]PQRM/KK94R^E'/DDHF_<\:E5[[`#?.CE!:/G^6PMOY`=RQHHN9
M#;=>RQPM<_)E3KW2:A_`XCQ"F;.-Q-E_D'$18B^/`K%1SA6U1(_CD!5X<8O<
MV95EZ]=!Y=/+MVU9K:3+V%A*7RZ4TJ8;]FUQ!&QQB&C)X^*[9&JQ?EEI/&9*
M3DEY]4B6H46.%CE/CO!ZL])K/*(E7@A>W:DLS1'ESNLK'6M?Z5A]+2.__$W2
MP>VC`R@)J7K#/J]RX`(.4R7IYV):R]G\G<H=%>HVQ:XQN4U!WF<AMY+!7IK$
MY8(5BOON6$]7`T;3MZ;O`],WUI]C5(#N%(A\7X6."L28!0>OR$T"RX7)@H.G
M-WH[*;3QH5&G?82--MYR\/8,43GEUAJ%AO0$:D+7*[UVM])N'."B8E'WL="@
M[C]'NF`$5Y`<Z8)AI9REV0^>)KU,[9>'5S6D!U"Y3P]J>9"J(=6$6F"D:M=P
M#G%4S&T`'B$5Y+15FXPI,VSN^]8@JG8<N)1/./?#\5D1983T!.S6L\MVI=8X
MH-5:6@[>XO[&HU+V\V>:"X^&"^O-7J5UB%M6I\.&Z[JIQ?9,"\V090"NF(9\
M&3"G@=,T5U9_<<\7^PJF`Z]'W!D*^(H-,/'E?I?$ESU>+BZF^_BXEXL+:A(7
MZG)QP;CI`'W72\(Z^Z\OH$5`,?92BX#-DB8:X&W7*[5.?0-94%*VT<>W&E)]
M*J8A/3)(-:&6T!W?LAQ,P:R'..WW,_>,493S6X2Z#,6D[T>X8/_T2"A9F8&"
ML52]TFN`3=[KGBP3;>V;%VP=!1`&95(L,Z?XQU_?Y.E1GA4\O4J]T:UTVIM$
M`@HN>=8S]3:O;()C'J:41+"XE,1:]))3;V*VF,A.]2<.O4EK]XM=7BX$2XSP
MP!F_QOO1=#TZ_<:_N0?;$/A?G;?<M_RO`WR"L@T_NZ:PLRUG=>41Q>T%KCQ2
M`*5?>(B.K/!!['%NH*T<]\'CDU]?R/\NU%*T=OKI-<.U%<*HU/3UN/25OLA\
M"B2V36F-0I_V+"XJ4S)P=0V<%0C>,.2X+8NRDM%-R<#59+Z:S#<I;7!<9%[2
MRD^%AZA@97]*:SX5GQ27&G*:"@IZ?ES&2/ZLG_Y#!#)3F[D#H+3QV'5@#@RM
MP8>QX'[H"0S?,9,'@IW5-[EO6-Q<@K7RY!Z3A'-.5#;L1IB&ENCKL)F)U<N<
M:X"+$%Q:F:&)^(B)N%7MYK1L/CH:/E1F;6FUWI7YW]#'SK#BI_`,RQ=LXEG&
M)E>5M$PX5IG0J_:T7BLR<)J&5\>BJI<Y"6I'1\,9O?;\F?;H<-1OEO^##3R!
MUW`#X0D_8!XY;@WMN!4"[*((B7JUV2BUD/A%ZS=-PXW.\=+P5G[;L>DSE0W(
M;.L>WK<<-A7<VZ1G4/%X_[A3<VK5UL9[5$#./.Y#1$U?Y:`O?60UA[CW/R?"
MP.#=O6OS0%:K/6MJYZ808!?%,,PKF'$L9J&FX).@X)QLLF.A8'T@M4BGP0HL
M`--D4TO8)CN[U'JM$&`712KDU(0KD5#01U-/#[:F9.V]/:&FN_'<?M1CQ!U$
MB8:#@?`L9XCA/>Y,V03^<DWFW@N/*6>?G;6T*BP$V%J`%(18"@W<(^%TV^8B
M!:/EO,8V)2)F[>QME*%!1=)!^8&:P^`[EW^)GY8?H!+T1]R#@4DI@DMXUM:*
MKQ!@%T58:,579.#*@-.B4'+S]-3>*?M^7R,WC[+MF4=Z\*RCU=M!P"Y9SO(I
M7,31!*P)N-0$O&E91KQF90VFNC+C(^_8DQ;)/*&JAXJGT\9:X$Z65&_9SD9[
M<KY/EMI\K*4BW>YY[$<T=;<JD]"KSR!W#8E:>$S<C03.O[C*!`]8`,_POGLO
MYNI-^,SR69_[PL1J%/C<M3N><&<JZ;;;J'?>^`PDDIGX%7^%;I`\__7NFLDJ
M%SY`[+%TY4!LA]!DW(D?_O*?V_?L\^]W]&2V:T)UW?W4.K*0.E)KRR?7E@JQ
MV4+PL[I3J[JRJ;IM+I8>K:KS+/_'1<[UVP?N,U/`-V-XW&3]*4#J\*'4=*&/
MV@L5T)U'"G#*WEJVS3B>`M'W,!!F"%HY*E(KIG(KIE7J:`?L/W^F=9#60:>@
M@YKG&YMZIZ.7W@J#A[Y(NT_,='$H-V`C#CJ%F^*O$-54Y$F-+'#.0`T%;J*U
MF`4NE/S!,D#^1,\F][`J-$7J7M:`&_`T*3_0A-:8!TMT7VKH>`B+$B'089QP
MCT0'?70L>1<87_/Y&)6M";L"`*,SYXFAY3K[UXM/J0>UBM-.EE9PIZO@+K6"
M6XR=SXDZ2?E8J!QF[E.!.NL+5OM%A13#B>N05A-T_XIZ3,%K/(`O`6'@@:&&
MG/!I/(Z,(>+(\%_A"T'</@@#\,BT(Z:UE-926DN=L)9J:2VUF9;R29=,LI>B
MI#J9O1L%6DEP8\3$?=0.48?_M-;16D=KG5/7.FVM==;2.E$(SI<^#ITKS=]%
M\I==1K(<J81F=!/Y2GV1(!]<+(S$-5N_1"=8T4!AX`?PD])HV1P+>F<N0:.2
M.OVRIUK?:7VG]9W6=R>L[SI%TG?/GQ4-/]_$!$-S3B"=J^3@R<V[?P0:3?E;
MT<\^6Y*K<3#U\TCI9FOKGDZU,[>1O9)JG\R691E&;<;?7_'`&;_^P"WO#\Q2
M_3IX![1PS]'F4!6(_:_.6^Y;_M?!'Y$#_MDUA7V'FWL'BWJ+B__M^;._TU"?
M+1LH#[;@AD^1</SXB\\B&+EF]C783`<1\TT,?GUQ+3__V?S\_L\_F_4+,)(N
MT#QZ\=LRFIDEATUPU\1=E%_@8,FFT7?WW+,XDD_FVP<A"27Z<A%9X3Y<C&8>
M=KW)"`CU->-AX.:IZ'QBSB4L("+W(1XJASQ+IJZW;^:]_LW068Z=E]?S0CV7
M0V<9;G-4D9,2\<8F17UW1M?^U[&VQ5.:+LL%(Y1(F)X"F>RKJ?(CDW:)P5O5
M:+=`H#XU>+N5-^AV]U'>H&"RZ:Q^#@:*<.(<.\NQ`HOB;9S=C+@OV$=V#1-0
MBML=V%0V!L<X6$@@AC$?8>*Y9F@$FPNWK(>_YN7RIZ3FU9"6E@QRKJUOMGTY
M%]ISD*+>*0M6.JU:!=R2;?5V<2E[E_)FQRD&&ZO%H):#A:=K+9V.6#J=M)G6
M7$,^:0%5>-(^*0%5K[1JIR6B3MB`NCQG;RW`PI#DSR<I=-C59`+R1R;^#2Q;
MIET$(_:]>EME']Y=:6%4"$A/0AAI>^F$Q%'KG'VP/#^@LCW",]`<\KDMM,`I
M!*0G(7#*8OT\?Z;MGYT%3ON<\4$@U#T[$CTOZ[3_^`]F[#@B(!&TQ3F@ED%:
M!AVW#$KOXWIR9VF"6@X]9).F-LMTP@2IT+\8<CYY?6N,A!G:XNO@%K/#W^*E
M7(S*@+]#?LXM9IE_G>!'_PKSOZU@ND7>U)]7#]PS[Z83<?73\O]\/Y[8[E2(
MU.B?*>-<YU>=;GY5<61I&<'3B1,G`I[>Z",";XV]+7&JX+]))0IS6WNM>/M5
M8O"TW-@N'E`2F,L-GB;.$P%/;_01@7?<ULO5O?#X<(LSEJ)N5XG!TV)#&R^%
M!4\3YQ&!=]PZ37ODFISVB(9O8LPMQW*&FIXT/>W#Y!X./3'DP;$8W=H6TSRP
M*1J^A%1ZS1T<"0\4'[P9B)X_.S**TH$,+9_VAP9,\?&X$83<UA2E*6H/:/@(
M!&4YOF4<"3UM8_45N@Q.R6'7E9ZV0_!WQSJ-,D\EAUW3]W8(?O\3KU+Y@MU@
M,5)-Z(6'71/Z=@B^$]Z8G5D.FPKN^9OTBBXSM909=DWIVR&8*@>?`GWKR+(^
MY2\K)@L.GM[H$P%/;_2)@*<W>CN[8N/J*ZW&$19#^)KTRZK,M\;:W-C4Y0]T
M^8-M4%*O]+JM2K-[N:U_4[Y]+"2HSY^=3"'M!"6ZI'8>?IK5QA8*0'.C5E7'
MS1?=:E-KJ6*`JG74B?-BJ]*K=2OM7OOX&'*7NGU'Z:HF:/OH^^'VUWR*N^5E
MA/0$A$RC1\7YEF%&4YZ&]*1Y)$%)I]K=1!N78?_*0VGE@?0$>**N58:&]-#L
M\?2@%AVI^S_U6RMYZ@C\K"B'>!-7:S$=%#KE;"W(]Y^A6(!EKRMP#H^$\FKZ
MLWJ]TFZU-DD^/F8^*2_DFL,UA^<BNU;M=$O'W5MTBRD,[/N%O`#`;<J%ZQJ7
M)6.DB])QD>8AS4.:AXKAM&]]^KEHL9='X;)GLG@_<\\812F\6V2JK,S_6`N7
M3R\E5L6EMC9W+Q>:NZ8;]FU1)"0<SNA?'POE%;2-2J/=JC0:O?V'[TO"1%H8
M'((-RJ5=#IN$I@70TASL0]R(*`G/GHKL*0ZD6SM6B\SHDK';85*[2T*FI\9N
M6A^?(HO7>Y56_;+2;#=.C-'7[<<<P79$_8B#1^U'+.<BRGC-_AOZ@368%HX-
MLI2RH/WV_OIH/WU7[G]S#W8_T)VX=2?N8ADJY0)/5QLY$?#T1A\1>,==8EWW
M_2H0>%IN;..1:>M%$V>I,%EP\/1&'Q%XQVV]Z`96Q0%/BPUMO!06/$V<1P3>
M<>LT[9%K<MHC&G0G;DU/>S6Y=2?N)X>Y^.`=-P_H3MQ/3$^Z$W?1-ZS@X!VW
M?-*=N#5%[1<-NA-WP>_\EASV1ZNF<F1\J3MQEP-V3=_;(5AWXBX9[)K0MT.P
M[L1=-M@UI6^'X#]T)^[B^D7E!D^?\I\(>'JC3P0\O=$G`I[>Z.WL"MV)&T?=
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MH+[%[X2!?8N;+UCH6/*A[[?O7C!3&-:8VSXVN_VMW:EU&JU6`G?N3/L"Y<\/
MW/*HULW;:?SQGY;P,/`R_23NA4V]E>/?/CJ3,/#IA[KJM#RSFI^^]=JQ;.`K
M+Q0O7A4!TD9I(&WF0_H$%!(UV5X*2KU7;W0[[?HCP5)\:MT'I(]#K?N`=!UJ
MW8!$3&&]?N\$('<_.H;K35R/!/,['H#0SGRU5GMXG+O7N:C7+FKMO[]:?_`T
M9M__%<(;GT4P<LV/SKWP@S&8"5\?'.'Y(VMR(SPL;,:'8AFV&]U(-C3^_"2&
MW)9P$%I1TSA6.)[#Y"3T1!J5#5A.M59+T+@V:/M?3^OB5DRDK-MZ/;`]M6JO
MV=EV13QPQJ]!?X^5YO[H^R%JZX\.0.M;II";^<'UY+`?L?X<#'EEP)^^M9"*
MKD,?[!]<8[QG^]H_6&_O[Z_V`'AZ1V\\=R*\8'IC<R>X<DQ\:8)X>^^#*0;4
M;7[WQ2"T/P&_Y<N$6;[Y<^&0;Z=WTXF@=7_FQ@BL/V^:_ETAX;>[D2>$K!&9
M[.Y&@,8[3+::__ZG,>+.4'Q#U!Q\V_STOC5QWYK-IMJX''BVA;563]AH:Y;:
M`M9H0ZY@"M.R0Y3$M\((/1+$\+@=FL+\`.8[FL=A0.3X=?">>]B@R0<VI(&O
MQFX(7L$:%-7\<\>IWD[S!R#T1":[8_Z;>W@%TY]#E$^(2&/JXY</+WYK-)L`
MW&5"HGO!R!.A^!8&$<A.US;W?7!R4+80@E*R9EW,U!N=3JW=;!\#:BZ+2GV-
M=JO1Z!T'BO=*?;UVMT92;.^8F=6]4D+NW=99L*YFKP/#=.9-``E&#&`DL4TT
M"9X(UGJST:BAD[D2HACL;\)&+7[#0<E_MFPP65Q'^#=\BG2Q'AFEA[@#;O*Y
M0>SU=IK^11H@8NQZ%K=O;9<[OXL`C"38\VON&,*[IF+#<JE_?G*=(=:MO@G!
MH>&^P`58@31GKF',H>M-P0,`\HV>,&F"+^+AG1<.KR83VS*(LM;P=CJM6@V-
M]-4(.5:T?1.&L";!U\$W,0QA<G@,4.BY]]Q&1OU^^\'DZ[B-6V!2-CS[.KB!
MW8+O\WDE,;ZNPF%L*,:?-T#E=P?$D0<6.>#A3OSD_N=WH`;@&]?)P>?5$&QB
M!%=*11NXT>#V'>Y%_-.\A:=6,J\\+A5F9M<<(T,*O1MNF=\1J'B.C\Y_P"Z_
M>W#O1F[H<[##;7#EE_M"-2"U*>*G_F>]=_&OT)&?-\!5EMP^.F#R!R%ZWA)3
MWX0O,-Z0BZM/%KA]OGB'$0>7/`9`,Y(C7@#CMO5_Q)R+D3A/7&G2VA!/F^/W
M[D'8]_G^]+'BMU';!L$245L@>&1Y@3@Q$FYL1<,1JF(D?WT`L4UOKT7]=^X'
M-UR)[%HSL4-JE\GGTB*[6V_58V1OC;(8Z9^Y!?AR<"4?A$#?(5J/TFA+-=?1
MD7*:DE>C9E<L?OC/^^QI33GQ=M&:$;.'Q]PN9F>!,`<4MP7.;FQN2)"&\*];
MX=T#5#Z^M::#'/9]\&&Y-[WE=`8=.\C9D=?9]\OTOB\&+(8]BDQ@I%F8=V[:
MI%>NW`I3^5_<D<MHICYOX//_B7'CKX,KA&.8VEG06#9_H.U4#VZ-IWD_%H]*
MN[U.6R%J#2SLC+'];7LQEW-G!38=EYG6O66&7!X-RK,:UUMO$?5FI]=J;+&*
MU'=1\0?JMP92YJM'Q&C2`644]EGW`'07UOQS@C2+L\VL,N>@9RV@<\S?._<]
M1XE$#M[2^$\G6M1&?NS:(8&M7-AYZ=NLU[NM.<LUL\I=L$`VD;TQ%CYXPOQG
M&."I5NS`1]K@,%AHMMN'PT)Q8QH+#,!Y7V9_N&A'/LA&N/B7.W+\?[J3'T`1
M"5[V3`7=5JU^P)77+[ZX]SM1P8UP'']JWW/'XOOF@$[G@&M'4T7*@8UL_"?A
M@.9EL]L\*"JV,=H?6R36VP<5`UMBX4!B(">=2Q[:!S#S]PD8\!]<+S/@L8C[
M9K-W&6F^Q:O=%2'%E?F-1O>R<_#U%UGRIQG]8!A(8CR%MH8[O7:C^7BXV$@7
M/KH"Z'4N>QOCXET([J)/N@"S.<LD)G_#';FH-RZ:]>RR9]84+_F=\`W/FL@\
M!SIJO<?<01^X->.K`LZB4-#2T$XW\95JG00W&[K$O\7?,HY?LP?+MIE'X`EV
MQL\99P;W1VP@!!-_A4"L@<OJM5^8.V#!2+"AY_H^FWBN(83I,X]C84=F.?0C
M0L2D'\UDK.+K8$!<66%G?1S;<9T+;AAH$2`VF/B)MSH$0&"-^Z'G2]#BB1N[
MS\L=DYT9YS,SP*@OZ[5:!:0;&[@>LS$)(X+&AW&-T`.68OTI33#)8JVJ2&"+
M/3X8?:3D1JV7?-Z4/F*Z9\0H$L<X$AMQG_G6V+*YQ^"7L<_@BQC[/'JO@LBS
M0[RAM!4M5?9/)4@"#RI\A<]/5.B*R:A7]#)F)G%G^K]^AI3VOM=1("TUQMMI
MPI:/(`/NYBF:`0]8@!U3^-;0P5CYB(-``''O1M)A!QPB#7'XOTQ3RR.%9!1#
MON?+]RC8B(0V`6$;/8QZR<=*>VL(`-K\[`Q9R%1.-PLG\)U0@;]HIK?)FB55
M2W[P0V,DH<BECN4[O'>JV!/G__NI=A=)3^W"#MB\@>UVS:^#*':;O/@8+/5O
M*P#3B[49K"X8Q0@;6`Z:>[;K(RFJ+XE8,XB(B#4Z*%JXE&U7N^MIQV^MZ([`
M!@"J*R`PN&M;AB5S/L%*?(3]6'&YH]9*%K((RAE46X:T;S]8>`B)!J)Y;_DN
MP/-XQMO*+)/,]JR$>*\KW(\0.M0*,P+ERC3I;@ZW$Y&2DB@$SV.IX=ALDJH6
MLR\MT,$@)WC`SJQS9F4D+X+EAV.\@P/F%_P]%MY0>&`S)5>.*JP?@K@1/F[8
MN`^XH1M4(&5=&`ELM\2#8F?JJQ&7>E2>QD4YQ.?@'00CF@?5[Q0$?>"Y9FB`
MT`8!;P4+S.-*WI?LP0U!84>N!E]H%?(AX&2HW,/DEE6L=U/P^\J\MPA1%0(7
ME1&;$'W@B"!JE4CF@T!(RS5&B9I040WS(T(WB5SZ:'GTW7M1R6R!!T!;J,XX
MB7<@/!3M7FP;Q\.E$9V+$'2]R,S"7ZE``:("WH@LZT3?#B(2CX:GA5OQU3O6
MY\X/6%Z$I`QD:4!`'H*J=>1,L.*`]L%7-^[E%ZX'NZXL*Z!NH'K6J4BU)9PA
M'T:+4*2;:P.MPV1YY\71L?+;Z3_!OH,%Q+KE405L_GEXHU6OU5OSY\6+@4Y?
M\OB*O!8%9:X<,Y4F\UXY.&O='SI`B&QYK*?1Z[92ES]7KV/_JSY(YOSR57=[
M+;P!LMVJK[S`\@/01S@II2NY4VX'TW^$G'H/"C_)TM]_#M?:"/@M794CKAYB
M_9]`0PF_I,1))99C!S\M#8%10(I-^!0%RN?;WZ^OF8L2F)QW;WK1GUZHCR"B
M?`NEIB=1@>)7>NX."!T?^)/,9AS.EGED)NI#4#>`(1C!LFEB7"JHLL%K=E8_
M![TA#5,V\-RQ,KD]/R#S6B:=T<@5%(-G#5!H(Z&$,0R#J!<_)R#,JVQAN9;4
MW:9-]C1###*4@;<@4`RFMLN"=S#01(ER7UP9=5IY-K9-@'@O/-&5^2!;K^N0
M2"F,H-@)*PNO7D<WK@?KB<L7O]TT_[/&C>YDV+6@^`?%U]:CSN5(:UUV:VO`
M1Q/N#;3U*J5TZIW>-J#!QH?CD';[G9B`H6O)NA5B8@O*>W4P&QW(0*;!+AQX
M/_AMUS(DN1?(GF"U:VU9H]=N'7:UZ8'6LM)6937G#;S+A"MH^K+66CWG%S<0
MD=A:KTI*<^8([<838RL<2X=<;'2@V.IT&RD8T[!L`V-:3188QN3F^YY@[%U>
M=NNK07PG^@'F]GLACAN%4U0N_0UH0<.:+#BH7I%KOC]D]WH9FET'X#TM<;XN
MP9X6U6XV+R]W6E0H[MRO@P$8R)Z/:<G@?8[`YX2_=K&9#K5IFT&;"M=%=:>B
MN/)W.O+96#$NNC+?:W>37(X%L^T(38Y<7@A-H]'J==>$ADS:@?#PBG94E6M*
M]SJL@;K]?N?*>D39;S?5(@N@O;ALUQI1#&1K8/)KHL65R[X.DB^_B+U81$MJ
M\2V:=J]`[ERE;QF4,B!%0=N/3NZ#&QT/K0@'M=KU6IP/O-:LJ0MMW@\1J.=2
M$;2OSF?!_=`C0;,J-VCAEN??\6B\8);YZXL/KALXH`XOZG_67_S6JG:C_*6U
M8=K[*O+QO>XJL,Y<HWK9VF89$7G%NW;E^^%85LC)W'[9ZS[\!N!V$]I>.?D^
M(=T,U[_UJFE%MC.DWRS_QP?0HU&)N&^+B&/VTNO2NGQ9BF@@7=>JM7JCLQSR
M/&#VMH!2747,+758J[<OGQ"!2X3Q:@J0Q]OU9F/_"\`HMP$^-9::68]T?[MI
M?U[%0\F8.\]?`LK[[:;UGT?$2$Y4\%%W9-Z/>N">&5>F?#^>V.Y4B%0][QA/
M[0/@Z0_7!JL$3=1]B-]9A=R4XK?37`_P+#![7$()V&!%>DYWI8UP8!1N((+G
MJ8"6T*D7;`EKL]X*Y=CM=-J'7-H[O*XN''-[#LU>U\KNSB7PZ*N]@5)^3DM7
MJ5X7%7M#WTHN6[Z3C3WNY`&X9;_XE:7<;SRWKX(LZ&4/>&CGAQUV4&,MJ<8:
M>=[/8BCV`?1.]-"*Z$%6(40VPGMQ27KG>]C(P'*&LA0F9=P*<W/O=A7ZVA)]
MS<@K7Q>2?8.^%1+;&23F$&R4J+SOT$!M!I`.8C&*SZR"8U\`;Q(AF`>XL1G`
M\U+!_&^HRNAOF,N=A-O>3K_P`':9A)8:9)VH?;/7:N=&.W)@FJOA*:E2_1P%
M10X"^8*(=#H@O12H&/3%%5,/7];UJH]]F]Y:E'G+)R(,+,._=KW)CM5<;_#C
MK0!PS<Q%QJ\#597+O)')5)O6QMT`6<>/8"S+N#M^ZYDZ*AK!$L$PHNT.$;$*
MHYL5=*YKJLU!Z@=,ATQ*\*'3H`ET2UQ>X0T"0N@7$2`FYSL(:%1N($PE;6IE
MM02_LXD9A)1L?<T;RF2.1.8F]2QVP5QD*W[#RKFA^`:&Q]"A&Q_QX[(]5/:!
M_UO@N*1"*;)*;N//>BOY?/A*&!'^'/-V`@.[,$J<[+]VI=<VL'M-L?OV"#H`
M>HLH`A9)TX/2O-J>G?='WD*4[!`+K45W6\LJ()JUM.K*6>V"8A;R6H1Z_LY-
MKVGO^#D\N_^FUH.77.1UG9R+*W27KR^8&0J\"//AG]??KO,K1RQ!3@'0>6AR
M^RWWWI"<E<U,RW#>36X3U7>_3M2HJIONT771K6\4;;WYZJ&O@T@LKFCU6.3M
M7A$>KT?%A9>L.8GNS7LR,F.V=%CY[:;>^`\>Q"]?5Z)GE-X$`N*FY2+@]^(S
M$NZB8F*[K/XK__'-,H?B"Y?W=S_Q/K9;!2V^SB7]9C/IO[`4[H*N[D^)>WHV
MU2'B*NG(L4[=]V9&<1X5&J(>&9N7OU\/#9[[7V$DG4:QMMI2CZ&3NOG=WJIF
MW!5(Y_M;%YO6P0-KM7/(]'/(`WG[]=0OOAJ!7$.CD7PN\7I4#Y3FG_5V\KFL
MZVFTD@/^1F?1M9?/W`D'L*(0SWPVJCC:K3=[[?U"OI,JW`SW:0?XD"O8%[9K
MG<Z:L+YS'YS8`\I[\I!6VO)-F#6MFM*TBH[$-H`\;[4?7$^]M%;]GUHG.?N%
MSP<C-;(U>LGFY4*\PWJ>0JW4>VG6V=>*9G)!#KB&S?8D$_A%.H1GXOZ3KO?!
M=='<H,:>YA@>]0-O\3VFJ*-$06.&?U)6AQ)6/ZUQ3G?7/#76S)P=;(NPD\<X
M+&5-C->;C;UB_$,(?D/&S<]VHJ/B9>#^@8F-+>G*B.@U#K\B1W<S9*R-1`HD
MJXY^1X?!QB883&,BR=-Q'1@;WL0[X%$_-W+Z5M5B+$7CW;QB!ZT88TL7OSN*
M#NP-M-J-3F^SI=R,N#?FQG3UWL9-%XK<@"')[$HM+-5:1#BFO"OO&L+'(JO'
ML>Y6JKM*WA)3E!M@BS(*UH#\O$NJ&WX=)*6\M_"IOJ%',%\%_VZ$0?=XX*B:
M(L;:'086\Y2UJ5+@995]GZBZAQ00SU1<Q-<JV:IBC(>P/_`4H,O&(HN.>/!E
M\)_J-UX$[@5]B`+_CIFNQ!B`Z)<_.X01FBE!1C7FH370E3Y__22X+]['"\#K
ML_5U968S]7DMY"+>+FI-:C&P#("=`&Q$,9C+/^NISWBO`-`)T+R_Q[.)*/5]
MYOL4J.V+6N^B65L-JJ3C:+'?<&>YG3H7V2MY/CI)+5G83+DD+Z2TE@%RL1+;
MCU7][5&;Q6RQY"Q%#^6#*_@L;II3A@8Z<XM+KYB2E=]B8@2>CH+5*-OD)I>!
MWDZ31Y1#31=4Y%44_VL8^`%0+^@&F?^\'@75MKCE$J5@Y_3$>N+5U'=8S4Q"
M>:/3[+92)>#VOJ("HFO#G/M6LWW9:G6.&T>-/9)4LPDB^_*T\+4A3=4;G4ZM
MW6P?-Y*:^R.J>J_;:G:/G*AF\;4A4?7:G6:C5SM2'.UP7W61H&JT6XW&L2J_
M!?C:F*:ZM6:S61(<_4.V;7>DU[NX3.[LG>$%+>0CVO+?@9]D!*[GT_5TQP_M
M`"=:KY1^L]YHU?;(E3F+?`H<[N$>^2*^[-5/$&$;,F:SUNXUNL>/)"Q5_(6/
M%5%1><6/#I[A@T>+OZUM0'3!"]RC_5!4?.5+LD1HK=G^8^;FP*&QA4+B([5(
M>T<G!_(Y>;,Y)4'B0G1K)L+NS_RLM]/U-#>']_%7NZ$\:?1ZW>[^EK@_*^'?
M`KL%"?/J7GA\*+:HV+A-\&>F&L+CQ(!V7^HVD:%EI2'KU0/9Q\N66AKL+BD[
ML1"CM6JKKC&Z2]AI.79[AXFI'`5VMZ/7WF%"GZ7$Z#81K678;58;A_&MCP*[
MV]!KO5K3$F`G$W@YO1XH!GL4V-V.7O?IQ1\"H_Y&OMW&6-V#T[8,OYUJ=Q-Y
ML+_%E@C'V]!M)U.Z]D3Q&F5HM"ZN)@JSS5KR>4$F_(8)2&O*D7JFBK_>D+P-
MV0CQZZ75+]N0SA%(GFCDP@KX6K6S3T&TT7K+A>DMS>E-#+X3QNY".MY1CK2J
MK7W*]5/?@<57TA;N0+=:WR0(>M@=Z*]V#OH;.P??Q)@#:3I#Q+2'US>XC0GC
MC?5.S]=O==']S^7GQKL99#[NDDJ(T:S@_NWF\C_UVN=&7>-Q;Z:&ILSM,#I/
MF=W/]?;3HY&N*]#`%VM$4RZ6VMQB5D`OFGG?)%FO_4==O'CLE90*A;,TV/Y/
MYW.]\^X)47>`:-Y'F,1R?,N@8O4'/?=^K-/N;9:TY?EVF9:TQ$N;32QLM.O-
M]F%.Y[(K*1"ZMCPQGNV0VVUU]YG?5$;,K4]H[7K]LM,^S#%%8=&UY5'O[.WF
M7JW;/E!.0FE0MSZE77::O7:S=BHR;;>0Z%Q#[5;]LMENG#;NUJ>U>JW3:'<[
MW4VB:T5`V%S\Z,X-N+T&[K;NX;<F3K&J4'O/B</K++;<R'V*!HEY!;A.=>/V
M<SRUU,.@>B;"]#]X[AA3JK$<T(K.9UN3TPVU&1,Q`:Q5PK<YL_G+`4X*\&2H
M[)K[HS5J&1QX/>@7]5JI2I>Y,"Y8PE40N)XCIH58QF5MT2K28*Y]L>"+>*"?
M]KRP.?&UZFI)JU7OUFMK7C2(@=[S,GL7'T1?U;+J;ID?L'*AM=U6F8AT.@F"
M%^CI%6;1CENV[!RLG>GQN@B^QUG#-F?9O<WAWU8I11?5?%`&=";X%>OKWXVX
MDYO-\3CF6BZ5UIN=7FL?/L.&2TZC^9WH!\F+Z\>!UT6!"J4OGBX-C!I+C?#5
M^X9AW\R9;*()U:_YLF8WGGP<*Y!X1:UF*;=L@Y4#8W5)#]O\%64S*;9=D6SB
M(89Q!=1X4U?5^8H**=82"FY<)LOX[6]V\,:T[O\V#-Y0[;GT)"R>A8;FEB-,
M*MLU\5P?&VN'8/J^9F?6.>-8XTND?F`/(\L8P7M8`XI*T;FJ16^%6<JZHXI@
MV.R%]:?T2-2\QAVP<(*-:UZ"AU"IR7_P6XLV"*F6^4AQ%9A1P+#8KUE]\1!9
MN##X*]>C??+?T%1G%D$J>]<D9<Q20!.X`.,Z`(=^`B=G8YGC`</"N$-`6_PZ
MC*^JF[WLM)8M!B;E`0PTQ49'%JEM.:%KF[`,4W@YP)\AI'_CX\F;_^DV&K4W
MU-V%Q16TXE_J;\[9@Q6,V.=/?\CG\1_`>)5]^G3-SE)#P!.9UTRLZ\4^8V55
MUKA4Y0?E$_5V[0U2T"M%0E&[F164&I.TRHQ9W45Z!1FO[E\86[5Y4RXP'S*]
MA5+5SG9GM(34J;$5MFG"?;%@:'`6*D!5JK8C$1O02H9.)J&']!@@Y>%#,WM>
M`:IA?(Q]G!@8D-S&YYK5VB]1><@AW>R>*'^+#<#A6CA9:J/O7"(%!OAD4JVS
M$;\'7A#"21-I#D@QZ56SU+(!TO=B(M'E?=>T!JKM;6HR[$`#6ODQ:G?\]E65
MZ<1H081*P#O\)P!R#!)AUFA44MB^A]]9G?IG)9LV1&E'&U-A]<M>I=[N9':'
MTVLDAZ39!Q-=1CVX0+K46U(@I>?@<D!\E(:O,B19+SI]S@`J7QO*\VJ&=C;,
M,W"],0E,2K&@>6A@%*\LL,;8ONLQ-C,ICVF:U'N0VU$'\V_Q&HCLU('[6C;@
MRN(KC58=CT@WFCE-WW'\1WCW()[R,?3%=1"GPB1D^!1Z2O^.]=2_N,%_1+"B
M>>4JZV;6Q6SV>IVT,WTP:(N$DB5F],Q^KG,*T.S5F_7N(Z/PRK9=`W5Y_O#O
M?^+'M>*5S;UB(UW2="T0'W]1ZQ_P/-5B9C744B![EXU:0;"^7-8TNO7+]%V`
M)X5TOR+@LEYKI6^S%75IZY-^J]MK[K17N^9M*D<:Z_>OF3B77\I[U_3))US/
M/M'YAU0VCHE;A;1]Y^)7!<#RY1Z1O+]5[A_W4=SR`[<\.DS<,R:7]^KIY)W.
M'F!-22.:Z*LKWP_'$0_(77EG^=29^!OZ)8]\4VJV`=PE7@"LU5%Z;P1W<1:Z
MX$)2_D(;M<ZV"XUBF7&]KK=3]=4_71O[U!Q*.^7Z95&YL?5`6WV8GHJ?[[J.
M%<=C<UW@.K7>JI/SU)"[+^5`9Y@Y:9]KY`0L6-G2X\X9"XUXIJBU6K=:QX$P
M\7BU,0N]Z@-5N"S2FO=9QF"--(4#X.&;F*@>V#G#//F:Y[(45X*\%X,R:1BT
MP['_1B4L8BTGI0/"ZSIX.)][2M[:ART_N\C'Q]Q>*&A?_N-*=&P3;J=__2'/
M$N2PRQMA[0DC<[[>GF"?:1Z%IJL/KZ##!TI<]5;Z9/&^95N!%;=56O,RPO)<
MP4ZWE\X*V&#ZPT"]5BRN76\U.HV=H;X5!@BZ8/I.3%S?6@K9]OW3EF*_E17#
M67@`5`#V_[FX8!]<-W!<<,+@"3KUO;C`==B6\^/U0/WV"?Y@/^FK`"#Z]05`
M+QQ3F"_4MYYKP[>C()B\?O7JX>&A^K/OV577&[YJU&K-5_CS*WSP13RT[1J9
M$2F(YGK1@",/5_4_$7`7]3_KT4\V[PL;7N#]/S,_OYH#^\K+SL$](QH$/JZ`
M63WQ"CMN7D0COF"N!T[3KR_JU5HT5.#^^B(!)/H6#RZ7`KDQ`AK+$=`H`P(:
MVR.@L9P"&D6A@,82!#1VH8#&<@IH%(4"EB-@!PIH+J>`9E$HH+D$`<U=**"Y
MG`*:1:&`Y0C8@0(NEU/`95$HX'()`BYWH8#+Y11P610*6(Z`'2B@M9P"6D6A
M@-82!+1VH8#6<@IH%84"EB-@!PIH+Z>`=E$HH+T$`>U=**"]G`+:1:&`Y0C8
M@0(ZRRF@4Q0*Z"Q!0&<7"N@LIX!.42A@.0+R@,Q`Z`G?#3U#;.)D)K#]'-N`
M'6<(SJIS\?UV!F$I?X6Z?8^Y]T,$[)ZNLLXF(O-`-IGON_?PI.!^Z,ET7Y-:
MUEN^RO]4R<PJY_E_?19XW$Q2X_\*W2!YZNO=-2:;PZP^&[@>>R<,<NI9LTZY
MYTU*)U4/?_G/[7OV^?<[>E*FJ*O'+JM_?Y5!80%PVI`X]2S_Q\7`$X)93B`P
MF99Y>-K[P'UF"MD#'?#1GP+V'2XC6RSTHWL)=QYA>LK>8NXX]Z.T;A@(CV*M
MG+TH("Z:+WY[*PP>^B)S]<-T@7#@`96\;&(".X`7$<S(`LJ#I0=N@BFZ2"%_
MP!;B\;/WKLT##$1-*S1%\C=#=@6"081C4'!,-QP6X3LU=#R$)3.V#83:P_"7
M_.C@]U:4NC_&#39#/P"`D68],;2HL7W1]N+RQ6^?DY6G2!#702=>`L"?6L(V
M$?-]P6J_*-:FFPJX`8+R`.2](;K(8@7R<@-N)EYPB,:17(TCPW^%+P2A;Q`&
M0+`%Q$TK'S?R3M/$<_LRV$F7EN0BE'",[_\`+@0'P210B$H$%90GVYFU1ISA
MR_TD$8.!=ESI1'AXY@N/$A^(GY:\8Q!?9H"U`W4`*]#29S!"="&I"/FBV8JO
MID3O)S5-$'U9P4[OS&F%2DK^V=,"(K?SXK=O8H(4C[?3<+&)Z)FY*R;1#,A3
M!!7][+,E&B)OR=EO/L$?]"TNQWJ-_X8__W]02P,$%`````@`O(:L1#=J@XRO
M!P``KUX``!4`'`!A=&YM+3(P,30P,S,Q7V-A;"YX;6Q55`D``^0T<5/D-'%3
M=7@+``$$)0X```0Y`0``W5Q;<]HZ$'[O3/^##WVM`X2VI\DT[1`@'6:2PB1M
M3]\ZBKV`IK9$)3D)_?5',B;E8DLB%R,S>0@8[>K;_719K61]^'071]X-,(XI
M.:DU#QHU#TA`0TS&)[5O7\_\][5/'U^^^/"/[_\XO3SWNC1(8B#"NY!E1AA"
M[Q:+B=?[X_="+"CSOL]U>5+5P;N#]Y[\^#4!'J+9:^\"S;QFZ[5WV&B^\1K-
MX[>'Q\V&U[[P?%_5$6'RZQIQ\"0FPD]J$R&FQ_7Z[>WMP=TUBPXH&]</&XU6
M?5&P-B]Y?,?Q2NG;UJ)LL_[CXOPJF$",?$RX0"3X*Z74Y,DUCXZ.ZNFOLBC'
MQSR5/Z<!$JF7C+B\PA+JF[\HYJM'?O/0;S4/[GA84SY@-()+&'EI]<=B-H63
M&L?Q-%*PTV<3!J.3&A(D]I4?&ZVY]*L.)9Q&.$0"PE,4*4NO)@""?R,HD=Q`
M6/.4]F^7_7L34"`PP4D\G2`6HP`2@0,4\8.`QG55MFZAM*Y@2ZD@B5+_G$N0
M*_#A3@`)5?7SITKQDR)(VPX-5BJ-%%N4K3HMJS.E9(3X=<I+POTQ0E/)3[-5
MATCPQ1/EWI;?:&;TO,H>_VQS+JOO)(S)?K"H($+7$*75_LPO5R\990?QB09<
M^O,Z=6VV"@^Q8*%"?ESA;;-I9R7J/(GC5)LOR8D7\B-&8YU[%O72')@>92$P
M.3K)P2GA$@.=*OTHJGFW@,<3(7\JW;]#!E.$P][=%`B'-@D'8@+,MFW82+O/
MCI4/,O(.72)O#M'8=R6N'1-0Y/E\'QLZ2+G=@TZ!B=E0CMA"MHS>[P1/5>#P
M!?3]0B/F+!MZ8^TZ0)GDG&-TC2,L,%@,53F%RT7;#@*:$,&':(:N(S7,R"<L
M@7`K,[;1LL.&5FS3QA"PC5O<&R#6X%]"I"*\(6(/HC-?O(H\%CC"O4'D"Q6P
M`&WF*Z]T)>C)-3-CH^4.&UU@^$9:?@-;C8I:L4KPHS<\(^J-.T1="1K\FM!(
MXN(J3A`S#3TYA<L.XV`$TI=ABN0[BA+01F^;I7?8B(I=G;.0V333O3FS0^.8
M$BLJ-HI6@H=-`]V;]]IAB.<8AG+MVR<=-,5"`2J.50HD*D%)H;DNSH$W$-%T
MX74ET!AZ1`";,LRA"R,<8"%#K21.TOBJFS!,QNL2VIGRT<HKP?=3.-$\Z_H[
M7/+*E=)6D[!1U(TX26O6.LN/6"-6S=2\DI:S2GUM6^/CRQ>+OR?:J)$=1AHM
MW<\'H\$46%K5D^W8F+27N'5C@E)R`CB#0,99[EJ7"]XL6W:Z^C/"Y)QR/B!=
MS*>4IQ/R8#1/2C8UT`V".]UA**1@O0.;K#>/6W[Y.PQ=F#((\-RM)&S'E`G\
M)_VJ#3**I:I!EM9N%[>"/@.1ID4*:QC+\8P+EF83,D-UG<L@60W"C/;;Q?GE
MDG8)'*1')A+U4O1IIDPO5PW"#+;;9;S*I>L*1<`O)5B2@'[_;[UD-2C9L"\C
MX:U34]*].7TB0S104ZI-U+-4>H?1OP;\.ALYM%F&".5NGQ"Z:I-Y^"J6V=5F
MPU)L=O],W\/-LCML9492BG<?"CWA7AI90>4**TBTO3ME;(+Y1$TC@U$7KG7T
MF66K1)^%)]Q+0/=51@ZX1;BS7K)*U&Q8:8Y#RQ_#05C-I:OE=LE"'N#-'>]"
MJAQ/$5J9EQM)/#8A^`SI0'7T]2RBM\^2#<Q1OJ-D8`Z2DN-BV6H4B"&C-UB:
M=SK[QB'LD_MVTI:FW:1Y9WT7MU52=MS_T%%JARNO[2G9&,16C7;Q!'E/C@YT
M!G`*!$98I+L:LO?`*9+&=FBLQEQ3PM!>1\7YW,)9+F89E].B\G,$#\\+%XI7
MG&$[%[F8C=S+[9G'$VJY;V,Z)5#RFR%+K6V^!)3@TP.Z0P:Q#'!TYWR,LA5G
MU,(YYLSGKCD]PP210-K;H5S_#I!.;*^87'=)1N([ETA\[J15I>FTSV/]^T2C
M[>8Z5CU)@0Q(9X+(&/KD#&&6GN-4(!9)T;PN9R];4:*V<$Y&U'NGID6YEF*`
MU!G`^?\^R=[][&8'IW/?`=6F)A^DL*+T/]:-69LX<KQ-V+R2ME6;L%*X=VW"
MSHWW*0V79FFC,:NOMSVF,:QIVO=6L.ZX!?U.I;0*_-`G<F9[;"HU3TG)+T.A
M69JT_DK;P>\$,TF2D',Y5GW4--^997>[;[(E;1LO4)E=X^`9C`W4A2_R;\-L
ML9+]HECC+',*=A=[M7D.N%_Z/F9HRE-2^G4;`4#(SR3Q:KTG@0Y&?<X3=5^2
M*=%A(>Q>R]40EW,]A]$Y[IW264:]`#L8K;ZI*GO=_`&H:['4$TN:MU"X-]1O
MXT3W3OTL6Y*"'*20>.\.6(#YWVUY`_/YLGM#<H%KW'M9=1GT?X@QI,YPS_':
MCM4;8GO#XJ9#W+O(X1*F640T&"U?$J(AKU"DTL05.\+R&'S9UR+*`5_]4_'J
M#8H4\"$P3,/U-;B&R:W4[)#=AYB;<Y3&.KGA^`'!9W1'[DK*,HS80W?DCA^6
ML_!SG+)<+%;1TCJU"P+AB#_@6*5.VS.?H]157?H5J,]QQZ,C-GQF^M.2!L&=
MIJ-MB+&^PS)SA(LG*)>O(K$X/?:0[-Z355&Y!O%TSK7,!DK_Y(S\'^YO59=?
M_@=02P,$%`````@`O(:L1.`6J!LX-0``2&0#`!4`'`!A=&YM+3(P,30P,S,Q
M7V1E9BYX;6Q55`D``^0T<5/D-'%3=7@+``$$)0X```0Y`0``[7U;<^.VEN[[
MJ3K_P:?WZ_1%DNU.4M-G2KXEGK$ME^U.9C^A:!*2,$V1"D':5G[]`"1%B1*N
M)"&`V:Y=E>VV`7"M]>&ZKO_^'V^+\.@%)AC%T;</@T]?/AS!R(\#%,V^??C^
M=/7QIP__\?__[__Y]__W\>-_GSW<'%W$?K:`47IT2]I,$0R.7E$Z/[K\Z^-E
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MWSY@M%B&</V[>0*G7!;7WZ>4GU":_T%'^]R"&O(SC.B$^1C`J9>%:8>T[8_=
M$:7QPD.1&4*+H5O1F0_Q<0$7SS#IDLC:N&THG!-B$C][AA\KQCNDDS5Z&VJC
M.!UWNF3*`7.:U@3)!O?2:/&1;IM?1L5F\8_S.,)QB`(OA<&9%]*-[7$.88J_
M1UY&MF)(]I-='CT_11'*%LNYERP\'V8I\KT0?_+CQ>><5X5!C9-][R7D?)G#
MG#8C/-2_T)*ARS\SE*Z>O.<0X@;4UKJW).4"8C]!2WI(Q=.S#*,(8NQ%P6.V
M6'C)*IX^HEE$#FW?B]*Q[\=91(B;W1-A^0CB"YAZ*&S"0S??[8[Y247$N")B
MHD3$$WQ+LT:SKM//MQ3%`PR]8IJ3F95X$:;4DU71'&'9B&8);HZ*XL`MR;]/
M8G+DI"LRY>ER7M+[<7-9BT9K2>A=G,)[;T4WF^;T,09IO703]$+NUB_50A@T
M6H'[HW1.6)L-@C=6ZQ-UL4`IG25TSR6G']U8R!NNU9:N,&BG9/O;7PB*+Z2-
M9:T^=B>'?W,QU_MW24SSB<H<IB5IC]DSAG]F!!#X0E%I+C'>2#F!Y)E'>M,=
M_H904Z.3\`&C@%Z*B]_2P3J]%^<*C-BO?32D*H,X8;X3\C?"U,//^4,APQ]G
MGK<D#X;!Z#,,4[S^#97CZ..70:DC^$?Y:_"8$EKH#"><PFOR(UY_)?2>89A_
M&_`;@R^%Q&Q0G%]V5:C-&X+!+K;CI$XS>:BM1RO?;%I*D&D2+Q3$M?YD+"'V
M*$X"F'S[0'IDF%`2YW="NA*+=^`O=#LBL_$RS+N1%01G](?-W\,8P^#;AS3)
MH#V0SD,/8W)K36/_Q_@-*<VNW3Y@:`(Z@?9``&4%CP1&!@]<1`\-SC9M%S4=
M%`.5_<9@9`(.GEI,@`5+QFQ8F$S\??``%]MZ26.XU!6KQH"IN'$&H$=RYX9X
M?$^&A$D"@YS<VYIBE+6?\7N!8R-0L32V^S"Q%P-G/Q/RX!A`9XT`8O8")[T"
MB,?#&J"!(PB=-T*(V0N<]@HA'@]KA(:.('31""%F+_"U5PCQ>%@C-'($H<M&
M"#%[@9]ZA1"/AS5"QRT0VM<UT-^L%^_3:ZPH=85>X&?'I:[&PUKJ)^:D3AK!
M)G+G]0.#+WT2O8B-M?1/C4G_*LZ2!L+G=0,#(PH80[(7<;$6_5?K!\(88YCB
M\3-.$\]/!6=`O2$8&%&H*$*AHQ7;I]N=&VU!VWF64"<`90QVVH.!&66*&A0,
M\8IP8-#NS`OPW,-SD=:$_!D,;+ZZ^2+D:$9*BIV1,-D.EQX*+M^6,,)P'`63
M=`Z3&EL"`!1Z@X'-1[<N/HH,.;I?J>Y38&#SF:V+R1[I[KRNU]X8]R%UW-ER
MR;B#XF7#[P8&-A_8RF>'C`775HAT:8"!S6>SYIE-B75G%=P@[QF%1&0P]VFC
M]^IY'!+B<.$MH'"-4AT"#&P^LW4NN3H<.0FE^AV8WPD,;3[-M2"0HLA@S9E;
M7.DSBDO/.\(M^4V2P6"??M%&J#X*&-I\]TM0X>R<>MRYBNV6TVH34)G=P="F
MZJ`+-+ELN7,/H9ZQ:W+EL#%:@Z%-K4(CE#A<N'/>;?QNM79*43<PM*F0:`23
MC!UWC&5:*+&8L:F,:(0-FXDNC&.=(Z(&!1C:5#YT>R>DO+ASPFPYMH]WW/)%
M2E1^+S"TJ8OH`"H);^Z<0XT>S0*1#&TJ,SH`3LR:.^=1W9KXNQ=F(M]U1FLP
MM*O0$(J9JR-G<>',@XDN^CA2`F2W*1C9U%<T0H/%@CM'TC@(4/'I>P\%U]&Y
MMT2I%PH@X?0`(YL*AT;("#AQY^"Y@"\PC'/-_6/JS>!EE,)DF2`,+XB@?43#
MD;-%EK^N+[*$')^[/83/I+:#@Y%=IX8&L'?#M#M'W+X0M*XD8&13:]$(0383
M3CZYF/>K%G86,')$>='!XXS+H`3)S_5`4<NAH_5T).]QI*H4O\>1OL>1OL>1
MOL>1OL>1OL>1'B*`YSV.]#V.U%&`WN-(74?H/8[4=83>XTA=1^@]CO0]CO0]
MCO0]CO0]CI1II[WWDDF2O\&"W$YX#Y/'N9>HFZMY`_0G[E2='W=NQG6:<P+Q
M.$OG<8+^VBB=I>#M=K0;H=H<-!8?[ER26;1>8YQI`U5TLAO:VA:D#0_NW)%9
M=$ZRE%;^H#5--%':ZFDWRK4M5#N,N&/IW')N:7!^*?2V&PFK@YLB,UW<NSO'
M3N/8$O2R&QG;$"L6$UW<S@UA)#VM.#WL1L^VPF;#@#M7]STBU0XI4;?^1,[*
MN%C#])-]]XU:?99#Z_NH;,X\#`,B,)JNPBLP3;QHEHOZ;+5I<N^MZ*_&KUX2
MW*CX<K0>W(;OAS^'019"\I*7D8]Y]$O=1KKZA@V/DRY`Y>E@.Y1+OYU;"E;(
M5R0.+;5V+CBQ=(D@>Y+LLNR.A;@QQQN6HH#F0KGS%E#JI6'B<[;];O:PY>P3
M9EA_GTE=BM,1CR&K4\H]/Z/+Q3*,5Q#F-^-)3H74O,OM8]7'R-0FP)X?(ADX
M`^X?'N4^E0)::V?5#^FP(.[R[8Z%1G9OVIIV>$P>E"_K%R.MGG5&"/O1XKDA
M']RJ)Y3-%X>2:)R<1GM!*S2-2KD`\"1Y0+-YBC5GC]Z85IVS#C1IM"4BL3,>
M4N_434W=`\_P*P\EN;VB3'88;6?>NH4>SA(83*('Z&<)#8LD#>[B*%G_D\"-
ML(KNJM/O6%!C=4&_3(W5V3<LJ+&ZQI>S570IHGYKM"I)G*VJ'W]#,"%HS5<W
M-'A9HNI2&\`!'5BGF$NFE4P6SCQ-*C)+`>1W^WW:I;H*K7%LJ[/489+`K,CL
MOSK:CJB<#@R[>TJFBM;K:)FE.&=Y(-5*"'I9531IKT()JDSVG,9NV`B[H0/Z
M)8/8#1U4(['H'#4";^1`")Q!\#;L=>'XRXMR*![2DRGC_C=.*[*VKH+YW4^0
MM*^+8:VJ90P_NSJ2CSL+FIE45["4F>VMQ.!U!05[3?/X%!^CEK1KDTJ[-JZT
M:Q,E[1K5'&8Z&7LX.U$[8D3ZLBZ'UU*3&>&4I_'J:N@#*KHZ!H:UT78C$!?4
M6ACZGV;Q"]D?4+$WDQ]VMV3R*W`#9UYX2=A(5QQM%:.51954ES#5)P";SXY?
M,:JP%#1PM0F[36RIA3@RVQ?L#K%]D:IE]4M#\7:I/N$<2N/RLB".;JZWLJ+R
M8$T^QL:_1ZDSV@MN1;FSE8(WK4)O,]H,RYNY'O_NO(ZX]%)JI<IEA=Z&U!_*
M!@1%0#31K/'G_M+M#DQ'[`/F477/)'#K^7.R5R6K;9*EFDE!+ZMJ+,6EQ490
MS)0SB%UE"9%KEE`'RROT1G_"<E4RMY/51%"M\!+RY,YAV&T^7"-QGHY<<T1<
MNY,'I&W*5D.)J#K(H<NOM,3DPID=L3TBCEQ`NH+&O6O&5MBW]*S::^M<_K"!
M2GC[?M8PZRB,R6X<H#"C]IE':MG)S3.7;WZ8!3"X(JQ3I^PL]8K]_=(C!VPT
MP^L4)&<K]@"R6%AS7S64GLR1\]"PX-S)W,2F4RE&4M;55"XT]=!9PR#J3)VZ
M6!S?EKJ"WY&SW=EYX-YEH=M86*MY]I36(1LZ(4?.8-4LM-5J0KT6F.QQX8Z:
MX3R.7F"2(G*CT,P2+NEI-XM>"[`4^')(J[`AEH8JXGMO12^'.N#M][.;5*\;
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MAN$N*AYPD%AO*`&]#RJ"(NH#AM9"80^"CXQWAZH>/,"0'N#D@I>NGA(OPK0'
MN?-;RBO'(>=&$/JJVM5J$0.>F,]6M;\H%RS0&,]"5C<%*#CG4E,.78A>[7S6
M[_`J\;M2'\2!Y&R-<69/&RW>G5%>;M,F=7W9;VP[K9J>T.7`N9<_K35`CC@C
MF4+J`#&[MW`1)\@+'\/8B_X+IBFDZ4G.O<B'R3FD:DBQN5:UO]749NQ5P+A8
M:G#CS"*ZB:/9$TP6]UE";L48TALQ2HLXNW/"]BRFUVYZ+UBW""0G7<,1+<8,
M&SKVF@O"'4<F/@\<#J0;<<,1;0<9MP!3=W;(Y-"#O>/@D\.1H]R=67*`P_\.
MOEXDV6R\7(;(]X2.P<+V5H.46RQ#Q@U`P*(Y'!Z@#]$RI:?6+`MIMQ4A((E?
MO)"JBK\_7@6>&!GU$:P&*'>+E1;3[IS(G*O)108IU4_Q]M_/LR2A)3OXKG@=
MC&HF"KK!W5Q/E]6.8X/.-=L?OD4AQ&D<Y4ZWI4:,LX(%G4Q%.;>"2%70S)4K
M8=:=!)<2!;YVZLIW/?Z['O]=C_^NQW_7X[_K\=_U^.]Z_'<]?N_U^#Q7RMK'
MKR.<HC2CX1X%'0\00\+_7(R+UB!6:Y`H@Z/+DL&7FGR>=`)BQY^Q6JVDPS6H
MR[3!&B8/Y%9+_=-NO;^\"/+C[_F-K>I`E4'AD6XP`/C&0T'HO8ZCO$2M%ZW$
MPN4TMZJV5!8OGWB#+OO_Z2T@QN?>$J5>^&L29TNQA'GMG5$#"D4LH+X+-WR.
MC'_-O!G9LQ!!=HQQ["-"K"207=#%'76>4-02#@RZIH]G"<P5$)RW_'XC0TGM
M;#S6V<P9O`55W^*^W5C-#"6+D[^K.?(1"7%#L<'J!TVE:/GQVT:<!WC8GI,F
M5"7_1.^2%07BK5?4QU0&.X78"-9T9(A91KTY6=\@G\P6>$%+!\9Y!&)QDUF0
M/9#0@O[*#>**(#0:S$YZ,1UT&K-E-)H_PF05DD?4(TQ>"(%8=:'(.MI)+::U
M6E18,/ARO(QFY):4SP,UF7,[V,D,IB-K(>D&GY!;5ZA;+](3MTI?.XF]="2O
MRD47S\R.;+K9,T8!\I+5HT>OQ$IY^GE]#"7_LFF*$_+J3J*/+>)HMK/)=-L!
M1&;JD7<VE?9+/7V_$`8.=$IL.6.=,P^A(^8[8U@>X)ES'WI^N:E+CS166SNI
MTS17!.-@X_%BTMF6O7LK9CU4[&XGEUESQR)=WMQQIYU,I^36GV"J<2<[!2\+
MH:BYQ<QC.B)G[V`\A@R&#624H<GTGGR++%JN@G:WG<6<7LW%S.7$I$(V3_]R
M[Z'@>T2^4=WSKZ-_0B]Y>HV?YG&&O2BX#.$+Y*L:]8:QF&FK)3P-&#6H$5"F
MYND5AB_<.NR:PUA,O74H]#:,&M0UJ%,S1TD*.UA]ZX$LIL4Z&();K!JTB$]>
M85#0I+0?/,57<2;$LO&`%C-EM<2T%<L&+?&WA/$41M1#Z`I"FEIJ[2=4AH]P
MKR/RGA;S9K5$2XTW@Q;[^CMNK8JGM*B]8K=[@*&U7/`M81#S9#"#W+JZ`$TL
M#(.G>#O`LDR/QL-!H2L86<O+WA(01>8D">/:V>:J+UV^41LAAO<)F14::9,;
MC0-&UI*IM\2L":=K`'\^W(50]]X'1CU4,D@YVKR"#4@^"%`Q5D'!1085(9!U
M!*.^:B*46*M`,:";J"7X/(^C@IRK.*%Q_2@J$]J2?S^3ZP>]CY!EBN*`!U7#
MX<"HK[J*%@Q7L!I06FQ]O:A)LD6!=+TI=0:COBHHE-FK`#*@E[@E,EMDBSOX
M6I2(N$+TMH^BV1V$`2QV9LYT4EZ,77X#C/JJS>A:"M6L,*#IV"$2/GCDMA2<
MK<KP`ZYF7MP-C/JJM5!@K(+#@'*"X#]#+S`JSN;)=/(<HED^,[C/8$$7,.JK
M.D+"5`6!B="!ZK+Z%%]Z5/^1FVSDM_5:<S#JJPI"P%`E=@,*"/(N2]+ORRL(
M"?8U#V:>Y/D]P'%?U0UBGBKY&U`SE%\FSX'S&.?PTZN*1/8[K<%Q7U4&?'XJ
MF1O0#-2N\D7U@9SV*<SO!$I/GOUNX+BO>@(%QC9F5U.59FLJHP=:)8)KU.&T
M!\=]50Z(.*HD;T`G4%:YS?/QO6BJGU7Z@N.^OO95N:O0,?"TKRW+@A+JFHPG
MT[JY@AQ9:XN%TM:E-A0X[NNSOR&S%90&E``UDM:VC2W2SE85:4H0BH<`QWU]
MPFLR64%FX(5>Z`$FT_6NO*&':QCE]@#'?7V7BWFJY&_@2;XIJ4ON)'F9J:+H
M&KFC"P#@=0''?7V22YBJ(##A&Y"#C_SB652JTPC%P0O"<;*2'3J*W<%Q7Y_L
M&@Q6,!EXPM<VS8V=:;-M;NV:^<&G=,2H#`1.^OK@;\1J!:)9=X/U5?-L]5L<
M!BB:59NN@H\!OS,XZ:N60)F]"B`#2H.MQ;Y^%9RM-C&=5XBO.%#H"D[ZJCQ0
M9&[C^6OVJG"5A>'J@E9PA4&9;*CP2/F3\/(4*SQLFXT&3OJJ?&C.;X6IB0Q_
MWALUYE6&B(S\YYY\%Z:7;S1<AG_MD/<$)WU52ZCQ5N%B0"FQ7NYK$AX$]PE6
M6W#25[4"CYM*VD:#&G(-%,[(07<#R?FGX<W&ZPE.^JHE4..MPL5^3H5).M^D
MQ1Q'P582FG+=,F!4[PQ.>JA>T&.O`M.`IF&3B4:@6Z@U`B=]U2;LL5$)UH#^
MX!&F:5&/H`QFR!WGY+*6]0,G?=48J'!6(=)&5=#-OC5.4H33<?!"77+RX)1X
MY87IZM>,^DJE$.)-(2A1?ABM<<!I#Y4*C3FMT&ZC4^@(;=^GYRHMYT,U(%O"
M0(3LLCY0%-S%D5_\0X2X[EC@M(?:B5;<5LASE!6'+)9TG\1+2-BG88%_9B@_
M?<M"28>ND+0FY3[T<J%5]-PHU$B2=[9:)8E+GGIA)/$0%FHA*8F<LVXTV.IW
M`20N>V>K)_)M27HUA=Y.E3R2@\F>#FI\.I.?B\\F^;(T09=";]L%D!3QT`2S
MQM^_$IB.9%LSCVJ7:=>ZS#55$<M-TR9L;[6$DN)RXNA8..PX@\]5EA")9@DD
MG%VA-_H3OTJ#O)/5>DJMD!+RY$[NMMP[55:O<=W&3-FC`]]-MKEQ#`?I0MEJ
M9:C:D7I-Q6TQ"B3=9?%V:Z)VY,#7E;E[QW=I]I1*O];.;N6I^B1F2WV77'?D
M7432RN6]W<YN&2HE>>^0Z\X^SCV5[N#Z6LY/;ZL_B-TZ5FTT1GH\]@#@[QA.
ML_`&347J/X7>ANIHM864#8LFMG4NG=DEN?3^FL2XD3XO[VBJ/I<+2%8,NK,R
MQ[Z?+;+<8',!EPFDU?(()>3G$.:RCV@ZQ20M"P1Q61,;PSKYA)T26)W.C"Y%
MX4ZQ#9%H&A[8=@IJ'687*-F3)`,^I/WS+DYA:;RU9/;<:"B>$B_(JV+Y68*H
M`9F(+G>2*O\PQABF6,4:VGA,JT92-5K5+:8:XUDPG[;!2&I5U6/=EHF5Y_NJ
M7TO6)2.HINSK4#)Y<ZX$JB7S)%LX(@%V:6[L6(3N%9%5E.4A:BLE<$%.[3(E
MF&+=0&$G*R8\WEQD2%E&O#-O7[52>C(+D?(@9@QZ-G;V1KR[\UK>KT&OB&\Y
M[<V$G*B;G[2D+D>NXLK)A=D((%>,5H:0ZD-)0!O1/.+9S3JJV)2;$VL]IE@L
M5E9;N_9`5;%R*#=8M&Q+]Y%71(]>8)(B\B_Z!]7JBEJ#6+44=OC@;L2YT7+R
M>WD2+C+X%-,B&O0^*4]AI#Z"'1-B,XDS4--CM./3'4/_TRQ^(<R_0)P69WOQ
M\^ZI7OP67.?_1S>%-567;TN45)G-&7`J]K1C-NP"1@T&W;D^7\#G]#HB+&7Y
M#D].T"*667!'XW6Q8R;L`CD5SMRQ[=2I_!YYA7D*!A<(^UK8,?K:L>B9`Y'#
MHMFRCQMK89FLCG+`5<!QVMNQMW5VGHG8ZJ)@8S=K*6>H9%6P;+:;@8&U?"$=
MK9!=;KJHL6AB:UOG-RDCT^\3%/EHR<P#KS<`&%A+-&)DDQ/QV46EQH[`I=?9
M=8UQ6G^-7'7G<1C0BN-ZL=R:(X&!M6PD7<&MS["D1.0A?1DNR/1\(0<!N1>7
MO@R#0SLS;$BX47!38+2VX("PH4+F6K#3TH+3`%MBW,UKE]Q^QU+KQ1[9=PE@
MR)^CKMXBVAU[@G;8B^6@Y9H4!8*NJ.VSJ%TQUFC*_.\2863317-G$K.EODNN
M._)N%&%D,ZQ73=X[Y!I4]C]FBX67K";3*P\E>5WER71SU*R5H9/HS,,(3Z:T
M1:X=N(T#*#7G=#*X(6._&EQ*5Z1.>36(]:V7_(!I2=N6Z6(2W4(/9TGA6"2H
M&Z8\@!7;<[<P,(VJZNP[LT56<AAC3)Y[N?=#K4248-N4]K5B##>)LP[G[MB#
M6-0^(/SC*H'PFKS!$HC3!_:ZUAW"BM'=%N(<`;AC56)/TR7T4QAP:A"J=K5H
MF;>RMNN<=V%J,@_Q[W%(&`]1NFJPNMF#6+3D6X1]7P;N6+M$=%^@%Q3`*&@!
M__80%IT!+(*_*P%W+&L5U=?1,DOQ?1(_>\_Y-*7"J6E31*CS>UMT'#@4X&+F
MNS"T<5Y;^4M_,MVNBW+YAC!-T5T4QYU,I^16$3`0U.IOT>7`Y&-+AWV)V:P-
MBHR-(_\P(8/W>E+J9]$AP21J*FROT>*D*K=KY"RMN_9,G1L'`?PK@?(FQDI!
MVFH#6#6(,@@[6_T&@QF9'+EC.SV4YVAYMKJ."$+P,24'<I[0AU)'_GBV8@U&
M'VGJME;31%@UXTJ@EUIV#R"<?AN--]R=K>Z\/,&FV(+,[N"4.?D0H,LFWHYP
MG%&>;BB\\Q;R_,VLYK8-V7PART"I\?#W@L01@W<WV+AG!B_OD%*S;*V=53,X
M;]:S<=BEVQG!5WOS>>AA<G?/S5.2(XK;QX%H>1=.*9%\W#$!;1,GW13W&]N.
MJ!<*F8T+DPEG5F)K/!PYHCH"QKTSZI'L!A!?WI,A89+`("=7>F()>EF-MV<O
M!LZ&)N3!&8#T''2-."+T[JS:EH<[5FI]CU0S3@8-G']_4G%$_=FQ1:,G:D<.
M&EV9NW>B-'/^M9I#?6<6L\6^1Z\[$F_D_FLUQ;F:Q'?I->@4NA57HI:CA=O!
M;L;QIEIP.4\&A7\X&[$U.[]8M*T,OPYI)0_JI&/-WJ^#91.VC&YSV$]0:9!F
M^75>0/+S`D7Y!9R_]^F,8M'&K[WJ]#GKXGVA`E;-=:?PMR\]"I10XG>WF%"@
M'3QBEEQT70W^)RNR*PESARGULY@7H-WVQ^&E"T=37DJ^C#)#IDA^;)8?74<Q
M\!:/L!,86`OXT%XR4D8D?IZ']$.BP40HGQS8RS-.T-L.C'Q4^24=VB'I)HYF
MU!E^G=9N0^&-@C>20F\+KDA\JF3^0Y*>%IQ^U"3,V93D[/3;3>?0:<7MN_,H
M(,K1J>EPZ<QSJVUZ:MO));2$+@?./2^=U@"YHI4VA-0!\H>/GY_C-#U#,<U%
M["WS2P<^CY.E..>UI)O=9!7,.<^X^\F9,)A@'"[B!'GA8QA[T7_!-,U?9N<T
M'7!R#NF+6I)T7+&_W306JDAH<...,PW_-#U;G1.^9S$-GZ"7K'6+0'*9:#BB
M`S7O&]\LFK/<AXG`X4!ZUC4<T9!SB?*-I068NK-#)@=G[C@.30Y';DONS))#
MU&>A'[Q""4[/26.JT'FB!]UD>H-\(C!R."9QD/FRRBU:HU@M/M)BR3(N!MJ,
M&T;R$?IQ%+2&4GT8J^5+#&"IQ;E!2U].S-,<)>W!5![%KA>/`3"U.#=H"21/
MN#">42+*KX^7RQ`57I)B`.4][3H"=0N:&K<&"R@4.SGA@=I7R'//"_ENB.(.
M=MV(NH5%R*1!R]]X2A[6^<?O8$J_BB5*'TY[.WY#9K`0\=A%RA>>$1:^7B39
M3'G?XK6WX_9C!@H1CR8SLD`?HF4ZF3[`61;2;BM"0A*_>.$5X?C[XU7@B<%1
M'\&.[X\9N/2X-IB,Y1:159O&$2QK9LA<57GM[7C^M#+=2ODQ>*/F$UP1A$N*
M>$AH#&'1P4<H7P8>FER)7[#V_$W\;7^3H/`W277SX`B*299?&N]XMMP('$F4
M^VJYD>C3R',,4>IW0+<0'7FQ9K("*^\N(?UP"5'&4VZM?G<(.9!YY=TAY-TA
MY-TAY-TAA/V*>7<(Z1R3B??C`04S>.<5(]YXSW&2OVS%6,CZ62U6HHR!`A<&
M=?IC,M++8QQF^<8IV7P8;:TFVE#?<=B4FU3!)S#X+4O].8IP'!4KZ@%B2#B<
MJ^PSJOVM&J&5Y:_!C4%%?&Y,NR97\&M4LZ9=Q<F87!P6WO-U=$E+@H:KL9^E
M\'8%PQ@%-S#[`1=(HHWL9'"K9FAE-+MBU:"B_WN$7F""\Z"\)_CFX=L+0B_Y
MS7KVJ:Q!K4$LYXY0Q4Z;)X,F@/^,YQ'^+5[^(+O"ABXQ)J(^EI-)J$(@8\&@
MSO[&0T'HO>9:"+&<]UO:-04K2Y=-N"3->5=;S3V,(KP*7[Q(=ER(>]DU]3;:
M3-A,K.7^LX'=PUM`C,^])4J]\-<DSB1/9UY[N[9<]5U#0/[F;6;@(ALG"W(J
MS!&<7KY!<IP3R,LZZI(;K*RC7:NL^MU5A8\*`9?=Y`\=+V'&L'L(O7L+CM_C
M)?8]&0P9D8T'3.Q;FCN0A#-6`)?FAR,&!9<FRB&,$)UY)O8Q%&*@ZYIH/.SA
MT`$L@SY&/7!@TV?=G9-:+[ORT(BBZ2#N#-L\]#DE\M",HJE!3N0A-Z_,#KW.
M7#N:2-N1ZX&^V/\NB9&'5G5_.S.9+?@]@MT1>:/,R$.K*D`UD>\2;#*2$"8H
MYFDJ=EJ`H1&5GLDCDL&!0>MT\2'N>VZO#1B:4=5)#SR66+B"V]!J\)ZN+SG+
MAU<S$1[@]?GT&C_-XXPZO9-%0H-<4P@E`5FB/F!H+87LWOQC"%A&^J$$?15G
MVH*N]P%#:T$A^H+>)UU\2.W^KYV"99;`W`%?=&[5&H&1D:>%\:-KCPF#SAW5
MM\3;\$XS,#)SAU4[P_;E(Q+BAF*#RK^F4G3A/&LHSD-DHBG43!?P!8;Q,B<Q
M"NZ]-(\H++(!K,F2Z/)T!P(C:W4E6!.7=<=HPI(YJ/3PX%%HK0"$HM#Y=)N,
M4BT_&@6/RSC"<0*#M;^GIKCE(X"1M<H.FA"H\6+0V[NF&E<$0M0'C*Q=N15%
M+Z/>Y",[]/SBC)KE_U';]46=P,C:Q5MUAY>1;]"]>RL"[-:+O%E)AY+85?J"
MD;5Z"XK25^7"X-W\$2Z])(]DH;L=3--0!P:UWF!DPVZI`X0Z'P;=J\D4R*9D
M-F0TIDL1`%$?<&S#PUU'[#+J#7I6/Y`/*1^IS,;@V(;WNHYXN60;]*X6J2/4
M2B2JCP".;5BY9$3>M,@6L<^?0TX/Y!489?`!^O&L$':5I^46IO,XJ#?XBUEX
ML?E@X-C::UD3L3KF[3AVQB;Z!/UY1-,DKAYA\D+>1_@\QL)"9)P>X-C:`[P3
M'`5LN;-6;XDL4AC1`#$93+M-P;&UUWDG^+#X,?A"+S-456YK5Y";\8C1%!Q;
M>X^W$K:('X,O]`/G4CNV]GIO#XXFGP:?^;MYX2[8E7RY;<&QM6=\>QAX#!E\
MT=>+T<8K+TQ7Y=>?XNTH*AX(R@.`8VOO^O;(:'%I,J]J\>G)=.V]OJG=S7V.
M\KN`$VMO_O:02/@RJ`U@I)HN/!=X$'`[@!-K6H'V``BY,J@TJ(PK4;!M:Z1%
M9PN=*%\Q(^D(3EQ4$:BN!Q7N#$9LK^\.9'_T`A131?4+O/5HTBDOY$$B[`1.
M^OF(5^/,9%CW?1+_#_332TSSM9"CB;YM!)X(>VW!23^?W4*&.HGBYEVCXM>H
M>N&P")"?TQI#@)-^OKJ;\%FA9N`YOD7*59R4M"C@LVD,3GK\).=R5,G<P*N\
M9K*G<-.\4NL4]W%R%<?4KS.O61`L2%/*0KKET"AT8-`8#YST^+W>AND*7`.O
M]ZLL"NKOH>\T_51E5**TT5OCTVO\3W)9X=Z7]88!)SU^\S?@M4+0@#Y`1DX>
M/TT)(?0TA6][#'#28ZV`+J,5<`8T`W<9996<J&2A4Y9XX.RV`Z<]U@&PF*F$
M;.#E/U[$693>>XC`?NGY\_*[/%ESFH/3'K_Z!3Q5DC?PZ'],R?+ZOKR"D&R(
MM>./ZVW$[0%.>_S,%[-506#@@5]^^2++365T!HB4\^S6X+3'3WH^2QN3H<%(
M#D(R1N0SPNLPNS4X[?%[GL]2)78S$<G3.%E0R_!9'&74_$4#I/8N9Z5=GZM=
MT1L&G/;X9=^`UPI!$\;V7!F-?+)5YF757F!PMMIXSI);]4*`FJPK..WQRU^1
MOPH=,T'JI99G,KW*PG!U@<*,:H"*')B/:>S_N/R3\/(44W[C*/^-`+`&HX'3
M'NL`FK-<P6I``_"'1PT.Z>4;-0IANOSOXI0L]C*T=V-&Y2&I/``X[?&K7XO+
M"B_3]O_'N9=`/'[Q$$$%A2A=G:U*$LDD*VE6<@10&@F<]OCMWXS="DHC$0%Y
MBISB@3:93C*J7R=+'I)IMJ0N5UR=@+PG^-IC+8$:>Q4T!O0&=W'T`*=9%-"5
M?AWA%*59,;;``U#8"7SML0Y!REF%A0%-PGU1J7,E\KW<-`%?>ZPKV.&CDJH!
MY<"8T!E06N^3V(<8$U(%`F:W!E][K!S@L[1Q<36QL6QN#>1E17TX4>05AU+U
MY.)O,`J=P=<>JPZ4.:PPLN^-?P,]#,G!A`H]!U4Q#1@(BIJ#K_W4(LAXJE`R
M42IM/1T>8`1?O5#AJ2+H`K[V6#L@X:M"P8168.T8,IX1(F8$^.+6QCVI.>W!
MUSZ_[`5,5<(W44%M_=TKLDF&]%[FA6%=9X?/5H2_I1=Q_<&U!@%?>_R&U^:T
MPL[`.W[C4;6CA&V$G<H@X&N/7^_:G%;8M7FX=W-!&/M^DN49SZ?TGED^F_!Y
MEB0PS[E$GE=^\0_!O4%C%/!3/Q__#5FMH&ZC".CJ+C@K:!5>`,LVX*=^J@28
MC%0@M-$`=!7*SG*L+U5'`F"$_<!/_=0K*#-7`<A1-GS>,'Y#/E`7!?U-31:$
M+O*\WB0)J$F#^M9'*%LL"W5'7G'<"_$G/UY\SJ5R^6>&TM4%3#T4X@\'GCZY
M;OB,EKB@QPD13Y$Y9A.7<;;:-"G/I?&KEP0WZ]00@CG6?G#PY>`+ZM&?PR`+
M8:DW%Y&/>?3GV4I%@NGJ&\#(IDINBONKLU-0.>NV2[EPTTT<4;Z#]!>?["UD
MY5X6^9&^?<!P5NJCRK^',1GZVX>4',^'OT;EK)"O2$JSU-H!([NV4OY>(PAR
M+DP[+#N35Z0YQQN6HN`^]*([;P&E%<],?`Z8T7$K%Y?9PY:S3YAA_7TF=2E.
M1PKG6)U2[M7@N5PLPW@%8>YO,\FID!:'X?8!-LL7F]H$V/-#)`-GP"U].:2`
MUMH!FZ60#POB+M_N9+EJ?*LNIB*>9"E.O2@@C^6'.*1A=O2/)MYFP@\"&X:E
M@[Q,3(GK;SD%B\BGP\R^XEO`AD7-_.0P/ADKZ3ESAK5E[E>ZP^/KJ/"K^#6)
ML1$5%?]KP&9!XKY-1;;\_CZ;(A'@%*(T2V#%I,'9R/@:L%EGN6^SD2T_=ZH%
MYX^/:XPS&%SDB<8+&@L'[ZV7"5Z[=PLGF_9@8&##U&IM,C623Q<I0]W8NC8N
M;H?8NAA?`P,;)N.^[ET<`7:1#=6-^;@ET#\@FLU3&(Q?8.+-X'H!WB?L6-<#
M4P`&-BM6]VW>:@BUBTRSMA7TS'NOJ?G<'15@8+,DN'-SNEO!=I&2UY%YO>;-
M^M36(@0,G#9DN#:[M67;1;IC1R8XXXEH:XIKD@(&3AMZ7)OD#:3;15KI#J?Y
MLUS:S]J7L@=(X2:_IZZ9U`V3YG"`R6(HF^F'I08,>FF):C/9#R]@@_FZ<W(_
M*HCPH_`*!G?7+(\?7M#)H>D`@W\%0Y8UT7:2UMPY=<@UX1-%&/F_>V%V(`5(
M_9M@\&[TZDB,G22"=V.*[KT3GN*4QB(>:+:J?!X,WNUCW4M4EA;?6GA-&4)T
MZ"B;\]##>#+-C48W"H$SS/9V8V$H*6>KG#"-Z);=7A;B57BRY"T1(?']#BIY
M3+VTR%6Z)1-)@`FWCUO!)BRL>&9=/D/..$%MTR9UW]]O;#N,0RAC-BQ,)OX^
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M!?KHU)NCY5-\&:546RU3,6B.9,HC6?V@XX*C"*:</W>7X0%1=N6L,P[W`4Z[
M=<8'?($2Z)->94(Z3#Y+O7O%)Z!:;[MNU4U6&>-85&?U`&"13Y_%7A(4'U4%
MB=G+KE=PU^!P673G'7@=O4!,QI:^`>H-[3JVML>)SU475Q?.@MFL3_$2V6UG
MU[&RHT7!8LH=;=4ZFXWD^K[=S)#;H/E;^RX3[J$@O:7M)!\RY`FG?-7>DZA8
M\!NJG;E`-Y>\(]??IA`<XE*;>T-=1[0X(WJA]D-^^C=Q![N><XSIR[K\B(AW
M9KXWS/5J1)]F?L??XZ)'$>H]2+LY-),SH6D&U^8)U1HR[\RJ_GM,)D=.5,NS
MRCU_IV[3N`Z=3EC1="=@3Q&A%)S!]X$R+[D/5&W`T(@6T?Q=H,:!.]D]<K+D
M3CN;5F!H1E.H?.K6!2D0]H9>MZ:ZIK0=.9;TQ>[>27)+1+?(%E(`:NW`T*;*
M=7<FLP6_1[`[(B]*?LM%OMT.#&TJ7A5%ODNP.[:%Q^P9HP!YR>K1JTXI6>P+
MKP\8]E3=*N3(H31$&^+HG6XRW7+1D;^$I)W!T+*.5@P#!SHEMIS9X\Q#Z,@=
MP!B6!]`&5^$CXYDH9H;;%@RM1D^KK0B&7IC'BVF]^TX%0['.?;?<X<BF`Z5B
M%*V8?'=N`_=)[$,8X"O"*$WQ2ROL3J9E4(_0Z"KL"$;6BISRA<XQ/DD9.=2V
M<^[A.:>*K*`U&%DK4:HJ:@GU7:P&)0&/4](O@BMU(6_W`",;+FIM!;W+@3M.
MP,*TXG?P-?^3.")?90`PLN&\UF@K4F?('>^0K;M'GOZ/D)S3JW:IK74!(QNZ
ME&9("5CHD1F79T]8NPL0.62YX6&2SF'R-/<B9EK?-M:XCD@`(QM*H69SYX`B
M<<>4\*^00FMD(U#YL'-04QSN:-(NX'.Z63J<3)?\QF!D(Z]?(VS9Q+N3>;I\
M09<OK$GR0)-6UE((;YY?Y5\54H1I#0=&-M0UC=!LRIX[*9BO/)3D&\*87%\7
MQ?[Q@/"/JP1"LF-`<K=-'[Q4M'NK#@&.;:B&&N&JPU(7Z87-87GYMH0TY\7O
M,8T^"(D4&J#)'@0<]T:-I,>40^EW181?T.`2&`4M`-T>`AP[KZIJPI)#B6I%
M9$ON/+*NX-AY]9<.*[+,K&VTC@]PABB1=+PJT=P%Q'Z"\F_P=(^R?N#8>566
M,A^5_-NHL#CR+[TO)M,IS+5HG/HCW+;@V'E%E)#V2K8.J*`VBK*M"5"S4*II
M"GF]P7%_%#]JW%3HM5':<%;&^J50*)F?XOLL\>?DC;^518ZW4!2Z@F/G%2`Z
MK%1`V-=>""T#.VGG<CV-M-QWHP'!<6^T(,T9K&"WKRIIK*;+`_SB`$V1GW?9
MVF_&47X',E(+7N&SX+@WJA?38J@F6AL=#6>C'P<!*L:ZRZA()M.=.5^6C.'M
M]JK]P8GS&A=M?BI<[.M;JA@=F+R0RQU[1M[%>;X,6(0!X5P5O_WW\QBG=W'Z
M3Y@^0#^>1>@O83ET8]\$)[W1YAB5P<8%P_K\&H?YX#!@<T@?S1$6J7[4!@`G
MO5'\J#-4P=B5V@=#_],L?B%LTFE5@%C\O`M?\=LR3PX]=M8W6EG)3;6.X,1Y
M58\Z(Q5,#G@\M:Q.6/)&(QL42[T-9+>\PU(#3IQ78%F63C5;'?#L:BF!WXNS
M,0HJU6M,?^76).Z.2'#BO-+03:%54]X!;64G@EG[Q%1F"/,3>/^3X*0_>E&#
M(J@FEP%EJMA&B/TXBWB.#5K]P4D_U*HZ_%2XM-&M-E=RKTTF+93=ZR'`B?,Z
MT28L50"UT8+RHC*8(3<Y"=\C\M4:,7>0&QZF.PXX<5[WV)BO"B\#RL3=MU5P
MMBI_]5L<DJ]R@VFD'<%I/]2'2HQ4$-C7&VXMZL+B4:QZD1LENP<X[8W.3L#!
M)ES&.C+LM2VVORKW!:>]T;,I\5+A9M^SJJW'?#TV0VJ>[?YKX-1YI9YA[JO9
MY(@FL%&J-UX`QLZ+6Z8(MD,(..V7_N^@@JFFIWW5W_;FO)4><'/]43RDF'W!
M:6\494J\5+@YH+\2.;WH`JD_&#CMC\ZI$7,5U!QMTN<-XS?DJW51T-_49$&(
MA>0Y5V%0DP;U!XQ0ME@2BA:>#[,4^5Z(/_GQXG,N%9IN!_Z9D5T'OM#MZ`*F
M'@KQ!POIQ`HR+BD9-^N4***)Q>D"OEA)AK9%2IXT3)WR=8XQ`W/>"\/]F:X@
M0-YT9Q/.S6QR1`D+TE_\F$ROM_0RS(^\;Q\PG-$?-G\/8[(TOGU(DPQ:!T^>
M.)[3`QAY->DEL>,`I`;GA@]WTI[MDRC/=L;K`\P\7;32U''DK0S0IGCTWQ0B
MA]+0=865>TEJ=XB59DYEM@<VR[D)EX820A43SJ#2I%"5D4>0P3-GAWB'4M@U
MK))DYJW2K#S5B4SJ%<W.S7EML3MR3C23_P%RD3["I5?$3HZCX!&F:5AF<TM@
M_H,X.ZE:;V##HX`_IQD6-V4^G%D05:1KH8N@:L,XHB]SV:-$U`\8<2XP^321
M<.-._L$=`J7[&+,],.-1H/XRD8F;C1*/%V<64T?@.'+6=(N2>Z^2TA="^AJI
MM0,#FWF<N2N`#<4>Y:[)'M_%:7%,TOWY.J()=E7QX/>EI>K[AI&8&W?>+7J5
MK09]TU'62'<G7ZU^D:6!9>5C79`"86_H=69S:B)M1\YL?;&[=RXWJZ\TL*D>
MW)W);,'O$>R.R!M5$1NX4D5,(/)=@MTY29]02C/K7$<!S<Q&'0#$IRJS/1@8
M40@:/&&Y;+B3@7R/Q#]0.G^`8:[8P7.T?(HOHY1<\J0//,V1:+5YJZ<V'QQ%
M,.7\.;/GV439D=N">;@/H'F^BI,%3,[G"$XOWZ"?I>B%T#A%/DS$2F=I1S"P
M$2359FTQ5-)*7!JT"]0/!ZQ80TO2#0RL5BY3]F12Y<6=6XDK.=N&UD*L5.#B
M61&:LNK,H9C3]@"799@E@P\9U,+.M+![/V&5LN70$FX;!%"/1+$5HZ%.!1A:
M"R!K,:L.*Q]W+)B-$R=<OBU185Q7*^#4Q3=H9?A^3JVNN'='"=XXP"[_#\VW
M46W;TMPF'7V&%EOOY_3I4`#N*'8.5;QQ:"U6S-#EM<::.^79S(:E#ZW%A35'
M48DK=^J;/4*?S+5T=0&7,48L;0"G):W.WCMP&#RX4^#L!I+M?',!N/!2808P
M5G-:K[UWH/`8D90B8P1-?J;CTSL5^<?_`E!+`P04````"`"\AJQ$GQSR[XA[
M``#?C0<`%0`<`&%T;FTM,C`Q-#`S,S%?;&%B+GAM;%54"0`#Y#1Q4^0T<5-U
M>`L``00E#@``!#D!``#MO6ESY#B2)OQ]S?8_X.U9V\XR4V95UM7''&NAJTK=
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M,?\Z706%X-+@>Q'E"/ZOM]6PM_Q7;]]__?:;]^\^Y^%O.`^R-*9W=$W$X_]8
M[+?TWW^31YMMS%];_.XYH^O^=XBS[$L^_\N$/@4%#3G]/W#Z[[_G]/^E_/5U
M\$CCWQ`^\N/=E1+.'PYHR4E?_@>9XPUO:1:EX47B]JI'LV=]Y_LBR`J/MV[-
MG^F]'](BB)W>N#5SIG>]H6Z\K>?-Q5-F`ZD;3YN9([YKT7U/:T8V'.26FO]\
MS9Y_\&;T<T&3D(;5N_&9&FLI"`LK*XQ_NCH@%G-SFV:'.(,BV;SEWN.K;Z3-
M_!?^F[]53FF1,+4OHF)_E:S3;"/,]>(Q+[)@552$Q*L+\G_[\W??_^[/7__^
MNV^_^_-W?S,G].5_5!PX>.&,YNDN6U$K]/(C'+Y9\/BW#[_[_1\^?/O5[[[_
MW8??6;P9=VR,#'?=-'G[\?XW_U&[ZR`)B9Q(6C/)S]7<__PW^3+C86-!Q6-:
MJ\&O$F)8/EH\"!#CNV-DB^Q0F8)L5;T>^W$`6CGBRU7*@J5M\?9`2-=9NO'2
MGNJ]4B\6?6EL,DJ8`F).5^^>TI<O0QHQJ.^_X3]P<_+-VZ_>ET'8O[!?_4T^
M]XX^1?QQ27$3;&B/_?C^ZS_]Z4_???OMGW[X_;=_^-.WE]]^]\/EWY3S9S`;
MO__V^OKZ=]]_?WWUU??OK[__\?O?7?VH?J&NF)62U8PC?.#<EF$>%'.HB)V`
M'&F&'1OF4(@SII59$%\Q'__YSW0_Y%'5$^?VH#H("NDI!Q(QDK"AH/YQ"@"S
M^XA!0>KU"4-2-)7(+Y@/"KD?NHR#)QOC?S@1TNH?0SB6E/KOA`]`8^;]7AO4
MKO<*S:!![Y.8J<3Z;)=E_$E1O@KBO](@NTC"<[;R-#'FRKD0]EP#Y%A@RJ%$
MCB5\,`NB0\*'@YOUB7"`6/<AX5(:^`')FDH9JJ7&`R-K8^(/YD%:^",`RF4C
M_SL:^^[STJ#6O4]<!HU[CZQ,+<YU`MS4L/=/A+#J*@A*(9$#\9CSL0&`V'&M
M("F-N$Z*IA;YQG-<LM_D+L;\F`0&N]Z%I92C=E`@!J.S]V."0>$'%$)G[!+Z
M)6X>59%*JE(6I47H3H;T$GU0AF2JM+<@*C(;$%"OH12P0<^ADJYITYJ744RS
M,^:KGM*L+ZDYD,4]G`Z?Y3^&H\@/BF&D&H?&68R(`4&&OU>T#!/\?7(U<7X_
MW6S2Y+Y(5[_</P?LJR]W!2^9XL5@%LE^'17`S+\>G"J++F81,>V$R(FD-1/<
M@\P)#G+'P$`TA[8/AN725KW60?XH$.[RMT]!L)4Z1N,BKWYSK&SEK_]V7S#%
MYBYON;Z,DB!91<SOI7DT4+'2:VZL:$+Y)TO@QQ)[&L2\=),)*:5%#EBV,@6X
M>AI)UZ2>2*J9&K1@+LY%CK5^ST&(`;3U(7B,!S-JBEESNS[ERZO%[V<Q!+84
M;+S7GMU=Z<6EUSUI905`P,_B(,^7:^$E%Y\CXT3:,"$TCJ<'8F>CC0_AQE@,
M8O:7#4/J:<9"@\>3J$30SGTHY&\^E6J_P'FZ":).@:C*?/3,A/(=O2"&Y$L.
MQ.%%Q@0`YD_4HJ3U*4HYFM&OT"RB^>*6D:191D/Q+A_HYI%FUIY%0PK<MVAA
M=@(7,9K4HRNQDQ.0^1D79(MC;/B<S;!<FKF;0:&<6]=.#76M/W#5D`!;OFAA
M*23P%(UV38@)C7\RD#S]XF=0[.;6HK/Q/%8_*1P>2P53(8%G:+1J`FQOWV/0
M+V>!LO=:.L&<6]_._;U6/PE8KZ6"I9#!<S3Z-2$F9%Y+*WD&7DLG=G-KT<5X
M7JN?%`ZOI8*ID,`+-%HU`S:D/DLKF18^2R>6'OT#2H?X\"EU\4,F)$!Z!@S"
M4L9Y;`H:K1D1U]NOA_3%&XQ]2P!K-*VZ!9*D"1M/Z89O&Y&\^GX%^W[;&FDN
MOE^:D;0U4S?V'1&YPZ:_4Y3(/SRG<4BS_+>$_GW'*TBB]=$;L(>TWX=Q)-Z3
MH"#%,_O;5NQFIVOQKRC/=S3K>U)!-]LT"[)]ZRF<Z$;.CW*!(PJIH,.,4\$X
M?T06/,JPL"OJ5@A&1F4$N\<&49_8P8P85/1@"E5M#?DD-/9P$HQOOP&WC*/B
M,K&1XJL:6\F^T?^TDZ/%BU;V2!LQVA@C?]MYR?3`-VA4TH",&C7`E(:2ST%C
M)\=$]O9;</,X!AP#J[CFG]#4*/8-_J=-'#5V'+(O@\'C@'$!J#&[CA)ZQ7YT
M+RYK*(!GI/I`:2H5^3`BQN&(&R?``9]R4@J:70G9L93-IRJ+/*=%;MJY4C$+
M:NNC\_*=_CUB`);6DY:O#>X<]#*BW;'H%9"YI;IL]>)ZR*6?"+0;4$'KEZ$3
M4G7R07J.Q11.!4.._R,Z3Z"5."-GH!.W&6N)@_S9U`N(L6#UPO)%.W+"?DVN
M$G(:).,OG)S*@C7OR5OLKO@/?`7Q$L3LP^.Q^FU)T!?_-F(PGYRR=<8VB,*+
MSUN:Y'21A$NVK,H.=,C6WIN0A+;^9K"/A:V<1<II0N[$1'+D)5"Y!C^L5$[+
M!=A4@%V5/B0`"Z^\Y<_&H9C+,U!@9K?:F%$%-2&M6O"`5<GIG<6]&@-ZX?WB
M1>O:CS%?^S`D1.,WM0IK`'=^3YIN:5;L;QF+12=\%HML>5+BACJX4`TM>-^I
M!=IU)'+X"1$3Y'T(U903PB8A\Y9.Z`0LVL!*J&@-$*Q6N\TNYO?$D)!N,[J*
MQ&[!O,9A>L`(@X!A;33T_H.J.+?;M_/WP([>."T'Z-B5KA&9)U>^)TK7;>&S
M9U>DZRAXC.*HX$<!$[G'5FYV7HA-2-=<IS%=:"=NP8!CD6M-K9TY\P<3)D:+
MUN5L\\&\6IQ>75\]7%W<D\7-.;G_<7%W\>/R^OSB[OZWY.+_?KQZ^"NJR&7$
M3WI_L/M_3M?1*L+GXVV5V,C?6VHPB,D:WI#I-<L:"E`Q@A:41DIGV8_1FAU_
M.!6"N)F$(B9R`M&:!+*I9"OP)K')H+[,&/BO5NDN*?+;8,]+K9AE8K_)=C3L
MOJ/U]JP%:>BHQ8X-G75'.9N4TX6K*PF0/N."RKV/A'W;PAZ4V*L</SH/[R#V
M9GO$UC(/INIW5&2/;H-,K^/]"S$36F#Y`3.@0UI\0LJ9I)R*;.O`$Z5.7\E;
MDI78MXP@_'V!+C*L3P^8"_!\&GJ3%K1Z(T>GVT<"VKGVPSH63#&JT3V,GM(&
M2*E>Z#R?1L:,/)Q:P.;3DW.:12]!$;U0HRBUUY)H:4!YK@%@G6M`ZN$HHLR1
M(6F6KV#^QT3RM'['0.P@,S\>:6DLWL9(S#"HBS^*P^J0*=,][KO`%D!Z4C[H
MW*?G^A"7TCOD=S$D=/7ZC"M;JQ1V8"$?_,Z6><SYZ^#3S28J>+T$WTXY2Y,B
M2IYHLNH7:ZU.ZTA!>S,]S$[2O!DMUO4'XU'Y-S]<*QTN<!]A()I&SF)8+N<\
ML6M1R:"X"0.R9D%QTX;%5K:X*&IHZQK`V7B`""<"X7;'BPV,OC("/-N#YA4#
MMJP`.,73ZA;PER#>]5UY-'1JHD,"VJOVP^HYJ=)N\W%"WG_UU<E7\O^K*_+>
M??6>;P^0Q:YX3K/H'S0\(5]->BN@>\V2+>J\BSJ7J/\7A[UEL(,#V"G<98A3
M`/]?7U4P7_B4?R7?-8QH@#/<HEE(*`\RP5Z9:*V)-O&(6I/G#?O+FQM5UJC_
ML.3Q/+!CL5T`?=%N<Q>G&'5"KH2,(8@WS`$H[<=)OP%Y__[D_7??L7&_A[0D
MXX#NV(ZONU:TP<[^_-W)=]]_??+-M]\+,_+UM^R?WYU\^^WOJL']-N:$L+]M
MZ8HGE&,\V[0J+=4?4^Y7T1D+),)0W"T9Q+=!%%XE9\$V*H*.C`S6EBC(0`<]
M:GB=&H%Z).%#^7']<C`JM^X$B)^X?1LE9#41(/=,N3D<\5'4&,`#C0%%,JND
MTFK1G'O-S+*FXF#6?1$\T8N$N<QM%N6T7'8NFI-XY[N,V>3C&>8[TMY/@MNW
M'H%)W:W@>@@18TA#]J1:]),692))D\Y$%"'$1#R27#@X#BJY$+:XD(_+A3](
M+B3TB3\0-1=X+\=!3@"6$XQE7`:*#D:R+)#Y9MLPK(<"=`36"TJ?VRS/P"V*
M(HL>=X6HV'Q(><IIBHH%]]R2+;3?YJ4%I\FJLVX!C2J-D,@]W/P@FRZ[S"(*
M*"V0&)W+\X:RI5F4ALR@9,5T@$[I4Y0DW/:?!NP/J_&]OX1QD2@]WP@@^E\=
M/+)7FV7#?JH*FXSG@+9#34P_'02%,BJ`9@>O443-#FBD18N/,,';ZG'QH3U9
M[:8M)F&LH<I![8ZRF&R9B8[1H<A?WM),;!+Z;9@JJ4('L\;@![=5^?[I,B-R
MMMSO(&R^W&)%%1N.@+G<'ZAW!M"Y>#NA=M@X')!H*/65&_K-/KYI(#!`!2H,
M&`0WJ)9EA4,S"45`X(&K5+W.[AL:+VDFD%H?:22-L"HF=[+]O.(!)5R>\`BD
MJ9I-M+\_GK<SQG6H9E$O+F1>KD\P'3Q;CU3"JEJK#LW'G;7)8/)GA_!,-0VL
M.&\D7#?I.]X!5`Y%ZY,MOTUI+8#+YYPTPM4M=[4*I(QNK&6K"4EH3VT&6U^/
MQU>KZ6RK5?<=&2^L0ZM4T+AD5&1DR[Y=WO?MP&,4"R4U/D]DIJ$@ALAU`:XC
M@:#*UV")>FA@<*Z[G1"A7W$;B)]IS2KX6KOS+FX+;1491+Y[8"G:ITXP!?3C
M`C)96&-QS!:(CBK<HX30SZMG-IKR94YY=V].5[M,[G:Q7Z[2S39(QM^_VZ9Y
M)'JSS(D^C</JHV(.09QS)'J#`F@?';(C6AIH@@W]VKO?/$Z9%1DEWK`!A3B;
M8"*%=B$'9![A*F&FF-;7)+O>;J`B`QUSJ.$I[\/.R7)-EFQ1*:[C@;S:>"1D
M<B1I7?BM1`3NK@;$T<A=Z65QQ@KH(*;Y'7VAR8[VW_35WWO@:!I8;XW.ZW=4
MAH]`X6N&W[7\(QHOHA`.?5N)7LF83Z!+HY@\E1=>ZBZUUVJYFA"TO]!!/!:I
M"T5O=%"W8`.@'EM=6XOPUN]!F3-R"4,"-Y\.W=&<,KX\+Y*P=42G?"U3%Z$G
M`N4PAJ!U3;(<+ZI?VT?^RBD(]G:=(65TE68A#<F:(G&17E^G=0"OOL`RH]'F
M<<<XND%UJ;J1@FG=K(EVS6<P?J`)LUTQOX@BW$1)Q.T6SW"I38;6G@Z1@W;`
MPW"/!;6<(:]L.9@SF2'Q<=!^`(.#.>B\M:&P&OEL,TF=LX]`<TDO?ZE-FA71
M/\0_3?VVC@3<R7\=K.Y![68T/\*_C2G_42I?:^H)N4F3;9:&N]4DEQJ[G=]W
M12I5KS4>C;<S$,J!@^5#$CFCIPNBY#K-\V5R'N5R(R=-EFMY#^Q[:T>GIP;N
MYX;`=KP`FT#>\"E?$":1K5D\&)OHXF3WO5%K?'PP!Q8>`E/>(P[KQ/&B,VOM
M`8L./DXQ,C5F88J)G0',T9G&)MV)4!%)'X3AU!6*$,/DU>7I7]7%BOXFV_H$
ML_E+#W,=+!!2RKTV_%$)/8"^RETK;DF<L^DM$M#A33\LM1;S`:@\O!F`&UJ0
MF#L_+ITDK3>-$?60,0,B//@E![%4@@#WVAI=L=L%Z"C*G#=$)NGA:Y2FQ_8V
MAF%"4/[;!&+'$A3/-"-EI<*;<OP7*'RZ-QR>/*@AX;GCP%@2M1[45`SGK&AB
MJU:::_;4!BI0#J=#>](NG&Y]CQR!,MUM\?IT[-<?82GL__K@7E.A#X:E5'W*
M,&]*,.=^FK+U]<5G;F1V4?[,<PK+]3E]-/:6PX2@O*4)Q+Y<8"Z3@33_@BP3
M<CB15S#RJ0AVT%WA\702/025KNN>8#A:FZ''YM'F=R9L8-&/L6711C^F9@7B
M9NU68K+^77\9JM9]#!.$CI!,(*MOJ3XA[9T59DK;?V*3$>VIN`"M4O/E>2R&
M=!U$U<EIIIFRO79%`U<.Q@6O_)AQM4VF@AT:W5(.&GJZHO\R]OODX`&KL0DS
M"F%-[1>"%)!WZ@=?RJ<O9]H:^\HR/HH,L,SV1"44.A44^YT=&R#E#H\R<84F
M<AM4'[=\U?QF@!;N>SZ'DZ$CL&,H?4I2:;J(LQ`%52;O'F/;G3)YZ<H>Q=,P
MW'E#RI7AX'%)K\(:Q2!]VCJ?H;D(,GZ;0EZU"#H-\FC%B]NC>%>8=^D9(@,5
M>PS#ZUT3\8Y?U9ESB#;5(V'AVM*+A[PE8K8\72/GH_'AAB*I]>1F\CB?FOU$
MHZ=G]N`%^_#!$[W9;1YIMER+=VN=\!_6/JT1<GP*=(3@S)QC>:\(D9(2D:1X
MQKO;'?1D6`5`W?CD7&&K_;9-.&`.%@,QA;C;.&<OC9KS/K6RG\%R?1;DSY=Q
M^DEW_KK_T+F.!EB?`3TP99\.KO)\`A$S`-MTC(LJ-40%U[G`0!#U;0R&I7#6
M53A_B=LL?8E"&I[N/^8TO$KJ4K$%OYE;WECCV.S`X0G0WMJ)*7V1J9#DB@PY
MW9,WG!*Y2KYHU1(WU*948J\,@3\W6CK=+K,\@-^I#8/.,8P`>W'_([F\7OYT
M3R[OEA_(\O;B;O%P=?,#69P]7/WEZN'JXAY?TPEWHV":#G"S"/.9Q47X7[N\
M$"?[']([RID9Q?0@C_&0^AO.7@<SR;.AHIN)&'FL9ZW'\-MEZP>13NJ5__FU
MF&4L'"U2T=!#<C2I:O[9;_G/*\[,72X;GS8[6P&<6?^5L@TLXIW2&&HCY0DM
MX8SIY\TV3O>4GM*$KJ-"W/Q8YNMH>)9N^.Z;JHN"UDN;$X:.IVU8T.DR5LXE
MU61Y62B?_E;,)VT"J")(']BB/>K;1P%PU1J*MLS:6LR-0D5;&8=IAU+W`1FA
M+XJ2%H8&*1J@KIU24`0'(V"$5$QWH3+QPA;2.>,"K?5P66I\'N6K=)<4MQG=
M1+N-K3<=)@CM14T@=\+1UAR>6N6S2#6-O"DG8JI'<4(9AG\\Z$\D2ES+::A"
M@C&^8<B_H0H=>!Q@K)A&_M]4*Z$,SV64!&Q1DCR=I7EAW&M$2P,L4Z,'-B25
M]00B9F!(E/@!"JL+'M<ULM4DR)RR&?-@@TLY&&B9/G4PK&(F-B,HD@VW!-]^
M]4UI!_AOQ+FG97(F#AA<)9=!E(E+Z+B%JL\5F`8@Y@2A`A`;R+WG498)D1/)
M54+XU/+627%,$]?9&V^L@&>-PG2UX\FRWK4G`L#O4)PO\@$L*@W?/+')(YRN
M`@O5K$V8-E2SM5^SWNV3T2"GYU3^MY47/@NV41'$MEMS%A2APC@KT#U7Y8A)
MY$TU_0MNLIM-L9($MFHC+]!OJME?,,4M\4<)GNT7>S'61D;6,@RIL&R5MPVB
M\+R,5ZO>.DDH#FK))I.VF1['IT"G?YR98ZCD);6JBXY(U,KC<!,UU_6\_6L<
M9E2HJWZ4`G8J8*]VC%!2D&!D^*.TY8&&#YYG\K,5IA>IN1L*%&'.=1-]CACJ
M]%%%&.[T@S>QAE$[Y&F1P54(-"+TL`7]500^&L%V#7[44@VIRHN5R';GM\$^
M>(RYJ6&_R7;,;S2OZQ\`&3T%7P!DR!S#`*BB1DIR<JM:$FQ;`>2!D"-3:O3;
M%OJ@1*_JUHTP"K!1&,<HP$);$)F..QKS>/,VR!0VP]`&Z\GBB0.&X#M:A1-2
M4B(E*:0)$%OX1OI/WI*L1+]EE/"TLW.4?LM8P43T,1[=L@T0+"A#!P563#`Z
MHM5W`@!1?8PWX+["\RE:]L]S]LH"Y$%U/:Z&,".(<'F"Q4A\P<,V>],U\L$R
M+,;Z*GFAN=]Q,0?*8&WR7)C0C=/*T5/:9Z>V>6.@.SXGVX<63X;&7:KU3>I<
M17H^?68A8'DN:;'Z^R[*6'18L.\8\?6@TZ[4,$'H4,L$<F=_H9S#3UV6LT@S
M#>/.D@=*L@E"2M9IQA9'!?]WQCNKX-HYFAX>>'!AK)I&,86I7@*:'F8G6813
M[&_95RL627A1W3MI&D)84(0*':Q`FUBA:OX)$11.1+[C`NJVU0DPLS=\#GC.
M)EV3;0UVRZ<*K&!WKTZ'M0U5CQ$L8K)77FVD9*VY&%<\(Z6G^BA#QTQ63+#L
M(#3+0FCT1)4Y](,<3E2#G3"',T'*RA#NQ0,1K8(^WE^<DZL;]G]_N;@_ZA.$
M/V5E*=95RLI$D,&C2GMSYI.R4MLR<`->GZ49/66EHXPL9:5G@J4A;X[.8>TY
M-`H7CE-;?;!Q]`H:!^Y1Z[?+JYO%S1F"UF]CJ:1')F]8TV=<3F?IBM(PYS+)
M#QBS5UZNK_)\Q]Z0JH[UZA,0PQ2AXU(CT-UB83E)JB^?)FX(X\?XJJD3'?[U
M2NBY0#U-LRS]Q-NKBW->*7/'62%2EJ&`S3MXL<5FNE[3#/3TK*\@6J7"3.4:
M1GFK-UFN;[.R0%MT46*K8/D+ROXH?F.<%W.C#I8C<V6&7M%KW69Z7A,C8JY(
MLC3TY"\1Q"NC<>(^B&4&+><##/4>)EDX^L?G1H9$U<<7J;7JX^=]WQDNI^9E
M!/3Y-1\+`&,&Q1LLMZ*HY^(SS591;G_-QC!!3!&,"K)>M*4%*Z>1>AZB%)H_
M1GX"GY:CA>':]A9[H8I4M`)L':CHI!=&07\*LBQ(BNIEC$NQM30PQ!P]P/32
M64ZH=0]#UR`O0,?J]DD2P--7QT0.C1VB0@CGTZH[NBWWOY;KF[2@56&VK;=3
MTH%V<AJ`QX+8#.6")P971Q80>30+0/6F/5N`)VPH/Y@P*I@1JFD\X?1]''!7
M/*141AYX0*,P;F*,OWGQ"C8MQMFL0+$`]@8M]INW%>C'?:LY'M2Y@5F_;F3X
M=5_!'L7(>Q.S6RW^7HLDY/_A!3PO0<Q-Z2W-HC0\/I9F&^Q8T88.@"P9T;OE
MR'.4XH<6A1,B:9">4Y^(PB5/^.4UV#U-'H2Q0[5-XPGUZN;L[F)Q?\&+9\3.
MZ^+F7/YP\7\_7OUE<7UQ\X"I@F:$+]MT'^S[F.!QI(L-,XHM'0P8M.5>,$^3
M97OF5$1;1--0TXP85)1I"M7"*"]X<")GRQ:Q*")+;Z`BLJ3-5!(4(E7T2)^B
MA%_B735+W=,@&QWR5FC&?1%DQ8RPBT-T\B4FPG:1V!6;^R*CO$F:"A-8>&QE
M>K21L8W=F?$&Z-UV&XN+<X.XNCCW*EFGV4:<8'>]G]:4+'0H;`Z_LXG=FME<
MKDQ:DP'[N<Z!F5^6$:?Y+I-[^<(<KT4A8M00PW<-JZ7`&P5/=M(^9_LBMDJB
M>7$;1'V;U8JF+ZTY<(V'#EZ\>UI=_IGPOZ.(9@9>6-@'T1.4G_2,RL%HG%R?
MG`QT\>D(R:Q-N=(-?0@^\P1XKV`/=3<[F`[M@KIP>IIH\:MVQ1`0D?=\_T/I
M+_A(=&Y!(52FS>QZ)&K>Y3%W.3<,/_NQ.>:2A#UYU_/:;]N>,/%^#N2BVI-!
MRG,7)Z2DVCIQQ9>GO>=/&M+8FOU/P")%M,B#Q21-W@J>10<\Z]L;PG.:8RPU
M&UPECJ!C<U[9^EA<)>SAXI:<LZ:H7]XNNXI82"Q^F;-(^)(&!7M96Y?M]`QH
MO^[(F.YUJ(\%:>B<D!:E$]+0(@TQ4E)#%2:,Q(X6X%4#>"W'X[W`T4=+C&(0
M#Q7QN+*-/7&7\?+MLH?_PW.6[IZ>RVLDI<$:3,Q;4)H[@+`"V0W;RWGU+2#E
M3%).+6,$V'S\2!"W)<2BA+@M(:XG@CAT+1L`QLY-;+-'*O8ZV1N+6"NDAP5I
MW6I65K[F_$@(#7^*BF=NU$QC!4-JH-<]FH`]%K_#FQVK:43.(WRB.#2*PM?[
M@:QO^JL*O,4Y*0;R$P<93@'2_7+'"5&"V!$?G3*)4ZS4<RI[8G1.U90,2"QB
M!,_!A$QSQM0Z#G&'IU>KWJ.5`#'(I/B0Q!_F&J@./HS5;PI+\9#>QL%*)*X6
M3_T-'QVL98<JSDBD![R=.7E(24V!"!*O(#0Q1:W4PB(5I4;;&GDP"?()XI6)
MH+^6($:E[![!C$+3/4Q5D[DY//C37))4;<@^I&?I9I,FYI&.*VV0\,>=$9W]
MFR9YN#PZV7=P15E=:L#LFJ2()5::A!=B;X;SHN_"HJIN@:L\EH@*E@LK*1&8
MPB]/6Z&.R?P,Q3B!V@,SL_F:9OR@='4OW/XL#O(\6D<K(34/*:^N//ZM:PSG
M_D`LX9T/R_217T59-C2J:9-#,MQP2O)'?T!P(FA*7M7<$3T,0II%+VSH"R5Q
MS:C5(:.8/:&24:MI&35&_#P=JZSY<T(:N<09<8^N@W4P[LFZCL_RYU==D?##
M+@K[MO]`):Q<O+3T,3]FW?1JZ-$CX96J(9K%GW<`8;4N](T>YJOB669/01+]
M0SR<!7IY&C/E%;7KH@];7EG`Y;JL0@KB>_8;L<BU[E0]SL.@B@G'8E6WT"=?
M99'HJ<4M^^DNCQ*:YV+M<;_;;()LSW]_'STE0DYX>DU>G<H+YF[9:ZPF;G'M
M4E<X%;?:=$5-5$.YZI]9T^9LJZF3AKR&5V!%AJ,JHK;2<$PM?"6&JE4NF80M
M16KTJ%*C!_JY.(W[<VC:0J_9WP^ZS!'@@WC9@J7"%K1*LX7%'3*S_(6(>"-<
MI_L0?(]Q/!F:&!+:]!C5?P+9G3G;$M;WPN]%7,V/"#"@ML'G(!VHN-(`8+<]
MH9A"Q!S2GH0M#)P+'%C<9BJ>VI#,4#;AE:XQ&,Z!D@UIZ!C'C@T6@MP^#X8U
MH)@*/#K_[B#LAFT[;25]UA;:_3=;VKK584*`S;0'(?8TH&[N.ZTG8'.J/LC*
M&WJ-`4(VUS:3T*$.VT;BB4#S1O"M5K2AG:LE(^P$^C4XV)$8H+]K&]R[NLB[
MZ;T4ML(^[^EH]X8+BME0GE0)IM-(D[=BKZKI4-VY:0QAL4FSHLRG\&05/YBC
M/%X,XOV-H8@3Y$:=)\"<O%Y-M)Y=JR-0BN[LN55DH)VT&MZ@M&%UN^:0VN8,
MG5\=$#SCY@$XO&55E=.T,LB92_^1AD\C]3#R>02<W_5A2U=!F](G9`O:J8"V
M^J?(7:B2H'5K)D`'Z:T9`U[45RU06PD/?^SQ+'BG[<6H\?0);P@P$8/P);?'
M4!K#6,);8V;LG)AN-E%1O>)9*O:Z:;+R:Y-H112L)Z(E].YQJ7J^O'>@30%;
M8#$M6-RA@Y.,ZWL4.@@X,IUV#@@LJ4.'`-;,<)=\K$Y^6A:@<_1NXF]V1Y"+
M[,^G^/(@A:VW/IH%Y8X[+W\LA>492F2.U?^UP?QBO[AH'5^OK,QX5PL_3_V<
MQB'-<ODJ/#,Y@E,S)PSMSVQ8T.E'W9K[V^I,LLCMO@8WYH-<CD?GJJSEV>PR
M%DMAGO.NI<><_GW'_.?%B\NY.>5\**>E`=1M!E\-)7(L-D\V$18P]S8D;%I'
M-R!I<"KC[N*4A,!=F@:B@>2A]5=NL*@8C,]5#<FAX3UA>B&<3Z^J,UEL2?<8
M):+*)1=G?/:FSDA#`<H=:4%U+A*H3J6U1\O#9VRY4OX74+G\$=[(.Q%:)_#0
M.*=A\=.ZIT'9FU&1@CS*E^NCDW)[^;_.WLJ0*K3K,@;?43X^D4MF,_5D3MUS
MOSS>'_+!:>2WY&,2[,*HJ%H-1IO6\>36'9+H/**=X!NY1RNI]V@H=\Z"C#@5
M-<+W1?!$F1G9!HF!SG:[[1F2`FF6:0RSNX]=3R1B)BFGHO.+$^%$T-?2'=3!
M16M!<ZY^*S\=OX(Q[``OKTI?R:<@:65IIZ?JSI562CKG1F7KF+YGP*"E!1TF
M#`#M:<3:#)\U+/#;9K0">9M%S,=O8WEY]L%D=*[>1%`--Q`'I70^]?N8T^7Z
M(B\B%F#1W'39>S0+:JG;>?EC^6(#>*N;>@@F/7)'E+80D2CIZ^1S$%^#^S&]
ML&D7N;V2-N?YU"C-;MF")`WOZ&&GQT7X7[M<U`&T.OW8>BQK^M!>S($AW68(
MQRTS\2CEW-C1>3E7@3<\I.HD[?/>(<Z+>MA_^*;I2Q#S!+7EDMB.&.1MX"90
M>Z_\%@5@_(?65$QJ/`]B-'[52FP'+]XVE5D$72(\UXO&=.&]KC$#K#I#8-+9
MJ1GP6CM#^"PU+05\/HV^VFR#*.-OLLS.HWR;YD&\7%^GR=-U]$+#19Y39[_K
M1!O*#3LRHG,]<TV&+#-2$>)K7T[JK:!%)#%,.C\32](>-J!QWCZJH/7E'GH`
M<8S50-T-S_9!*+?A:4`#N6T-QJ2JDP!$YX6'Q='R^">X@K4NXJCSA*TSJ7;E
M3F;$H'RI*53]A5[MPH-Z+B9-G`I[JL".QE-:B;+6-=K(\8Q!<;)*-_0A^.SI
M"95TH/V@!F`G>A-#"1N+2?7&1X?0!PZ)H9$'')#!.9MWYY1QA6>U6A40%Y^W
M-,FIG?<S(077-]\$9G<[0LX2N9%V(5`Y$9/NS0'[+,T1^3L+T1UHJ&\JM[/V
M)^"/%WL_96MPP7SO"B`SLM">T!Q^SSG\>B:I^LJ+N9B4=2+P]\]!1M^>!KGH
MI;\'"T]'D4$;=VHGUS-V&PBR)$J>\EN:B6_CF+(=(@/6CV`07N>0<3F#L"E$
MS,&DEF.#?'.=YOD7`JN\[%Q"1N-!#<53W^[`2#;G4[D;^JEU-B!+$_;CBK;6
MK9XNU)H^M"]U8$CGD!C]='#YV@$13`H\-2/NZ(H>741W0`>=LW75!B.OZZ@*
M<`?#30V`T5EY,&TW.HQO*M&=P^*8U'E:I&C<L)686K5DP*&&=3JYNMX\HOD'
M&O#C1^&2Q>NK798Q"R).]CG[9;>'0#MG5]:H]RE.2(L4J6@1L1HNJ1%YS/3G
M!W'U!E9W/19K6I?)YK3@1]N*9Q*W>+2I>!2POW(^OLC]GH0$)*MY]LB?@\Z_
M>ZF6D9/WT:L9/?WJF8:[F"[7JHOTA+#;.WU;NF#^WYX!'44I2?!=7MV]JN!F
M8S(&-)8B:'J49R4KBK3^<<M)XPD?'&5?'TFX"3Z"HN?QRYWQA`M&H"UO<P17
MY_$1MQ1YVRYOIJ^OO'GDPF8,'KJW^;^'9QZ@!^^1!P'K/+'B0@UXM9T,M+A(
MKP;]*<@R;K6B]FTBTCMC=,%FPFWH>HTDVZ/'3:O.JWG43Y+A^3(I6^WP$6)G
M[4,:TG@PCNZU<V,]#LH!C\<N?75E2]LKPF29E`MV]O>:.!'4$9B!F=G5<NW-
M6CWOMQDY7\,_5BVU7FK6;?B39F_?`R%7+U7EJB5S0'K[3&HX3**G<8V4AUW^
M$,4T+]*$5D4<]2\^T.(Y#>UR&2XD07J16<,^EOEZ?%W]0II?21H(+.8$P%M6
M<5,#WDIB"/J4C?AAM]6';7!N!`TD[<C<5%?=ELQ);R%6=:+X0Y2>M8NQ%MQN
M/LD]X=-],Z9$LV#.2$*P3=:,]V#HG,Z8+-2MJ61QX*,H#CRHDFP_@#SN#P:6
M#R'B*:7MQ!%B_GK8!YY\&EV)S?J<CZS!\QD]^6CVE,7GR+@GW.$DJ*34\:L?
M2[P45#Z`_,R'X,@J>;\U6&*H5U2TV9\^.9G1GSNK8O/>2<C3SC?!AIZGFR"R
M;OHVR3N`>_EI&*NX2:WT-W(8,G\]#R/:)D'!!GB_.Z&RF;G@Z31MQC,6FVV<
M[BD55WHM16.\#W3S2#-3SZPF`':N0@.IH_'E6"(&$SF:_"S'XW#?-G#:*'(E
M#+@3$T/"IC\K,2!I\RE-F=!4*HK6;AU.AO:LQU".):K\^W0JX7Y/R-"K+\CD
M+^_CR@TY#ZO&%I)LXSK[=`!1F*[RV]=10J\*NC%>MH[P)+`"C#&8U'_$5I\&
M&L@"<?)$T,?AGE\AG^`*/493/'T)R%A:AV<GH!7SY(NR?L>MEF3$)T+'+J,P
MS25K?7*P7,A/2$5]COU1]X!I&GXUFZ>I7#TUU=^HXJVIT>=")`9Y`!ZUC6=J
M1MFH,+8S(,:X]Z+SNIXENXN>GKVJ;VT?`%^.:\\2K85M4?LM*?.OG.!)4\&7
M9D02!;>NT[.F,2=UH5F4YSL:XHGA?)7#L'K733,`CN7*5L>+)-0?\6,#;M(D
M.SSQYU*[,=Z#H>.W,5FH*0PN*97M-IISO/Q,2YL>R@*-5\(C\*AF='6T.]X[
MDBX"F*_3??WCCQ'->"N__35OY&=3GF%(#;QW\Q!876.`>@*FVHY9D,'W9#82
M4K.FS"82"J"&;0/<?4&W4A`[XFBB`4-6Z"3ZT)VU_%Q+U#&6=R#A`1YO;J,6
M=A[;0B<`S,%5LMT5N;!+[^WJ,70DP/UO+RR=$,L))T1,(>]Q56;8P1J"`.]E
MU4)GYEJ5$@>K0%^[U6GH2*'QE;TPS17J:YRE$7;PAJ#@\69JH;3S74J)A%6T
M;_P]U3<(/=4W#HKU#7Y/I88U!`&5I_K&TU-]`ZU`'JDC73W2Y-FR64N4)L_"
MZ:IQVFHN'R'RHKV=(I>)+GM:MHX$K&%Z-8Q,/1F)Q^N/J>"S9:5=2J$4_1C*
M3<WENN<M%D73,>*H'>;B,2^R8%4,A1.C/`.D8X,_8U3[Q_QJWCZE6A3M1-"R
MIZMM11Q!7X?IV).N7U,+V_&E71<KC:A.$!?]ME[8-BCJ)P(=W*B@J2^^K56_
MT^$--+AP`!*K@(`[=ZW`6=[BVY4V#V=[3O-5%HERNN7Z=)<S-Y[S"*#6Z/OH
M*8G6T8JWMFRNG^`][MGS504I71,TQG-`G.XX#.H*;4V5.]^*K@A<6TZY1?O@
M&I22.E0%RC^YY-B::7HVL5#EL<VFO%5PW&)3T+!I6U+'$:J,:(_4X<IXQL@V
M9,GIZMU3^O)E2",9K;`?CH,4]JN_7=.G(+Y@CRWVBKJ:7G?3-Q4J(.F'T<T=
MLA%$#@$JE)GV[<%"#XT8:0,.M0Q-)>SR0<J:E0,CT1D_=U#0\\*=)@&E/`!5
MC(S\NK/[`95(]-ISA3QX1,3\4$D2[39VN\!]4T';)W=@=(Z[EP-P;>EB>7?W
M_L+&+X_&4VC$?KB#;Z_,([B8Y'1OVS/.A!34/K,93*N[2$[0-9Z;&R38OK2%
MT&KWI\TE%H%"\C=RJTLV(0F==C6#[22[&`N/YX<+GL*U$&S/6X..I7H^Y?T0
MK)ZCA&;[]OO856GI2$!Y3SVL3OOS:O3QW5V8*K1\(-%!2&">T4``M1YQ6/IF
MK-C:94E4[#+>M?$R^LQ_RAU+B]64H/V>%F2GGJ<:+,2P&HYK`3H"L/40,'!?
M-BR:9H5#0W(YG[*=I9M-V1S$SE]U)T)YJ3X(QX(FQY3MA&!Z+([R[BA\Z&@,
M!W.72JG7.DF5R,_8TS\IHC"*=[R<X9Z7!(EJAHO/JW@7TO"2@>8M?W8R^[9<
M7P3,SB1/^2W-9%.@?3\!FZVR.5X%VCE/R^9.7K,UF#2C,>WJO0;&@`<',RBG
M470QO69"&SSMK0W]-UP,T0&[ZF08H*%:G!`^"\?NZ>SHX*Y.,110_6TJ9M(Y
MYZH@89^[B!YC>LO(TBRCH7Z-H+6,0^2@_?TPW&YX6\\@]92IEQ<^GGL>B.`^
MV%!PC?RHF=2"*"5OT9??!GM>46>[;-<1@5O"ZZ'I9%-,(.4,C$M-@Z\VL.P<
M_F0>=3M53]@DK)H^.E3P*(F`UO)HH!U+5'67"QM+\-X(8?3!AFM/!KX6V+&(
M:]-['T9]UBL\'G&M.?P[5O'_-9(+(/[)KMD/3)CRR_W0!))[L$<V5U.=G#BV
M57#GUNCG8A?$FB/C:K<U[I-!XXJQF3B132H?!'C8'`<+4P4+TV$6OBF?]`6N
M$'`2+1Z.&Z=0X6D/QUPEJS3;IIGPG.=!09?K@U\-!9H6E.`.U!B`5)Q=.1AV
M0OA<KA4'OP;<)8>""'ATQU1@!P[U&$KKC/??BJLE/M#B.0VODA>:%SR@77Y*
MF#`\1]M;RH2(!;A/UM<TF!.&SC+;L$!Q8[:<3)K9)Z2>3QH"*-S\&+";/XI[
MKVJH4<*,"*/$EA:,.L]+/^[)*MUL@P1?#PMKT3?*3MO*O<>:H57W<I7G.YY\
MO$K.TB2/0BK-R66:R?>Y*C_,@G^7/#)QL6,\`B2%X\T6;<U419(I.SD@2AC5
MZ@:GBBYI$89/UDS+F*AB3)0PE6\S9LT80R5C#@W$1(RQ3\L@Y0R2;,PX=D:=
MA!G%R"`X$7:1%]&&Q73AQYRN=_%U]&+?A,N..'3H9,L*RP-4-14BR1!!!U44
MY<N!!N).0HS[((+'2DXR[W=L3"/P/LTX>2D=+[I[YI<AWW'K8A0(]<V#:9K9
M"Z#W`NV<5,.(&`<?@5B]?$97E'UTL8:@P>J9+&ZO2,[_)J]%Y$N/NG'"2CI<
M>0FM<*L',P@MG]FY2!(@VK#B0O7B1'A")!&!1HLT3365*@1=MVI<@[O8\-RI
MK4\?YZ'0OGXLUIE6DU>4"2=-6K3Y%DM%G2=7Y#7E)T0^`55T,!7/;M."69PH
MB.-]L[H0A@Y?Z#"JRLU1:'^@;^.D9Z3IL\VXE+.@DRCURVL7N?>]TC?CIH3M
M:\M0H5]I8%,0-F^.)"!0RKK1JO]`T#TTKHHM0IX^&%8^]3ZNEA!HB<,`Q,[R
MLAHNTY7`^CH:K!Y%`(SPYX$%HNF.*F)<N6"@:/,M#NY7SS3<Q72YOJ,QSSS<
M!EFQ?\B")`]6HC+W='_P%Y-NX7[$H0K_75G16<26=/A:O1Q/Q`32IG7"E_B'
M?\;0"1P[,\#.3G@IBO9,A8^6S&<HS-[-Y?2^!67H?(`5$XY5X4B^\9VHGQP=
M^+K<7HB-%M_6$@RCMG;'U'MF0GGF7A`#`HCIZ/F([P_F_]2"I'5N2BGR6/)^
MH)LTBX+X/DZ#Y,^T8.NO*'DZ"QBH[(SRW7*'4X/&1$&7PA;0._T#RZE$S"7U
M9")G$SD=J"'5-(CO_WQVANL(/')([JO^,00S%X+Y2RV8*RF8*S$=62K`U@8-
MIP4L#=!\(<1UFCP]T&QSRZ3I.<@I3UI$A6Q1?<:,^U/*CUOP,V'5B-"F9;LK
M>:A@Q)T=G=17.9IO[O'QI)Z`J:/[!'A30[Q@P8ZGR&LC(C]YQZ#VBK=T:PSO
M^ACH5(`[>SH74#%*;SFI6A](0^R$Z*P$QK;R(S.F&&9,CSG!VH#>4ZF,LA%^
M&N6Q+KNAG\ZSW=-BNXVCE0@AS?H!Z2>#E`)HH!Q+*1M*^%C2&HRCSSQN)/;E
M`I900@XE:`8C*1L8TA)U]<"`BGAH[ATO.]T6?`?B:1?S:7OVE"Q]"6)>.O3Q
M_C(,''(J%F1!LRI6\+MY.S&9N^=F.JGFRTJ^C^2>,!H(<Q&C0$]UT-_=OR.7
MYPN,28NQP&<-^*`"OVZ#1Y:\L%?WX?2%M:Z#;UU>FW;X,J:#87]$`5"_V]":
MA*?9UNSH4.RMZ`34>*=%(YW@:G>^H]P@/*3MOY_MLHR9<-MF3F,\"CJ1X,<F
M8\D_(8RB=,EO'M(O#JMMV&):4L;6GVD:)K6:+FVBF.9%RFS"-MCS*(*?P9*<
M*=+ZQRVGB\:'CZA@/N4-%MKEM31IB'^H/A;O.\L_EE%F04\!)+TP!$JOU<T,
M4DZ!/H)@BZ>%H%([!/D%UZ\BK$-C26I,2!(.1AJDSCJ8J(_/X>2#[<ZK)"^B
M8L=[1,F=SSN:4X;\V2'[8$<9-`%ARX2.0SLJZ:@I\*Q$6=]1$4&8A/"&_^<K
MC.F%<;YJ4P\1U5^5!2YE<416$D&687#2ZN$D@XM*3UIHYFN]NM9Z[&>"Q#?C
M,\ZQFNU5&$80_HE",M&!%M)X@HJ.MMZL\U=TUG=ZVS$8&TYCK'Q6BTS-^-+^
M0_"/(*'J:\\UN?%>"K#;4PI0G?5(.8Z4`Q%&>J90SK-W9#XX'CM(MI]F(P<B
M"]>T:F.P]Z/1&0]EO@ZB,`X^+9+P3+93M0BC5'-!PB$UD$[)DQPI'',Y%E%8
M@A2'?9#A!J1LZHO$V0]HA]IIZU7#0U__%&QHGI\%VZ@(XA^R=+=U\+]*(J`N
M6`/M6&+D4%*.)6(P0D_LB^CZ&N4Y%'M8JQ+6$Q^,S"\/:=2P:QY0)P]M_V$7
M//&&7,R.+/(\745!0=77]77MEVX^B)?6`SJ6GFJT\`S->$3>VA'/_PXVVW]M
M(P+5]%$_4U"/1^+##71([<>'%<A#NQ=/&:7\P]AT=.B9">JUCT%TVC!6?\?4
MC0''F[M[8.-71^9K>R5^V,'VB?L8>F?6K*%W#HCW[+ZX1F8Q-&?`\];V/M#B
MM9%X.H5<J[U;OU#[M"9E0Z)5$#_PA'5-W6&%JB4$ZN\&(';.XY;#B1A/6I*.
M;K6*'IF[OW2%5@AH`5)O:J)MP\[50-5\\LO1BB8Y/:<O-$[%_0LR)[:A&0NF
MX^@?XF,.FXJ>W)P399C<M",3.HE228>T"%79WT-2".S,Y%PXP<$&A\3XR-(0
M'K%AU6$#K`$;2W6'D^X>%L&K'WN2[V)^\^T]S5[8.^1>D<\@-=CPQP!LM_UP
M-8=4DQ`8J%\%1H^0R`]D7H%$&QR9:J5!A&2HDCX=YI.GX$FF.!Q"(?5LD'!'
M!Z9[:W,U%H.ZC(8%F\<=E"^U5QT2+@^I;QUT^A`DQ@J@5GHC@J#^TQ#RL6BU
MC]<V\U![T1&0;AJD`;QQF!TJ,H]JHZW#3M5"56>\J6'WF$=A%&3[^X`WBQ>W
M1M@T6E03`+MQ00.I>V:W&GM"^&A>A2UO=4'4*W%*0'`W'PP)GOYV@P&IFU&!
MFN??!!OV8_LLLU/O0@.*T-T%C$!W1+,MCB>$3^3_/.BC@;'UX-Q@P3L`F(NT
MT4%_8WGVB*MOXV!5^E.[A63O1)`UI`)"Y\+*:A@1XQ!EN[$!L%_Z6B,0I5)(
M%KPZ%5"O=37R/U)[C?;5)0_T<[$+8MN&/%8T@7O^F0(W;K&3DW(RMBXZTP%^
M4\[^`HUK=)%JD^YV-B(]7TR[7*^C%<UR?I*#LK?J,Z"JN+YW+M124`'D6!2K
M8;\E[8$HUGZX$(1T'241)_W#+@KY6=N1<9SR=MQY$/-#C0'?W$VXX<N8EH`[
M61/ET*Y9-9KATQY[QUWV<GW+Z#$/;E=5W9D,ZCQ[H'0Z,(LAO,U"-0C+C4+F
M+Y\V+T]HPIX93W#3KK-#=\*!*#-M]?[;<A"RO+-*IX<C"H5"^Y2.;])=4MP&
M4?@Q"6E6YZNODK_2('OXE#X\I[L\2,*+F+Y0P])R2YHPI>?6P#O5TH("X22(
MH-':O;I*""=#&!U2$2*2$OQ*?C3H6PY])Z`WVUE10IB8O4>PWI\<YYY_XH)]
MXJ+ZQ%100I(R<-1M37F]DV+/89T>/M'XI>^*<<W1'4O:L(?2K!GA;:TD)3R1
MRV@LT%BMKQ%%.I/C[5JO0E!"%BTYV@"#0WA.!F`6:_8<904=.]JJJ>*.MUK@
M_6U82>L5Q5S#\#7VZYO7%'6Y(^VQ7"6MUQ9Y'6OZ"+'7D9I[V*OE)QK*QQJ%
M>P_I)1,OA=U2VW?WIX!&9#[,Z:1W&2U2RKS%2I(\I*2BBB5/-B9;2HZDG#O'
M5D#<E,37F?S&!2ZZB"*WT44CD(RP6(%RKJQ+JLCB.6^K,AS9^9H4G^[/0904
M-.%[)Y>4YHLDK+J5ELWO!RLO3<G`]&@V@=?IG=M,(GR6.-17-U"^G>HN!_L&
MRK[@UA6XJL4OIHLJ)D2').HRUSU-<V)3Q1NMFJTZ@L4?9Q4X:<B`1D9:>$/E
M8O590SX>3_+)$9,H(&N.%JZGP.0>IXP'"EF(,:Q@PS'$H'9Y&("?@BP+F"FY
MRO,=#1_2]J7;:2)*:8VB!!,Z(&&"&<!C$:MF$3F-+V\.[G!/$UEO#1\I>.*+
M)#X6HV\K?"N)+Y?UY/ESD`&8BCD^Y.*)1>-/04')O0`I[M1H?5PDL82%BJJ#
M"7/]].K64!.[^,P;0^3T-F.VZC;(EME]P2L0_Q+$.WI+,\%QJQC#FCAP+P=K
M5G0[`C2B2"HB1%#AI:QDF1%)B`A*Y);?%\-I84G`C,<#88L(K7BP%3S8\DM.
M)L'KT_EA6LCLLZ<,M?SL+^*SUVQ`%OFX&@.3GA%.EF""[3*O73%<FU]V>USP
M<8\]CKXM'`1QS3A`D,0J0XIBOZDT@O*&H2@D#V+YC/,='=1B30W`(#78ZAP#
ML!VQJN=4.S_\JFU@C9\,8KF#$3*(T,8``".R(,%8-PUJ:`P5T\.2G--\E45;
M_I3E^BQ-Y`,OT^R!9ILH">0?V+\?:9#QO"V+0*(T-(H27&F#!!'NC.A<E-90
MDLOODA9ADTF+&O]CBQZ1!.'#D/$XT4!?,^A%"WJZYK^JH6^G@6X?N4PC!?QV
M2CM6((E]/*V#.C3R,PT^/<0:^N<!O_2R]0RWZ,F,(FP7,4/0G8Y3+3'E$X\M
M%L)(:@RH82!OE&VK)<:(:G*LR"(K*]TU:"EFH;@^-2M1$FUVFQOZZ>+ONZC8
M7T9\_SM*GFXH#:E<&BHLH%O8->H#8>I@QF59I^Q"DB>,/I$/(/43B'Q$N514
MQVX8`[>9V)8PME')MG7-MD2R32[-U,$.RJ!O1KYUQ,V0;Y=8(\0IK)NF?FA\
MT^;3/>#P->A=$.4T/-V7=[A:19%#M&!["PP"[9P2/Y9U2N0D<KJO;A_&$S2Z
MX3NP@91D$M_COKJ4&%&D.`U`9.&AH3H:]`$PTD4/P\%LT5/T0A.9U5NNEX]Q
M]"2^JEG]LFX^2,"F!W0L6]7H*C7/5I6M"?!QE".:,D/-%E/IA&CLPYLQX2")
M.@P42!U$#&O/*-OJ#^E%P.N:12\1N_TX!0TD9^2/@>GVV!]2P@=7O6[PN'QK
M.&*'ND@)#41IOAA-@G4A5HF;;4S%/2>KN'T5'*((P!HO@_I()6J^&*&MKTB*
MYZ`@ST$N`@&&G%=;/M,C\,BB@P'%M#G0WJ>5'B;CO@BRXN/VDE)FF0ZNUS,*
M!C3306(!+9Q.IV<^F'S<\@,)(L=R>$TD?"Q@C^;M;LNK]H76`)N#:>$@B06&
MU4<="@SJCK]:G^_H69H+N\&SS%:!@(($:!R@A*54;5YYP\?*B."\IQVE-PS'
M:EYC+!Q"M5.2M[0"3SQC]UGXZ_-*FA7_+,+'AU-\%O=P90PXR`(0O3T8CC^T
MQF"L"B!Y:D2T4UY3D3ZUK_3IH0%?T=,+;*!RISQ"4TT2^S_P$8D?+&[`)*RB
M@L7W&9I_/>[)XL?K4\+&/M+G(%[S*>PW"(*729`CB6(,M="PHD:I@C[]:@3M
M@],)=XS7=A&-D@ALMQDUM$['$"E,1V>7Q&@\P0!2/!X]7ZP!'9TRROAH9`'!
MD$(9=&+1:Y.WLN=W=$6C%Y]#U$:$0,(#0XC]\I63:A[B<]2>"+,*H>HD-8*0
M8&J(2*(#&W54AP@6NCC6>D(^*WB,:;Y<'S9]N$RSJN^#50CA0A\TNG!CR,#:
MI$5'7.APU.B%IU(K8GCBDO$YP8+ZK,4)?BO!42<5GK?,I^*$>T0#S0IDL9"'
MT1@.D]PMQEAFL&I5T7KXZ;Y^N'V*98`>?+IE$/"`>:M[G+3MW.F^L7/PT=5X
M>)FJ?JKPME7X<=^H,()8:U[`2"(O!S4VS-$8Z;!/'SQ1Y;I<5\O#YHE6X9:&
M#&P?/!V\3GLU,9@;ECK1T3(R>`(D%U!,F>ID1TNQ$,4Z(Z)"%K8,ZYA!*[PA
M!?.S`2O^R9[X'=)I'*TB^?DN:5_:MN=:7,U\F'N>M8!Z9*D<+;9S6N-YO0E\
M".&,AN]EM-%,L17M<`/TB'"0N'\#!=)<#SVH/=[N/5K)VI7R($P0+\*7*$^S
MO5-JQ90F`L=O`KS?M42KNMBLGDRJV0B3)NYX/Z1)\1SOZ_*M=0TWJ.`BS(R,
M\'T-`*,,)(RUV32J,%7EL?(<3<.:9E736M2(+(M]ML.(*GS.PQ#\0.:CU?*H
M(7.0^I`I7OCH96SP+`H(&O!-7N`@+2!3F0B"'4#T2&(C9\TW3)!8J/TX#7ZK
M[;#3_8]I'$;)4[T4LXJBS"AB:>6K!:WMWUOO>C/C5,YM957P!%"N8,N_D&<:
MASU:B&=;?++O+!OVUB`9#Y[+[]RD9)`%4E;J;-67=U"7QUG,5;OSI_L/0<($
MC7_XR\BP#M>$#E3>Q@"@=L%6%]PP<]/,)'PJ?"SDAJ^]0*M+49B6;1IXZRG@
M.:5V?+[?`$`D`8V%%FJ3/H8J.%)>]W(7Q_OS*-X5-#P+ME$1Q+*/^-]W0?R0
MZ@OVM"M2ET=`IX;<V*)/'`M2I*1%2F+5)0:<'*\!A"S]FY<CO%N<X$A8<F15
M<J3L[R\XPH(CI#$1%I8@"YS\3(I10LK=GGA=&?F9MXRJFSWLV/_<,LJTN/B\
MI4G>FR+ON_UND`S0E9$&\+KW#HI)[?XK._$?.9-44^'C*B]XK0XF._&?K81'
MIX+G<FWDA/B0A%7F&JB[.-)0_498A%4/N;/MV])+`#H@ZH.DC-,;@W"'JEN+
M(8[EEF:!Z,,24YZPV)3KJT91,EP=?&V_SR$0?!&$4G_,-ZQZE&>D=DRWNRS?
M!4EQS67#];XC)1G@FX\T\`;Z,U7SB)B(\SXD>W15NZ9MA4Y:!)RW)(T/#XGK
M-U<_DUN4!G3/Q$R4$`6\=9`_"HR[_.U3$&P9UO???$GC(J]^PPW*-V^_>O^V
M-"GEK_^V+)YI5MU<O4C"<_I"XW3+WZ4,1TSC!@N*4(&$%>B.1^:3FMOH^?WF
MK7G50@-%H.&%\[;JDU;?WLY[.>]6;(&+QDG;2Z_6:UN+KM<F;9+O8A[9F5:N
M'LX`<<['+]US.T[Y=QS5J!;O.Y7>VCM1BY=&MBSNE6FU&^P3:)_N9+0H8N$]
M;X,]_X^XAD>K9)K61D/$8#N6#4/M=)6JIY!R3GF3%Z#"OGZ`'NW`O!!N2X3R
M&JX*X9JBJP(U54J#9F%F&CE?R+S(BB@O%N$+;ZB>LS#A+MT'<;'_8<?O9"C8
MM^!9_ZC@[SJ8D7<C.G<0X`J]L^03\TE%0`31)0G2T#@A+2J@P<18N"N,85,4
M".ZYO<2YU[G[R/*,ZKM:\55XSJP)+\.\HS&_DOPV8"_-7FR7\70D>^<;QDKY
M#]L%L/T#H-?#+BSIJ'9)@Y1$3DA)AI1T4`098R*^H<(?B\KF(B4?[O]\=H;&
M"7M+N]&"V574Y]/V^]4S#7<Q7:YOLW1+LX)778N7XO>BB*7]`W]U4S]M3`_*
M15L`[L29Y52Q?5Y./B%BNO#4-0'RLR#QGRA\\QB`4T?`8$[;5JRU_MI2IF=,
M3J_7T8K6+_&!;AYI9NN.^XE`NUP5M$[668QK2Z(<.KONC8F&#J(!]YM:T3-+
M)FOD;CX5$DTT%Y\CXX5H,P'*@[5?N;.0XG\C/_._XO`^KB\+YCDZ`J%U#<?2
M,+/@NEG\]E1H.W\(0R$AY^DFB!)<)MWGQ<&M=X_P&-GLKN3,)_!E7:!2Y'NU
M^7`2E,4^?G55E2=4[#+)2X-9\%Y!T5KQ/BF94;#E3<=NMOQP,K0U/X:BNA\;
M99#N^_+@5KU7D(SL>I\4S:<`RE7U=930JX)NC(-S`TI0/L`(9*?62)]TX5.)
MF(O#9<R,$<S#F`NLUNT82RL"5;RAQ>G^@3U^\9@76;"RWO6QH`SMQ:R88"7.
M)X21..''VCD5MO0MZ>!RA%[X[W>;39#MQ1FEDH[@09W30N<V[67>R*=:"SP"
M+?^8T_4NOH[6QOL])J30N=P#F)8*+.<2/AFWS]6"K%&\=#>>\;G5KEBZ^=6.
M3")0N1^R-#=NW6E(#:T#K<!:ZIR8AN`F66=\Q_LZK\/=J]`TT3G_3ML@ZU:A
MX77J!_KFY\C;RC9K?=9NLQ.%).=TF]%5)(ILV<\QY3^P-UQLTJR(_B%^KWQ[
M4P\_VO/`BC+'8UA/45=%FK1IGY":NM"1-OV3XU**DT-SAR*JF)!GUS3/_TC:
MG`M;3Q@/_1\D^H0^\8>\3O1P1:\C&QE]/>RX%L:G+T1)^J"TAWXN=D%LF_<P
MI@?;-<((L"I<.\K5E1.QI37&!_JFG/D%FK#'5GH-FC08B^Y\H4_;.IB&+P=S
MH$*0HQ?O-H>>P@%ZN'^+]ZW.6J)Q77U"HG4_/1("47_]D`6\U>P]7>VRB->'
M,\T3!Z[+/RSRG!:YJAA;NQAR>PAT%L&5-;JR[7(":4@)TRY[%U1_E.2@BKCG
MY4DZ"D_`E_M>:F24!?#1(:^(E&ZBW4;>ZM'T03&K@C*@`-,B>@!4-PP3X\M+
M?&C3N&BZ0A*'OLF.H-8E*&P-?8PD3],<V4#LO'I]MMLLV]5.J0F`KL44D+IU
M=P<-T>%48$PD8*W!+07$>/FD$2^\P66G?&5H<>7^`/CC?_8L&2VPO$96MS4)
M4VPC2PU3$!PC=%0@PW.%;MKCX3YOTH*6AY+9H\[2A(E-$;%_\3_D/BE/.\J@
M#M>6"9T#[FQ8=9Q?"':+!!$T4*=$9X"/-%'J)/W#/M]%],>]SNQ\1Q_2JYPW
MSESI;X'O:U)F3`ZHQYX%7+/;S-A\WA:WH@!Y4?PT>.6=%/ESP-ZXNMQ+]N-X
MSM+=TS/<%?+SX:4DW(D&)%'UF:$OF??2O<&%M[4>VZY'<KIZ]Y2^?!DQ^Y87
M<C4B?SY>A\C?_NU*_(=+0_7DB\_;*).;O$%AG,XV)0<55)C#/1;?9DIM@$@S
MB?!9*.(&=X0U+-K`"GM@@04&EK*JC0;L!'7._=/'XBIA\8<PS9?!BLJ.V^9[
MJ8KY</NJ2D#=/<O'@C1C3P@?7=Z",6]IJ2^2=IB]94+-_!J_[CSAX7@P#1ZW
M/61C1+=9E*RB+;^\O??]`?>2]0HSL*^LU18HM?^8!+*8BH;G4;Y2Z+]VMVV8
M(/3>L0GD00O1FD:J>8BJT%TP+II[I++H*>+WC_.PF,7(4^'SV>U^!5_1K,IT
M=)2RC/3@&XJEC>HS@F_0&]L@H\UX4P/D=YU04W$J+BQ:KGD>QRB7HIP,=760
M"DJ/?:B'$CF69T7X:/B,B"N.K<3!C%XR!0ZGZX!&`((D=S&D*-KK?G1:,E^`
M)/*S9>;6-A8ZF`L=]AP!Z<O8UPV($44R1J^]K?HFI[LB+X*$[XNA<W-]DF3D
MT7K$"&J!4%W/5UXG4"_.W+($2FHX<@8:L(.197U78SF9G^PJIZ/+*-C@3#\E
M]44:]:US14J*9\VM>DC6Z$/":[%B'Y#<&=63I^_E$>(L7V8BM?^<QB'[UQC]
M^&W)0SLY>W9T)%QN"%4TV#J*M*D@\HS^6,L5?\;/GF=4WB09[$F4U%?F1DSB
M@SA&V9O%4?3-%I%.<@_EE:\2)D4T+^Z"@MX7XAH!RL20+3N>C)NU6%#$X9T'
M0`]ZZ&H^X01.B"1!&AH($^66D&^/-@"B"G$&M+GF*WCV?MI`CL<_@%%'`\H=
M--TY32.2P`>##6&;G]5H=GDFVG7S.!SL";9SAH-L![:T)L\Z@:)%5LIOI\,F
M9Z,M%-C']LB5Q\>$Q22*9QJEHTWHP!P$,P+8O8%9KDW%-*(T./`):S]X.P%O
MJU(Z!'GL2?$A26];Z*#F,)RQ`OI8B\-\A:75T%A/"[JP,8L5`SIB>93-PV9>
MIL+]H4P#2,]=W]B'S?I,_MGM\&.+<.QUWR#,L59\#^MUOI.%D<OUT6/SR]0K
M^'$B#!(-.;*@F]TLZVOY-85'1BTGC!0>FS8]#W@;ZHH'VXH'ZQ239</(!"3!
MEX]14$=C'A9A_$32LMG-'B^5U"6*,9G4!]T\G=2:_5H22C:`NTF65MW#JTDJ
MC8T86]AEJ=/.J2650OOUNEQ1&N:7#.?Q656SK)*.`%!?(2VDGKT3,9SP\=W3
MR_#!D"4><>%ZA4G>O]'>&T(0V+A^(*Z+)*=)Q&*6?/>89DP1Q%;>+LEYSP3V
MTTI]*@;+*4\3C=,U5!I4-[_D4;EEQF^Y%GGLN#RO<I7\]!RMGH^>R8^3TM`V
MD>3T#.BDDB-C>C(-)25Y@7Q)JPQ>R%5"!+F.(2*2(J+H9@J6"'M5L:3,Q40)
M^218TE9NN<T]#4N\DE`X>((M0O*S*T9)*@^C`E7-\R$H>*>?/3\&?$[S519M
M[9H:FQ##4<.CACI8OE--%0?@^9T*]6R$A3OF.,^.-7=3X2QHM@&/59PDUJ)>
M1R^N'C&,N(^E"I.NDOO=8T[_ON.KI_6:,M/PE"_7K>X8RXPW-G\)8MK?(D=M
MU+P>!!K->++H6)(%.5*'Z2R$:2B2FB0/=PX:\"PSTJ*+)["9A#OUBHQY[KSA
M3EISAWGY5;M]#5OCT`FYXQ[C8&0/LG!G#!,T'/.,8']\=NK8(UZ8]+S0JJV)
M#*E^BHKC6,LLD61%$&9GS@YR-["IIC?M?20!PBG,D'HR/SXT!MZ#;EQR62(:
M<(E^..D$!RSLMQG]`-9?L03WJ?<KDC?WM%S"?_<%;T00H6BT-IXP?S(29B39
M-Q>SI=E#M+=9'B:WTTGJ!_X_/("^#*+L+T&\,SZW;$P/-$XU`SS<1HV(>6+]
M2/A,(J;BB3B]<98J2)[$__*.:F3-<;Y,@M,]=IP6*+(HT$)=AX,]<UWUBNG:
M*_2JB\H=%9?R/:2G-*'K:!4%L;1M.?O\EY2OX\WZH7B0!XKW/-@QD-:JFQ"1
MDAYO0=M0)`U)4M*$CP9'Y$8+Z:I!NI;CP=I0_;<3`9>P<6R&1`U#JN].LI(A
M9;N!1YVT=*R^.U<<+HL=GRFRJ9<3*["$V+Y>1!=P>[H0J*V>UFJ@>;7;+%K1
M]Z8QNSUA\!X-%BP8W`9J33]IVT9!`44L/P;L%K!M'S#X7@RV8NW0RF]8ID<+
M<NOH^99F][QCO$,DVZ6!(%SM`S84D#1K8WYD@(AIV&(P$UR=K=5FC<A+X.75
M`.B"*>,OUHJ8^H"AR;09Z9FIKU<IF8<EN/A<T"2D8;45774?--B^4*_ZC8F"
M9M8LH!^+8#6UJ<MH.H2"5\].BWASA%AL2AZ:&DP[M7-!1I9WLU7KX>2;I4Y[
M!2=U)<QR??Q8Q2TI?:9WB`I0@#(,KNOPZCG<P'2-#\2M*.-#8VI%.RK7=S,*
M2)0R$38T@8JASNE"%3.%FS?[T*R=2D-%PR:>DL6Q3LD'([H8<@^&#.@-LINY
M=>J!R6\[(8'HN.$(H(_73/*25M'L=;7*^+Y^W51N5;.#_2JMZ[+$?6MH0@%7
M13!.5UAH`2*U%TNGLDJA3_F5-<`65"$KSJW`.RJ^)`-T(&<:Y'VU6H_[]A:#
MXMX$T+IT>TD?+%"W%G./8+^Y^;E31]0\,U^LV.]9&.%T#[/C(T!S$\YLT=W,
MWBV^;*ET3BIJ**]H'I\A3)G#3@%?*Z_(G'])#5$Z`Y(-R%(<?I9C..'A939&
M+2H7Y;*&28_^N4A*Q2L@)E7AT]0(CU`>#0^B2(L@G@+"`R?<U#)/=+18-F"Z
M+X*LF`+$*7V*DH0W2GD,8MXZ9*IZ<XGC(K$JDC%&,>V[CU$K;Z`(M2CM^%@T
MN2ZM@;6I=&];UXG.$<ES2^5I)JNXUYPJ:*AK`][V.%%YR+(D@">:]<'<>^+F
M$"B4U9C\(W]28Z^.22*+4JU5>S@PM=7K40S3;1RL1/^MQ5-3?Y_718=7Y;6K
MR[5X`\M@U9(X<#1KS0J-0->TB"#66+%6.71%D"_A!4E,4;$W,QH.!$^MTRUY
MN^BWOM0W72.Q=%#R,<0=D;Q$%V>Y&0^30,S)<DQVXKLY9SYVO-9'&VW4UL\(
M^Z/@[3X9KRJ$,V-`;R#'1.[K?NCD+5F\KL#.6@YZP[M>9KRB*$]C%OQB/;5-
MF,_`+1/3:BQKLDARE@;P1[%LA-'"%-AYX+<W;*<8X[AQ),#<II$TP5,.YFH%
M7/M$:$S`'.M7U:K5Q.0;D482K!FRP7/%"K)*G1"^R1I5;=\P!VW^\K`UX`W<
MJG0T_76(V"SL@H>)>V!4<R9HO!GV=10\1G%4[,_B(,^C=;02LO&0\JYGQ[\U
MBMO<J8.$;S[,Z&R&EK1D3_R:&CF<R,V=)'CT!_A8;A)FB/[S<<V,U2$SF*Y3
MR8S#/^`)[Q`Q!4FLYVU`U"&?K_68LV:XLMKU&<MVW<\--2XYM*`(?SS``+3:
M]9^TSDJ?$#8:1<3W:L`9E,&,#["G.&;"9G"#%3(3`!R&A>`XAJFQ,3R(86AI
M/*+,7LKVQ2I=[^-$&"2V=&3!L8"V^DOTEF1C*F"9C`E&-2P3&B;[N'',KR][
M5?067A]R)(>O;!E)8P=#10\[,+99\RYU42<=QG@>:"9Q'(89V\1741XS-[=\
M*V8`[2J(8/696Y.L98>'R#*8(QJOX;3F>)9K^BC4K!#'V;,!U>(X^TRS,@R[
MN!1%<<[$''&JSWF-0:N%@!B'KGBJ=D;5\['BV$EJ=]R?W5_&8^EZ,%7V6#HR
MCU*/$>PF1.G/?`QRJ@9Z/3&JK^CX652PFJ&I;(-?0#I?99%+/&Q^-,:=.IY`
MU+&TQ"L7@.1XS)C\\*T]PA^0^@B*Z]H>TSD9;U-B&8W.4Y=T]LP^%KU*M';:
M*N@THP@:7)J"[K2>$O/XK;&#X22>0-$3;)3@O)]K3%B*N`Y9Q&:EJL.1F8V>
M0E3X/`2/\>"I%=4TN+Y^QZ^OJ<G]68R9O7O79"\.V&"O5V@&.NCU20R$H%]'
M";TJZ,;8S>I(X"E6:\/2R1(?1\1`''WL)D&"J)BI(VZ6U4O'LN;357*WV039
M?KG6^J!E<AKD4;Y<\Q$B4/B0AHREZB:3W>!]G">!K-K'8E*GM:"DR^/7X>3H
M,B&"/O][_00B'@'8AW)^9K%`L0D;<U4^D+'F47"+_?VEYM:&/P/<9XZO>.IU
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MZJY10L12<:'C@BU=\6U#FFW\PH(6'5Q1P0%`\Z!`3B-\WKQV9RQH_-<\5$_E
M:,2!C19&F0P@<?1"<[X[MZ=!-D$G`KJ.DHB_T`^[*.15[Q-B.DL3D<'8!3'#
MM9[@X"Z;5*T19\!3:TL?&&019]?>.02<'6.'PXK_)8W9)^=-&L:*.!64,<:<
M2B98V_R&PFL(.XUQU_A>ZI'H@TX?<.3--Z\CY-2KKW/0J=5='`;K/'J)0IJ$
M"G-E;=8/Z&$,0X\`6YNF:CZ`81H;:XTIK##M(QKCN(MR?%CDS;<@QLA/A7PC
MI!Y]!#`\5\EV5^2W6?I8MK#BFXWK8!=;-X4R(8DF-M+"UE@>.>^$M&;*W7\Q
M%V?(8(6U#:RZ<Z'NTL&7F$&R)[+W$4G9ZY'OY**3O/D.<4`Q+.5VD<2@B'ML
MO-_Q"M/E^I8R66'+5/[SQ><H+QC_Y?VTXOP##8U*>(R)@53I6$#MI%)%03)3
MO68R_U<UO;K#N20`&`V,`Y2IXK8!ROY%*Z#R6G:IHL"W5<\+E;SY?OX*`D"\
M2$[TV)HG=:&3I6T:XT!C$X95A\A4F_X&9T!5Q'`<`5=#-5I8-:=P0;;^1P58
M0Q&[_B03:O?F=YCJCUP_FRPZ"IK/EAY@159J9*J'%B>D]4H(<3*A=8'V#T&4
M7*=Y?KK_D89/[-W$042^"'R.MJ?[JV25;N@]$Q=1$'6=R@;!I_L^8GR;U/%T
MS^1O!']P:`:F:PXQM)Y^0OCSR1O^!E^0TSTI7X*TW^*$_T&^"*G?A%2O(O[:
M2UT6?^`\`87T"SRJOL"C]@L\NGP!!$>YYC(^AJ?$9K(\$&;^='\3%+N,+EC(
M:ILJ4U"!SHXIP>E:B3--D6/)SWPTYD-<?9_,\AQ7S_>"$+Z;8$//TPU3*?MH
MH#47WF\?`-&)&1](?I9#,1K>[A<Q-)&=SX$D9KWV/V"KI8K'V`V`=XDZ7L'Y
MW)E1(W(#)L)NZ18,)'V4F_X>Z&=>&&=UBE<]&_@6TBX8C="5@U&=FW6#DI,W
MY7#X36\S\3*Y][)?MKR$/E]E49G9Z:L1/Z?LYTV4]";;!J['LR(-?+VE)1NZ
M@E<3X!MDBN,CY(`,"I<U/OQT33+%"8QP4O@^MUD"X$>6-7:S!":W63J8@;$L
MVD'M@'T[=U-:0"[>%.B`L3JJLL'6D7T<G'S_5U=T@V"/>QZ@2#:X+=54%QS9
MZ"A$T;$X%LU%8;FV[5II1@QZD3\$5;<57L_@DCI9A\HQSCM88*N;5'Q2``)?
MIQM)IV7=OUHT/=SYS6[S2#.FS*)6I:1;G;<W<N)Z"B"N>PC4L5#)\<(YRV*E
MZDAB-0>Z\LX14*,A=<^(\6OK[!VQ.YJRENP8%!*?:Z1+:D]KHDCS^=?K-'GB
MQQ]OF3P\!SGE#7`B87Y4]1M:@SA$#MK'#L,]EDH^XZTX@EW-(<TDJ/*&*3`6
MEAC!G:^AZ!JY7S.Y]7#`B\?'M"A.H[1XIEFPI;LB6N5G:;;]0+DY,'+!0S1`
MG/`PL$Z#(S&#'$TA?`[Y6<Y"D"]_);CLW;(SL,<C8"LV!XE+-M0NM5,V4RT/
M_;_E5N4RRO+BC`V.5D'\D$5!O%Q?1RN:L("-K;G#W:I0F@-URM&2-.@.@34;
M.D>^A'<2%$A%@@@:/*ZOJ)"2#)@]F9P#5\?H6=@<D+C"OYT:O_LNP4@,6`L1
M6%5,*-1,0+9#X&8)AG<(G,R`KT6[IXP/H:-)Z]IQ6YH@$8\]\'X)EB0P6['I
ML%]AMU_30<_E9^]:+A1VRU\G!V,M-R7WM50/SU'F:J@&C+DY:?C8RX8-_?(K
M*&"V6I-SX`J]]9J%!4@MV&C*:A=YV1H!#WO&EJEQ^L2?4SY@L=TRULN+%<R#
M+0,R(/&5$;QCL6PF58:(M*8ABJ"F0+>.8GYF3-Q._/'=_3MR>;[`%#KY8B[M
M"@F::4B"(W-55,=#QGKHTU1`K`O3S89O,P7Q?1!3AVA'306VC8`&7*>P0&:.
MZL&$CT88JB#&Y-$XP!K4J@&5L]'(`HI!K3+H#3"@4CY;3NN"9H+^#2TXX=QF
MKTDU&6:320VELUG!AY8)8C98Z$*.R/_CA>*PE62+129M$X:%:S/,];L6LCZ\
M;:37$@QE'->N1R--2.(MY[C6'`\<*.FX1GH<T@.LNK9#`Q9Q@4='J#V+/(XE
MVN<JPHA9@2)-Z&VPYZ2MCC\J)X-X70V4SK5RU5!2CD5U]M$"2.L:T$V-:2NG
MX?!60P*F]E8#TN4A]&K-JI^9EP^U6G#:T`5=@MHQH,]&$Z5#:BA4RH7"+8V`
MNX6L5+$)[H-Q7JV.\$V%W]U6WW35?---!SFRI:V#1@\O=NW5V<,F-<3S11+R
MFWJBY(DFJXCF1JWIS(B`.&8#:-V;BNHI).!5!^U)*+JTO2YD]HOE$:"MVI.0
M+)Y-U4P=EACJF(<I6`:_W$7A$[T17RN(F3RF&9^]=TB"#Q(##40,H'8ZS@:_
M$#&'5)-(,PMA:OSU0'2//1PQ9@)C4F&,ZUG(H@M3A1P.*0RUT2>-OBVBE_LT
MWHG^CS8I]+Z),.GS?@B='"T?1NIQF)+FR``XI,IM$.35."0^7J<"FN2X6OY]
M=K(S&OZX*U;/49*GR1F_$#.[HSEEX)[/*&^(XK*Q;4H4=I_;''IG-Y7?0=',
M)7(RJ683.1VALW_%F#WVR3U!/S>@5Q)T5H%>B>G(P@%;G3;85K=3:-_BXBNV
M<+F*#JK_+M-LL2JB3?!XE5S$(<WB_6*U*^B'/8W3*+RFNU_H)@IL#T=X/PGN
MR,0(3%*=A>*+XZOHN"B742<E>7*5D/(!1#R!E(\@U3,013L3<^O+;ODR$DXY
M'LJ86K`ZI<YKQJZ@9%>4$%JR*Q#LVI3LBLMG((GA1K53`X<[1C)2'E;Y8Q(Q
MM<M%`ZL'^CG(/YRS=V*_J9R!<ZAH1QDT7K1EPK$2-//Y^0Y!@7P@YZ0B4D54
M:(/'$1F0U@QX=_YN=@ZXAY+CLJ!H6!!4+"@C3)2!I9,9&(XN76R`AS'[4_J<
MY#^FVU]8,-L\VB)RU!(`"0@'(!U+H1A.RO&D)9-X@C;TB.R#*R=(SR6D73T!
M20!DHD7JN,9`A7SJ9X(HC(-/8OO+(2;IF0Y;#=,'IU,@(0>5>[8(HP<K%/\[
MV&S_=5(<'H4LMI]CE6ZV08)MTTBM)`:5)RH-&6F-<4N3)-_'+T%BE=(9(`'B
MF@=AZ9<)[2F(W+,/JG0N5/8NVA/6MC4%B9LVTRJUHS92*9_]IS3;L`#_.:+K
MB\]TM>/WB2S7ZVCEMO$T2`UVQ\D`;&<'0LPA8A*I9Y%R&D(__YI`>NPI.:!<
M2Y0K@9+6*%,Y#5EX8*R8!KM'AEKILVU$LR@-%?=Q]F1OF^$P&SCMU^TDR\4?
M`:_4U/)K.&5]S%OOSZJ\[5+3FZ0]$;9-T"$$U<<&O-W2D(O&ZM[#>P\1>/B4
M/CRGNYPMI-AR@[>%*2BUZ<NB)0"B_0.0CD6$#2?5>)XJ)]6,Z?RB9:-]2T#\
MT*WRW6$,G(F4J4V>@8B-I@&7[&-J-4"MSEI"H$9R`.*@1E0S@#1B-&#\XX-J
MAJ/P&/L&`Q&<[Y3__>XQIW_?L?C_XH6WIF?/,XD@AZ9#W:RMAM,]E5N-)&(H
MX6,5`>>LN:5IH<SN6@P%37M;N%[*0)7%+BX?)@3=_D('T5#N%&$\2#9F>EC@
M+2T&A=*HD<601((IF=DJ1S\9B3=2ACP=B4.QR3$9"BP^R&!I8R)7/KD=V<7U
MG+[0.-V*!AI)>!L4HG^,;-SXE%&ZT>F!)G5A31TV2^3`C$XJJ6R3W"(BMI\E
MF:;3:44(8UI]3#Z$1WS82C[4W4\K0L@2[\YZ89"9<U0*GU(<4U7NYF3@]+2;
MX3$6OAFUS'K3WAI$`&\JQD2!9$O>3(N-@8^FHDEXOTV3/,UH6)WM\O'`%F1A
MJ^MLX"MEC/F7>GIS)A+>"DR$.V[ASFO<];%(!(9CA@^N`XXLJ+#7<8,B0%L%
M]UDLQ,%*$%P\B?^QCR;T%&"J``9`=0+;:CP1$Q!8EU>)R>%8I#.HX$G^+ZX(
MQ$B;-!4>!JKDH>OW=!MDXN-PTT*+(BX?YAZ+&)($C4.,87=R3_5$&8;44Q$8
MB%\;7/>H8TJ\R((-.P4>#C2LM->GUW20[-;!JMAE4?+D$F-H"<#TG-9#ZG20
M;0\WT">@ELT&WTG3MGGX(WG(T!TW#K&/K^JG`.J:5*".Q4>.0^UV\$%Q=RF6
M6+"N3;4J,^P==/HR3;_C:\T=(%8=7:_GO/G#JE/LM>8*C($.P==P]WW\&B".
MV@G9!N,KZX;<44*GCLC'&CA1@W3ZN=@Q&Z6^NT1M'2W(@L8(5O#M].U-2>`+
MP%M08('C<MCVDC[LQ:W%?+ZBK#OZ0I,=O:.K]"F)Q#6BU?4*'VCQG(:'`_Y!
M0].*+0?*4.5<3DSH!J)B#&E1.6GN8R&2T`DY&L9HH:@%&X4%-]5E?;S37??:
M$G"WZR_TVEHR9XF?3]T?Z.HYX5<([^]I]A*M:'Z6YH7U?7\J,M!%SFIXG5,V
M]4A2#25B+`K?ZX4G6+%Q.5E3BL:S&HJ?44&S7O;F4Z4/0904-.$]W%0ZU&M\
M.O.@O%X/@&[*M!X"HQVN+[Y($A95D4WK_8'TP4P&3-R+0G!\"@^D7UZNRVJ'
M2]IWTY6FFK-G/FRE<2^@S@YV>>WD<EW7#5]VA0-NT66&HGIU)M>J``LP?>N,
M`5G^5J,B!B7)2OT8\=+8\Z`PNY^N=R**RV)+",,7Q?*!\'E7Z]<O19N$4[R^
M?4[5Z_V1)$]U6F!^JVU+!3PT\ISFJRS:<OXOUW?I/HB+??F`A_2.QNPAX6V0
M%7LKYVI.%=3EVH`_EK#67.Z,R]FUMC^DI"1`!`4\'GHLT.F:9"5H?"Y\.I"D
M2$E6?MDMIX#,Z5LK]'`H8*O-/E4:DOIR?4.+>YZ-NZ49[[@>/)G%";KY(.&"
M'E`G#UO*&C,H/!\I)I!F!GSXX`8GG0F.?3CAC">IT\7;>@:2\,)`A]11QK`"
M^?04C;*\X!M*C&84Q)R^[$EF%5RHJ<#V$-6`Z[35Y&-),UBH!I'#\40*]HA6
M#2*N'%PWID#DT1UT)$C(G/Z@8AGT`AW0*J_2R_+P41*V3SAG&>.V*`TS<^V#
M5&`<O`&X[G9K=2HM"0^Z`K2F(?#U#LC*W'5][&Z]2\(H><+@Z7V_TT'7@F8:
M%J=OJF,:UV^H8#Y)>_:=^<5I;!D1A%'*[Y9[H1_8^H%?G6:7OM=2@DWD#X#L
MI/3+\2*-T,P@U10\`8$S,KZ,;B';E%/(+F>K:'[+8*;0-$2AP]C@D8401JII
ML&U@H)=^O8G^BZZ*BYQ?L5C0D&\F&D4/O1-A#A?W0^AIEL.'D7J<V,2&CPHL
M7Y_6K[]B`X6N'UXRFG/]"+/=$UFLWG[]]7=O?]Q]>/^'[Q!$#%Y(D80%.GW1
MG"-6*XO/5D/Z*:EW%?L>H<WU:3*>%G1AMQNL&-!)2[/9I+7]WV\@`+.%DP*O
MLN_\,I]^T[*%RRM.A;SYH[B4-.6'Q1K4%1\$^HS^?1=E9305MCB&+,QP,`(&
M&Q36%F`<,W:99N73C&*0_ID@08@*A-;H\-O3RZ'P<8@5@LIZ<.783H3`/L#P
MA8`DQM`JA#K(T&F#SVFON'4;.]=]?B/[EG'L15S.?IFFO,'].0LX%^&&#>5G
M5_J^F/Z@C>M#8$^"N;.F<SRJBN$%+1EY</-0D1/_X`1EBE.$]P<T\00G4W!%
MK&R:%4]0<85Y\77%%+'F":9EBGO@@H@KR"(87P-C<.3.S[KX;-#NDO"PI.,C
MO^^]/L//G\[WB1X^I7^E@5GO%5N:(/&0/?#.;N&.7P!U5/5%!)56LPIA%L6^
M(K\JAY."CZ1&PLY5^I*O0'[<%:OG*,G3A)SQ@O^L:;MYQLBQ?[/W(&_X2I7L
MV>_%S.*9DK5@3,$8PW^=D\[I6H`8;23F'!>-D9T0C*8=)^=!@Y^30A+=.9H$
M==SG9@\F-&J+-9-)_BCV1+M"%!O"L+4I=BQPLVV"B!!=;MSP!'AC@+<V;LR>
M9300')G?C$W+BT%;)F$+T\Z,&;+PS<4:&%3/V)L"#XM6DSU+DSQBSU&M8+OF
M7#$5).A2PNA4E=2B=3`2^G9-A_=?3?K^]N&-[R=`$J3H%4(=BVBUP>]Z9'ZG
M.'<0IVFRRV^#??`8TTZ@4YX"MZM\L:0-?<FR)2-Z]D`J"D20("6-WK5520=/
M\#$N`QX%`[8E`_K6$/E$#/"HFX$1`61AAZ-%,+K4V\$<>-BVGT3Q8W'QF1<*
MY_Q9-VG!*)>WBS=GA8SB$7-J("&*#=ACL2WGDM9D(F>7E?ZD-1\^#30&5-J"
MFDBHLEZ>A!-"M0][9L.*)#ZRUEEUR&2KL&.=3;Y_#IAL+%Z"B+U7%$?%_G1?
MO@1=KLNWLJL;LB>/Y[2R*3L&CBU+,J1-AYSN*Y,E2I)+6GA"JM'YP&N*I.:R
MGW+)D:#-D<=]I>VB$.?31!P9Z;CS2"PQ9P2R4,O=;%@>A;:Q&1YF\"9-[B@_
M2,.-[562%U&QXR\0Q/T]C[KF7T\!)+`:`M5IS\B$LIE`#F9`=$`:!]%;DC68
MH@-,/2V_``(E%U`Z2$CB(2.54L=`)OKDDSUB=F43K/;6+<U:\V"S/@<`.LOY
M\J_(&I=IW[D\U[BM7AU".[WY#:5_9A)KGO'HB+G/5@KC>,BY?INEO/5HE#R9
M>E7%5)BM%!6,CB!7`TDS$H?_=("P;2#@<)?>&)#X1[U6:/93="KA%0(W*8;+
M-'N@V29*`AF%UTE.*U]I1A'4BYJ"[L9@[1PC3XFWIO(5?3T9C_?UQ%HNWT4A
M60LK6Z(&DV%U=]?C?%@=6&1NWDI]AP,`&]V=KZ?V-0UR>O%Y&\E-9-Z>\?U0
M'*&="]5;6P&DT_^6#R/-N&D:G)J79%B^_OV.K=TX@F;_M*U-D[0[=6D8;@CG
MCK:O,QZ$`M8]7*<EV@[B&A49HY**\8]^"F+]]J7:PNGH@`81>H#J*I]R..06
MY5B@CF]9)%F)#7)/<BQP[:1]1I^"C+=;JA$BC@D,-&\X$AA6NS%N&%@\/7'6
M%G2Q27>&W<J4DV%ZCJBA:"X8J`<3.1H^1^"`0ZA`A2,0H_D-3SPS'<0Q'S+^
MQ2`.O49&`88D>S"D.)K&(WJM&4.9+UE8%%\U7[\IC<I/]V?I9ALD=KW.[2CC
MN&+$D`D:VR`HD!:)=NU=SFL(2C)XH@9?],M=P::(?H;M=B1KP8F6/6G78>9\
MRWPU$2=&N.$$B!7(8A$GXV!QA8J%91C#Q!V7A!J:.(TA-Z((&]D8@M:8M&Z9
M\5PFS?+<R5B89=W347$Y%N,%"!M;&&6CSP:QE84RSY<]7:Q6V8Z&MUFZYOM&
M92U%?K;+,GY\+@EO&/OD/TRC,Q?2T)>`VK&AD[Z1LTE[.M_<Q74QZ#@8Z><M
MOY:L`PW\GE`'23:Z.]1>C.?<^WB2;V.^X5%-@-OE:%ZYN[7Q!*0XUJ]:J<.:
MBKNJH\YE"X"9_B.9&$CO'PK$?+(KJGA/@YQW"MQPFR(BDE;;\]-],Z1THHM/
M018N19XQ;ZV%[M*8-^CA?[1U4A.]!;0_FXRYG>T\3N7M(R=#VH]J7ZG`P]GV
MN"H@%`\\(>4CV0^MU>W/_+&D?.Y_SAOY(^'L;K,)LGVKWC\GHJUW5$3((@L(
MGN1%NOJ%I'('1LT7\+!D6C-G%,%,:N->I<.XV6T>Z6`;M>D>#!5\3<'"F3S"
M"9%/1!$9_I./73[*6L#[(L@*=+R4?^!NXV,2%8PAI_0I2A(>:#P&,<_(3,2.
MBR3$SXP+&7*=]G,";"$SF;W7+HBF,O:OQT_^(&+-JT06>OZ0I7E?>F'2H*?O
M%5[[DJJ?K5-:??E$7G4AG\E_PY[Z*UI,F?&T,7@'BX8G/IGBN/<3BB&E!_AA
M(E:$=!VQ)[`W^V$7A=R[X&3(59[ONO!?_=I18\EG63BJS?CK\89LM;NF4;%C
MXE\!F6O=V/?HU[IR[&?CE-ZO]<3&!2(X)S$/)T63W#B6W.,-_LMI\_L[2'%J
MN_MU2Q["729*J'IEXM4N>#2F:M(EC]I.S6CF^:>6;OQ<?%SY'K)5C/AC^;)5
MHQC[G2+[)X`O65R8,J5-KIX#9I&G9]=/U5Y-U;`)950]!M)F%5%:V`D0_T$B
M3D1-NC*5-CW6"Q4T^#6"L^$S6P*X6KW7$^$WAQMGC_#['OU:(_Q^-D[K3>HG
M3NA/(,);0UZVP]N5#/@9N[3![=2F&)`=+<^[Y5>R_FKB>HV!FC2N5UNGUV/<
M6]LQ/]'HZ9F)[H)I=/!$*X=UFUG<!##W:X&O(&9C_VS;W]5[D/)%FJ:[XE5^
M5=L!_V2_25D"TD\PP"D410ROE77P)0\HW`M0%:&!RT,48>16NUR6489;P#CB
M*Z%=;H[*=A?WEKO76<SMY";8A9J4_7<T+]B?.(=6Z6;#^"XK,_A&57J<+"9;
MB+@,(=<&O1I<&0.X&1ME/3RZ67U%7JS>FG%T9'[QS+AOAW[5//;'F-2]]6S:
M(?-PN#_&H-E&O5,(S;V#)#<]"`E>X6&O2:SP.,NW*4SP*_)_/44L*)9RMN_U
M:M=S]A]@4J_76SZ(S.]A_1"#'J_>K/SUK%4<[<>T"Q8WXS&SU7X<SBD^6N<4
M[^@FB'AN_"Q-BBQ8%;L@Y@WKOW9:NLS\BBC6+[-_%K@MJ/JM2.NUQ.T=^'8#
MP3^+!??(&^8Y]S3(\B\./@'.N!W&#ID'[R!&R*,OIM1+@QVCM]I\&SUV6:I7
M'@K)85X*I#LG`.O[K?>IWGJ?5M;[='B#A?9%WS-:;LMFH0@^@:NE[M]&\$]&
M67<>Q<3#H.1A5O-PU>(AO_=%]#)]H3D?O4TS69=:5\>S'UOMK?A&5]DT,-Y7
M)Y$)F\^(L@<5T6/,EDGLF_SV-OEK\B$Y?TA^9/^Y_RT1+42+$_$P^CG8;/G`
MW]Z^_^MW']Y_<_Y;]GY;]G'$2K=XYJ_+7X4WJF-O*MXFH>)#,PK1"R4;!N*9
MJ1A_H>(Y8D,IO[EFCZ49*Y034?=S!?(@B%)IYH4>5PQ)E.31ZB]!O(,LLCQZ
M$10+K(E8/-LRJGXR$8_&MU3Z)X-?36GD().;.W&.N/+?J@S2ATW_?4H>^[W.
MW$6.O2[G]7CQSG;?0UKPRS0&'/I$!V`,W@7MQM<XC)[Y6/;TWF?^SAF.G+X,
M(K:NXW\\Z,4;4GG9)^/KKHCBZ!_<NO(EUVD<K'YY>[]Z9BCSJG*!%RSP`9LT
MI/'KJ&6<AILZ#P5YR!K.<,USE,_8@L[HHE;/--S%=+D613ZG^[,XR/.'X#&V
M7RIJ2($O]K0P.W:]',UMC:Q]8D9<S"`_BSF=9NCPH=OP=S0+O@8_XGRR>9M%
M+\Q(W3);+O3K`[7I&*V8#16B*,%TKFJ2`TD]DOPLQX((G0UK38RH]JO,)UK-
MX0<AYDK)TNI</Q%H4Z>"ICG_(6T<I)@Y\-G&JNF^U'Q"]\`>L%RW`H;%Y\CX
MUJ#^R5#63`7E6,CX..Y%VPLBOLUQDR9O@];O'MB/.;]!@F_2_,R)X;%VVL^F
M-7:Z;S;C]7*M6C5Y55:+\VW&NUE!6_+0]M&>'9WE4[N4=5B:SU.^J83/K#K*
MA=F%;4Y",:,IC@H>XUXE8?02A;L@MC+%O9/!3+$"2L<4\W'<%C<C%986)!4R
M/@PXAZ$3+KW#T$@6H'+\%!7/=U0VLLV?H^U#>I$44;&7ELW68=B2AW88]NSH
MAMK-8%*D1`Y7>@;075M_M'T:^HD1(99L`'>0CGI@Y"#=E,"C$O1BLXW3/:7Y
M>931%9O%_?(9>]8N+G@NW2RY8D,*I.K2&&:GNV@UD=0S"9M*6G/Q)&(<OJBZ
MF,KJ<XXA@8S\:1IDH21LN>PP(07E,<Q@JB6/RYN80LHY^'(R%E]2:P?-/^-\
M<<]5PBM'T\PNSWPT"VH9T'GYSOTJY0`\5DS/=VV@W,MT#]O4F#L':]29#&I_
M>J!T+J:HAR`U,*K/,6Q2%-]BQDTKQNF;8$-M$@H'<\`VJ`Y?O+,MQ?Y%^-\Q
M)0T\WQEN`ZU'2/3;9ET)F5^DW9;[1[.A5_,=,!JAP;@^'^']P1?6_0)EM&[N
ME2:?1<G?=VR1?<6PL-7V"]^73FQ6PLK9,(M?#9C.JD.,)?5@(N0&36QH]G$T
MB]J!+S.?]10%-&4YS764T*N";JPO<^TG`FU+5=`Z\:8HG:J+J7[F8XD8C,\V
M:3^7D8G2?2MO2_5`/_-#:8O'7)Q/L[!2QS,!+507A,(ZE0-9^%8.1668%-]B
MR"CU?X@YR^K2%:5A?LD`\F/&_"C*<EW=W&$=WNFI09NH0;#=\CLY@?#O3ZHI
MW'A5DQ#U5?1$%[70=7H`?U+`!;?09O)K%DV:"*^'S:[+'!=/['_.@OSYDM+!
MM(!N*HC55L+H67N4-:MB).%#"1\+FBUPQ1`(#"N.83T%!OMF#/X@D+04T"N&
MVH-JM6(T15T4;%Y"]PIE5><M-61`<\):>$-*7`V?1I&'E&!T4%(A@@I4GV;#
M)K^'97$X#3XHB$AN!;ZAG\2?C%/EAM3`#J*:@NUOL2QG$CFU/@4J9Y\0-E^.
MF#D$'1?I63O0C`2!"B**/85Q@.5IK(0%=Y322A7UAR%M]'!&8Q/41]=$-U7V
M5N*5;%>U2CK0ZUD-P(Y)"5HG&$]DVU]N4Z14(EK%3H8)?*DZ)(YF1S+ULO@*
MVEE4R?B\R$2LER^+9YH]/`=)[Z4NQK'`7._SZMI:V#-\@M86]0Y3_19$O`8I
MV'NH;^["$-O\D^^OK2&&/^?KJZO+3I!XHK:9S>XT33#<;.Y\SNV</A;-VREZ
M&6N=?0\%Z&BQ%]2QX/-!+6MQ`M"Z=R0040M$T0,"/!Y4"YE1)*B4L-FK&4IC
MN<SN>/_4@PLLFOV3\J_&N1TGVE"QF2,CE*41Y5C>?U@,/CFZL*6]`UD/PI`(
M&HD1AS>-MKM\H7'$/K*O=:H>@N^QYW%'GR)>@L"][WT1%,)]G]-\E47;OF2\
M-FD]2`QT_\,`:O?,9C.%U'-(:Q*BK1!??'F-+VPF@6P5>DB8\>:(H:QZJ-:'
MX'.TV6V6ZS45N5&3V^K4$T'V_!40CL6H'$:J<1-=P6:_56[Y_FGU_L+](-DE
MUXF1>H]<(T,@B?B69BW7K=X?'CEY)4GH!9<9[(&L=FLF_VUK+JJ3"&Y8#W;)
MMKN,%UT5O!M`'O!6K<%31H4]1N-\'"3:-JT_(,Y(]NJ/FJB)K,X/69J/LW>O
MIHYR+U_'#)>]_4XWOC*9*V@B6.6-QHR;'3^%P>U:UD"6U@!=XM5+&]RWSX=4
MX17L^(GS-FD8K:.5F-*R<(LDY)DKZT+S2=\%/&Z8EM$3[#*)XV+M)Q_&+;R"
M7#P=42)Y9B:WV7%LZ_!%-S-H^K2W?YBKN<?"?A&&$:<8Q-*/+=='QKJ\5\QH
ML6],#"0!8`&UTR"SGDI*=[]<=R.<'_K=_:S[SB,B3:P#&X"LB`?4X<`-2=;$
M5D?5F11+!9TO+JL:)]W3["5:T7Z;>9,F\B9,81YS<=M$^^]G:5[<I,5?:7%'
M5^E3$OVCUVYIW<9T+P(=D4W)8E4',%(^C*CBLQ-2/U'&86SE>!"_\0>R,079
MTX(TST04A,W)UX])5O^9'W!L^$0_\Y_Q%8Q.KMA&,=C46CUC[_-8$*=A/X8+
M*0:F"2Q#:E`)*V.PG2BFFJ@T/.2B7V$`,E'.*,N_L/`E%EB+%'\*RDY^M2DG
M*^&UU="<KMX]I2]?1L(F2/V4/Q]KIOQMV<"/!Z]58<-!O8-I'&)(#2J8,`;;
MWZQ1Y%NJ*<<%02CV@IP!*LM]T+AD.T'5^E4K*9TYN_LXG&IYU%]HQ^\&,[Q'
M_;WQ5A'`JX&>\IC],\QPERE_HQ-2O1,I7XK4;T5:KS5-T;'S$014G^-@Y0)5
MUXQ&38VVU\#,Q^NQWG^1B[<DY)$?#X$?4OZK<8SZ\%X#CC>'SC(A8L6T+D&^
MJ-@6K%Z5+\#XKU^/O_@5?LHRF;CM/0((G@Y#Q5/+/4P<K_TZO5)U"I!?^R[N
MQ9YMX:!\_FM='6@8.H.]KT\7GQ#^:'G+_*\BS+?@JT#^PO_*\QPRT9CV'B%Y
MM8'\D-I.&JT/Z*Q'N4=-:Y'GNTVU-I`V^3S*5^DN*>Z"PCA=:4<4],B4!?1>
M>1=S26MR$_=5TPF?CV!KTA=O#2RL@&53`',_'C;7MT1V8LQ6>X=/CEFJKH?E
MJ3+$LD;X(;UETO+,[)\\/B&*3ZH#/D:U9C;T0,K-[``KFW>45?8/*:D(D/+$
MB2PZJVC`5YV-!%AVT.-KZ6T%^*"5<SH58/OBLYD_,9)R-`=-5E>DV:NQ3U/<
MWN[8XB$?DY!F!X^[H7V7$6BZG-H2AVV@:\\*9>OURX/&\LOJ5@Q!YTB$"2.%
M(LDU%A.JDXYM$W5"$EK`V:EY/GJGW[ZTSCOQT0\MM>`'LE#*U108="IVLP,C
MA%;5YGMXNB]_]6,:LR>:]><?I@(:1NG`*3UK/8F<[NN&-.4\1/&#$S9:8WO<
M5[4FY%G.0Q8I#`KF<'PP))70M\VTXA7;W<-A@M";>B:0S:^=:<>V")(E/B"9
M^2;;"JCJ\ADTCL]:@CVNG.F*[XQ;-KO'G/Y]QTSQQ0MO*\?WEXRW6_KF@FV5
M]`/IQ*#U,"+&D9_%2!PWVHZ,`6Y#02-4^LT`M43-V0>C[`HENY;R;8DTX4U+
M%;<ZZS>QM<2@G=405,7-?,TXH/N@04"!^R(CP32K43"0RAD/-!Z^A/*FZ5Y;
MTS\9R@NIH`S)'-AUT_.@`/-$6M'2NB*=7,VG&M62[B8M[FE1Q)1[Q*N$WWVF
MO*E::T.&"4+[)!/(RH4^/_W:S.(5*.(60LB;K3T_AXU9-_VX8,N+:\T5V":1
MY/6<MU^;1*C7FHNONV'ZM?KJ:PSKC='`8%EX=,3-9O%Q+&L>2><CROGP/=[J
M9/P0+="=LF&@0W*5&US[#;<)-@:^-^6D+Q!M=GGAHA)7(><@V[LR5+WAK2HS
MO9NY6^<=K>H^>CH)&OO884J@73B'0/9WW&S-ZF^[B<,#NP"L*U\0),]=)<K(
M(9L*YBLXX7#Q>1O)IO/*:^ZF.0S3>3#T^FY,%DYQ@5K]%)`KZ<!8QT\,<8-"
MZZ%H'/EDRC?M>2Z%YKV"!K[B?_C!BMK<VAW!&NN9K^[JS7[&36"EQ'](^:1?
MQ1V.9JPK#_V(H\2=_DTO)3O@SK-.KQ)&<=/X.CBCT:(K%N85^W.Z3?/(.#>B
MF@X>[73@=*Q!.8*40S#%&^8O'_:_/'S,T"].9IZ_3Y8DP&M&Y#_8S^P_W#ZS
M/_S_4$L#!!0````(`+R&K$1[!T'!^D8``!OK!``5`!P`871N;2TR,#$T,#,S
M,5]P<F4N>&UL550)``/D-'%3Y#1Q4W5X"P`!!"4.```$.0$``.U]6W/C.)+N
M^XDX_Z%.[^M65UNRJ[LG=G;#UQK/VI;#=DWO/"%8(B1QFR+5O+BL^?4'X$VD
MA"L)*@FV8R)ZJE0`B"^_Q"V1R/R/_WI;^Q]><11[8?#7'TY^_.F'#SB8AZX7
M+/_ZP]>7FX^__/!?__E__\]__+^/'__GXNGNPU4X3]<X2#[<DS(+#[L?OGO)
MZL/UOSY>NUX21A_^D;?U@33UX^<??_E`_OB2XMAUMO_^X=[9?CB9_ON'R4\G
MIQ]^.OG+V>0O)S]].+__\/$C_8;O!;]_<V+\@?0IB/_ZPRI)-G_Y].G[]^\_
MOGV+_!_#:/EI\M-/TT]EP1_RDG]YB[U&Z>_3LNS)I_^YOWN>K_#:^>@%<>($
M\UTMV@RKWLFOO_[Z*?M74C3V_A)G]>_"N9-D4I+VZP.W!/W;Q[+81_K3QY/)
MQ^G)CV^Q^P.5013Z^`DO/F2?_TNRW>"__A![ZXU/NYW]MHKPXJ\_.$FP_DCE
M^-,TK_UO)3/G@7L=)%ZRO0T68;3.^OS#!]KNUZ?;JO/.//$"+UUO5@XI,\=I
MXLT=/_YQ'JX_T;*?A,U]ZM;5RS"(0]]SG02[%XY/27E>89S$7P,G)6J$W18=
M5FBT]VX_.A$1V0IG?>L%0_,+!@$])^2_E/!XMIAM<)01;8P06>L]`;ETXM6-
M'W[O!0>C\8XPKG`\C[P-E<UL<9'&7H#CF`S`YW2]=J+M;/'L+0,RZ\X=,B[G
M\S`E`S-8/I+.S3T<MQGDW3[8$>X3]IU<I9/M2^0$,>TO$78+(-RF.G;Q,0J)
MMB9;.@O^D7H;2GV+[C&;Z=BUAS#!C\[6^4:+:O>H7KNSUD;>*QG0KRU5<%>[
M\RRP7GM)-CJ)H,FPI<I*=C/MQH:HM8X=I3J0;%OTJ:C8\?//Z;<8_Y$29->O
M%%Z+CAPT86[F"ZN)R*DFHE`\$9F9`;M\&!3^"QW%QP=??+:G1:`U*$F#AA8$
MIS:3M^ZJH#%S<W('[=AOP]S\[.S-J*T[*6_3R%S=NG^-ZJ"SQ!5.',\__C11
M?A=T;UQTX@6_)6FKDYG1S_<T9;9G6-9BOQUNSXIBPSW,^>UE+6JMA]-*9QDK
M-&KN)-->K(Q&S*VA7>;.@T:,=^O$2+].S'>LRW3+:ZN_/4A[DA4:-=KM>?T+
M;OZ%I+6LU=LVLI5J+^9F?9.=::^HS&:,G<]Q=KAN+S%>2UH=9%UF^%&4?R'`
M2[H"TZN,7^E5QLGG#$+Q\YWS#3.DNG\O\FNCK;S2I__\<(P>/I*))G2O@W9=
MW:M]U#X_)V37TZ'7M?I'ZO=+F#A^JQ[7:AZIKP^XG6RK>L>2*8YBW$ZFNYH&
M^YH<]E-;D#L)DEEJ$^&83%W9A=$=Z4:C@V2^Q8%+;W7R7VD#AJXXLPOI<-[X
MG$^O@,-(-G_37Y"H\?-O<1*1[I4-^11OUCQ2KHM^RF=QI3X6$LFD'>/YC\OP
M]9.+/2+UDRG]`^W_].-/)\5-]+^1GU#^Y2>\].@'@^3!66-&AWE%4;&?K/-W
M'C7[ZD3SLD7RQP9YAU?G18E/F^P&].-\Y?D5[XLH7.O+K^Q+*$7R(8Q<'/WU
M!U(GC4DGP\P04*[T/5-P29!$CG]+%/WMO_%6R,%>632QEX1#*"4+)T>FX9S`
M<"F4&]]9<L3?*(.F-HI]'T(I[LF1Q7V91A3EC1>3Z?J?V(G(_NJ*K%@<R?.*
MHU,;21"@*?F8'IF/$LP+:9;#0;T(.K-1[GL(2EF?`LFZ.E@(%)]9%GVV6?K[
M4$H:SH!HV`W#&_)++"%BKS3ZV68J#L&49'P&)2-7$74Z:N71+_83TH134O(S
MR,;TQO-Q=$E&ZC*,Q-O21DGTJXTTL(&4!/P"<S((U^LP>$["^>_/Y)"+XUF:
M4!]GZKTM/B8(*J*3G^SE1P:LY.M7-E^?]JT-^W(P;(%0\%ENI48+)_Z6R3^-
M/RX=9Y/K$O:3N/QE7ZF*GU'EX#I;W'@!Z9!'YIPP]B1F"YWJK2T7!E"]Y.Z2
M\OYG!8%L&)K"W!L,7"A<(\8'@F^!R;DC-V,+^I]UWB^L<T`47OI.',\6V1@_
M?_-8NP!I'2"[")\:"86,_MO-9AW05;AVO$!`XV%A(`.+$B]L*ID8[.;PF6Q%
M<7S^6'8UPW:/U]]P)!J3_%I`%ALQ19R1*41ABM=7''T+=Y<T$/1>M**760O(
M,-2>7AX*OAW:/GXO6_'+K`5D>FK/+P\%W_!M'[]7K?AEU@*R9[7GEX>";TBW
MC]_K5OPR:P&9Q]KSRT/!-]X?AU^.1T`QZ;Q\#Q4Y4Z@%9$O3X4P-!=_2/PC.
M2"'<AC5>/2@C6VOB1$#X%P-#X.XF3*,6U/&JH1-8HY`N<R(<_.L#JQ;"\C1^
MYP7XEOQ1R214%48GEAF#&CTW=A:!L2&<QS%.8@7#<K,@.AF(`:C)!9NXPZZ/
MPCZ0PRK\5909W"N/3F!M/@QN1"0R>C\*+FDH$Y$!EOPS.H$UW_`)X!A<BSZ/
M@A^R@&\<S[U^V^`@QN>!.TM6.&J(1$"?0FUT`FN\T657$=(X+'6J/._!AS77
MZ#)ZT'EC5KBD_GCDV.,V?SO[Z#NY3T/Y@/8!BP<LOQHZ@373**^8,A!C&IO2
M08E.8`TUFOL<VMTQC+\[S_GF^5Y"[^J"_/2["GT"*\[?;2IL6U6;0!-8BX[6
MD40'U#C&:0VQ^I&%7PE-8*U`6@1*=8`!;A3;YB(02US$A2"2(K]$*>GZ`7;1
M#*[>"IK`VI(DG'*F?#U\8]2,6AR9-BK!K(XFL#8J$[K`!3:.18'&C"FARDEG
ME$836/-5*XXY.,;A];`+'*,UQXNJH0FLY:L5R3)`X_"!T.*8)0A8JU<K9MDP
MC/D\#..TID8CFL#:N,SNPBD:8^MJ4H_N<>3+!%$89OX=`[\6FL":O`S0+$$W
MCK6WE7U%)$Y8FYD!VL7@QK$&-YU+_N'XJ>B!%:,TFD);SH0D<2^@6#A&<3BN
M/:*4T;E?%$VAG\RUX)(%8AP'W'/7]?)N/SJ>>QM<.ALOH1CXE@UV#32%=I)J
MP:L`RS@6W"O\BOTPNU1[3IPEO@[(MF\3>3&^P@MO[M%(U.DZS6PX5VE$MAS[
M-81'XJZ-HRFTEU8+I3$#N_O2SHZ)";VAT]K(H2FL=:P5_VP8(SM>,_>S'2Y!
MT70P)C(#!W$NQ-ZT8'AQ)YIYYMZ#4+P'H7@/0O$>A.(]",5[$(IA<?@>A.(]
M",5[$`K+^7T/0O$>A.)0,N]!*&SA]ST(Q7L0BF%S]AZ$XCT(Q7L0BO<@%.]!
M*`P9@^Y&%(2BJ9F/3C2+,IQNY@WPB*,LE+2R4PNO`:N"5JA#&H6=H0DW#QU^
MGB:K,/+^M;MDD5*_7Q$ZO$4'REE0QF%S8.&\C>-4F^>\$G1@C,X<[V",P^;`
MPBA.C*!8$SI(1F>F][",PP11\]YKL70KU(:.I*%%NR(><YX,L.\,&KD^E!9L
M02WHT!IMB6;A@#9E]$2Q=)WFU(".O]&-VAT&8U:.(8U;M<59F-K'IN`;,B`]
M&D0@_<PJ&<6SQ6R#H^Q[<(F.;@/22UQU2L&MC%,#PI/,\7'\A%]QD&)Q)*F]
MDL"^9'P)\LQ-!]T?A;6A4/]@6<2O4PF`RJT#[$:FS:D(R#@,#$^$""+$U7G@
MUMX&%'`%%`OK`7N;"5EC$RV#,XJA_`4'1#`^#9KCKLEB2(5"HR[(V9;4!/9#
M:\&W'-`XAO<5)IV=>SDC!.PZC!+O7]E?!70+:@'[I+6@6@QF'&;$+XX7W(5Q
M/`NNO'A3>+S/%GF`Q!/1P!96!'90:S.N97C&\=CM0#(ZFS%@M[06K+(@C.&5
M6X4KWYA2Q54A<E<:V`.M_7ZZ`6$,T5L?PB!L@BOC?<N/2]*ZP$YKVC2K`!K'
MA<XM?7&-8X4#TUY):'\V)8K8[#*0=#X>#6%1I7N'F$Y)F&P?KM^H9%(O7N7O
M":_P-]$0EM:%]H+KP+<2MK$<E\I(A+6-9/6;V'PIK0OM-]=!!92PC>,HQ952
MFP4<VHVN`^5"3,86;\@=&TZ4MMV-<M!.<OI;L?W>C^'<=.U$`5'+N/02N7!B
M;TY-MYZ?)L(K=TE-:/\X;7H5\(S#N^(W["U7!-$YZ86SQ`\I=<F?+3+0M3MI
M=4UHUR"T6YVV@K2'V>,CE:%<[=.\:S=^^!WN9K\6L:3JC%[4F(-J`'?\9)&A
MW7B,PE>/D'2Q_1IC]S:HK#WGA*#7/%R1@C5$N['A1)UAD<%?F/5AFKJ&!/2H
M:K?M`CXYM>)*94-F+BP-(*7G[O^F<1XP^B5\PO,PF'L^;@!]"<U-$'U\#MAC
MP:2"]22>,41[OUYO_'"+\04.\,++PIN7NV;L7H9K>KZ5W8TKMP'L%-&7&G#.
M(1I2&84O3=VK@/S9Q^T]+'C5@5TMCJM`B@(9AYEYG.X:QU4894^/]N;H(5Q*
MU?4_OVTA<+.\9X\17I-#KVBC)*L+[`ER7(51D<8X+J6;2(M(J,'R,HS%V7\%
MU8`=32`UY4`0T-&2;+CM!LX@??252":-[D;X;HL1)^(/[?HLN%PYP1+?!C>.
M%V6O;VFWR\M=UHRA7!?:R^4XBJ`ECNYF]2%L2XC\(NS0/!/Y_]<D5F0N47ND
MIM@(M/?,<2<4/;F,(R;5(6:R*]LXGGM50"@=%P)WEJQPE._SM91+I4%H'QU-
MZE7U1Q7Z*/SX!#*L)\[H-#\Q&H+V]1G,',613:E;OUAL0#Y$K9*07DO%5!H<
M@!>2+OFJ6J0*?Q1&9"G\9D[[+GK4;&D`?DY'4J!#W.,P(:O?&!IQM8#V>S)\
M`Z^!>A2/D]B(;P-R)C7EGR-H;#!!R4PXZ$APCF-V(9-GL9$\G_^1>A&95Q,G
M6'IT198=O*1UH4.7M226K25*:$=QK#I`2@1(ILQD^^@[04(V:C3W8!8V0T<Y
MN(U`1T'K5TN$L+O/(4/0%W4!&EELH,.J&=47/=@CWJ)4EV\FMBB"QM!D1#[$
M$ISFU`7.$$,@SS%VXQLB27K%1B0Q6]#0DS0]K.RB6UX930;I<"PCEK/X*,$=
MA4&E#K5$.%LTPTN3U3;_`=-,PO071551;Q!-!NE.W%U]]$0P!I?A.OH,V"S#
M$%^_X6CNQ9(X_)*Z:`)KQ^U-3[AHQ[;V_.9$D4,#!>8855>=_6IH`FN/[4T1
M6$#-/1Z'TX$GO"F.=+/%0YC@TMPLX)]7!4T&:5IMQ[T(9'>_N0$?:QGB,G)`
M01-8VZE1[="#;>SA.N"QEL(EFR/Z?]3$\^KX=&P\XL@+W?V[*X&^Z#2#)@/)
M#*%UE-5%.(8()&S,YV2,1-&6#(?,@5!;*_;JH\E`LDD84`<&-&/.V)M,U4AO
MHV3,VC`=2/*)'K1A^I.Y)2/7ANL`:)/QG&XV?B8GQR_E=!LLPFB=$Z80(4*M
M!32UT>ZI`0XZU:[9,)./CB<R.-2+H2EPEE8-CGB^/4TTH[!0YLZ8+\X;/1I)
MR&R41%/@C*P&^#P`-`YOB5(<#V$P)W_<W=(%+N-H0U\=^F&<1BJA@;LVC:8#
M2>JJO=YW13V.9Q'TON8V(*A2*L3+D$@B2JAS21YH8>Z1P9C]&!-L-]A)4F$&
MR3;-H2FL;=*(,K#UK*TX@%<BSF,^@B2-Z.U,\=KC916%Z7)5O&[.9<52#O7*
M:`IKJNQ!%?3`0Z]7'.9KKPT+@WN1AO$W+UEQWO*J54136/-C7XPK`8<.:-R&
M;=Z%MF)--(4U'H+P72&'#O^@2_A+^.@[\SP2Z)+M>*G7`)K"&@N/3C]+`-#Q
M'3A:L-N)-*_6=D^DR@/S2UA+V\K3B9;-H5-8`V)?&M)!'-`!EN6SQ@O1^)AT
MA-[(E^^KMI>^$\<>V>5F%+Z$U+*Z_ZO"A-*Z;70*:WH\PES323;&+)=NU?4O
MJ>=FAP"0*,Q7.)Y'WB:/JG.1QEZ`XRQ08+I>.]%VMGCVED$F`C(9YZ_X"`6/
MH4\.8C@^=F3F6;1T@B((T"Y^=!Z4[K$FI"I`D./O0DNKY,@UT3Y`K.=._:Z-
M(L*[B.X7HFL7OM@Y\]A=`8XS;4IC.,80`&GV9T<Y]MQ6>V:\S69]6H,(\=BS
M%J\?"A.2K"K`7,/KTD[;5*8)C5:`1[@"!9S!JX=Q/..N?$?7>'YX?']@]EL^
MA4$GK0LPZKA]TAMV.LT`CSL5%C@#3Q/E>$8>/2273L\`EV):MZCL"@!#J]D1
ME5'$J0$\8+@"%5RTC7U`U$-F@J6MW-UFTI/UW["[;.][T*%5D*&EW5NU\=>^
M6?!!VH4_[DCN)(_Q#'=J!/:2$CXY,--#+@X@3%6"KN@Y&^FT`S#$E?JG,JCU
M&@(>QKJL\'RJ=#&/9ZCF%O9CC\K\JPK#KED08%QE-UFKT"=TQWEGZ.9>;T@I
MMP$\F@Z$S1DN.GC&,U*>TV\Q_B,EK5^_TIGBZ.DP][ZO]-"!705B'.UU16G<
M\.I`)[7DBY4W8@1(QC-":I>8876)Z527F*'X$O/],G-8EYDE@61S](UT+#.9
M9QQM!6#YE<9]02C$/8K'.30+=CQ;[(W;;?Y?E=E<K0'@;+9]JXFJ#&##`W&\
MIJ[P*_;#S()/0"\QS5WI!`HJH%$;.-EL3_SK"0#:M]J41:(F/O5I0E0-.&UL
MSY.#!#FT`[89K?@:X]GB.DZ\-1&,*`Q,LR!POM>>F3_`"NUF;>JRW`NC/$S)
M$YXWG#AW"5EJAP;AA;E>4\#I7GO6EQ;2@';$[C5DD/KBHE(?./-KWZN,H@C&
M$1R"ZX*BKC.J30"G@>U]RE&6PCA>E]^2S;D79<_SHSR+MN//%G<AS<+SBMT\
M@8&Z%K5I#CA3;,\:U5(BQE*E`<<NJ!QBU'6(7PDZEVS/JB(&7FK$KU9K1.UI
M5"6CFAN)U/*J5!\Z5VS/>J(L@YUYS6J=J:(&::Q#G"K0R5W[7FP$L"MEL#O2
MTA,1$I$YW=S7+(U%.EOI]*%0&SJ):\\JHBB!2EMLM\ZN*;!,8,4#F2S=A8ZA
M5JD%Z'RLO1MME:50:8[=%MQK)PJ\8$GC#S^O"`7J&B.I"9UXM6=-44!?:8C=
M=M\'_+UVPQF%`?EC'D<DUKTTUFT*.A=KSSK41AR54MEM^MUWH=+5)*7ZT-E8
M>U8?91E4.M.#]=<NK[07^HCOW2=M(#YIU0&_E@G]'CO4Z=B=D?W7/(TB0E[F
M9J,R*;1J;]R>;&U%,AXW5EZ\`)BI8%Q1*Y[G*^RF/IXMA%)66M`UF[(V?D4+
MH.,9C.6]HU.[<H09B'^:4!:=+L6',MSZ"%LQSA%6NUR#&5CO+_3K<SRSWWKK
MH;B),;Z\U\`^S/CTM9O+'8(R'.\L*-X-T!(97_>ABWWI3LE0R\!/,HPJC#F1
M]!CN'C!<@[/W_!UF11A^T`;.,+[WB+22,*#1G[+/5C_<XV05NFI#5J\5NT,P
MM`,\GMU7_GX>9IA9%(6A6M^SJS,R0]-KUMW-ZSF=NY>YB>MBNRM3Z-/Y=R?*
ME4AI_]3Q&[9$<3"(U]1X]$&NEG(HY"OG;Y[H25*C'/"NR"A[;`79AVLWR>W%
MM)-#X%*;P(.SQE?AVO%$#Y;Z^!SPV]@#?>#,*_T@MUO[KM<;/]QBG(7.F65=
MO\?K;S@2K;J\.L#/8/LBF.,V(Y#"*`(K%`=/J3HTR@&_ASVN"NPCA\XT=Z0%
MB2="<@+!MPE>B[8JW1L'?D%[A/V-$1D9TT6@79%$S+59-RXL;=L6-[1M&P=^
MBFM&0]H=OY2$8VH!;!4EQK@&,L,*5G;9Z,E;KG2O0C3;!'[#>R1]TY9);]&(
M[/(%O,*)X_GOSH!#<P;,GPJ3WHI=UDB!AS"(FAYL$J.@L6_\29P&#8C)[H-^
M)8F+;?7'OWDXHB_+MG?T79G$R*C6`+#UT2C?$I62R6$D^E)(+1MPAX"E]D:M
M=H`-B>K42E1#$>M(-.0VV*1)G,GG1&HM$M0"-A]JLR=1`B;`45@&61`GK9B?
M#,)JV"/SDY$9!UD8IZVH+VH!F_-ZI'X'<!QQ4TWLK51,Q$:_`VRH.^9^U)"X
MH.<IC@=;E7"<@>X\V7E.[KT$$Y@93#0+;)<SSCW#!ZZ[A$:QY]DYY-;DH.3F
M7RL/%#C/%(_L"8B'=#R^D#7K[*RRSIY7UMF9DG66VJU3@O[=2-O12,M-`M"%
M))Z]U533XS2S&I3.$&PA,9[_N`Q?/[G8RP<8^</^N"(_H3N\=/QK`B/9<HRF
MC%)`EE&3%#7)9V/D\M@O)7D?N-;(_2)`AD:.R`[ENM=7`T+ES)KGQ=K'/<(S
M2@'9Z5AR84Q'!WT=Q?:3^_;W8JO@(*Y0&\@$U]_TI(?=<G<I_M-P\F7I'8U"
M;6`SG2*)FAK0@#>$#4A[!;AWB`0#'&WK^*1V64$M8,.9(F=LPL6P1K$>W*11
MX"7T!6/@WGAO]$^QW`S/K01LQ^K$MA`5M#73D"]B>1:[I#EU"D\YR9K/K0-I
MA.IUI1<A-G8%`S.]UQ%)E_/#PM!I&(3,L,ED@[![D:9/T@L':NE<?5`6.D4"
MAQ`.>ZS>VTW>.9F*7,]/J:'[F9K(,SOW]=O<3UWLWA!Y4=_HM+2C[4=5OMBR
M&Y`][>WOJU"9%?I?"'H6FK&$ET-29*7'P[*JT)D8^B9>1]V:4K%[[C/[2A@X
M\8(276RFA9A&<:YL]^@7.$%"!T8/<(SCP'@9!N3[B4>6R<>RUZK[3F%-Z#P&
M':A60#8.1[T:4/J`+GYTMG2_I$/]83WH#`1FB&?C`MO0<2[ERM>U@5L^?A1?
MS_'*HQ-8LUX+SJ1XC&4@-\15MX/,G<`?UF3SZ&1L1C_3TH'.;-^/5U/N<R9S
M@C7Z$32!L34:5PCC^L80U(#.#'J>-C1O9;0)HXS=*R?!LT7C)Z$/CJPRFL"8
M.GOBF.?>HR(&P^Y476-RYF%/;\E^*LY"J\Z^!SB*5][F$4=SRM12]&A=N0TT
ML=<T*56`5M*`/I9REJ>:G?\VCE.Z5-]F#J8>Z6W&VDT8Y4!O@P03-HG(R%]C
MCS-)&&@536",D$=1'D/R&<M!MY+#HQ/-HNR:T<V>,90F7;4;-EYM-($Q51YU
M'E*4@[%#\C#]**_CQ%M3X%]CO$C].YIVI(W+'*L=-+'7N5)9C;0E,M`35Z;P
M],YH18-;/5&N>.L4HRB:P-A'C[?X<$"7;-J=S+7C!>+YFLJTO^O\O'TT@3'%
M'G4Z,2:I4C%[R!AK:.><CRB%S7!>$$U@K+H@^]L=Y)+'GT%B2G)8+*=!E^Z_
M%0D5U4$3>^VT:MS*T)<T_V)[2$=>3DR@8(U_MG2M%]O&ORCG6-%H;\2)6]EH
M[79B4L,J\<=4;V0P>5@T.6:KC!;N\>B)U"/RL#!P#$,]HN1D@P<KY&6TP^LP
MHF$*_-`)_ALG9+DGFY%+)YCCZ!)3JZ?89T*U/G!00C85C'V5!AZ[A^==&"Q?
M<+1^3".RDXSQ+L_?Q?:2R&H9TJTJO<8M2[B2.;UEB]"I3LQ.\.V%8/G3:3YP
M#FSIFM"R1>`GUAT40%>C9&(8V%+S@+]?1>GR?+,A)UU'Z/PN+`_\I+H#'XSU
M1@!RF)FLG_`<>YN$3I?+U*?5MJ3S4?CJ^-2:^/7YQG7$O*JW`/R<VBS36K"A
M_11Z/2K>*40OE54%>GU]W&-A':WE+Z\Y"*]23)7_):S_^V4:40[:F]146H5^
MRZU"N9:RJ((>ZK*RZW25'3PN<B#Q5Q)!)>B'WEUI8BXA$KQ]Y0L;F-$?*`;H
MN^W_W?;_;OM_M_V_V_[?;?_OMO]WVS]48E:>QV6CV[=!G'A)2E_#Y`B>B/")
MX%9B3K4:`3;=*Q.K"PK:^M)ZO!I1`<.?`;;'&QS]NK"A7X?PCMJD*>J(=N_\
MRPDP/T8)OS"P!5Z94E[GH=]@<(BY<SS7=[Z?!UEZ:"?8BJGA%`<VFBN3P^_^
M0%\T_-U9XSB^=#9>XOA?HC#=B/GAE0<V72L3).@_]"L%#D-?4F=)).`1G3J/
MXW#N$:"2F!^"*D.R$`N)DF`8J.?^^3+"63!3CKG@L!"T1=>0/8`-#,S]0T8/
M]_S.*@8:#/-0IB+![SH\L&/Y)2E"[>$O=#=:=5<\C8GJ0$63Y(J;P8JL_\.\
MM+KSYCB(\15-4QIFCS3SW<P:1S3U4Y$H2I'"5HU!!8'4X;8UL($>PVF$@-2G
M;W:><?1*P,6J@U16$2H`I-9(50$QT)/O=;`D.Z5,`]48XU:`BM^HPY2P\T.+
MU5?;1=T[@1Y+*G6AXB[J$*:*`_I\;.C^.?T6>Z[G1-MGA^ZIE9)Q\.I`AV@T
M?%4HQ&FY)U@-$0UA.5O4G6-D=X7RRE`A&M6HX]"MA&I@QY1'WYD7,Y1TAF:5
MA0IPJ"ETQCS-0S.@*(3#]-D%BD<(Y;1;BSLXL)L&'G[%0*>*U:'"#VH1Q+HV
M4H<WBB$_6RS(.2Z*Z3T,.:GS`H^*BH,&"]3ABSV4>9"&:79Z2.F*,UL\DGX2
MV7"-Y_OE0,/PM2>)B\68?<BD%TX>,>G1\=RO`>E==7R[#?Z)G>CE>_BR"M/8
M"=QK'[]BOEU=KQG0T'@=J6T!=:#V)64D+]^Q_\IRIF[3#&BLO&-QOX,ZT"V5
M.I*5%R78P,@O&P*-8W<T_FM@H>U?'`V8?<=NCD=I'GL);\)4J`FM&P0-;==1
M(SJ!-N:78G)'<.]X08(#ZB-X@S&-!%=Z"A8OM[@;.'E-T$!W'9E60S=0[Y6F
M#:B\"J,XU&Q@]1IH"ICJHR.)8E3&@DV:):],AT2COF/W):P_\"\B*?)85*B*
MIH!I-SK2J0C/6'3)WH+!7K]1[X(8/T9$'Q_5H]JW:@=-`;V>.C+>!FM)_Z]#
M6F9Y6TG=?3::6FG*DF+:64N&-6C/7=?+^Y'W_BK%B@3**J*IO?8N)7`5I0/S
MD&I$0+X,@QS*31C1:#I>4,0:)W__1K9[=/]')A<O='E$MVP.3>VUB76`7"G%
MP(QCM9[G2;IJO9>.=:7*:&JO(4P98$7OP.Q?]U[@K=/U`_Z>9TRZ\>C)S@N6
M#QB[.%^/.(JL/!&8_`::VFLU,RV'2J<&9E';`XB?'+([=2^VQ8,Q[KV7N!J:
MVFL=4X!6D3FPQUE$\Y;>*P[R_<QL,?OF>\M,]ER3B:`*FMIK^)+`J@@<F,EK
M=[AX":\=:J7+KF+EYZM&<71JK[%+`*DB;6"F+G*"CY*OFQN,B=8U7MGP>./7
M0*?V&K;$J"KV!F;0*GI-#G^789PI'MT<2IC;*XU.[35.\1%5C`W*!M4XMN7)
M>#+4I#MT#Z9TP#VLAD[MM4@I0-LY<PQK\,VR7C2,HD\TY1+WNI93'IW::X82
M8:IX&YCU*>]SG,5;?M6\WE&IBT[MM2NIXJNX'9@1J3&=Y"BHDW8\6S0O(LDB
M7]Y%*DVZ:DVA4WL-3"WA5HHP,'-3`TYY:UF#=;&M8"DI@+@)=&JOL4@39D7X
MP&Q!N;5JMBC7HAT6KL,%MP8ZM=<")$95L3<PXP_I]9P*>DF?7&69+G.AD_.8
M@#Y>%71JK_%'`JLB<&#&GUSMO'E^@"X,S@2M^^K%8;25+;:*U=&9O<8A#8@5
MR0,S%C66BMT-]&ZQJ*T5V69!:6E5:0B=V6M::@6V4H&!69QJYX#R:'"Q_5OH
MNUZPK)8:!;\I?F5T9J\]2AE@16]G\U1OTWAY!KS8[H)-W'A\(Y5"571FKZ%*
M$=[N]<G@B*VV%3>I[V^O/#\EXBC"-^;^?7\0.;R$"F:0=JVA,WL-7>T15QHQ
M,#/8O?-&G02J2\:4_.>1]!DGUV_TD2M_LR:OB<[L-8&IH:M8'9@!K)RFRNX_
M"79AK++HS%X3%@]/Q=7`;%3UZV*R78A3LCFXPV3/H.&;S*N)SNRU2*FAJUBU
M.\S5+%GM0L.?!VXM#&(QWS"40+TR.K/2E*4'L%*%@5FU=K$0!7:L1B%T9J_E
MZ@!(1<O`;%7/.$G\;!XI'A)F+M1RIF3UT&=[K5,JV"H^H<Q29F;<\RCQXN3<
M?:4.DMFSTG#K^,GV2TK]7A.,XUTB7U$X*ZUVT&<K#5BML5:Z`F6_,J0K\SG=
MB]`<FM125Q.D1R`763D#]R$,YOE?1/JBVQ;Z;*4EK!/>2F]Z,(P=.TOI8Q1N
M,!$?#4;P1^IENY8B0^FQ4Y.677GTG4SH57\4<I-*ZX(F)^7V3CT?J;@)X!2D
M*M+G#$`-A':GD^3"N]B^D&]+@@8KU!Y,HE$YD6Q54,,X4BV@"*61@Q5J`Z<=
M5>104P$:\.Q6@#Q*8X6,&W)86!XX&:DB3QQK"0?0***0WJ11X"5IA(E4;KPW
M^B=^[BYY)>#<I)UX%J*"SHIB*,PT]2*7)0HORP"G$.V^/->1@"7Z,DB<=%S6
M2D$G"ZV+7L#.07)0.^DI;C>E!#7*0:<,;<J?3=)^ARVG*7_!+Z>I7@XZ<:@2
M37L=MGRVXT[X=PKY$.25H5.,]GCP;&"$CM?<LS(\X/*,UL':=M`(=+I316HU
M]8()<Q0'&"[DKS%>I/Z=MQ"9*Q5J0R57;<FIIF(T<8Y;([Y$8=QJY<@J0B5T
M/8X>5!!ATSL8NU],UVEV,7:%2:]I;FZ"@?S9QQEK`0UV'25%$E2N4,37CD8^
M`95*UJA6F11&]TW+K[G^!7A).S2P.8B(M>4V!2I-[7'FGP*@L30329@X_@!N
MJ>L8BUOJXJ[_SWM9S7.R9HA,,36:0E7[+IPUD(UBWU9?.@2Z6"\&=(.LPPQ[
M'MP#,0K^OCA><$=VD;/@RHLW8>P5;S/C&"?QB8!1<46@^^'N'$MA];;5/O9B
M]Q`FN/!'`_+$NL+?$B+EN1_&]`)/OJ*Q*X#Z7+U$#GW1^HSG:>11;SZB=9FG
M?O$/N>*H.V!IM`>\.'+)X(RLMA@'ELNY>GC#N9$]+#08CRE-N3,V-ONXALH-
MU\6)50QRK3H0J$CHX+Y)W#,`7I.5IHBS7'57DN=<5`G(\X@G;N867]Q]N^]<
MU9)^RWQ2E!L!=D`R-$.VPFWYI6\=D=2O]+`PL+>2'E-RMBM00YN@&S%U)/,R
MHRRT7Q)3Q*Q)F=WW@;'1C)0B9H-5%MH%294-3M\MG_%T%XL[!>^7UFT"NSD9
M7CB[B`':;88SUFM&%@+A,@Q(\XE'_D;_8?\!(6\2T&ID.'Y2+4ADS"+:X('-
MLNK!XJY2_!+2[*'T!"&/T:K>`I0W5$N^&*3K81V0(3[&\Q^7X>LGC\".DWQ5
MR?^\OY[DOZ+;[/_H(EDBNG[;>%&5W8RA#8HUH5R@C&B!!L9Q//*@UM3;@,@C
MS39,9!^;A_Z16,-95:!\GHP0KP+.V%H/Z.W4Q/<U<')7&^Q2D[H6\8RZ4/Y)
M/6H`!Z4YUQ.SZ95W;E-%#'(*GFN/YI2'<AXRMXZ+D)74V1VS+)-&(2?!D*T7
M0R>`<05-C<Y]0"6;G<..#69.+D,H%D&@'B,OF'L;9C(XO0;0"6`\PGYF9Q'4
M4C,Z1SZ#U`QZ^,B?E$?Q+,H.)JO0)[AT(Q]IMH1.`&,6&M,5?<RETG0.KS:8
MZ>0V(%TAAYDG<FQY3C(+:A5'67E*$36"3F"-@;K^('K(H$]Y>E??U03(/<1I
MU$836(N>*K&:D`9JL2V6L"PQ.`<,ETYY532QPVE+!X^Q,U@_X;^[$*K>!`W^
M9P^Q>KB@3VJ\%#QI;@B<+?;PQ#>A+M-MVD(3V+>%6I2W!6CL7'>4=7>6)G'B
M!-GM4IN5]Z`^FL"^]#.Q]C)!&3N5F>8UG&/LQC=$$OL'#CZ7_#IH`NM:ILF?
M&(BQ0U%_^72*?9Y?6.MO@]]6WGRU!X;>XNU>+3`6W3;-H0FL+YGN`MP68ZD$
M=@>3;A[^[IV$N@ALZ95>+46<\K&84Q]-8/W6NIV(!:!*'1A8QK0L'$$YB=T&
MS^FW&/^1TA5H0?I$EI^81M*O;O9G$7V>]>KX6.#UT*5--('UE-.:$KH"W1E(
MAJ445Z3SKT3RK[B\PL_GLM^\9'^2$^0?5V\#3>PP@[4"5I$,$^B#0_&!E\87
M^A\Z;]TX7O0/QT^Y5Y\*5='4(O.7(IZ*QX$9OYHK4'G17GC\OH07.,`+CZ;J
MS94S]F@R9KI.<0ENWR*:6F0JZP:S4@<8-X8^MG2UV6L'F6QUYUCTJ%RY#32U
MP]S6"EBE#D,SN.WY9!43&CG,/*\<U2G@H!J:VF1&DV.IV!N8R>RZB!90GBM*
M?QS539AJ?32UR&2F`ZHB=F`VLT92]7U`'!]BM8IH:I'U3`E-Q:'=>=NH8'8K
M1Z&LV-W-3+DM2;;4JC2!IG;8U=K@JK3!?F.:$'*V-A5'RTXZT6@(3>TSK^FA
MJ_1C!!G8=J:&&"S<3]F#G<CIF["_87=)[Z8(@M?LG9AF3*#6K9J(?[=[[G9@
MRZGW)^_%5O;2KUUKX(&`NC#`6LI;BV&8;_\.K7Q?`X]O\N84APR;UYX0):-G
MB<\4?9ML%_^<.%%R!"MV;H\OK/1M3-B-!B"C$?5,,Q_Q0+T[=Q":D25*0)5]
M;_<N-4,F5P*]]B##(?6D$]H"&*B[J/@&9W==UV%Z8#0#%##IN),$&_=`O4TU
M@<P"@55&MR6@*$K@VI!#'ZIWJNI49V;%R*=)P(=E,.M$"7N@;JI94#'R=>K1
M=^<YWSR?8+_TG3CV%N1\3KOX$E)'COU?>?K0ND&@H%'F5:.+!`;J]&KH?`CC
M]W*\\^&OYAQ@\P/B=0"4:&2'L+I!K$M.G&Y$7ADJ!)115="#:\PKUKSI@-GM
MEE:$-FV!1H,R.C&T13]0=UDF'#.&!@--@X:/ZE]M](4Q5`=;Q5&A88QHWR)H
MZ"F(N88C`W-^ND/1%8'!HE.CH*&J!J(QA1B&ZA3<9OXTOCH5T_!8[)Z=1&#.
M7;@W13%N^##1-FC@K;[4IY,T#'@:=TO<R=&DRY43+/%M()Q3>:JB5!DT")=1
M75"&"^Z8;(GQ9`264CVXYAR;678U>$>WDW=/M^.GR-OU5I;\;J_DF+S9^!`M
MSP]%EQQ9^J>R#'#^.X;LV235.SP">KB)91BE@)S.F)(7D%-UUFYZ[ITW;YWR
M,_\PRP'Y@''DSR9IO\,#2LS0@2VRW5!BJUX..*.=&EM['89VPC2][[A3R+S$
M*`V<DTYYN6)W'9I$WC.)=+UVHNUL(3RESH(+)_;BV8*6R`1_'[I8FA_)2./`
M.>XX;#+.^Z;0#O.MQ+T3_8Z3`E;=5A[<8X=NMK/X"H)'K<H-@'I$F>*0H1\Z
M`AC%`EW)\#R.TW6&(+Y^P]'<BW$65$$P_TOK@GI5]:,E.MBAEY/^-.3)BW^_
MB3"N!Q[75!16$["^5\=7&)X,H)]K]#FU;/"<7LCA:*T]L^RJPKIE0<PL3>S0
M[SCZ5Y!_A#X1&KV.:S&WL!N!=<J"4YI#*4"_^NA??:Z\5\_%@=M!>>I-P+IF
MP:G.O@R@7XH85IS;8),F-&[HM^+JGPIVX:2^Z"9)H3:L7]:1U$4,?Z"O13+;
M7A;&OPHA??WFQ0E-M9P%,,G<ROCQM57KPSI;]7A`UA'`0$.N,R:\TIF0=^)5
MJ@?K(=4CYRK`>XRL#N\#461K>_>$@/2$J/7VB^,%=V$<7VR+3F=NGG3CLO(V
M%]O;@'"9)T*CQ>_"W&?O8LMJC)[!U9TL^N[$N/TWCB`]NR^W=^@NM@]9A&.)
MGPB[PF"<1HY!N$SI]@0S%@5Y<-;X*EP3J2JIQZXXL+L*GQ@9D0T(=M-8[,>D
M;A&-<L!.+#PBV+3M]]QNOJIY*7L%4+QKE$S-W#K`[BU#F)U%LC%V:P:C*G5$
MTOGYL#"P`XV0&#:73`R6#W>BU3B^?BR[FF&33M:"6L#^,6R*.$-3B,)N7O4\
MKZ'S7\%/TW59&+N3ML6K&S835D/T`G:JSMH],MMY=0.YBW`(8+-TT&/+B6KE
MT`WDKJ%'U'Z/+=^("A>0.RWW;E$#4%X50UHGU24%[;@C#:)77'7(O,:Y%:`\
M)5I0P;CI$L(:IL_W\6ZT`7T:Q+QTNJ8V9YH"3!]X5%<H0,\&'3UH`\S8DF\R
M0VPC-Q?+9?@*DS^OO<`1Q8#1:P74ET%[M.MC@_:P5J&ZX5JE&`A?J3IH^)9N
MY(I!0>^N3$_F[O^F>3[DV4(0MT>I'FADEF[3-@>-,2=FDW/U0TI/CT0ULTU&
MT=WR71!OV`HKH1/`1U3:@U4*Q9@'\3YKQ_82HX\#O4PM8R=P+\.`[BUQ,/?`
M4L35>G2^WR,=!S&M=@!<PN["8$D?PCRFT7SEQ'C77YD?EZ0FL/.5KMPY$Z<<
MI-T6R"*DXZ,3)=LL?A\=JF1/?[&M_XOLED>Y$6!?*@4V.;<#.@C'HQ'2*_?#
MPM#Q>[2(DI,-[B+%V1J=?_L6)LF%%R8K'#F;;$6-+\-HP[U+4*D&'=F'*7C&
MQD@.8YCF1=*],/(<_]D/G>"_<9)DAZU+&MX]NL3TB"VF3[4^=,P?51XU\,`:
MD_K>:UUL+XG$EB%]<T)MZF4)5[+RMFP1V"^J]3+<'J[EUX]\X!S8TI6[98O`
MOE<=%$!7HV1B&-B&X)'V[L:+XN22%*;'ZQ<ZL\X6=]X<!Z3CCU'HIG.^EW2+
M5H"=NCIPQUB+M*$/<XN1P7C&\Y`<>KLJ@GHSP/Y=/6B"%G;HV$0B77A9>5%W
M55!N!=J-K`=5T,(^T+LP<E;RPR4%4/3\?+/QB_0+8OKE-:$=TLQ2KH87^G*,
M]QH_6[\(?GI'0,Y5CL]WTQ57@/9$,TNJ$"9T`!^>B6=!CJI9QQ]P0GL<2VP[
MG/+03F1FF12AA`ZHP[O&Q-^OHG2I/./RRD,YC?5#I`CE4./=X#GV-LEL\827
MJ4^K;4GWH_#5\6G.HZ_/-ZXCIE:]!2C/L'[(UL,-'>JF;YO-G8*_N$)M*+>R
M'LUX#6P#W4K?>V312<(`/SK;+$6>Q+N;5Q[*<4R7!9;=7@!IF&81/M@*2UR`
MX?&HT02H?YB0'`:9FKCZXQ?6Z6A>=Q%Q<Z>C!"94U?!]CWC)$OD?Y'D3*=6S
MVY=(%>)X_$;&ZTFDS*7<M>3=C^C=CPC\VO#=C^C=C^C=CPCZH</,^?W)<Y?X
MP<G[0IH-H\Q*(N915@_8ST>9/P4<`S4&G)->O#Z'?IJM#I))DU$6V)]&?:9D
M]WVHUV#DLW]+$P(^B,,@GP>>B(")<%8J\Z-J?6`'&&7V-/`,]#(LNXB_);OM
M6Z]Q$W\31C2.[MKY=AM<^Z3G_O9\GB;X?HO]T'/O</H[7GL2J[R1QJ%#'*GJ
M@BFP`[UL^QIXI,$X>]+Z@M^<^/Z*8"6_E'JO,OZU&H'V>%%F7AO50*_A_AZN
M@OAOX>9W,IOM,(D9%=6!]E]1)E`&`OK>C&=[=SS7=[YGIA(Q2X<EH=U0E+EA
M=[W'1`ZF)LE''`3QUG]U`MDR*:X%[6;2:AIDPRA9^W58K/W=6>,XOG0V7N+X
M7Z(PE1AI>.6A_4C4YSL!@-TY?E@DD6W4FJRD*P\OKM\PV4`199LM%MY<>N:0
M583V"%$_;:@@J?@;W8N<8[_E@@PNU/XFI`/:][=<AMYR#=8!1:X"NDHE%<30
M[F6,.?_:^4:+XZLB@CG,JQJ0=WE`48YZ(ET?//1[+(@`^Q/`;.\='"+J_?_3
M1<6?#""2=R5\`4&[[MKMD](N,/X$V`2UQP";IX,N`R^'D`'R)\"6*#7"]KL,
MO6CQ-C`X\D+>V76O!)H`AK767X08O3=VH6TJK$/6.^X)\*`,F@`&E-X3)5?8
MNZX.[-3U\CU\684I=0<G*D3??2<82U[KB>J@":!MYD#6##YDG0>-YJY$TDV8
M:I/4K(,F@`&<]4DZ['Q?+FWU_W4S9BPCG.4&$:TBC4)H"K,S[K*0'``PYB%A
MRJ94=E"\G.P50U-`3_M#F8H$O^OPP-:5PD!QA5^Q'VXR/('[Z"396[L\R$2)
M06('TFT(36'VPEQB6)N"-J`&QK`>C3Q8@+MG1:[X/1_H\:7L<.`^;\(@#DDO
M2L]'3;+D+:`IX.9;DT`U-`/UNF[8@15I%-5!4\!]NB)QLOX/U!7[T7?F^0J^
MS/ZCMLR)*J$IX'Y==4F3`1BHFW7MJ=N]$SC+`H,2:2IUT13P8;PB=ZHX!NH`
M_8R)*'*YDCD>)XFO0Z):;30%3*.B2*,Z$F-NSH;VDD3KT@51P)0^8E/D350'
MG0)>#2JR)>N_,==F0QP]43FJ;CV8A=$IH(E#D15NQP?JURRPW-P)8BXIUT6G
M5D4=T,(UT,<>(M1JV7756T"G@,8299[T.&9`',7-\!-^Q4&*G_`\7`9>MEDK
MHQ7=XV05NLT"_V+F[&W?&#H=Z$TG@V[V_7,[S*/0G1<\7P4TRN_V&4>OWAS'
MEV$LS`;)J8%.`0T^1K1```S:H&?*Y<<+$AS0]XTRDO>+HM.!>M8KL\M"-%"3
M7A%AKG+JO,'<:&&,HN@4T";4B2H1HH&:](X<2_$4T&34G5I-I`.U"^['E+QR
M$N[P9)5%IX`&H^XD\B`-U`38S.`>;AT_V18]?PGKS_AX%"HW@,X&ZG6NQJL6
MSH$>D(MNSQ;EBYA'',TI%4ON"!5406<#=;Q1(U2";*`!$AC9*7*_,!Z!W`KH
M;*`&*C7ZA+@&:G.L;L\#M^[!0G.UYU='?*NPI"(Z&Z8Y2G4LJN`;:*B%<K=&
M5@7']4)Z&_B*[QT:5Y!VC7,N$55"9[8:C-2P#34>PV,4_B^>)]<Q#6U%EG-Z
M#A9XUQV416>VFGB$D,R%7S"\=0V_!]5IF-5Y^>Y&HPET9JN%IPW2BO.!F7YJ
M,&["J,"AP.ZN,#JSVOS#Q50Q-C`+4,,7C2H:#1Y8YO,)HYLPI"\5LO1.[IH4
MI?!IOY5\\S3:0V=6VX:ZP*Y48V"6HILT<)MGYZ\TQF#E0T!QT5W^R_?PGV1[
MR#WAZ#6#SJRV+[5`6_$_,-N3#$H6P8."(%C:DE]O`WVVV@*E"[6B?6!6J(>4
MN@:170B1/Q4'C]K]<NBSU?8F%IR*HH%9F<[781HDCXY'%.[:F:^*/O.8XA1'
MGZVV,`E05;P-S,#TG)!IX>OF!F.R##2V#%PG7FX-]-EJDY(86$7@P(Q)1:^O
MTNP2GNJ>Z/J,71I]MMI\Q`>U<T<8%FG5"DS@QA[IHO``PRZ-/EMM.^*#JD@;
M5!:51QPMPFA-O5TNPB"EU^K4+_9@*UUX.G&M@'K-H,]6VY!:H*W8'Y@=*;\J
M\N9D><CR#;]B]V*[>\)#3E!K`>>RJNBSU38F1805MP.S..TLF;/%3>K[VRO/
M3ZF5,P\._9R$\]^O_R!R>`FIK,(@^T5`=XO6T&>KK4WM05=*,3!;TV\.O4Q,
MKM_H=7%,IZV',"&35!%49>?<P=,#Y0;09ZOM2UHX*[8'9EEJ..L\KXC<XO-7
MQR.<>KZ7;"^V!3RBW@5>)?<FI9;0SU9;F=H!KA1A8+:F(M1A?I2?+68IO?TB
M4Q4F"KZA[K-<ZY.\)OK9:GN4&L"*V(%9J!["X`DOTL"E,]1M$"=>DN;]$GB#
M"RNAGZVV5DFQ54P.S&;UF.=<WXJ\^'=%T,]66Z7VD%2<#,P,=4XPNA3G8Q3.
M<1P3F`)ZV*71SU:;H?B@=D\MAD5:?9]&3N'T)8$7./E"7AW/^5.C0F7TL]5&
M*F6,%<-VOV>[PTZ,R6+NY=8X:D8]8?`O*HY^MM5B)4-5<3PPRU2EB$\XP-\=
M7^%H*JB"?K;:$B5!5G$X-`M4Z6AWOB0`ED3E\ETV=W_#*8]^MMN*)(!543<P
M.U'5YQNR-/AT'^WX?M.N'5]LB6PV3L!]$Z75"/K9:GN1-M:*^8'9C';>L7O7
M'*V85VD$_6*UI4@;:\5\9R-1JZM`,YNJ\_D\2K,\0@MZ*B@.V/%E&E&1$U&2
M@_@\_XM@KZ71"OK%5C-32["5FD"9G$SMOI<Y3N&6NRB#?K'5^,2$4E$(96LR
M%3B(]2RM,(\*:!760[_8:L%2AE?1W]FLM3_1?ZH+[8YT;E^0]+>&)`DJ'+B[
MD$X-6=*W:8&7KC>Y60ZG"?42BW^<A^O\^]=_I%ZRO<*)X_GQ#T=6O_SC@IAE
M[(+HIZ,/E.?Y"KNICXL;HPN:J(\N_$0A"O6N7G*2+<&N3+&%./_N1&X6F$X`
MTM@W$&PFM0.R.*/,)%Z[4['E4,A7)`D.&^40;"8VH^QQME5[<.TFN;V8=G((
MW$??"1Z<-9;F0>[C<P@VE]R!/G#FE7Z0VZU]U^N-'VXQSOR89EG7I8D$N740
MS,57WP2SU4DDA5%$@"R\7*3JT"B'8"[*8%1@'[FQ:)`#78EXLKL3Q(TVUSB"
MN9$[XL;&B(S^K$J83\'Q+$WBQ`E<<KQ_"GWZ1)S^8Q^**?P@@KE^-*M)AK54
M)K!1K)H&I9,_G#V.ZN;?0C#7KOUK5N^:7,G/E!)O,F^=[$V@G8K\A6Z-XML@
M=SOZ$H5Q+]L#_M<0S/6RK<K,EJ"QW82+%UX>0O]+ZKGTRM0ZC284++"7I$2?
M2C'UJ-&,KZ$3F'MS6U6:(T)CT=T!;^,SJ\-M'*?8O<KR0>7P\G<K-9-$7+Y:
M$:JJ=F/H!/8NX>B:V$I"W6/3_YHK6I`YD;EV;@1V/JC'F#897T,GP%<BEDV;
M'!%V#[L_!FV&/9^=P-ZTV*;)3`$:2TB0']&N`_LU^3?L+5=D2)Z_XLA9XG(1
M>XS8(4".W`-T,O![I>%JO4RLQO(U#-]<P37*,\^_?8T(<[U`)P._:COVJ#`K
M6N@T&`,9%:5<P`>&5D?0"?!=H6UC0UNZQA*-0-I0NDJ-85^"&AZ:74$GEMY/
M0@V0%O(UEK9ER$-D/&>,]ZO/GL1J+NO-$`[<W^0R^Z8MLR=,'<W([_1A"O6.
MIQ'F<+2>R`;&<7N#3OZ$5ZK'%_%0\PYE6#\JR/^C\`B&]U=.GC!X;XV/W0\T
M^7-<NX()UUS2I7%LE6Z)A+P@]N;_</ST2)NCYC?1Y$]VO]NG(,UEJ!J^E577
MSO`2)C1XQI'T7>7S:/)^6]R'3,&3<0UC!`QLFG^_3S8F2'/9QECG7-```$6(
MA/<X``IQ`*@SV,7VTG?B6.-E_WXM^][J,Q#8_326;+.2/+4+Q50@E+S$Y]89
MSJM\%D\\IT<^&+NIK0.2OI@_+`S\WEW("YM*)@:[.7R,O%<BAT>?K%Y4&-)W
MRNP*P&_6V<2P2>0"L)M(&]^9Z]`VLE?BM;PW4LH.R@*_X=:AC=5W8R]'8*A[
MPF0_Y\T3[*K1QRP/_+)9AT)>_[N_RP"ED4:IF"UJIU;)II19'OJI;YL-*0^(
MY3-JW0TE#PKJ['YY(7^*Z6D]#&+I@-5L"?B%+)=.-OOZX*#V19S[TSO'<WWG
M>Q9_DDLEIR3TT\\6PF=<+K)QV;U]??$2.HW=!J[WZKDTD*AD-F:5!W]/V6HZ
MYB&Q?)MT@.LW+UD]83]_$K?R-B_A=9!0ZZC,=*#9$O1#13ZAB@H@AS>P*;D,
MXA9?>1&>DUI%=.`X]1/Z6D`\3:O5AGZTUX8EQMRM#G:H')/^7H1.Y.8]5>66
M60OZ29II3KD@+=]:WP:OY`P81M*=<[,@]-NJ[O3R<8$MSISAN9M"Q`-ROQST
M&Q]#0Y`%RW+[1!D^4[(1KA<#?X_29O^[#V`DM$EWM7OA48%?3ARP("9KU^FA
M;5.R*_?;@.:?]U[I+0\_$K.X`K2;/D/4K+V'J/MVFP1:QNT']C)O,P4>(.@>
M)&;8T6<M",8/[+I]J!)LU>D+N]U3A]EX_$-W96Y+,5NCA'*P6RV>J,0DJTE5
M!MRKM\U*TNB]L1!-@&S);]=WI=`$UIS4%+Z`H%UW[1Y/]U[@K=.UE*-&.32!
MM0KM,\#FZ:#+EC/EO*DQ52^')K"V(46F]KMLN;'U.?T6>Z[G1-MGIYK]90[3
MO#IH8J%%2(C&6*PU('9WB.AN;+:HW?K+#SK2RF@"[)`DI(Y#MQ*J@=F9*O?A
M\Z7(:YI;%DV`@T"H"9UA<>*AL7N!K#M$WBDD8F*61U,+C4]<),9B]QDU[>[E
M&1:;=?>3$D]AC3I\47,MNPP$=@^TQRB<8^S&-T0Z-!0\S6$Q6Q3>_<*++F%%
M-`7,@,ZGBG.+(H4RZ-7NTHE7G,ST@M)H"IBX7)4A2?^-'2W,AA1J=O@\(?4"
MO%6GJ%X#36&,*%UIVL=@N?>D,%7&`_Z>_9/X#:U*`V@*8XQI-6VJ0S+F0P`;
M)&.W1\_"`!*X&5:U$V*C"IK"F'+:\2P`8>QFU,885^5E/Y%@FEW\S)(5CEY6
M3L`,SMWERM10%]`4QO[43N^.*!1C=S-6A_&Q(9#5%,:B=EP-UA2(,2,LX"Q\
MA;\ENR'+B93)+XRF,`:\5GK![CZ8@<>HR:XX-L^B)QHILQ$W>7>F+OY5P:*G
MU1PZA3'XM5*"M@#'D*3@QO&B;/8Z)V>$=3[9/7GQ[S<1QF1ZPX2^Y,E)1(N-
M:A/H%,;(V$HG=$`9B\0/,UVPH%Z_;3`-;/"/D#XX\(GH6B@!NQ%T:I%!4@^6
MN5#TP].$*_H,!0=N!SVH-X%.+3!ZM@%E+KKZ\'1`LA>4546G%EA0=<"8"RQN
MZ#KB"2\]BHQVH@KC=H7C>>1E'>-9O67UT*D%UE!E).8"9ANBK?#4FBW(IZGU
MEI.SAEL6G5I@Q!3VWEST9G#OI9JR-9Q'U(S3O-KHU"9[H1H><Q&-S=X:EF>]
M_$;E)7Q,H_G*B7$M9!MO="I41:<6V,UTP%0TVNIY*+H]VXOQEMD$OT1AW/J&
MD=L@.K7(;M8>8J4MG8UK-EY49<]00]=;>/.L2FUZ/`^R?:50L7K\+#JSR&+7
MMR`J)84Q[7'6I7/7]?)>Y-GF9XN]D5:D1N(M3JKUT9D%ACIM1!6GG<UTH#>+
MU2M$'+V2S3-[)#R$65P6G#]TC+/+JOJ_7X9Q\A`F_\3)$YZ'R\#[%U-K>O\F
M.K/(%MBK%'9>618OB^=^UCAVV;*AYI,@%ED/U1I`9Q;9#M4A52K0V7+8605B
M//]Q&;Y^\C)ESA4@__,^]?FO11PHNLR6AP99`EZUBNC,`I.A.I2*XLX&0WCO
ME@Z)2PNYT.<7BFD<3V2[XN/V!IU98`\%ED^EZY;[FG:4WC_RW4#@5I<'(?UI
M6$/`7"?1F06FZ&&*K1HP(\A@V%FHI9]==0W7O_H??A*=V61T[U$(E6H.S%(O
MOIB/YV$:\+R7M.JC,UML]CJ(*E9AO%7;W[Z4UX<=;F'*)M"9!5;W-J`J<CO;
MV0T_R6,^\<RZ_S4@/6X`><#<=\RZ[:#/%MBW6R.KV.YLL.[G*K4\";L7V^*G
MOX4^Z3'W'::T(OILBY%:"4I%H*5.I+59*+\$S*<ID5LYNP;Z;)%)6(!A]]+2
M3D+9LY#8!4*Y+OILD057"4U%MZ5NGUT?2#4?\DD]),Q_#7VVP%+<,_Y*"3N;
MEX?L6\&-ZLI[J[=GA)'=3,!T!'VVS:1\5-%4JMW9FNSBA1=D7@-?4L^EDSGH
MVEJ+)KS;(2JNK<RZZ+-%%E@E-!7W5L<V$'G,Z2J!?F/HLTVFS%;P*C7I;*3D
M31&?ZL*[(SW?%RC]K2%1`AF3,WLEF(9,J2=TX*7K#<&U=N8X3;RYX\<_SL-U
MW@\:-!+_D9+6\2N=5*]PXGA^_`-`X-6\&]=9-P0AYF15T$\@86-K7<F"_JGW
MO(P1"!T[E"-,W@!B@[`[0-X^*'D"%$X-!)RV@$..&I4[#*-C4Q[FEU<'`6<D
MX'.D3.HNV?R8:)7&56>61[#I"H3L*!%:P3!%)NB-?IN$>["I#/2FV+V.6QXF
MOVV>/=B4!OL<B)FJNCRP<+#/F*!UBM<DSSA)_"(.9X2S/XC#H:O51K")"PXI
M8%QY*2,9Q?Q8O3//S[G4)!8&V49=LCT5U4/P^0HT-JD2));'G-U#)9U9F>41
M<%X#&45L9GE0[-ZE%O?OTMUIHQPZ@4UBP*6"S=Q!WT=!6?P0)OF"0F>DVX`&
M(5>ED5\7G<!:>-I1*\9C^396+R7AB4TFG4:W+<_JK9^+\`365M,4OH"@77?M
MGCC;9;@[&4#&R!H#;)X.NFPY4ZVR1IX,)VND@*G]+EN^.KUX"0UQ=!NX-/P?
MO=44KU3,\N@$UN:BMVIQ(5B>D_T`UV]>LGK"?L9&O/(V+^%UD)#MF?38I]D2
M.H&UY/`)550`.;R!F>=NPFB-H\N5AQ?7;WB>)MXK`;3PYC@26^:D%=$)K+FF
M#3<,NYT2SG'8[)ISWYU"9D->%70";-GI<I_<0`&=>X-G5=_S?U#,="BIAB;`
M.2E%1+!LZG(XXQB9`PG'-P%\7Z3"-<\2WQ:L*>6!]K%\PIOB921#`C(U$59&
M$\"G21U50@H,.H/C0!X/-%]60+T<4.\%F@"^I.J@D\>5D+'[1^AW,6WB.UR_
M;;S\,EXM^YV);Z`)X&NLCFII"K\QRSZTTK5YJ);]AX84J98::0`70Y]!$\"'
M5#W.B)HB,&:5&^YAP&"VWPG@FZF>-OL-<,9.]H!S4;\OTB>`[Z/::X`2KC$D
MI7S&<Z+AR?8*;\+8$SX]:I9$$\#031V&]B$*8UDI`6F\PV3YVFV6KIQ$&-B-
M51Q-`",VM2>4!Z6W))+,QXJ?:-_H[I7\Y?\#4$L#!!0````(`+R&K$3(%9?E
MD18``(KY```1`!P`871N;2TR,#$T,#,S,2YX<V155`D``^0T<5/D-'%3=7@+
M``$$)0X```0Y`0``[3W;<N,VLN];M?_`]5-.U6H\GDER,E.9;,D7)=ZU+9>M
MV62?MB`2DG"&`A2"E*U\_>D&KR!!BI3D,1C[948FNH&^`(UN7!H__N-QZ3MK
M&D@F^*>CDS=OCQS*7>$Q/O]T]'DR&OQP](^?_OJ7'_\V&/QV>G?EG`LW6E(>
M.M<`,V/4<QY8N'`N_AA<>"P4@?/ON"X'JGKS_9L?'/@YB:CTR.;OSC79."?O
M_^Z\>WORK?/VY.-W[SZ>O'6&U\Y@@&U(=T&7Q`E),*?A#5E2N2(N_72T",/5
MQ^-CXH:,LVBY6I!@"051R%SBRS>N6!YCC6_?OS\!ZGV*](U$L#RG,Q+YX:>C
MWR/B*V*/'&"7RX\DY,N.]2K$#.?AX>'-P_LW(I@#R-N3X]^NK^X5]6D+/N-?
M-.C':>"G\.^/L7A*)$W!L=0+,X0B\'?'<6$&ZC?4^]L55%RLE#4`,RY#PMV<
MB`K1"8LG'SY\.%:E*2BG<Q)2K[;R#\>!\.EQ`I9BN2+B8;#1V934?3,7Z^.D
M$$7^?O#V9)`)_:,;!0%TRCJ\I!01W^F('F5F'"@PM./154#=+7R1P%6LS:#;
M#.CCRB><0+_?C.#OM"+ZZ"[,#6.)H67&UU2&9I2XS(#$"7.E&4<5(<I)"45P
M'BW-W'EA<!QN5J`TP0<`10/F9GC;D72$@,YJ9?C],92F@)*Y9A:@P,"`#%=!
M#3R4&!`B.9@3LLIP9D1.%2%)@4&N2<F`A&$]&A0&;!J%5!;04!+2B*-*BFVA
MO2.<BY"$8"U_^I&L5HS/!'[&<?81^]@$D!S\\?GNLI6U4ATSM=!#[EWPD(6;
M2Z@70+&=(X=!WVZ$R"CPZ`P:4M2!A7,&N>DO_"3<<^(ZG$(E/QZ7:T@KC23U
MQOPG]1L&FX0Z%`::K00K`3%AY!6V@P?!N)%?W\"Q)NH#R/Y,<"E\YJ$-.24^
M&M?[!:6A_,Q)!/,CFD+40`LXLQ[>@?#O060T442Q(B>IR8FK<K[)*ON?5X74
M"OJ6P.P1+JC";*L='<FLJO>[J<KY1JO\574HKTR.<CP;KVB@R&@:5-L0S"K[
MMDEE>96.F#EYI:_CK$%99T0N1KYX:*LK`[Q95=^U5Q76Z:A*7U6%_@&5;L!6
MV.!X=AI)QJF4X`K<1\LE"3;CV3V;<XB67`(>@JN\<@@&;T&X+D-O1WD0^]5A
M5NGWZ%@PZ?I"1@'%/_)64(]I.\KI2%K"[X6VG+PQ)VWMQ2KZCOHDGJO"S20@
M7"(&#)-8A;6E9N7\;UDY";ZC*G"*-;Q8@=\&`F:%<(-^]>\16Z$%BH5M+#$+
M^H>RH%/<V-=.L5^LD&]$2&_)ADQ]&LNV^,$LT@]ED2**D^"\6$&>0[R^AO;6
MN5'//Q@%>?*V:J$SE!<KQS.Q7+)0>1LPO,$/P=F'\GRR;`(PR_FD+.="%<H,
M:)6\6,FC,0PWL9"3WV9YOBO+,X9^L8*[CZ:2_AX!5Q=K[%.Q""M?S<)\7Q9F
MCN?$B"]6K@6'561N,<G<8M'L%M>ZV/O49=;AMT_C:CO?I+]>PZO=]#9!E^0@
M/2"IR:S_[YY*_W&K+U?[=5%54:];8,P:JP3']?'7JQ;2D(D4PJVB!AK*S=*O
M1+_FH.Q5\H6`0#=EY<]F.5>"WP+BJW`+40`I!1)%86\',PN_$B8W1AVOZHB#
MB*+DM2]&(;^KA-`QSJLT]_-VSFE(F'\0QRFMRJR_2FA^*,\I:?:U`^RVIY"(
M;T(?PRC=QSUHC>;N4%E9.'!W<)+F7VZWJ/.6M1&_#<BLO,I*1I-/_>+'YQ89
M:R.O):Q9+97%B19J>1TGIIA&&R--`&9%5%8)ZJ*>%S\V3/M[IG'1`LZLBDKX
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MMT.A$A65@M$^3HD_.CX`/R#PKOSH.K**&Y],NW(#*-2WCA'HUUT9*0V%P[)S
MG-ZBA%_YW4HH`$Y$$#J\<J>\\3IH?!_]2KBJ'OW:J1'QF/JA3+\,\JK>/$HO
MIK`5(97+HGM0HNKJ1DK31?$:0JHH^-<@Q1O@I\')NUW;S[3<L?T4;[_VM]WY
M;D.3'P1:+1=Y)4C<!R3NY/N=B%-U9A?MVQ)3Q#H0!1U$D6+LT;+YNGH;`HJ8
M-S'B0>C8C89="#"GAV@Y-E($;/*[MHTU)6EH,DXFO/2/;E9I>\Z'5G04$;._
M!GDU72DI9Y)H0T2*@S_V$$(EET2;MC,D]6N/U@UI*=JT7T!+?N]!0S7-11L2
M<JSXYR"OH"L!Y205;9I/<?#'/DV7\UVT:CM%4K^,K2?Y<U3SS:DBAE,9!FH&
MQ"@./</_M@./W4N5G>8C?&-\?AG2)88^1PY)H#X=A4&$SJ>"`G>/"6^B\+PH
M2')9<.;[N!F3PDJ(!*'1"$M_#D2T2AMA4#UPYU38NX=ZJ3R;/(A;<&\I6`/O
M/A3NEVNZG-*@P-@VP)BE.+W*1T\L">//S1,X[+0E5_6@]O$U$E'0CJUZ2(NX
M^AG:'O.S!>%S>LE'A`7_)GY$Q[/*]3S%6COPX@!;"O"S2+`Q,3@COMS"85PV
MC=-5?#IR090L/`3CEUQ"(U`IJ&A%F`>=4$3S!?RU9-%RQ'@<<&2<MX3O`^L%
MM?U*`F`JE)=21M3[E86+<SHM6M06L+UG68W-MCPGP+UF>B)N?9C8U4PYSRZ)
M-_->Q>F#",X$3Y(+CF=X?D(FYR?`01BZ+E3J7?*0!N`&3@1N`@E>[@P[U]`'
M\12TK8ZUP5PU"L3RBI$I\\%].O.)E.J<*-8Y$?'&@O[5W'GVJ.[I!.?1Z6'D
M=D[7U!?JR--]2.84%+\B?*..SVYPM^74UWM16P3-,PC3[SMR?]#^D4_PJ5T8
M\U,BF1S/$$(U>2T\ZJN+!"89'*(RR^1SS7P8^-!'P2BHW>/LPS4-%]!BG2RZ
M(EK&=W:"/1W:X.]>4X([8MXPS!7-[RBN<4"$I;1KB-CVKLF>8&Z_X_Z3/*-(
M8C$.4-M7%HX7?EP`9N!&4WI9)Z9ALEE;"9O*!19%26.E!Q1_:J\JU->#6,3'
M?IWJ"L"1<GFP;EJH\4\SCN.S%J;%J</6:X_`"FXOQ@I8V27'A'C,2Y(4CD00
M^WJIKSQTX4_)2O[COA4E(PV&&1HA(/#Y)L@%`>HN'EVU4G*']18G/5-I49\>
M==F2^,]&?D$1,:UF):5E6E=4WSI1'F_3'L0Q3V7J8;^IYZ$9S!YV8`H1`2/^
MO2\(_Q<-H<_#.#_#:"8XPP-+064>:H]BT;QT0Q_.@V@^7*W\)`RL\%4/8A$?
MX*12L/#CV1V=XRD3$6R`X$"LB8^!\.?[D4<JG'5!LHK7_(Y=%KW())[1V&N$
MZT&TKP^E2QZC4\P6BZ/JCDI*`G=1W0?HAF>1;K<;D5UE<O":+9+:G9`4/;EK
M\@>!CEP=Z.9RBSBX(LSSR8-*$Z@6J"H\U$)8Q,4_<>=:GI$5"XFO4"ILU(-8
MQ,?/$<&5=H9+S5(*EX$=K0:>C5`6<3.<!S3>/GAD15^L]/WK+UEX#%K'!?[Z
M)8N4Q',E01/Q:8E%`C_S&<=S\!.TMQFAE?[3#&81/U<,0CI)"TOIL15:0JP'
MI+,_XF,>M8SNB&^1!#`4CGQ<%;BGP1K8D0UJW0YK$6<7?`Y6+-Y<K..H`<8B
M3@KI(:X)W\I4.W"+^--W@2O\F(LMHK\V^V'MNEUK#'M6Y&XBE/MX=@LUTBS!
M;AQ'5XJ*9#/PP.<T>+:%I^$2ESUOP<G\S#T:9`/ADO\'O/[)@Y@L1(27/B]\
MO*Q5G(F[8O9A?[XU4Y,'ZJ_I+N)(,?]<XEBP(*2[]8\<MP\B&3]0+V:M5;>?
M"#R56!+-'G7T0437!*V:.I\WHA1W7-(UA'3SO;@^T0*X#TSK\W#J`B)+M9.U
M#M2#=;G*`;4(U$0D-1_D:@6]Y]+_$^W!7#QBB"+I;0#Z`3]D'*@7ICQU-.*6
M!FKCPKQ%TQ)5VSE3WYYKRZ/.3K<PY?T8F4//4]N5X#DJ/LXC6L_I=MB]6<YT
M]W2'Y0K[WA"6QBR-1#"AP9)Q$A?`WU.PL^J$M:*N;N>\2PWM//*O,IP+I)X3
M7,XND&M2?4MX;=<8X)[Q*!QGRVAY0Q_B#?KX1#Q(_(92C\8CM49U3:H_;+5/
M-E@.9QY*G-([`M;;.]TDR^WZCF@S9`^X!1W-&?B4L7D;S\93G\V5]HI^2B-4
M+VQ^-F--Q`5!7U(%W\8YK01AOWT'AR((/Z_`;00]::O)Q;W0!J#>L`C3[YF0
M2DMHDZOL50#V,L\']*JT&30^YY*>T$>+63?7FB`MFE/C,Y>:BWN'QWHJQS)-
M(-;Q(=5!D/7V2*8=N$6AC-:G8K+5:P/CF1Z!@FE(@]"Z'MD6VR+M:O2G46B!
MC]--QD<=U]NP+.(V=K7&LW3(Y<07%QX:@.SB!4^1DCD0>*_.X<8I?6`6TYFI
MA]("ZV<]DAK+G+GQ%)SXT1!8>FLF1;`Q#+S6&'UPP;3QE,?5^8@J#*CRI<@=
M<"WJQ859(9TH3C>_"-\#HK*!9UX]:H*W:'XI=-1T4CS=Y-NI(Z9Y.*V@^]"E
MBX9G%/G^YISY44B]Y%A3O/[W>P1^=LW=UETKL,>H79-'7![(`L,(_KD%&BEF
MN,+3'OK:_G;@'BQ[I_TWY>-.-U;FXA[P50R!P?#(",S,%07KT[P&7`_<`Y[S
M4SJZ3U'ZW@-.[FD8QA^2C3*U4FMD;CMH#_@U/:51?X:D%;0]YT?TK";UIY>V
MP%ET[$>?WZO'THW%%M%?>#8D?L1]C1E(X2^5DZ*^XW7$LZ<+&KS0\XA.A+H8
M")W-&%=V0;+(?X7)#)02GS]-0V/4CS[?U8!8%&G4F(-;(,IEJW03<[O]J"#8
MOT*<S&1J/ZJ&JR+?;:![$H(H9[,C^UVP^B"&\Z0)B"=TUN1(M)#';NC:WD)2
M@VU#'V(L''BX=-!V\!M0>C#\`^%2ZDF\L%F>9'4WL`&L!_NUQ16#Q$J#8Z'4
M=,E_73!W46(K/FU5L^;0J8;]%AT.N)<&4%*FFKSD^?L/X]E,W5F4&,]DCLA8
M92Q8$[]TTG"_:GIA%2M9GO(T>@V#I!N:16[<I<HGC!\2PG_&?W`C.,MCI"64
M;`'=#S5/0[RF&ZC4N_@V"@[FY-;$1)Q23F<,-P[R5'HC2L)(.[*X3R7V3P\Z
M=YE^#4<WMT)J9K#[2<V#7MIZ#"FX;MXUZH&%FS0N:1C;[5&L\FZT#:`R#Z6C
M("U@+0K9[MT%]2+?E),O[X824W.M@7Q3`K<=*[!GI:$ZWWSF+&R>D1*(/2>?
M@Q[PJ9\T8_\A\2I:3K0E'(MFV9QJ?<\U/R.1S!GYHD]YWVOW*JR4@\E-ROW&
M;GHW8O:7ZS&GNS.ND*WD?4NWW;F_V]?+#Y&6^$"YB)]9$HWI<[<;^]W0>[`1
M9V1LYZGA(+7U56I=)Y)]*OE3RTB?=O:LIZ^2ZCA)[5%'#R34^&2*:2>S'7P?
MUH>R_+:[)(!O2AF^7WWV!*#7)/A"PX23HA7@229TM22FKS)TP-ESQ>B`0:JZ
M>:$VN;(M@(M')E62(N5<*;NG;1>T1[%F?R#KED,P[<MD(2BVY^K^B<GFU8+:
MH[Q\B#6EN*Z%L6>XZ?=)F/PR"BA-\TG?P9`YIV%^B[3V(LIV1(N6^332;P,Q
M3:*@Q&4U+A*TQ+"(RS2W46P9DID@O6-BR(%4`V=1T#><3D48GC(1+FA`5NIE
M>WDF@FI&RZV0%AUFN\6#62,6R%"["8J/@*@4?1[T-R]R#><-.R+:QO,]=07W
M=F&Z"Z9M7&-&I9V8[H!H$<\P!GTQ1Y(36IO2FK<!MHBW>.QE.3/OB4\K+#7`
M6,3)<`9SM2+UAH9(8S6S;CV(17R47Y(R>&7U(/8X95>"S_%^>?$J,U.G(YIR
MRW?"ZL,J04:_C$]K8YQ#N>E]J.V@7UFYK1Y_&I,O=\R;TQM5-Q@],A6!>O*@
M^J#25E"+1N$0'.7UO?`5BL&2&(LMHA\B&>^7*'07$#`*KF?:KWEHI#V*17PJ
MM^(2!LPET_R*D0CPB,*23"_YA>_1P-\,W2BDUQOJ"^9=T>@+7;+JVQT'JL\B
M"7WF3)VOPD@/@G@BK\^'>#X[TW%-=^B(9Q''_Q0++G\1JR_0D7,NJD\&-()9
MQ$_QB8;&]QLLI+W8BVXIYW+CKPDW#+QM@!;Q!+8`7.&S!:.8[P*L`%`^GLW`
MW3<8U>VP%G$6G]XKO>=0_/CU79#MCSG$]%5><M`_6R3D0O[=89Z=N)I(OA',
M6G[25,);^"F#6<1/LA"A/RMQ2T+XD8;T#?=G.^-:Q/E6]GK$`_?N5^":"W!J
M4R=V.U]MD"SB5=],;^B5S7`6<71/5R2N#761I16H9ZTM@D4\7A,>S:"U"*?/
M>LZ:P2SB!_.1-+U'5%-N$0<-2R^F)Y+;@=NS%->TLE2[\]L%R1Y6L_PCB44O
M)78SE?9@%;&\WEL^.F(L+O+UK(FD]5UVL2%^N$DHG8CB6SRU._.-.!9M5R>$
MCF?I]D)^RD5[-;(!:K]#+T^\,Q2'5,T[0RF,UOV>^[I7YLQQK^B:XS&!>?GN
M?@O8'IB,=`,%1@_QF"!X78M>$WR#54OCO`6N#YP&XO^H&UY(7)W%7'="EA(U
M&8I[P->Y>.#9A&7BPFA<.F'98VP*9*L,&8IN,UO%\AZH4=M%0`7@3D+Z&K@(
M1D+@<HAZ"=U;`BB27#JFMGL5>\OGR2]2CR+NZ3.Z_AZ*RE,+D\SD0>#;5<6Y
MIRMF_X6ASB\D3WAUD(2.9K\8,L(QB2`#3LH#H@[`(E<0S.Q,!$N4S*G@D4Q2
MME6Z:))S65^W[H;Y9`H]W(T!_40FB9,"L/09EX*S7WW>JPV.17HWO+8P7!/F
M)X=M3S>5#.G-3S5L1;:(]QO![^@,C!%6@[D"$FR8I;0P?`M<#R;U6]#-DKB;
MTO)"\6L/N!C";P__5DF+I*SD=:T#Z`%O15M1?E?,E+&M);Q%HRVCZHYR^D!\
MLQ5MA+*(FRQF&<Z!XCEX,M7T<K4@/>B/&?&8'<]'HT=\7Y_)I>E-L(YX?9)$
MV=%I*XEV>#V0A)KA!Z=$8F2^Q(3U\496OM1TNBG`I(=]'TC@)2\&J0QCU/N5
MLOD"_A^NP16>TSN*FRDPFG'5'KG$A/_ZHU!?OVFKU@,OEBM?;"B5YRR@;BB"
M9(\#4Y;C7=/*'E9;!(LVM3*2@=)3`8J+:6S@K0;0(IYRB5>XJ!991'><B^22
MXQI;?`F^>CZF`<8Z3NJW#6O*+=HAU,Y"G!&Y:'Q#.P?HP812.N<1@IWB=-/(
MGP[4`Q[OZ#Q;X%0O7ZL=3Z/ONQW4(@<X><NF[F*YN?CI]/44SV.GMW3O*,K:
M!:]!W3Q./(EBT-(:15.@)>F<\JO_$I\A0J*S]*?ZQGU[%'MV:O0T-\:G*@V7
MSSMA6:348G[O4E8HM2"K47Y#2QN/'5%[8'U3/:8+D=[I)OF$[\F!TVC0>0.L
M19K.TW5?K/'04[V+LQ7R.9V=8^DN(`;[Z:]_^7]02P$"'@,4````"`"\AJQ$
MOF)3?5:T``!KWPD`$0`8```````!````I($`````871N;2TR,#$T,#,S,2YX
M;6Q55`4``^0T<5-U>`L``00E#@``!#D!``!02P$"'@,4````"`"\AJQ$-VJ#
MC*\'``"O7@``%0`8```````!````I(&AM```871N;2TR,#$T,#,S,5]C86PN
M>&UL550%``/D-'%3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`O(:L1.`6
MJ!LX-0``2&0#`!4`&````````0```*2!G[P``&%T;FTM,C`Q-#`S,S%?9&5F
M+GAM;%54!0`#Y#1Q4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`+R&K$2?
M'/+OB'L``-^-!P`5`!@```````$```"D@2;R``!A=&YM+3(P,30P,S,Q7VQA
M8BYX;6Q55`4``^0T<5-U>`L``00E#@``!#D!``!02P$"'@,4````"`"\AJQ$
M>P=!P?I&```;ZP0`%0`8```````!````I('];0$`871N;2TR,#$T,#,S,5]P
M<F4N>&UL550%``/D-'%3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`O(:L
M1,@5E^61%@``BOD``!$`&````````0```*2!1K4!`&%T;FTM,C`Q-#`S,S$N
M>'-D550%``/D-'%3=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``"+,
$`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">
<div align="justify" style="text-indent: 45pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Nature of Business &#8211;</font>&#160;Actinium Pharmaceuticals, Inc., incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;API&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase 1/2 clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div>
</div>
<div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &#8220;Company&#8221;, &#8220;Actinium&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that&#160;was in the market for a merger with an appropriate operating company.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&#160;&#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000;
 text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April&#160;11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&#8217;s common stock.&#160;&#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Basis of Presentation - Unaudited Interim Financial Information &#8211;</font>&#160;The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary&#160;for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 28, 2014.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Development Stage Company &#8211;</font>&#160;The Company is considered a development stage company and has had no commercial revenue to date. The Company has been focusing on the development of its clinical drug candidates.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Principles of Consolidation &#8211;</font>&#160;The condensed consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font
 style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Use of Estimates in Financial Statement Presentation &#8211;</font>&#160;The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Cash and Cash Equivalents &#8211;</font>&#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At March 31, 2014 and December 31, 2013, all of the Company&#8217;s cash was deposited in one bank.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Property and Equipment &#8211;</font>&#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Impairment of Long-Lived Assets &#8211;&#160;</font>Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Derivatives &#8211;</font>&#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Fair Value of Financial Instruments &#8211;</font>&#160;Fair value is defined as the
 price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities&#160;in&#160;active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div>
<div align="right" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font>&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The following tables set forth liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of March 31, 2014 and December 31, 2013. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font></div>
<div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="40%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 1</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font
 style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 2</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 3</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Total</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr>
<td align="left" width="40%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr>
<td align="left" width="40%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Derivative liabilities:</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="40%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;&#160;At March 31, 2014</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="7%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="7%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div>
</td>
<td align="left" width="1%"
 valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="2%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div>
</td>
<td align="right" width="8%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">19,128,761</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="2%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">19,128,761</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" width="40%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;&#160;At December 31, 2013</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="7%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="7%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="8%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">6,707,255</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">6,707,255</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
</table>
</div>
<div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Income Taxes &#8211;</font>&#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust:
 none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Research and Development Costs &#8211;</font>&#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Share-Based Payments &#8211;</font>&#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Earnings (Loss) Per Common Share &#8211;</font>&#160;The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &#160;The potentially dilutive securities (options and warrants) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the three months ended March 31, 2014, potentially issuable shares included stock options to purchase 2,265,229 shares and warrants to purchase 9,680,333 shares of the Company&#8217;s common stock. For the three months ended March 31, 2013, potentially issuable shares included stock options to purchase 2,330,134 shares and warrants to purchase 12,770,636 shares of the Company&#8217;s common stock.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Recent Accounting Pronouncements &#8211;</font>&#160;The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Subsequent Events &#8211;</font>&#160;The Company&#8217;s management reviewed all material events through the date of the condensed consolidated financial statements were issued for subsequent event disclosure consideration.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EW5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details) (Subsequent Event [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>May 12, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 28, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2014

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2014

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Warrant [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Restricted common stock and options, Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 11.95<span></span></td>
        <td class="nump">$ 11.76<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of expiration</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options and restricted stock vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
        <td class="nump">$ 35,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Sublease agreement termination date</a></td>
        <td class="text">Sep. 30,
				 2016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SubsequentEventsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SubsequentEventsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseExpirationDate1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8,17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SecurityDeposit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchasedDuringPeriodShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3TAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="5">3 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Options And Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Options And Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Machinery and equipment [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2012

</div>
          <div>Actinium [Member]

</div>
          <div>pures</div>
        </th>
        <th class="th">
          <div>Sep. 25, 2013

</div>
          <div>Actinium [Member]

</div>
          <div>pures</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation, Date of Incorporation</a></td>
        <td class="text">Oct.
				06,
				 1997<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest acquired by company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100.00%<span></span></td>
        <td class="nump">93.70%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition', window );">Common Stock issuable in consideration for equity interest acquisition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Three years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharesExchangeRatio', window );">Shares received by each API shareholder of Actinium common stock for each API share exchanged</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.333<span></span></td>
        <td class="nump">0.333<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially issuable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,265,229<span></span></td>
        <td class="nump">2,330,134<span></span></td>
        <td class="nump">9,680,333<span></span></td>
        <td class="nump">12,770,636<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockShares', window );">Common stock shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,970,137<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ExchangedInCommonStockShares', window );">Common stock shares exchanged</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,322,055<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock issuable in consideration for equity interest acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ExchangedInCommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares exchanged.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ExchangedInCommonStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharesExchangeRatio">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares exchange ratio.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SharesExchangeRatio</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:decimalItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when an entity was incorporated</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityIncorporationDateOfIncorporation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestmentOwnershipPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E44BI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 09, 2013

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 07, 2012

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>MSKCC [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>MSKCC [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>MSKCC [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 27, 2012

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 04, 2013

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2011

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven', window );">Amount paid under agreement in 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve', window );">Amount paid under agreement in 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen', window );">Amount paid under agreement in 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen', window );">Amount owed under agreement from 2011 to 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">815,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaintenanceFeesAndResearchPayments', window );">Maintenance fees and research payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">200,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PlacementAgentServicesFees', window );">Placement agent services fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsIssuedToPurchaseCommonStock', window );">Warrants issued to purchase common stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,976<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockExercisePriceParOrStatedValuePerShare', window );">Common stock exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidToEachPatient', window );">Amount paid to each patient after Completing clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,185<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StartUpFeeForClinicalTrial', window );">Start-up fee for clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">79,623<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfReceivablesOfPlacementAgentForServices', window );">Description of receivables of placement agent for services</a></td>
        <td class="text">Agreement entered in 2013 has similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock.<span></span></td>
        <td class="text">Placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfWarrantsReceivablesByPlacement', window );">Description of warrants receivables by placement</a></td>
        <td class="text">Warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable<span></span></td>
        <td class="text">The placement agent or its designees have also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PeriodOfExerciseOfWarrants', window );">Period of exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Within 6 months of the final closing of the 2012 common stock Offering<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PercentageOfSolicitationFee', window );">Percentage of solicitation fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PeriodicFeeForFinancialAdvisoryServices', window );">Monthly fee for financial advisory services</a></td>
        <td class="nump">25,000<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfAdditionalReceivableByPlacementAgent', window );">Description of additional receivable by placement agent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockPurchaseByHoldingOfWarrant', window );">Warrant held by placement agent to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,251,015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Paid for research conducted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">189,537<span></span></td>
        <td class="nump">129,850<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments', window );">Royalty description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><div><font size="2">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire. </font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Net payable to MSKCC</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 189,537<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 81,185<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidToEachPatient">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount to be paid for each Patient that has completed the clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidToEachPatient</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand eleven.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidUnderAgreementInYearTwoThousandEleven</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand thirteen.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand twelve.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockExercisePriceParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock exercise price par or stated value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockExercisePriceParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockPurchaseByHoldingOfWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock purchase by holding of warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockPurchaseByHoldingOfWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfAdditionalReceivableByPlacementAgent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of additional receivable by placement agent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfAdditionalReceivableByPlacementAgent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfReceivablesOfPlacementAgentForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of receivables of placement agent for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfReceivablesOfPlacementAgentForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfWarrantsReceivablesByPlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of warrants receivables by placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfWarrantsReceivablesByPlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaintenanceFeesAndResearchPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maintenance fees and research payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MaintenanceFeesAndResearchPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Owed amount under agreement in year two thousand eleven to fourteen.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PercentageOfSolicitationFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of solicitation fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PercentageOfSolicitationFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PeriodicFeeForFinancialAdvisoryServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Periodic fee for financial advisory services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PeriodicFeeForFinancialAdvisoryServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PeriodOfExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PeriodOfExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PlacementAgentServicesFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent services fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PlacementAgentServicesFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RelatedPartyTransactionsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RelatedPartyTransactionsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StartUpFeeForClinicalTrial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up fee for clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_StartUpFeeForClinicalTrial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsIssuedToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Issued To Purchase Aggregate Shares Of Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_WarrantsIssuedToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount for accounts payable to related parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the commitments made for future artist advances payable and royalty guarantees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 928<br><br> -SubTopic 440<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of other research and development expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Note 2 &#8211; Related Party Transactions</font></font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;">MSKCC:</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">In 2010, General Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly named General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC), a principal owner of the Company.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">
<div style="text-align: justify; text-indent: 45pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer Research (SKI),&#160;an entity related to MSKCC (&#8220;License Agreement&#8221;).&#160;&#160;The agreement was amended in August 2006.&#160;&#160;Pursuant to the agreement, the Company licenses certain intellectual property from SKI, including critical patents with respect to the Company&#8217;s core technology, and also supports ongoing research and clinical development of related drug candidates.&#160;&#160;</font></font></div>
</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company is obligated to make the following milestone payments:</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Milestones</font></div>
</td>
<td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Payments</font></div>
</td>
<td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr>
<td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="88%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval&#160;for each licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%"
 valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" width="88%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(2) upon the receipt of regulatory approval from the U.S. FDA for each&#160;licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
</table>
</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Certain amounts due under the License Agreement were deferred and then forgiven under a forbearance-related arrangement.&#160;&#160;On June 19, 2011, the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement, in respect of the $50,000 annual maintenance fees and research payments.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">
<div style="text-align: justify; text-indent: 45pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;On September 4, 2013, the Company entered into a letter agreement with SKI to set forth the amount that the Company owes SKI for the period from 2011 to 2014 under the License Agreement.&#160;&#160;The total amount that the Company owes SKI for the period from 2011 to 2014 is $815,100 plus all relevant licensed intellectual property related pass through costs to be determined.&#160;&#160;The amount owed does not include amounts the Company may owe for patent expenses under the License Agreement.&#160;&#160;As of March 31 2014, amount owed under this letter agreement for 2014 annual maintenance fee and 2014 research funding was approximately $0.2 million plus pass through costs, respectively.</font></div>
</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On March 27, 2012, the Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225.&#160;&#160;The Company will pay $31,185 for each patient that has completed the clinical trial.&#160;&#160;Upon execution of the agreement, the Company paid a start-up fee of $79,623 in 2012.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family:
 'times new roman'; font-size: 10pt; display: inline;">For the three months ended March 31, 2014 and 2013, the Company incurred $189,537 and $129,850, respectively, for maintenance fees and research conducted by MSKCC.&#160;&#160;As of March 31, 2014 and December 31, 2013, the Company has payable to MSKCC of $189,537 and $81,185, respectively, related to clinical trials.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;">Placement Agent:</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">
<div style="text-align: justify; text-indent: 45pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On August 7, 2012, the Company entered into an engagement agreement with Healthcare Investment Banking as its placement agent for the 2012 Common Stock Offering.&#160; A director of the Company was the Head of Healthcare Investment Banking at the placement agent.&#160;&#160;&#160;Pursuant to the agreement, the placement agent was engaged as the exclusive agent for the 2012 Common Stock Offering. &#160;&#160;In consideration for its services, the placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.&#160;&#160;The placement agent or its designees have also received warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.&#160;&#160;The placement agent will also receive the same fee and expense schedule for any cash exercise of warrants within 6 months of the final closing of the 2012 Common Stock Offering and a 5% solicitation fee for any warrants exercised as a result of being called for redemption by the Company.&#160;&#160;Upon the final closing of the 2012 Common Stock Offering of the units, the placement agent has been engaged by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee of $25,000.&#160;&#160;The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company&#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.&#160;&#160;For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent.&#160;&#160;The placement agent also was engaged by the Company as placement agent for its Stock Offering and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold warrants to purchase 1,251,015 shares of the Company&#8217;s Common Stock.</font></div>
</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On December 9, 2013, the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering. The agreement entered in 2013 has similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company has uplisted its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During quarter ended March 31, 2014, the placement agent received a cash fee of approximately $0.4 million from the sale of securities and was issued warrants to purchase 68,976 shares of the Company&#8217;s Common Stock at $9 per share for a period of 5
 years.</font></div>
<div>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">50,000,000<span></span></td>
        <td class="nump">50,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="nump">200,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">25,562,346<span></span></td>
        <td class="nump">24,565,447<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
        <td class="nump">25,562,346<span></span></td>
        <td class="nump">24,565,447<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
        <td class="text"><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;Lives</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2014</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2013</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" width="67%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Office equipment</font></div></td><td width="9%" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;3 years</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">17,179</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">15,480</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Less: accumulated depreciation</font></div></td><td width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(2,965</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size:
 10pt;">)</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(1,560</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Property and equipment, net</font></div></td><td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">14,214</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">13,920</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"></font>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>May 09, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Actinium Pharmaceuticals, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001388320<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,562,846<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivatives [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of derivative warrant instruments activity</a></td>
        <td class="text"><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Units</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Fair Value</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Balance, December 31, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,968,623</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">6,707,255</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Transfer from liability classification to equity classification</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(46,025</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">)</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(139,565</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">)</font></div></td></tr><tr bgcolor="white"><td width="76%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Change in fair value</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">12,561,071</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Balance, March 31, 2014</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,922,598</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">19,128,761</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font></td></tr></table></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font>&#160;</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock', window );">Summary of fair values of derivative warrants on basis of valuation model</a></td>
        <td class="text"><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">March 31,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">December 31,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2014</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2013</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Market value of common stock on measurement date (1)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">12.45</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">5.89</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Adjusted exercise price</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">9.95</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2.48</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr
 bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Risk free interest rate (2)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.32</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.27</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Warrant lives in years</font></div></td><td valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0.5 years</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0.5 years</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Expected volatility (3)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">71</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">73</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Expected dividend yield (4)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Probability of stock offering in any period over 5 years (5)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">25</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Range of percentage of existing shares offered (6)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">35</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Offering price range (7)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">9</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">9</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td width="6%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(1)</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The market value of common stock at the above measurement dates is based on the Company&#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for March 31, 2014.</font></div></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;&#160;</font></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(2)</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</font></div></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(3)&#160;&#160;</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div></td></tr></table></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(4)&#160;&#160;</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></div></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(5)&#160;&#160;</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Management determines the probability of future stock offering at each evaluation date.</font></div></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(6)&#160;&#160;</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Management estimates that the range of percentages of existing shares offered in each stock offering will be&#160;0% and 35% of the shares outstanding at March 31, 2014 and December 31, 2013, respectively.</font></div></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(7)&#160;&#160;</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt;
 margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Represents the estimated offering price range in future offerings as determined by management.</font></div></td></tr></table></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative warrants on basis of valuation model.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41678-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5580258-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41641-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EB1AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">166 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements Of Operations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
        <td class="nump">2,460,968<span></span></td>
        <td class="nump">1,085,707<span></span></td>
        <td class="nump">31,548,346<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">1,676,053<span></span></td>
        <td class="nump">933,135<span></span></td>
        <td class="nump">30,100,379<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">1,405<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,265,427<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,122<span></span></td>
        <td class="nump">554,308<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
        <td class="nump">4,138,426<span></span></td>
        <td class="nump">2,022,964<span></span></td>
        <td class="nump">65,468,460<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss From Operations</a></td>
        <td class="num">(4,138,426)<span></span></td>
        <td class="num">(2,022,964)<span></span></td>
        <td class="num">(65,468,460)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income and (Expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(575)<span></span></td>
        <td class="num">(1,967,215)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">260,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on change in fair value of derivative liabilities</a></td>
        <td class="num">(12,561,071)<span></span></td>
        <td class="nump">1,334,512<span></span></td>
        <td class="num">(16,041,077)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income and (Expense)</a></td>
        <td class="num">(12,561,071)<span></span></td>
        <td class="nump">1,333,937<span></span></td>
        <td class="num">(17,748,292)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (16,699,497)<span></span></td>
        <td class="num">$ (689,027)<span></span></td>
        <td class="num">$ (83,216,752)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net Loss Per Common Share - Basic and Diluted</a></td>
        <td class="num">$ (0.66)<span></span></td>
        <td class="num">$ (0.03)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted Average Number of Common Shares Outstanding - Basic and Diluted</a></td>
        <td class="nump">25,228,299<span></span></td>
        <td class="nump">21,391,665<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (a),(c),(d),(e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeGainLossOnDerivativeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">Note 7 &#8211; Equity</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">In January 2014, the Company completed the final tranche of a private placement of the Company&#8217;s common stock and warrants and received approximately $3.3 million total gross proceeds from accredited investors (&#8220;2014 Closing&#8221;). The Company paid its placement agent total cash fees of approximately $395,000 and paid attorney fees of $40,000 for their services. In the 2014 Closing, the Company sold 551,810 shares of common stock at $6.00 per share and granted 137,952 units of five-year warrants with an exercise price of $9.00 per share. The warrants are exercisable for a period of five years from the date of issuance. The transaction date fair value of the warrants of $0.6 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rateh1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years. As of March 31, 2014, all the warrants were outstanding.</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On March&#160;24, 2014, the Company filed a shelf registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) which was effective on April 17, 2014.&#160;&#160;This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the &#8220;Sales Agreement&#8221;) with MLV &amp; Co. LLC (&#8220;MLV&#8221;) dated March 24, 2014.&#160;The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock.&#160;To date 500 shares have been sold under the Sales Agreement with MLV (see Note 8 &#8211; Subsequent Event).</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Placement Agent &#8211;&#160;</font>During January 2014, in connection with 2014 Closing, the Company issued Laidlaw &amp; Co. warrants to purchase an aggregate of 68,976 shares of common stock with an exercise price of $9.00 per share. The transaction date fair value of the warrants of $0.2 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate &#8211; 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years.</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">Approval of the Equity Incentive Plan</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During 2013, the Company granted employees, consultant and board members 312,500 shares of restricted stock. During the quarter ended March 31, 2014, the Company granted an additional 325,167 shares of restricted stock. During the three months ended March 31, 2014, 180,104 shares were issued for shares granted under the Equity Incentive Plan. Of the total shares of restricted stock, 22,500 shares vest 1 year from the grant date, 149,167 shares have a vesting period of 4 years and 150,000 shares vest at date of grant. The remaining restricted shares granted are performance based and vest over time.</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt;
 word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">All restricted stock issued and outstanding is being amortized over their respective vesting periods. The unrecognized compensation expense related to the restricted stock granted at March 31, 2014 was $1,391,318. During the three months ended March&#160;31, 2014 and 2013, the Company recorded expense of $1,410,588 and $0, respectively, related to the restricted stock granted.</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">Stock Option Plan</font></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The following is a summary of stock options:</font></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Weighted</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Average</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font
 style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Weighted</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Remaining</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Aggregate</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Number of</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Average</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Contractual</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Intrinsic</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Units</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Exercise Price</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Term (in years)</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Value</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size:
 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Outstanding, December 31, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,985,384</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">3.23</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">8.34</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">5,908,696</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;Issued</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">291,500&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;7.86</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">10&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt;
 display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;Exercised</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(11,655)</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0.78</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Outstanding, March 31, 2014</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2,265,229</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">3.84</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font>8.34</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times
 new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;$</font></div></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">19,514,362</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During the quarter ended March 31, 2014, the Company granted employees and board members 291,500 options to purchase the Company&#8217;s common stock with exercise prices ranging from $5.55 to $8.19 and a term of 10 years and vest over a 4-year period.&#160;&#160;The fair value of $1.7 million was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.88% - 2.07% (2) expected life of 6 years, (3) expected volatility of 87.76%, and (4) zero expected dividends.</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During quarter ended March 31, 2014, the Company received gross proceeds of $5,220 for exercise of options for 11,655 shares of the Company&#8217;s common stock.</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at March 31, 2014 was $5,399,710. During the three months ended March&#160;31, 2014 and 2013, the Company recorded option expense of $281,404 and $94,200, respectively.</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">Warrants</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Following is a summary of warrant activities for the quarter ended March 31, 2014:</font></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;<table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;">Weighted</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Average</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Weighted</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Remaining</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Aggregate</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Number of</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Average</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Contractual</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Intrinsic</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black;
 border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Units</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Exercise Price</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Term (in years)</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Value</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Outstanding, December 31, 2013</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">9,673,290</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.06</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">4.89</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom">&#160;</td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160; 47,396,307</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left"
 style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;&#160;Granted</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">306,928</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">7.88</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160; 6.63</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;&#160;Exercised</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(299,885</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">)</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.04</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Outstanding, March 31, 2014</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-family: 'times new
 roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">9,680,333</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.28</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">4.71</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">107,268,785</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During the quarter ended March 31, 2014, the Company granted warrants to purchase 137,952 shares of the Company&#8217;s common stock to investors and warrants to purchase 68,976 shares of the Company&#8217;s common stock to its placement agent in connection with the 2014 Closing. .</font>&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During the three months ended March 31, 2014, the Company also granted a consultant warrants to purchase 100,000 shares of the Company&#8217;s common stock with exercise prices of $5.55 per share and a term of 10 years.&#160;&#160;These warrants vest when certain milestones are met.&#160;&#160;</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font>&#160;&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During the quarter ended March 31, 2014, 299,885 warrants were exercised by the warrant holders. The Company issued 253,330 shares of common stock and received gross proceeds of $23,709.</font></div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During the quarter ended March 31, 2014 and 2013, the Company recorded stock-based compensation related to the warrants of $58,934 and $0, respectively.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">Note 6 &#8211; Commitments and Contingencies</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">License and Research Agreements</font></div>
<div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"></font>&#160;</div>
<div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td width="6%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;">
<div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">a.</font></div>
</td>
<td width="91%" valign="top">
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Abbott Biotherapeutics Corp &#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</font></div>
</td>
</tr>
</table>
</div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</font></div>
<div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Milestones</font></div>
</td>
<td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Payments</font></div>
</td>
<td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr>
<td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="88%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div>
</td>
<td align="right"
 width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" width="88%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="88%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,500,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" width="88%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(4) Biological License Application filing with U.S. FDA</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="88%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(5) First commercial sale</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,500,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" width="88%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(6) after the first $10,000,000 in net sales</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,500,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font></td>
</tr>
</table>
</div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font:
 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.&#160;&#160;The milestone payment for the Phase 1 Clinical Trial was recorded as research and development expense. The Company has not initiated a Phase II Clinical Trial and no payment has been made to Abbott Biotherapeutics Corp. since the July 24, 2012 payment.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;">
<div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">b.&#160;&#160;</font></div>
</td>
<td width="91%" valign="top">
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Memorial Sloan Kettering Cancer Center (MSKCC) &#8211; see related party disclosure.</font></div>
</td>
</tr>
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="91%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;">
<div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">c.&#160;&#160;</font></div>
</td>
<td width="91%" valign="top">
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Oak Ridge National Laboratory (ORNL) &#8211; API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end.&#160;&#160;For 2013, the Company was obligated and paid approximately $0.3 million to purchase of radioactive material with ORNL.&#160;&#160;For 2014, the Company signed a contract with ORNL to purchase $0.4 million of radioactive material.</font></div>
</td>
</tr>
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="91%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;">
<div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">d.&#160;&#160;</font></div>
</td>
<td width="91%" valign="top">
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company clinical trials, Phase 1 and Phase 2.&#160;&#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&#160;&#160;The down payment totaling $239,000 was paid in 2007 and 2012.&#160;&#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&#160;&#160;The total project is now estimated at approximately $2.2 million. As of March 31, 2014, approximately $1.0 million has been expensed to date. &#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></div>
</td>
</tr>
</table>
<div>&#160;</div>
<table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td width="6%" valign="top" style="text-align: justify;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top" style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;">
<div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">e.&#160;&#160;</font></div>
</td>
<td width="91%" valign="top" style="text-align: justify;">
<div style="text-align: justify; text-indent: 0pt; display: block;">
<div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On June 15, 2012, the Company entered into a license and sponsored research agreement of BC8, a novel murine monoclonal antibody, with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody).&#160;&#160;FHCRC has currently completed Phase 1 and Phase 2 of the clinical trial and the Company intends to start preparation for a
 pivotal trial leading to an FDA approval.&#160;&#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC.&#160;&#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA.&#160;&#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter.&#160;&#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year.&#160;&#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&#160;&#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</font></div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;">&#160;</div>
<div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During the quarters ended March 31, 2014 and 2013, the Company recorded fees of $37,500 and $37,500, respectively, related to this agreement.</font></div>
</div>
</td>
</tr>
</table>
</div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;">
<div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">f.&#160;&#160;</font></div>
</td>
<td width="91%" valign="top" style="text-align: justify;">
<div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-size: 10pt; display: inline;">On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC for&#160;</font>Actimab-A<font style="font-size: 10pt; display: inline;">.&#160;&#160;The Company will pay $31,366 for each patient that has completed the clinical trial. The Company paid a start-up fee of $19,749 in 2013.&#160;&#160;During the clinical trial additional fees apply and will be invoiced when applicable. For the three months ended March 31, 2014, the Company paid approximately $16,000 for patient enrollment.</font></font></div>
</td>
</tr>
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="91%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;">
<div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">g.&#160;&#160;</font></div>
</td>
<td width="91%" valign="top" style="text-align: justify;">
<div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-size: 10pt; display: inline;">On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center for&#160;</font>Actimab-A<font style="font-size: 10pt; display: inline;">.&#160;&#160;The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500.&#160;&#160;The estimated cost is based on treating 24 patients through 2013.&#160;&#160;Upon execution of the agreement, the Company paid $33,946. During 2013, there was one patient treated and the Company paid $34,383 in July 2013. There have been no patients treated in 2014.</font></font></div>
</td>
</tr>
</table>
<div>&#160;</div>
<table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;">
<div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">h.&#160;&#160;</font></div>
</td>
<td width="91%" valign="top">
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. The Company paid the $22,847 start-up fee in February 2013. There were no payments made during the three months ended March 31, 2014 for this agreement.</font></div>
</td>
</tr>
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="91%"
 valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;">
<div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">i.&#160;&#160;</font></div>
</td>
<td width="91%" valign="top">
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable. The Company accrued $16,000 fee at December 31, 2013 and paid the fee in January 2014.</font></div>
</td>
</tr>
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="91%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
</tr>
<tr>
<td width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td>
<td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;">
<div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">j.&#160;&#160;</font></div>
</td>
<td width="91%" valign="top">
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On January 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology Inc.&#160;&#160;(&#8220;Goodwin&#8221;). Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab&#8482;-B. Total cost of the agreement is $2,813,960. The Company paid a non-refundable payment of $562,790 upon execution of the agreement. Periodic payments will be made upon reaching certain milestones. As of March 31, 2014, the remaining cost of the agreement is $2,077,000.</font></div>
</td>
</tr>
</table>
</div>
<div style="font: 13px/normal 'times new roman'; text-align: left; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&#160;New York, NY. The agreement terminated on May 31, 2013. On June 4, 2013 and amended on October&#160;4, 2013, the Company entered into a rental agreement for office space at 546 Fifth Avenue,&#160;New York, NY. This agreement terminates on July 6, 2014. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details) (Memorial Sloan Kettering Cancer Center [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">New Drug Application [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract', window );"><strong>Summary of milestone payments related to related party</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RelatedPartyMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Receipt of Regulatory Approval From U.S. FDA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract', window );"><strong>Summary of milestone payments related to related party</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RelatedPartyMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 1,750,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RelatedPartyMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Related party milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RelatedPartyMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentsMilestoneMethodTableTextBlock', window );">Summary of milestone payment</a></td>
        <td class="text"><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Milestones</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Payments</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(4) Biological License Application filing with U.S. FDA</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,750,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(5) First commercial sale</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size:
 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(6) after the first $10,000,000 in net sales</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"></font></td></tr></table></div><div>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePaymentsMilestoneMethodTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payments milestone method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MilestonePaymentsMilestoneMethodTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of set forth liabilities measured at fair value on a recurring basis</a></td>
        <td class="text"><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="40%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 1</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 2</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 3</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Total</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="40%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="40%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Derivative liabilities:</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="40%" valign="bottom"><div align="left" style="text-indent: 0pt;
 margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;&#160;At March 31, 2014</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="8%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">19,128,761</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">19,128,761</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="40%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;&#160;At December 31, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="8%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">6,707,255</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">6,707,255</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font></td></tr></table></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
        <td class="text"><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Note 8 &#8211; Subsequent Events</font></div>
<div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
<div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify; display: block; margin-left: 0pt; margin-right: 0pt;">
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">In April 2014, the Company granted certain employees 50,000 shares of restricted common stock and options to purchase 600,000 shares of the Company&#8217;s common stock with exercise prices ranging from $11.76 to $11.95 and a term of 10 years. These options and restricted stock vest over a 4-year period.&#160;&#160;Effective May 12, 2014,&#160;<font style="display: inline; font-size: 10pt;">the Company entered into a sublease agreement for office space located at 379 Thornall Street, Edison, NJ. This agreement terminates on September 30, 2016. The Company issued a security deposit of approximately $35,000 to the existing tenant.</font></font></font><br /><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</div>
<div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">On April 28, 2014, the Company issued 500 shares of its common stock and received net proceeds of $6,000.</font></div>
<div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Nature of Business</a></td>
        <td class="text"><div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Nature of Business &#8211;</font>&#160;<font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;API&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase 1/2 clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></font></div>
<div style="font: 13px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &#8220;Company&#8221;, &#8220;Actinium&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that&#160;was in the market for a merger with an appropriate operating company.</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&#160;&#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April&#160;11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</font></div>
<div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal;
 -webkit-text-stroke-width: 0px;">&#160;</div>
<div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&#8217;s common stock.&#160;&#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation - Unaudited Interim Financial Information</a></td>
        <td class="text"><div><font size="2" style="font-family: times new roman,times;"><font style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 60px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: inline; font-weight: bold;">Basis of Presentation - Unaudited Interim Financial Information &#8211;</font>&#160;The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary&#160;for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 28, 2014. </font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DevelopmentStageCompanyPolicyTextBlock', window );">Development Stage Company</a></td>
        <td class="text"><div><strong><font size="2">Development Stage Company &#8211;</font></strong>&#160;The Company is considered a development stage company and has had no commercial revenue to date. The Company has been focusing on the development of its clinical drug candidates.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><div><strong><font size="2">Principles of Consolidation &#8211;</font></strong>&#160;The condensed consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in Financial Statement Presentation</a></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Use of Estimates in Financial Statement Presentation &#8211;</font>&#160;The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div><strong><font size="2">Cash and Cash Equivalents &#8211;</font></strong>&#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At March 31, 2014 and December 31, 2013, all of the Company&#8217;s cash was deposited in one bank.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div><strong><font size="2">Property and Equipment &#8211;</font></strong>&#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Impairment of Long-Lived Assets &#8211;&#160;</font>Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
        <td class="text"><div><strong><font size="2">Derivatives &#8211;</font></strong>&#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Fair Value of Financial Instruments &#8211;</font>&#160;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities&#160;in&#160;active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 45pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div><div align="right" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><div ><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The following tables set forth liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of March 31, 2014 and December 31, 2013. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font></div></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="40%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 1</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new
 roman'; font-size: 10pt; display: inline;">Level 2</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 3</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Total</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="40%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="40%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Derivative liabilities:</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="9%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="40%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;&#160;At March 31, 2014</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="8%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">19,128,761</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">19,128,761</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="40%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;&#160;At December 31, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="8%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">6,707,255</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="2%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">6,707,255</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font></td></tr></table></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font>&#160;</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div><strong><font size="2">Income Taxes &#8211;</font></strong>&#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
        <td class="text"><div><strong><font size="2">Research and Development Costs &#8211;</font></strong>&#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Payments</a></td>
        <td class="text"><div><strong><font size="2">Share-Based Payments &#8211;</font></strong>&#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
        <td class="text"><div><strong><font size="2">Earnings (Loss) Per Common Share &#8211;</font></strong>&#160;The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &#160;The potentially dilutive securities (options and warrants) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the three months ended March 31, 2014, potentially issuable shares included stock options to purchase 2,265,229 shares and warrants to purchase 9,680,333 shares of the Company&#8217;s common stock. For the three months ended March 31, 2013, potentially issuable shares included stock options to purchase 2,330,134 shares and warrants to purchase 12,770,636 shares of the Company&#8217;s common stock.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div><strong><font size="2">Recent Accounting Pronouncements &#8211;</font></strong>&#160;The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div><strong><font size="2">Subsequent Events &#8211;</font></strong>&#160;The Company&#8217;s management reviewed all material events through the date of the condensed consolidated financial statements were issued for subsequent event disclosure consideration.</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DevelopmentStageCompanyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for development Stage of the company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DevelopmentStageCompanyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2303973<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -Subparagraph (a)-(d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationRelatedCostsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 40<br><br> -Section 45<br><br> -URI http://asc.fasb.org/section&amp;trid=2197723<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16385135&amp;loc=d3e33801-111570<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41675-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting subsequent events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of activities related to related party</a></td>
        <td class="text"><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Milestones</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Payments</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval&#160;for each licensed product</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(2) upon the receipt of regulatory approval from the U.S. FDA for each&#160;licensed product</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,750,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"></font></td></tr></table></div><div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"></font>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESIHK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">3 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">166 Months Ended</th>
        <th class="th" colspan="5">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 24, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Employee Stock Option [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Employee Stock Option [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Employee Stock Option [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Equity Incentive Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Employees Directors And Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Investor [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Consultant [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Private Placement [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]

</div>
          <div>Laidlaw and Co [Member]

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Restricted Stock [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Restricted Stock [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualAbstract', window );"><strong>Equity Textual [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PlacementAgentCashFees', window );">Placement agent cash fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">395,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PlacementAgentAttorneyFees', window );">Placement Agent Attorney Fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">551,810<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">137,952<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Fair value of warrants determined utilizing the Black-Scholes option pricing model</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.55<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">5.55<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair Value Assumptions, Risk Free Interest Rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.32%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.27%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.64%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair Value Assumptions, Expected Volatility Rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">71.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">87.76%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">88.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair Value Assumptions, Expected Dividend Rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair Value Assumptions, Expected Term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RegistrationStatementDescription', window );">Registration Statement Description</a></td>
        <td class="text"><div>This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the &#8220;Sales Agreement&#8221;) with MLV &amp; Co. LLC (&#8220;MLV&#8221;) dated March 24, 2014.&#160;</div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaximumOfferingPrice', window );">Maximum Offering Price</a></td>
        <td class="nump">75,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Common stock pursuant to sales agreement</a></td>
        <td class="text"><div>The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock.&#160;To date 500 shares have been sold under the Sales Agreement with MLV.</div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsIssuedToPurchaseCommonStock', window );">Warrants Issued To Purchase Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,976<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">137,952<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,976<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">180,104<span></span></td>
        <td class="nump">312,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Description restricted stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Of the total shares of restricted stock, 22,500 shares vest 1 year from the grant date, 149,167 shares have a vesting period of 4 years and 150,000 shares vest at date of grant. The remaining restricted shares granted are performance based and vest over time.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AdditionalNumberOfRestrictedStockGranted', window );">Additional number of restricted stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">325,167<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,399,710<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">5,399,710<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,391,318<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Expense related to restricted stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">281,404<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">94,200<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">58,934<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,410,588<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based compensation term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation vested period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueAssumptionsExpectedDiscountRate', window );">Expected discount rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.88%<span></span></td>
        <td class="nump">2.07%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsExercisedByWarrantHolders', window );">Warrants Exercised By Warrant Holders</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">299,885<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,562,346<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24,565,447<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">25,562,346<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">253,330<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,709<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">291,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">180,104<span></span></td>
        <td class="nump">312,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock option exercise prices</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="nump">$ 5.55<span></span></td>
        <td class="nump">$ 8.19<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,220<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 18,273<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,220<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of option exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,655<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr>
        <td colspan="25"></td>
      </tr>
      <tr>
        <td colspan="25">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AdditionalNumberOfRestrictedStockGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of restricted stock granted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AdditionalNumberOfRestrictedStockGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_EquityTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueAssumptionsExpectedDiscountRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value Assumptions Expected Discount Rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueAssumptionsExpectedDiscountRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaximumOfferingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum offering price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MaximumOfferingPrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PlacementAgentAttorneyFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent attorney fees</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PlacementAgentAttorneyFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PlacementAgentCashFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent cash fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PlacementAgentCashFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RegistrationStatementDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Registration statement description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RegistrationStatementDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsExercisedByWarrantHolders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants exercised by warrant holders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_WarrantsExercisedByWarrantHolders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsIssuedToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Issued To Purchase Aggregate Shares Of Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_WarrantsIssuedToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569655-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4582445-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockDescriptionOfTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of significant modifications (such as a change in expiration dating, vesting rights, or exercise prices) to an equity-based compensation plan, including the terms of the modifications.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="nump">$ 19,128,761<span></span></td>
        <td class="nump">$ 6,707,255<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="nump">$ 19,128,761<span></span></td>
        <td class="nump">$ 6,707,255<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28370219&amp;loc=SL20226008-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">166 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PropertyAndEquipmentTextualAbstract', window );"><strong>Property and Equipment (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">$ 1,405<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (4,122)<span></span></td>
        <td class="num">$ (554,308)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PropertyAndEquipmentTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PropertyAndEquipmentTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDUBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">166 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (16,699,497)<span></span></td>
        <td class="num">$ (689,027)<span></span></td>
        <td class="num">$ (83,216,752)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">1,750,926<span></span></td>
        <td class="nump">94,200<span></span></td>
        <td class="nump">8,460,774<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
        <td class="nump">1,405<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,265,427<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,122<span></span></td>
        <td class="nump">554,308<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">900,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">292,692<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(260,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_GainOnChangeInFairValueOfDerivatives', window );">Loss (gain) on change in fair value of derivative liabilities</a></td>
        <td class="nump">12,561,071<span></span></td>
        <td class="num">(1,334,512)<span></span></td>
        <td class="nump">16,041,077<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num">(449,522)<span></span></td>
        <td class="num">(50,000)<span></span></td>
        <td class="num">(370,086)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">236,317<span></span></td>
        <td class="num">(437,121)<span></span></td>
        <td class="nump">957,001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued expenses - related party</a></td>
        <td class="nump">108,352<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">189,537<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
        <td class="num">(2,490,948)<span></span></td>
        <td class="num">(2,312,338)<span></span></td>
        <td class="num">(53,186,022)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment made for patent rights</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(3,000,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(1,699)<span></span></td>
        <td class="num">(1,112)<span></span></td>
        <td class="num">(833,950)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
        <td class="num">(1,699)<span></span></td>
        <td class="num">(1,112)<span></span></td>
        <td class="num">(3,833,950)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Borrowings on convertible debt, net of offering costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">645,888<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Sales of stock, net of offering costs</a></td>
        <td class="nump">2,871,477<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">58,945,832<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of options</a></td>
        <td class="nump">5,220<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">18,273<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
        <td class="nump">23,709<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,491,104<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
        <td class="num">(63,344)<span></span></td>
        <td class="num">(65,333)<span></span></td>
        <td class="num">(203,344)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By (Used in) Financing Activities</a></td>
        <td class="nump">2,837,062<span></span></td>
        <td class="num">(65,333)<span></span></td>
        <td class="nump">62,897,753<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash</a></td>
        <td class="nump">344,415<span></span></td>
        <td class="num">(2,378,783)<span></span></td>
        <td class="nump">5,877,781<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
        <td class="nump">5,533,366<span></span></td>
        <td class="nump">5,618,669<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
        <td class="nump">5,877,781<span></span></td>
        <td class="nump">3,239,886<span></span></td>
        <td class="nump">5,877,781<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flows information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">561<span></span></td>
        <td class="nump">1,243<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature discount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">372,850<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_InsurancePrepaidThroughPremiumFinance', window );">Insurance prepaid through premium finance</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">297,825<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfWarrantsIssuedWithDebt', window );">Fair value of warrants issued with debt</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">377,150<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfWarrantsIssuedWithStock', window );">Fair value of warrants issued with stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">5,985,238<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfWarrantsIssuedToPlacementAgent', window );">Fair value of warrants issued to the placement agent</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,170,282<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock', window );">Conversion of notes payable and accrued interest to stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">981,729<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification', window );">Transfer warrant derivatives from liability to equity classification</a></td>
        <td class="nump">$ 139,565<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,417,984<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversion of notes payable and accrued interest to common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfWarrantsIssuedToPlacementAgent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued to the placement agent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueOfWarrantsIssuedToPlacementAgent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfWarrantsIssuedWithDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued with debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueOfWarrantsIssuedWithDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfWarrantsIssuedWithStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued with stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueOfWarrantsIssuedWithStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GainOnChangeInFairValueOfDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain on change in fair value of the derivatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_GainOnChangeInFairValueOfDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_InsurancePrepaidThroughPremiumFinance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Insurance prepaid through premium finance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_InsurancePrepaidThroughPremiumFinance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeBenefitsAndShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromDebtNetOfIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivatives [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivatives</a></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">Note 5 &#8211; Derivatives</font></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&#8217;s common stock at prices below such warrants&#8217; respective exercise prices and these provisions could result in modification of the warrants&#8217; exercise price based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined under FASB ASC Topic No. 815 &#8211; 40. The warrants granted in connection with the issuance of the Company&#8217;s Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &#8220;Lower Price&#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.</font></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Activities for derivative warrant instruments during the three months ended March 31, 2014 were as follows:</font></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Units</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Fair Value</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Balance, December 31, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,968,623</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman';
 font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">6,707,255</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Transfer from liability classification to equity classification</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(46,025</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">)</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(139,565</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">)</font></div></td></tr><tr bgcolor="white"><td width="76%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Change in fair value</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent:
 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">12,561,071</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Balance, March 31, 2014</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,922,598</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">19,128,761</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During the quarter ended March 31, 2014, 46,025 warrants were exercised. The fair value of these warrants totaling $139,565 were measured on the various exercise dates and reclassified to additional paid-in capital.</font></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font>&#160;</div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 45pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date.</font></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">March 31,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;">&#160;</font></td><td valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">December 31,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2014</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2013</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Market value of common stock on measurement date (1)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">12.45</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">5.89</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Adjusted exercise price</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">9.95</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2.48</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Risk free interest rate (2)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.32</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman';
 font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.27</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Warrant lives in years</font></div></td><td valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0.5 years</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0.5 years</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Expected volatility (3)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">71</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">73</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Expected dividend yield (4)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Probability of stock offering in any period over 5 years (5)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">25</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Range of percentage of existing shares offered (6)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom"
 style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">35</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">%</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Offering price range (7)</font></div></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">9</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">9</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td width="6%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(1)</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The market value of common stock at the above measurement dates is based on the Company&#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for March 31, 2014.</font></div></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;&#160;</font></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(2)</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</font></div></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(3)&#160;&#160;</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Because the Company does not have adequate trading
 history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div></td></tr></table></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font>&#160;</div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(4)&#160;&#160;</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></div></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(5)&#160;&#160;</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Management determines the probability of future stock offering at each evaluation date.</font></div></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(6)&#160;&#160;</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Management estimates that the range of percentages of existing shares offered in each stock offering will be&#160;0% and 35% of the shares outstanding at March 31, 2014 and December 31, 2013, respectively.</font></div></td></tr></table></div><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="6%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="3%" valign="top" style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(7)&#160;&#160;</font></div></td><td width="91%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Represents the estimated offering price range in future offerings as determined by management.</font></div></td></tr></table></div><div align="left" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 7.7pt; margin-left: 9pt; word-spacing: 0px; display: block; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"></font>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668309&amp;loc=d3e80748-113994<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41635-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5708775-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4H<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624258-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4E<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624181-113959<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5708773-113959<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668309&amp;loc=d3e80784-113994<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4D<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624177-113959<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5580258-113959<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41641-113959<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note Payable (Details) (Premium Finance Agreement [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Premium Finance Agreement [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NotePayableAndConvertibleNotesTextualAbstract', window );"><strong>Note Payable and Convertible Notes (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 94,481<span></span></td>
        <td class="nump">$ 157,825<span></span></td>
        <td class="nump">$ 157,825<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Down payment pursuant to the agreement</a></td>
        <td class="nump">15,995<span></span></td>
        <td class="nump">63,344<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent', window );">Amount required to pay in monthly installment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 15,995<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NotePayableAndConvertibleNotesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NotePayableAndConvertibleNotesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the required periodic payments applied to principal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentPeriodicPaymentPrincipal</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-04.12(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 4<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 13, 16<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>133</ContextCount>
  <ElementCount>220</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/NotePayable</Role>
      <ShortName>Note Payable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Derivatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Derivatives</Role>
      <ShortName>Derivatives</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Derivatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesTables</Role>
      <ShortName>Derivatives (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual</Role>
      <ShortName>Related Party Transactions (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/NotePayableDetails</Role>
      <ShortName>Note Payable (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesDetails</Role>
      <ShortName>Derivatives (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Derivatives (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesDetails1</Role>
      <ShortName>Derivatives (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Derivatives (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual</Role>
      <ShortName>Derivatives (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequenteventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element atnm_ProjectEstimatedCost had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_EquityMethodInvestmentOwnershipPercentage had a mix of decimals attribute values: 2 4.</Log>
    <Log type="Info">Element us-gaap_FairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 2 4.</Log>
    <Log type="Info">Element us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized had a mix of decimals attribute values: -6 0.</Log>
    <Log type="Info">'Monetary' elements on report '034 - Disclosure - Equity (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheets (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Consolidated Statements of Operations (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>atnm-20140331.xml</File>
    <File>atnm-20140331.xsd</File>
    <File>atnm-20140331_cal.xml</File>
    <File>atnm-20140331_def.xml</File>
    <File>atnm-20140331_lab.xml</File>
    <File>atnm-20140331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option activities</a></td>
        <td class="text"><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Remaining</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Aggregate</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Number of</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"
 colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Contractual</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Intrinsic</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Units</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Exercise Price</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Term (in years)</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Value</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, December 31, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,985,384</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td
 align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">3.23</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">8.34</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">5,908,696</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;Issued</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">291,500&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;7.86</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">10&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;Exercised</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(11,655)</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.78</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size:
 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">-</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">-</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, March 31, 2014</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,265,229</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">3.84</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">8.34</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;$</font></div></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">19,514,362</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"></font>&#160;</div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option activities</a></td>
        <td class="text"><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Remaining</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Aggregate</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Number of</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"
 colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Contractual</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Intrinsic</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Units</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Exercise Price</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Term (in years)</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Value</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, December 31, 2013</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9,673,290</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td
 align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1.06</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">4.89</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160; 47,396,307</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;Granted</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">306,928</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">7.88</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160; 6.63</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;&#160;Exercised</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(299,885</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1.04</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td
 align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, March 31, 2014</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9,680,333</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1.28</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">4.71</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">107,268,785</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div><div>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
